PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HEALY, B				HEALY, B			TL-201 ABNORMALITIES FOUND INDICATIVE OF ISCHEMIA IN HYPERTROPHIC CARDIOMYOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, CIRCULATION, V83, P1660	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-28	WOS:A1991GM79000008
J	KATZ, H; HOMAN, M; VELOSA, J; ROBERTSON, P; RIZZA, R				KATZ, H; HOMAN, M; VELOSA, J; ROBERTSON, P; RIZZA, R			EFFECTS OF PANCREAS TRANSPLANTATION ON POSTPRANDIAL GLUCOSE-METABOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN RESISTANCE; C-PEPTIDE; HYPERINSULINEMIA; GLUCONEOGENESIS; STIMULATION; RECIPIENTS; EXTRACTION; SECRETION; TRANSPORT	Background. Because a pancreas allograft is placed in the pelvis, pancreas transplantation abolishes the normal gradient between portal-vein and peripheralvein insulin concentrations and causes systemic hyperinsulinemia. Whether pancreas transplantation restores carbohydrate metabolism to normal is not known. Methods. We studied seven patients with insulin-dependent diabetes mellitus after pancreas-kidney transplantation, seven nondiabetic patients after kidney transplantation (to control for immunosuppression), and eight normal subjects. Measurements were made after an overnight fast and after ingestion of a mixed meal. Results. Although plasma glucose concentrations did not differ in the two transplant groups, plasma insulin concentrations were significantly higher in the diabetic pancreas-kidney recipients than in the nondiabetic kidney recipients, both before the meal (mean +/- SE, 102 +/- 15 vs. 53 +/- 6 pmol per liter; P < 0.05) and afterward (123 +/- 22 vs. 61 +/- 6 nmol per liter per six hours; P < 0.05). Plasma C-peptide concentrations were the same in both groups, indicating that hyperinsulinemia was due to decreased insulin clearance rather than increased insulin secretion. Despite drainage of the venous effluent from the transplanted pancreas into the systemic circulation, the values for splanchnic clearance of ingested glucose, suppression of hepatic glucose release, incorporation of carbon dioxide into glucose, stimulation of glucose oxidation, glucose uptake, and forearm glucose clearance were all similar in the transplant groups and differed minimally from the values in the normal group. The similar rates of glucose uptake in the presence of higher systemic insulin concentrations indicated that the extrahepatic tissues of the diabetic pancreas-kidney recipients were insulin-resistant. Conclusions. Despite systemic delivery of insulin, pancreas-kidney transplantation in patients with diabetes results in carbohydrate metabolism similar to that in nondiabetic subjects receiving the same immunosuppressive agents after kidney transplantation.	MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities					NCRR NIH HHS [RR-00585] Funding Source: Medline; NIDDK NIH HHS [DK-29953, DK-39994] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029953, R01DK039994, R01DK029953] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL PM, 1986, J CLIN INVEST, V78, P1479, DOI 10.1172/JCI112739; BERGMAN RN, 1974, AM J PHYSIOL, V227, P1314, DOI 10.1152/ajplegacy.1974.227.6.1314; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; BROSNAN JT, 1982, FED PROC, V41, P91; BUTLER PC, 1990, DIABETES, V39, P1373, DOI 10.2337/diabetes.39.11.1373; Consolazio CF., 1963, HDB PHYSL, P313; DEBODO RC, 1963, RECENT PROG HORM RES, V19, P445; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; FALHOLT K, 1991, METABOLISM, V40, P122, DOI 10.1016/0026-0495(91)90161-O; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628; GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84; HEDING LG, 1975, DIABETOLOGIA, V11, P201, DOI 10.1007/BF00422322; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HORWITZ DL, 1975, J CLIN INVEST, V55, P1278, DOI 10.1172/JCI108047; ISSEKUTZ B, 1977, METABOLISM, V26, P157, DOI 10.1016/0026-0495(77)90051-8; KAIHARA S, 1968, J LAB CLIN MED, V71, P400; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KRUSZYNSKA YT, 1987, METABOLISM, V36, P281, DOI 10.1016/0026-0495(87)90189-2; KRYSHAK EJ, 1990, DIABETES, V39, P142, DOI 10.2337/diabetes.39.2.142; LUZI L, 1990, DIABETOLOGIA, V33, P549, DOI 10.1007/BF00404143; MARCO J, 1973, NEW ENGL J MED, V288, P128, DOI 10.1056/NEJM197301182880305; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; MCMAHON M, 1989, DIABETES, V38, P291, DOI 10.2337/diabetes.38.3.291; MCMAHON MM, 1989, DIABETES, V38, P97, DOI 10.2337/diabetes.38.1.97; MYERS SR, 1991, J CLIN INVEST, V87, P930, DOI 10.1172/JCI115100; OSEI K, 1990, DIABETES, V39, P1235, DOI 10.2337/diabetes.39.10.1235; OSTMAN J, 1989, DIABETES, V38, P88, DOI 10.2337/diab.38.1.S88; POLONSKY K, 1990, DIABETES S1, V39, pA15; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; RADZIUK J, 1978, METABOLISM, V27, P657, DOI 10.1016/0026-0495(78)90003-3; RIZZA RA, 1985, DIABETOLOGIA, V28, P70; RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131; RIZZA RA, 1981, AM J PHYSIOL, V240, pE630, DOI 10.1152/ajpendo.1981.240.6.E630; RUDERMAN NB, 1968, AM J PHYSIOL, V214, P1346, DOI 10.1152/ajplegacy.1968.214.6.1346; STALMANS W, 1974, EUR J BIOCHEM, V41, P117; STEELE R, 1956, AM J PHYSIOL, V187, P15, DOI 10.1152/ajplegacy.1956.187.1.15; SUTHERLAND DE, 1986, CLIN CHEM S10, V10, pB83; WARDZALA LJ, 1985, J CLIN INVEST, V76, P460, DOI 10.1172/JCI111994; WOLFE RR, 1986, AM J PHYSIOL, V250, pE306, DOI 10.1152/ajpendo.1986.250.3.E306	41	129	129	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1278	1283		10.1056/NEJM199110313251804	http://dx.doi.org/10.1056/NEJM199110313251804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922222	Bronze			2022-12-28	WOS:A1991GM04100004
J	LAMM, DL; BLUMENSTEIN, BA; CRAWFORD, ED; MONTIE, JE; SCARDINO, P; GROSSMAN, HB; STANISIC, TH; SMITH, JA; SULLIVAN, J; SAROSDY, MF; CRISSMAN, JD; COLTMAN, CA				LAMM, DL; BLUMENSTEIN, BA; CRAWFORD, ED; MONTIE, JE; SCARDINO, P; GROSSMAN, HB; STANISIC, TH; SMITH, JA; SULLIVAN, J; SAROSDY, MF; CRISSMAN, JD; COLTMAN, CA			A RANDOMIZED TRIAL OF INTRAVESICAL DOXORUBICIN AND IMMUNOTHERAPY WITH BACILLE CALMETTE-GUERIN FOR TRANSITIONAL-CELL CARCINOMA OF THE BLADDER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER; THERAPY; PROPHYLAXIS; THIOTEPA; TUMORS	Background. In carcinoma of the bladder, both intravesical chemotherapy and immunotherapy can induce tumor regression and reduce the rate of recurrence, but the relative merits of these two therapies are unclear. We conducted a multi-institutional study to address this question. Methods. Patients with rapidly recurrent (stage Ta or T1) or in situ transitional-cell carcinoma of the bladder were randomly assigned to receive either doxorubicin administered intravesically or bacille Calmette-Guerin (BCG) administered both intravesically and percutaneously. The 262 eligible patients were followed for a median of 65 months. Complete responses to treatment of carcinoma in situ were confirmed by biopsy and cytologic analysis of the urine. Results. For patients with Ta and T1 tumors without carcinoma in situ, the estimated probability of being disease free at five years was 17 percent after doxorubicin, as compared with 37 percent after immunotherapy with BCG (P = 0.015). The median times to treatment failure (termination of treatment due to persistence, recurrence, or progression of disease) were 10.4 and 22.5 months, respectively. For patients with carcinoma in situ the complete-response probability estimates (i.e., the estimated probability of documented disappearance of disease) were 34 percent for doxorubicin (23 of 67 patients) and 70 percent for BCG (45 of 64 patients) (P < 0.001); the median times to treatment failure were 5.1 and 39 months, respectively. The probability of being disease-free at five years' survival among the patients with carcinoma in situ was 18 percent after treatment with doxorubicin and 45 percent after BCG therapy. Patients treated with BCG had a higher incidence of toxic systemic effects and a larger number of local irritative symptoms than patients treated with doxorubicin, but few of these adverse reactions were severe. Conclusions. As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer.	LOUISIANA STATE UNIV,MED CTR,NEW ORLEANS,LA 70112; SW ONCOL GRP,CTR STAT,SEATTLE,WA; UNIV MICHIGAN,ANN ARBOR,MI 48109; VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37240; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; HENRY FORD HOSP,DETROIT,MI 48202; W VIRGINIA UNIV,MED CTR,MORGANTOWN,WV 26506; UNIV COLORADO,DENVER,CO 80202; UNIV ARIZONA,CTR CANC,TUCSON,AZ 85721; WAYNE STATE UNIV,DETROIT,MI 48202	Louisiana State University System; Southwest Oncology Group; University of Michigan System; University of Michigan; Vanderbilt University; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; Henry Ford Health System; Henry Ford Hospital; West Virginia University; University of Colorado System; University of Colorado Denver; University of Arizona; Wayne State University	LAMM, DL (corresponding author), SW ONCOL GRP,8216-38,OPERAT OFF,5430 FREDERICKSBURG RD,SUITE 618,SAN ANTONIO,TX 78229, USA.				NCI NIH HHS [CA-42777, CA-37429, CA-04915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA004915, U10CA042777, U10CA037429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLPHS HD, 1983, J UROLOGY, V129, P29, DOI 10.1016/S0022-5347(17)51902-3; ANDERSON S, 1980, STATISTICAL METHODS; BROSMAN SA, 1982, J UROLOGY, V128, P27, DOI 10.1016/S0022-5347(17)52736-6; CATALONA WJ, 1987, J UROLOGY, V137, P220, DOI 10.1016/S0022-5347(17)43959-0; DERESIEWICZ RL, 1990, J UROLOGY, V144, P1331, DOI 10.1016/S0022-5347(17)39732-X; EDSMYR F, 1978, UROL RES, V6, P263, DOI 10.1007/BF00262632; GARNICK MB, 1984, J UROLOGY, V131, P43, DOI 10.1016/S0022-5347(17)50189-5; HERR HW, 1988, J CLIN ONCOL, V6, P1450, DOI 10.1200/JCO.1988.6.9.1450; HERR HW, 1987, J UROLOGY, V138, P1363, DOI 10.1016/S0022-5347(17)43644-5; JAKSE G, 1981, J UROLOGY, V125, P185, DOI 10.1016/S0022-5347(17)54959-9; KALISH LA, 1987, J CLIN ONCOL, V5, P2004, DOI 10.1200/JCO.1987.5.12.2004; Koss LG, 1975, TUMORS URINARY BLADD; KOWALKOWSKI TS, 1988, CURRENT TREND UROLOG, P89; LAMM DL, 1982, J UROLOGY, V128, P931, DOI 10.1016/S0022-5347(17)53283-8; LAMM DL, 1988, UROLOGY ONCOLOGY DIL, P107; LUTZEYER W, 1982, J UROLOGY, V127, P250, DOI 10.1016/S0022-5347(17)53725-8; MARTINEZPINEIRO JA, 1990, J UROLOGY, V143, P502, DOI 10.1016/S0022-5347(17)40002-4; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; PINSKY CM, 1982, IMMUNOTHERAPY HUMAN, P309; PROUT GR, 1983, J UROLOGY, V130, P677, DOI 10.1016/S0022-5347(17)51400-7; RAWLS WH, 1990, J UROLOGY, V144, P1328, DOI 10.1016/S0022-5347(17)39731-8; REITSMA DJ, 1989, BCG SUPERFICIAL BLAD, V310, P171; SCHELLHAMMER PF, 1986, J UROLOGY, V135, P261, DOI 10.1016/S0022-5347(17)45603-5	23	484	496	3	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1205	1209		10.1056/NEJM199110243251703	http://dx.doi.org/10.1056/NEJM199110243251703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922207				2022-12-28	WOS:A1991GL28200003
J	BUKRINSKY, MI; STANWICK, TL; DEMPSEY, MP; STEVENSON, M				BUKRINSKY, MI; STANWICK, TL; DEMPSEY, MP; STEVENSON, M			QUIESCENT LYMPHOCYTES-T AS AN INDUCIBLE VIRUS RESERVOIR IN HIV-1 INFECTION	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; HTLV-III/LAV ENVELOPE; PERIPHERAL-BLOOD; REVERSE TRANSCRIPTION; CELL ACTIVATION; AIDS VIRUS; TYPE-1; DNA; EXPRESSION	To better understand the basis for human immunodeficiency virus type 1 (HIV-1) persistence and latency, the form in which viral DNA exists in the peripheral T lymphocyte reservoir of infected individuals was investigated. In asymptomatic individuals, HIV-1 was harbored predominantly as full-length, unintegrated complementary DNA. These extrachromosomal DNA forms retained the ability to integrate upon T cell activation in vitro. In patients with acquired immunodeficiency syndrome (AIDS), there was an increase in integrated relative to extrachromosomal DNA forms. By analysis of DNA from patient lymphocyte subpopulations depleted of human lymphocyte antigen-Dr receptor-positive cells, quiescent T cells were identified as the source of extrachromosomal HIV-1 DNA. Thus quiescent T lymphocytes may be a major and inducible HIV-11 reservoir in infected individuals.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; NATL INST MED RES,DIV VIROL,LONDON NW7 1AA,ENGLAND	University of Nebraska System; University of Nebraska Medical Center; MRC National Institute for Medical Research					NIAID NIH HHS [R01 AI049152, R01 AI032890] Funding Source: Medline; NIMH NIH HHS [R01 MH064411] Funding Source: Medline; PHS HHS [A124481, A130386] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUKRINSKY MI, UNPUB; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1987, NEW ENGL J MED, V317, P278; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KESHET E, 1979, J VIROL, V31, P376, DOI 10.1128/JVI.31.2.376-388.1979; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULLINS JI, 1986, NATURE, V319, P333, DOI 10.1038/319333a0; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHANK PR, 1978, CELL, V15, P1383, DOI 10.1016/0092-8674(78)90063-6; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; STECK FT, 1966, VIROLOGY, V29, P642, DOI 10.1016/0042-6822(66)90288-1; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; WEISS R, 1984, RNA TUMOR VIRUSES, V1, P209; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	43	529	542	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					423	427		10.1126/science.1925601	http://dx.doi.org/10.1126/science.1925601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925601	Green Accepted			2022-12-28	WOS:A1991GK72900047
J	STEWART, PL; BURNETT, RM; CYRKLAFF, M; FULLER, SD				STEWART, PL; BURNETT, RM; CYRKLAFF, M; FULLER, SD			IMAGE-RECONSTRUCTION REVEALS THE COMPLEX MOLECULAR-ORGANIZATION OF ADENOVIRUS	CELL			English	Article							CRYO-ELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; SPHERICAL VIRUSES; POLYPEPTIDE-IX; HEXON; MICROGRAPHS; CHROMATIN; TYPE-2; CORE; VISUALIZATION	The three-dimensional structure of adenovirus has been determined by image reconstruction from cryoelectron micrographs. Comparison with the high resolution X-ray crystal structure of hexon, the major capsid protein, enabled an unusually detailed interpretation of the density map and confirmed the validity of the reconstruction. The hexon packing in the capsid shows more extensive intermolecular interfaces between facets than previously proposed. The reconstruction provides the first three-dimensional visualization of the vertex proteins, including the penton base and its associated protruding fiber. Three minor capsid proteins that stabilize and modulate capsomer interactions are revealed. One of these components stabilizes the group-of-nine hexons in the center of each facet and the other two bridge hexons in adjacent facets. The strategic positions of these proteins highlight the importance of cementing proteins in stabilizing a complex assembly.	EUROPEAN MOLEC BIOL LAB,BIOL STRUCT & BIOCOMP PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	STEWART, PL (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA 10815, 2T32 CA 09171-13] Funding Source: Medline; NIAID NIH HHS [AI 17270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; BURNETT RM, 1990, USE OF X-RAY CRYSTALLOGRAPHY IN THE DESIGN OF ANTIVIRAL AGENTS, P35; BURNETT RM, 1985, J MOL BIOL, V185, P125, DOI 10.1016/0022-2836(85)90187-1; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; CORDEN J, 1976, P NATL ACAD SCI USA, V73, P401, DOI 10.1073/pnas.73.2.401; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; EVERITT E, 1975, VIROLOGY, V67, P197, DOI 10.1016/0042-6822(75)90417-1; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; FURCINITTI PS, 1989, EMBO J, V8, P3563, DOI 10.1002/j.1460-2075.1989.tb08528.x; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HOMO JC, 1984, J MICROSC-OXFORD, V136, P337, DOI 10.1111/j.1365-2818.1984.tb00543.x; JENG TW, 1989, J MOL BIOL, V205, P251, DOI 10.1016/0022-2836(89)90379-3; LAVER WG, 1969, VIROLOGY, V39, P599, DOI 10.1016/0042-6822(69)90111-1; MIRZA MA, 1982, BIOCHIM BIOPHYS ACTA, V696, P76, DOI 10.1016/0167-4781(82)90012-4; NERMUT MV, 1984, ADENOVIRUSES, P5; NEWCOMB WW, 1984, J VIROL, V51, P52, DOI 10.1128/JVI.51.1.52-56.1984; PEREIRA HG, 1974, J MOL BIOL, V85, P617, DOI 10.1016/0022-2836(74)90319-2; PHILIPSON L, 1983, CURR TOP MICROBIOL, V109, P1; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROBERTS RJ, 1984, J BIOL CHEM, V259, P3968; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570, DOI 10.3181/00379727-84-20714; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; RUSSELL WC, 1982, J GEN VIROL, V63, P69, DOI 10.1099/0022-1317-63-1-69; SCHRAG JD, 1989, CELL, V56, P651, DOI 10.1016/0092-8674(89)90587-4; STEWART PL, 1990, SEMIN VIROL, V1, P477; TATE VE, 1979, NUCLEIC ACIDS RES, V6, P2769, DOI 10.1093/nar/6.8.2769; TORBET J, 1983, EMBO J, V2, P63, DOI 10.1002/j.1460-2075.1983.tb01381.x; VANOOSTRUM J, 1987, J MOL BIOL, V198, P73, DOI 10.1016/0022-2836(87)90459-1; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0	36	238	245	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					145	154		10.1016/0092-8674(91)90578-M	http://dx.doi.org/10.1016/0092-8674(91)90578-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913814				2022-12-28	WOS:A1991GJ32000013
J	JARDETZKY, TS; LANE, WS; ROBINSON, RA; MADDEN, DR; WILEY, DC				JARDETZKY, TS; LANE, WS; ROBINSON, RA; MADDEN, DR; WILEY, DC			IDENTIFICATION OF SELF PEPTIDES BOUND TO PURIFIED HLA-B27	NATURE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; AMINO-ACID SEQUENCES; HEAT-SHOCK PROTEIN; DEVELOPMENTAL BIOLOGY; ANTIGEN PRESENTATION; VIRAL PEPTIDES; HLA ANTIGENS; MHC	A pool of endogenous peptides bound to the human class I MHC molecule, HLA-B27, has been isolated. Microsequence analysis of the pool and of 11 HPLC-purified peptides provides information on the binding specificity of the HLA-B27 molecule. The peptides all seem to be nonamers, seven of which match to protein sequences in a database search. These self peptides derive from abundant cytosolic or nuclear proteins, such as histone, ribosomal proteins, and members of the 90K heat-shock protein family.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University	JARDETZKY, TS (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ALBERTS B, 1989, MOL BIOL CELL, P496; ATTSCHUL SF, 1990, J MOL BIOL, V215, P403; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; TERHORST C, 1977, P NATL ACAD SCI USA, V74, P4002, DOI 10.1073/pnas.74.9.4002; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VANBLEEK GM, 1990, NATURE, V348, P213; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WATSON JD, 1987, MOL BIOL GENE, P466; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	46	857	892	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					326	329		10.1038/353326a0	http://dx.doi.org/10.1038/353326a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922338				2022-12-28	WOS:A1991GG65400049
J	BERNAT, RL; DELANNOY, MR; ROTHFIELD, NF; EARNSHAW, WC				BERNAT, RL; DELANNOY, MR; ROTHFIELD, NF; EARNSHAW, WC			DISRUPTION OF CENTROMERE ASSEMBLY DURING INTERPHASE INHIBITS KINETOCHORE MORPHOGENESIS AND FUNCTION IN MITOSIS	CELL			English	Article							MAMMALIAN KINETOCHORE; CHROMOSOME CONDENSATION; CENP-B; CYTOPLASMIC DYNEIN; AUTOIMMUNE SERA; MOVEMENT; SCLERODERMA; ANTIBODIES; PROTEINS; ANAPHASE	The relationship between the kinetochore and the centromeric heterochromatin that surrounds it is unknown. Anti-centromere autoantibodies (ACAs) that recognize antigens found in the heterochromatin beneath the kinetochore disrupt mitotic events when microinjected into human cells. We show here that ACAs interfere with two different stages of centromere assembly during interphase, resulting in abnormal kinetochore structures during mitosis. Antibody injection prior to late G2 results in the subsequent failure to assemble a trilaminar kinetochore. Such chromosomes bind microtubules but are incapable of movement. Antibody disruption of events during G2 produces unstable kinetochores that prevent the normal transition into anaphase. These experiments present a novel way to examine events in the pathway of kinetochore assembly that occur during interphase, at a time when this structure cannot be visualized directly.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06032	University of Connecticut	BERNAT, RL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCZON RD, 1987, J CELL BIOL, V105, P855, DOI 10.1083/jcb.105.2.855; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; BRINKLEY BR, 1988, NATURE, V336, P251, DOI 10.1038/336251a0; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; PALMER DK, 1991, IN PRESS P NATL ACAD, V88; PANKOV R, 1990, CHROMOSOMA, V99, P95, DOI 10.1007/BF01735324; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RATTNER JB, 1986, CHROMOSOMA, V93, P515, DOI 10.1007/BF00386793; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1990, ELECTRON MICROSC REV, V3, P269, DOI 10.1016/0892-0354(90)90005-D; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SNYDER J A, 1985, European Journal of Cell Biology, V39, P373; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TAYLOR EW, 1959, J BIOPHYS BIOCHEM CY, V6, P193, DOI 10.1083/jcb.6.2.193; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; WORDEMAN L, 1991, IN PRESS J CELL BIOL; YEN TJ, 1991, IN PRESS EMBO J, V10; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	43	81	84	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1229	1238		10.1016/0092-8674(91)90045-Z	http://dx.doi.org/10.1016/0092-8674(91)90045-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913807				2022-12-28	WOS:A1991GG55200017
J	KIYOSAWA, K; SODEYAMA, T; TANAKA, E; NAKANO, Y; FURUTA, S; NISHIOKA, K; PURCELL, RH; ALTER, HJ				KIYOSAWA, K; SODEYAMA, T; TANAKA, E; NAKANO, Y; FURUTA, S; NISHIOKA, K; PURCELL, RH; ALTER, HJ			HEPATITIS-C IN HOSPITAL EMPLOYEES WITH NEEDLESTICK INJURIES	ANNALS OF INTERNAL MEDICINE			English	Note						HEPATITIS VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; ACCIDENTS, OCCUPATIONAL; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE	NON-A; B VIRUS	Of 357 needlestick accidents occurring at a university hospital between 1981 and 1989, 200 involved 196 health care workers who were then prospectively followed for 6 months; 110 of these 196 workers were exposed to blood from antibody to the hepatitis C virus (anti-HCV). Only 4 of these 110 exposed persons (4%; 95% CI, 1% to 9%) developed non-A, non-B hepatitis. Hepatitis was accompanied by anti-HCV seroconversion in 3 of these 4 persons. Three of the four were icteric, and each had a peak alanine aminotransferase level exceeding 8.5-mu-kat/L. There was no instance of anti-HCV seroconversion among the 106 recipients of an anti-HCV-positive needlestick who did not manifest biochemical or clinical evidence of hepatitis. This study documents that HCV-related non-A, non-B hepatitis can be transmitted infrequently by needlestick injury.	JAPANESE RED CROSS SOC, CENT BLOOD CTR, SHIBUYA KU, TOKYO 150, JAPAN; NIAID, HEPATITIS VIRUSES SECT, BETHESDA, MD 20892 USA; NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	KIYOSAWA, K (corresponding author), SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, 3-1-1 ASAHI, MATSUMOTO, NAGANO 390, JAPAN.							ALTER HJ, 1991, IN PRESS VIRAL HEPAT; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MASUKO K, 1985, GASTROENTEROLOGY, V88, P151, DOI 10.1016/S0016-5085(85)80147-5; PONZETTO A, 1987, J INFECT DIS, V155, P72, DOI 10.1093/infdis/155.1.72; SHIKATA T, 1977, J INFECT DIS, V136, P571, DOI 10.1093/infdis/136.4.571; XEEFF LB, 1979, GASTROENTEROLOGY, V77, P161; YOSHIZAWA H, 1982, GASTROENTEROLOGY, V82, P502	10	299	302	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					367	369		10.7326/0003-4819-115-5-367	http://dx.doi.org/10.7326/0003-4819-115-5-367			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1907441				2022-12-28	WOS:A1991GC06500006
J	SHEWRING, DJ; WALLACE, D; HEALY, CMJ				SHEWRING, DJ; WALLACE, D; HEALY, CMJ			LESSON OF THE WEEK - SKIN AVULSION DURING MANIPULATION OF FRACTURES	BRITISH MEDICAL JOURNAL			English	Article							COLLES		ADDENBROOKES HOSP,DEPT PLAST & RECONSTRUCT SURG,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	SHEWRING, DJ (corresponding author), ADDENBROOKES HOSP,DEPT ORTHOPAED & TRAUMA,CAMBRIDGE CB2 2QQ,ENGLAND.							Benjamin A, 1982, WATSON JONES FRACTUR, P650; CASSEBAUM WH, 1950, JAMA-J AM MED ASSOC, V143, P963, DOI 10.1001/jama.1950.02910460021006; FATAH MF, 1984, BRIT J PLAST SURG, V37, P184, DOI 10.1016/0007-1226(84)90008-0; MCQUEEN M, 1988, J BONE JOINT SURG BR, V70, P649, DOI 10.1302/0301-620X.70B4.3403617; MCQUEEN MM, 1986, J BONE JOINT SURG BR, V68, P232, DOI 10.1302/0301-620X.68B2.3958009; RYAN TJ, 1987, OXFORD TXB MED, P20; SOUTHWOOD W F, 1955, Plast Reconstr Surg (1946), V15, P423; [No title captured]	8	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					513	514		10.1136/bmj.303.6801.513	http://dx.doi.org/10.1136/bmj.303.6801.513			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912865	Green Published, Bronze			2022-12-28	WOS:A1991GD80400022
J	WATSON, EK; MAYALL, E; CHAPPLE, J; DALZIEL, M; HARRINGTON, K; WILLIAMS, C; WILLIAMSON, R				WATSON, EK; MAYALL, E; CHAPPLE, J; DALZIEL, M; HARRINGTON, K; WILLIAMS, C; WILLIAMSON, R			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS THROUGH PRIMARY HEALTH-CARE SERVICES	BRITISH MEDICAL JOURNAL			English	Article							IDENTIFICATION; GENE	Objective - To evaluate the uptake of cystic fibrosis carrier testing offered through primary health care services. Design - Carrier testing for cystic fibrosis was offered to patients of reproductive age through primary health care services. Setting - Three general practice surgeries and four family planning clinics in South West Hertfordshire District Health Authority. Subjects - Over 1000 patients aged 16-44 attending two general practices and four family planning clinics and a stratified random sample of patients aged 16-44 from one general practice's age-sex register. Results - When screening was offered opportunistically the uptake was 66% in general practice and 87% in family planning clinics. Ten per cent of those offered a screening appointment by letter took up the invitation. Of the screened population, 76% had previously heard of cystic fibrosis, 35% realised it is inherited, and 18% realised that carriers need not have any family history. If they found themselves in an "at risk" partnership 39% would consider not having children and 26% would consider terminating an affected pregnancy, but in each case most people were unsure how they would react. Conclusions - Most people offered a cystic fibrosis test opportunistically wish to be tested, and the responses of those tested indicate that knowledge of carrier state would be considered in future reproductive decisions.	SW HERTFORDSHIRE DIST HLTH AUTHOR,WATFORD WD1 8UB,ENGLAND		WATSON, EK (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.							CALNAN M, 1986, SOC SCI MED, V22, P673, DOI 10.1016/0277-9536(86)90039-0; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DODGE JA, 1988, LANCET, V2, P672; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MANT D, 1990, BRIT MED J, V300, P916, DOI 10.1136/bmj.300.6729.916; MODELL B, 1990, J MED GENET, V27, P475, DOI 10.1136/jmg.27.8.475; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SKRABANEK P, 1986, LANCET, V1, P143; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; WATSON EK, 1990, HUM GENET, V85, P435, DOI 10.1007/BF02428303; WATSON EK, 1991, BRIT J GEN PRACT, V41, P237; WILLIAMSON R, 1989, PRENATAL DIAG, V9, P727, DOI 10.1002/pd.1970091008; 1990, CYSTIC FIBROSIS ADUL	16	105	105	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					504	507		10.1136/bmj.303.6801.504	http://dx.doi.org/10.1136/bmj.303.6801.504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD804	1912861	Green Published, Bronze			2022-12-28	WOS:A1991GD80400018
J	HALLSMITH, P; BENNETT, J				HALLSMITH, P; BENNETT, J			TATTOOS - A LASTING REGRET	BRITISH MEDICAL JOURNAL			English	Article									BRIGHTON GEN HOSP,DEPT PUBL HLTH MED,BRIGHTON BN2 3EW,ENGLAND	Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital	HALLSMITH, P (corresponding author), BRIGHTON GEN HOSP,DEPT PLAST SURG,BRIGHTON BN2 3EW,ENGLAND.							LANIGAN SW, 1989, BRIT J DERMATOL, V120, P819, DOI 10.1111/j.1365-2133.1989.tb01380.x; PIGGOT TA, 1988, BRIT J PLAST SURG, V41, P112, DOI 10.1016/0007-1226(88)90036-7; SCUTT RWB, 1970, J ROYAL NAVAL MED SE, P56; 1969, BMJ, V1, P4	4	5	5	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					397	397		10.1136/bmj.303.6799.397	http://dx.doi.org/10.1136/bmj.303.6799.397			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1912808	Green Published, Bronze			2022-12-28	WOS:A1991GB59900018
J	WILLIAMS, SV; NASH, DB; GOLDFARB, N				WILLIAMS, SV; NASH, DB; GOLDFARB, N			DIFFERENCES IN MORTALITY FROM CORONARY-ARTERY BYPASS GRAFT-SURGERY AT 5 TEACHING HOSPITALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; HEART-DISEASE; VOLUME; CARE; QUALITY; RISK; RATES; STAFF	Objective.-To measure hospital- and surgeon-specific mortality rates for patients with coronary artery bypass graft (CABG) surgery and to examine possible reasons for any differences. Design.-Cohort study using hospital discharge abstracts and itemized bills. Setting.-Five major teaching hospitals in Philadelphia, Pa. Patients.-Consecutive sample of all 4613 patients over a 30-month period. Main Outcome Measure.-In-hospital mortality rates. Results.-We observed differences in hospital mortality rates for patients who underwent coronary artery catheterization and CABG surgery during the same admission (diagnosis related group 106) but not for patients who underwent only CABG surgery during the admission (diagnosis related group 107). There were threefold differences in surgeon-specific mortality rates. The hospital mortality rates for coronary artery catheterization and CABG surgery during the same admission changed during the study and coincided with moves of surgeons among study hospitals. Our measures of illness severity did identify patients who were more likely to die, but differences in severity of illness did not explain differences in hospital- or surgeon-specific mortality rates. Patient mortality rates were not associated with the volume of procedures performed by individual surgeons. We found inconclusive evidence for an association with surgeons' clinical skills, and, to a lesser extent, with the hospital's volume of procedures and the hospital's organization and staffing. A greater intensity of hospital services was not necessary for a lower mortality rate. Conclusions. -We conclude that studies of CABG mortality should examine mortality rates by diagnosis related group, collect data from more than 1 year, examine associations with surgeons: clinical skills, include information on hospital organization and staffing, and cautiously explore more efficient ways of providing care.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,SUITE 621 CURTIS,PHILADELPHIA,PA 19107; UNIV PENN,SCH MED,GEN INTERNAL MED SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,DEPT HLTH POLICY,PHILADELPHIA,PA 19107	Jefferson University; University of Pennsylvania; University of Pennsylvania; Jefferson University								FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; FLOOD AB, 1978, J HEALTH SOC BEHAV, V19, P240, DOI 10.2307/2136557; FLOOD AB, 1982, HEALTH SERV RES, V17, P341; GERMAN DC, 1986, NEUROSCI LETT, V61, P1; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; JUNOD FL, 1987, ANN THORAC SURG, V43, P59, DOI 10.1016/S0003-4975(10)60167-1; KELLY JV, 1987, HEALTH SERV RES, V22, P369; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LAWRIE GM, 1987, ANN THORAC SURG, V44, P180, DOI 10.1016/S0003-4975(10)62037-1; LUFT HS, 1987, HEALTH SERV RES, V22, P157; PARSONNET V, 1989, CIRCULATION, V79, P3; SERGEANT P, 1986, J CARDIOVASC SURG, V27, P618; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1985, SAS VERSION 5	22	92	94	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					810	815		10.1001/jama.266.6.810	http://dx.doi.org/10.1001/jama.266.6.810			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1907670				2022-12-28	WOS:A1991GA07300032
J	GLEICHER, N				GLEICHER, N			EXPANSION OF HEALTH-CARE TO THE UNINSURED AND UNDERINSURED HAS TO BE COST-NEUTRAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CESAREAN-SECTION RATES; HOUSE-STAFF; CONSENSUS	Any attempt to address the problem of more than 30 million uninsured and 25 million seriously underinsured citizens in the United States has to be able to offer medical services to this 20% of the population in a cost-neutral way for the US economy, since present economic conditions do not permit further expansion in health care costs. A medical system compartmentalized by medical specialty should be able to save approximately 20% of present-day health care expenditures within each specialty, which then can be used to provide the necessary coverage. Some suggestions are made as to how such cost savings can be achieved. Only an effort spearheaded by physicians can achieve the outlined targets, since, otherwise, physician efforts will easily subvert such attempts. A physician initiative that could solve the crisis would reestablish physicians as leaders in determining national health care policy and should consequently improve the recently disappointing societal image of the profession.	CTR HUMAN REPROD,CHICAGO,IL		GLEICHER, N (corresponding author), FDN REPROD MED INC,CTR HLTH POLICY STUDY,750 N ORLEANS ST,CHICAGO,IL 60610, USA.							ASCH DA, 1988, NEW ENGL J MED, V318, P771, DOI 10.1056/NEJM198803243181209; FRIEDMAN E, 1990, JAMA-J AM MED ASSOC, V264, P2977, DOI 10.1001/jama.264.23.2977; FRIEDMAN E, 1990, JAMA-J AM MED ASSOC, V264, P2851; GLEICHER N, 1984, JAMA-J AM MED ASSOC, V252, P3273; GLICKMAN RM, 1988, NEW ENGL J MED, V318, P780, DOI 10.1056/NEJM198803243181212; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; LEVINSKY NG, 1988, NEW ENGL J MED, V318, P778, DOI 10.1056/NEJM198803243181211; LINTON AL, 1990, NEW ENGL J MED, V323, P1463, DOI 10.1056/NEJM199011223232106; LOGERFO JP, 1990, JAMA-J AM MED ASSOC, V264, P1995, DOI 10.1001/jama.264.15.1995; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LUNDBERG GD, 1990, JAMA-J AM MED ASSOC, V263, P86, DOI 10.1001/jama.263.1.86; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; NEWCOMER LN, 1990, NEW ENGL J MED, V323, P1702, DOI 10.1056/NEJM199012133232411; WEINER JO, 1990, MED HLTH PERSPECT S, V44, P3; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WOOD L, 1986, PC PROD, V3, P20	17	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2388	2390		10.1001/jama.265.18.2388	http://dx.doi.org/10.1001/jama.265.18.2388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ955	1901923				2022-12-28	WOS:A1991FJ95500036
J	EALICK, SE; COOK, WJ; VIJAYKUMAR, S; CARSON, M; NAGABHUSHAN, TL; TROTTA, PP; BUGG, CE				EALICK, SE; COOK, WJ; VIJAYKUMAR, S; CARSON, M; NAGABHUSHAN, TL; TROTTA, PP; BUGG, CE			3-DIMENSIONAL STRUCTURE OF RECOMBINANT HUMAN INTERFERON-GAMMA	SCIENCE			English	Article							HUMAN IMMUNE INTERFERON; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; IFN-GAMMA; EXPRESSION; MACROPHAGE; CLONING; CDNA; GENE; LYMPHOKINE	The x-ray crystal structure of recombinant human interferon-gamma has been determined with the use of multiple-isomorphous-replacement techniques. Interferon-gamma, which is dimeric in solution, crystallizes with two dimers related by a noncrystallographic twofold axis in the asymmetric unit. The protein is primarily alpha-helical, with six helices in each subunit that comprise approximately 62 percent of the structure; there is no beta-sheet. The dimeric structure of human interferon-gamma is stabilized by the intertwining of helices across the subunit interface with multiple intersubunit interactions.	UNIV ALABAMA, CTR COMPREHENS CANC, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; SCHERING PLOUGH CORP, RES, BLOOMFIELD, NJ 07003 USA; UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering Plough Corporation; University of Alabama System; University of Alabama Birmingham	EALICK, SE (corresponding author), UNIV ALABAMA, CTR MACROMOLEC CRYSTALLOG, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA.				NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ANDERSON P, 1982, J BIOL CHEM, V257, P1301; ARAKAWA T, 1986, J BIOL CHEM, V261, P8534; ARAKAWA T, 1987, BIOCHEMISTRY-US, V26, P5428, DOI 10.1021/bi00391a032; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; DELUCAS LJ, 1989, SCIENCE, V246, P651, DOI 10.1126/science.2510297; DIJKEMA R, 1985, EMBO J, V4, P761, DOI 10.1002/j.1460-2075.1985.tb03694.x; DIJKMANS R, 1988, CURR OPIN IMMUNOL, V1, P269, DOI 10.1016/0952-7915(88)90013-1; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GRAY PW, 1987, MOL CLONING ANAL LYM, P151; HOGREFE HH, 1989, J BIOL CHEM, V264, P12179; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; ITOH K, 1980, J IMMUNOL, V124, P2589; JOHNSON HM, 1982, J IMMUNOL, V129, P2357; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JUNG V, 1990, CELL, V265, P1827; LANGFORD MP, 1983, BIOCHEM BIOPH RES CO, V117, P866, DOI 10.1016/0006-291X(83)91676-5; LE HV, 1985, BIOL INTERFERON SYST, P73; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; MAGAZINE HI, 1988, P NATL ACAD SCI USA, V85, P1237, DOI 10.1073/pnas.85.4.1237; MCINNES CJ, 1990, NUCLEIC ACIDS RES, V18, P4012, DOI 10.1093/nar/18.13.4012; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; PESTKA S, 1983, J BIOL CHEM, V258, P9706; PLATSOUCAS CD, 1984, NATURAL KILLER ACTIV, P161; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; ROGER D, 1990, NUCLEIC ACIDS RES, V18, P4259, DOI 10.1093/nar/18.14.4259; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SEELIG GF, 1988, BIOCHEMISTRY-US, V27, P1981, DOI 10.1021/bi00406a026; SEELIG GF, 1989, J INTERFERON RES S2, V9, pS184; SENDA T, 1990, P JPN ACAD B-PHYS, V66, P77, DOI 10.2183/pjab.66.77; TANAKA S, 1983, NUCLEIC ACIDS RES, V11, P1707, DOI 10.1093/nar/11.6.1707; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TROTTA PP, 1986, UCLA S MOL CELL BIOL, V50, P497; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P4804; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHEELOCK EF, 1965, SCIENCE, V149, P310, DOI 10.1126/science.149.3681.310; WINDSOR WT, UNPUB; WONG GHW, 1983, J IMMUNOL, V131, P788; YPHANTIS DA, 1987, BIOCHEMISTRY-US, V26, P5422, DOI 10.1021/bi00391a031	46	394	423	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					698	702		10.1126/science.1902591	http://dx.doi.org/10.1126/science.1902591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902591				2022-12-28	WOS:A1991FK18500046
J	THORPEBEESTON, JG; NICOLAIDES, KH; FELTON, CV; BUTLER, J; MCGREGOR, AM				THORPEBEESTON, JG; NICOLAIDES, KH; FELTON, CV; BUTLER, J; MCGREGOR, AM			MATURATION OF THE SECRETION OF THYROID-HORMONE AND THYROID-STIMULATING HORMONE IN THE FETUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL; PREGNANCY; NEWBORN	Background. Data on human fetal thyroid function have largely been derived from histologic studies or studies of cord-blood samples obtained at hysterotomy or delivery. These data may not represent true normal values. Cordocentesis (ultrasound-guided blood sampling from the umbilical cord) is a technique that allows investigation of physiologic processes in fetuses not under stress. Methods. We measured serum thyroid-stimulating hormone, total and free thyroxine (T4), total and free triiodothyronine (T3), and thyroxine-binding globulin in blood samples from 62 fetuses. The samples were obtained by cordocentesis (n = 58) or cardiocentesis (n = 4) at 12 to 37 weeks of gestation. Maternal serum samples were obtained immediately before fetal blood sampling. Results. Fetal serum thyroid-stimulating hormone, thyroxine-binding globulin, and total and free T4 and T3 concentrations increased significantly with the length of gestation (P < 0.001). The only significant association among these variables, independent of the length of gestation, was between thyroid-stimulating hormone and free T4 (P < 0.0001). Maternal serum concentrations of these variables did not change during gestation, and there was no significant relation between fetal and maternal values. Most fetal serum concentrations of thyroid-stimulating hormone were higher, whereas most serum total and free T3 concentrations were lower than the respective values for normal adults. The fetal serum total T4, free T4, and thyroxine-binding globulin values reached the level of the mean adult values at approximately 36 weeks of gestation. Conclusions. The increases in fetal serum concentrations of thyroid-stimulating hormone, thyroxine-binding globulin, and total and free T4 and T3 during gestation reflect increasing maturation of the pituitary, thyroid, and liver. The finding of increasing fetal serum concentrations of thyroid-stimulating hormone in the presence of increasing thyroid hormone concentrations suggests that the sensitivity of the fetal pituitary gland to negative feedback is limited or is counterbalanced by increasing stimulation by thyrotropin-releasing hormone from the hypothalamus.	KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; WYNN INST METAB RES,LONDON,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON WC2R 2LS,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; Imperial College London; University of London; King's College London; University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				BALLABIO M, 1989, CLIN ENDOCRINOL, V31, P565, DOI 10.1111/j.1365-2265.1989.tb01280.x; DEESCOBAR GM, 1987, HORM RES, V26, P12, DOI 10.1159/000180681; Fisher D A, 1976, Recent Prog Horm Res, V33, P59; FISHER DA, 1981, NEW ENGL J MED, V304, P702, DOI 10.1056/NEJM198103193041205; FISHER DA, 1983, CLIN PERINATOL, V10, P615, DOI 10.1016/S0095-5108(18)30954-0; FISHER DA, 1973, J CLIN ENDOCR METAB, V36, P397, DOI 10.1210/jcem-36-2-397; FISHER DA, 1970, PEDIATRICS, V46, P208; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GREENBERG AH, 1970, J CLIN INVEST, V49, P1790, DOI 10.1172/JCI106397; KLEIN AH, 1982, EARLY HUM DEV, V6, P321, DOI 10.1016/0378-3782(82)90070-6; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; MAN EB, 1969, AM J OBSTET GYNECOL, V103, P338, DOI 10.1016/0002-9378(69)90492-X; MONIZ CF, 1985, J CLIN PATHOL, V38, P468, DOI 10.1136/jcp.38.4.468; MORRISS FH, 1974, BIOL NEONATE, V25, P44; NICOLAIDES KH, 1986, LANCET, V1, P1065; ROSEN F, 1966, J CLIN ENDOCR METAB, V26, P1343, DOI 10.1210/jcem-26-12-1343; SHEPARD TH, 1967, J CLIN ENDOCR METAB, V27, P945, DOI 10.1210/jcem-27-7-945; WU SY, 1978, ENDOCRINOLOGY, V103, P235, DOI 10.1210/endo-103-1-235	18	273	280	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 21	1991	324	8					532	536		10.1056/NEJM199102213240805	http://dx.doi.org/10.1056/NEJM199102213240805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX918	1899469				2022-12-28	WOS:A1991EX91800005
J	SOMMER, A; TIELSCH, JM; KATZ, J; QUIGLEY, HA; GOTTSCH, JD; JAVITT, JC; MARTONE, JF; ROYALL, RM; WITT, KA; EZRINE, S				SOMMER, A; TIELSCH, JM; KATZ, J; QUIGLEY, HA; GOTTSCH, JD; JAVITT, JC; MARTONE, JF; ROYALL, RM; WITT, KA; EZRINE, S			RACIAL-DIFFERENCES IN THE CAUSE-SPECIFIC PREVALENCE OF BLINDNESS IN EAST BALTIMORE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLAUCOMA; IMPAIRMENT; RACE	Background. Bilateral blindness unrelated to simple refractive error is twice as prevalent among blacks as among whites, although the difference narrows among the elderly. The reasons for this race- and age-related pattern are uncertain. Methods and Results. A randomly selected, stratified, multistage cluster sample of 2395 blacks and 2913 whites 40 years of age and older in East Baltimore underwent detailed ophthalmic examinations by a single team. We identified 64 subjects who were blind in both eyes. The leading causes of blindness were unoperated senile cataract (accounting for blindness in 27 of the total of 128 eyes), primary open-angle glaucoma (17 eyes), and age-related macular degeneration (16 eyes). Together, these three disorders accounted for 47 percent of all blindness in this sample. Unoperated cataract accounted for 27 percent of all blindness among blacks, among whom it was four times more common than among whites; whites were almost 50 percent more likely than blacks to have undergone cataract extraction before the age of 80 (P < 0.002). Primary open-angle glaucoma accounted for 19 percent of all blindness among blacks; it was six times as frequent among blacks as among whites and began 10 years earlier, on average. By contrast, age-related macular degeneration resulting in blindness was limited to whites, among whom it was the leading cause of blindness (prevalence, 2.7 per 1000; 95 percent confidence interval, 1.2 to 5.4); it affected 3 percent of all white subjects 80 years of age or older. Conclusions. The pattern of blindness in urban Baltimore appears to be different among blacks and whites. Whites are far more likely to have age-related macular degeneration, and blacks to have primary open-angle glaucoma. The high rate of unoperated cataracts among younger blacks and among elderly subjects of both races suggests that health services are underused. Half of all blindness in this urban population is probably preventable or reversible.	JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DANA CTR PREVENT OPHTHALMOL,BALTIMORE,MD 21205; SURVEY RES ASSOCIATES INC,BALTIMORE,MD; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,GLAUCOMA SERV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,CORNEAL SERV,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	SOMMER, A (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,1041 HYG BLDG,615 N WOLFE ST,BALTIMORE,MD 21205, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609; Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X	NCRR NIH HHS [RR-04060] Funding Source: Medline; NEI NIH HHS [EY-03605, EY-05091] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY003605] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; Cairns L, 1984, Trans Am Ophthalmol Soc, V82, P166; EDERER F, 1986, AM J PUBLIC HEALTH, V76, P160, DOI 10.2105/AJPH.76.2.160; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2; GANLEY JP, 1983, VITAL HLTH STATI 228, V11; GOLDSTEIN H, 1980, RES SERIES AM F BLIN, V26; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; KAHN HA, 1973, DHEW NIH73427 NAT EY; KAHN HA, 1989, STATISTICAL METHODS; KIRCHNER C, 1979, VISUAL IMPAIRMENT BL, V73, P151; KOSOKO O, 1986, OPHTHALMOLOGY, V93, P882; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; PEARSON ES, 1958, BIOMETR TABLES ST, V1, P203; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; SOMMER A, 1977, AM J OPHTHALMOL, V83, P334, DOI 10.1016/0002-9394(77)90729-2; SOMMER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1766; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; Taylor J M, 1981, Ophthalmology, V88, p41A; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027; WILSON R, 1985, ANN OPHTHALMOL, V17, P653; 1985, ARCH OPHTHALMOL-CHIC, V103, P1796; 1983, NIH832469 DEP HLTH H, P12; 1980, VISION PROBLEMS S	28	551	579	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1412	1417		10.1056/NEJM199111143252004	http://dx.doi.org/10.1056/NEJM199111143252004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922252	Bronze			2022-12-28	WOS:A1991GP52400004
J	NAKAMURA, RM; KING, R; KIMBALL, EH; OYE, RK; HELGERSON, SD				NAKAMURA, RM; KING, R; KIMBALL, EH; OYE, RK; HELGERSON, SD			EXCESS INFANT-MORTALITY IN AN AMERICAN-INDIAN POPULATION, 1940 TO 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH	Objective. - To describe the infant mortality experience of an American Indian community and to demonstrate the utility of examining community-level mortality data. Design. - Descriptive, population-based historical review of infant death certificates. Setting. - The Warm Springs Indian Reservation, Oregon. Patients or Other Participants.-Infant tribal members of the Confederated Tribes of Warm Springs, 1940 to 1990. Interventions. - None. Main Outcome Measures. - Categorization of causes of infant deaths and calculations of mortality rates. Results. - The infant mortality rate, while lower in each decade since the 1940s, was still 2.6 times the national (all races) rate in the 1980s. Neonatal deaths did not account for many of the excess deaths. The postneonatal mortality rate has consistently been much greater than the national rate and was five times greater in the 1980s. Almost all of the excess infant mortality since 1980 has been due to the sudden infant death syndrome. Conclusions. - While there has been a dramatic decrease in infant mortality for this American Indian population, it remains higher than the national rate. Examining the causes of infant death has enabled this population to develop focused strategies to reduce infant mortality.	PORTLAND AREA INDIAN HLTH SERV RES & EVALUAT BRANCH,SEATTLE,WA; UNIV CALIF LOS ANGELES,DEPT MED,DIV GEN INTERNAL MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles								DOLLFUS C, 1990, PEDIATRICS, V86, P176; FROST F, 1980, AM J PUBLIC HEALTH, V70, P974, DOI 10.2105/AJPH.70.9.974; GARDNER MJ, 1989, STATISTICS CONFIDENC, P17; HOINGFELD LS, 1987, PEDIATRICS, V80, P575; KENEN R, 1987, SOC BIOL, V34, P26; Kleinman J C, 1990, MMWR CDC Surveill Summ, V39, P31; Lynberg M C, 1990, MMWR CDC Surveill Summ, V39, P1; PASSEL JS, 1986, SOC BIOL, V33, P163; RHOADES ER, 1987, PUBLIC HEALTH REP, V102, P361; STARZYK P, 1989, INFANT MORTALITY WAS, P4; WHITE RH, 1990, TRIBAL ASSETS REBIRT, P187; 1990, TRENDS INDIAN HLTH; 1989, MMWR CDC SURVEILL SU, V38, pR5; 1985, VITAL STATISTICS US; 1955, VITAL STATISTICS US; 1945, VITAL STATISTICS US; 1987, ALCOHOLISM SUBSTANCE, V5; 1989, 1ST DEP HUM SERV ANN; 1965, VITAL STATISTICS US; 1991, 2ND DEP HUM SERV ANN; 1975, VITAL STATISTICS US; 1982, AM INDIAN ALASKAN NA	22	22	23	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2244	2248		10.1001/jama.266.16.2244	http://dx.doi.org/10.1001/jama.266.16.2244			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920723				2022-12-28	WOS:A1991GK66100032
J	KARALIS, K; SANO, H; REDWINE, J; LISTWAK, S; WILDER, RL; CHROUSOS, GP				KARALIS, K; SANO, H; REDWINE, J; LISTWAK, S; WILDER, RL; CHROUSOS, GP			AUTOCRINE OR PARACRINE INFLAMMATORY ACTIONS OF CORTICOTROPIN-RELEASING HORMONE INVIVO	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; FACTOR-LIKE IMMUNOREACTIVITY; WALL-INDUCED ARTHRITIS; RAT LEYDIG-CELLS; FACTOR RECEPTORS; BETA-ENDORPHIN; LEWIS RATS; BIOCHEMICAL MANIFESTATIONS; INDUCED SECRETION; MOUSE SPLEEN	Corticotropin-releasing hormone (CRH) functions as a regulator of the hypothalamic-pituitary-adrenal axis and coordinator of the stress response. CRH receptors exist in peripheral sites of the immune system, and CRH promotes several immune functions in vitro. The effect of systemic immunoneutralization of CRH was tested in an experimental model of chemically induced aseptic inflammation in rats. Intraperitoneal administration of rabbit antiserum to CRH caused suppression of both inflammatory exudate volume and cell concentration by approximately 50 to 60 percent. CRH was detected in the inflamed area but not in the systemic circulation. Immunoreactive CRH is therefore produced in peripheral inflammatory sites where, in contrast to its systemic indirect immunosuppressive effects, it acts as an autocrine or paracrine inflammatory cytokine.	NIAMSD,ARTHRIT & RHEUMATISM BRANCH,BETHESDA,MD 20892; NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CALOGERO AE, 1989, PEPTIDES, V10, P189, DOI 10.1016/0196-9781(89)90096-X; CARR DJJ, 1990, J NEUROIMMUNOL, V28, P53, DOI 10.1016/0165-5728(90)90040-T; CASE JP, 1989, J CLIN INVEST, V84, P1731, DOI 10.1172/JCI114356; CHROUSOS GP, 1988, MECHANISMS PHYSICAL; CROFFORD LJ, UNPUB; CUMMINGS S, 1983, J NEUROSCI, V3, P1355; DAVE JR, 1985, ENDOCRINOLOGY, V116, P2152, DOI 10.1210/endo-116-6-2152; DESOUZA EB, 1985, J NEUROSCI, V5, P3189; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; FABBRI A, 1990, ENDOCRINOLOGY, V127, P1541, DOI 10.1210/endo-127-3-1541; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; FUKUHARA M, 1969, BIOCHEM PHARMACOL, V18, P475; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GRINO M, 1987, BIOCHEM BIOPH RES CO, V148, P1208, DOI 10.1016/S0006-291X(87)80261-9; GUILLEMIN R, 1955, ENDOCRINOLOGY, V57, P599, DOI 10.1210/endo-57-5-599; Guillemin R, 1985, NEURAL MODULATION IM; HARGREAVES KM, 1989, NEUROENDOCRINOLOGY, V49, P476, DOI 10.1159/000125155; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IRWIN M, 1988, AM J PHYSIOL, V255, pR744, DOI 10.1152/ajpregu.1988.255.5.R744; IRWIN M, 1990, ENDOCRINOLOGY, V126, P2837, DOI 10.1210/endo-126-6-2837; IRWIN M R, 1987, Brain Behavior and Immunity, V1, P81, DOI 10.1016/0889-1591(87)90009-2; KARALIS K, 1991, PEDIATR RES, V29, pA80; KAVELAARS A, 1989, J IMMUNOL, V142, P2338; KAVELAARS A, 1990, ENDOCRINOLOGY, V126, P759, DOI 10.1210/endo-126-2-759; KELLER SE, 1988, P NATL ACAD SCI USA, V85, P9297, DOI 10.1073/pnas.85.23.9297; KELLER SE, 1983, SCIENCE, V221, P1301, DOI 10.1126/science.6612346; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LEE NM, 1980, PP NATL ACAD SCI US, V77, P3525; MARGIORIS AN, 1988, J CLIN ENDOCR METAB, V66, P922, DOI 10.1210/jcem-66-5-922; MCGILLIS JP, 1989, J NEUROSCI RES, V23, P346, DOI 10.1002/jnr.490230316; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; OLSCHOWKA JA, 1982, PEPTIDES, V3, P995, DOI 10.1016/0196-9781(82)90071-7; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; PLOTSKY PM, 1984, ENDOCRINOLOGY, V114, P164, DOI 10.1210/endo-114-1-164; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; SAFFRAN M, 1955, ENDOCRINOLOGY, V57, P439, DOI 10.1210/endo-57-4-439; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; SINGH VK, 1989, J NEUROIMMUNOL, V23, P257, DOI 10.1016/0165-5728(89)90058-1; SINGH VK, 1988, IMMUNOL LETT, V18, P5, DOI 10.1016/0165-2478(88)90061-2; SINGH VK, 1990, NEUROSCI LETT, V120, P151, DOI 10.1016/0304-3940(90)90025-5; SMITH EM, 1986, NATURE, V321, P881, DOI 10.1038/321881a0; STEPHANOU A, 1990, BRAIN BEHAV IMMUN, V4, P67, DOI 10.1016/0889-1591(90)90007-D; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; TECOMA ES, 1985, LIFE SCI, V36, P1799, DOI 10.1016/0024-3205(85)90152-3; TSURUFUJI S, 1978, J PHARMACOBIO-DYNAM, V1, P8; UDELSMAN R, 1986, NATURE, V319, P147, DOI 10.1038/319147a0; ULISSE S, 1989, J BIOL CHEM, V264, P2156; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; WEBSTER EL, 1990, ENDOCRINOLOGY, V127, P440, DOI 10.1210/endo-127-1-440; WEBSTER EL, 1988, ENDOCRINOLOGY, V122, P609, DOI 10.1210/endo-122-2-609; WILDER RL, 1987, J CLIN INVEST, V79, P1160, DOI 10.1172/JCI112933	57	429	438	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					421	423		10.1126/science.1925600	http://dx.doi.org/10.1126/science.1925600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925600				2022-12-28	WOS:A1991GK72900046
J	HEALY, B				HEALY, B			MONONUCLEAR CELL SECRETORY PRODUCTS CONTRIBUTE TO BONE TURNOVER FOLLOWING OOPHORECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P5134	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-28	WOS:A1991GJ47400008
J	CHO, SG; ATTAYA, M; MONACO, JJ				CHO, SG; ATTAYA, M; MONACO, JJ			NEW CLASS-II-LIKE GENES IN THE MURINE MHC	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CHAIN GENE; NUCLEOTIDE-SEQUENCE; BETA-CHAIN; MOUSE; ALPHA; CDNA; HAPLOTYPE; SUBREGION; DISTINCT	MAJOR histocompatibility complex (MHC) class I molecules present endogenous antigens to CD8+ (cytotoxic) T cells. MHC class II molecules present primarily exogenously derived antigens to CD4+ T cells. Three new genes (Ma, Mb1 and Mb2) located between the Pb and Ob genes of the murine MHC have properties indicating that they are members of the MHC class II gene family, but they are the most divergent class II members so far identified and are almost as closely related in sequence to class I genes as they are to the known class II genes.			CHO, SG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298, USA.							BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BRAUNSTEIN NS, 1986, EMBO J, V5, P2469, DOI 10.1002/j.1460-2075.1986.tb04523.x; CHO SG, 1991, P NATL ACAD SCI USA, V88, P5197, DOI 10.1073/pnas.88.12.5197; Compagnone-Post P, 1988, GENOMICS, V2, P8, DOI 10.1016/0888-7543(88)90103-6; COSGROVE D, IN PRESS CELL; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; JONSSON AK, 1987, J BIOL CHEM, V262, P8767; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LAWRANCE SK, 1985, NUCLEIC ACIDS RES, V13, P7515, DOI 10.1093/nar/13.20.7515; LIU CP, 1988, J IMMUNOL, V140, P3631; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MALOY WL, 1981, J BIOL CHEM, V256, P2863; MATHIS DJ, 1983, CELL, V32, P745, DOI 10.1016/0092-8674(83)90060-0; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P5520, DOI 10.1073/pnas.80.18.5520; SCHREIER PH, 1986, NUCLEIC ACIDS RES, V14, P2381, DOI 10.1093/nar/14.5.2381; SHARMA S, 1987, IMMUNOL INVEST, V16, P425, DOI 10.3109/08820138709087096; TIEBER VL, 1986, J BIOL CHEM, V261, P2738; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	23	120	127	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					573	576		10.1038/353573a0	http://dx.doi.org/10.1038/353573a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922366				2022-12-28	WOS:A1991GJ64300073
J	HOLBROOK, SR; CHEONG, CJ; TINOCO, I; KIM, SH				HOLBROOK, SR; CHEONG, CJ; TINOCO, I; KIM, SH			CRYSTAL-STRUCTURE OF AN RNA DOUBLE HELIX INCORPORATING A TRACK OF NON-WATSON-CRICK BASE-PAIRS	NATURE			English	Article							DNA; MISMATCHES	THE crystal structure of the RNA dodecamer duplex (r-GGACUUCGGUCC)2 has been determined. The dodecamers stack end-to-end in the crystal, simulating infinite A-form helices with only a break in the phosphodiester chain. These infinite helices are held together in the crystal by hydrogen bonding between ribose hydroxyl groups and a variety of donors and acceptors. The four noncomplementary nucleotides in the middle of the sequence did not form an internal loop, but rather a highly regular double-helix incorporating the non-Watson-Crick base pairs, G . U and U . C. This is the first direct observation of a U . C (or T . C) base pair in a crystal structure. The U . C pairs each form only a single base-base hydrogen bond, but are stabilized by a water molecule which bridges between the ring nitrogens and by four waters in the major groove which link the bases and phosphates. The lack of distortion introduced in the double helix by the U . C mismatch may explain its low efficiency of repair in DNA. The G . U wobble pair is also stabilized by a minor-groove water which bridges between the unpaired guanine amino and the ribose hydroxyl of the uracil. This structure emphasizes the importance of specific hydrogen bonding between not only the nucleotide bases, but also the ribose hydroxyls, phosphate oxygens and tightly bound waters in stabilization of the intramolecular and intermolecular structures of double helical RNA.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	HOLBROOK, SR (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720, USA.		Cheong, Chaejoon/GWC-3135-2022					ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BHATTACHARYYA A, 1989, J MOL BIOL, V209, P583, DOI 10.1016/0022-2836(89)90596-2; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; COMARMOND MB, 1986, ACTA CRYSTALLOGR B, V42, P272, DOI 10.1107/S0108768186098233; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; EISENSTEIN M, 1990, NUCLEIC ACIDS RES, V18, P3185, DOI 10.1093/nar/18.11.3185; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; PATEL DJ, 1984, FED PROC, V43, P2663; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016	18	318	319	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					579	581		10.1038/353579a0	http://dx.doi.org/10.1038/353579a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922368				2022-12-28	WOS:A1991GJ64300075
J	NICOLA, NA; METCALF, D				NICOLA, NA; METCALF, D			SUBUNIT PROMISCUITY AMONG HEMATOPOIETIC GROWTH-FACTOR RECEPTORS	CELL			English	Review							COLONY-STIMULATING FACTOR; GM-CSF RECEPTOR; GRANULOCYTE; IDENTIFICATION; CLONING		ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital	NICOLA, NA (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.		Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GESNER T, 1989, BLOOD, V74, P2652; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; Metcalf D, 1988, MOL CONTROL BLOOD CE; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1991, INT CONGR SER, V971, P101; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1991, IN PRESS EMBO J; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7	17	172	175	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 4	1991	67	1					1	4		10.1016/0092-8674(91)90564-F	http://dx.doi.org/10.1016/0092-8674(91)90564-F			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913811				2022-12-28	WOS:A1991GJ32000001
J	APARICIO, OM; BILLINGTON, BL; GOTTSCHLING, DE				APARICIO, OM; BILLINGTON, BL; GOTTSCHLING, DE			MODIFIERS OF POSITION EFFECT ARE SHARED BETWEEN TELOMERIC AND SILENT MATING-TYPE LOCI IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							AUTONOMOUSLY REPLICATING SEQUENCES; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; DNA-SEQUENCES; SIR GENES; EFFECT VARIEGATION; YEAST; IDENTIFICATION; EXPRESSION; TRANSCRIPTION	Genes placed near telomeres in S. cerevisiae succumb to position-effect variegation. SIR2, SIR3, SIR4, NAT1, ARD1, and HHF2 (histone H4) were identified as modifiers of the position effect at telomeres, since transcriptional repression near telomeres was no longer observed when any of the modifier genes were mutated. These genes, in addition to SIR1, have previously been shown to repress transcription at the silent mating loci, HML and HMR. However, there were differences between transcriptional silencing at telomeres and the HM loci, as demonstrated by suppressor analysis and the lack of involvement of SIR1 in telomeric silencing. These findings provide insights into telomeric structure and function that are likely to apply to many eukaryotes. In addition, the distinctions between telomeres and the HM loci suggest a hierarchy of chromosomal silencing in S. cerevisiae.			APARICIO, OM (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Aparicio, Oscar/0000-0002-5591-0277	NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER; NCI NIH HHS [CA14599-16] Funding Source: Medline; NIGMS NIH HHS [GM43893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALBERTS B, 1989, MOL BIOL CELL, P1219; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUTTON LL, 1986, MOL CELL BIOL, V6, P1352, DOI 10.1128/MCB.6.4.1352; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FUSSELL CP, 1975, CHROMOSOMA, V50, P201, DOI 10.1007/BF00283240; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HABER JE, 1979, GENETICS, V93, P13; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; HOPPER AK, 1975, GENETICS, V80, P77; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; IVY JM, 1985, GENETICS, V111, P735; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLAR AJS, 1979, GENETICS, V93, P37; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LIMADEFARIA A, 1983, MOL EVOLUTION ORG CH, P701; LOISON G, 1980, CURR GENET, V2, P39, DOI 10.1007/BF00445692; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAWLINS DJ, 1990, J MICROSC-OXFORD, V157, P83, DOI 10.1111/j.1365-2818.1990.tb02949.x; RINE J, 1979, GENETICS, V93, P877; RINE J, 1987, GENETICS, V116, P9; ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015; ROSE M, 1984, MOL GEN GENET, V193, P557, DOI 10.1007/BF00382100; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; SPRADLING AC, 1990, GENETICS, V126, P779; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V18, P309, DOI 10.1016/0092-8674(79)90050-3; TRAVERSE KL, 1989, CHROMOSOMA, V97, P261, DOI 10.1007/BF00371965; VANHOLDE KE, 1989, SPRINGER SERIES MOL, P497; White M.J.D., 1973, ANIMAL CYTOLOGY EVOL, P1; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	71	621	648	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1279	1287		10.1016/0092-8674(91)90049-5	http://dx.doi.org/10.1016/0092-8674(91)90049-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913809				2022-12-28	WOS:A1991GG55200021
J	GREENBLATT, J				GREENBLATT, J			ROLES OF TFIID IN TRANSCRIPTIONAL INITIATION BY RNA POLYMERASE-II	CELL			English	Review							TATA-BINDING-PROTEIN; ACTIVATION DOMAIN; GENE; BOX; COMPLEXES; ELEMENTS; CLONING; USF		UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1L6, ONTARIO, CANADA	University of Toronto	GREENBLATT, J (corresponding author), UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA.							BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURATOWSKI S, 1991, IN PRESS P NATL ACAD; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FLORES O, 1991, IN PRESS P NATL ACAD; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEE WS, 1991, IN PRESS CELL; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCCRACKEN S, 1991, IN PRESS SCIENCE; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, IN PRESS MOL CELL BI; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	42	175	176	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1067	1070		10.1016/0092-8674(91)90027-V	http://dx.doi.org/10.1016/0092-8674(91)90027-V			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913802				2022-12-28	WOS:A1991GG55200001
J	PIOMELLI, D; PILON, C; GIROS, B; SOKOLOFF, P; MARTRES, MP; SCHWARTZ, JC				PIOMELLI, D; PILON, C; GIROS, B; SOKOLOFF, P; MARTRES, MP; SCHWARTZ, JC			DOPAMINE ACTIVATION OF THE ARACHIDONIC-ACID CASCADE AS A BASIS FOR D1/D2 RECEPTOR SYNERGISM	NATURE			English	Article							SIGNAL TRANSDUCTION; ADENYLATE-CYCLASE; D1; METABOLITES; EXPRESSION; NEURONS; INHIBITION	UNDERSTANDING the actions of the neurotransmitter dopamine in the brain is important in view of its roles in neuropsychiatric illnesses 1. Dopamine D1 receptors, which stimulate both adenylyl cyclase 2 and phospholipase C3, and D2 receptors, which inhibit them 4,5, can nevertheless act synergistically to produce many electrophysiological and behavioural responses 6. Because this functional synergism can occur at the level of single neurons, another, as yet unidentified, signalling pathway activated by dopamine has been hypothesized 7. We report here that in Chinese hamster ovary (CHO) cells transfected with the D2 receptor complementary DNA, D2 agonists potently enhance arachidonic acid release, provided that such release has been initiated by stimulating constitutive purinergic receptors or by increasing intracellular Ca2+. In CHO cells expressing D1 receptors, D1 agonists exert no such effect. When D1 and D2 receptors are coexpressed, however, activation of both subtypes results in a marked synergistic potentiation of arachidonic acid release. The numerous actions of arachidonic acid and its metabolites in neuronal signal transduction 8 suggest that facilitation of its release may be implicated in dopaminergic responses, such as feedback inhibition mediated by D2 autoreceptors, and may constitute a molecular basis for D1/D2 receptor synergism.			PIOMELLI, D (corresponding author), CTR PAUL BROCA,INSERM,U109,UNITE NEUROBIOL & PHARMACOL,2TER RUE ALESIA,F-75014 PARIS,FRANCE.		GIROS, Bruno/ABD-5790-2021	GIROS, Bruno/0000-0001-5876-9822				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BLEY KR, 1990, NEURON, V2, P379; BURCH RM, 1989, MOL NEUROBIOL, V3, P156; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DECAMILLI P, 1979, NATURE, V278, P252, DOI 10.1038/278252a0; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; FREEMAN EJ, 1991, J NEUROCHEM, V56, P1079, DOI 10.1111/j.1471-4159.1991.tb02032.x; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KEBABIAN JW, 1972, P NATL ACAD SCI USA, V69, P2145, DOI 10.1073/pnas.69.8.2145; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SIDHU A, 1986, EUR J PHARMACOL, V128, P213, DOI 10.1016/0014-2999(86)90768-5; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; VALLAR L, 1989, TRENDS PHARMACOL SCI, V10, P74, DOI 10.1016/0165-6147(89)90082-5	28	264	266	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					164	167		10.1038/353164a0	http://dx.doi.org/10.1038/353164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1909771	Green Published			2022-12-28	WOS:A1991GE73100053
J	HUNZIKER, W; HARTER, C; MATTER, K; MELLMAN, I				HUNZIKER, W; HARTER, C; MATTER, K; MELLMAN, I			BASOLATERAL SORTING IN MDCK CELLS REQUIRES A DISTINCT CYTOPLASMIC DOMAIN DETERMINANT	CELL			English	Article							CANINE KIDNEY-CELLS; PLASMA-MEMBRANE PROTEINS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; COATED PIT LOCALIZATION; EPITHELIAL-CELLS; INTRACELLULAR-TRANSPORT; LYSOSOMAL MEMBRANE; VIRAL GLYCOPROTEINS; BIOGENESIS	In MDCK cells, Golgi to basolateral transport of several membrane proteins has been found to involve a cytoplasmic domain determinant. In some cases (Fc receptor, lysosomal glycoprotein Igp120), the determinant appears similar to that required for endocytosis via clathrin-coated pits; for Igp120, elimination of a single cytoplasmic domain tyrosine both blocks internalization and results in apical transport. In other cases (LDL receptor), the determinant does not involve the cytoplasmic domain tyrosine required for endocytosis. Thus, contrary to current models, basolateral transport in MCDK cells occurs not by default but depends on one or more cytoplasmic domain determinants, the precise nature of which is unknown. For some proteins, it is closely related to coated pit determinants. The fact that many membrane proteins can reach the apical surface in the absence of this determinant suggests that signals for apical transport are widely distributed.			HUNZIKER, W (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Mellman, Ira/ABG-5896-2020; Matter, Karl/C-4880-2008; Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Matter, Karl/0000-0001-8026-7220; Hunziker, Walter/0000-0002-5265-4933				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LI CX, 1991, J BIOL CHEM, V266, P9263; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROMAN LM, 1986, J CELL BIOL, V103, P2607, DOI 10.1083/jcb.103.6.2607; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	53	277	279	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					907	920		10.1016/0092-8674(91)90437-4	http://dx.doi.org/10.1016/0092-8674(91)90437-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1909606				2022-12-28	WOS:A1991GE46000010
J	SMITH, I; COOK, B; BEASLEY, M				SMITH, I; COOK, B; BEASLEY, M			REVIEW OF NEONATAL SCREENING-PROGRAM FOR PHENYLKETONURIA	BRITISH MEDICAL JOURNAL			English	Article							DEFICIENCY; QUALITY	Objective-To review the neonatal screening programme during 1984-8. Design-Analysis of data from screening laboratories and paediatricians. Subjects-All live births in United Kingdom. Main outcome measures-Structure of programme; number of infants tested and number with phenylketonuria; number of infants missed; ages at testing and treatment. Results-The proportion of infants tested approached 100%. The incidence of phenylketonuria was 11.7/100 000 births (445 subjects): 273 had classic phenylketonuria and three had defects of cofactor metabolism. One child with phenylketonuria was known to have been missed compared with three in 1979-83 and six in 1974-8. Seven subjects had been missed over the 15 years due to negative test results. All seven had been tested with the bacterial inhibition assay, although only 53% of infants had been so tested; the difference between the expected and observed proportion was significant (Fisher's exact test, p = 0.017). Eleven infants with classic phenylketonuria were not tested by 14 days of age and 23 (8%) did not start treatment until after 20 days, an improvement compared with 36 (15%) in 1979-83. There were, however, wide regional variations (0% to 27% treated after 20 days). Conclusion-The screening programme achieves high coverage and effectiveness, although some children are still missed. A national practice for screening may help reduce regional variations.			SMITH, I (corresponding author), INST CHILD HLTH,DEPT CHILD HLTH,MRC,DEPT HLTH PHENYLKETONURIA REGISTER,LONDON WC1N 1EH,ENGLAND.							GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; GREEVES LG, 1990, EUR J PEDIATR, V149, P713, DOI 10.1007/BF01959529; HUNTER R, 1988, HEAL HEAL SCREENING; LEEMING RJ, 1984, ARCH DIS CHILD, V59, P58, DOI 10.1136/adc.59.1.58; MCCABE ERB, 1983, PEDIATRICS, V72, P390; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; SMITH I, 1986, ARCH DIS CHILD, V61, P130, DOI 10.1136/adc.61.2.130; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1990, INBORN METABOLIC DIS, P183; SMITH I, 1985, BUTTERWORTHS INT MED, V5, P166; WESTWOOD AS, 1982, EUR J PEDIATR, V71, P859; WHITEHEAD TP, 1981, J CLIN PATHOL, V34, P947, DOI 10.1136/jcp.34.9.947; 1981, SCREENING EARLY DETE; 1981, BMJ, V282, P1680	14	57	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					333	335		10.1136/bmj.303.6798.333	http://dx.doi.org/10.1136/bmj.303.6798.333			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912773	Bronze, Green Published			2022-12-28	WOS:A1991GA60600018
J	EWBANK, JJ; CREIGHTON, TE				EWBANK, JJ; CREIGHTON, TE			THE MOLTEN GLOBULE PROTEIN CONFORMATION PROBED BY DISULFIDE BONDS	NATURE			English	Article							ALPHA-LACTALBUMIN; STATE	THE molten globule is a compact protein conformation that has a secondary structure content like that of the native protein, but poorly defined tertiary structure. It is a stable state for a few proteins under particular conditions 1 and could be a ubiquitous kinetic intermediate in protein folding 2. The extent to which native interactions, above the level of the secondary structure, are preserved in this conformation is not so far known. Here we report that alpha-lactalbumin can adopt a molten globule conformation when one of its four disulphide bonds is reduced. In this state, the three other disulphide bonds rearrange spontaneously, at the same rate as when the protein is fully unfolded, to a number of different disulphide bond isomers that tend to maintain the molten globule conformation. That the molten globule state is compatible with a variety of disulphide bond pairings suggests that it is unlikely to be stabilized by many specific tertiary interactions.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; HOLLECKER M, 1989, PROTEIN STRUCTURE PR, P145; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IYER KS, 1973, J BIOL CHEM, V248, P707; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; PFEIL W, 1986, FEBS LETT, V198, P287, DOI 10.1016/0014-5793(86)80422-7; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; SHECHTER Y, 1973, BIOCHEMISTRY-US, V12, P3407, DOI 10.1021/bi00742a007; THOMPSON MP, 1988, BIOCHEM BIOPH RES CO, V157, P944, DOI 10.1016/S0006-291X(88)80965-3	18	139	140	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					518	520		10.1038/350518a0	http://dx.doi.org/10.1038/350518a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1901628				2022-12-28	WOS:A1991FG14300057
J	ROCHA, B; VONBOEHMER, H				ROCHA, B; VONBOEHMER, H			PERIPHERAL SELECTION OF THE T-CELL REPERTOIRE	SCIENCE			English	Article							TRANSGENIC MICE; MONOCLONAL-ANTIBODY; BETA-GENES; TOLERANCE; RECEPTOR; THYMUS; EXPRESSION; THYMOCYTES; ANTIGENS; DELETION	T lymphocytes undergo selection events not only in the thymus, but also after they leave the thymus and reside in the periphery. Peripheral selection was found to be dependent on T cell receptor (TCR)-ligand interactions but to differ from thymic selection with regard to specificity and mechanism. Unlike thymic selection, peripheral selection required binding of antigen to the TCR, and it induced expansion of T cell clones. Tolerance to self antigens that are restricted to the periphery occurred through the elimination of self-reactive T cells and by the clonal anergy, which was associated with down-regulation of the alpha-beta-TCR and CD8.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		ROCHA, B (corresponding author), HOP NECKER ENFANTS MALAD,CNRS,UA 122,INSERM,U25,F-75730 PARIS 15,FRANCE.							BEHLKE MA, 1987, J EXP MED, V165, P257, DOI 10.1084/jem.165.1.257; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FREITAS AA, 1975, EUR J IMMUNOL, V5, P831, DOI 10.1002/eji.1830051207; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P454; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1982, EUR J IMMUNOL, V12, P463, DOI 10.1002/eji.1830120603; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MILLER JFAP, 1979, THYMUS, V1, P3; MILLER RA, 1984, J IMMUNOL, V133, P2925; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; PENIT C, 1988, J IMMUNOL, V140, P3315; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROCHA B, 1990, EUR J IMMUNOL, V20, P1919; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4	27	645	655	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1225	1228		10.1126/science.1900951	http://dx.doi.org/10.1126/science.1900951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900951				2022-12-28	WOS:A1991FA69100039
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABELING FOR SODIUM-NITROPRUSSIDE EMPHASIZES RISK OF CYANIDE TOXICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-28	WOS:A1991EX58700009
J	HEALY, B				HEALY, B			INVASIVE MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION INCREASES RISK OF HEMORRHAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P256	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-28	WOS:A1991GM79000006
J	MOREL, P; GOETZ, FC; MOUDRYMUNNS, K; FREIER, E; SUTHERLAND, DER				MOREL, P; GOETZ, FC; MOUDRYMUNNS, K; FREIER, E; SUTHERLAND, DER			LONG-TERM GLUCOSE CONTROL IN PATIENTS WITH PANCREATIC TRANSPLANTS	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; RETINOPATHY; RECIPIENTS; PREVALENCE; DIAGNOSIS; NEUROPATHY; ALLOGRAFTS; GLYCEMIA; RISK	Objective: To evaluate the long-term effect on blood glucose levels of successful transplantation of part or all of an intact human pancreas in patients with insulin-dependent diabetes mellitus (IDDM). Design: Cohort study. Setting: Referral medical center. Patients: Thirty-seven patients with adequate data, representative of a group of 62 patients with functioning grafts (that is, insulin-independent) at 2 years after transplantation. The 62 patients came from a total of 178 patients in the University of Minnesota series as of July 1987, for a 2-year success rate of 35% (95% CI, 27.8% to 41.8%). These patients were compared to two diabetic control groups (18 patients with IDDM under standard insulin treatment in a university diabetes clinic and 11 patients with IDDM whose pancreas grafts had failed) and to two nondiabetic groups (14 nondiabetic patients who received immunosuppressive drugs after kidney transplantation and 196 healthy control subjects). Measurements: Glycosylated hemoglobin was measured by the high-pressure liquid chromatography method, as total A1 (Hb A1) and the A1C subfraction (Hb A1C); results were expressed as a percentage of total hemoglobin. Main Results: Before pancreas transplantation, the 37 patients in the study group had a mean Hb A1 of 10.8%, consistent with moderate to marked hyperglycemia and not statistically different from the levels in the diabetic control groups. All 37 patients had values above the therapeutic target range of 5.4% to 7.4%. However, at 1 and 2 years after transplantation, the mean Hb A1 value had fallen sharply to 6.7% and 6.5%, respectively, well within target range (CI of the difference, 3.4% to 4.8%; P < 0.001). These levels did not differ from the mean Hb A1 in the nondiabetic kidney transplant recipients but were slightly above the 6.2% value for the 196 healthy controls (CI of the difference at 1 year, 0.2% to 0.8%). Serial values were available on 6 subjects for 5 years; these values were all well within target range. As expected, Hb A1C values were parallel to those of Hb A1. Conclusions: Pancreas transplantation, in our successful cases, lowered glycosylated hemoglobin to normal or near-normal levels that were sustained for as long as 5 years. These results compare favorably with those in our patients on standard treatment, and also with those in similar patients on intensive control reported by others. Further effort to improve transplant methods appears to be warranted.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NCRR NIH HHS [RR/400] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BILOUS RW, 1987, DIABETES S1, V36, pA43; BOUDREAUX JP, 1987, TRANSPLANTATION, V44, P376, DOI 10.1097/00007890-198709000-00010; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; CORRY RJ, 1986, SURG GYNECOL OBSTET, V162, P547; COSIMI AB, 1988, ARCH SURG-CHICAGO, V123, P621; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; HANSSEN KF, 1986, DIABETOLOGIA, V29, P677, DOI 10.1007/BF00870275; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; KLEIN BEK, 1987, DIABETES CARE, V10, P273, DOI 10.2337/diacare.10.3.273; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; LIPSETT L, 1990, DIABETES S1, V39, pA126; LITTLE RR, 1986, CLIN CHEM, V32, P1146; MOREL P, 1990, TRANSPLANTATION, V49, P294, DOI 10.1097/00007890-199002000-00014; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; OSWALD GA, 1984, LANCET, V1, P1264; PETERSON CM, 1986, DIABETES ANN, P137; POZZA G, 1983, DIABETOLOGIA, V24, P244; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; SELAM JL, 1989, INT HDB PANCREAS TRA, P479; SINGER DE, 1989, ANN INTERN MED, V110, P125, DOI 10.7326/0003-4819-110-2-125; SMITH JL, 1989, TRANSPLANTATION, V47, P304, DOI 10.1097/00007890-198902000-00023; SUTHERLAND DER, 1989, ANN SURG, V210, P274, DOI 10.1097/00000658-198909000-00003; SUTHERLAND DER, 1981, ANN INTERN MED, V95, P537, DOI 10.7326/0003-4819-95-5-537; SUTHERLAND DER, 1988, SURGERY, V104, P453; TYDEN G, 1989, DIABETES, V38, P94, DOI 10.2337/diab.38.1.S94; VANDERVLIET JA, 1988, TRANSPLANTATION, V45, P368, DOI 10.1097/00007890-198802000-00024; WHITE LJ, 1984, ANN INTERN MED, V101, P710, DOI 10.7326/0003-4819-101-5-710; WISEMAN M, 1984, DIABETOLOGIA, V26, P401; YUDKIN JS, 1988, DIABETOLOGIA, V31, P201, DOI 10.1007/BF00290585	31	67	68	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					694	699		10.7326/0003-4819-115-9-694	http://dx.doi.org/10.7326/0003-4819-115-9-694			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929037				2022-12-28	WOS:A1991GL69700005
J	WONG, ND; WILSON, PWF; KANNEL, WB				WONG, ND; WILSON, PWF; KANNEL, WB			SERUM-CHOLESTEROL AS A PROGNOSTIC FACTOR AFTER MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FOLLOW-UP; LIPOPROTEIN CHOLESTEROL; COLESTIPOL-NIACIN; DRUG PROJECT; RISK-FACTORS; MORTALITY; ATHEROSCLEROSIS; PREVENTION	Objective: To determine the relation between serum cholesterol levels and the long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality in persons who recover from myocardial infarction. Design: Prospective, longitudinal study. Setting: A geographically defined population-based cohort of adults participating in the Framingham Heart Study. Patients: Men (n = 260) and women (n = 114), 33 to 88 years of age (mean age, 62 years), who had a history of myocardial infarction. Measurements: A complete physical examination, including electrocardiographic evaluation, blood pressure measurement, height and weight measurements, determination of smoking habits, and casual determinations of blood glucose and serum cholesterol, was done approximately 1 year after recovery from initial myocardial infarction. Patients were followed after infarction for the occurrence of reinfarction or death (mean follow-up, 10.5 years; range, 0.8 to 31.6 years). Main Results: The mean cholesterol level after infarction was 5.21 mmol/L (242.8 mg/dL); 20% of patients had levels below 5.17 mmol/L (200 mg/dL), and 22% had levels of 7.11 mmol/L (275 mg/dL) or more. Compared with patients who had cholesterol levels below 5.17 mmol/L, patients with levels of 7.11 mmol/L or more were at increased risk for reinfarction (relative risk, 3.8; 95% CI, 1.6 to 8.7), death from coronary heart disease (relative risk, 2.6; CI, 1.4 to 4.8), and all-cause mortality (relative risk, 1.9; CI, 1.2 to 2.9) based on multivariate Cox regression analyses adjusted for other coronary risk factors. Intermediate cholesterol levels (5.17 mmol/L to 7.11 mmol/L) were generally not associated with increased risk. The association between elevated serum cholesterol and increased risk was strongest in men; however, elevated cholesterol levels were found to be most strongly related to death from coronary disease and to all-cause mortality in persons who were 65 years of age or more. Conclusions: Patients who have recovered from a myocardial infarction and who have high cholesterol levels are at an increased long-term risk for reinfarction, death from coronary heart disease, and all-cause mortality. Our results confirm the prognostic value of cholesterol levels measured after myocardial infarction and support the role of lipid management in this population.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA	Framingham Heart Study	WONG, ND (corresponding author), UNIV CALIF IRVINE, COLL MED, PREVENT CARDIOL PROGRAM, C240 MED SCI 1, IRVINE, CA 92717 USA.		Wilson, Peter W.F./J-2455-2016					ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COX DR, 1972, J R STAT SOC B, V34, P187; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DIXON WJ, 1985, BMDP STATISTICAL SOF; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FROST PH, 1987, AM HEART J, V113, P1356, DOI 10.1016/0002-8703(87)90648-X; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON T, 1973, DHEW NIH74478 PUBL; HELIOVAARA M, 1982, AM J CARDIOL, V55, P325; JENKINS CD, 1976, CIRCULATION, V53, P342, DOI 10.1161/01.CIR.53.2.342; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KHAW KT, 1986, J CARDIOPULM REHABIL, V6, P474; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHLANT RC, 1982, CIRCULATION, V66, P401, DOI 10.1161/01.CIR.66.2.401; ULVENSTAM G, 1984, PREV MED, V13, P355, DOI 10.1016/0091-7435(84)90027-6; WEDEL H, 1989, 29TH ANN M AHA COUNC; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360	28	148	155	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					687	693		10.7326/0003-4819-115-9-687	http://dx.doi.org/10.7326/0003-4819-115-9-687			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929036				2022-12-28	WOS:A1991GL69700004
J	MORRISSEY, JF; REICHELDERFER, M				MORRISSEY, JF; REICHELDERFER, M			MEDICAL PROGRESS - GASTROINTESTINAL ENDOSCOPY .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BILE-DUCT STONES; RETROGRADE CHOLANGIOPANCREATOGRAPHY ERCP; MALIGNANT OBSTRUCTIVE-JAUNDICE; CONTRAST BARIUM ENEMA; TERT-BUTYL-ETHER; COLORECTAL-CANCER; ULCERATIVE-COLITIS; FLEXIBLE SIGMOIDOSCOPY; RANDOMIZED TRIAL; COLONOSCOPIC DECOMPRESSION				MORRISSEY, JF (corresponding author), UNIV WISCONSIN, SCH MED, DEPT MED, 600 HIGHLAND AVE, MADISON, WI 53792 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ANDERSEN JR, 1989, GUT, V30, P1132, DOI 10.1136/gut.30.8.1132; BENAGE D, 1990, GASTROINTEST ENDOSC, V36, P553, DOI 10.1016/S0016-5107(90)71162-5; BILBAO MK, 1976, GASTROENTEROLOGY, V70, P314; BLUE MG, 1991, GASTROENTEROLOGY, V100, P564, DOI 10.1016/0016-5085(91)90232-A; BORNMAN PC, 1980, BRIT J SURG, V67, P425, DOI 10.1002/bjs.1800670614; BRUNETAUD JM, 1987, GASTROENTEROLOGY, V92, P663, DOI 10.1016/0016-5085(87)90015-1; CAIRNS SR, 1989, GUT, V30, P535, DOI 10.1136/gut.30.4.535; CHESPAK LW, 1989, RADIOLOGY, V170, P995, DOI 10.1148/radiology.170.3.2916069; CHODASH HB, 1990, GASTROINTEST ENDOSC, V36, P213; COENE PPLO, 1990, GUT, V31, P913, DOI 10.1136/gut.31.8.913; COTTON PB, 1990, GASTROENTEROLOGY, V99, P1128, DOI 10.1016/0016-5085(90)90634-D; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P94, DOI 10.1016/S0016-5107(91)70637-8; COTTON PB, 1990, ANN GASTROINTESTINAL, P91; CRANLEY JP, 1986, GASTROENTEROLOGY, V91, P419, DOI 10.1016/0016-5085(86)90577-9; CREMER M, 1990, GASTROINTEST ENDOSC, V36, P451, DOI 10.1016/S0016-5107(90)71113-3; DANCYGIER H, 1989, GASTROINTEST ENDOSC, V35, P220, DOI 10.1016/S0016-5107(89)72762-0; DAVIDSON BR, 1988, GUT, V29, P114, DOI 10.1136/gut.29.1.114; DEAL SE, 1991, GASTROINTEST ENDOSC, V37, P262; DEVIERE J, 1989, GASTROENTEROLOGY, V96, P1210, DOI 10.1016/0016-5085(89)91644-2; DOWSETT JF, 1989, GASTROENTEROLOGY, V96, P1180, DOI 10.1016/0016-5085(89)91639-9; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; ELLIS CN, 1991, GASTROINTEST ENDOSC, V37, P262; ENGLAND WL, 1989, MED DECIS MAKING, V9, P3, DOI 10.1177/0272989X8900900103; FOERSTER EC, 1990, GASTROINTEST ENDOSC, V36, P444; FOUTCH PG, 1990, GASTROINTEST ENDOSC, V36, P212; FULLARTON GM, 1990, GUT, V31, P231, DOI 10.1136/gut.31.2.231; GASKIN KJ, 1988, NEW ENGL J MED, V318, P340, DOI 10.1056/NEJM198802113180602; GEENEN JE, 1989, NEW ENGL J MED, V320, P82, DOI 10.1056/NEJM198901123200203; GEENEN JE, 1991, GASTROINTEST ENDOSC, V37, P377, DOI 10.1016/S0016-5107(91)70739-6; GOFF JS, 1988, ARCH INTERN MED, V148, P2673, DOI 10.1001/archinte.148.12.2673; GOSCHE JR, 1989, AM SURGEON, V55, P111; GRIMM H, 1989, ENDOSCOPY, V21, P70, DOI 10.1055/s-2007-1012903; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; GUNDRY SR, 1984, ARCH SURG-CHICAGO, V119, P703; GYDE S, 1990, GUT, V31, P1089, DOI 10.1136/gut.31.10.1089; HARIG JM, 1988, GASTROINTEST ENDOSC, V34, P23, DOI 10.1016/S0016-5107(88)71224-9; HARMS BA, 1987, SURGERY, V101, P234; HARMS BA, 1990, AM J SURG, V159, P34, DOI 10.1016/S0002-9610(05)80604-X; HATFIELD ARW, 1990, GUT, V31, P1339, DOI 10.1136/gut.31.12.1339; HATFIELD ARW, 1982, LANCET, V2, P896; HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125, DOI 10.1016/S0016-5107(91)70668-8; HUIBREGTSE K, 1988, ENDOSCOPIC BILIARY P, P1; IHSE I, 1990, BRIT J SURG, V77, P121, DOI 10.1002/bjs.1800770202; INGOLDBY CJH, 1989, GUT, V30, P1129, DOI 10.1136/gut.30.8.1129; IRVINE EJ, 1988, GUT, V29, P1188, DOI 10.1136/gut.29.9.1188; JENSEN DM, 1988, GASTROENTEROLOGY, V95, P1569, DOI 10.1016/S0016-5085(88)80079-9; JOHNSON GK, 1991, GASTROINTEST ENDOSC, V37, P38, DOI 10.1016/S1052-5157(18)30684-6; KAUFMAN AR, 1989, GASTROINTEST ENDOSC, V35, P214, DOI 10.1016/S0016-5107(89)72761-9; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KNYRIM K, 1989, GASTROENTEROLOGY, V96, P776; KOZAREK RA, 1988, AM J GASTROENTEROL, V83, P55; KOZAREK RA, 1991, GASTROENTEROLOGY, V100, P1362; LANSPA SJ, 1990, GASTROENTEROLOGY, V98, P1117, DOI 10.1016/0016-5085(90)90323-S; LASHNER BA, 1989, DIGEST DIS SCI, V34, P1536, DOI 10.1007/BF01537106; LASSON A, 1987, SCAND J GASTROENTERO, V22, P897, DOI 10.3109/00365528708991932; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LEUNG JWC, 1989, LANCET, V1, P1307; LEUNG JWC, 1988, GASTROINTEST ENDOSC, V34, P318, DOI 10.1016/S0016-5107(88)71364-4; LIEBERMAN D, 1990, Gastroenterology, V98, pA294; LINDSELL DRM, 1990, LANCET, P142; LOFBERG R, 1990, GASTROENTEROLOGY, V99, P1021; LOIZOU LA, 1990, GUT, V31, P812, DOI 10.1136/gut.31.7.812; LOVE RR, 1984, ARCH INTERN MED, V144, P2209, DOI 10.1001/archinte.144.11.2209; Marcon NE, 1990, CAN J GASTROENTEROL, V4, P542; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; MORSON BC, 1984, GUT, V25, P437, DOI 10.1136/gut.25.5.437; MUELLER PR, 1990, NEW ENGL J MED, V322, P1364, DOI 10.1056/NEJM199005103221906; MULLER S, 1989, GUT, V30, P1385, DOI 10.1136/gut.30.10.1385; NEOPTOLEMOS JP, 1987, BRIT MED J, V294, P470, DOI 10.1136/bmj.294.6570.470; NEOPTOLEMOS JP, 1990, BRIT J SURG, V77, P32, DOI 10.1002/bjs.1800770111; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEUHAUS H, 1991, GASTROINTEST ENDOSC, V37, P31, DOI 10.1016/S0016-5107(91)70617-2; NICKL NJ, 1990, AM J GASTROENTEROL, V85, P675; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1973, DOI 10.1016/0016-5085(85)90029-0; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; OCONNOR M, 1986, AM J SURG, V151, P18, DOI 10.1016/0002-9610(86)90006-1; PROVENZALE D, 1990, ANN INTERN MED, V113, P760, DOI 10.7326/0003-4819-113-10-760; PROVENZALE D, 1988, J CLIN GASTROENTEROL, V10, P46, DOI 10.1097/00004836-198802000-00011; RALLS PW, 1980, RADIOLOGY, V134, P347, DOI 10.1148/radiology.134.2.7352212; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; REX DK, 1990, GASTROENTEROLOGY, V98, P855, DOI 10.1016/0016-5085(90)90007-N; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; ROSCH T, 1990, GASTROINTEST ENDOSC, V36, pS33, DOI 10.1016/S0016-5107(90)71013-9; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SAUERBRUCH T, 1989, GASTROENTEROLOGY, V96, P146, DOI 10.1016/0016-5085(89)90775-0; SAUERBRUCH T, 1986, GASTROENTEROLOGY, V90, P1998, DOI 10.1016/0016-5085(86)90273-8; SCHAPIRO M, 1987, GASTROINTEST ENDOSC, V33, P63, DOI 10.1016/S0016-5107(87)71510-7; SCHMITZMOORMANN P, 1985, GUT, V26, P406, DOI 10.1136/gut.26.4.406; SHEPHERD HA, 1988, BRIT J SURG, V75, P1166, DOI 10.1002/bjs.1800751207; SHERMAN S, 1990, ANN GASTROINTESTINAL, P69; SILVERSTEIN FE, 1989, GASTROENTEROLOGY, V96, P1058, DOI 10.1016/0016-5085(89)91623-5; SIVAK MV, 1989, AM J SURG, V158, P228, DOI 10.1016/0002-9610(89)90256-0; SMART CR, 1990, MAYO CLIN PROC, V65, P892, DOI 10.1016/S0025-6196(12)62581-6; SMITH RC, 1985, SURGERY, V97, P641; SPEER AG, 1987, LANCET, V2, P57, DOI 10.1016/S0140-6736(87)92733-4; SPEER AG, 1988, ANN INTERN MED, V108, P546, DOI 10.7326/0003-4819-108-4-546; STARLING JR, 1979, ANN SURG, V190, P36, DOI 10.1097/00000658-197907000-00008; STRODEL WE, 1989, SURG CLIN N AM, V69, P1327; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TATE JJT, 1988, GUT, V29, P1322, DOI 10.1136/gut.29.10.1322; THISTLE JL, 1989, NEW ENGL J MED, V320, P633, DOI 10.1056/NEJM198903093201004; THISTLE JL, 1990, VIEWPOINTS DIG DIS, V22, P1; THOMAS WM, 1990, GUT, V31, P1294, DOI 10.1136/gut.31.11.1294; TIO TL, 1990, GASTROINTEST ENDOSC, V36, P342, DOI 10.1016/S0016-5107(90)71061-9; VAIRA D, 1989, LANCET, V2, P431; VENU RP, 1983, JAMA-J AM MED ASSOC, V249, P758, DOI 10.1001/jama.249.6.758; VENU RP, 1989, DIGEST DIS SCI, V34, P56, DOI 10.1007/BF01536154; VENU RP, 1990, GASTROENTEROLOGY, V99, P1475, DOI 10.1016/0016-5085(90)91178-9; WAYE JD, 1980, GASTROINTEST ENDOSC, V26, P80; WILLIAMS CB, 1989, ANN GASTROINTESTINAL, P143; WINAWER S J, 1991, Gastroenterology, V100, pA410; WINSTANLEY PA, 1985, GUT, V26, P730, DOI 10.1136/gut.26.7.730; YASUDA K, 1990, GASTROINTEST ENDOSC, V36, pS17, DOI 10.1016/S0016-5107(90)71010-3; YASUDA K, 1988, GASTROINTEST ENDOSC, V34, P1, DOI 10.1016/S0016-5107(88)71220-1; 1988, LANCET, V2, P1116; 1988, GASTROINTEST ENDOS S, V34, pS23; 1988, GASTROINTEST ENDOS S, V34, pS6; 1990, CA, V40, P77; 1980, CANCER COLON RECTUM, V30, P208	126	28	28	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1214	1222		10.1056/NEJM199110243251705	http://dx.doi.org/10.1056/NEJM199110243251705			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922209				2022-12-28	WOS:A1991GL28200005
J	MCCONNELL, SK; KAZNOWSKI, CE				MCCONNELL, SK; KAZNOWSKI, CE			CELL-CYCLE DEPENDENCE OF LAMINAR DETERMINATION IN DEVELOPING NEOCORTEX	SCIENCE			English	Article							VISUAL CORTICAL-NEURONS; CEREBRAL-CORTEX; MIGRATION PATTERNS; REELER MOUSE; LINEAGE; DIFFERENTIATION; TRANSPLANTATION; INVITRO; FERRET; RETINA	The neocortex is patterned in layers of neurons that are generated in an orderly sequence during development. This correlation between cell birthday and laminar fate prompted an examination of how neuronal phenotypes are determined in the developing cortex. At various times after labeling with [H-3]thymidine, embryonic progenitor cells were transplanted into older host brains. The laminar fate of transplanted neurons correlates with the position of their progenitors in the cell cycle at the time of transplantation. Daughters of cells transplanted in S-phase migrate to layer 2/3, as do host neurons. Progenitors transplanted later in the cell cycle, however, produce daughters that are committed to their normal, deep-layer fates. Thus, environmental factors are important determinants of laminar fate, but embryonic progenitors undergo cyclical changes in their ability to respond to such cues.			MCCONNELL, SK (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NEI NIH HHS [EY08411] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008411] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; AUSTIN CP, 1990, DEVELOPMENT, V110, P713; DRAGER UC, 1981, J COMP NEUROL, V201, P555, DOI 10.1002/cne.902010407; HOY CA, 1987, J BIOL CHEM, V262, P11927; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; JACKSON CA, 1989, J NEUROSCI, V9, P1242; KIM GY, IN PRESS J NEUROBIOL; LEMMON V, 1981, J NEUROSCI, V1, P83, DOI 10.1523/JNEUROSCI.01-01-00083.1981; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PINTOLORD MC, 1982, DEV BRAIN RES, V4, P379, DOI 10.1016/0165-3806(82)90181-X; PRICE J, 1988, DEVELOPMENT, V104, P473; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; REH TA, 1989, J NEUROSCI, V9, P4179; REH TA, 1986, DEV BIOL, V114, P463, DOI 10.1016/0012-1606(86)90210-1; SHATZ CJ, 1990, COLD SPRING HARB SYM, V55, P469; von Waechter R, 1972, Brain Res, V46, P235; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N	26	635	638	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					282	285		10.1126/science.1925583	http://dx.doi.org/10.1126/science.1925583			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925583				2022-12-28	WOS:A1991GJ64200038
J	HARKIN, T				HARKIN, T			ANOTHER POUND OF CURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH PROMOTION		US SENATE,COMM SENATE APPROPRIAT,SUBCOMM LABOR,WASHINGTON,DC 20510		HARKIN, T (corresponding author), US SENATE,SUBCOMM DISABIL POLICY SENATE LABOR & RESOURCES COMM,WASHINGTON,DC 20510, USA.							AINSWORTH TH, 1983, LIVE DIE, P115; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BECKER MH, 1990, ANN INTERN MED, V113, P419, DOI 10.7326/0003-4819-113-6-419; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; LAWRENCE RS, 1990, HEALTH AFFAIR, V9, P122, DOI 10.1377/hlthaff.9.2.122; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; OMALLEY MS, 1909, PREVENTING DISEASE R, P251; PATTERSON J, 1989, AM J PREV MED, V5, P44, DOI 10.1016/S0749-3797(18)31128-0; PROVENZANO G, 1980, LOW LEVEL LEAD EXPOS, P299; SKOLNICK A, 1991, JAMA-J AM MED ASSOC, V265, P2453, DOI 10.1001/jama.265.19.2453; 1991, STRATEGIC PLAN ELIMI; 1990, OTAH416 PUBL; 1991, JAMA-J AM MED ASSOC, V265, P2437; 1990, HLTH PEOPLE 2000; 1988, PHS DHHS992966 US DE	16	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1692	1693						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1909382				2022-12-28	WOS:A1991GF41900037
J	BURNEY, PGJ				BURNEY, PGJ			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ADULT ASTHMA; MANAGEMENT; ENGLAND; WALES; ADMISSIONS; PREVALENCE; MORTALITY; EDUCATION; INCREASE				BURNEY, PGJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.			Burney, Peter/0000-0001-8635-5678				Alderson M., 1987, POP TRENDS, V49, P18; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; [Anonymous], 1990, BMJ, V301, P651; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BLAINEY D, 1991, HLTH TRENDS, V22, P151; BUCKNALL CE, 1988, LANCET, V1, P748; BUCKNALL CE, 1988, BRIT MED J, V296, P1637, DOI 10.1136/bmj.296.6637.1637; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; HAY I, 1987, LANCET, V1, P609; HILL AM, 1989, BRIT MED J, V298, P1479, DOI 10.1136/bmj.298.6686.1479; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; HILTON S, 1986, LANCET, V1, P26; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; NOCON A, 1991, ARCH DIS CHILD, V66, P458, DOI 10.1136/adc.66.4.458; REES PJ, 1991, BMJ, V302, P1166; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; WARNER JO, 1989, ARCH DIS CHILD, V64, P165; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; 1991, CM1523; 1990, BMJ, V301, P797	27	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					571	573		10.1136/bmj.303.6802.571	http://dx.doi.org/10.1136/bmj.303.6802.571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE948	1912890	Green Published, Bronze			2022-12-28	WOS:A1991GE94800029
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALGLUCERASE APPROVED FOR GAUCHERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V264, P1239	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-28	WOS:A1991FP63500007
J	ROSSI, G; JIANG, Y; NEWMAN, AP; FERRONOVICK, S				ROSSI, G; JIANG, Y; NEWMAN, AP; FERRONOVICK, S			DEPENDENCE OF YPT1 AND SEC4 MEMBRANE ATTACHMENT ON BET2	NATURE			English	Article							RAS PROTEINS; YEAST; SECRETION; BINDING; SUPPRESSION; MUTANTS; GENES	MANY small GTP-binding proteins are synthesized as soluble proteins that are post-translationally modified as a prerequisite for membrane attachment 1. Ypt1 and Sec4 are homologous Raslike GTP-binding proteins that have been proposed to regulate the specificity of vesicular traffic at different stages of the secretory pathway by cycling on and off membranes 2-6. Here we show that BET2, initially identified as a gene required for transport from endoplasmic reticulum to Golgi apparatus in yeast 7, encodes a factor that is needed for the membrane attachment of Ypt1 and Sec4. DNA sequence analysis has revealed that Bet2 is homologous to Dpr1 (Ram1), an essential component of a protein prenyltransferase that modifies Ras 8, enabling it to attach to membranes 9,10. We propose that Bet2 modifies Ypt1 and Sec4 in an analogous manner.	YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; PETERSENBJORN S, 1990, YEAST, V6, P345, DOI 10.1002/yea.320060407; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUOHOLA H, 1988, J CELL BIOL, V107, P1456; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	25	103	106	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					158	161		10.1038/351158a0	http://dx.doi.org/10.1038/351158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903184				2022-12-28	WOS:A1991FL03500055
J	CASTILLA, A; PRIETO, J; FAUSTO, N				CASTILLA, A; PRIETO, J; FAUSTO, N			TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-ALPHA IN CHRONIC LIVER-DISEASE - EFFECTS OF INTERFERON ALFA THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-B; FACTOR-BETA; EXTRACELLULAR-MATRIX; COLLAGEN FORMATION; CONTROLLED TRIAL; RAT HEPATOCYTES; DNA-SYNTHESIS; DISSE SPACE; ITO CELL; FIBROSIS	Background. Cirrhosis is a diffuse process of hepatic fibrosis and regenerative nodule formation of unknown pathogenesis. Transforming growth factor (TGF) beta-1 induces the production of extracellular matrix proteins by liver cells and has been implicated in the pathogenesis of hepatic fibrosis in laboratory animals. TGF-alpha is a hepatocyte mitogen that participates in liver regeneration. Methods. Using Northern blot analysis, we studied the expression of TGF-beta-1 messenger RNA (mRNA) in liver specimens from 42 patients with chronic hepatitis and cirrhosis and 12 subjects with either normal or fatty livers. The results were correlated with measurements of procollagen Type I mRNA in liver tissue, procollagen Type III peptide in serum, and the degree of histologic injury. We also investigated whether TGF-alpha mRNA would be detectable in biopsy specimens of livers with proliferative activity. Results. TGF-beta-1 mRNA expression correlated closely with the expression of procollagen Type I mRNA (r = 0.94) and serum procollagen Type III peptide (r = 0.89) and with the histologic activity index (r = 0.73). All patients with increased fibrogenic activity (serum procollagen Type III peptide level, > 11.9-mu-g per liter) had increased levels of TGF-beta-1 mRNA (2 to 14 times the levels in the control group or in patients with normal fibrogenic activity), and both TGF-alpha and H3 histone (a marker of DNA synthesis) mRNAs were detectable in patients with regenerative nodules. Six of eight patients with hepatitis C treated with interferon alfa for one year had sustained clinical responses with normalization of serum procollagen Type III peptide and aminotransferase activity. All these patients had normal levels of TGF-beta-1 mRNA in liver specimens obtained at the end of the year. Conclusions. TGF-beta-1 may have an important role in the pathogenesis of fibrosis in patients with chronic liver disease, and TGF-alpha expression may be associated with liver regeneration in these patients.	UNIV NAVARRA,UNIV CLIN,CTR BIOMED RES,DEPT INTERNAL MED,PAMPLONA,SPAIN; BROWN UNIV,DEPT PATHOL & LAB MED,DIV BIOL & MED,PROVIDENCE,RI 02912	University of Navarra; Brown University			Yang, Chen/G-1379-2010	Prieto, Jesus/0000-0002-1091-9593	NATIONAL CANCER INSTITUTE [R37CA023226, R01CA023226, R01CA035249] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35249, CA-23226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNONI G, 1990, GASTROENTEROLOGY, V98, P197, DOI 10.1016/0016-5085(90)91310-3; ARMENDARIZBORUNDA J, 1990, FASEB J, V4, P215, DOI 10.1096/fasebj.4.2.2298342; BIAGINI G, 1989, J HEPATOL, V8, P115, DOI 10.1016/0168-8278(89)90170-0; Bissell D.M., 1990, HEPATOLOGY TXB LIVER, P424; BISSELL DM, 1990, HEPATOLOGY, V11, P488, DOI 10.1002/hep.1840110322; BISSELL M, 1990, PROGR LIVER DISEASES, V9, P143; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Brouwer A, 1988, LIVER BIOL PATHOBIOL, P665; CAMPS J, 1989, Journal of Hepatology, V9, pS17, DOI 10.1016/0168-8278(89)90210-9; CARR BI, 1986, CANCER RES, V46, P2330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CONN HO, 1987, DIS LIVER, P725; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FAUSTO N, 1989, LAB INVEST, V60, P4; FRENCH SW, 1988, AM J PATHOL, V132, P73; GEERTS A, 1987, CIRRHOSIS LIVER METH, P83; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HAHN EG, 1987, CIRRHOSIS LIVER METH, P63; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IRABURU M, 1989, J MED VIROL, V27, P39, DOI 10.1002/jmv.1890270109; KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MAK KM, 1984, GASTROENTEROLOGY, V87, P188; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MCMAHON JB, 1986, CANCER RES, V46, P4665; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MILANI S, 1990, AM J PATHOL, V137, P59; MINATO Y, 1983, HEPATOLOGY, V3, P559; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKATSUKASA H, 1990, LAB INVEST, V63, P171; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; OKANOUE T, 1983, ARCH PATHOL LAB MED, V107, P459; PRIETO J, 1989, HEPATOLOGY, V9, P720, DOI 10.1002/hep.1840090511; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROJKIND M, 1988, LIVER BIOL PATHOBIOL, P1269; RUWART MJ, 1989, HEPATOLOGY, V10, P801, DOI 10.1002/hep.1840100509; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERLOCK S, 1989, DISEASES LIVER BILIA, P410; THOMSON BJ, 1987, LANCET, V1, P539; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; ZERN MA, 1990, CONNECTIVE TISSUE HL, P99	55	667	681	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					933	940		10.1056/NEJM199104043241401	http://dx.doi.org/10.1056/NEJM199104043241401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	1900574				2022-12-28	WOS:A1991FE37600001
J	KITAMURA, D; ROES, J; KUHN, R; RAJEWSKY, K				KITAMURA, D; ROES, J; KUHN, R; RAJEWSKY, K			A B-CELL-DEFICIENT MOUSE BY TARGETED DISRUPTION OF THE MEMBRANE EXON OF THE IMMUNOGLOBULIN MU-CHAIN GENE	NATURE			English	Article							PRE-B; MONOCLONAL-ANTIBODY; LYMPHOCYTES-B; HEAVY-CHAINS; LIGHT-CHAIN; BONE-MARROW; STEM-CELLS; REARRANGEMENT; LAMBDA-5; LOCUS	OF the various classes of antibodies that B lymphocytes can produce, class M (IgM) is the first to be expressed on the membrane of the developing cells. Pre-B cells, the precursors of B-lymphocytes, produce the heavy chain of IgM (mu-chain), but not light chains 1. Recent data suggest that pre-B cells express mu-chains on the membrane together with the 'surrogate' light chains lambda-5 and VpreB (refs 2-7). This complex could control pre-B-cell differentiation, in particular the rearrangement of the light-chain genes 8. We have now assessed the importance of the membrane form of the mu-chain in B-cell development by generating mice lacking this chain. We disrupted one of the membrane exons of the gene encoding the mu-chain constant region by gene targeting 9 in mouse embryonic stem cells 10. From these cells we derived mice heterozygous or homozygous for the mutation. B-cell development in the heterozygous mice seemed to be normal, but in homozygous animals B cells were absent, their development already being arrested at the stage of pre-B-cell maturation.	UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY	University of Cologne			Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Roes, Jurgen/0000-0003-3235-2345				CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Coffman R L, 1982, Immunol Rev, V69, P5; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1033; COOPER MD, 1989, IMMUNOGLOBULIN GENES, P1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRUTZMANN R, 1981, THEISIS U COLOGNE; Guise J. W., 1989, Immunoglobulin genes., P275; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973	29	1535	1604	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					423	426		10.1038/350423a0	http://dx.doi.org/10.1038/350423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1901381				2022-12-28	WOS:A1991FF04200050
J	YOOL, AJ; SCHWARZ, TL				YOOL, AJ; SCHWARZ, TL			ALTERATION OF IONIC SELECTIVITY OF A K+ CHANNEL BY MUTATION OF THE H5 REGION	NATURE			English	Article							POTASSIUM CHANNELS; SHAKER LOCUS; XENOPUS OOCYTES; DROSOPHILA; BRAIN; CDNA; EXPRESSION; CATIONS; CLONING	THE high ionic selectivity of K+ channels is a unifying feature of this diverse class of membrane proteins. Though K+ channels differ widely in regulation and kinetics, physiological studies have suggested a common structure: a single file pore containing mulitiple ion-binding sites and having broader vestibules at both ends 1-5. We have used site-directed mutagenesis and single-channel recordings to identify a molecular region that influences ionic selectivity in a cloned A-type K+ channel from Drosophila. Single amino-acid substitutions in H5, the fifth hydrophobic region 6, enhanced the passage of NH4+ and Rb+, ions with diameters larger than K+, without compromising the ability of the channel to exclude the smaller cation, Na+. The mutations that substantially altered selectivity had little effect on the gating properties of the channel. We conclude that the H5 region is likely to line the pore of the K+ channel.			YOOL, AJ (corresponding author), STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.		Yool, Andrea/AAK-9907-2020	Yool, Andrea/0000-0003-1283-585X				ARMSTRONG CM, 1975, QUART REV BIOPH, V7, P179; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P558; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUY HR, 1989, MONOVALENT CATIONS B; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATTESON DR, 1986, J GEN PHYSIOL, V87, P795, DOI 10.1085/jgp.87.5.795; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAYLOR PS, 1987, J PHYSIOL-LONDON, V388, P437, DOI 10.1113/jphysiol.1987.sp016623; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; VANDERLEY P, 1986, J BIOL CHEM, V261, P2222; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	25	374	382	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					700	704		10.1038/349700a0	http://dx.doi.org/10.1038/349700a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1899917				2022-12-28	WOS:A1991EY62700049
J	WEISSMAN, JS; STERN, R; FIELDING, SL; EPSTEIN, AM				WEISSMAN, JS; STERN, R; FIELDING, SL; EPSTEIN, AM			DELAYED ACCESS TO HEALTH-CARE - RISK-FACTORS, REASONS, AND CONSEQUENCES	ANNALS OF INTERNAL MEDICINE			English	Article							SOCIOECONOMIC-STATUS; PATIENT DELAY; BREAST-CANCER; CASE-MIX; SURVIVAL; VARIABLES; DIAGNOSIS; DISEASE; AREA; POOR	Objective: To determine characteristics of patients reporting delays in care before hospitalization and the reasons for those delays. Design: Survey; personal interviews. Setting: Five hospitals in Massachusetts. Patients: Subjects were drawn from a consecutive sample of all adult patients (excluding obstetrics or psychiatry patients) hospitalized during the first 6 months of 1987 as part of a larger study of hospital costs. For the current study, if patients were re-admitted, we included in our analysis only data on the first admission during the study period. We obtained usable survey data from 12068 of 17231 eligible patients. Results: Delays in care were reported by 16% of patients. The odds of reporting delays in care among patients who were black, poor, uninsured, or without a regular physician were 40% to 80% greater than those for other patients (P < 0.01). Most patients who reported delays thought that their problem was not serious (64%). Cost was an important factor in delaying care for patients in lower socioeconomic positions; the odds of delaying care because of cost for patients who were both poor and uninsured were 12 times greater than the odds for other patients (P < 0.001). After controlling for diagnosis-related groups (DRGs) and severity, patients who reported delays had 9% longer hospital stays compared with others (P < 0.001). Conclusions: Patients generally thought to be disadvantaged are at especially high risk for delaying care for conditions that eventually lead to hospitalization. Because these delays are associated with longer hospital stays and potentially poorer health outcomes, interventions that reduce delays seem especially important.	HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,PARCEL B,1ST FLOOR, 25 SHATTUCK ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center					AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [F32HS000024] Funding Source: NIH RePORTER; AHRQ HHS [1 F32 HS00024] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; BULLOUGH B, 1972, J HEALTH SOC BEHAV, V13, P347, DOI 10.2307/2136826; BURR WA, 1980, JAMA-J AM MED ASSOC, V244, P44; Christoffersson J G, 1988, DRG Monit, V6, P1; CLEARY PD, 1984, J HEALTH SOC BEHAV, V25, P334, DOI 10.2307/2136429; COCKERHAM WC, 1986, SOC SCI MED, V22, P1263, DOI 10.1016/0277-9536(86)90193-0; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; CURBOW B, 1986, HEALTH PSYCHOL, V5, P375; DOWD BE, 1986, MED CARE, V24, P694, DOI 10.1097/00005650-198608000-00005; Duffy J E, 1984, Hygie, V3, P29; DUTTON DB, 1978, AM SOCIOL REV, V43, P348, DOI 10.2307/2094495; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; HACKETT TP, 1973, NEW ENGL J MED, V289, P14, DOI 10.1056/NEJM197307052890104; HALVORSEN R, 1980, AM ECON REV, V70, P474; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LEGRAND J, 1978, ECONOMICA, V45, P125, DOI 10.2307/2553499; MCKINLAY JB, 1972, J HEALTH SOC BEHAV, V13, P115, DOI 10.2307/2136896; Mechanic D., 1989, PATHWAYS HLTH ROLE S, P9; NEALE AV, 1986, SOC SCI MED, V23, P305, DOI 10.1016/0277-9536(86)90352-7; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; RIESSMAN CK, 1974, SOC POLICY, V5, P41; Roos N P, 1988, Health Care Financ Rev, V9, P53; ROOS NP, 1982, MED CARE, V20, P945, DOI 10.1097/00005650-198209000-00007; RUSHING WA, 1978, AM SOCIOL REV, V43, P521, DOI 10.2307/2094776; SAFER MA, 1979, MED CARE, V17, P11, DOI 10.1097/00005650-197901000-00002; SIEMIATYCKI J, 1980, NEW ENGL J MED, V303, P10, DOI 10.1056/NEJM198007033030103; TEMOSHOK L, 1984, CANCER, V54, P3048, DOI 10.1002/1097-0142(19841215)54:12<3048::AID-CNCR2820541239>3.0.CO;2-M; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YELIN EH, 1983, AM J PUBLIC HEALTH, V73, P563, DOI 10.2105/AJPH.73.5.563; 1986, FED REGISTER, V51, P31561; 1983, DHS8320001 NAT CTR H	36	407	411	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					325	331		10.7326/0003-4819-114-4-325	http://dx.doi.org/10.7326/0003-4819-114-4-325			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1899012				2022-12-28	WOS:A1991EX52100013
J	CHAPMAN, AB; GABOW, PA; SCHRIER, RW				CHAPMAN, AB; GABOW, PA; SCHRIER, RW			REVERSIBLE RENAL-FAILURE ASSOCIATED WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN POLYCYSTIC KIDNEY-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							GLOMERULAR FILTRATION RATE; TUBULAR REABSORPTION; ARTERY STENOSIS; BLOOD-PRESSURE; SODIUM ION; HYPERTENSION; CAPTOPRIL; ALDOSTERONE; RENIN; INSUFFICIENCY	The renin-angiotensin-aldosterone system appears to play an important initiating role in the pathogenesis of hypertension in patients with autosomal-dominant polycystic kidney disease (ADPKD). Therefore, angiotensin-converting enzyme (ACE) inhibitors would appear to be appropriate therapy for hypertension in such patients. However, because ADPKD is a bilateral disorder, ACE-inhibitor therapy may worsen renal function, as occurs in patients with bilateral renal artery stenosis. We describe eight episodes of reversible acute renal deterioration in five patients with ADPKD, massive renal involvement, and chronic renal insufficiency. In all cases, ACE-inhibitor therapy either predisposed the patient to or precipitated the acute event. Two of the patients who had acute renal failure while receiving ACE-inhibitor therapy experienced a recurrence when rechallenged with such therapy. Furthermore, patients receiving combined therapy with an ACE inhibitor and a diuretic and patients who experience a cyst hemorrhage while receiving ACE inhibitor therapy are also at risk for reversible renal dysfunction. Caution is therefore recommended in using ACE inhibitors to treat hypertension in patients with ADPKD who are at high risk because of compromised renal function and massive cystic involvement.			CHAPMAN, AB (corresponding author), UNIV COLORADO, HLTH SCI CTR, BOX 283, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NIDDK NIH HHS [5-P01-DK34039] Funding Source: Medline; ORS NIH HHS [MORR-00051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK034039] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); ORS NIH HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL PE, 1988, KIDNEY INT, V34, P683, DOI 10.1038/ki.1988.233; BENNETT WM, 1987, J UROLOGY, V137, P620, DOI 10.1016/S0022-5347(17)44156-5; Braasch WF, 1933, SURG GYNECOL OBSTET, V57, P467; BROWN EA, 1983, ANN RHEUM DIS, V42, P52, DOI 10.1136/ard.42.1.52; CHAPMAN AB, 1990, NEW ENGL J MED, V323, P1091, DOI 10.1056/NEJM199010183231602; COLLSTE P, 1979, BRIT MED J, V2, P612, DOI 10.1136/bmj.2.6190.612-c; CORNELL SH, 1970, J UROLOGY, V103, P24, DOI 10.1016/S0022-5347(17)61883-4; CURTIS JJ, 1983, NEW ENGL J MED, V308, P377, DOI 10.1056/NEJM198302173080707; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DANIELSEN H, 1986, ACTA MED SCAND, V219, P399; DAVIN JC, 1985, LANCET, V1, P820; ETTINGER A, 1969, J UROLOGY, V102, P156, DOI 10.1016/S0022-5347(17)62101-3; FRANG D, 1988, International Urology and Nephrology, V20, P13, DOI 10.1007/BF02583026; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; GABOW PA, 1990, KIDNEY INT, V38, P1177, DOI 10.1038/ki.1990.330; GRAHAM PC, 1988, KIDNEY INT, V33, P1084, DOI 10.1038/ki.1988.115; HANSSON L, 1974, SCAND J UROL NEPHROL, V8, P203, DOI 10.3109/00365597409132130; Hollenberg NK, 1983, CARDIOVASC REV REP, V4, P852; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; HRICIK DE, 1990, J AM SOC NEPHROL, V1, P845; IGLESIAS CG, 1983, AM J KIDNEY DIS, V2, P630; JACKSON B, 1984, LANCET, V1, P225; MILUTINOVIC J, 1984, Q J MED, V53, P511; MURPHY BF, 1984, BRIT MED J, V288, P844, DOI 10.1136/bmj.288.6420.844; NASH DA, 1977, ARCH INTERN MED, V137, P1571, DOI 10.1001/archinte.137.11.1571; Ritter SA, 1929, J UROLOGY, V21, P583, DOI 10.1016/S0022-5347(17)73123-0; Schacht FW, 1931, ARCH INTERN MED, V47, P500, DOI 10.1001/archinte.1931.00140210163013; SCHRIER RW, 1971, NEW ENGL J MED, V285, P1292, DOI 10.1056/NEJM197112022852305; SCHRIER RW, 1971, NEW ENGL J MED, V285, P1231, DOI 10.1056/NEJM197111252852205; SCHROEDER ET, 1976, KIDNEY INT, V9, P511, DOI 10.1038/ki.1976.65; STEEN VD, 1990, ANN INTERN MED, V113, P352, DOI 10.7326/0003-4819-113-5-352; SUKI WN, 1989, ARCH INTERN MED, V149, P669, DOI 10.1001/archinte.149.3.669; THIND GS, 1985, J CLIN HYPERTENS, V4, P337; VALVO E, 1985, AM J NEPHROL, V5, P176, DOI 10.1159/000166929; WAEBER B, 1984, KLIN WOCHENSCHR, V62, P728, DOI 10.1007/BF01725706; ZEIER M, 1988, NEPHRON, V49, P177, DOI 10.1159/000185052	36	41	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					769	773		10.7326/0003-4819-115-10-769	http://dx.doi.org/10.7326/0003-4819-115-10-769			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929024				2022-12-28	WOS:A1991GP80000004
J	HEALD, A; FLEPP, M; CHAVE, JP; MALINVERNI, R; RUTTIMANN, S; GABRIEL, V; RENOLD, C; SUGAR, A; HIRSCHEL, B				HEALD, A; FLEPP, M; CHAVE, JP; MALINVERNI, R; RUTTIMANN, S; GABRIEL, V; RENOLD, C; SUGAR, A; HIRSCHEL, B			TREATMENT FOR CEREBRAL TOXOPLASMOSIS PROTECTS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							PYRIMETHAMINE; CLINDAMYCIN	Objective: To determine whether long-term maintenance treatment for toxoplasmosis protects against Pneumocystis carinii Pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Design: Cohort study. Setting: Switzerland. Patients: A total of 453 patients with human immunodeficiency virus (HIV) entered the Swiss HIV Cohort Study. Ninety-nine patients with cerebral toxoplasmosis but no previous or simultaneous P. carinii pneumonia were compared with 240 patients with AIDS and other severe opportunistic infections (Centers for Disease Control [CDC] stage IVC1 infection other than toxoplasmosis and P. carinii pneumonia) as well as with 114 patients receiving inhaled pentamidine in a study of primary pneumocystis prophylaxis in patients infected with HIV. Measurements: Life-table analysis for P. carinii-free survival. Main Results: Six of 99 (6%) patients with toxoplasmosis, 50 of 240 (21%) patients with other severe opportunistic infections, and 8 of 114 (6%) patients receiving inhaled pentamidine developed P. carinii pneumonia. Life-table analysis showed that the incidence of pneumonia was substantially lower in patients with toxoplasmosis compared with that in patients with other severe opportunistic infections and was similar to the incidence in patients receiving pentamidine as prophylaxis. Analysis of the medication records from patients with toxoplasmosis showed that pyrimethamine and sulfonamides were administered 50% of the time; pyrimethamine and clindamycin, 25% of the time; and pyrimethamine alone, 9.9% of the time but that only one of the six patients with toxoplasmosis who developed P. carinii pneumonia received pyrimethamine and sulfonamides in the month before diagnosis. Conclusion: Patients with cerebral toxoplasmosis have a low risk for subsequently developing P. carinii pneumonia. This decreased risk is probably the result of chronic suppressive treatment with pyrimethamine and sulfonamides.	UNIV GENEVA, DIV MALAD INFECT, 24 RUE MICHELI CREST, CH-1211 GENEVA 4, SWITZERLAND; MED POLIKLIN BERN, BERN, SWITZERLAND; MED POLIKLIN, BASEL, SWITZERLAND; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								CAMPOS N, 1988, COMPUT METH PROG BIO, V27, P223, DOI 10.1016/0169-2607(88)90086-7; GIRARD PM, 1989, LANCET, V1, P1459; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HUGHES WT, 1978, J PEDIATR-US, V92, P285, DOI 10.1016/S0022-3476(78)80028-6; JACQUIER P, 1989, CONTRIBUTION ETUDE T; KIRBY HB, 1971, ANN INTERN MED, V75, P505, DOI 10.7326/0003-4819-75-4-505; KOVACS JA, 1989, J INFECT DIS, V160, P312, DOI 10.1093/infdis/160.2.312; QUEENER SF, 1988, ANTIMICROB AGENTS CH, V32, P807, DOI 10.1128/AAC.32.6.807; SANDE MA, 1990, MED MANAGEMENT AIDS, P241; STURCHLER D, 1987, SCHWEIZ MED WSCHR, V117, P161; [No title captured]	11	28	28	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					760	763		10.7326/0003-4819-115-10-760	http://dx.doi.org/10.7326/0003-4819-115-10-760			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929023				2022-12-28	WOS:A1991GP80000002
J	CAPLAN, LR				CAPLAN, LR			DIAGNOSIS AND TREATMENT OF ISCHEMIC STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROVASCULAR-DISEASE; CEREBRAL-ISCHEMIA; INFARCTION; THERAPY; RISK; TIME				CAPLAN, LR (corresponding author), NEW ENGLAND MED CTR HOSP,DEPT NEUROL,750 WASHINGTON ST,BOSTON,MA 02110, USA.							ADAMS HP, 1984, STROKE, V15, P371, DOI 10.1161/01.STR.15.2.371; BILLER J, 1989, NEUROLOGY, V39, P262, DOI 10.1212/WNL.39.2.262; CAPLAN L, 1988, NEUROLOGY, V38, P624, DOI 10.1212/WNL.38.4.624; CAPLAN LR, 1991, AM J NEURORADIOL, V12, P593; CAPLAN LR, 1988, NEUROLOGY, V38, P791, DOI 10.1212/WNL.38.5.791; CAPLAN LR, 1990, NEUROLOGY, V40, P696, DOI 10.1212/WNL.40.4.696; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; CAPLAN LR, 1989, NEUROLOGY, V39, P1246, DOI 10.1212/WNL.39.9.1246; CAPLAN LR, 1986, CLIN NEUROPHARMACOL, V9, P399, DOI 10.1097/00002826-198610000-00001; CAPLAN LR, 1988, ANNU REV MED, V39, P273, DOI 10.1146/annurev.med.39.1.273; CAPLAN LR, 1983, STROKE, V14, P431, DOI 10.1161/01.STR.14.3.431; CAPLAN LR, 1981, STROKE, V12, P111, DOI 10.1161/01.STR.12.1.111; CAPLAN LR, 1984, STROKE, V15, P571, DOI 10.1161/01.STR.15.3.571; CAPLAN LR, IN PRESS VERTEBROBAS; CAPLAN LR, 1985, STROKE PATHOPHYSIOLO, P549; CAPLAN LR, 1986, STROKE CLIN APPROACH, P3; CASTAIGNE P, 1973, BRAIN, V96, P133, DOI 10.1093/brain/96.1.133; DYKEN ML, 1984, STROKE, V15, P1105; FAUGHT E, 1979, NEUROLOGY, V29, P4, DOI 10.1212/WNL.29.1.4; FISHER CM, 1978, ARCH NEUROL-CHICAGO, V35, P126, DOI 10.1001/archneur.1978.00500270008002; FISHER CM, 1969, ACTA NEUROPATHOL, V12, P1, DOI 10.1007/BF00685305; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; HELGASON C, 1986, ARCH NEUROL-CHICAGO, V43, P681, DOI 10.1001/archneur.1986.00520070039015; MILLER A, 1985, STROKE, V16, P668, DOI 10.1161/01.STR.16.4.668; MOHR JP, 1982, STROKE, V13, P3, DOI 10.1161/01.STR.13.1.3; PESSIN MS, 1987, ANN NEUROL, V21, P290, DOI 10.1002/ana.410210311; PESSIN MS, 1987, ANN NEUROL, V21, P85, DOI 10.1002/ana.410210115; TETTENBORN B, 1990, J NEUROL, V237, P159; 1991, NEW ENGL J MED, V325, P445	29	51	53	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2413	2418		10.1001/jama.266.17.2413	http://dx.doi.org/10.1001/jama.266.17.2413			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920747				2022-12-28	WOS:A1991GM79000029
J	EBELL, M				EBELL, M			A SINGLE TEAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2367	2367						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920739				2022-12-28	WOS:A1991GM79000010
J	JACOBS, GH; NEITZ, J; DEEGAN, JF				JACOBS, GH; NEITZ, J; DEEGAN, JF			RETINAL RECEPTORS IN RODENTS MAXIMALLY SENSITIVE TO ULTRAVIOLET-LIGHT	NATURE			English	Article							SPECTRAL SENSITIVITY; PHOTOSENSITIVITY; SCIUREUS; MONKEYS; SAIMIRI; SYSTEM; RAT	HIGH sensitivity to near-ultraviolet light is a fundamental feature of vision in many invertebrates 1,2. Among vertebrates there are some amphibians, birds and fishes that are also sensitive to near-ultraviolet wavelengths 3-6. This sensitivity can be achieved through a class of cone photoreceptor containing an ultraviolet-sensitive pigment 7-9. Although these receptors were thought not to exist in the eyes of mammals, we now report that some rodents have a retinal mechanism that is maximally sensitive to ultraviolet light.			JACOBS, GH (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106, USA.							BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BENSHOFF HM, 1987, BRAIN RES, V420, P397, DOI 10.1016/0006-8993(87)91264-9; DOUGLAS RH, 1986, J COMP PHYSIOL A, V159, P415, DOI 10.1007/BF00603986; EBREY TG, 1977, VISION RES, V17, P147, DOI 10.1016/0042-6989(77)90213-9; EMMERTON J, 1980, J COMP PHYSIOL, V141, P47, DOI 10.1007/BF00611877; GOLDSMITH TH, 1980, SCIENCE, V207, P786, DOI 10.1126/science.7352290; HAROSI FI, 1983, SCIENCE, V222, P1021, DOI 10.1126/science.6648514; HAWRYSHYN CW, 1985, VISION RES, V25, P11, DOI 10.1016/0042-6989(85)90075-6; JACOBS GH, 1989, EXPERIENTIA, V45, P317, DOI 10.1007/BF01957461; JACOBS GH, 1983, VISION RES, V23, P239, DOI 10.1016/0042-6989(83)90112-8; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; Jacobs GH, 1981, COMP COLOR VISION; Menzel R, 1979, HDB SENSORY PHYSL, VVII/6A, P503; NEITZ J, 1986, J COMP PSYCHOL, V100, P21, DOI 10.1037/0735-7036.100.1.21; NEITZ J, 1984, J OPT SOC AM A, V1, P1175, DOI 10.1364/JOSAA.1.001175; PERRY RJ, 1991, J PHYSIOL-LONDON, V443, P561; RAPP LM, 1990, INVEST OPHTHAL VVIS, V31, P1187; STARK WS, 1982, PHOTOCHEM PHOTOBIOL, V36, P371, DOI 10.1111/j.1751-1097.1982.tb04389.x; VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G; [No title captured]	20	320	326	3	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					655	656		10.1038/353655a0	http://dx.doi.org/10.1038/353655a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922382				2022-12-28	WOS:A1991GK67200068
J	KELLY, A; POWIS, SH; GLYNNE, R; RADLEY, E; BECK, S; TROWSDALE, J				KELLY, A; POWIS, SH; GLYNNE, R; RADLEY, E; BECK, S; TROWSDALE, J			2ND PROTEASOME-RELATED GENE IN THE HUMAN MHC CLASS-II REGION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; LYMPHOCYTE-T; TRANSPORTERS; CELLS; SEQUENCES; PATHWAY; CLONING; CDNA	ANTIGEN processing involves the generation of peptides from cytosolic proteins and their transport into the endoplasmic reticulum where they associate with major histocompatibility complex (MHC) class I molecules 1-6. Two genes have been identified in the MHC class II region, RING4 and RING11 in humans, which are believed to encode the peptide transport proteins 7-12. Attention is now focused on how the transporters are provided with peptides. The proteasome, a large complex of subunits with multiple proteolytic activities, is a candidate for this function 13-16. Recently we reported a proteasome-related sequence, RING1O, mapping between the transporter genes 17. Here we describe a second human proteasome-like gene, RING12, immediately centromeric of the RING4 locus. Therefore RING12, 4, 10 and 11 form a tightly linked cluster of interferon-inducible genes within the MHC with an essential role in antigen processing.			KELLY, A (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAIROCH A, 1990, PROSITE DICT PROTEIN; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BLANCK G, 1988, J IMMUNOL, V141, P1734; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; Maniatis T., 1982, MOL CLONING; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SH, UNPUB P NATN ACAD SC; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TIWARI JL, 1985, HLA DISEASE ASS; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	33	344	353	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					667	668		10.1038/353667a0	http://dx.doi.org/10.1038/353667a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922385				2022-12-28	WOS:A1991GK67200073
J	KETTE, F; WEIL, MH; GAZMURI, RJ				KETTE, F; WEIL, MH; GAZMURI, RJ			BUFFER SOLUTIONS MAY COMPROMISE CARDIAC RESUSCITATION BY REDUCING CORONARY PERFUSION-PRESSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTONIC SOLUTIONS; SODIUM-BICARBONATE; CARBON-DIOXIDE; OUTPUT; FLOW	Objective. - To investigate the effects of hypertonic buffer solutions on coronary perfusion pressure (CPP) and resuscitability during experimental closed-chest cardiac resuscitation. Design. - Randomized, placebo-controlled trial. Setting. - Mammalian research laboratory. Participants. - Forty-four domestic pigs. Interventions. - Cardiac arrest was induced by ventricular fibrillation in mechanically ventilated pigs anesthetized with pentobarbital sodium. Precordial compression was started at the third minute of untreated ventricular fibrillation and maintained for an interval of 8 minutes. A hypertonic solution of sodium bicarbonate, Carbicarb (an equimolar mixture of sodium bicarbonate and sodium carbonate [International Medication Systems, Ltd]), or sodium chloride or an isotonic solution of sodium chloride was infused into the right atrium over a 1-minute interval starting at the sixth minute of ventricular fibrillation. Restoration of spontaneous circulation was attempted by DC transthoracic countershock after 11 minutes of ventricular fibrillation. Main Outcome Measures. - Plasma osmolality, CPP, and cardiac resuscitability. Results. - Infusion of hypertonic buffer and sodium chloride solutions increased plasma osmolality from an average of 280 to 330 mOsm/kg. This was accompanied by a significant decrease in the aortic pressures and CPPs generated during precordial compression. No such changes occurred after infusion of isotonic sodium chloride. Restoration of spontaneous circulation, as in earlier studies, was contingent on the levels of CPP prior to attempted defibrillation. Accordingly, none of 13 animals in which the CPP declined to less than 10 mm Hg after infusion of the hypertonic solutions were successfully resuscitated. This contrasted with nine animals that received isotonic sodium chloride and served as controls. Coronary perfusion pressure consistently exceeded 10 mm Hg in these control animals, and spontaneous circulation was restored in each instance. Conclusions. - Hypertonic solutions and specifically buffer solutions administered in the absence of vasopressor agents may adversely affect cardiac resuscitation efforts by reducing CPP below critical thresholds.	UNIV HLTH SCI CHICAGO MED SCH, DEPT MED,DIV CRIT CARE,3333 GREEN BAY RD, N CHICAGO, IL 60064 USA; UNIV HLTH SCI CHICAGO MED SCH, DEPT MED,DIV CARDIOL, N CHICAGO, IL 60064 USA	Chicago Medical School; Chicago Medical School				Gazmuri, Raul J./0000-0002-3848-7227	NHLBI NIH HHS [R01HL39148-02, R01HL42590-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042590, R01HL039148] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL JB, 1969, J APPL PHYSIOL, V27, P251, DOI 10.1152/jappl.1969.27.2.251; [Anonymous], 1986, JAMA-J AM MED ASSOC, V255, P2905, DOI [10.1001/jama.1986.03370210073024, DOI 10.1001/JAMA.1986.03370210073024]; BINET L, 1949, CR SOC BIOL, V143, P1416; BINET L, 1929, PARIS MED, V77, P498; BISHOP RL, 1976, JAMA-J AM MED ASSOC, V235, P506, DOI 10.1001/jama.235.5.506; BOURKE GJ, 1985, INTERPRETATION USES, P115; COTE CJ, 1979, ANESTHESIOLOGY, V50, P30, DOI 10.1097/00000542-197901000-00007; GAZMURI RJ, 1990, J AM COLL CARDIOL, V15, P482, DOI 10.1016/S0735-1097(10)80080-4; GUDIPATI CV, 1988, CIRCULATION, V77, P234, DOI 10.1161/01.CIR.77.1.234; GUERCI AD, 1986, CIRCULATION, V74, P75; HUSEBY JS, 1981, CHEST, V79, P552, DOI 10.1378/chest.79.5.552; KETTE F, 1990, CIRCULATION, V81, P1660, DOI 10.1161/01.CIR.81.5.1660; KETTE F, 1989, CRIT CARE MED, V17, pS130; KRAVATH RE, 1970, PEDIATRICS, V46, P267; LEVINE BA, 1981, P SOC EXP BIOL MED, V167, P279; MATTSON DE, 1986, STATISTICS DIFFICULT, P161; MELLANDER S, 1971, CIRC RES, V28, pI39; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; VONPLANTA M, 1989, CIRCULATION, V80, P684, DOI 10.1161/01.CIR.80.3.684; VONPLANTA M, 1988, J CLIN PHARMACOL, V28, P594, DOI 10.1002/j.1552-4604.1988.tb03182.x; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011	24	103	108	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2121	2126		10.1001/jama.266.15.2121	http://dx.doi.org/10.1001/jama.266.15.2121			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920701				2022-12-28	WOS:A1991GJ47400034
J	RAZA, MW; BLACKWELL, CC; MOLYNEAUX, P; JAMES, VS; OGILVIE, MM; INGLIS, JM; WEIR, DM				RAZA, MW; BLACKWELL, CC; MOLYNEAUX, P; JAMES, VS; OGILVIE, MM; INGLIS, JM; WEIR, DM			ASSOCIATION BETWEEN SECRETOR STATUS AND RESPIRATORY VIRAL ILLNESS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ABO BLOOD-GROUP; NEISSERIA-MENINGITIDIS; DIABETES-MELLITUS; GROUP ANTIGENS; ORAL CARRIAGE; INFECTION; SUSCEPTIBILITY; ETIOLOGY; WOMEN	Objective - To determine whether non-secretion of blood group antigens is associated with respiratory virus diseases. Design - Study of secretor status in patients with respiratory virus diseases determined by an enzyme linked immunosorbent assay (ELISA) developed to identify Lewis (Le) blood group antigen phenotypes (Le(a) non-secretor; Le(b) secretor). Subjects - Patients aged 1 month to 90 years in hospital with respiratory virus diseases (584 nasal specimens). Main outcome measures - Criteria for validation of ELISA (congruence between results on ELISA testing of 1155 saliva samples from a previous study and previously established results on haemagglutination inhibition (HAI) testing, proportions of Le(a), Le(b), and Le- phenotypes in 872 samples of nasal washings from a previous study compared with the normal population). Secretor status of patients determined by ELISA and viruses isolated. Results - Agreement between HAI and ELISA for 1155 saliva samples was 97%. Lewis antigens were detected by ELISA in 854 (97.9%) of nasal washings (Le(a) 233 (26.7%), Le(b) 621 (71.2%), and Le- 18 (2.1%)) in proportions predicted for a northern European population. Secretors were significantly overrepresented among patients from whom influenza viruses A and B (55/64, 86%; p < 0.025), rhinoviruses (63/72, 88%; p < 0.01), respiratory syncytial virus (97/109, 89%; p < 0.0005), and echo-viruses (44/44, p < 0.0005) had been isolated compared with the distribution of secretors in the local population. Conclusion - Secretion of blood group antigens is associated with respiratory virus diseases.	UNIV EDINBURGH, SCH MED, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; CITY HOSP EDINBURGH, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND	University of Edinburgh								ANDERSEN J, 1960, DIABETES, V9, P20, DOI 10.2337/diab.9.1.20; BLACKWELL CC, 1990, EPIDEMIOL INFECT, V104, P203, DOI 10.1017/S0950268800059367; BLACKWELL CC, 1987, BRIT MED J, V295, P1024, DOI 10.1136/bmj.295.6605.1024; BLACKWELL CC, 1989, EPIDEMIOL INFECT, V102, P1, DOI 10.1017/S0950268800029629; BLACKWELL CC, 1986, LANCET, V2, P284; BLACKWELL CC, 1987, J CLIN LAB IMMUNOL, V22, P133; BLACKWELL CC, 1986, LANCET, V2, P687; BLACKWELL CC, 1989, DIABETES RES CLIN EX, V12, P101; BLACKWELL CC, 1989, P ROYAL COLLEGE PHYS, V19, P129; BURFORDMASON AP, 1988, J MED VET MYCOL, V26, P49; CHAUDHURI A, 1978, T ROY SOC TROP MED H, V72, P664, DOI 10.1016/0035-9203(78)90031-7; COLLIER A, 1988, BRIT MED J, V296, P1162, DOI 10.1136/bmj.296.6630.1162; HAVERKORN MJ, 1969, AM J HUM GENET, V21, P360; KINANE DF, 1982, BRIT MED J, V285, P7, DOI 10.1136/bmj.285.6334.7; MACKENZIE JS, 1978, J HYG-CAMBRIDGE, V80, P21, DOI 10.1017/S0022172400053365; MAY S J, 1989, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P407, DOI 10.1016/0378-1097(89)90266-8; MCDONALD JC, 1962, BRIT MED J, P89, DOI 10.1136/bmj.2.5297.89; MOLLISON PL, 1979, BLOOD TRANSFUSION CL, P414; Mourant AE., 1976, DISTRIBUTION HUMAN B; POTTER CW, 1969, J HYG-CAMB, V67, P67, DOI 10.1017/S0022172400041437; RAHAT A, 1990, VOX SANG, V59, P101, DOI 10.1111/j.1423-0410.1990.tb05019.x; SHINEBAUM R, 1987, BRIT MED J, V294, P208, DOI 10.1136/bmj.294.6566.208; THOM SM, 1989, FEMS MICROBIOL IMMUN, V7, P401	23	63	65	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	1991	303	6806					815	818		10.1136/bmj.303.6806.815	http://dx.doi.org/10.1136/bmj.303.6806.815			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932971	Green Published, Bronze			2022-12-28	WOS:A1991GH94600021
J	HANSEN, HS; FROBERG, K; HYLDEBRANDT, N; NIELSEN, JR				HANSEN, HS; FROBERG, K; HYLDEBRANDT, N; NIELSEN, JR			A CONTROLLED-STUDY OF 8 MONTHS OF PHYSICAL-TRAINING AND REDUCTION OF BLOOD-PRESSURE IN CHILDREN - THE ODENSE SCHOOLCHILD STUDY	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; HYPERTENSION; INTERVENTION; HEALTH; HEMODYNAMICS; EXERCISE	Objective - To examine the effect of physical training on physical fitness and blood pressure in children aged 9-11 years. Design - Prospective randomised controlled intervention study of a sample of children drawn from a population survey of coronary risk factors in children. Setting - Odense, Denmark. Subjects - 69 children with mean blood pressure greater-than-or-equal-to 95th centile (hypertensive group) and 68 with mean blood pressure < 95th centile (normotensive group), randomly selected from a population of 1369 children. Intervention - 67 children were randomised to receive three extra lessons a week of an ordinary school physical education programme for eight months. Main outcome measures - Physical fitness assessed by calculation of maximum oxygen uptake and blood pressure recorded by one unblinded observer. Results - After three months neither blood pressure nor physical fitness had changed significantly. After adjustment for values in weight, height, heart rate, and the variable in question before training physical fitness rose significantly at the end of eight months' training, by 3.7 mlo2/kg/min (95% confidence interval 2.2 to 5.3) in the normotensive training subgroup and by 2.1 mlo2/kg/min (0.1 to 4.2) in the hypertensive training subgroup compared with that in the controls. Systolic and diastolic blood pressures in the training subgroups fell significantly by 6.5 mm Hg (3.2 to 9.9) and 4.1 mm Hg (1.7 to 6.6) respectively in the normotensive group and by 4.9 mm Hg (0.7 to 9.2) and 3.8 mm Hg (0.9 to 6.6) respectively in the hypertensive group. Conclusions - Physical training lowers blood pressure and improves physical fitness in children and might have implications for an important non-pharmacological approach to primary prevention of essential hypertension.			HANSEN, HS (corresponding author), ODENSE SCHOOLCHILD STUDY GRP,LUNGSTEDVANGEN 31,DK-5250 ODENSE SV,DENMARK.							[Anonymous], 1987, PEDIATRICS, V79, P1; BERENSON GS, 1990, AM J MED SCI, V299, P79, DOI 10.1097/00000441-199002000-00001; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; DEMARCO T, 1989, J SCHOOL HEALTH, V59, P337, DOI 10.1111/j.1746-1561.1989.tb04739.x; DWYER T, 1983, INT J EPIDEMIOL, V12, P308, DOI 10.1093/ije/12.3.308; ERIKSSON BO, 1973, ACTA PHYSIOL SCAND, V87, P27, DOI 10.1111/j.1748-1716.1973.tb05363.x; FAGARD R, 1985, INT J SPORTS MED, V6, P57, DOI 10.1055/s-2008-1025814; GUNSOLLEY JC, 1989, J CLIN PERIODONTOL, V16, P156, DOI 10.1111/j.1600-051X.1989.tb01633.x; HANSEN HS, 1990, J HYPERTENS, V8, P641, DOI 10.1097/00004872-199007000-00007; HANSEN HS, 1989, EUR J APPL PHYSIOL, V58, P618, DOI 10.1007/BF00418508; JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30; LINDER CW, 1983, MED SCI SPORT EXER, V15, P232; MONTOYE HJ, 1986, EFFECTS PHYSICAL ACT, V19, P127; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; PUSKA P, 1982, PREV MED, V11, P550, DOI 10.1016/0091-7435(82)90068-8; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; STONE EJ, 1985, J SCHOOL HEALTH, V55, P168, DOI 10.1111/j.1746-1561.1985.tb04113.x; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd; TELL GS, 1987, CARDIOVASCULAR RISK, P203; VACCARO P, 1989, SPORTS MED, V8, P139, DOI 10.2165/00007256-198908030-00002; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; 1986, HYPERTENSION, V8, P444; 1983, WHO TECH REP SER, V686, P1; 1983, SPSSX USERS GUIDE, P487; 1988, ARCH INTERN MED, V148, P1023	26	121	125	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					682	685		10.1136/bmj.303.6804.682	http://dx.doi.org/10.1136/bmj.303.6804.682			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912915	Bronze, Green Published			2022-12-28	WOS:A1991GG98000020
J	RUBIN, EM; KRAUSS, RM; SPANGLER, EA; VERSTUYFT, JG; CLIFT, SM				RUBIN, EM; KRAUSS, RM; SPANGLER, EA; VERSTUYFT, JG; CLIFT, SM			INHIBITION OF EARLY ATHEROGENESIS IN TRANSGENIC MICE BY HUMAN APOLIPOPROTEIN-A-I	NATURE			English	Article							HIGH-DENSITY-LIPOPROTEIN; DETERMINING ATHEROSCLEROSIS SUSCEPTIBILITY; CHOLESTEROL; GENE; PATHOGENESIS; DISEASE; MOUSE	EPIDEMIOLOGICAL surveys have identified a strong inverse relationship between the amount in the plasma of high density lipoproteins (HDL), apolipoprotein AI (ApoA-I), the major protein component of HDL, and the risk for atherosclerosis in humans 1,2. It is not known if this relationship arises from a direct antiatherogenic effect of these plasma components or if it is the result of other factors also associated with increases in ApoA-I and HDL levels. Because some strains of mice are susceptible to diet-induced formation of preatherosclerotic fatty streak lesions, and because of available techniques for the genetic manipulation of this organism, the murine system offers a unique setting in which to investigate the process of early atherogenesis. To test the hypothesis that induction of a high plasma concentration of ApoA-I and HDL would inhibit this process, we studied the effects of atherogenic diets on transgenic mice expressing high amounts of human ApoA-I. We report that transgenic mice with high plasma ApoA-I and HDL levels were significantly protected from the development of fatty streak lesions.	UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	RUBIN, EM (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DIV RES MED & RADIAT BIOPHYS,BERKELEY,CA 94720, USA.							BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; CHEUNG MC, 1991, J LIPID RES, V32, P383; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; ISHIDA B, 1989, GENETIC FACTORS ATHE, P198; IZZO C, 1981, CLIN CHEM, V27, P371; LEBOEUF RC, 1990, J LIPID RES, V31, P9; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MILLER NE, 1978, LIPIDS, V13, P914, DOI 10.1007/BF02533850; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1989, GENETICS, V122, P163; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PATSCH J, 1983, P NATL ACAD SCI USA, V80, P1435; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RUDEL LL, 1973, J LIPID RES, V14, P364; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; STEWARTPHILLIPS JL, 1989, CLIN INVEST MED, V12, P121; WALSH A, 1989, J BIOL CHEM, V264, P6488	23	862	922	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					265	267		10.1038/353265a0	http://dx.doi.org/10.1038/353265a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1910153				2022-12-28	WOS:A1991GF67400062
J	GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ				GULLIFORD, MC; PETRUCKEVITCH, A; BURNEY, PGJ			SURVIVAL WITH BLADDER-CANCER, EVALUATION OF DELAY IN TREATMENT, TYPE OF SURGEON, AND MODALITY OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DEATH RATES; GEOGRAPHICAL VARIATION; MORTALITY; QUALITY; RADIOTHERAPY; CYSTECTOMY; CARCINOMA; SEVERITY; ILLNESS; CARE	Objective-To determine whether length of delay before treatment; specialty and grade of the surgeon; and use made of surgery, radiotherapy, and chemotherapy influenced the survival of patients with cancer of the bladder, after adjusting for case severity. Design-Retrospective cohort study. Setting-South East and South West Thames health regions. Patients-609 men aged under 75 resident in the South Thames regions who had been registered as new cases of bladder cancer in 1982, 35 of whom were excluded, leaving 574 eligible patients. Analysis was based on 75% retrieval rate for case notes. Main outcome measures-Duration of survival from date of diagnosis of the bladder tumour. Results-10 prognostic variables were used to adjust for case severity. The median delay from referral to first treatment was 48 (interquartile range 27-84) days. Treatment after a short delay was associated with shorter survival because of the early treatment of more severe cases. Consultants treated 68% of patients, trainee surgeons treated less severe cases. Initial treatment was by a urologist in 67% of cases, but the specialty of the surgeon was not associated with prognosis. The associations of radiotherapy, cystectomy, and systemic chemotherapy with survival were interpreted in terms of selection bias as well as therapeutic effect. Conclusions-Case severity was the most important influence on survival and influenced length of delay before treatment, grade and specialty of the surgeon, and main treatment allocation. After adjusting for case severity variations in these processes of care were not strongly associated with variations in survival.			GULLIFORD, MC (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT PUBL HLTH MED,ST THOMAS CAMPUS,LONDON SE1 7EH,ENGLAND.		Gulliford, Martin C/I-8606-2018	Gulliford, Martin C/0000-0003-1898-9075; Burney, Peter/0000-0001-8635-5678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABEL PD, 1988, BRIT J UROL, V62, P103, DOI 10.1111/j.1464-410X.1988.tb04286.x; ASO Y, 1986, PROG CLIN BIOL RES, V162, P257; BISHOP MC, 1990, BRIT J UROL, V65, P433, DOI 10.1111/j.1464-410X.1990.tb14781.x; Buck N, 1987, REPORT CONFIDENTIAL; CHARLTON JRH, 1983, LANCET, V1, P691; DELAMOTHE T, 1990, BRIT MED J, V301, P1011; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P759; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GULLIFORD MC, 1991, BRIT MED J, V302, P1128, DOI 10.1136/bmj.302.6785.1128; HOLLAND WW, 1988, EUROPEAN COMMUNITY A; HOPESTONE HF, 1984, UROLOGY, V24, P315, DOI 10.1016/0090-4295(84)90199-7; Hopkins A., 1990, MEASURING QUALITY ME; KARJALAINEN S, 1990, J EPIDEMIOL COMMUN H, V44, P210, DOI 10.1136/jech.44.3.210; MAMEGHAN H, 1989, BRIT J UROL, V63, P251, DOI 10.1111/j.1464-410X.1989.tb05185.x; MOMMSEN S, 1983, SCAND J UROL NEPHROL, V17, P163, DOI 10.3109/00365598309180162; MOULD RF, 1986, LANCET, V1, P1385; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; RICHARDS B, 1986, PROG CLIN BIOL RES, V162, P271; SHEARER RJ, 1988, BRIT J UROL, V62, P558, DOI 10.1111/j.1464-410X.1988.tb04426.x; Silman A J, 1981, Community Med, V3, P291, DOI 10.1007/BF02549184; SOLOWAY MS, 1987, CANCER, V60, P502, DOI 10.1002/1097-0142(19870801)60:3+<502::AID-CNCR2820601512>3.0.CO;2-W; SPIESSL B, 1989, UICC TNM ATLAS, P245; TONKIN K, 1988, MANAGEMENT BLADDER C, P228; TRUNKEY D, 1989, BRIT MED J, V299, P31, DOI 10.1136/bmj.299.6690.31; WALLACE DM, 1965, LANCET, V2, P332; 1990, REV NATIONAL CANCER, P9; 1980, BMJ, V280, P590; 1982, CANCER STATISTIC MB1	31	54	54	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					437	440		10.1136/bmj.303.6800.437	http://dx.doi.org/10.1136/bmj.303.6800.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912834	Green Published, Bronze			2022-12-28	WOS:A1991GC46500014
J	LEYLAND, AH; PRITCHARD, CW; MCLOONE, P; BODDY, FA				LEYLAND, AH; PRITCHARD, CW; MCLOONE, P; BODDY, FA			MEASURES OF PERFORMANCE IN SCOTTISH MATERNITY HOSPITALS	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY	Objective - To develop measures of hospital Performance over time with particular reference to maternal and neonatal care by controlling for case mix. Design - Analysis of computerised records of births. Setting - Scotland, 1980-7. Subjects - Over half a million singleton live births and stillbirths. Main outcome measures - Numbers of perinatal deaths and caesarean sections. Results - Scottish maternity hospitals perform more or less equally with regard to perinatal mortality. When caesarean sections are considered, there is evidence that hospitals differ in their treatment of different groups of women; in two examples one hospital had an increased rate among women of parity 2 or more and another had a reduced rate of repeat caesarean section. Conclusions - Developing measures of performance over time by controlling for case mix is a valid system for monitoring hospital outcomes and activity, and allows comparison either between hospitals or with data for all Scottish maternity hospitals. Hospital profiles permit identification of differences for particular patient groups after allowance is made for other case mix variables.			LEYLAND, AH (corresponding author), UNIV GLASGOW,SOCIAL PAEDIAT & OBSTET RES UNIT,GLASGOW G12 8RZ,SCOTLAND.		Leyland, Alastair/C-6069-2011; McLoone, Philip/H-2353-2017	McLoone, Philip/0000-0003-0002-8700; Leyland, Alastair/0000-0003-3741-7099				Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; Brand R, 1990, Paediatr Perinat Epidemiol, V4, P221, DOI 10.1111/j.1365-3016.1990.tb00640.x; Brand R, 1990, Paediatr Perinat Epidemiol, V4, P22, DOI 10.1111/j.1365-3016.1990.tb00615.x; COLE SK, 1980, PERINATAL AUDIT SURV, P39; DEMPSTER AP, 1981, J AM STAT ASSOC, V76, P341, DOI 10.2307/2287835; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DESHARNAIS SI, 1988, MED CARE, V26, P1129, DOI 10.1097/00005650-198812000-00004; KNOX EG, 1986, J EPIDEMIOL COMMUN H, V40, P193, DOI 10.1136/jech.40.3.193; LOWRY S, 1988, BRIT MED J, V296, P992, DOI 10.1136/bmj.296.6627.992; LYNCH ML, 1990, VARIATION HOSPITAL C; PAYNE CD, 1985, GLIM SYSTEM RELEASE; PICKERING RM, 1986, POP STUD-J DEMOG, V40, P115, DOI 10.1080/0032472031000141876; SMITH P, 1990, J ROY STAT SOC A STA, V153, P53, DOI 10.2307/2983096; STILWELL J, 1988, J EPIDEMIOL COMMUN H, V42, P157, DOI 10.1136/jech.42.2.157; TYSON J, 1990, PEDIATRICS, V85, P195; WILLIAMS RL, 1980, AM J OBSTET GYNECOL, V136, P559, DOI 10.1016/0002-9378(80)91003-0; WONNACOTT TH, 1972, INTRO STATISTICS; 1991, LANCET, V337, P331	19	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					389	393		10.1136/bmj.303.6799.389	http://dx.doi.org/10.1136/bmj.303.6799.389			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1912806	Bronze, Green Published			2022-12-28	WOS:A1991GB59900015
J	KALLIO, T				KALLIO, T			ASSESSMENT OF BLOOD ECHOGENICITY AS AN ALTERNATIVE MEASURE TO ERYTHROCYTE SEDIMENTATION-RATE	BRITISH MEDICAL JOURNAL			English	Article							RED-CELL AGGREGATION; HEMATOCRIT; FLOW	Objective-To determine the relation between erythrocyte sedimentation rate and blood echogenicity and whether measurement of erythrocyte sedimentation rate could be replaced by measurement of blood echogenicity in monitoring acute phase reactions. Design-Simultaneous measurement of echogenicity of flowing blood and erythrocyte sedimentation rate in blood samples and comparison of results. Setting-A radiological department in a university hospital. Subjects-83 patients with a suspected venous thrombosis and 36 healthy volunteers. Main outcome measures-Correlations between the erythrocyte sedimentation rate, packed cell volume, and echogenicity of flowing blood. Results-Blood echogenicity correlated poorly with the packed cell volume, but strongly correlated with the erythrocyte sedimentation rate (when the packed cell volume was within reference limits) (correlation coefficient = 0.73). Blood samples with a greatly raised erythrocyte sedimentation rate were highly echogenic. Only one of the 30 samples with an erythrocyte sedimentation rate below 10 mm in first hour had a higher echogenicity than the least echogenic sample of the 19 with a sedimentation rate above 30 mm in first hour. Conclusions-Echogenicity of flowing blood correlates with the erythrocyte sedimentation rate and its measurement may compete with conventional methods for evaluating the long term changes in acute phase reactions. Also, it has the added advantage that non-invasive in vivo measurements of blood echogenicity may become possible.			KALLIO, T (corresponding author), TURKU UNIV HOSP,DEPT DIAGNOST RADIOL,SF-20520 TURKU,FINLAND.							ALANEN A, 1985, INVEST RADIOL, V20, P521, DOI 10.1097/00004424-198508000-00014; BORDERS SE, 1978, ANN BIOMED ENG, V6, P83, DOI 10.1007/BF02584535; Fahraus R.S., 1921, ACTA MED SCAND, V55, P1, DOI [10.1111/j.0954-6820.1921.tb15200.x, DOI 10.1111/J.0954-6820.1921.TB15200.X]; KALLIO T, 1988, INVEST RADIOL, V23, P832, DOI 10.1097/00004424-198811000-00006; NEIJADLIK DC, 1977, AM J CLIN PATHOL, V68, P766; RAMPLING MW, 1986, KLIN WOCHENSCHR, V64, P1084; Shung K. K., 1983, J CARDIOVASC ULTRAS, V2, P401; SHUNG KK, 1985, J BIOMECH ENG-T ASME, V107, P309, DOI 10.1115/1.3138561; SIGEL B, 1983, RADIOLOGY, V148, P799, DOI 10.1148/radiology.148.3.6878705; SIGEL B, 1982, INVEST RADIOL, V17, P29, DOI 10.1097/00004424-198201000-00005; STUART J, 1988, BMJ-BRIT MED J, V297, P1143, DOI 10.1136/bmj.297.6657.1143; WOLVERSON MK, 1981, RADIOLOGY, V140, P443, DOI 10.1148/radiology.140.2.7255721; YUAN YW, 1988, J ACOUST SOC AM, V84, P52, DOI 10.1121/1.397238; 1988, J CLIN PATHOL, V41, P1203; 1982, LANCET, V1, P377	15	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					87	89		10.1136/bmj.303.6794.87	http://dx.doi.org/10.1136/bmj.303.6794.87			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1907211	Green Published, Bronze			2022-12-28	WOS:A1991FW58600019
J	BOLLAG, G; MCCORMICK, F				BOLLAG, G; MCCORMICK, F			DIFFERENTIAL REGULATION OF RASGAP AND NEUROFIBROMATOSIS GENE-PRODUCT ACTIVITIES	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; TYPE-1 GENE; GAP; P21; DOMAIN; STIMULATION; INTERACTS; ENCODES; CLONING; LIPIDS	THE ras-encoded p21ras proteins bind GTP very tightly, but catalyse hydrolysis to GDP very slowly 1. In humans, two genes encode proteins that stimulate this GTPase activity (GAP, or GTPase-activating proteins)2, one of relative molecular mass 120,000, referred to as p120-GAP, and another NF1-GAP, which is encoded by the neurofibromatosis type-1 gene 3-5. Both GAPs are widely expressed in mammalian tissues 6,7. Here we show that although they will both bind oncogenic mutants of p21ras, neither will stimulate their GTPase activity. NF1-GAP binds to the p21ras proteins up to 300 times more efficiently than p120-GAP. The two GAPs are inhibited to different extents by certain lipids: micromolar concentrations of arachidonate, phosphatidate and phosphatidylinositol-4,5-bisphosphate affect only NF1-GAP. This inhibition does not compete with p21ras, and lipid-inactivated NF1-GAP can still bind p21ras. We used the detergent dodecyl maltoside, which inhibits only NF1-GAP, to distinguish between the two activities in cell extracts and found both types present together in several mammalian cell lines. In contrast, GAP activity in extracts of Xenopus oocytes was not affected by dodecyl maltoside. By these criteria, the mammalian cells contain both GAP activities and the oocytes have only p120-like GAP activity. These results indicate that more than one GAP regulates p21ras in the same cell.			BOLLAG, G (corresponding author), CETUS CORP,DEPT MOLEC BIOL,1400 53RD ST,EMERYVILLE,CA 94608, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	24	303	309	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					576	579		10.1038/351576a0	http://dx.doi.org/10.1038/351576a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1904555				2022-12-28	WOS:A1991FR03400062
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERNATIONAL-CONFERENCE ON HARMONIZING TECHNICAL REQUIREMENTS FOR DRUG APPROVALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-28	WOS:A1991FP63500005
J	NAMBUDRIPAD, R; STARK, W; OPELLA, SJ; MAKOWSKI, L				NAMBUDRIPAD, R; STARK, W; OPELLA, SJ; MAKOWSKI, L			MEMBRANE-MEDIATED ASSEMBLY OF FILAMENTOUS BACTERIOPHAGE-PFL COAT PROTEIN	SCIENCE			English	Article							RESOLUTION	Filamentous bacteriophage Pfl assembles by a membrane-mediated process during which the viral DNA is secreted through the membrane while being encapsulated by the major coat protein. Neutron diffraction studies showed that in the virus most of the coat protein consists of two alpha-helical segments arranged end-to-end with an intervening mobile surface loop. Nuclear magnetic resonance studies of the coat protein in the membrane-bound form have shown that the secondary structure is essentially identical to that in the intact virus. A comparison indicates that during membrane-mediated viral assembly, while the secondary structure of the coat protein is largely conserved, its tertiary structure changes substantially.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	Boston University; Columbia University; University of Pennsylvania								ALBERI J, 1975, IEEE T NUCL SCI, VNS22, P255, DOI 10.1109/TNS.1975.4327648; CROSS TA, 1983, BIOCHEMISTRY-US, V13, P211; GREENWOOD J, 1989, VIROLOGY, V171, P444, DOI 10.1016/0042-6822(89)90613-2; HUNTER GJ, 1988, J MOL BIOL, V204, P663; MAKOWSKI L, 1978, J APPL CRYSTALLOGR, V11, P273, DOI 10.1107/S002188987801331X; MAKOWSKI L, 1980, J MOL BIOL, V140, P149, DOI 10.1016/0022-2836(80)90101-1; MAKOWSKI L, 1984, BIOL MACROMOL, V1, P203; MARVIN DA, 1966, J MOL BIOL, V15, P8, DOI 10.1016/S0022-2836(66)80205-X; Model P., 1988, BACTERIOPHAGES, P375; NAMBUDRIPAD R, IN PRESS J MOL BIOL; OHAKAWA I, 1981, J BIOL CHEM, V256, P9951; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; SCHEFER J, 1986, NUCL INSTRUM METH A, V252, P180; SCHOENBORN BP, 1984, NEUTRONS BIOL, P1; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; STARK W, 1988, J MOL BIOL, V199, P171, DOI 10.1016/0022-2836(88)90387-7; WICKNER W, 1975, P NATL ACAD SCI USA, V72, P4749, DOI 10.1073/pnas.72.12.4749	17	55	56	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1305	1308		10.1126/science.1925543	http://dx.doi.org/10.1126/science.1925543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925543				2022-12-28	WOS:A1991FN85700039
J	LUBS, MLE; BAUER, MS; FORMAS, ME; DJOKIC, B				LUBS, MLE; BAUER, MS; FORMAS, ME; DJOKIC, B			LISCH NODULES IN NEUROFIBROMATOSIS TYPE-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; IRIS HAMARTOMATA		MIAMI CHILDRENS HOSP, MIAMI, FL 33155 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, DIV GENET, MIAMI, FL 33152 USA	University of Miami								[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; CAWTHON, 1990, CELL, V62, P609; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHARLES SJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1571, DOI 10.1001/archopht.1989.01070020649012; CROWE FW, 1956, CLIN PATHOLOGICAL GE, V146, P153; FLUELER U, 1986, NEUROPEDIATRICS, V17, P183, DOI 10.1055/s-2008-1052525; GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Kendall M. G., 1955, RANK CORRELATION MET; LEWIS RA, 1984, OPHTHALMOLOGY, V91, P929; LEWIS RA, 1981, OPHTHALMOLOGY, V88, P348; Lisch K, 1937, Z AUGENHEILKD, V93, P137; LITTLER M, 1990, J MED GENET, V27, P307, DOI 10.1136/jmg.27.5.307; MURPHY E A, 1973, Birth Defects Original Article Series, V9, P19; Riccardi V, 1986, NEUROFIBROMATOSIS PH, P29; Riccardi V M, 1981, Adv Neurol, V29, P1; Siegel S., 1988, NONPARAMETRIC STAT B; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WAARDENBURG PJ, 1918, NED TIJDSCHR GENEES, V2, P1453; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WARD K, 1990, AM J HUM GENET, V46, P943; ZEHAVI C, 1986, CLIN GENET, V29, P51	23	96	100	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1264	1266		10.1056/NEJM199105023241807	http://dx.doi.org/10.1056/NEJM199105023241807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	1901624				2022-12-28	WOS:A1991FJ82300007
J	ERICKSON, JW; CLINE, TW				ERICKSON, JW; CLINE, TW			MOLECULAR NATURE OF THE DROSOPHILA SEX DETERMINATION SIGNAL AND ITS LINK TO NEUROGENESIS	SCIENCE			English	Article							SCUTE GENE-COMPLEX; DOSAGE COMPENSATION; N-MYC; MELANOGASTER; ACHAETE; EXPRESSION; LETHAL; PROTEINS; ELEMENT; DAUGHTERLESS	In 1921 it was discovered that the sexual fate of Drosophila is determined by the ratio of X chromosomes to sets of autosomes. Only recently has it been found that the X chromosome to autosome (X:A) ratio is communicated in part by the dose of sisterless-b (sis-b), an X-linked genetic element located within the achaete-scute complex of genes involved in neurogenesis. In this report, the molecular nature of the primary sex determination signal and its relation to these proneural genes was determined by analysis of sis-b+ germline transformants. The sis-b+ function is conferred by protein T4, a member of the helix-loop-helix family of transcription factors. Although T4 is shared by sis-b and scute-alpha, the regulatory regions of sis-b, which control T4 expression in sex determination, are both separable from and simpler than those of scute-alpha, which control T4 expression in neurogenesis. Dose-sensitive cooperative interactions in the assembly or binding of sis-dependent transcription factors may directly determine the activity of the female-specific promoter of Sex-lethal, the master regulator of sexual development. In this model there is no need to invoke the existence of analogous autosomal negative regulators of Sex-lethal.			ERICKSON, JW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV GENET,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM 23468] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023468] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELL LR, IN PRESS CELL; BENEZRA R, 1990, CELL, V61, P45; Bridges CB, 1925, AM NAT, V59, P127, DOI 10.1086/280023; Bridges CB, 1921, SCIENCE, V54, P252, DOI 10.1126/science.54.1394.252; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CLINE TL, UNPUB; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P1297; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ENGELS WR, 1987, GENETICS, V117, P745; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARELL J, 1990, CELL, V61, P39; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; KEYES L, UNPUB; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LINDSLEY DL, 1985, DROSOPHILA INFO SER, V62; LINDSLEY DL, 1990, DROSOPHILA INFO SER, V68; LINDSLEY DL, 1987, DROSOPHILA INFO SER, V65; LINDSLEY DL, 1986, DROSOPHILA INFO SER, V64; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEINMANNZWICKY H, 1990, ADV GENET, V27, P189; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; Villeneuve A.M., 1990, Advances in Genetics, V27, P117	44	75	75	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1071	1074		10.1126/science.1900130	http://dx.doi.org/10.1126/science.1900130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1900130				2022-12-28	WOS:A1991EZ66500050
J	NELSON, KE; VLAHOV, D; COHN, S; LINDSAY, A; SOLOMON, L; ANTHONY, JC				NELSON, KE; VLAHOV, D; COHN, S; LINDSAY, A; SOLOMON, L; ANTHONY, JC			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN DIABETIC INTRAVENOUS-DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; ABUSERS; EXCHANGE; AIDS	Objective. - To evaluate the association between diabetes and human immunodeficiency virus (HIV) seroprevalence in a population of intravenous (IV) drug users. Design. - Cross-sectional survey in a cohort of IV drug users. Setting. - Community-based study clinic. Subjects. - The study included 2921 individuals with a history of IV drug use in the past 10 years; over 90% had injected drugs in the past year and 77% in the past month; only 15% were receiving drug treatment. Outcome Measures. - The HIV seroprevalence among IV drug users with and without a history of diabetes. Results. - Those IV drug users with a history of diabetes had significantly lower HIV seroprevalence (9.8%) than nondiabetic IV drug users (24.3%; P =.03). Despite similar duration and intensity of drug use and sexual practices, diabetic IV drug users tended not to share injection paraphernalia and were less likely to attend shooting galleries than nondiabetic IV drug users. Conclusion. - Our data suggest that the apparent protective effect of diabetes against HIV infection in IV drug users is most likely due to their safer injection practices afforded by their ready access to sterile injection equipment.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MENTAL HYG,BALTIMORE,MD 21218	Johns Hopkins University; Maryland Department of Health & Mental Hygiene	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY ST,ROOM 763,BALTIMORE,MD 21218, USA.		Anthony, Jim/H-3637-2011	Anthony, Jim/0000-0001-7176-0929	NIDA NIH HHS [DA0S664, DA04334] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R37DA004334] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Allen J, 1981, INFECTION COMPROMISE, P229; BUNING EC, 1986, LANCET, V1, P1435; CHAISSON RE, 1987, AM J PUBLIC HEALTH, V77, P169, DOI 10.2105/AJPH.77.2.169; ELIASHIV A, 1978, ARCH SURG-CHICAGO, V113, P1180; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; MARMOR M, 1987, AIDS, V1, P39; NELSON KE, 1991, J INFECT DIS, V164, P457, DOI 10.1093/infdis/164.3.457; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROBERTSON JR, 1990, AIDS DRUG MISUSE; ROSEMAN JM, NIH851468 US DEP HLT, P1; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; TAN JS, 1975, J LAB CLIN MED, V85, P26; TIRELLI U, 1986, JAMA-J AM MED ASSOC, V255, P2289, DOI 10.1001/jama.1986.03370170053010; VLAHOV D, 1990, AM J EPIDEMIOL, V132, P847, DOI 10.1093/oxfordjournals.aje.a115727; Vlahov D, 1991, NIDA Res Monogr, V109, P75	17	35	35	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2259	2261		10.1001/jama.266.16.2259	http://dx.doi.org/10.1001/jama.266.16.2259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920726				2022-12-28	WOS:A1991GK66100035
J	STARFIELD, B				STARFIELD, B			PRIMARY CARE AND HEALTH - A CROSS-NATIONAL COMPARISON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES	Ten Western industrialized nations were compared on the basis of three characteristics: the extent of their primary health service, their levels of 12 health indicators (eg, infant mortality, life expectancy, and age-adjusted death rates), and the satisfaction of their populations in relation to overall costs of the systems. Information was derived primarily from published sources. Indices were developed to characterize the extent of primary care in each country and the standing of each country relative to the others on the health indicators. There was general concordance for primary care, the health indicators, and the satisfaction-expense ratio in nine of the 10 countries. Ratings for the United States were low on all three measures. West Germany also had low ratings. In contrast, Canada, Sweden, and the Netherlands had generally high ratings for all three measures. The lack of concordance in the ratings in the United Kingdom may be a result of relatively low expenditures tor other social services and public education in that country. The findings may add to the debate and deliberations concerning modifications in organization and financing of care that are currently being considered in the United States.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University	STARFIELD, B (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY MANAGEMENT,DIV HLTH POLICY,BALTIMORE,MD 21218, USA.							ALPERT J, 1974, PHS US DHEW HRA74311; Beeson P B, 1991, Pharos Alpha Omega Alpha Honor Med Soc, V54, P2; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; Fry J, 1986, PRIMARY HLTH CARE 20; HEINZ J, 1990, COMMUNICATION   0212; HELLANDER I, 1990, HLTH LETT, V6, P9; IGLEHART JK, 1991, NEW ENGL J MED, V324, P503, DOI 10.1056/NEJM199102143240725; MILLIS JS, 1966, GRADUATE ED PHYSICIA, P37; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; STARFIELD B, IN PRESS PRIMARY CAR; STEPHEN W, 1979, ANAL PRIMARY MED CAR; WEINER JP, 1987, MILBANK Q, V65, P426, DOI 10.2307/3349946; WILLIAMS B, 1991, PREVENTIVE HLTH CARE; 1986, MMWR, V35, P29; 1978, IOM PUBLICATION, V7802; 1990, CALL ACTION; 1990, 1990 WORLD BANK WORL; 1986, SOCIAL POLICY STUDIE, V3; 1990, MMWR, V39, P205; 1981, HS90 SWED HLTH SERV; 1986, WORLD STATISTICS ANN	21	149	151	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2268	2271		10.1001/jama.266.16.2268	http://dx.doi.org/10.1001/jama.266.16.2268			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920727				2022-12-28	WOS:A1991GK66100037
J	KNAUS, WA; WAGNER, DP; LYNN, J				KNAUS, WA; WAGNER, DP; LYNN, J			SHORT-TERM MORTALITY PREDICTIONS FOR CRITICALLY ILL HOSPITALIZED ADULTS - SCIENCE AND ETHICS	SCIENCE			English	Article							INTENSIVE-CARE UNIT; HEALTH-CARE; APACHE-II; RESOURCE-ALLOCATION; RATIONING DECISIONS; DISEASE; INEVITABILITY; TECHNOLOGY; STRATEGIES; PRINCIPLES	Modern life-sustaining therapy often succeeds in postponing death but may be ineffective at restoring health. Decisions that influence the time and circumstances of an individual's death are now common and require an accurate and comprehensive characterization of likely outcome. Evaluation of alternative outcomes requires acknowledgment that most patients find some outcomes to be worse than death. Improved understanding of major predictors of patient outcome, combined with rapidly expanding technical abilities to collect and manipulate large amounts of detailed clinical data, have created a new intellectual and technical basis for estimating outcomes from intensive medical care. Such objective probability estimates, such as the system described here, can reduce uncertainty about difficult clinical decisions and can be used by physicians, patients, and society to reorient health care toward more scientifically and ethically defensible approaches.	GEORGE WASHINGTON UNIV,MED CTR,DEPT HLTH CARE SCI,DIV AGING STUDIES & SERV,WASHINGTON,DC 20037	George Washington University	KNAUS, WA (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT ANESTHESIOL,DIV INTENS CARE MED,INTENS CARE UNIT,RES UNIT,WASHINGTON,DC 20037, USA.		Knaus, William/AAX-2138-2020; Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005787] Funding Source: NIH RePORTER; AHRQ HHS [HS05787] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; AFIFI AA, 1971, NEW ENGL J MED, V285, P1497, DOI 10.1056/NEJM197112302852702; CHANG RWS, 1988, INTENS CARE MED, V14, P558, DOI 10.1007/BF00263530; CHANG RWS, 1989, LANCET, V2, P143; CRAWSHAW R, 1990, WESTERN J MED, V152, P441; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P393, DOI 10.7326/0003-4819-99-3-393; GARDNER RM, 1990, MED INFORMATICS COMP, P366; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1990, J CLIN EPIDEMIOL S, V5, P893; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; KALB PE, 1989, JAMA-J AM MED ASSOC, V261, P2389, DOI 10.1001/jama.261.16.2389; KNAUS WA, 1985, J CHRON DIS, V38, P295, DOI 10.1016/0021-9681(85)90075-X; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1984, J CHRON DIS, V37, P455, DOI 10.1016/0021-9681(84)90029-8; KNAUS WA, IN PRESS CHEST; KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206; KRUSE JA, 1988, JAMA-J AM MED ASSOC, V260, P1739, DOI 10.1001/jama.260.12.1739; LUBITZ J, 1984, HLTH CARE FINANC REV, V7, P53; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MCCLISH DK, 1989, MED DECIS MAKING, V9, P125, DOI 10.1177/0272989X8900900207; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; MEDAWAR PB, 1984, LIMITS SCI, P4; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V5, P43; PERKINS HS, 1986, CRIT CARE MED, V14, P105, DOI 10.1097/00003246-198602000-00006; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; POSES RM, 1990, MED DECIS MAKING, V10, P6, DOI 10.1177/0272989X9001000103; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHROEDER SA, 1979, NEW ENGL J MED, V300, P1306, DOI 10.1056/NEJM197906073002304; Seneff M, 1990, J INTENSIVE CARE MED, V5, P33, DOI DOI 10.1177/088506669000500107; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SIEGEL JH, 1980, J TRAUMA, V20, P558, DOI 10.1097/00005373-198007000-00005; Sox HC, 1988, MED DECISION MAKING; SPIEGELHALTER DJ, 1984, J R STAT SOC A STAT, V147, P35, DOI 10.2307/2981737; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; WAGNER DP, 1986, ARCH INTERN MED, V146, P1389, DOI 10.1001/archinte.146.7.1389; WENNBERG JE, 1988, HEALTH AFFAIR, V7, P99, DOI 10.1377/hlthaff.7.1.99; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZIMMERMAN JE, 1989, CRIT CARE MED 2 S, V17; 1987, GUIDELINES TERMINATI; 1990, HLTH CARE FINANC REV, V11, P1	52	165	168	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					389	394		10.1126/science.1925596	http://dx.doi.org/10.1126/science.1925596			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925596				2022-12-28	WOS:A1991GK72900036
J	WANG, CY; LOONEY, DJ; LI, ML; WALFIELD, AM; YE, J; HOSEIN, B; TAM, JP; WONGSTAAL, F				WANG, CY; LOONEY, DJ; LI, ML; WALFIELD, AM; YE, J; HOSEIN, B; TAM, JP; WONGSTAAL, F			LONG-TERM HIGH-TITER NEUTRALIZING ACTIVITY INDUCED BY OCTAMERIC SYNTHETIC HIV-1 ANTIGEN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATERNAL ANTIBODIES; GLYCOPROTEIN GP120; ENVELOPE PROTEIN; TYPE-1 ENVELOPE; AIDS VACCINES; T-CELL; PEPTIDE; CHIMPANZEES; DETERMINANT	A titer for homologous viral neutralization activity (> 1:19,683) was observed after a 3.5-year immunization period with an octameric, branching peptide representing the principal neutralizing determinant (PND) of the human immunodeficiency virus-1IIIB envelope protein. Booster immunizations elicited persistent and potent antibodies in guinea pigs, exceeding responses produced by a conventional bovine serum albumin conjugate by 100-fold. Peptide length, central presentation of a conserved sequence, and inclusion of an upstream sequence contributed to immunogenicity. Titers (> 1:1,000) of heterotypic neutralizing antibodies also developed. Octameric PND peptides are a promising approach for an acquired immunodeficiency syndrome (AIDS) vaccine.	VET ADM MED CTR,SAN DIEGO,CA 92161; VET ADM MED CTR,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; ROCKEFELLER UNIV,NEW YORK,NY 10021	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; Rockefeller University	WANG, CY (corresponding author), UNITED BIOMED INC,LAKE SUCCESS,NY 11042, USA.		Tam, James P/A-2176-2011	Tam, James P/0000-0003-4433-198X	NIAID NIH HHS [IU01-AI-30238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; MATTHEWS TJ, 1988, SCI AM, V259, P120, DOI 10.1038/scientificamerican1088-120; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCOTT CF, 1990, P NATL ACAD SCI USA, V87, P8597, DOI 10.1073/pnas.87.21.8597; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TSCHACHLER E, 1990, J VIROL, V64, P2250, DOI 10.1128/JVI.64.5.2250-2259.1990; Wang C.-W., UNPUB; WANG CY, 1989, Patent No. 328403; WANG JJG, 1986, P NATL ACAD SCI USA, V83, P6159, DOI 10.1073/pnas.83.16.6159	26	124	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					285	288		10.1126/science.1925584	http://dx.doi.org/10.1126/science.1925584			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925584				2022-12-28	WOS:A1991GJ64200039
J	DAVIES, M; ALBANDAVIES, H; COOK, C; DAY, J				DAVIES, M; ALBANDAVIES, H; COOK, C; DAY, J			SELF TESTING FOR DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To develop a simple, economically viable, and effective means of population screening for diabetes mellitus. Design - A postal request system for self testing for glycosuria with foil wrapped dipsticks. Preprandial and postprandial tests were compared with a single postprandial test. The subjects were instructed how to test, and a result card was supplied on which to record and return the result. All those recording a positive test result and 50 people recording a negative result were invited for an oral glucose tolerance test. Setting - General practice in east Suffolk, list size 11 534. Patients - All subjects aged 45-70 years registered with the practice were identified by Suffolk Family Health Services Authority (n = 3057). The 73 subjects known to have diabetes from the practice's register were excluded, leaving 2984 subjects, 2363 (79.2%) of whom responded. 1167 subjects completed the single test and 1196 the two tests. Main outcome measures - Response rate and number of patients with glycosuria. Sensitivity, specificity, and positive predictive value of a single postprandial test and preprandial and postprandial tests. Number of new cases of diabetes identified and cost of screening. Results - Of the patients completing the single postprandial test, 29 had a positive result; an oral glucose tolerance test showed that eight (28%) had diabetes, six (21%) impaired glucose tolerance, and 14 (48%) normal glucose tolerance. 44 of the group who tested before and after eating had a positive result; nine (20%) had diabetes, five (11%) impaired tolerance, and 26 (11%) normal tolerance. Screening cost 59p per subject and 81 pounds per case detected. Of the 17 people with previously undiagnosed diabetes, eight were asymptomatic and 11 had not visited their general practitioner in the past three months. Conclusions - A postal request system for self testing for postprandial glycosuria in people aged 45-70 is a simple and effective method of population screening for diabetes mellitus.	W HILL HOSP,DARTFORD,KENT,ENGLAND; LATTICE BARN SURG,IPSWICH IP4 5PA,SUFFOLK,ENGLAND		DAVIES, M (corresponding author), IPSWICH DIABET CTR,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.			Davies, Melanie/0000-0002-9987-9371				Bitzen P O, 1986, Scand J Prim Health Care, V4, P85, DOI 10.3109/02813438609014809; BUTTERFIELD WJ, 1967, BMJ-BRIT MED J, V4, P505, DOI 10.1136/bmj.4.5578.505; EDMONDS ME, 1986, Q J MED, V60, P763; FORREST RD, 1987, DIABETIC MED, V4, P254, DOI 10.1111/j.1464-5491.1987.tb00875.x; GATLING W, 1985, J ROY COLL PHYS LOND, V19, P248; HOWARDWILLIAMS J, 1984, DIABETOLOGIA, V27, P198; JARRETT RJ, 1982, DIABETES HYPERGLYCAE, P179; LAING W, 1982, DIABETES MODEL HLTH, P37; NABARRO JDN, 1988, DIABETIC MED, V5, P816, DOI 10.1111/j.1464-5491.1988.tb01117.x; RAYNER C, 1989, WOMAN           0619; REID JJA, 1960, MED OFFR, V103, P325; SHARP CL, 1964, P ROY SOC MED, V57, P193, DOI 10.1177/003591576405700319; VASQUEZ B, 1984, DIABETOLOGIA, V26, P127, DOI 10.1007/BF00281119; WAUGH NR, 1986, THESIS U DUNDEE DUND; 1985, WHO TECH REP SER, V727; 1962, BMJ, V1, P1497	16	21	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					696	698		10.1136/bmj.303.6804.696	http://dx.doi.org/10.1136/bmj.303.6804.696			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912918	Green Published, Bronze			2022-12-28	WOS:A1991GG98000025
J	ONG, ELC; BILTON, D; ABBOTT, J; WEBB, AK; MCCARTNEY, RA; CAUL, EO				ONG, ELC; BILTON, D; ABBOTT, J; WEBB, AK; MCCARTNEY, RA; CAUL, EO			INFLUENZA VACCINATION IN ADULTS WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									MONSALL HOSP,ADULT CYST FIBROSIS UNIT,MANCHESTER M10 8WR,ENGLAND; MONSALL HOSP,REG DEPT INFECT DIS & TROP MED,MANCHESTER M10 8WR,ENGLAND; REG PUBL HLTH & DIST VIROL LAB,BRISTOL BS2 8EL,ENGLAND					Ong, Edmund/0000-0002-6594-0509; Bilton, Diana/0000-0002-1913-9171				DAVIES JR, 1989, EPIDEMIOL INFECT, V102, P325, DOI 10.1017/S0950268800030004; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; GRILLI EA, 1983, J HYG-CAMBRIDGE, V91, P147, DOI 10.1017/S0022172400060125; ONG ELC, 1989, THORAX, V4, P739; WANG EEL, 1984, NEW ENGL J MED, V311, P1653, DOI 10.1056/NEJM198412273112602	5	23	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					557	557		10.1136/bmj.303.6802.557	http://dx.doi.org/10.1136/bmj.303.6802.557			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912886	Green Published, Bronze			2022-12-28	WOS:A1991GE94800024
J	MUELLER, LD; GUO, PZ; AYALA, FJ				MUELLER, LD; GUO, PZ; AYALA, FJ			DENSITY-DEPENDENT NATURAL-SELECTION AND TRADE-OFFS IN LIFE-HISTORY TRAITS	SCIENCE			English	Article							FOOD-LIMITED ENVIRONMENTS; POPULATION-GROWTH; K-SELECTION; REGULATED SELECTION; DROSOPHILA MODEL; ESCHERICHIA-COLI; R-SELECTION; EVOLUTION; PLEIOTROPY	Theories of density-dependent natural selection state that at extreme population densities evolution produces alternative life histories due to trade-offs. The trade-offs are presumed to arise because those genotypes with highest fitness at high population densities will not also have high fitness at low density and vice-versa. These predictions were tested by taking samples from six populations of Drosophila melanogaster kept at low population densities (r-populations) for nearly 200 generations and placing them in crowded cultures (K-populations). After 25 generations in the crowded cultures, the derived K-populations showed growth rate and productivity that at high densities were elevated relative to the controls, but at low density were depressed.			MUELLER, LD (corresponding author), UNIV CALIF IRVINE,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92717, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007008] Funding Source: NIH RePORTER; NCRR NIH HHS [S07 RR07008] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON WW, 1971, AM NAT, V105, P489, DOI 10.1086/282741; ANDERSON WW, 1983, AM NAT, V121, P649, DOI 10.1086/284092; ASMUSSEN MA, 1983, GENETICS, V103, P335; BARCLAY HJ, 1981, AM NAT, V117, P944, DOI 10.1086/283779; BRADSHAW WE, 1989, AM NAT, V133, P869, DOI 10.1086/284957; CHARLESWORTH B, 1971, ECOLOGY, V52, P469, DOI 10.2307/1937629; CLARKE B, 1972, AM NAT, V106, P1, DOI 10.1086/282747; GUO P, UNPUB; HAYMER DS, 1983, GENETICS, V104, P343; LENSKI RE, 1988, EVOLUTION, V42, P433, DOI 10.1111/j.1558-5646.1988.tb04150.x; Loeschcke V, 1987, GENETIC CONSTRAINTS; LUCKINBILL LS, 1978, SCIENCE, V202, P1201, DOI 10.1126/science.202.4373.1201; MAC ARTHUR ROBERT H., 1967; MACARTHUR RH, 1962, P NATL ACAD SCI USA, V48, P1893, DOI 10.1073/pnas.48.11.1893; MUELLER LD, 1988, P NATL ACAD SCI USA, V85, P4383, DOI 10.1073/pnas.85.12.4383; MUELLER LD, 1988, AM NAT, V132, P786, DOI 10.1086/284890; MUELLER LD, 1990, EVOL ECOL, V4, P290, DOI 10.1007/BF02270928; MUELLER LD, 1981, P NATL ACAD SCI-BIOL, V78, P1303, DOI 10.1073/pnas.78.2.1303; MUELLER LD, 1986, EVOLUTION, V40, P1354, DOI 10.1111/j.1558-5646.1986.tb05761.x; MUELLER LD, 1988, EVOLUTION, V42, P1090; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROSE MR, 1985, THEOR POPUL BIOL, V28, P342, DOI 10.1016/0040-5809(85)90034-6; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; ROUGHGARDEN J, 1971, ECOLOGY, V52, P453, DOI 10.2307/1937628; Roughgarden J., 1979, THEORY POPULATION GE; TAYLOR CE, 1980, EVOLUTION, V34, P1183, DOI 10.1111/j.1558-5646.1980.tb04064.x	26	95	95	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					433	435		10.1126/science.1907401	http://dx.doi.org/10.1126/science.1907401			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FY288	1907401	Green Submitted			2022-12-28	WOS:A1991FY28800036
J	CAREY, WD				CAREY, WD			GASTROENTEROLOGY AND HEPATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT INTERFERON-ALFA; PRIMARY BILIARY-CIRRHOSIS; CHRONIC HEPATITIS-C; NON-B-HEPATITIS; CONTROLLED TRIAL; NON-A; ADJUVANT THERAPY; DOUBLE-BLIND; CHOLECYSTECTOMY; OMEPRAZOLE				CAREY, WD (corresponding author), CLEVELAND CLIN,CLEVELAND,OH 44106, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BACHS L, 1989, LANCET, V1, P574; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; GADACZ TR, 1990, SURG CLIN N AM, V70, P1249; GALLE PR, 1990, HEPATOLOGY, V12, P486, DOI 10.1002/hep.1840120307; GHENT CN, 1988, GASTROENTEROLOGY, V94, P488, DOI 10.1016/0016-5085(88)90442-8; HASAN F, 1990, HEPATOLOGY, V12, P589, DOI 10.1002/hep.1840120323; Koretz R L, 1990, Hepatology, V12, P613; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MATON PN, 1989, GASTROENTEROLOGY, V97, P827, DOI 10.1016/0016-5085(89)91485-6; MAYER RJ, 1990, NEW ENGL J MED, V322, P399, DOI 10.1056/NEJM199002083220610; MCFARLAND RJ, 1990, GASTROENTEROLOGY, V98, P278, DOI 10.1016/0016-5085(90)90815-I; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PRYSTOWSKY JB, 1990, SURG CLIN N AM, V70, P1231; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; Zuckerman A J, 1990, Hepatology, V11, P320, DOI 10.1002/hep.1840110224	21	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3121	3123						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1904104				2022-12-28	WOS:A1991FQ77000018
J	SWAT, W; IGNATOWICZ, L; VONBOEHMER, H; KISIELOW, P				SWAT, W; IGNATOWICZ, L; VONBOEHMER, H; KISIELOW, P			CLONAL DELETION OF IMMATURE CD4+8+ THYMOCYTES IN SUSPENSION-CULTURE BY EXTRATHYMIC ANTIGEN-PRESENTING CELLS	NATURE			English	Article							TRANSGENIC MICE; T-CELLS; TOLERANCE; RECEPTOR; THYMUS	ONE mechanism ensuring self tolerance of T cells is the clonal deletion of thymocytes bearing alpha-beta T-cell receptors 1-4. The stage of thymocyte development at which the interaction with antigen-presenting cells (APCs) leads to deletion, however, has not been determined directly. Indirect evidence suggests that intrathymic APCs induce deletion of CD4+8+ thymocytes 3-6 (which die by apoptosis 7) but deletion at less 8 and more mature 9 developmental stages has also been implied. It is also not clear if clonal elimination of thymocytes can be triggered by peripheral antigens carried on extrathymic APCs migrating through the thymus 10. Here we show antigen-specific induction of apoptosis in CD4+8+ thymocytes cultured in suspension, by thymic as well as splenic APCs. Thus the recognition of antigen by CD4+8+ thymocytes may lead to deletion, suggesting that this is the central mechanism of tolerance induction, which is not limited by the antigen-presenting ability of the thymic stroma.	POLISH ACAD SCI,INST IMMUNOL & EXPTL THERAPY,UL CZERSKA 12,PL-53114 WROCLAW,POLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences								CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LONGO DL, 1980, NATURE, V287, P44, DOI 10.1038/287044a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	18	268	269	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					150	153		10.1038/351150a0	http://dx.doi.org/10.1038/351150a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903182				2022-12-28	WOS:A1991FL03500052
J	HUGHES, JS				HUGHES, JS			HOW WELL HAS CANADA CONTAINED THE COSTS OF DOCTORING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-INDUCED DEMAND; EXPENDITURES; CARE	Canada's provinces have had varying success at containing the costs of physician services through the use of fee schedules and expenditure targets. This article examines the wide variation in the increases in the costs of physician services among Ontario, Quebec, and British Columbia between 1975 and 1987. Cost increases during that time resulted from various combinations of increases in prices (fees) and utilization, stimulated by an increased supply of physicians. Differences among the three provinces resulted from differences in the aggressiveness of fee schedule controls and whether expenditure targets were imposed. Regardless of the degree of expenditure increases, utilization increased steadily in all three provinces and was associated most consistently with growth in the supply of physicians. This was most dramatically illustrated in Quebec, which noted the most rapid rise in physician-to-population ratio. Cost containment may ultimately require constraints on the number of new physicians in addition to controls on fees and utilization.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510	Yale University								AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; BARER ML, 1988, MILBANK Q, V66, P1, DOI 10.2307/3349985; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FUCHS VR, 1990, SCIENCE, V247, P534, DOI 10.1126/science.2300814; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GABEL JR, 1985, J HEALTH POLIT POLIC, V9, P595, DOI 10.1215/03616878-9-4-595; GINSBURG PB, 1990, HEALTH AFFAIR, V9, P178, DOI 10.1377/hlthaff.9.1.178; Hadley J, 1979, Inquiry, V16, P247; HOLOHAN J, 1979, MILBANK MEM FUND Q, V57, P183; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; LEE PR, 1989, JAMA-J AM MED ASSOC, V261, P2382, DOI 10.1001/jama.261.16.2382; LEVY JM, 1990, JAMA-J AM MED ASSOC, V264, P717; LOMAS J, 1989, HEALTH AFFAIR, V8, P80, DOI 10.1377/hlthaff.8.1.80; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; REINHARDT UE, 1985, J HEALTH ECON, V4, P187, DOI 10.1016/0167-6296(85)90008-6; RICE TH, 1983, MED CARE, V21, P803, DOI 10.1097/00005650-198308000-00004; ROBACK G, 1990, PHYSICIAN CHARACTERI; STOBERT S, 1988, PAYMENT SCHEDULE INC; WILENSKY GR, 1983, MILBANK FUND Q, V61, P252, DOI 10.2307/3349907; 1988, AM OSTEOPATHIC ASS Y, P514; 1990, Q DEMOGRAPHIC STATIS, P10; 1983, Q ESTIMATES POPULATI, P8; 1990, NATIONAL HLTH EXPEND; 1990, CONSUMER PRICES PRIC, P58; 1990, SOC SECURITY B, V53, P58; 1990, SOC SECURITY B, V53, P60	26	26	26	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2347	2351		10.1001/jama.265.18.2347	http://dx.doi.org/10.1001/jama.265.18.2347			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ955	1901921				2022-12-28	WOS:A1991FJ95500028
J	BRETT, A; GRODIN, M				BRETT, A; GRODIN, M			ETHICAL ASPECTS OF HUMAN-EXPERIMENTATION IN HEALTH-SERVICES RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST CONTAINMENT; CONTROLLED TRIAL		HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,PROGRAM ETH & PROFESS,CAMBRIDGE,MA 02138; BOSTON UNIV,SCH MED,CITY BOSTON DEPT HLTH & HOSP,BOSTON,MA 02118; BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118	Harvard University; Harvard Medical School; Harvard University; Boston University; Boston University	BRETT, A (corresponding author), NEW ENGLAND DEACONESS HOSP,DEPT MED,BOSTON,MA 02215, USA.			Grodin, Michael/0000-0002-0929-8929				[Anonymous], 1986, HIST THEORY INFORM C; BLOCK PC, 1988, NEW ENGL J MED, V319, P1251, DOI 10.1056/NEJM198811103191904; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BROOTEN D, 1986, NEW ENGL J MED, V315, P934, DOI 10.1056/NEJM198610093151505; Dresser Rebecca S, 1981, IRB, V3, P3, DOI 10.2307/3563611; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; LEVINE RJ, 1986, ETHICS REGULATION CL; MAHLER DM, 1982, JAMA-J AM MED ASSOC, V247, P481, DOI 10.1001/jama.247.4.481; MAIN EK, 1987, NEW ENGL J MED, V316, P480; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; Rivlin Alice M., 1975, ETHICAL LEGAL ISSUES; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; SIDEL VW, 1981, NEW ENGL J MED, V304, P918; Veatch, 1987, PATIENT PARTNER THEO; WEINSTEIN MC, 1986, MED DECIS MAKING, V6, P194, DOI 10.1177/0272989X8600600402; ZIBRAK JD, 1986, NEW ENGL J MED, V315, P292, DOI 10.1056/NEJM198607313150505; 1981, FED REG         0126, V45; US DHEW OS780012 PUB	18	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1854	1857		10.1001/jama.265.14.1854	http://dx.doi.org/10.1001/jama.265.14.1854			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE862	1900895				2022-12-28	WOS:A1991FE86200027
J	SWAN, IRC; GATEHOUSE, S				SWAN, IRC; GATEHOUSE, S			CLINICAL AND FINANCIAL AUDIT OF DIAGNOSTIC PROTOCOLS FOR LESIONS OF THE CEREBELLOPONTINE ANGLE	BRITISH MEDICAL JOURNAL			English	Article							AUDIOLOGIC EVALUATION; ACOUSTIC NEUROMA; TESTS	Objective-To assess the diagnostic efficiency and costs of protocols used for investigating patients with suspected lesions of the cerebellopontine angle. Design-Prospective evaluation of tests of auditory brain stem responses and acoustic reflex thresholds, electronystagmography, and calorics. Positive test results were confirmed or refuted by high resolution computed tomography with intravenous enhancement. Setting-Single general otolaryngology clinic in a teaching hospital. Patients-270 consecutive patients with sensorineural hearing loss requiring investigation to exclude a lesion of the cerebellopontine angle. Main outcome measures-Estimated costs of various diagnostic protocols and performance in detecting tumours of the cerebellopontine angle. Results-Protocols including tests of auditory brain stem responses and acoustic reflex thresholds as sifting tests before computed tomography were clinically acceptable and presented considerable savings over the use of computed tomography in all patients (74000 pounds or 84000 pounds v 122000 pounds). The use of electronystagmography and calorics could not be justified on clinical or financial grounds. Conclusions-Audiological tests of auditory brain stem responses and acoustic reflex thresholds followed by computed tomography constitute the most cost effective protocol for determining suspected lesions of the cerebellopontine angle. Implications-The cost effectiveness of diagnostic protocols should be evaluated throughout the health service.	GLASGOW ROYAL INFIRM,MRC,INST HEARING RES,SCOTTISH SECT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow	SWAN, IRC (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT OTOLARYNGOL,GLASGOW G4 0SF,SCOTLAND.							BARRS DM, 1987, OTOLARYNG HEAD NECK, V96, P523, DOI 10.1177/019459988709600601; CASHMAN MZ, 1983, J OTOLARYNGOL, V12, P180; Harder H, 1988, Acta Otolaryngol Suppl, V452, P5; HART RG, 1981, NEUROSURGERY, V9, P450, DOI 10.1227/00006123-198110000-00021; JERGER S, 1983, AUDIOLOGY, V22, P144; JOHNSON EW, 1977, ARCH OTOLARYNGOL, V103, P152; Jongkees L B, 1973, Otolaryngol Clin North Am, V6, P73; JOSEY A F, 1987, Ear and Hearing, V8, p19S, DOI 10.1097/00003446-198708001-00006; MAIR IWS, 1988, SCAND AUDIOL, V17, P163, DOI 10.3109/01050398809042188; MOFFAT DA, 1989, J LARYNGOL OTOL, V103, P51, DOI 10.1017/S0022215100108023; MUSIEK FE, 1986, EAR HEARING, V7, P100, DOI 10.1097/00003446-198604000-00008; Norre M E, 1978, Acta Otorhinolaryngol Belg, V32, P421; PRIEDE VM, 1984, J LARYNGOL OTOL, V88, P641; REIMER A, 1987, SCAND AUDIOL, V16, P101, DOI 10.3109/01050398709042163; SANDERS JW, 1974, ARCH OTOLARYNGOL, V100, P283; THOMSEN J, 1988, ACTA OTOLARYNGOL S S, V452, P16; TURNER RG, 1984, EAR HEARING, V5, P187, DOI 10.1097/00003446-198407000-00002; 1988, LANCET, V2, P1294	18	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					701	704		10.1136/bmj.302.6778.701	http://dx.doi.org/10.1136/bmj.302.6778.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1902384	Green Published, Bronze			2022-12-28	WOS:A1991FE33300027
J	WHEELER, DA; KYRIACOU, CP; GREENACRE, ML; YU, Q; RUTILA, JE; ROSBASH, M; HALL, JC				WHEELER, DA; KYRIACOU, CP; GREENACRE, ML; YU, Q; RUTILA, JE; ROSBASH, M; HALL, JC			MOLECULAR TRANSFER OF A SPECIES-SPECIFIC BEHAVIOR FROM DROSOPHILA-SIMULANS TO DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							COURTSHIP SONG RHYTHMS; PERIOD GENE; SPECTRAL-ANALYSIS; MUTANTS; LOCUS; DNA; CYCLES	Drosophila males modulate the interpulse intervals produced during their courtship songs. These song cycles, which are altered by mutations in the clock gene period, exhibit a species-specific variation that facilitates mating. We have used chimeric period gene constructs from Drosophila melanogaster and Drosophila simulans in germline transformation experiments to map the genetic control of their song rhythm difference to a small segment of the amino acid encoding information within this gene.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254; UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND	Brandeis University; Brandeis University; Howard Hughes Medical Institute; University of Leicester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021473, P01GM033205] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21473, GM-33205] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETCLARK HC, 1969, ANIM BEHAV, V17, P755, DOI 10.1016/S0003-3472(69)80023-0; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; COWLING DE, 1981, ANIM BEHAV, V29, P924, DOI 10.1016/S0003-3472(81)80030-9; CROSSLEY SA, 1988, ANIM BEHAV, V36, P1098, DOI 10.1016/S0003-3472(88)80069-1; EWING AW, 1988, ANIM BEHAV, V36, P1091, DOI 10.1016/S0003-3472(88)80068-X; Hall J.C., 1990, Advances in Insect Physiology, V22, P221, DOI 10.1016/S0065-2806(08)60007-7; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KYRIACOU CP, 1982, ANIM BEHAV, V30, P794, DOI 10.1016/S0003-3472(82)80152-8; KYRIACOU CP, 1990, BEHAV GENET, V20, P617, DOI 10.1007/BF01065875; KYRIACOU CP, 1980, P NATL ACAD SCI-BIOL, V77, P6729, DOI 10.1073/pnas.77.11.6729; KYRIACOU CP, 1986, SCIENCE, V232, P494, DOI 10.1126/science.3083506; KYRIACOU CP, 1989, ANIM BEHAV, V37, P850, DOI 10.1016/0003-3472(89)90069-9; LOGAN IG, 1989, ANIM BEHAV, V37, P860, DOI 10.1016/0003-3472(89)90070-5; PETERSEN G, 1988, EMBO J, V7, P3939, DOI 10.1002/j.1460-2075.1988.tb03280.x; RAUP DM, 1988, SCIENCE, V241, P94, DOI 10.1126/science.241.4861.94; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; ROBERTS DH, 1987, ASTRON J, V93, P968, DOI 10.1086/114383; RUTILA JE, 1986, J VIROL, V58, P526, DOI 10.1128/JVI.58.2.526-535.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILCHER FV, 1976, ANIM BEHAV, V24, P622, DOI DOI 10.1016/S0003-3472(76)80076-0; TAJIMA Y, 1990, NEUROSCIENCE, V39, P245, DOI 10.1016/0306-4522(90)90237-X; THACKERAY JR, 1990, J MOL EVOL, V31, P389, DOI 10.1007/BF02106054; WHEELER D, UNPUB; WHEELER DA, 1988, BEHAV GENET, V18, P675, DOI 10.1007/BF01066850; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0	29	160	164	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1082	1085		10.1126/science.1900131	http://dx.doi.org/10.1126/science.1900131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1900131				2022-12-28	WOS:A1991EZ66500054
J	FARNSWORTH, CL; MARSHALL, MS; GIBBS, JB; STACEY, DW; FEIG, LA				FARNSWORTH, CL; MARSHALL, MS; GIBBS, JB; STACEY, DW; FEIG, LA			PREFERENTIAL INHIBITION OF THE ONCOGENIC FORM OF RASH BY MUTATIONS IN THE GAP BINDING EFFECTOR DOMAIN	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; P21; PRODUCT; MUTANT; GTPASE; RAS-P21; GENES	The double mutation, D33H/P34S, reduced the transforming activity of oncogenic Ras(H) proteins, G12V and Q61L, 400- and 20-fold, respectively. Remarkably, this same mutation did not reduce the transforming activity of normal Ras(H), nor did it impair the ability of the protein to restore a functional Ras pathway in cells whose endogenous Ras proteins were inhibited. Another mutation in this region, D38N, had similar effects. The mutations reduced downstream coupling efficiency of normal Ras as assessed by yeast adenylyl cyclase stimulation. However, this was offset by decreased GTPase activating protein (GAP) binding, since the latter resulted in elevated GTP-bound mutant Ras in cells. The mutations produced a similar decrease in downstream coupling efficiency of oncogenic Ras, but decreased GAP binding did not compensate because the GTPase activity of oncogenic Ras is not stimulated by GAP. These results imply that preferential inactivation of oncogenic Ras in human tumors may be achieved by reagents designed to inhibit the GAP-binding/"effector" domain of Ras proteins.	MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486; CLEVELAND CLIN EDUC FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44106	Merck & Company; Cleveland Clinic Foundation	FARNSWORTH, CL (corresponding author), TUFTS UNIV,DEPT BIOCHEM,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HATA Y, 1990, J BIOL CHEM, V265, P7104; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1990, SCIENCE, V248, P247; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	40	80	80	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					625	633		10.1016/0092-8674(91)90246-U	http://dx.doi.org/10.1016/0092-8674(91)90246-U			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1899358				2022-12-28	WOS:A1991EX36100018
J	PRINCE, RL; SMITH, M; DICK, IM; PRICE, RI; WEBB, PG; HENDERSON, NK; HARRIS, MM				PRINCE, RL; SMITH, M; DICK, IM; PRICE, RI; WEBB, PG; HENDERSON, NK; HARRIS, MM			PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS - A COMPARATIVE-STUDY OF EXERCISE, CALCIUM SUPPLEMENTATION, AND HORMONE-REPLACEMENT THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE MASS; SPINAL OSTEOPOROSIS; PARATHYROID-HORMONE; WOMEN; FOREARM; FRACTURES; DENSITY; RADIUS; CALCITRIOL; ESTROGEN	Background. Osteoporosis among older women is a major public health problem. We studied the effects of three approaches to the prevention of osteoporosis in women with low bone density. Methods. One hundred twenty postmenopausal women (mean [+/- SD] age, 56 +/- 4) who were selected because they had low forearm bone density were enrolled in a double-blind, placebo-controlled, randomized study comparing the effects of an exercise regimen (exercise group, n = 41), exercise plus dietary calcium supplementation (exercise-calcium group, n = 39), and exercise plus continuous replacement of estrogen and progesterone (exercise-estrogen group, n = 40). Periodically during the two-year study period, we measured the women's bone density at three forearm sites, measured indexes of calcium metabolism, and recorded symptom scores. A comparison group of 42 women (mean age, 55.5 +/- 3.1) with normal bone density was also followed for two years. Results. Significant bone loss in the distal forearm occurred in the group with normal bone density (control group) and the exercise group (change, -2.7 percent and -2.6 percent of the base-line value per year, respectively). Bone loss at the distal forearm site was significantly lower in the exercise-calcium group (-0.5 percent of the base-line value per year), and bone density increased at this site in the exercise-estrogen group (+2.7 percent of the base-line value per year). Bone loss at the median forearm site was significantly lower in the exercise-calcium group (-1.3 percent of the base-line value per year) than in the exercise group (-2.4 percent), and bone density at this site increased significantly in the exercise-estrogen group (+0.8 percent of the base-line value per year). Breast tenderness occurred in 47 percent of the women in the exercise-estrogen group but in only 20 percent in the other two treatment groups. Vaginal bleeding occurred at some time in 52 percent of the women who had not had a hysterectomy in the exercise-estrogen group, as compared with 11 percent and 12.5 percent, respectively, in the exercise and exercise-calcium groups. Conclusions. In postmenopausal women with low bone density, bone loss can be slowed or prevented by exercise plus calcium supplementation or estrogen-progesterone replacement. Although the exercise-estrogen regimen was more effective than exercise and calcium supplementation in increasing bone mass, it also caused more side effects.	KING EDWARD MEM HOSP WOMEN,SUBIACO,WA,AUSTRALIA; UNIV WESTERN AUSTRALIA,SIR CHARLES GAIRDNER HOSP,DEPT CLIN BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA; UNIV WESTERN AUSTRALIA,SIR CHARLES GAIRDNER HOSP,DEPT ENDOCRINOL & DIABET,NEDLANDS,WA 6009,AUSTRALIA	King Edward Memorial Hospital; University of Western Australia; University of Western Australia; University of Western Australia	PRINCE, RL (corresponding author), UNIV WESTERN AUSTRALIA,SIR CHARLES GAIRDNER HOSP,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA.			Briffa, Kathy/0000-0002-0731-4112				BIJVOET OLM, 1969, CLIN SCI, V37, P23; CHOW R, 1987, BMJ-BRIT MED J, V295, P1441, DOI 10.1136/bmj.295.6611.1441; CUMMINGS SR, 1989, J BONE MINER RES  S1, V4, pS327; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; HAGENFELDT Y, 1988, J STEROID BIOCHEM, V31, P49, DOI 10.1016/0022-4731(88)90204-X; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUTCHINSON TA, 1979, LANCET, V2, P705; KANDERS B, 1988, J BONE MINER RES, V3, P145; KENT JC, 1979, BIOCHEM BIOPH RES CO, V89, P155, DOI 10.1016/0006-291X(79)90957-4; KROLNER B, 1980, SCAND J CLIN LAB INV, V40, P665, DOI 10.3109/00365518009091979; LINDSAY R, 1980, LANCET, V2, P1151; MAZESS RB, 1984, J NUCL MED, V25, P281; MCARDLE WD, 1986, EXERCISE PHYSL ENERG, P642; NICHOLSON GC, 1985, CLIN ENDOCRINOL, V22, P597, DOI 10.1111/j.1365-2265.1985.tb02995.x; NORDIN BEC, 1991, J CLIN ENDOCR METAB, V72, P401, DOI 10.1210/jcem-72-2-401; NORDIN BEC, 1987, MED J AUSTRALIA, V146, P300; PRICE RI, 1989, J BONE MINER RES, V4, P149; PRINCE R, 1988, METABOLISM, V37, P727, DOI 10.1016/0026-0495(88)90005-4; PRINCE RL, 1990, J CLIN ENDOCR METAB, V70, P1119, DOI 10.1210/jcem-70-4-1119; PRINCE RL, 1985, BRIT MED J, V290, P735, DOI 10.1136/bmj.290.6470.735; RIGGS BL, 1987, J CLIN INVEST, V80, P979, DOI 10.1172/JCI113191; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; ROSS PD, 1988, J BONE MINER RES, V3, P1; SCHLENKER RA, 1976, CALC TISS RES, V20, P41, DOI 10.1007/BF02546396; SHEIKH MS, 1988, J CLIN INVEST, V81, P126, DOI 10.1172/JCI113283; STJOHN A, 1988, CLIN CHIM ACTA, V178, P215, DOI 10.1016/0009-8981(88)90227-6; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1989, J BONE MINER RES S2, V4, P1	28	438	449	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1189	1195		10.1056/NEJM199110243251701	http://dx.doi.org/10.1056/NEJM199110243251701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922205				2022-12-28	WOS:A1991GL28200001
J	OSMANI, AH; MCGUIRE, SL; OSMANI, SA				OSMANI, AH; MCGUIRE, SL; OSMANI, SA			PARALLEL ACTIVATION OF THE NIMA AND P34CDC2 CELL CYCLE-REGULATED PROTEIN-KINASES IS REQUIRED TO INITIATE MITOSIS IN ASPERGILLUS-NIDULANS	CELL			English	Article							MATURATION-PROMOTING FACTOR; GERMINAL VESICLE BREAKDOWN; XENOPUS CDC2 PROTEIN; HISTONE H-1 KINASE; CONTROL GENE CDC2+; FISSION YEAST; ASPERGILLUS-NIDULANS; M-PHASE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION	We show that in Aspergillus nidulans, p34cdc2 tyrosine dephosphorylation accompanies activation of p34cdc2 as an H1 kinase at mitosis. However, the nimA5 mutation arrests cells in G2 with p34cdc2 tyrosine dephosphorylated and fully active as an H1 kinase. Activation of NIMA is therefore not required for p34Cdc2 activation. Furthermore, mutation of nimT, which encodes a protein with 50% similarity to fission yeast cdc25, causes a G2 arrest and prevents tyrosine dephosphorylation of p34cdc2 but does not prevent full activation of the NIMA protein kinase. Mitotic activation of p34cdc2 by tyrosine dephosphorylation is therefore not required for activation of NIMA. These data suggest that activation of either the p34cdc2 protein kinase or the NIMA protein kinase alone is not sufficient to initiate mitosis. Parallel activation of both cell cycle-regulated protein kinases is required to trigger mitosis.			OSMANI, AH (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA.		Osmani, Stephen A./AAS-3904-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42564] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERGEN LG, 1984, J BACTERIOL, V159, P114, DOI 10.1128/JB.159.1.114-119.1984; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TACHIBANA K, 1987, J CELL SCI, V88, P273; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439	44	209	225	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					283	291		10.1016/0092-8674(91)90180-7	http://dx.doi.org/10.1016/0092-8674(91)90180-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913824				2022-12-28	WOS:A1991GL47000008
J	PULVERER, BJ; KYRIAKIS, JM; AVRUCH, J; NIKOLAKAKI, E; WOODGETT, JR				PULVERER, BJ; KYRIAKIS, JM; AVRUCH, J; NIKOLAKAKI, E; WOODGETT, JR			PHOSPHORYLATION OF C-JUN MEDIATED BY MAP KINASES	NATURE			English	Article							V-JUN; PROTEIN; AP-1; TRANSCRIPTION; ACTIVATION; ENCODES	THE proto-oncogene c-jun is a component of the AP-1 transcription factor family involved in the mediation of nuclear events elicited by extracellular stimuli 1-3. The c-jun protein is negatively regulated by phosphorylation of residues near the carboxy terminus which are dephosphorylated in response to phorbol esters 4. Here we identify two serine residues in the amino terminal A1 transactivation domain which are phosphorylated in response to a variety of mitogens, phorbol esters and activated ras (ref. 5). We present evidence that mitogen-activated protein-serine (MAP) kinases (pp54 and pp42/44) specifically phosphorylate these sites and that their phosphorylation positively regulates the transacting activity of c-jun. The MAP kinase enzymes pp54 and pp42/44 are regulated by tyrosine as well as serine/threonine phosphorylation 6,7. MAP kinase activation of c-jun may underlie the common stimulation of this transcription factor by mitogens, growth factors and oncogenes.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114	Ludwig Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; KYRAIKIS JM, 1991, FASEB J, V5, pA797; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; VICENDO P, 1991, BIOCHEM J, V278, P435, DOI 10.1042/bj2780435; WOODGETT JR, 1990, SEMIN CANCER BIOL, V4, P389	20	1405	1437	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					670	674		10.1038/353670a0	http://dx.doi.org/10.1038/353670a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922387				2022-12-28	WOS:A1991GK67200075
J	PATERSON, CM; SAUNDERS, NJS				PATERSON, CM; SAUNDERS, NJS			MODE OF DELIVERY AFTER ONE CESAREAN-SECTION - AUDIT OF CURRENT PRACTICE IN A HEALTH REGION	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; VAGINAL DELIVERY; BIRTH	Objective - To audit the subsequent obstetric management of women who had had one previous baby delivered by caesarean section. Design - Retrospective analysis of a regional obstetric database. Setting - Data derived from the 17 obstetric units in North West Thames region. Subjects - 1059 women who delivered a singleton fetus of at least 37 weeks' gestation with a cephalic presentation in 1988 who had a history of one previous caesarean section and no other deliveries. Main outcome measures - Mode of delivery, postnatal morbidity, and duration of hospital stay. Results - 395 (37%) women were delivered by elective repeat caesarean section and 664 (63%) were allowed a trial of labour. Maternal height and birth weight of the previous infant differed significantly between those who were and those who were not allowed to labour. 471 (71%) of those allowed to labour achieved a vaginal delivery. In individual units there was no significant correlation between the proportion of patients allowed to labour and the rate of the successful trial of labour. There was a trend towards greater success rates in units that allowed a longer duration of labour (p < 0.05) and units with greater use of oxytocin for augmentation of labour (not significant). Both elective and intrapartum caesarean section was associated with a significantly higher rate of postnatal infection than vaginal delivery (14.7% and 16.0% v 3.4%). Conclusions - In patients with a history of caesarean section there is no evidence that the likelihood of successful vaginal delivery after trial of labour is modified by the proportion of such patients allowed the option of attempted vaginal delivery. Until selection criteria of adequate prognostic value can be identified a more liberal approach to allowing women a trial of labour seems justified.			PATERSON, CM (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON W2 1PG,ENGLAND.							DUFF P, 1988, OBSTET GYNECOL, V71, P380; EVRARD JR, 1977, OBSTET GYNECOL, V50, P594; FLAMM BL, 1989, OBSTET GYNECOL, V74, P694; GARDNER MJ, 1989, CONFIDENCE INTERVAL; LAVIN JP, 1982, OBSTET GYNECOL, V59, P135; MEEHAN FP, 1988, EUR J OBSTET GYN R B, V31, P109; MOLLOY BG, 1987, BRIT MED J, V294, P1645, DOI 10.1136/bmj.294.6588.1645; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; WHITESIDE DC, 1983, J REPROD MED, V28, P785; [No title captured]	10	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					818	821		10.1136/bmj.303.6806.818	http://dx.doi.org/10.1136/bmj.303.6806.818			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932972	Bronze, Green Published			2022-12-28	WOS:A1991GH94600022
J	LARSEN, JP				LARSEN, JP			PARKINSONS-DISEASE AS COMMUNITY-HEALTH PROBLEM - STUDY IN NORWEGIAN NURSING-HOMES	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY	Objective - To examine the extent of underdiagnosis and overdiagnosis of Parkinson's disease and to determine quality of treatment in a defined population. Design - Clinical evaluation of an elderly population. Setting - 40 Norwegian nursing homes. Subjects - 3322 residents of nursing homes, of whom 500 were selected by nursing staff for evaluation on the basis of a structured information programme on Parkinson's disease and 269 were examined in detail by neurologists. Main outcome measures - Patients' scores on clinical rating scales, diagnosis of parkinsonism, and effect of changing drug treatment. Results - 169 (5.1%) patients were found to have clinical idiopathic Parkinson's disease, 31 of whom had not had the disease diagnosed previously. In addition, 31 patients without the disease were taking antiparkinsonian drugs unnecessarily. Eighty patients were judged to be receiving "optimal" treatment. In the remaining 58, the treatment was changed, and 36 patients showed a definite functional improvement after a 12 week observation period. Conclusions - The quality of life of many elderly patients with Parkinson's disease could be improved by increasing medical and neurological services.			LARSEN, JP (corresponding author), CENT HOSP ROGALAND,DEPT NEUROL,N-4011 STAVANGER,NORWAY.							BARBEAU A, 1984, CLIN NEUROL NEUROSUR, V86, P164, DOI 10.1016/0303-8467(84)90193-8; CROXSON S, 1989, GENERAL PRACTIT 1027, P4; DEPEDRO J, 1987, ACTA NEUROL SCA S112, V75, P40; Gottfries C G, 1982, Arch Gerontol Geriatr, V1, P311, DOI 10.1016/0167-4943(82)90031-0; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; LARSEN J P, 1988, Tidsskrift for den Norske Laegeforening, V108, P1377; LARSEN J P, 1988, Tidsskrift for den Norske Laegeforening, V108, P1380; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MARSDEN CD, 1987, MOVEMENT DISORD, V2, P65; MARTILA RJ, 1987, HDB PARKINSONS DISEA, P38; MARTTILA RJ, 1976, ACTA NEUROL SCAND, V53, P81; MUTCH WJ, 1986, BRIT MED J, V292, P534, DOI 10.1136/bmj.292.6519.534; PLAYFER J, 1989, GERIATRIC MED, V19, P77; QUINN NP, 1986, BRIT MED J, V293, P379, DOI 10.1136/bmj.293.6543.379; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; SCHOENBERG BS, 1985, NEUROLOGY, V35, P841, DOI 10.1212/WNL.35.6.841; SCHOENBERG BS, 1987, MOVEMENT DISORD, V2, P17; WEBSTER DD, 1968, MOD TREAT, V5, P257	18	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					741	743		10.1136/bmj.303.6805.741	http://dx.doi.org/10.1136/bmj.303.6805.741			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932932	Green Published, Bronze			2022-12-28	WOS:A1991GG98100017
J	DENNIS, M; WARLOW, C				DENNIS, M; WARLOW, C			THE HEALTH OF THE NATION - RESPONSES - STRATEGY FOR STROKE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; MORTALITY; TRENDS				DENNIS, M (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1986, BRIT MED J, V292, P191, DOI 10.1136/bmj.292.6514.191; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; ISARD P, IN PRESS DISEASES; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MALMGREN R, 1987, LANCET, V2, P1196; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; 1991, LANCET, V337, P1235; 1988, BMJ, V297, P126; 1988, PREVALENCE DISABILIT; 1988, BMJ, V296, P320; 1991, CM1523; 1991, BMJ, V302, P1057	18	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					636	638		10.1136/bmj.303.6803.636	http://dx.doi.org/10.1136/bmj.303.6803.636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1932911	Green Published			2022-12-28	WOS:A1991GF67500031
J	HAYWOOD, GA; JOY, MD; CAMM, AJ				HAYWOOD, GA; JOY, MD; CAMM, AJ			INFLUENCE OF POSTURE AND REFERENCE POINT ON CENTRAL VENOUS-PRESSURE MEASUREMENT	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,LONDON SW17 0RE,ENGLAND; ST PETERS HOSP,CHERTSEY KT16 0PZ,SURREY,ENGLAND	St Georges University London								Blomqvist CG., 1983, COMPR PHYSIOL, V3, P1025, DOI DOI 10.1002/CPHY.CP020328; SYKES M K, 1963, Ann R Coll Surg Engl, V33, P185; WILSON JN, 1962, ARCH SURG-CHICAGO, V85, P563	3	7	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					626	627		10.1136/bmj.303.6803.626	http://dx.doi.org/10.1136/bmj.303.6803.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932904	Green Published, Bronze			2022-12-28	WOS:A1991GF67500024
J	FRYMOYER, PA; SCHEINMAN, SJ; DUNHAM, PB; JONES, DB; HUEBER, P; SCHROEDER, ET				FRYMOYER, PA; SCHEINMAN, SJ; DUNHAM, PB; JONES, DB; HUEBER, P; SCHROEDER, ET			X-LINKED RECESSIVE NEPHROLITHIASIS WITH RENAL-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARBONIC-ANHYDRASE-B; POTASSIUM-LOSING NEPHROPATHY; RED-BLOOD-CELLS; BARTTERS-SYNDROME; TUBULAR-ACIDOSIS; HUMAN-ERYTHROCYTES; URIC-ACID; TRANSPORT; HYPERCALCIURIA; NEPHROCALCINOSIS	Background and Methods. Nephrolithiasis may occur as a consequence of a number of hereditary disorders. We describe a large kindred from northern New York with hereditary nephrolithiasis accompanied by urinary concentrating defects, nephrocalcinosis, renal insufficiency, and renal wasting of potassium, phosphate, calcium, and uric acid. The pattern of inheritance was established by examining the patients and their records and interviewing family members. Selected members of the family were evaluated in detail, with measurement of erythrocyte cation fluxes and carbonic anhydrase (carbonate dehydratase) activity. Results. The kindred consisted of 162 family members from six generations. All nine affected persons were male and appeared to have inherited the disease from their mothers. No affected man transmitted the gene to a son, but the daughters of affected men were carriers. The patients presented in childhood with calcium nephrolithiasis and proteinuria, with progression to nephrocalcinosis, urinary concentrating defects, and renal insufficiency. Renal biopsies revealed tubular atrophy, interstitial fibrosis, and glomerulosclerosis; the characteristic features of other forms of hereditary nephritis were absent. Abnormalities in the renal excretion of calcium, phosphate, potassium, and uric acid were found only in the adult members of the kindred, although renal biopsies were abnormal even in younger members. In one patient who has had a renal transplant for seven years, the disease has not recurred. Conclusions. This kindred manifested an X-linked recessive nephrolithiasis with renal failure, a new form of hereditary renal disease. Most of the identifiable physiologic abnormalities occurred after the development of nephrolithiasis and renal insufficiency and may not be of pathogenetic importance.	SUNY HLTH SCI CTR,DEPT PATHOL,SYRACUSE,NY; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Syracuse University	FRYMOYER, PA (corresponding author), SUNY HLTH SCI CTR,DEPT MED,NEPHROL SECT,750 E ADAMS ST,SYRACUSE,NY 13210, USA.				NCRR NIH HHS [RR-229] Funding Source: Medline; NIADDK NIH HHS [AM01495] Funding Source: Medline; NIDDK NIH HHS [DK33640] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [K08AM001495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033640, R37DK033640] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARANT BS, 1970, PEDIATRICS, V46, P344; BARTTER FC, 1962, AM J MED, V33, P811, DOI 10.1016/0002-9343(62)90214-0; Bergeron M, 1989, METABOLIC BASIS INHE, P2569; CORVILAIN J, 1972, J CLIN ENDOCR METAB, V34, P452, DOI 10.1210/jcem-34-3-452; DILLON MJ, 1979, Q J MED, V48, P429; DUHM J, 1987, J MEMBRANE BIOL, V98, P15, DOI 10.1007/BF01871042; DUNHAM PB, 1980, P NATL ACAD SCI-BIOL, V77, P1711, DOI 10.1073/pnas.77.3.1711; ELIN RJ, 1988, CECIL TXB MED, V2, P2394; FANCONI A, 1971, HELV PAEDIATR ACTA, V26, P144; FREDERICK EW, 1963, NEW ENGL J MED, V269, P821, DOI 10.1056/NEJM196310172691601; GREGER R, 1985, PHYSIOL REV, V65, P760, DOI 10.1152/physrev.1985.65.3.760; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KONDO T, 1978, J CLIN INVEST, V62, P610, DOI 10.1172/JCI109167; MABRY CC, 1987, NELSON TXB PEDIATRIC, P1535; MCCREDIE DA, 1974, AUST PAEDIATR J, V10, P286; MCCREDIE DA, 1971, MED J AUSTRALIA, V1, P129, DOI 10.5694/j.1326-5377.1971.tb87473.x; MEYER WJ, 1975, ANN INTERN MED, V83, P56, DOI 10.7326/0003-4819-83-1-56; NORMAN ME, 1978, J PEDIATR-US, V92, P394, DOI 10.1016/S0022-3476(78)80426-0; OHLSSON A, 1984, ACTA PAEDIATR SCAND, V73, P868, DOI 10.1111/j.1651-2227.1984.tb17793.x; PIERRATOS A, 1989, CAN MED ASSOC J, V141, P1055; POTTER WZ, 1974, AM J MED, V57, P971, DOI 10.1016/0002-9343(74)90177-6; RICKLI EE, 1964, J BIOL CHEM, V239, P1065; SACHS JR, 1974, J GEN PHYSIOL, V63, P389, DOI 10.1085/jgp.63.4.389; SHAPIRA E, 1974, J CLIN INVEST, V53, P59, DOI 10.1172/JCI107559; SIECK UV, 1984, OBSTET GYNECOL, V63, pS22; SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302; STAPLETON FB, 1978, J PEDIATR-US, V92, P911, DOI 10.1016/S0022-3476(78)80359-X; TRYGSTAD CW, 1969, PEDIATRICS, V44, P234; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; WIATER LA, 1983, AM J PHYSIOL, V245, pC348, DOI 10.1152/ajpcell.1983.245.5.C348; WILBUR KM, 1948, J BIOL CHEM, V176, P147; 1986, NEW ENGL J MED, V314, P39	32	123	126	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					681	686		10.1056/NEJM199109053251003	http://dx.doi.org/10.1056/NEJM199109053251003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1908057				2022-12-28	WOS:A1991GD49700003
J	INGOLD, AL; LANDEL, C; KNALL, C; EVANS, GA; POTTER, TA				INGOLD, AL; LANDEL, C; KNALL, C; EVANS, GA; POTTER, TA			CO-ENGAGEMENT OF CD8 WITH THE T-CELL RECEPTOR IS REQUIRED FOR NEGATIVE SELECTION	NATURE			English	Article							PROTEIN KINASE P56LCK; I ALPHA-3 DOMAIN; TRANSGENIC MICE; LYMPHOCYTES-T; RECOGNITION; DELETION; MOLECULE; ANTIGEN; SELF; SUBSTITUTION	ALTHOUGH it is established that the CD8 and CD4 co-receptors are involved in T-lymphocyte recognition and activation in the periphery, it is less clear whether these molecules participate in thymic selection events. Analysis of thymic selection in mice transgenic for T cell-receptor genes 1-4 or for major histocompatibility complex (MHC) genes 5, or mice injected with antibodies against CD8, CD4 or MHC molecules 6-8, is consistent with the participation of CD8 and CD4 in thymic selection. But antibody-mediated crosslinking of surface receptors in thymic organ cultures 9 has indicated that CD8 is not involved in thymic deletion. We show here that mice transgenic for a mutant MHC class I molecule that cannot interact with CD8 do not delete CD8-dependent T cells reactive with the wild-type molecule. This finding unequivocally establishes that for negative selection in the thymus, CD8 must interact with the same MHC class I molecule as the T cell receptor.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80206; SALK INST BIOL STUDIES,MOLEC GENET LAB,SAN DIEGO,CA 92138	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Salk Institute	INGOLD, AL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.							BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BIEBERICH C, 1986, MOL CELL BIOL, V6, P1339, DOI 10.1128/MCB.6.4.1339; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JANEWAY CA, 1989, IMMUNOL REV, V109, P77, DOI 10.1111/j.1600-065X.1989.tb00020.x; KALINKE U, 1990, NATURE, V348, P642, DOI 10.1038/348642a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LOH DY, 1989, COLD SH Q B, V54, P147, DOI 10.1101/SQB.1989.054.01.018; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MCDONALD HR, 1982, IMMUNOL REV, V68, P89; POTTER TA, 1987, J EXP MED, V166, P956, DOI 10.1084/jem.166.4.956; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YACHELINI P, 1990, J IMMUNOL, V145, P1382; YOSHIOKA T, 1987, J IMMUNOL, V139, P3861; ZUNIGAPFLUCKER JC, 1989, COLD SPRING HARB SYM, V54, P153	23	85	85	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					721	723		10.1038/352721a0	http://dx.doi.org/10.1038/352721a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908563				2022-12-28	WOS:A1991GC06400060
J	THORNICROFT, G; STRATHDEE, G				THORNICROFT, G; STRATHDEE, G			MENTAL-HEALTH	BRITISH MEDICAL JOURNAL			English	Article							CARE; SCHIZOPHRENIA; CAMBERWELL				THORNICROFT, G (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ALLEBECK P, 1989, SCHIZOPHRENIA BULL, V15, P81, DOI 10.1093/schbul/15.1.81; American Psychiatry Association, 2018, MENT ILLN; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; BRUCE ML, 1991, ARCH GEN PSYCHIAT, V48, P470; CROFTJEFFREYS C, 1989, PSYCHOL MED, V19, P549, DOI 10.1017/S0033291700024132; DAVIES L, 1990, BRIT J PSYCHAITRY, V154, P522; FARROW S, 1991, INDICATIONS MENTAL H, P1; Glover G, 1990, Health Trends, V22, P111; GOLDBERG D, 1991, INDICATORS MENTAL HL, P30; GOLDMAN HH, 1981, HOSP COMMUNITY PSYCH, V32, P21; GROVES T, 1991, BRIT MED J, V302, P1416, DOI 10.1136/bmj.302.6790.1416; HIRSCH S, 1988, PSYCHIATRIC BED RESO; JENKINS R, 1990, BRIT J PSYCHIAT, V157, P500, DOI 10.1192/bjp.157.4.500; LEFF J, 1986, PROVISION MENTAL HLT, P49; MACCARTHY B, 1989, PSYCHOL MED, V19, P725, DOI 10.1017/S0033291700024326; MANN A, 1991, INDICATORS MENTALHLT, P6; MURPHY E, 1991, BRIT MED J, V302, P1064, DOI 10.1136/bmj.302.6784.1064; PATMORE C, 1990, HLTH SERV J, P1510; SARTORIUS N, 1990, PUBLICHLTH IMPACT ME, pR7; SCHINNAR AP, 1990, AM J PSYCHIAT, V147, P1602; STRATHDEE G, 1990, J ROY SOC MED, V83, P222, DOI 10.1177/014107689008300407; THOMPSON C, 1989, INSTRUMENTS PSYCHIAT; THORNICROFT G, 1990, HOSP COMMUNITY PSYCH, V41, P1073; THORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475, DOI 10.1192/bjp.158.4.475; WARR P, 1987, UNEMPLOYMENT WORK ME; WING J, 1989, HLTH SERVICES PLANNI; 1987, MODEL COMPREHENSIVE; 1983, CENSUS 1981; 1991, IMPLICATIONS FIELD M; 1991, HLTH NATION; 1981, GLOBAL STRATEGY HLTH; 1990, BRIDGE TROUBLED WATE; 1983, COMMON CONCERN	33	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					410	412		10.1136/bmj.303.6799.410	http://dx.doi.org/10.1136/bmj.303.6799.410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB599	1912812	Green Published, Bronze			2022-12-28	WOS:A1991GB59900024
J	HOLLSTEIN, M; SIDRANSKY, D; VOGELSTEIN, B; HARRIS, CC				HOLLSTEIN, M; SIDRANSKY, D; VOGELSTEIN, B; HARRIS, CC			P53 MUTATIONS IN HUMAN CANCERS	SCIENCE			English	Article							TUMOR SUPPRESSOR GENE; WILD-TYPE P53; LUNG-CANCER; MUTANT P53; CELL-LINES; DNA DAMAGE; CHEMICAL CARCINOGENESIS; SV40-TRANSFORMED CELLS; SEQUENCE SPECIFICITY; STRUCTURAL ASPECTS	Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and hemopoietic tissues. Analysis of these mutations can provide clues to the etiology of these diverse tumors and to the function of specific regions of p53. Transitions predominate in colon, brain, and lymphoid malignancies, whereas G:C to T:A transversions are the most frequent substitutions observed in cancers of the lung and liver. Mutations at A:T base pairs are seen more frequently in esophageal carcinomas than in other solid tumors. Most transitions in colorectal carcinomas, brain tumors, leukemias, and lymphomas are at CpG dinucleotide mutational hot spots. G to T transversions in lung, breast, and esophageal carcinomas are dispersed among numerous codons. In liver tumors in persons from geographic areas in which both aflatoxin B1 and hepatitis B virus are cancer risk factors, most mutations are at one nucleotide pair of codon 249. These differences may reflect the etiological contributions of both exogenous and endogenous factors to human carcinogenesis.	NCI,HUMAN CARCINOGENESIS LAB,BLDG 37,ROOM 2C05,BETHESDA,MD 20892; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CANCER INSTITUTE [R37CA043460, T32CA009071, R01CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43460, CA 09071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1990, ONCOGENE, V5, P893; BENNETT W, IN PRESS ONCOGENE; BOHR VA, 1987, CANCER RES, V47, P6426; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASSON AC, 1991, J CELL BIOCH F S, V15, P21; Chang Eileen, COMMUNICATION; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; DEJONG PJ, 1988, P NATL ACAD SCI USA, V85, P3499; DELLARCO VL, 1985, ANEUPLOIDY ETIOLOGY; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; GAIDANO G, IN PRESS P NATL ACAD; HANAWALT PC, 1987, ENVIRON HEALTH PERSP, V76, P9, DOI 10.2307/3430458; HARRIS CC, 1989, CARCINOGENESIS, V10, P1563, DOI 10.1093/carcin/10.9.1563; HARRIS CC, 1978, NATURE, V272, P633, DOI 10.1038/272633a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HOLLSTEIN MC, UNPUB; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DA, COMMUNICATION; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN T, IN PRESS CANCER RES; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; LUTZ WK, 1990, MUTAT RES, V238, P287, DOI 10.1016/0165-1110(90)90020-C; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARX JX, 1989, SCIENCE, V243, P737, DOI 10.1126/science.2783787; MASHIYAMA S, IN PRESS ONCOGENE; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLER CW, 1990, CANCER RES, V50, P7950; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; MINNA JD, COMMUNICATION; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURAKAMI Y, COMMUNICATION; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, COMMUNICATION; RAYCROFT L, 1990, SCIENCE, V249, P1046; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEILLET C, COMMUNICATION; THILLY WG, 1990, ANNU REV PHARMACOL, V30, P369; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VOGELSTEIN B, UNPUB; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WOGAN GN, 1989, ENVIRON HEALTH PERSP, V81, P9, DOI 10.2307/3430797; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; 1987, IARC MONOGRAPHS, V1; 1990, IARC SCI PUBL, V100	95	7637	7893	26	1527	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					49	53		10.1126/science.1905840	http://dx.doi.org/10.1126/science.1905840			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905840	Green Submitted			2022-12-28	WOS:A1991FV17700030
J	NEITZ, M; NEITZ, J; JACOBS, GH				NEITZ, M; NEITZ, J; JACOBS, GH			SPECTRAL TUNING OF PIGMENTS UNDERLYING RED-GREEN COLOR-VISION	SCIENCE			English	Article							POLYMORPHISM; RHODOPSIN; CONE; PHOTOPIGMENT; SENSITIVITY; BLUE	Variations in the absorption spectra of cone photopigments over the spectral range of about 530 to 562 nanometers are a principal cause of individual differences in human color vision and of differences in color vision within and across other primates. To study the molecular basis of these variations, nucleotide sequences were determined for eight primate photopigment genes. The spectral peaks of the pigments specified by these genes spanned the range from 530 to 562 nanometers. Comparisons of the deduced amino acid sequences of these eight pigments suggest that three amino acid substitutions produce the approximately 30-nanometer difference in spectral peaks of the pigments underlying human red-green color vision, and red shifts of specific magnitudes are produced by replacement of nonpolar with hydroxyl-bearing amino acids at each of the three critical positions.	UNIV CALIF SANTA BARBARA,DEPT PSYCHOL,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,NEUROSCI RES INST,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara				Neitz, Maureen/0000-0002-5404-3343	NEI NIH HHS [EY-02052, EY-07200] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007200, R01EY002052] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		DAWIS SM, 1981, VISION RES, V21, P1427, DOI 10.1016/0042-6989(81)90250-9; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; Green CB, 2010, COMMUNICATION; GYLLENSTEN U, 1989, PCR TECHNOLOGY; JACOBS GH, 1987, VISION RES, V27, P2089, DOI 10.1016/0042-6989(87)90123-4; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; KOSOWER EM, 1988, P NATL ACAD SCI USA, V85, P1076, DOI 10.1073/pnas.85.4.1076; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1989, NATURE, V342, P679, DOI 10.1038/342679a0; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ J, 1984, J OPT SOC AM A, V1, P1175, DOI 10.1364/JOSAA.1.001175; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NUNN BJ, 1984, NATURE, V309, P264, DOI 10.1038/309264a0; POKORNY J., 1979, CONGENITAL ACQUIRED; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Wyszecki G., 1982, COLOR SCI, V8; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	18	390	398	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					971	974		10.1126/science.1903559	http://dx.doi.org/10.1126/science.1903559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1903559				2022-12-28	WOS:A1991FM04000038
J	OLDSTONE, MBA; NERENBERG, M; SOUTHERN, P; PRICE, J; LEWICKI, H				OLDSTONE, MBA; NERENBERG, M; SOUTHERN, P; PRICE, J; LEWICKI, H			VIRUS-INFECTION TRIGGERS INSULIN-DEPENDENT DIABETES-MELLITUS IN A TRANSGENIC MODEL - ROLE OF ANTI-SELF (VIRUS) IMMUNE-RESPONSE	CELL			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PANCREATIC BETA-CELLS; COXSACKIE-B-VIRUS; CLASS-II MHC; DIFFERENTIATED FUNCTIONS; AUTOIMMUNE-DISEASE; PROTEIN-STRUCTURE; CROSS-REACTIVITY; MICE; EXPRESSION	We investigated the potential association between viruses and insulin-dependent (type 1) diabetes (IDDM) by developing a transgenic mouse model. By inserting into these mice a unique viral protein that was then expressed as a self-antigen in the pancreatic islets of Langerhans, we could study the effect on that expressed antigen alone, or in concert with an induced antiviral (i.e., autoimmune) response manifested later in life in causing IDDM. Our results indicate that a viral gene introduced as early as an animal's egg stage, incorporated into the germline, and expressed in islet cells does not produce tolerance when the host is exposed to the same virus later in life. We observed that the induced anti-self (viral) CTL response leads to selective and progressive damage of beta-cells, resulting in IDDM.			OLDSTONE, MBA (corresponding author), SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,VIROL SERV,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NIAID NIH HHS [AI-09484] Funding Source: Medline; NIA NIH HHS [AG-04342] Funding Source: Medline; NINDS NIH HHS [NS-01330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BAEKKESKOV S, 1990, CURR TOP MICROBIOL, V164, P1; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOTTAZZO GF, 1983, LANCET, V2, P1115; BUCHMEIER MJ, 1981, VIROLOGY, V113, P73, DOI 10.1016/0042-6822(81)90137-9; BUCHMEIER MJ, 1979, VIROLOGY, V99, P111, DOI 10.1016/0042-6822(79)90042-4; BUCHMEIER MJ, 1978, VIROLOGY, V89, P133, DOI 10.1016/0042-6822(78)90047-8; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DOLSTONE MBA, 1990, J EXP MED, V171, P2077; DOLSTONE MBA, 1989, SCI AM, V260, P42; DYRBERG T, 1990, CURR TOP MICROBIOL, V156, P1; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Gamble D R, 1980, Epidemiol Rev, V2, P49; GLADISCH R, 1976, Z KARDIOL, V65, P837; HAMAFURA T, 1988, DIABETES, V37, P204; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN B, 1986, MANIPULATING MOUSE E; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; HULTQUIST G, 1973, UPSALA J MED SCI, V78, P139, DOI 10.3109/03009737309178618; JENSON AB, 1984, PROG MED VIROL, V29, P197; JENSON AB, 1980, LANCET, V2, P354; KING ML, 1983, LANCET, V1, P1397; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; KLAVINSKIS LS, 1989, J VIROL, V63, P4311, DOI 10.1128/JVI.63.10.4311-4316.1989; KLAVINSKIS LS, 1989, VIROLOGY, V168, P232, DOI 10.1016/0042-6822(89)90262-6; KLAVINSKIS LS, 1987, J GEN VIROL, V68, P1867, DOI 10.1099/0022-1317-68-7-1867; KOEVARY S, 1983, SCIENCE, V220, P727, DOI 10.1126/science.6836309; LERNER RA, 1971, SCIENCE, V173, P60, DOI 10.1126/science.173.3991.60; LERNMARK A, 1985, DIABETOLOGIA, V28, P195; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LOHR JM, 1990, LANCET, P644; Maniatis T., 1982, MOL CLONING; MENSER MA, 1978, LANCET, V1, P57; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO, P241; OLDSTONE MBA, 1982, NATURE, V300, P360, DOI 10.1038/300360a0; OLDSTONE MBA, 1984, SCIENCE, V224, P1440, DOI 10.1126/science.6203172; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1985, VIROLOGY, V142, P158, DOI 10.1016/0042-6822(85)90430-1; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1980, J IMMUNOL, V124, P831; OLDSTONE MBA, 1982, SCIENCE, V218, P1125, DOI 10.1126/science.7146898; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1983, VIROLOGY, V127, P426, DOI 10.1016/0042-6822(83)90155-1; OLDSTONE MBA, 1978, UCLA S MOL CELLULAR, V9, P43; PAK CY, 1988, LANCET, V2, P1; PATTERSON K, 1981, LANCET, V1, P1048; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SISSONS JGP, 1980, P NATL ACAD SCI-BIOL, V77, P559, DOI 10.1073/pnas.77.1.559; SOUTHERN PJ, 1987, VIROLOGY, V157, P145, DOI 10.1016/0042-6822(87)90323-0; SOUTHERN PJ, 1986, VACCINES 86 MODERN A, P239; THOMSON G, 1988, AM J HUM GENET, V43, P799; TISHON A, 1988, J IMMUNOL, V140, P1280; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; UNGER R H, 1985, P1018; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WRIGHT KE, 1990, VIROLOGY, V177, P175, DOI 10.1016/0042-6822(90)90471-3; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; [No title captured]	64	682	690	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					319	331		10.1016/0092-8674(91)90165-U	http://dx.doi.org/10.1016/0092-8674(91)90165-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1901765				2022-12-28	WOS:A1991FH09200014
J	COLE, GM; REED, SI				COLE, GM; REED, SI			PHEROMONE-INDUCED PHOSPHORYLATION OF A G-PROTEIN BETA-SUBUNIT IN SACCHAROMYCES-CEREVISIAE IS ASSOCIATED WITH AN ADAPTIVE RESPONSE TO MATING PHEROMONE	CELL			English	Article							ALPHA-FACTOR RECEPTOR; YEAST SACCHAROMYCES-CEREVISIAE; FACTOR SIGNALING PATHWAY; MAMMALIAN G-PROTEIN; GENE-PRODUCT; A-CELLS; STE2 GENE; KINASE; CYCLE; IDENTIFICATION	The mating pheromone response in S. cerevisiae is activated by a G protein-mediated signaling pathway in which G-beta-gamma is the active transducer of the signal. When exogenous pheromone is added to vegetatively growing cells, G-beta is rapidly phosphorylated at several sites; phosphorylation does not require de novo protein synthesis. A mutation in G-beta was constructed that eliminates signal-induced phosphorylation. This mutation leads to enhanced sensitivity to and impaired ability to recover from pheromone, but does not affect the ability of G-beta-gamma to transmit the mating signal. These phenotypes suggest that G protein phosphorylation mediates an adaptive response to pheromone-induced signaling. G-beta phosphorylation does not require either the pheromone receptor C-terminus or the product of the SST2 gene, both of which mediate separate adaptive responses to pheromone. However, G-beta phosphorylation is greatly facilitated by the presence of the G-alpha subunit, which has also been shown to participate in an adaptation to pheromone.			COLE, GM (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, MB-7, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM049429] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49429, GM 13116] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BOYLE B, 1991, IN PRESS METH ENZYMO; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELDS S, 1988, MOL CELL BIOL, V8, P551, DOI 10.1128/MCB.8.2.551; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HICKS JB, 1976, NATURE, V260, P246, DOI 10.1038/260246a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KATZ ME, 1987, GENETICS, V115, P627; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LIPKE PN, 1976, J BACTERIOL, V127, P610, DOI 10.1128/JB.127.1.610-618.1976; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; MORTIMER RK, 1969, YEASTS, V1, P385; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHERMAN F, 1986, LABORATORY COURSE MA; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SPRAGUE GF, 1981, J MOL BIOL, V153, P305, DOI 10.1016/0022-2836(81)90280-1; STETLER GL, 1984, P NATL ACAD SCI-BIOL, V81, P1144, DOI 10.1073/pnas.81.4.1144; STONE DE, 1990, MOL CELL BIOL, V10, P4439, DOI 10.1128/MCB.10.9.4439; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILKINSON LE, 1974, EXP CELL RES, V89, P175, DOI 10.1016/0014-4827(74)90200-6; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	69	95	95	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					703	716		10.1016/0092-8674(91)90500-X	http://dx.doi.org/10.1016/0092-8674(91)90500-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1900039				2022-12-28	WOS:A1991EZ47800006
J	WAGNER, JL; HERDMAN, RC; WADHWA, S				WAGNER, JL; HERDMAN, RC; WADHWA, S			COST-EFFECTIVENESS OF COLORECTAL-CANCER SCREENING IN THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							OCCULT BLOOD-TEST; LARGE BOWEL; CONVENIENT APPROXIMATION; FLEXIBLE SIGMOIDOSCOPY; LIFE EXPECTANCY; POLYPS; CARCINOMA; SENSITIVITY; STAGE; RISK	Objective: To assess the cost effectiveness of a periodic program of colorectal cancer screening in the elderly. Design: A model was constructed of four strategies for the periodic screening of persons 65 to 85 years of age. The effect of each strategy on life expectancy and health care costs was estimated under assumptions that were uniformly unfavorable to screening. Cost and added years of life were discounted at 5% per year. Cost per year of life gained from screening was calculated for each screening strategy. Data Sources: Assumptions used in the model were based on a review of pertinent studies; those studies with results more unfavorable to screening were given more weight. Strengths and weaknesses of studies are discussed. Main Results: A program of annual fecal occult blood testing (FOBT) in the elderly would detect at least 17% of the expected cases of cancer and could cost $35 000 per year of life saved. Screening schedules that include periodic sigmoidoscopy would prevent more cases of cancer but could cost between $43 000 and $47 000 per year of life gained. These estimates are based on uncertain assumptions, but results were not extremely sensitive to further relaxation of the values of the most uncertain assumptions. In no case did the cost per year of life gained from annual FOBT exceed $55 000 or did the cost per year of life gained from FOBT with sigmoidoscopy every 5 years exceed $61 000. Conclusions: Although colorectal cancer screening is costly in the aggregate, its potential medical benefits make it a reasonably cost-effective preventive intervention for the elderly.			WAGNER, JL (corresponding author), US OFF TECHNOL ASSESSMENT, WASHINGTON, DC USA.							AHLQUIST D, 1991, Gastroenterology, V100, pA346; AHLQUIST DA, 1989, CANCER, V63, P1826; AHLQUIST DA, 1990, GASTROENTEROLOGY, V100, pA1; ALLISON JE, 1985, DIGEST DIS SCI, V30, P860, DOI 10.1007/BF01309517; ARMINSKI T. C., 1964, DIS COLON RECTUM, V7, P249, DOI 10.1007/BF02630528; BANG KM, 1986, J OCCUP ENVIRON MED, V28, P709, DOI 10.1097/00043764-198608000-00033; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BERG JW, 1970, CANCER, V25, P1076, DOI 10.1002/1097-0142(197005)25:5<1076::AID-CNCR2820250511>3.0.CO;2-L; Blatt LJ., 1961, DIS COLON RECTUM, V4, P277; CHAPMAN I, 1963, ANN SURG, V157, P223, DOI 10.1097/00000658-196302000-00007; CORREA P, 1977, CANCER, V39, P2258; DEMERS RY, 1985, PREV MED, V14, P55, DOI 10.1016/0091-7435(85)90020-9; EDDY D, 1987, BREAST CANCER SCREEN; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; EDDY DM, 1980, SCREENING CANCER THE; ENGLAND WL, 1989, MED DECIS MAKING, V9, P3, DOI 10.1177/0272989X8900900103; FENOGLIO CM, 1974, CANCER, V34, P819, DOI 10.1002/1097-0142(197409)34:3+<819::AID-CNCR2820340706>3.0.CO;2-S; FIELDING LP, 1989, LANCET, V1, P595; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GNAUCK R, 1984, CA-CANCER J CLIN, V34, P134, DOI 10.3322/canjclin.34.3.134; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; GRINNELL RS, 1964, ANN SURG, V159, P132, DOI 10.1097/00000658-196401000-00023; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; HOFF G, 1987, SCAND J GASTROENTERO, V22, P769, DOI 10.3109/00365528708991912; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; Hughes L E, 1968, Aust N Z J Surg, V38, P30; IRVIN TT, 1988, BRIT J SURG, V75, P419, DOI 10.1002/bjs.1800750508; KRONBORG O, 1975, BR J SURG S, V72, pS26; KUNE GA, 1987, BRIT J SURG, V74, P1064, DOI 10.1002/bjs.1800741135; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1989, GASTROENTEROLOGY, V97, P597, DOI 10.1016/0016-5085(89)90629-X; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; MOR V, 1988, J AM GERIATR SOC, V36, P873, DOI 10.1111/j.1532-5415.1988.tb05778.x; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; NEUGUT AI, 1985, CANCER, V55, P1586, DOI 10.1002/1097-0142(19850401)55:7<1586::AID-CNCR2820550729>3.0.CO;2-I; OTT DJ, 1989, COLON CANCER DIAGNOS; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RESTREPO C, 1981, DIS COLON RECTUM, V24, P29, DOI 10.1007/BF02603446; RHOADS GG, 1987, JAMA-J AM MED ASSOC, V258, P3254, DOI 10.1001/jama.1987.03400220053020; RIBET A, 1980, LANCET, V1, P417; RICKERT RR, 1979, CANCER-AM CANCER SOC, V43, P1847, DOI 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-L; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STEMMERMANN GN, 1973, CANCER-AM CANCER SOC, V31, P1260, DOI 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-N; STEVENSON G, 1989, COLON CANCER DIAGNOS; SUGARBAKER PH, 1985, CANCER PRINCIPLES PR; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WILLIAMS CB, 1982, ENDOSCOPY, V14, P74, DOI 10.1055/s-2007-1021584; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WINDELER J, 1987, INT J COLORECTAL DIS, V2, P223, DOI 10.1007/BF01649510; 1989, ANN REPORT C; 1988, BASIC CLIN PERSPECTI; 1979, OTA PUBLICATION H, V96; 1990, OTA BPH65 PUBL; 1990, CANCER LETT, V11, P3; 1989, NIH892789 PUBL; 1990, OTA PUBLICATION H, V416	63	123	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					807	817		10.7326/0003-4819-115-10-807	http://dx.doi.org/10.7326/0003-4819-115-10-807			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929029				2022-12-28	WOS:A1991GP80000011
J	SACHS, BP; HELLERSTEIN, S; FREEMAN, R; FRIGOLETTO, F; HAUTH, JC				SACHS, BP; HELLERSTEIN, S; FREEMAN, R; FRIGOLETTO, F; HAUTH, JC			HOME MONITORING OF UTERINE ACTIVITY - DOES IT PREVENT PREMATURITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RISK SCORING SYSTEM; LOW-BIRTH-WEIGHT; PRETERM LABOR; CONTROLLED TRIAL; PREGNANCIES		HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; UNIV CALIF IRVINE,IRVINE,CA 90801; UNIV ALABAMA,BIRMINGHAM,AL 35294	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of California System; University of California Irvine; University of Alabama System; University of Alabama Birmingham	SACHS, BP (corresponding author), BETH ISRAEL HOSP,BOSTON,MA 02215, USA.							DYSON DC, 1991, AM J OBSTET GYNECOL, V164, P756, DOI 10.1016/0002-9378(91)90510-X; HAVERKAMP AD, 1979, AM J OBSTET GYNECOL, V134, P399, DOI 10.1016/S0002-9378(16)33082-4; HILL WC, 1990, OBSTET GYNECOL, V76, pS13; IAMS JD, 1988, AM J OBSTET GYNECOL, V159, P595, DOI 10.1016/S0002-9378(88)80016-4; KESSEL SS, 1984, JAMA-J AM MED ASSOC, V251, P1978, DOI 10.1001/jama.251.15.1978; KOSASA TS, 1990, OBSTET GYNECOL, V76, pS71; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; LEVENO KJ, 1986, NEW ENGL J MED, V315, P615, DOI 10.1056/NEJM198609043151004; MAIN DM, 1985, AM J OBSTET GYNECOL, V151, P892, DOI 10.1016/0002-9378(85)90667-2; MAIN DM, 1987, OBSTET GYNECOL, V69, P61; MAIN DM, 1989, OBSTET GYNECOL, V74, P873; MORRISON JC, 1990, OBSTET GYNECOL, V76, pS76; MORRISON JC, 1989, INT J GYNECOL OBSTET, V28, P127, DOI 10.1016/0020-7292(89)90471-2; MORRISON JC, 1987, AM J OBSTET GYNECOL, V156, P536, DOI 10.1016/0002-9378(87)90046-9; MOU SM, 1991, AM J OBSTET GYNECOL, V165, P858, DOI 10.1016/0002-9378(91)90429-U; OWEN J, 1990, AM J OBSTET GYNECOL, V163, P873, DOI 10.1016/0002-9378(90)91086-R; PORTO M, 1987, FEB SOC PER OBST ORL; SCIOSCIA A, 1988, 8TH ANN M SOC PER OB; TEJANI NA, 1983, OBSTET GYNECOL, V61, P556; TUCKER JM, 1991, OBSTET GYNECOL, V77, P343; 1990, MONTHLY VITAL STA S4, V39; 1990, MONTHLY VITAL STAT 7, V39; 1989, MATERNAL FETAL MED S	23	34	34	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1374	1377		10.1056/NEJM199111073251911	http://dx.doi.org/10.1056/NEJM199111073251911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922241				2022-12-28	WOS:A1991GN47000011
J	DEKEYSER, J; DEKLIPPEL, N; EBINGER, G				DEKEYSER, J; DEKLIPPEL, N; EBINGER, G			THROMBOCYTOSIS AND ISCHEMIC COMPLICATIONS IN GIANT-CELL ARTERITIS	BRITISH MEDICAL JOURNAL			English	Article							TEMPORAL ARTERITIS; MANIFESTATIONS				DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS,ACAD ZIEKENHUIS,DEPT NEUROL,B-1090 BRUSSELS,BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				BENGTSSON BA, 1982, ACTA MED SCAND S, V658, P1; CALAMIA KT, 1980, CLIN RHEUM DIS, V6, P389; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; REICH KA, 1990, AM J MED, V89, P67, DOI 10.1016/0002-9343(90)90100-R; SELROOS O, 1973, ACTA MED SCAND, V193, P431	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					825	825		10.1136/bmj.303.6806.825	http://dx.doi.org/10.1136/bmj.303.6806.825			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932974	Green Published, Bronze			2022-12-28	WOS:A1991GH94600025
J	GATELEY, CA; MADDOX, PR; MANSEL, RE				GATELEY, CA; MADDOX, PR; MANSEL, RE			PNEUMOTHORAX - A COMPLICATION OF FINE NEEDLE ASPIRATION OF THE BREAST	BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP S MANCHESTER,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND; UNIV WALES COLL MED,DEPT SURG,CARDIFF CF4 4XN,S GLAM,WALES	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cardiff University								BEVELAQUA FA, 1982, CHEST, V81, P693, DOI 10.1378/chest.81.6.693; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; DIXON JM, 1991, BRIT MED J, V302, P428, DOI 10.1136/bmj.302.6774.428; LEAHY BC, 1986, MED INT, V35, P1446; THOMPSON AM, 1988, J HAND SURG-BRIT EUR, V13B, P195, DOI 10.1016/0266-7681(88)90137-4	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					627	628		10.1136/bmj.303.6803.627	http://dx.doi.org/10.1136/bmj.303.6803.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932905	Green Published, Bronze			2022-12-28	WOS:A1991GF67500025
J	NEWMAN, LG; WALLER, J; PALESTRO, CJ; SCHWARTZ, M; KLEIN, MJ; HERMANN, G; HARRINGTON, E; HARRINGTON, M; ROMAN, SH; STAGNAROGREEN, A				NEWMAN, LG; WALLER, J; PALESTRO, CJ; SCHWARTZ, M; KLEIN, MJ; HERMANN, G; HARRINGTON, E; HARRINGTON, M; ROMAN, SH; STAGNAROGREEN, A			UNSUSPECTED OSTEOMYELITIS IN DIABETIC FOOT ULCERS - DIAGNOSIS AND MONITORING BY LEUKOCYTE SCANNING WITH INDIUM IN-111 OXYQUINOLINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY INFECTIONS; CONCISE COMMUNICATION; PEDAL OSTEOMYELITIS; CIPROFLOXACIN; MELLITUS; SCINTIGRAPHY; THERAPY; DISEASE; BONE	Objective. - The prevalence of osteomyelitis in diabetic foot ulcers is unknown. Early diagnosis of this infection is critical, as prompt antibiotic treatment decreases the rate of amputation. We therefore assessed the prevalence of osteomyelitis in 35 diabetic patients with 41 foot ulcers. We compared results of roentgenograms, leukocyte scans with indium in 111 oxyquinoline, and bone scans with the diagnostic criterion standards of bone histologic and culture findings. Leukocyte scans were repeated at 2- to 3-week intervals during antibiotic treatment. Design. - Cohort study Setting. - Institutional and private, ambulatory and hospitalized patients. Patients. - Consecutive sample of 54 diabetic patients. Thirty-five patients with 41 foot ulcers were included. Results. - As determined by bone biopsy and culture, osteomyelitis was found to underlie 28 (68%) of 41 diabetic foot ulcers. Only nine (32%) of the 28 cases were diagnosed clinically by the referring physician. Underscoring the clinically silent nature of osteomyelitis in these ulcers, 19 (68%) of 28 occurred in outpatients, 19 (68%) of 28 occurred in ulcers not exposing bone, and 18 (64%) of 28 had no evidence of inflammation on physical examination. All patients with ulcers that exposed bone had osteomyelitis. Of the imaging tests, the leukocyte scan had the highest sensitivity, 89%. In patients with osteomyelitis, the leukocyte scan image intensity decreased by 16 to 34 days of antibiotic treatment and normalized by 36 to 54 days. Conclusion. - The majority of diabetic foot ulcers have an underlying osteomyelitis that is clinically unsuspected. Leukocyte scans are highly sensitive for diagnosing osteomyelitis in diabetic foot ulcers and may be useful for monitoring the efficacy of antibiotic treatment. We recommend that diabetic patients with foot ulcers that expose bone should be treated for osteomyelitis. Diabetic patients with foot ulcers that do not expose bone should undergo leukocyte scanning, which eliminates the risk of bone biopsy in diagnosing osteomyelitis and allows for the diagnosis and treatment of this well-known but often silent precursor of lower extremity amputation.	MT SINAI MED CTR, DEPT SURG, DIV ORTHOPED SURG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DIV VASC SURG, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT NUCL MED, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT PATHOL, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT RADIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	NEWMAN, LG (corresponding author), MT SINAI MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, BOX 1087, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.			Stagnaro-Green, Alex/0000-0003-2434-3852				ALAZRAKI N, 1985, AM J ROENTGENOL, V145, P767, DOI 10.2214/ajr.145.4.767; BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BEAM TR, 1988, 2ND INT S NEW QUIN G; EYMONTT MJ, 1981, RADIOLOGY, V140, P475, DOI 10.1148/radiology.140.2.6454901; FIERER J, 1979, REV INFECT DIS, V1, P210; GELFAND MJ, 1977, JAMA-J AM MED ASSOC, V237, P245, DOI 10.1001/jama.237.3.245; GREENBERG RN, 1987, ANTIMICROB AGENTS CH, V31, P151, DOI 10.1128/AAC.31.2.151; HOOGKAMPKORSTANJE JAA, 1989, J ANTIMICROB CHEMOTH, V23, P427, DOI 10.1093/jac/23.3.427; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; KOLYVAS E, 1978, CLIN NUCL MED, V3, P461, DOI 10.1097/00003072-197812000-00003; LESLIE C A, 1989, Comprehensive Therapy, V15, P23; MAURER AH, 1981, J NUCL MED, V22, P941; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MCCARTHY K, 1988, J NUCL MED, V29, P1015; NORRBY SR, 1989, SCAND J INFECT DIS, P74; PARK HM, 1982, J NUCL MED, V23, P569; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; RATOPOULOS V, 1982, AM J ROENTGENOL, V139, P1077; ROSENBLATT DS, 1989, CLIN DIABETES, V7, P85; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SCHER KS, 1988, SURGERY, V104, P661; SELDIN DW, 1985, J NUCL MED, V26, P988; SINHA S, 1972, MEDICINE, V51, P191, DOI 10.1097/00005792-197205000-00006; THAKUR ML, 1977, J NUCL MED, V18, P1022; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1989, REV INFECT DIS, V11, pS1259; WHEAT J, 1985, AM J MED, V78, P218, DOI 10.1016/0002-9343(85)90388-2; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; 1980, NIH812284 PUBL, P5	29	250	251	2	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1246	1251		10.1001/jama.266.9.1246	http://dx.doi.org/10.1001/jama.266.9.1246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1908030				2022-12-28	WOS:A1991GC85800034
J	DAGOSTINO, RB; BELANGER, AJ; KANNEL, WB; CRUICKSHANK, JM				DAGOSTINO, RB; BELANGER, AJ; KANNEL, WB; CRUICKSHANK, JM			RELATION OF LOW DIASTOLIC BLOOD-PRESSURE TO CORONARY HEART-DISEASE DEATH IN PRESENCE OF MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY	BRITISH MEDICAL JOURNAL			English	Article							REGRESSION DILUTION BIAS; PROLONGED DIFFERENCES; RISK-FACTORS; FOLLOW-UP; J-CURVE; HYPERTENSION; REDUCTION; STROKE	Objective - To examine the hypothesis that a J curve relation between blood pressure and death from coronary heart disease is confined to high risk subjects with myocardial infarction. Design - Cohort longitudinal epidemiological study with biennial examinations since 1950. Setting - Framingham, Massachusetts, USA. Subjects - 5209 subjects in the Framingham study cohort followed up by a person examination approach. Main outcome measures - Coronary heart disease deaths and non-cardiovascular disease deaths in men and women with or without myocardial infarction relative to blood pressure. Results - Among subjects without myocardial infarction non-cardiovascular disease deaths were twice to three times as common as coronary heart disease deaths. Furthermore, there was no significant relation between non-cardiovascular disease death and diastolic or systolic blood pressure. Also coronary heart disease deaths were linearly related to diastolic and systolic blood pressures. Among high risk patients (that is, people with myocardial infarction but free of congestive heart failure) death from coronary heart disease was more common than non-cardiovascular disease death. There. was a significant U shaped relation between coronary heart disease death and diastolic blood pressure. Although there was an apparent U shaped relation between coronary heart disease death and systolic blood pressure, it did not attain statistical significance when controlling for age and change in systolic blood pressure from the pre-myocardial infarction level. None of the above conclusions changed when adjustments were made for risk factors such as serum cholesterol concentration, antihypertensive treatment, and left ventricular function. The U shaped relation between diastolic blood pressure and high risk subjects existed for both those given antihypertensive treatment and those not. Conclusions - These data suggest that an age and sex independent U curve relation exists for diastolic blood pressure and coronary heart disease deaths in patients with myocardial infarction but not for low risk subjects without myocardial infarction. The relation seems to be independent of left ventricular function and antihypertensive treatment.	BOSTON UNIV,STAT UNIT,BOSTON,MA 02215; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02118; WYTHENSHAWE HOSP,DEPT CARDIAC,MANCHESTER M23 9LT,LANCS,ENGLAND	Boston University; Boston University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	DAGOSTINO, RB (corresponding author), BOSTON UNIV,COLL LIBERAL ARTS,DEPT MATH,BOSTON,MA 02215, USA.				NHLBI NIH HHS [HL-40423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL040423, R01HL040423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ANDERSON TW, 1978, LANCET, V2, P1139; COOPE J, 1990, J HUM HYPERTENS, V4, P1; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cupples LA, 1987, FRAMINGHAM HEART STU; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; LEW EA, 1973, AM J MED, V55, P281, DOI 10.1016/0002-9343(73)90130-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEWART IMG, 1979, LANCET, V1, P861; STOKES J, 1987, CIRCULATION, V75, P65; WALLER PC, 1988, J HUM HYPERTENS, V2, P7	17	191	194	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					385	389		10.1136/bmj.303.6799.385	http://dx.doi.org/10.1136/bmj.303.6799.385			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1912805	Bronze, Green Published			2022-12-28	WOS:A1991GB59900014
J	FOOTE, J; MILSTEIN, C				FOOTE, J; MILSTEIN, C			KINETIC MATURATION OF AN IMMUNE-RESPONSE	NATURE			English	Article							SOMATIC MUTATION; ANTIBODY; ANTI-2-PHENYLOXAZOLONE; 2-PHENYLOXAZOLONE; SEQUENCES; OXAZOLONE; MOUSE	IS the affinity maturation of antibodies under thermodynamic or kinetic control, or both? We compared the physical constants of hapten binding by antibodies from 2-phenyl-5-oxazolone-specific hybridomas from primary, secondary and tertiary responses. In addition to an increase in equilibrium constant, there was a shift in the antibody repertoire after the primary response towards an immunoglobulin family with an extremely high on-rate constant. This shift occurred in spite of the average or below-average affinity of this group of antibodies. This is consistent with B-lymphocyte proliferation being subject to a kinetic selection, with a premium on binding target antigens rapidly, in parallel with a thermodynamic selection based on binding tightly.			FOOTE, J (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; Benson S. W., 1960, FOUNDATIONS CHEMICAL, P81; BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; DAY LA, 1963, ANN NY ACAD SCI, V103, P611, DOI 10.1111/j.1749-6632.1963.tb53721.x; DENIZOT FC, 1979, MOL IMMUNOL, V16, P509, DOI 10.1016/0161-5890(79)90078-6; DILDROP R, 1984, IMMUNOL TODAY, V5, P85, DOI 10.1016/0167-5699(84)90034-3; EISEN H N, 1964, Methods Med Res, V10, P115; EVEN J, 1985, EMBO J, V4, P3439, DOI 10.1002/j.1460-2075.1985.tb04102.x; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KAARTINEN M, 1983, NATURE, V304, P320, DOI 10.1038/304320a0; MAKELA O, 1978, J EXP MED, V148, P1644, DOI 10.1084/jem.148.6.1644; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; SCHLESINGER DH, 1975, NATURE, V255, P423, DOI 10.1038/255423a0; SEGAL I, 1975, ENZYME KINETICS, P73; SEHON AH, 1963, ANN NY ACAD SCI, V103, P626, DOI 10.1111/j.1749-6632.1963.tb53722.x; SMITH TW, 1975, BIOCHEMISTRY-US, V14, P1496, DOI 10.1021/bi00678a023; TITMAN JJ, 1991, J CHEM SOC CHEM COMM, P419, DOI 10.1039/c39910000419; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	20	262	286	0	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					530	532		10.1038/352530a0	http://dx.doi.org/10.1038/352530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1907716				2022-12-28	WOS:A1991GA22600063
J	HUGGINS, GR; WENTZ, AC				HUGGINS, GR; WENTZ, AC			OBSTETRICS AND GYNECOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORPLANT		NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	HUGGINS, GR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							DARNEY PD, 1990, STUD FAMILY PLANN, V21, P152, DOI 10.2307/1966714; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; SHOUPE D, 1989, AM J OBSTET GYNECOL, V160, P1286, DOI 10.1016/S0002-9378(89)80014-6; 1987, BMJ, V294, P991; 1991, FERTIL STERIL, V55, P14	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3139	3141						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1904105				2022-12-28	WOS:A1991FQ77000028
J	CINKOSKY, MJ; FICKETT, JW; GILNA, P; BURKS, C				CINKOSKY, MJ; FICKETT, JW; GILNA, P; BURKS, C			ELECTRONIC DATA PUBLISHING AND GENBANK	SCIENCE			English	Article							LIBRARY	GenBank, the national repository for nucleotide sequence data, has implemented a new model of scientific data management, which we term electronic data publishing. In traditional publishing, both scientific conclusions and supporting data are communicated via the printed page, and in electronic journal publishing, both types of information are communicated via electronic media. In electronic data publishing, by contrast, conclusions are published in a journal while data are published via a network-accessible, electronic database.			CINKOSKY, MJ (corresponding author), UNIV CALIF LOS ALAMOS SCI LAB, THEORET BIOL & BIOPHYS GRP, F10, MS K710, LOS ALAMOS, NM 87545 USA.		Gilna, Paul/I-3608-2016	Gilna, Paul/0000-0002-6542-0191	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [N01GM072110] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-7-2110] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JS, 1984, NUCLEOTIDE SEQUENC 2; ANDERSON JS, 1984, NUCLEOTIDE SEQUENC 1; ARMSTRONG J, 1985, NUCLEOTIDE SEQUENC 1; ATENCIO E, 1987, NUCLEOTIDE SEQUENC 1; BELL G, 1990, COMPUTERS DNA; BENTON D, 1990, NUCLEIC ACIDS RES, V18, P1517, DOI 10.1093/nar/18.6.1517; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Burks C, 1989, Proc Natl Acad Sci U S A, V86, P408, DOI 10.1073/pnas.86.2.408; BURKS C, 1989, BIOMOLECULAR DATA RE, P17; BURKS C, 1990, METHOD ENZYMOL, V183, P3; Burks Christian, 1989, BIOMOLECULAR DATA RE, P327; CINKOSKY MJ, 1988, RESTRUCTURING GENBAN; Colwell Rita R, 1989, BIOMOLECULAR DATA RE; COMER D, 1988, INTERNETWORKING TCP; DATE CJ, 1990, INTRO DATABASE SYSTE; Dawid I B, 1989, Proc Natl Acad Sci U S A, V86, P407, DOI 10.1073/pnas.86.2.407; FICKETT J, 1982, LA9274MS LOS AL UNCL; Fickett J.W., 1989, MATH METHODS DNA SEQ, P1; FICKETT JW, 1986, TRENDS BIOCHEM SCI, V11, P190, DOI 10.1016/0968-0004(86)90142-8; FICKETT JW, 1989, BIOMOLECULAR DATA RE, P295; FICKETT JW, 1987, MATH MODELS DNA SEQU, P1; KAHN P, 1990, METHOD ENZYMOL, V183, P23; KAHN P, 1989, BIOMOLECULAR DATA RE, P339; KAHN P, 1988, NUCLEIC ACIDS RES, V16, P1; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P149, DOI 10.1093/nar/12.1Part1.149; MIYAZAWA S, 1990, SFI S SCI C, V7, P47; MOORE JF, 1989, FOCUS ROCHESTER, V11, P69; QUARTERMAN JS, 1986, COMMUN ACM, V29, P932, DOI 10.1145/6617.6618; STEVENS JC, 1990, COMPUTERS DNA, P69; WELLS RD, 1989, BIOMOLECULAR DATA RE, P335; [No title captured]	31	50	50	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1273	1277		10.1126/science.1925538	http://dx.doi.org/10.1126/science.1925538			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925538				2022-12-28	WOS:A1991FN85700030
J	STEIN, D; ROTH, S; VOGELSANG, E; NUSSLEINVOLHARD, C				STEIN, D; ROTH, S; VOGELSANG, E; NUSSLEINVOLHARD, C			THE POLARITY OF THE DORSOVENTRAL AXIS IN THE DROSOPHILA EMBRYO IS DEFINED BY AN EXTRACELLULAR SIGNAL	CELL			English	Article							MATERNAL-EFFECT MUTATIONS; FEMALE-STERILE MUTATIONS; RECEPTOR TYROSINE KINASE; DORSAL-VENTRAL POLARITY; DNA-BINDING SUBUNIT; WILD-TYPE CYTOPLASM; TOLL GENE-PRODUCT; FAINT-LITTLE-BALL; NF-KAPPA-B; REL ONCOGENE	Twelve maternal effect loci are required for the production of Drosophila embryos with a correct dorsoventral axis. Analysis of mosaic females indicates that the expression of the genes nudel, pipe, and windbeutel is required in the somatic tissue, presumably in the follicle cells that surround the oocyte. Thus, information coming from outside the egg cell influences dorsoventral pattern formation during embryogenesis. In transplantation experiments, the perivitelline fluid from the compartment surrounding the embryo can restore dorsoventral pattern to embryos from females mutant for nudel, pipe, or windbeutel. The positioning of the transplanted pervitelline fluid also determines the polarity of the restored dorsoventral axis. We propose that the polarizing activity, normally present at the ventral side of the egg, is a ligand for the Toll receptor. Presumably, local activation of the Toll protein by the ligand initiates the formation of the nuclear concentration gradient of the dorsal protein, thereby determining dorsoventral pattern.			STEIN, D (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL, SPEMANNSTR 35, W-7400 TUBINGEN, GERMANY.		Roth, Siegfried/E-8241-2010	Roth, Siegfried/0000-0001-5772-3558; Vogelsang, Lisa/0000-0002-6817-5953				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BUSSON D, 1983, GENETICS, V105, P309; CamposOrtega J. A., 1985, EMBRYONIC DEV DROSOP, P9, DOI DOI 10.1007/978-3-662-22489-2_2; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FASANO L, 1988, DEVELOPMENT, V104, P245; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; IP YT, 1991, CELL, V64, P439; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; King R. C., 1970, OVARIAN DEV DROSOPHI; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KONRAD KD, 1988, DEV BIOL, V127, P133, DOI 10.1016/0012-1606(88)90195-9; KONRAD KD, 1988, ROUX ARCH DEV BIOL, V197, P75, DOI 10.1007/BF00375930; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LIND JH, 1990, SLAVON E EUR REV, V68, P1; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LINDSLEY DL, 1987, DROS INF SERV, V65, P40; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RICE TB, 1973, THESIS YALE U NEW HA; Roberts D.B., 1986, P1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENS LM, 1991, CELL CELL ITNERACTIO; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; WARN RM, 1982, DEV BIOL, V89, P540, DOI 10.1016/0012-1606(82)90344-X; Wieschaus E., 1986, P199	58	220	226	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1991	65	5					725	735		10.1016/0092-8674(91)90381-8	http://dx.doi.org/10.1016/0092-8674(91)90381-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904007				2022-12-28	WOS:A1991FP51600004
J	PACKER, GJ; GORING, CC; GAYNER, AD; CRAXFORD, AD				PACKER, GJ; GORING, CC; GAYNER, AD; CRAXFORD, AD			AUDIT OF ANKLE INJURIES IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the treatment of ankle injuries in an accident and emergency department could be improved by an audit of existing treatment and the creation and use of a protocol. Design-The study consisted of three parts: a review of the current treatment and published reports on treatment, the formation of a protocol, and a study of treatment after introducing the protocol. Setting-Accident and emergency department of a district general hospital. Patients-550 patients attending the department with ankle injuries over four months. Results-The review of treatment showed that patients with fractures were detected and treated adequately, but most had radiography. Patients with ligamentous injuries may have been undertreated. After introducing the protocol the number of patients undergoing radiography was reduced from 205 (80%) to 186 (70%) (0.0027 < p < 0.01). In 87% of the notes reviewed the protocol had been completed. Sixty six patients with ligamentous injuries were reviewed in the department or soft tissue clinic compared with 20 before the protocol was introduced. There was a 53% reduction in inappropriate referrals to the fracture clinic (13 before upsilon nine after). Conclusions-Using a protocol can, at little expense, improve the treatment of ankle injuries and reduce the cost of radiology in an accident and emergency department. Implication-Treatment of other conditions may be improved by introducing a protocol.			PACKER, GJ (corresponding author), N TYNESIDE GEN HOSP,N SHIELDS NE29 8NH,TYNE & WEAR,ENGLAND.							BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; 1990, LANCET, V335, P1313	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					885	887		10.1136/bmj.302.6781.885	http://dx.doi.org/10.1136/bmj.302.6781.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	1902753	Bronze, Green Published			2022-12-28	WOS:A1991FG42100025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW CONTRACEPTIVE IMPLANT SYSTEM APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-28	WOS:A1991EX58700010
J	FRANKS, NP; LIEB, WR				FRANKS, NP; LIEB, WR			STEREOSPECIFIC EFFECTS OF INHALATIONAL GENERAL ANESTHETIC OPTICAL ISOMERS ON NERVE ION CHANNELS	SCIENCE			English	Article							APLYSIA NEURONS; RECEPTORS; STEREOISOMERS; PHARMACOLOGY; INHIBITION; RESPONSES; HALOTHANE; BINDING; SYSTEM; SITES	Although it is generally agreed that general anesthetics ultimately act on neuronal ion channels, there is considerable controversy over whether this occurs by direct binding to protein or secondarily by nonspecific perturbation of lipids. Very pure optical isomers of the inhalational general anesthetic isoflurane exhibited clear stereoselectivity in their effects on particularly sensitive ion channels in identified molluscan central nervous system neurons. At the human median effect dose (ED50) for general anesthesia, the (+)-isomer was about twofold more effective than the (-)-isomer both in eliciting the anesthetic-activated potassium current I(K)(An) and in inhibiting a current mediated by neuronal nicotinic acetylcholine receptors. For inhibiting the much less sensitive transient potassium current I(A), the (-)-isomer was marginally more potent than the (+)-isomer. Both isomers were equally effective at disrupting lipid bilayers.			FRANKS, NP (corresponding author), IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,PRINCE CONSORT RD,LONDON SW7 2BZ,ENGLAND.			Franks, Nicholas/0000-0003-4874-4212	NIGMS NIH HHS [GM 41609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFIMOFF JK, 1987, ANESTHESIOLOGY, V66, P55, DOI 10.1097/00000542-198701000-00010; ANDREWS PR, 1982, ANESTHESIOLOGY, V57, P314, DOI 10.1097/00000542-198210000-00014; ARIMURA H, 1986, BRIT J PHARMACOL, V89, P573, DOI 10.1111/j.1476-5381.1986.tb11158.x; CHEMERIS NK, 1982, J PHYSIOL-LONDON, V323, P1; COTE IL, 1980, J PHARMACOL EXP THER, V214, P161; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; EDAMURA FY, 1970, 159TH NAT M AM CHEM; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; HILL MW, 1974, BIOCHIM BIOPHYS ACTA, V356, P117, DOI 10.1016/0005-2736(74)90299-5; HUANG LYM, 1980, SCIENCE, V207, P195, DOI 10.1126/science.7350656; JUDGE SE, 1982, BRIT J PHARMACOL, V75, P353, DOI 10.1111/j.1476-5381.1982.tb08793.x; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P115, DOI 10.1113/jphysiol.1972.sp009931; KENDIG JJ, 1973, ANESTHESIOLOGY, V39, P518, DOI 10.1097/00000542-197311000-00011; LAASBERG LH, 1971, J BIOL CHEM, V246, P4886; MARIETTA MP, 1977, J PHARMACOL EXP THER, V202, P157; MEINWALD J, 1991, SCIENCE, V251, P560, DOI 10.1126/science.1846702; MILLER KW, 1973, MOL PHARMACOL, V9, P131; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; PFEIFFER CC, 1956, SCIENCE, V124, P29, DOI 10.1126/science.124.3210.29; RICHARDS CD, 1980, TOPICAL REV ANAESTHE, V1, P1; SKOLNICK P, 1982, BRAIN RES, V233, P143, DOI 10.1016/0006-8993(82)90936-2; STEWARD A, 1973, BRIT J ANAESTH, V45, P282, DOI 10.1093/bja/45.3.282; TICKU MK, 1981, BRAIN RES, V211, P127, DOI 10.1016/0006-8993(81)90071-8; WAHLSTROM G, 1984, BRAIN RES, V310, P261, DOI 10.1016/0006-8993(84)90149-5; WEISKOPF RB, 1989, ANESTHESIOLOGY, V70, P793, DOI 10.1097/00000542-198905000-00015; WHITE PF, 1980, ANESTHESIOLOGY, V52, P231, DOI 10.1097/00000542-198003000-00008; WOLFSON B, 1978, ANESTHESIOLOGY, V48, P187	30	250	257	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					427	430		10.1126/science.1925602	http://dx.doi.org/10.1126/science.1925602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925602				2022-12-28	WOS:A1991GK72900048
J	MACAYA, RF; GILBERT, DE; MALEK, S; SINSHEIMER, JS; FEIGON, J				MACAYA, RF; GILBERT, DE; MALEK, S; SINSHEIMER, JS; FEIGON, J			STRUCTURE AND STABILITY OF X.G.C MISMATCHES IN THE 3RD STRAND OF INTRAMOLECULAR TRIPLEXES	SCIENCE			English	Article							DIMENSIONAL NMR-SPECTRA; C-MYC GENE; HELIX FORMATION; H-DNA; BASE-PAIRS; SEQUENCE; CLEAVAGE; INHIBITION; COMPLEXES; BINDING	Intramolecular DNA triplexes that contain eight base triplets formed from the folding of a single DNA strand tolerate a single X.G.C mismatch in the third strand at acidic pH. The structure and relative stability of all four triplets that are possible involving a G.C Watson-Crick base pair were determined with one- and two-dimensional proton nuclear magnetic resonance techniques. Triplexes containing A.G.C, G.G.C, or T.G.C triplets were less stable than the corresponding parent molecule containing a C.G.C triplet. However, all mismatched bases formed specific hydrogen bonds in the major groove of the double helix. The relative effect of these mismatches on the stability of the triplex differs from the effect assayed (under different conditions) by two-dimensional gel electrophoresis and DNA cleavage with oligonucleotide EDTA.Fe(II).	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	MACAYA, RF (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.			Malek, Shiva/0000-0002-9526-7968; Macaya, Roman/0000-0001-8335-3984	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008185, R01GM037254, T32GM008375] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 37254-01, GM-08375, GM-08185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DOAN TL, 1987, NUCLEIC ACIDS RES, V15, P7749; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANER R, 1990, BIOCHEMISTRY-US, V29, P9761, DOI 10.1021/bi00494a001; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; KATO M, 1990, BIOCHEM J, V268, P175, DOI 10.1042/bj2680175; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEE JS, 1979, NUCLEIC ACIDS RES, V6, P3073, DOI 10.1093/nar/6.9.3073; LEE JS, 1989, GENE, V82, P191, DOI 10.1016/0378-1119(89)90044-9; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; MACAYA RF, UNPUB; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MANZINI G, 1990, J MOL BIOL, V213, P833, DOI 10.1016/S0022-2836(05)80267-0; MARCK C, 1978, NUCLEIC ACIDS RES, V5, P1017, DOI 10.1093/nar/5.3.1017; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOOREN MMW, 1990, NUCLEIC ACIDS RES, V18, P6523, DOI 10.1093/nar/18.22.6523; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; WANG EG, UNPUB; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	46	63	63	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					270	274		10.1126/science.1925581	http://dx.doi.org/10.1126/science.1925581			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925581				2022-12-28	WOS:A1991GJ64200034
J	CASH, JD				CASH, JD			HIGH POTENCY FACTOR-VIII CONCENTRATES - VALUE NOT PROVED	BRITISH MEDICAL JOURNAL			English	Article											CASH, JD (corresponding author), SCOTTISH NATL BLOOD TRANSFUS SERV,HEADQUARTERS MED UNIT,EDINBURGH EH1 1JH,SCOTLAND.							BELL BA, 1990, LANCET, V336, P638, DOI 10.1016/0140-6736(90)93444-T; BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x; CASH JD, 1988, LANCET, V1, P1270; CASH JD, 1991, BRIT MED J, V302, P849, DOI 10.1136/bmj.302.6780.849-b; KESSLER GM, 1990, LANCET, V335, P1403; MONTORO JB, 1991, LANCET, V338, P1222	6	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					633	634		10.1136/bmj.303.6803.633	http://dx.doi.org/10.1136/bmj.303.6803.633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932909	Green Published, Bronze			2022-12-28	WOS:A1991GF67500029
J	LAZARUS, NB; KAPLAN, GA; COHEN, RD; LEU, DJ				LAZARUS, NB; KAPLAN, GA; COHEN, RD; LEU, DJ			CHANGE IN ALCOHOL-CONSUMPTION AND RISK OF DEATH FROM ALL CAUSES AND FROM ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ALAMEDA COUNTY; MORTALITY; LINKAGE; WOMEN; MEN	Objective - To examine the association between alcohol consumption and mortality from all causes and from ischaemic heart disease with a focus on differentiating between long term abstainers and more recent non-drinkers. Design - Cohort study of changes in alcohol consumption from 1965 to 1974 and mortality from all causes and ischaemic heart disease during 1974-84. Setting - Population based study of adult residents of Alameda County, California. Subjects - 2225 women and 1845 men aged 35 and over in 1965. Main outcome measures - Alcohol consumption in 1964 and 1974 and mortality from all causes and from ischaemic heart disease during 1974-84. Results - There was a significantly higher risk of death from all causes and from ischaemic heart disease in women who gave up drinking between 1965 and 1974 than in women who continued to drink (relative risk 1.72, 95% confidence interval 1.11 to 2.66, and 2.75, 1.44 to 5.23, for all causes and ischaemic heart disease respectively). A significant increase in risk was not seen in men who gave up drinking (1.32, 0.87 to 2.01, and 0.95, 0.41 to 2.20, respectively). Among men, long term abstainers compared with drinkers were at increased risk of death from all causes and from ischaemic heart disease, though the associations were not significant (1.40, 0.98 to 2.00, and 1.40, 0.76 to 2.58, for all causes and ischaemic heart disease respectively). Conclusion- Some of the increased risk of death from all causes and from ischaemic heart disease associated with not drinking in women seems to be accounted for by higher risks among those who gave up drinking. Men who are long term abstainers may also be at an increased risk of death. The heterogeneity of the non-drinking group should be considered when comparisons are made with drinkers.	CALIF DEPT HLTH SCI,HUMAN POPULAT LAB,BERKELEY,CA 94704; CALIF PUBL HLTH FDN,HUMAN POPULAT LAB,BERKELEY,CA 94704	California Department of Public Health			Kaplan, George/AAJ-2398-2020					ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BELLOC NB, 1973, HEALTH SERV REP, V88, P344, DOI 10.2307/4594792; Berkman LF, 1983, HLTH WAYS LIVING ALA; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CASTELLI WP, 1977, LANCET, V2, P153; COLSHER PL, 1989, ANNU REV PUBL HEALTH, V10, P203, DOI 10.1146/annurev.pu.10.050189.001223; CRIQUI MH, 1985, BEHAVIORAL EPIDEMIOL, P67; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; Ellison R C, 1990, Epidemiology, V1, P337; ERNST N, 1980, CIRCULATION, V62, P41; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1974, 2ND US DEP HLTH ED W	25	68	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					553	556		10.1136/bmj.303.6802.553	http://dx.doi.org/10.1136/bmj.303.6802.553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912885	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1991GE94800023
J	LOCKYER, MJ				LOCKYER, MJ			PREVALENCE OF MULTIPLE-SCLEROSIS IN 5 RURAL SUFFOLK PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine a point prevalence of multiple sclerosis in part of Suffolk. Design-Multiple source search for patients with multiple sclerosis in five general practices. Patients were reviewed and categorised by using general practice notes. Setting-Five rural general practices in Suffolk, 12 May 1988. Subjects-31 379 patients registered with five practices. Main outcome measures-Multiple sclerosis diagnosed by a specialist. Results-The search produced a provisional list of 62 eligible patients with multiple sclerosis. Review of case notes showed that 48 had probable disease, 10 early disease, and four possible disease. The probable cases gave a crude prevalence of 153/100 000 population (95% confidence interval 109/100 000 to 196/100 000). Conclusions-Although the results should be interpreted cautiously because of the small sample size, they suggest that the prevalence of multiple sclerosis in Suffolk is higher than has been estimated from hospital data.			LOCKYER, MJ (corresponding author), IXWORTH SURG,BURY ST EDMUNDS IP31 2HD,SUFFOLK,ENGLAND.							Allison RS, 1954, ULSTER MED J      S2, V23, P5; FOG M, 1966, ACTA NEUROL SCAND, VS 42, P9; OBRIEN B, 1987, MULTIPLE SCLEROSIS; POSKANZER DC, 1963, J NEUROL NEUROSUR PS, V26, P368, DOI 10.1136/jnnp.26.4.368; POSKANZER DC, 1980, J EPIDEMIOL COMMUN H, V34, P229, DOI 10.1136/jech.34.4.229; SHEPHERD DI, 1980, J NEUROL NEUROSUR PS, V43, P310, DOI 10.1136/jnnp.43.4.310	6	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					347	348		10.1136/bmj.303.6798.347	http://dx.doi.org/10.1136/bmj.303.6798.347			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912778	Bronze, Green Published			2022-12-28	WOS:A1991GA60600024
J	GAILLARD, JL; BERCHE, P; FREHEL, C; GOUIN, E; COSSART, P				GAILLARD, JL; BERCHE, P; FREHEL, C; GOUIN, E; COSSART, P			ENTRY OF L-MONOCYTOGENES INTO CELLS IS MEDIATED BY INTERNALIN, A REPEAT PROTEIN REMINISCENT OF SURFACE-ANTIGENS FROM GRAM-POSITIVE COCCI	CELL			English	Article							GROUP-A STREPTOCOCCI; BACTERIUM LISTERIA-MONOCYTOGENES; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MAMMALIAN-CELLS; EPITHELIAL-CELLS; YERSINIA-ENTEROCOLITICA; STAPHYLOCOCCUS-AUREUS; INTRACELLULAR GROWTH; MOLECULAR-CLONING	We report the identification of a previously unknown gene, inlA, which is necessary for the gram-positive intracellular pathogen Listeria monocytogenes to invade cultured epithelial cells. The inlA region was localized by transposon mutagenesis, cloned, and sequenced. inlA was introduced into Listeria innocua and shown to confer on this normally noninvasive species the ability to enter cells. Sequencing of inlA predicts an 80 kd protein, internalin. Two-thirds of internalin is made up of two regions of repeats, region A and region B, and the C-terminus of the molecule is similar to that of surface proteins from gram-positive cocci. Internalin has a high content of threonine and serine residues, and the repeat motif of region A has regularly spaced leucine residues. As evidenced by Southern blot analysis, inlA is part of a gene family. One of them is the gene situated directly downstream of inlA, called inlB, which also encodes a leucine-rich repeat protein.	INST PASTEUR, DEPT BIOTECHNOL, UNITE GENIE MICROBIOL, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	GAILLARD, JL (corresponding author), UNIV PARIS 05, MICROBIOL LAB, F-75730 PARIS 15, FRANCE.							ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BEACHEY EH, 1987, REV INFECT DIS, V9, pS475; BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CAILLAUD F, 1987, PLASMID, V17, P58, DOI 10.1016/0147-619X(87)90009-6; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; COSSART P, 1989, MOL BIOL MED, V6, P463; COSSART P, 1989, INFECT IMMUN, V57, P3629, DOI 10.1128/IAI.57.11.3629-3636.1989; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FELMLEE T, 1985, J BACTERIOL, V163, P88, DOI 10.1128/JB.163.1.88-93.1985; FERRETTI JJ, 1989, MOL MICROBIOL, V3, P469, DOI 10.1111/j.1365-2958.1989.tb00193.x; FIEDLER F, 1987, B I PASTEUR, V85, P287; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1985, J EXP MED, V161, P1384, DOI 10.1084/jem.161.6.1384; FISCHETTI VA, 1984, J EXP MED, V159, P1083, DOI 10.1084/jem.159.4.1083; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GEOFFROY C, 1987, INFECT IMMUN, V55, P1641, DOI 10.1128/IAI.55.7.1641-1646.1987; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; HAANES EJ, 1989, J BACTERIOL, V171, P6397, DOI 10.1128/jb.171.12.6397-6408.1989; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HAVELL EA, 1986, INFECT IMMUN, V54, P787, DOI 10.1128/IAI.54.3.787-792.1986; HEATH DG, 1989, P NATL ACAD SCI USA, V86, P4741, DOI 10.1073/pnas.86.12.4741; HOF H, 1987, ANN INST PASTEUR MIC, V138, P268, DOI 10.1016/0769-2609(87)90207-9; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOLLINGSHEAD SK, 1987, MOL GEN GENET, V207, P196, DOI 10.1007/BF00331578; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JONES KF, 1988, P NATL ACAD SCI USA, V85, P8271, DOI 10.1073/pnas.85.21.8271; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1988, CURR TOP MICROBIOL, V138, P141; KOHLER S, 1990, INFECT IMMUN, V58, P1943; KUHN M, 1988, INFECT IMMUN, V56, P79, DOI 10.1128/IAI.56.1.79-82.1988; KUHN M, 1989, INFECT IMMUN, V57, P55, DOI 10.1128/IAI.57.1.55-61.1989; LEBLONDFRANCILLARD M, 1989, INFECT IMMUN, V57, P2569, DOI 10.1128/IAI.57.8.2569-2573.1989; LEIGHTON I, 1975, PROBLEMS LISTERIOSIS, P239; LOVINY T, 1985, BIOCHEM J, V230, P579, DOI 10.1042/bj2300579; LUDWIG W, 1984, FEMS MICROBIOL LETT, V25, P199; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Maniatis T., 1982, MOL CLONING; MAURELLI AT, 1988, ANNU REV MICROBIOL, V42, P127, DOI 10.1146/annurev.micro.42.1.127; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MENGAUD J, 1991, INFECT IMMUN, V59, P1043, DOI 10.1128/IAI.59.3.1043-1049.1991; MENGAUD J, 1991, MOL MICROBIOL, V5, P367, DOI 10.1111/j.1365-2958.1991.tb02118.x; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MILLER L, 1988, J BIOL CHEM, V263, P5668; MILLER VL, 1989, INFECT IMMUN, V57, P121, DOI 10.1128/IAI.57.1.121-131.1989; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; MOUW AR, 1988, J BACTERIOL, V170, P676, DOI 10.1128/jb.170.2.676-684.1988; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; PEREZDIAZ JC, 1982, PLASMID, V8, P112, DOI 10.1016/0147-619X(82)90049-X; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIFFARETTI JC, 1989, P NATL ACAD SCI USA, V86, P3818, DOI 10.1073/pnas.86.10.3818; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; RACZ P, 1972, LAB INVEST, V26, P694; RACZ P, 1970, ACTA MICROBIOL HUNG, V17, P221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEEWIND O, 1990, J BACTERIOL, V172, P3310, DOI 10.1128/jb.172.6.3310-3317.1990; Seeliger H.P.R., 1986, BERGEYS MANUAL SYSTE, P1235; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TRIEUCUOT P, 1990, NUCLEIC ACIDS RES, V18, P4296, DOI 10.1093/nar/18.14.4296; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WELCH DF, 1979, INFECT IMMUN, V23, P863, DOI 10.1128/IAI.23.3.863-872.1979; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	75	659	699	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1127	1141		10.1016/0092-8674(91)90009-N	http://dx.doi.org/10.1016/0092-8674(91)90009-N			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905979				2022-12-28	WOS:A1991FU89900006
J	NEMUNAITIS, J; RABINOWE, SN; SINGER, JW; BIERMAN, PJ; VOSE, JM; FREEDMAN, AS; ONETTO, N; GILLIS, S; OETTE, D; GOLD, M; BUCKNER, CD; HANSEN, JA; RITZ, J; APPELBAUM, FR; ARMITAGE, JO; NADLER, LM				NEMUNAITIS, J; RABINOWE, SN; SINGER, JW; BIERMAN, PJ; VOSE, JM; FREEDMAN, AS; ONETTO, N; GILLIS, S; OETTE, D; GOLD, M; BUCKNER, CD; HANSEN, JA; RITZ, J; APPELBAUM, FR; ARMITAGE, JO; NADLER, LM			RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOID CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; GM-CSF; ADVANCED MALIGNANCY; HEMATOPOIESIS; CHEMOTHERAPY; PRIMATES; CELLS; MICE; IL-3	Background. The period of neutropenia after autologous bone marrow transplantation results in substantial morbidity and mortality. The results of previous phase I-II clinical trials suggest that recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) may accelerate neutrophil recovery and thereby reduce complications in patients after autologous bone marrow transplantation. Methods. We conducted a randomized, double-blind, placebo-controlled trial at three institutions. The study design and treatment schedules were identical, and the results were pooled for analysis. One hundred twenty-eight patients were enrolled. Sixty-five patients received rhGM-CSF in a two-hour intravenous infusion daily for 21 days, starting within four hours of the marrow infusion, and 63 patients received placebo. Results. No toxic effects specifically ascribed to rhGM-CSF were observed. The patients given rhGM-CSF had a recovery of the neutrophil count to 500 x 10(6) per liter 7 days earlier than the patients who received placebo (19 vs. 26 days, P < 0.001), had fewer infections, required 3 fewer days of antibiotic administration (24 vs. 27 days, P = 0.009), and required 6 fewer days of initial hospitalization (median, 27 vs. 33 days; P = 0.01). There was no difference in the survival rate at day 100. Conclusions. In patients undergoing autologous bone marrow transplantation for lymphoid neoplasia, rhGM-CSF significantly lessens morbidity. Further studies will be required to establish its optimal dosage and schedule of administration.	IMMUNEX CORP,SEATTLE,WA; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,SEATTLE,WA 98195; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; UNIV NEBRASKA,MED CTR,OMAHA,NE 68105; HOECHST ROUSSEL PHARMACEUT PTY LTD,SOMERVILLE,NJ 08876	Immunex Corporation; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center	NEMUNAITIS, J (corresponding author), VET AFFAIRS MED CTR,111-ONC,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA.			Singer, Jack/0000-0003-4001-4549	NATIONAL CANCER INSTITUTE [P01CA018029, P01CA047748, P01CA034183] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34183, CA 18029, CA 47748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ARMITAGE JO, 1989, BLOOD, V73, P1749; BLEIBERG I, 1990, BLOOD, V75, P1262; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; FREEDMAN AS, 1990, J CLIN ONCOL, V8, P784, DOI 10.1200/JCO.1990.8.5.784; FRENCK RW, 1990, J INFECT DIS, V162, P109, DOI 10.1093/infdis/162.1.109; GABRILOVE JL, 1989, SEMIN HEMATOL S2, V2, P1; GEISSLER K, 1990, BLOOD, V75, P2305; GIANNI AM, 1989, LANCET, V2, P580; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HERRMANN F, 1989, J CLIN ONCOL, V7, P159, DOI 10.1200/JCO.1989.7.2.159; HILL RS, 1989, BONE MARROW TRANSPL, V4, P69; ISHIBASHI T, 1986, BLOOD, V67, P1512; Koch GG, 1988, BIOPHARMACEUTICAL ST, P403; LIESCHKE GJ, 1989, ANN INTERN MED, V110, P357, DOI 10.7326/0003-4819-110-5-357; LINK H, 1988, BEHRING I MITT, V83, P313; METCALF D, 1986, BLOOD, V68, P46; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MONROY RL, 1987, BLOOD, V70, P1696; NADLER LM, 1984, LANCET, V2, P427; NEMUNAITIS J, 1988, BLOOD, V72, P834; NEMUNAITIS J, 1990, BONE MARROW TRANSPL, V7, P49; NEMUNAITIS J, 1989, AUTOLOGOUS BONE MARR, V4, P631; NIENHUIS AW, 1987, J CLIN INVEST, V80, P573, DOI 10.1172/JCI113106; PETERS WP, 1988, BLOOD, V72, P1310; PETERSEN FB, 1990, J CLIN ONCOL, V8, P638, DOI 10.1200/JCO.1990.8.4.638; SMITH PD, 1990, J INFECT DIS, V161, P999, DOI 10.1093/infdis/161.5.999; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; 1980, STATISTICAL ANAL FAI, P143	30	467	470	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1773	1778		10.1056/NEJM199106203242504	http://dx.doi.org/10.1056/NEJM199106203242504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	1903847				2022-12-28	WOS:A1991FR68100004
J	NAUMANN, D; HELM, D; LABISCHINSKI, H				NAUMANN, D; HELM, D; LABISCHINSKI, H			MICROBIOLOGICAL CHARACTERIZATIONS BY FT-IR SPECTROSCOPY	NATURE			English	Article								Infrared signals of microorganisms are highly specific fingerprint-like patterns that can be used for probing the identity of microorganisms. The simplicity and versatility of Fourier-transform infrared spectroscopy (FT-IR) makes it a versatile technique for rapid differentiation, classification, identification and large-scale screening at the subspecies level.			NAUMANN, D (corresponding author), BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,NORDUFER 20,W-1000 BERLIN 65,GERMANY.							HELM D, 1991, J GEN MICROBIOL, V137, P69, DOI 10.1099/00221287-137-1-69; NAUMANN D, 1988, J MOL STRUCT, V174, P165, DOI 10.1016/0022-2860(88)80152-2; NAUMANN D, 1988, MIKROCHIM ACTA, V1, P373, DOI 10.1007/BF01205910; NAUMANN D, IN PRESS MODERN TECH; THRELKELD CH, 1982, J FOOD SCI, V47, P1222, DOI 10.1111/j.1365-2621.1982.tb07652.x	5	752	785	7	150	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					81	82		10.1038/351081a0	http://dx.doi.org/10.1038/351081a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1902911				2022-12-28	WOS:A1991FK19300066
J	JAMJOOM, AB; KANE, N; SANDEMAN, D; CUMMINS, B				JAMJOOM, AB; KANE, N; SANDEMAN, D; CUMMINS, B			EPILEPSY RELATED TO TRAUMATIC EXTRADURAL HEMATOMAS	BRITISH MEDICAL JOURNAL			English	Article									FRENCHAY HOSP,DEPT NEUROSURG,BRISTOL BS16 1LE,AVON,ENGLAND									ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1975, EPILEPSY NONMISSILE, P136	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					448	448		10.1136/bmj.302.6774.448	http://dx.doi.org/10.1136/bmj.302.6774.448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	1900725	Bronze, Green Published			2022-12-28	WOS:A1991EZ03300022
J	HELD, PJ; LEVIN, NW; BOVBJERG, RR; PAULY, MV; DIAMOND, LH				HELD, PJ; LEVIN, NW; BOVBJERG, RR; PAULY, MV; DIAMOND, LH			MORTALITY AND DURATION OF HEMODIALYSIS-TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS	Decrease in the average duration of hemodialysis treatment time is a continuing phenomenon. We investigated the relationship of 3-year mortality to duration of dialysis in a 1984-1985 national random sample of 600 hemodialysis patients from 36 dialysis units. Mortality was negatively associated with duration of dialysis treatments, as shown by the Cox model, adjusted for other patient and dialysis unit covariates. With adjustment for other covariates, patients receiving an average dialysis treatment duration of less than 3.5 hours had relative mortality risks of 1.17 to 2.18 compared with those with treatments longer than 3.5 hours (mortality risk of 1.0). Reverse causation (the possibility that more seriously ill patients received dialysis for a shorter time) appears unlikely. We conclude that duration of the dialysis procedure is an important element in determining patient mortality as one of the factors determining the adequacy of dialysis.	BETH ISRAEL MED CTR,DEPT NEPHROL,NEW YORK,NY 10003; UNIV PENN,WHARTON SCH,PHILADELPHIA,PA 19104; GEORGETOWN UNIV,DEPT NEPHROL,WASHINGTON,DC 20057; DIST COLUMBIA GEN HOSP,WASHINGTON,DC 20003	Harvard University; Beth Israel Deaconess Medical Center; University of Pennsylvania; Georgetown University	HELD, PJ (corresponding author), URBAN INST,RENAL RES PROGRAM,2100 M ST NW,WASHINGTON,DC 20037, USA.							ALEXANDER VD, 1984, SAMPLE DESIGN NATION; DAUGIRDAS JT, 1989, INT J ARTIF ORGANS, V12, P411; GILL RD, 1988, ANN STAT, V16, P1069, DOI 10.1214/aos/1176350948; GOTCH FA, 1990, AM J KIDNEY DIS, V15, P511, DOI 10.1016/S0272-6386(12)70369-4; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HARRELL F, 1980, SAS SUPPLEMENTAL LIB, P119; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELD PJ, 1987, EFFECTS 1983 COMPOSI; HELD PJ, AM J KIDNEY DIS, V15, P441; KMENTA J, 1973, ELEMENTS ECONOMETRIC; KRAKAUER H, 1986, ISRAEL J MED SCI, V22, P3; LAIRD NM, 1983, KIDNEY INT, pS101; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; SANTIAGO G, 1983, KIDNEY INT S13, V23, pS95; SARGENT JA, 1983, KIDNEY INT S13, V23, pS19; VARDI Y, 1982, ANN STAT, V10, P616, DOI 10.1214/aos/1176345802; 1990, USRDS 1990 ANN DATA; 1987, RES REPORT END STAGE; 1989, INSTRUCTION MANUAL R; 1983, FED REG         0511, V48, P21254	20	211	213	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					871	875		10.1001/jama.265.7.871	http://dx.doi.org/10.1001/jama.265.7.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899455				2022-12-28	WOS:A1991EX58700037
J	PARKS, S; WIESCHAUS, E				PARKS, S; WIESCHAUS, E			THE DROSOPHILA GASTRULATION GENE CONCERTINA ENCODES A G-ALPHA-LIKE PROTEIN	CELL			English	Article							BINDING REGULATORY PROTEINS; POLYMERASE CHAIN-REACTION; MATERNAL-EFFECT MUTATIONS; SINGLE-STRANDED-DNA; ALPHA-TUBULIN GENES; MOLECULAR CHARACTERIZATION; INSITU HYBRIDIZATION; NERVOUS-SYSTEM; X-CHROMOSOME; MELANOGASTER	Gastrulation is a complex process requiring the coordination of cell shape changes and cell movements. In Drosophila, gastrulation begins immediately upon cellularization of the blastoderm stage embryo with the formation of the ventral furrow and posterior midgut. Cells that form both of these invaginations change their shape via apical constriction. Embryos from mothers homozygous for mutations in the concertina (cta) gene begin furrow formation by forming a zone of tightly apposed cells, constrict some cells, and then fail to constrict enough cells to form an organized groove. The cta gene has been cloned, and sequence analysis suggests that it encodes an alpha-subunit of a G protein. G proteins have a role in cell-cell communication as mediators of signals between membrane-bound receptors and intracellular effectors. The phenotype of embryos from homozygous cta mothers suggests that the cta gene plays a role in a signal transduction pathway used during gastrulation.	JOHNS HOPKINS MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine	PARKS, S (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.				NICHD NIH HHS [5R 37HD15587] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD015587] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKAM M, 1987, DEVELOPMENT, V101, P1; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAKER PC, 1967, DEV BIOL, V15, P432, DOI 10.1016/0012-1606(67)90036-X; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERLOT CH, 1987, J BIOL CHEM, V262, P3918; BONNER JJ, 1976, CHROMOSOMA, V58, P87, DOI 10.1007/BF00293443; BURNSIDE B, 1971, DEV BIOL, V26, P416, DOI 10.1016/0012-1606(71)90073-X; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARLSON KE, 1986, MOL PHARMACOL, V30, P463; DESOUSA SM, 1989, J BIOL CHEM, V264, P18544; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE HJ, 1986, NATURE, V323, P76, DOI 10.1038/323076a0; ETTENSOHN CA, 1985, Q REV BIOL, V60, P289, DOI 10.1086/414426; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GUSTAFSON T, 1962, EXP CELL RES, V27, P260, DOI 10.1016/0014-4827(62)90229-X; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; KALFAYAN L, 1981, CELL, V24, P97, DOI 10.1016/0092-8674(81)90505-5; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KREITMAN M, 1989, GENE ANAL TECH, V6, P84, DOI 10.1016/0735-0651(89)90021-6; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LIU G, 1988, J CELL SCI, V90, P123; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Maniatis T., 1982, MOL CLONING; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; NARDI JB, 1976, J EMBRYOL EXP MORPH, V36, P489; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1979, S SOC DEV BIOL, V37, P185; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; PARKS S, 1986, DEV BIOL, V117, P294, DOI 10.1016/0012-1606(86)90372-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRIMON N, 1989, GENETICS, V121, P333; Poulson D. F., 1950, BIOL DROSOPHILA, P168; PROVOST NM, 1988, J BIOL CHEM, V263, P12070; QUAN R, 1987, P NATL ACAD SCI USA, V86, P4321; REED RR, 1989, SCIENCE, V244, P790; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SCHMIDT CJ, 1989, CELL REGUL, V1, P125, DOI 10.1091/mbc.1.1.125; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SCHOENWOLF GC, 1984, DEV BIOL, V105, P257, DOI 10.1016/0012-1606(84)90284-7; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1989, GENETICS, V121, P101; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SIMPSON P, 1983, GENETICS, V105, P615; SOUTHERN EM, 1975, J MOL BIOL, V98, P504; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAMBI NC, 1989, J BIOL CHEM, V264, P18552; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TOBIN SL, 1980, CELL, V19, P121, DOI 10.1016/0092-8674(80)90393-1; Trinkaus J.P., 1984, CELLS ORGANS; TURNER FR, 1977, DEV BIOL, V57, P403, DOI 10.1016/0012-1606(77)90225-1; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WAKIMOTO BT, 1990, GENETICS, V125, P141; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YOON JS, 1989, J BIOL CHEM, V264, P18536; ZUSMAN SB, 1985, DEV BIOL, V111, P359, DOI 10.1016/0012-1606(85)90490-7; ZWAAN J, 1973, AM ZOOL, V13, P1039; ZWAAN J, 1971, DEV BIOL, V25, P96, DOI 10.1016/0012-1606(71)90021-2	81	257	259	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 25	1991	64	2					447	458		10.1016/0092-8674(91)90652-F	http://dx.doi.org/10.1016/0092-8674(91)90652-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1899050	hybrid			2022-12-28	WOS:A1991EV33600020
J	GRAHAM, R; GILMAN, M				GRAHAM, R; GILMAN, M			DISTINCT PROTEIN TARGETS FOR SIGNALS ACTING AT THE C-FOS SERUM RESPONSE ELEMENT	SCIENCE			English	Article							MEDIATES TRANSCRIPTIONAL RESPONSE; GROWTH-FACTOR; PHORBOL ESTERS; BINDING-SITE; CYCLIC-AMP; GENE; IDENTIFICATION; INDUCTION; YEAST; EXPRESSION	The c-fos serum response element (SRE) is a primary nuclear target for intracellular signal transduction pathways triggered by growth factors. It is the target for both protein kinase C (PKC)-dependent and -independent signals. Function of the SRE requires binding of a cellular protein, termed serum response factor (SRF). A second protein, p62TCP, recognizes the SRE-SRF complex to form a ternary complex. A mutated SRE that bound SRF but failed to form the ternary complex selectively lost response to PKC activators, but retained response to PKC-independent signals. Thus, two different signaling pathways act through discrete nuclear targets at the SRE. At least one of these pathways functions by recruitment of a pathway-specific accessory factor (p62TCF). These results offer a molecular mechanism to account for the biological specificity of signals that appear to act through common DNA sequence elements.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				graham, regina/0000-0003-0103-2971	NATIONAL CANCER INSTITUTE [R01CA045642, P01CA046370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027270] Funding Source: NIH RePORTER; NCI NIH HHS [CA46370, CA45642] Funding Source: Medline; NIAID NIH HHS [AI27270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BUSCHER M, 1988, ONCOGENE, V3, P301; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; Curran T, 1988, ONCOGENE HDB, P307; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, UNPUB; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ORITA S, 1989, GENE, V75, P13; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAN S, 1990, NATURE, V62, P367; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	33	238	241	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					189	192		10.1126/science.1898992	http://dx.doi.org/10.1126/science.1898992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1898992				2022-12-28	WOS:A1991ET17300038
J	BELIZAN, JM; VILLAR, J; GONZALEZ, L; CAMPODONICO, L; BERGEL, E				BELIZAN, JM; VILLAR, J; GONZALEZ, L; CAMPODONICO, L; BERGEL, E			CALCIUM SUPPLEMENTATION TO PREVENT HYPERTENSIVE DISORDERS OF PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACELLULAR FREE CALCIUM; BLOOD-PRESSURE; ORAL CALCIUM; PREECLAMPSIA; WOMEN; HYPOCALCIURIA; METABOLISM; REDUCTION; TRIAL	Background. Calcium supplementation has been reported to reduce blood pressure in pregnant and nonpregnant women. We undertook this prospective study to determine the effect of calcium supplementation on the incidence ot hypertensive disorders of pregnancy (gestational hypertension and preeclampsia) and to determine the value ot urinary calcium levels as a predictor of the response. Methods. We studied 1194 nulliparous women who were in the 20th week of gestation at the beginning of the study. The women were randomly assigned to receive 2 g per day of elemental calcium in the form of calcium carbonate (593 women) or placebo (601 women). Urinary excretion of calcium and creatinine was measured before calcium supplementation was begun. The women were followed to the end of their pregnancies, and the incidence of hypertensive disorders of pregnancy was determined. Results. The rates of hypertensive disorders of pregnancy were lower in the calcium group than in the placebo group (9.8 percent vs. 14.8 percent; odds ratio, 0.63; 95 percent confidence interval, 0.44 to 0.90). The risk of these disorders was lower at all times during gestation, particularly after the 28th week of gestation (P = 0.01 by life-table analysis), in the calcium group than in the placebo group, and the risk of both gestational hypertension and preeclampsia was also lower in the calcium group. Among the women who had low ratios of urinary calcium to urinary creatinine (less-than-or-equal-to 0.62 mmol per millimole) during the 20th week of gestation, those in the calcium group had a lower risk of hypertensive disorders of pregnancy (odds ratio, 0.56; 95 percent confidence interval, 0.29 to 1.09) and less of an increase in diastolic and systolic blood pressure than the placebo group. The pattern of response was similar among the women who had a high ratio of urinary calcium to urinary creatinine during the 20th week of gestation, but the differences were smaller. Conclusions. Pregnant women who receive calcium supplementation after the 20th week of pregnancy have a reduced risk of hypertensive disorders of pregnancy.	CTR ROSARINO ESTUDIOS PERINATALES,ROSARIO,ARGENTINA					Belizan, Jose/0000-0002-8412-3010				ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BELIZAN JM, 1988, AM J OBSTET GYNECOL, V158, P898, DOI 10.1016/0002-9378(88)90091-9; BELIZAN JM, 1980, AM J CLIN NUTR, V33, P2202, DOI 10.1093/ajcn/33.10.2202; BELIZAN JM, 1983, AM J OBSTET GYNECOL, V146, P175, DOI 10.1016/0002-9378(83)91049-9; BELIZAN JM, 1983, JAMA-J AM MED ASSOC, V249, P1161, DOI 10.1001/jama.249.9.1161; BELIZAN JM, 1989, B PAN AM HLTH ORGAN, V27, P414; BLACKEBOROUGH P, 1990, BR J NUTR, V63, P65; CHALMERS TC, 1988, DATA ANAL CLIN MED Q, P75; DAVISON JM, 1990, 7 WORLD C HYP PREGN, P89; GERTNER JM, 1986, AM J MED, V81, P451, DOI 10.1016/0002-9343(86)90298-6; HALLER H, 1989, AM J HYPERTENS, V2, P238, DOI 10.1093/ajh/2.4.238; HOWARTH AT, 1977, AM J OBSTET GYNECOL, V129, P499, DOI 10.1016/0002-9378(77)90086-2; KILBY MD, 1989, BRIT J OBSTET GYNAEC, V96, P1242; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P159; LOPEZJARAMILLO P, 1989, J OBSTET GYNAECOL, V19, P648; LOPEZJARAMILLO P, 1990, LANCET, P293; MACINTOSH MCM, 1989, BRIT J OBSTET GYNAEC, V96, P1243; MARYA RK, 1987, GYNECOL OBSTET INVES, V24, P38, DOI 10.1159/000298772; MCCARRON DA, 1985, ANN INTERN MED, V103, P825, DOI 10.7326/0003-4819-103-6-825; MONTANARO D, 1987, 10TH INT C NEPHR LON; REPKE JT, 1989, AM J OBSTET GYNECOL, V160, P684, DOI 10.1016/S0002-9378(89)80059-6; RODRIGUEZ MH, 1988, AM J OBSTET GYNECOL, V159, P1452, DOI 10.1016/0002-9378(88)90573-X; SOWERS JR, 1989, AM J OBSTET GYNECOL, V161, P441, DOI 10.1016/0002-9378(89)90539-5; TAUFIELD PA, 1987, NEW ENGL J MED, V316, P715, DOI 10.1056/NEJM198703193161204; TOHME JF, 1990, J CLIN ENDOCR METAB, V70, P951, DOI 10.1210/jcem-70-4-951; VILLAR J, 1984, ANN NY ACAD SCI, V435, P509, DOI 10.1111/j.1749-6632.1984.tb13868.x; VILLAR J, 1987, OBSTET GYNECOL, V70, P317; VILLAR J, 1990, AM J OBSTET GYNECOL, V163, P1124, DOI 10.1016/0002-9378(90)90669-X; VILLAR J, 1989, AM J OBSTET GYNECOL, V161, P1019, DOI 10.1016/0002-9378(89)90777-1; VILLAR J, 1983, INT J GYNECOL OBSTET, V21, P271, DOI 10.1016/0020-7292(83)90016-4; ZEMEL MB, 1990, NEW ENGL J MED, V323, P434, DOI 10.1056/NEJM199008163230702; 1990, AM J OBSTET GYNECOL, V163, P1689	32	235	241	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1399	1405		10.1056/NEJM199111143252002	http://dx.doi.org/10.1056/NEJM199111143252002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922250				2022-12-28	WOS:A1991GP52400002
J	PRASHKER, MJ; MEENAN, RF				PRASHKER, MJ; MEENAN, RF			SUBSPECIALTY TRAINING - IS IT FINANCIALLY WORTHWHILE	ANNALS OF INTERNAL MEDICINE			English	Article							RELATIVE-VALUE; PHYSICIAN	Objective: To determine the financial return of additional training in a cognitive-oriented medical subspecialty (rheumatology) and in a procedure-oriented medical subspecialty (gastroenterology) relative to general internal medicine. Design: Analysis of existing data to compare lifetime discounted earnings of physicians in different medical specialties. Participants: General internists, gastroenterologists, and rheumatologists were surveyed. Main Outcome Measures: Using data from surveys conducted by Medical Economics and the American College of Rheumatology, we constructed lifetime earnings streams that allowed the calculation of the net present values of discounted lifetime earnings in general internal medicine, gastroenterology, and rheumatology. Net present values of lifetime earnings were calculated for each group at two discount rates. Sensitivity analyses were done to estimate how changes in relative income would affect calculations of the net present values. Main Results: The average net incomes before taxes for general internists, gastroenterologists, and rheumatologists in 1988 were $115 825, $201 875, and $118 056, respectively. At 5% and 10% discount rates, the net present values of the estimated career earnings stream for additional training in gastroenterology relative to general internal medicine were +$1 101 863 and +$512 952, respectively; for additional training in rheumatology relative to general internal medicine, the respective values were -$84,748 and -$92,467. If the incomes of general internists were decreased by 3% and the incomes of gastroenterologists were decreased by 25% to reflect the effect of potential changes due to the resource-based relative value scale (RBRVS), or if gastroenterology training were increased to 3 years and rheumatology fellowship stipends were increased by 30%, large differences would still exist between the groups. Conclusion: Gastroenterologists have an extremely large return on their additional investment in training, but rheumatologists have a negative return. When considered exclusively as a financial decision, fellowship training in a cognitive-oriented medical subspecialty such as rheumatology is a poor investment. Even major changes in reimbursement policies will not affect the relative pecuniary attractiveness of procedure-oriented medical subspecialties.	BOSTON CITY HOSP, BOSTON, MA 02118 USA; BOSTON UNIV HOSP, BOSTON, MA 02218 USA	Boston Medical Center; Boston University	PRASHKER, MJ (corresponding author), BOSTON UNIV, CTR ARTHRITIS, 80 E CONCORD ST, BOSTON, MA 02215 USA.			Meenan, Robert/0000-0003-0180-3211; Prashker, Mark/0000-0002-3917-0053	NIAMS NIH HHS [AR20613] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Becker G.S., 2002, HUMAN CAPITAL, V2, P1; BRIGHAM E, 1982, FINANCIAL MANAGEMENT; CLARK L, 1989, MED EC          1204, P94; FEIN R, 1971, FINANCING MED ED; FELDMAN R, 1978, Q REV ECON BUS, V18, P91; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; LANGWELL KM, 1980, J HUM RESOUR, V15, P278, DOI 10.2307/145337; LEFFLER K, 1979, SOUTH ECON J, V46, P591, DOI 10.2307/1057430; LEFFLER K, 1981, J HUM RESOUR, V16; LEFFLER KB, 1978, J LAW ECON, V21, P165, DOI 10.1086/466915; LINDSAY CM, 1973, J HUM RESOUR, V8, P331, DOI 10.2307/144707; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; MENNEMEYER ST, 1978, J HUM RESOUR, V13, P75, DOI 10.2307/145302; Owens A, 1989, Med Econ, V66, P130; OWENS A, 1989, MED ECON, V66, P147; OWENS A, 1989, MED ECON, V66, P141; ROPER WL, 1988, NEW ENGL J MED, V319, P865, DOI 10.1056/NEJM198809293191311; SCHULTZ TW, 1961, AM ECON REV, V51, P1; SLOAN FA, 1970, IND LABOR RELAT REV, V24, P47, DOI 10.2307/2521285; SLOAN FA, 1971, J HUM RESOUR, V6, P466, DOI 10.2307/144886; 1990, 1990 MEMBERSHIP SURV; 1991, FED REG         0605, V56, P25792	22	25	25	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					715	719		10.7326/0003-4819-115-9-715	http://dx.doi.org/10.7326/0003-4819-115-9-715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929041				2022-12-28	WOS:A1991GL69700010
J	CHAIN, B				CHAIN, B			PENICILLIN AND BEYOND	NATURE			English	Editorial Material											CHAIN, B (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND.			Chain, Benny/0000-0002-7417-3970					0	3	3	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					492	494		10.1038/353492a0	http://dx.doi.org/10.1038/353492a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922352				2022-12-28	WOS:A1991GJ64300021
J	MCLAUCHLIN, J; HALL, SM; VELANI, SK; GILBERT, RJ				MCLAUCHLIN, J; HALL, SM; VELANI, SK; GILBERT, RJ			HUMAN LISTERIOSIS AND PATE - A POSSIBLE ASSOCIATION	BRITISH MEDICAL JOURNAL			English	Article							MONOCYTOGENES; EPIDEMIOLOGY; BRITAIN	Objectives - To study trends in human listeriosis and determine possible sources of infection. Design - Descriptive analysis of laboratory reports of human listeriosis together with a survey of subtypes of Listeria monocytogenes isolated from patients and foodstuffs and an interview survey of patients to obtain food histories. Setting - United Kingdom and Republic of Ireland 1985 to 1990. Results - There was a near doubling in the incidence of human listeriosis in England, Wales, and Northern Ireland between 1985 and mid-1989 followed by a sharp decline. The upsurge in cases was caused largely by two strains of L monocytogenes, which accounted for 30-54% of the annual totals. These strains were less common before 1987 and after July 1989. A survey of pate in England and Wales in July 1989 showed that it frequently contained L monocytogenes. A similar survey in July 1990 showed a reduction in the proportions of samples contaminated. In 1989 pates from a single plant (manufacturer Y) were more likely to be contaminated by L monocytogenes and at higher levels than those from other producers. Most strains of L monocytogenes recovered from manufacturer Y's pate in 1989 were indistinguishable from those responsible for the 1987-9 upsurge in human listeriosis and were uncommon among isolates from pates from other manufacturers and from a wide range of other foodstuffs. Patients infected with the types of L monocytogenes found in pate were significantly more likely to have recently eaten pate than those affected by other strains. The start of the decline in numbers of cases of listeriosis coincided with government health warnings on pate consumption and the suspension of supplies from manufacturer Y. Conclusions - Contamination of pate was a likely contributory cause of the increase in the incidence of listeriosis between 1987 and 1989.	CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,FOOD HYG LAB,LONDON NW9 5HT,ENGLAND; COMMUNICABLE DIS SURVEILLANCE CTR,PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND	Public Health England; Public Health England	MCLAUCHLIN, J (corresponding author), CENT PUBL HLTH LAB,PUBL HLTH LAB SERV,DIV MICROBIOL REAGENTS & QUAL CONTROL,LONDON NW9 5HT,ENGLAND.							CAMPBELL DM, 1990, J INFECTION, V20, P241, DOI 10.1016/0163-4453(90)91219-4; Gilbert R. J., 1989, PHLS (Public Health Laboratory Service) Microbiology Digest, V6, P33; JOHNSON JL, 1990, J FOOD PROTECT, V53, P81, DOI 10.4315/0362-028X-53.1.81; JONES D, 1990, LANCET, V336, P1171, DOI 10.1016/0140-6736(90)92778-G; MCLAUCHLIN J, 1987, J APPL BACTERIOL, V63, P1, DOI 10.1111/j.1365-2672.1987.tb02411.x; MCLAUCHLIN J, 1989, J INFECTION, V18, P179, DOI 10.1016/S0163-4453(89)91290-5; MCLAUCHLIN J, 1986, J MED MICROBIOL, V22, P367, DOI 10.1099/00222615-22-4-367; MCLAUCHLIN J, 1990, EPIDEMIOL INFECT, V104, P191, DOI 10.1017/S0950268800059355; MORRIS IJ, 1989, LANCET, V2, P1285; SAUNDERS NA, 1989, ACTA MICROBIOL HUNG, V36, P205; 1989, LISTERIA FOUND PATE; 1989, ADVICE VULNERABLE GR; 1989, DHSS PLCMO893 DEP HL	13	188	194	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					773	775		10.1136/bmj.303.6805.773	http://dx.doi.org/10.1136/bmj.303.6805.773			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932944	Bronze, Green Published			2022-12-28	WOS:A1991GG98100029
J	ROLINK, A; MELCHERS, F				ROLINK, A; MELCHERS, F			MOLECULAR AND CELLULAR-ORIGINS OF LYMPHOCYTE-B DIVERSITY	CELL			English	Review							IMMUNOGLOBULIN GENE REARRANGEMENT; BONE-MARROW CULTURES; TRANSFERASE-POSITIVE CELLS; ANTIGEN RECEPTOR COMPLEX; LIGHT CHAIN GENES; MU-HEAVY-CHAINS; PRE-B; STROMAL CELLS; LINEAGE CELLS; SCID MICE				ROLINK, A (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BAUER SR, 1988, EMBO J, V7, P111, DOI 10.1002/j.1460-2075.1988.tb02789.x; BAUER SR, 1991, IN PRESS BLOOD; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BILLIPS LG, 1990, BLOOD, V75, P611; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BOSMA M, 1988, CURR TOP MICROBIOL, V137, P197; BOSMA MJ, 1989, PROGR IMMUNOLOGY, V7, P527; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CARMACK CE, 1990, J EXP MED, V172, P371, DOI 10.1084/jem.172.1.371; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COUTINHO A, 1989, IMMUNOL REV, V110, P63, DOI 10.1111/j.1600-065X.1989.tb00027.x; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; DEENEN GJ, 1990, EUR J IMMUNOL, V20, P557, DOI 10.1002/eji.1830200315; DENIS KA, 1989, IMMUNOGLOBULIN GENES, P45; DHOOSTELAERE LA, 1989, EUR J IMMUNOL, V19, P37, DOI 10.1002/eji.1830190107; DIGHIERO G, 1985, J IMMUNOL, V134, P765; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ELLIOTT JF, 1988, NATURE, V331, P627; ERA T, 1991, IN PRESS J EXP MED; EVANS RJ, 1991, J EXP MED, V173, P305, DOI 10.1084/jem.173.2.305; FEDDERSEN RM, 1990, MOL CELL BIOL, V10, P569, DOI 10.1128/MCB.10.2.569; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; FULOP GM, 1989, BLOOD, V74, P1537; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; FULOP GM, 1988, CELL IMMUNOL, V113, P192, DOI 10.1016/0008-8749(88)90017-2; GISLER RH, 1987, J IMMUNOL, V138, P24; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GREGOIRE KE, 1979, J IMMUNOL, V123, P1347; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; GU H, 1990, EMBO J, V6, P3299; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA K, 1991, J EXP MED, V173, P409, DOI 10.1084/jem.173.2.409; Hardy R R, 1990, Semin Immunol, V2, P197; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HERMANS MHA, 1989, J IMMUNOL, V142, P67; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOLMBERG D, 1989, IMMUNOL REV, V110, P889; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; JACOBSEN K, 1990, EUR J IMMUNOL, V20, P2395, DOI 10.1002/eji.1830201106; JACOBSEN K, 1990, EXP HEMATOL, V18, P304; KALLED SL, 1990, J EXP MED, V172, P559, DOI 10.1084/jem.172.2.559; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; Katoh S, 1990, Dev Immunol, V1, P113, DOI 10.1155/1990/28760; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KINASHI T, 1988, P NATL ACAD SCI USA, V85, P4473, DOI 10.1073/pnas.85.12.4473; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KING AG, 1988, J IMMUNOL, V141, P2018; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1987, Genomics, V1, P277, DOI 10.1016/0888-7543(87)90055-3; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LAWLER AM, 1989, P NATL ACAD SCI USA, V86, P6704; LEVITT D, 1980, CELL, V19, P617, DOI 10.1016/S0092-8674(80)80038-9; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MAEDA T, 1989, J IMMUNOL, V142, P3652; MAKI R, 1980, SCIENCE, V209, P1366, DOI 10.1126/science.6774416; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MATTEI MG, 1991, NATURE, V329, P172; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; MELCHERS F, 1979, INSERM S, V10, P281; MELCHERS F, 1977, DEV HOST DEFENSES, P11; MELCHERS F, 1989, IMMUNOGLOBULIN GENES, P23; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; Osmond D G, 1990, Semin Immunol, V2, P173; OSMOND DG, 1990, CURR TOP MICROBIOL, V166, P149; OSMOND DG, 1990, IN PRESS BLOOD; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PARKHOUSE RME, 1990, IMMUNOLOGY, V69, P298; PERRY RP, 1981, P NATL ACAD SCI-BIOL, V78, P247, DOI 10.1073/pnas.78.1.247; PESCHEL C, 1989, J IMMUNOL, V142, P1558; PHILLIPS RA, 1989, PROG IMMUNOL, V7, P305; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; PRABHAKAR BS, 1984, J IMMUNOL, V133, P2815; Rathbun G., 1989, Immunoglobulin genes., P63; REICHMANFRIED M, 1990, P NATL ACAD SCI USA, V87, P2730, DOI 10.1073/pnas.87.7.2730; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; RETH MG, 1986, EMBO J, V5, P2131, DOI 10.1002/j.1460-2075.1986.tb04476.x; RITCHIE KA, 1984, NATURE, V312, P517, DOI 10.1038/312517a0; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; ROSENBERG YJ, 1977, J IMMUNOL, V118, P612; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; Selsing E., 1989, Immunoglobulin genes., P111; SHAPIRO MA, 1987, J IMMUNOL, V139, P3834; SHERWOOD PJ, 1990, INT IMMUNOL, V2, P399, DOI 10.1093/intimm/2.5.399; SIDEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1823, DOI 10.1073/pnas.78.3.1823; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STORB U, 1989, PROGR IMMUNOLOGY, V7, P316; STRASSER A, 1989, J EXP MED, V170, P1973, DOI 10.1084/jem.170.6.1973; THOMAS PS, 1988, LEUKEMIA, V2, P171; THORENS B, 1985, EMBO J, V4, P361, DOI 10.1002/j.1460-2075.1985.tb03637.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; TSUBATA T, 1991, IN PRESS EUR J IMMUN; TSUKADA S, 1990, J IMMUNOL, V144, P4053; TUTTER A, 1989, P NATL ACAD SCI USA, V86, P7460, DOI 10.1073/pnas.86.19.7460; VAKIL M, 1986, EUR J IMMUNOL, V16, P1151, DOI 10.1002/eji.1830160920; VAKIL M, 1986, EUR J IMMUNOL, V16, P1159, DOI 10.1002/eji.1830160921; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; WELCH PA, 1990, INT IMMUNOL, V2, P697, DOI 10.1093/intimm/2.8.697; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMADA G, 1991, IN PRESS P NATL ACAD; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; Zachau H. G., 1989, Immunoglobulin genes., P91	141	329	335	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1081	1094		10.1016/0092-8674(91)90032-T	http://dx.doi.org/10.1016/0092-8674(91)90032-T			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913803				2022-12-28	WOS:A1991GG55200004
J	EGGER, M; SMITH, GD; TEUSCHER, AU; TEUSCHER, A				EGGER, M; SMITH, GD; TEUSCHER, AU; TEUSCHER, A			INFLUENCE OF HUMAN INSULIN ON SYMPTOMS AND AWARENESS OF HYPOGLYCEMIA - A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PORCINE INSULIN; HYPOGLYCEMIA UNAWARENESS; AUTONOMIC NEUROPATHY; DIABETES-MELLITUS; PORK INSULIN; COUNTERREGULATION; RESPONSES	Objective - To investigate the apparent increased risk of severe hypoglycaemia associated with use of human insulin by comparing the pattern of symptoms of hypoglycaemia with human insulin and porcine insulin. Design - Randomised controlled double blind crossover trial of treatment with human insulin and porcine insulin, with two treatment periods of six weeks. Setting - Diabetes outpatient department of a university teaching hospital in Berne, Switzerland. Patients - 44 patients (25 men, 19 women) aged 14 to 60 years, with insulin dependent diabetes mellitus. All patients met the following criteria: receiving treatment with fast acting soluble insulin and long acting protamine insulin; performing multiple daily fingerstick blood glucose self measurements; and had stable glycaemic control with about one mild hypoglycaemic episode a week during the preceding two months. Intervention - Patients were randomised to receive either human or porcine insulin for six weeks and were then changed over to the other type of insulin for a further six weeks. Main outcome measure - Questionnaire recording "autonomic" and "neuroglycopenic" symptoms that occurred during hypoglycaemic episodes confirmed by a blood glucose concentration less-than-or-equal-to 2.8 mmol/l. Results - Insulin doses and blood glucose, glycated haemoglobin A1c, and fructosamine concentrations were similar during the two treatment periods. 493 questionnaires on hypoglycaemia (234 during treatment with human insulin and 259 during treatment with porcine insulin) were analysed. With human insulin patients were more likely to report lack of concentration (52% v 35%, p = 0.0003) and restlessness (53% v 45%, p = 0.004) and less likely to report hunger (33% v 42%, p = 0.016) than during treatment with porcine insulin. The difference in the pattern of symptoms during the two treatments was similar to that between the 12 patients with a history of recurrent hypoglycaemic coma and the 32 patients without such a history. Conclusions - The pattern of symptoms associated with human insulin could impair patients' ability to take appropriate steps to avoid severe hypoglycaemia. Caution should be exercised when transferring patients from animal insulin to human insulin, and a large scale randomised trial of the two types of insulin may be justified.	UNIV BERN, DEPT MED, DIABET SECT, CH-3000 BERN, SWITZERLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of Bern; University of London; London School of Hygiene & Tropical Medicine			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; ARMITAGE P, 1988, STATISTICAL METHODS; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; CLARK AJL, 1982, LANCET, V2, P354; CRYER PE, 1990, DIABETES CARE, V13, P536, DOI 10.2337/diacare.13.5.536; CRYER PE, 1990, ELLENBERG RIFKINS DI; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; FROESCH ER, 1986, CLIN ENDOCRINOLOGY T, P841; GAUTSCHY B, 1986, KLIN WOCHENSCHR, V64, P499, DOI 10.1007/BF01713056; HEINE RJ, 1989, LANCET, V2, P946; HEPBURN DA, 1989, LANCET, V1, P1394; Home P D, 1984, Diabet Med, V1, P93; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JAKOBER B, 1990, KLIN WOCHENSCHR, V68, P447, DOI 10.1007/BF01648896; KERN W, 1990, DIABETES, V39, P1091, DOI 10.2337/diabetes.39.9.1091; KERN W, 1989, LANCET, V2, P485; LEFEBVRE PJ, 1990, ELLENBERG RIFKINS DI; MARKUSSEN J, 1981, AKTUEL ENDOKRINOL, V1, P104; MATTHEWS DR, 1987, LANCET, V1, P778; PEACOCK I, 1983, LANCET, V1, P149; PICKUP J, 1986, BRIT MED J, V292, P155, DOI 10.1136/bmj.292.6514.155; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; SCHLUTER KJ, 1982, DIABETES CARE, V5, P78, DOI 10.2337/diacare.5.2.S78; SMITH RJ, 1985, JOSLINS DIABETES MEL; TATTERSALL RB, 1989, BRIT MED J, V299, P339; TEUSCHER A, 1987, LANCET, V2, P382	31	54	54	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1991	303	6803					622	626		10.1136/bmj.303.6803.622	http://dx.doi.org/10.1136/bmj.303.6803.622			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932903	Green Published, Bronze			2022-12-28	WOS:A1991GF67500023
J	WANG, C; LEHMANN, R				WANG, C; LEHMANN, R			NANOS IS THE LOCALIZED POSTERIOR DETERMINANT IN DROSOPHILA	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; EGF-LIKE REPEATS; BICOID PROTEIN; MATERNAL GENE; ABDOMINAL SEGMENTATION; PATTERN-FORMATION; ANTERIOR PATTERN; NEUROGENIC GENE; EMBRYO; MELANOGASTER	Segmental pattern in the Drosophila embryo is established by two maternal factors localized to the anterior and posterior poles of the egg cell. Here we provide molecular evidence that the localized posterior factor is the RNA of the nanos (nos) gene. nos RNA is localized to the posterior pole of early embryos, and nos protein acts at a distance to direct abdomen formation. Synthetic nos RNA has biological activity identical to that of the posterior pole plasm. Injection of nos RNA rescues the segmentation defect of embryos derived from females mutant for all nine known posterior group genes. Injection of nos RNA into the anterior is able to direct formation of ectopic posterior structures. Our results demonstrate that a localized source of nos RNA is sufficient to specify abdominal segmentation and imply that other posterior group genes are required for localization, stabilization, or distribution of the nos gene product.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WANG, C (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							ALTON AK, 1988, GENETICS, V118, P235; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEHMANN R, 1989, DEVELOPMENT, V107, P21; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1977, ROUX ARCH DEV BIOL, V183, P249, DOI 10.1007/BF00867325; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Sambrook J, 1989, MOL CLONING LABORATO; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VASSIN H, 1987, GENETICS, V116, P433; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; Wieschaus E., 1986, P199	47	423	436	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					637	647		10.1016/0092-8674(91)90110-K	http://dx.doi.org/10.1016/0092-8674(91)90110-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1908748				2022-12-28	WOS:A1991GC74500005
J	ISLES, CG; ROBERTSON, I; MACLEOD, JAJ; PRESTON, T; EAST, BW; HOLE, DJ; LEVER, AF				ISLES, CG; ROBERTSON, I; MACLEOD, JAJ; PRESTON, T; EAST, BW; HOLE, DJ; LEVER, AF			BODY CONCENTRATION OF CESIUM-137 IN PATIENTS FROM WESTERN ISLES OF SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							ESSENTIAL-HYPERTENSION; CESIUM-137 LEVELS; RESIDENTS; POTASSIUM; SEDIMENTS; CS-137	Objectives - To compare caesium-137 concentrations in patients from the Western Isles Health Board, Glasgow area, and other parts of the Scottish mainland, and to investigate the source of Cs-137 in patients from the Western Isles. Design - Study of hypertensive patients having electrolyte concentrations measured, including Cs-137. Interview by questionnaire of island subjects about intake of foods likely to contain radiocaesium and the source of these foods. Measurement of Cs-137 and Cs-134 in food, urine, and vegetation. Setting - Scottish mainland and Western Isles, 1979-86. All measurements before Chernobyl nuclear accident. Patients - 413 consecutive patients referred to the blood pressure unit for investigation of hypertension. 60 from the Western Isles, including 44 from North Uist; 32 from North Uist participated in the dietary analysis. Main outcome measures - Concentration of radiocaesium in the body, urine, food, and vegetation. Islanders' consumption of local produce. Results - Patients from the Western Isles had five times higher body concentrations of Cs-137 (median 2.54 (interquartile range 1.25-3.73)) Bq/gK) than did patients from around Glasgow (0.47 (0.26-0.66) Bq/gK) and other parts of the Scottish mainland (0.42 (0.24-0.71) Bq/gK). Islanders often consumed local milk and mutton, but ate local fish rarely. Cs-137 and CS-134 were present in coastal (21.6 Bq/kg CS-137, 0.25 Bq/kg CS-134) and moorland (135.9, 0.65 Bq/kg) grasses and in islanders' urine (2.01, 0.013 Bq/l). Lower concentrations (0.336, 0.004 Bq/l), were found in the urine of Glasgow controls (p < 0.001 for both isotopes). Conclusions - Islanders have excess body Cs-137 concentrations, most of which probably comes from local milk and lamb. The radioactivity is not above the recommended safety limit. The presence of Cs-134 suggests that nuclear reprocessing is the source of some of the radiocaesium.	WESTERN INFIRM & ASSOCIATED HOSP,MRC,BLOOD PRESSURE UNIT,GLASGOW G11 6NT,SCOTLAND; SCOTTISH UNIV RES & REACTOR CTR,E KILBRIDE G75 0QU,LANARK,SCOTLAND; RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND	Scottish Universities Research & Reactor Center			Preston, Thomas/D-5259-2012					[Anonymous], 1977, SOURCES EFFECTS IONI; BERETTAPICCOLI C, 1982, CLIN SCI, V63, P257, DOI 10.1042/cs0630257; BODDY K, 1975, PHYS MED BIOL, V20, P296, DOI 10.1088/0031-9155/20/2/011; BODDY K, 1971, PHYS MED BIOL, V16, P275, DOI 10.1088/0031-9155/16/2/310; BONI AL, 1966, ANAL CHEM, V38, P89, DOI 10.1021/ac60233a024; BRADFORD WR, 1984, SCI TOTAL ENVIRON, V35, P267, DOI 10.1016/0048-9697(84)90008-1; CAWSE PA, 1983, SPECIAL PUBLICATIONS, V3; CLARKE RH, 1989, NATURE, V338, P197, DOI 10.1038/338197a0; COMANS RNJ, 1989, NATURE, V339, P367, DOI 10.1038/339367a0; EAST BW, 1984, SEMINAR ENV TRANSFER, V2, P541; GRUETER H, 1971, HEALTH PHYS, V20, P655; HANSON WC, 1987, HLTH PHYS, V13, P383; HOWARD BJ, 1985, J ENVIRON RADIOACTIV, V2, P183, DOI 10.1016/0265-931X(85)90008-6; HUNT GJ, 1989, RADIOACTIVITY SURFAC; HUNT GJ, 1985, RADIOACTIVITY SURFAC; ISLES CG, 1983, CLIN SCI, V64, pP3; JEFFERIES DF, 1982, DEEP-SEA RES, V29, P713, DOI 10.1016/0198-0149(82)90003-6; MACKENZIE AB, 1979, J RADIOANAL CHEM, V48, P29, DOI 10.1007/BF02519771; NEWTON D, 1977, INT J ENVIRON STUD, V11, P83, DOI 10.1080/00207237708737341; NEWTON D, 1982, HEALTH PHYS, V42, P735; POPPLEWELL DS, 1981, RADIOL PROTEC B, V41, P20; PROUT WE, 1965, J INORG NUCL CHEM, V27, P473, DOI 10.1016/0022-1902(65)80367-0; RUNDO J, 1964, BRIT J RADIOL, V37, P108, DOI 10.1259/0007-1285-37-434-108; STATHER JW, 1984, NRPB R171 NAT RAD PR; TOGO M, 1983, HEALTH PHYS, V45, P162; WILLIAMS DE, 1981, HLTH PHYS, V40, P1; WILLIAMS ED, 1982, EUR J CLIN INVEST, V12, P321, DOI 10.1111/j.1365-2362.1982.tb02239.x; 1977, NRCP52 NAT COUNC RAD; 1987, LANCET, V2, P1245; 1966, ARCL16 AGR RES COUNC	30	2	2	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1568	1571		10.1136/bmj.302.6792.1568	http://dx.doi.org/10.1136/bmj.302.6792.1568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1906765	Bronze, Green Published			2022-12-28	WOS:A1991FU54900024
J	HAUPT, Y; ALEXANDER, WS; BARRI, G; KLINKEN, SP; ADAMS, JM				HAUPT, Y; ALEXANDER, WS; BARRI, G; KLINKEN, SP; ADAMS, JM			NOVEL ZINC FINGER GENE IMPLICATED AS MYC COLLABORATOR BY RETROVIRALLY ACCELERATED LYMPHOMAGENESIS IN E-MU-MYC TRANSGENIC MICE	CELL			English	Article							NUCLEIC-ACID-BINDING; SIMPLEX VIRUS TYPE-1; V-H-RAS; C-MYC; IMMUNOGLOBULIN ENHANCER; VIRAL INTEGRATION; B-CELLS; PROTEIN; EXPRESSION; ONCOGENE	To search for genes that can collaborate with myc in lymphomagenesis, we exploited retroviral insertional mutagenesis in E-mu-myc transgenic mice. Moloney murine leukemia virus accelerated development of B lymphoid tumors. Three quarters contained a provirus within the known pim-1 or pim-2 loci, new loci bmi-1 and emi-1, or combinations of these. bmi-1 insertions predominated, occurring in half the tumors, and resulted in elevated bmi-1 mRNA levels. Significantly, the bmi-1 gene, which is expressed in diverse normal cells, encodes a Cys/His metal-binding motif (C3HC4) that resembles those in several DNA-binding proteins and defines a new category of zinc finger gene. Thus, myc-induced lymphomagenesis can entail the concerted action of several genes, including the presumptive nuclear regulator bmi-1.			HAUPT, Y (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PO ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA.		Adams, Jerry M/E-1199-2013	Haupt, Ygal/0000-0001-5925-0096; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, IN PRESS BIOCH BIOPH; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1989, ONCOGENE, V4, P575; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1989, PROG INORG CHEM, V37, P143; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLISSARD GW, 1989, VIROLOGY, V168, P354, DOI 10.1016/0042-6822(89)90276-6; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAN E, 1991, IN PRESS J CLIN INVE; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAPPA R, 1991, J VIROL, V65, P805, DOI 10.1128/JVI.65.2.805-812.1991; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WEBB E, 1989, MOL BIOL MED, V6, P475; WEINBERG RA, 1989, CANCER RES, V49, P3713	59	486	530	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1991	65	5					753	763		10.1016/0092-8674(91)90383-A	http://dx.doi.org/10.1016/0092-8674(91)90383-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904009				2022-12-28	WOS:A1991FP51600006
J	KRISTIANSEN, IS; EGGEN, AE; THELLE, DS				KRISTIANSEN, IS; EGGEN, AE; THELLE, DS			COST-EFFECTIVENESS OF INCREMENTAL PROGRAMS FOR LOWERING SERUM-CHOLESTEROL CONCENTRATION - IS INDIVIDUAL INTERVENTION WORTH WHILE	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PRIMARY-PREVENTION; SMOKING; THERAPY; HEALTH; TRIAL; MEN	Objective - To evaluate the relative cost effectiveness of various cholesterol lowering programmes. Design - Retrospective analysis. Setting - Norwegian cholesterol lowering programme in Norwegian male population aged 40-49 (n = 200 000), whose interventions comprise a population based promotion of healthier eating habits, dietary treatment (subjects with serum cholesterol concentration 6.0-7.9 mmol/l), and dietary and drug treatment combined (serum cholesterol concentration greater-than-or-equal-to 8.0 mmol/l). Main outcome measure - Marginal cost effectiveness ratios - that is, the ratio of net treatment costs (cost of treatment minus savings in treatment costs for coronary heart disease) to life years gained and to quality of life years (QALYs) saved. Results - The cost per life year gained over 20 years of a population based strategy was projected to be L12. For an individual strategy based on dietary treatment the cost was about L12 400 per life year gained and L111 600 if drugs were added for 50% of the subjects with serum cholesterol concentrations greater-than-or-equal-to 8.0 mmol/l. Conclusions - The results underline the importance of marginal cost effectiveness analyses for incremental programmes of health care. The calculations of QALYs, though speculative, indicate that individual intervention should be implemented cautiously and within more selected groups than currently recommended. Drugs should be reserved for subjects with genetic hypercholesterolaemia or who are otherwise at very high risk of arteriosclerotic disease.			KRISTIANSEN, IS (corresponding author), UNIV TROMSO,INST COMMUNITY MED,N-9000 TROMSO,NORWAY.		Thelle, Dag Steinar/ABD-1867-2020	Thelle, Dag Steinar/0000-0002-4417-5967				BJARTVEIT K, 1988, Tidsskrift for den Norske Laegeforening, V108, P2285; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; EGGEN A E, 1989, Tidsskrift for den Norske Laegeforening, V109, P857; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HALL J P, 1988, Medical Journal of Australia, V148, P273; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1988, STAT MED, V7, P1109, DOI 10.1002/sim.4780071104; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; MARTENS LL, 1989, AM J MED S4A, V87, P54; OSTER G, 1986, AM J PUBLIC HEALTH, V76, P647, DOI 10.2105/AJPH.76.6.647; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; SALONEN JT, 1981, AM J EPIDEMIOL, V114, P81, DOI 10.1093/oxfordjournals.aje.a113177; SLATTEBREKK OV, 1990, STF81A90003 NORW I H; STEIN EA, 1989, AM J MED S4A, V87, P20; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; THURMER H, 1991, INT J RISK SOC MED, V1, P267; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC, 1980, CLIN DECISION ANAL; WESTLUND K, 1972, SCAND J CLIN IN S127, V30, P3; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1988, ARCH INTERN MED, V148, P36; 1990, COST EFFECTIVENESS O; 1988, CARDIOVASCULAR DISEA; 1986, CAUSES DEATH 1985; 1984, JAMA-J AM MED ASSOC, V251, P365; 1984, JAMA-J AM MED ASSOC, V251, P351; 1988, EUR HEART J, V9, P571	36	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1119	1122		10.1136/bmj.302.6785.1119	http://dx.doi.org/10.1136/bmj.302.6785.1119			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1904286	Green Published, Bronze			2022-12-28	WOS:A1991FL43900018
J	SURTEES, SJ; STOCKTON, MG; GIETZEN, TW				SURTEES, SJ; STOCKTON, MG; GIETZEN, TW			ALLERGY TO PENICILLIN - FABLE OR FACT	BRITISH MEDICAL JOURNAL			English	Article							SKIN	Objective - To assess whether, on the basis of one blood test, penicillin allergy might be excluded sufficiently for general practitioners to give oral penicillin to patients claiming a history of penicillin allergy. Design - Prospective study of patients referred by general practioners. Setting - Outpatient allergy clinic in a district general hospital. Patients - 175 referred patients who gave a history of immediate type reaction to penicillin, of whom 144 attended as requested and 132 completed the investigations. Main outcome measures - History and examination, serum radioallergosorbent test to phenoxymethyl-penicillin and benzylpenicillin, and oral challenge with penicillin. Results - Of 132 patients, four were confirmed to have penicillin allergy by the radioallergosorbent test and 128 had an oral penicillin challenge without ill effect. Conclusions - Most patients who gave a history of penicillin allergy are not so allergic, and their actual allergic state should be substantiated whenever feasible. For patients reporting minor or vague reactions negative findings with a radioallergosorbent test to phenoxymethylpenicillin and benzylpenicillin provide sufficient evidence to give oral penicillin safely.			SURTEES, SJ (corresponding author), DIST GEN HOSP,DEPT CLIN CHEM,EASTBOURNE BN21 2UD,E SUSSEX,ENGLAND.							BEELEY L, 1984, BRIT MED J, V288, P511, DOI 10.1136/bmj.288.6416.511-a; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; FOX AM, 1965, BMJ-BRIT MED J, V2, P206, DOI 10.1136/bmj.2.5455.206; HOLGATE ST, 1988, BRIT MED J, V296, P1213, DOI 10.1136/bmj.296.6631.1213; JARISCH R, 1981, CLIN ALLERGY, V11, P155, DOI 10.1111/j.1365-2222.1981.tb01579.x; KIRK CR, 1988, BRIT MED J, V296, P1236, DOI 10.1136/bmj.296.6631.1236; MYERS PC, 1985, BRIT MED J, V291, P450; OSWALD NTA, 1983, BRIT MED J, V287, P265, DOI 10.1136/bmj.287.6387.265; Pearce S. J., 1982, ADVERSE DRUG REACT, V94, P344; SIMMONDS J, 1978, BRIT MED J, V2, P1404, DOI 10.1136/bmj.2.6149.1404; SMITH AG, 1989, ADVERSE DRUG REACT, V134, P500; Sorensen H T, 1986, Scand J Prim Health Care, V4, P252	12	65	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1051	1052		10.1136/bmj.302.6784.1051	http://dx.doi.org/10.1136/bmj.302.6784.1051			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903664	Green Published, Bronze			2022-12-28	WOS:A1991FK56300021
J	HAN, JW; MCCORMICK, F; MACARA, IG				HAN, JW; MCCORMICK, F; MACARA, IG			REGULATION OF RAS-GAP AND THE NEUROFIBROMATOSIS-1 GENE-PRODUCT BY EICOSANOIDS	SCIENCE			English	Article							GTPASE ACTIVATING PROTEIN	Ras-GAP (GTPase activating protein) is a regulatory protein that stimulates the intrinsic guanosine triphosphatase (GTPase) activity of the proto-oncogene product p21ras. A domain of the neurofibromatosis gene product (NF1) that has sequence similarity to the catalytic domain of Ras-GAP and to yeast IRA gene products also has a specific stimulatory activity toward p21ras GTPase. Arachidonic acid and phosphatidic acid inactivate GAP, but no agents have been identified that stimulate GAP and thereby switch p21ras off. With the use of recombinant Ha-c-Ras and Ras-GAP, NF1, and GAP catalytic domains, it was found that prostaglandins PGF2-alpha and PGA2 stimulated Ras-GAP and that prostacyclin PGI2 inhibited Ras-GAP. The stimulatory effect of PGF2-alpha was saturable and structure-specific and competed with the inhibitory effect of arachidonic acid. Arachidonic acid also inhibited the catalytic activity of NF1, but prostaglandins were not stimulatory. These results suggest a mechanism for the allosteric control of Ras function through the modulation of arachidonate metabolism.	CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608		HAN, JW (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOPHYS,CTR ENVIRONM HLTH SCI,ROCHESTER,NY 14642, USA.				NATIONAL CANCER INSTITUTE [R01CA038888] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT A, 1979, PRACTICAL APPLICATIO, P149; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALLENBECK R, 1990, J BIOL CHEM, V265, P21922; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOORE PK, 1985, PROSTANOIDS PHARM PH, P32; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1989, J BIOL CHEM, V264, P10820; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	26	101	101	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					576	579		10.1126/science.1902323	http://dx.doi.org/10.1126/science.1902323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1902323				2022-12-28	WOS:A1991FJ12700051
J	RAUB, W				RAUB, W			INTERFERON-GAMMA PREVENTS INFECTION IN CHRONIC GRANULOMATOUS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P509	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-28	WOS:A1991FD65900006
J	NEGLIA, JP; MEADOWS, AT; ROBISON, LL; KIM, TH; NEWTON, WA; RUYMANN, FB; SATHER, HN; HAMMOND, GD				NEGLIA, JP; MEADOWS, AT; ROBISON, LL; KIM, TH; NEWTON, WA; RUYMANN, FB; SATHER, HN; HAMMOND, GD			2ND NEOPLASMS AFTER ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER STUDY-GROUP; ACUTE LYMPHOCYTIC-LEUKEMIA; MALIGNANT NEOPLASMS; CHILDREN; THERAPY; RADIOTHERAPY; CHEMOTHERAPY; PROPHYLAXIS; SURVIVAL; SARCOMAS	Background. Effective forms of treatment for acute lymphoblastic leukemia (ALL) in childhood now result in survival rates above 70 percent at five years, but the treatments are potentially carcinogenic. To determine the magnitude of this risk and identify possible risk factors for the development of second neoplasms, we studied a large cohort of children treated for ALL. Methods and Results. We undertook a retrospective cohort study of 9720 children who had been given a diagnosis of ALL between June 1972 and August 1988 and had been treated according to the therapeutic protocols of the Children's Cancer Study Group. The median follow-up was 4.7 years (range, 2 months to 16 years). We found that 43 second neoplasms occurred among the children in the cohort, including 24 neoplasms of the central nervous system, 10 new leukemias and lymphomas, and 9 other neoplasms. This represented a 7-fold excess of all cancers and a 22-fold excess of neoplasms of the central nervous system. The estimated cumulative proportion of children in whom a second neoplasm developed was 2.53 percent 15 years after diagnosis (95 percent confidence limits, 1.74 percent and 3.38 percent). An even higher risk, particularly of central nervous system tumors, was evident in children five years of age or less at the time of the diagnosis of ALL (P = 0.012). All central nervous system neoplasms developed in children who had previously undergone irradiation. There was no association with exposure to cyclophosphamide or anthracyclines. Conclusions. There is a substantial excess of second neoplasms, especially of the central nervous system, among children treated for ALL. Children five years old or younger and those receiving radiation are at higher risk, especially for second tumors arising in the central nervous system.	CHILDRENS CANC STUDY GRP,440 E HUNTINGTON DR,SUITE 300,POB 60012,ARCADIA,CA 91066; CHILDRENS HOSP,COLUMBUS,OH 43205; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; ABBOTT NW HOSP,MINNEAPOLIS,MN; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Southern California; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Robison, Leslie/N-8122-2018	Neglia, Joseph/0000-0002-5525-0598	NATIONAL CANCER INSTITUTE [K08CA001240] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo V, 1985, P AN M AM SOC CLIN, V4, P172; BAILAR JC, 1964, BIOMETRICS, V20, P639; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COCCIA PF, 1983, LEUKEMIA RES ADV CEL, P241; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; FRIED M, 1987, CANCER, V60, P2548, DOI 10.1002/1097-0142(19871115)60:10<2548::AID-CNCR2820601033>3.0.CO;2-H; GAYNON PS, 1988, AM J PEDIAT HEMATOL, V10, P42; Goldes J, 1984, Pediatr Dermatol, V1, P295, DOI 10.1111/j.1525-1470.1984.tb01132.x; HAMMOND G D, 1986, Cancer, V58, P407, DOI 10.1002/1097-0142(19860715)58:2+<407::AID-CNCR2820581302>3.0.CO;2-U; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LABOTKA RJ, 1983, CANCER, V52, P846, DOI 10.1002/1097-0142(19830901)52:5<846::AID-CNCR2820520517>3.0.CO;2-B; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LITTMAN P, 1987, INT J RADIAT ONCOL, V13, P1443, DOI 10.1016/0360-3016(87)90308-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALONE M, 1986, CANCER, V57, P1979, DOI 10.1002/1097-0142(19860515)57:10<1979::AID-CNCR2820571016>3.0.CO;2-R; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; MEADOWS AT, 1977, CANCER, V40, P1903, DOI 10.1002/1097-0142(197710)40:4+<1903::AID-CNCR2820400822>3.0.CO;2-E; MEADOWS AT, 1989, NEW ENGL J MED, V321, P1830; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIKE V, 1982, LANCET, V2, P1326; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MOSIJCZUK AD, 1981, AM J DIS CHILD, V135, P313, DOI 10.1001/archpedi.1981.02130280003002; NESBIT ME, 1982, CANCER RES, V42, P674; ORTEGA JA, 1977, CANCER RES, V37, P535; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; PRATT C B, 1988, Pediatric Research, V23, p345A; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; R&DEG;rth M., 1991, P AN M AM SOC CLIN, V10, P221; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; SULLIVAN MP, 1982, BLOOD, V60, P948; SUSSMAN A, 1990, CANCER CAUSE CONTROL, V1, P75, DOI 10.1007/BF00053186; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; ZARRABI MH, 1983, CANCER, V52, P1712, DOI 10.1002/1097-0142(19831101)52:9<1712::AID-CNCR2820520927>3.0.CO;2-I; 1989, NIH8292789 NCI PUBL	40	434	442	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1330	1336		10.1056/NEJM199111073251902	http://dx.doi.org/10.1056/NEJM199111073251902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922234	Bronze			2022-12-28	WOS:A1991GN47000002
J	HIGGINS, DL; GALAVOTTI, C; OREILLY, KR; SCHNELL, DJ; MOORE, M; RUGG, DL; JOHNSON, R				HIGGINS, DL; GALAVOTTI, C; OREILLY, KR; SCHNELL, DJ; MOORE, M; RUGG, DL; JOHNSON, R			EVIDENCE FOR THE EFFECTS OF HIV ANTIBODY COUNSELING AND TESTING ON RISK BEHAVIORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INTRAVENOUS-DRUG-USERS; HUMAN IMMUNODEFICIENCY VIRUS; HOMOSEXUAL MEN; SEXUAL-BEHAVIOR; TAKING BEHAVIOR; SAN-FRANCISCO; CONDOM USE; FOLLOW-UP; KNOWLEDGE; AIDS	Objective. - To review published abstracts, journal articles, and presentations for evidence of the effects of human immunodeficiency virus (HIV) antibody counseling and testing on risk behaviors. Studies reviewed focused on homosexual men, intravenous drug users in treatment programs, pregnant women, and other heterosexuals. Data Sources. - Peer-reviewed journals (January 1986 through July 1990) and published abstracts and oral presentations from the second (1986) through the sixth (1990) International Conferences on AIDS. Study Selection. - We identified 66 studies that included data on the behavioral effects of HIV antibody counseling and testing. By consensus of the authors, 16 of these were excluded because of small sample size or inadequate study design. Data Extraction. - Studies were assessed by the authors according to methodological strength (sample selection, inclusion of appropriate comparison groups, and inclusion of statistical tests of significance). Data Synthesis. - All longitudinal studies of homosexual men reported reductions in risky behavior among both tested and untested men, and a few reported greater decreases among seropositive men than among seronegative men and those untested or unaware of their serostatus. For intravenous drug users in treatment, we found reductions in intravenous drug use and sexual risk behaviors regardless of counseling and testing experience. We found little evidence for the impact of counseling and testing on pregnancy and/or pregnancy termination rates for either seropositive or seronegative high-risk women. We noted substantial risk reduction among heterosexual couples with one infected partner. Findings among other heterosexuals at increased risk were scanty and mixed. Conclusions. - Further studies should specifically address the behavioral consequences of counseling and testing in various settings.			HIGGINS, DL (corresponding author), CTR DIS CONTROL,CTR PREVENT SERV,DIV SEXUALLY TRANSMITTED DIS HIV PREVENT,ATLANTA,GA 30333, USA.							BANDURA A, 1986, SOCIAL F THOUGHT ACT; BARBACCI M, 1989, 5 INT C AIDS MONTR; BECKER MH, 1988, AM J PUBLIC HEALTH, V78, P394, DOI 10.2105/AJPH.78.4.394; BEEKER C, 1988, 4TH INT C AIDS STOCK; CALSYN DA, IN PRESS AM J PUBLIC; CARBALODIEGUEZ A, 1990, 6TH INT C AIDS SAN F; CASADONTE PP, 1990, INT J ADDICT, V25, P409, DOI 10.3109/10826089009053168; CIRARUVIGNERON N, 1988, 4TH INT C AIDS STOCK; CLEARY PD, 1987, TAKING CARE UNDERSTA, P119, DOI DOI 10.1017/CBO9780511527760.009; COATES TJ, 1989, 5TH INT C AIDS MONTR; COHEN JB, 1988, 4TH INT C AIDS STOCK; COHN DL, 1988, 4TH INT C AIDS STOCK; CORBY N, 1990, 6TH INT C AIDS SAN F; COWAN JE, 1990, 6TH INT C AIDS SAN F; CUMMINGS CC, 1989, HUMAN BEHAVIOR CANCE; DEVINCENZI I, 1990, 6TH INT C AIDS SAN F; DOLL LS, 1990, HEALTH PSYCHOL, V9, P253, DOI 10.1037/0278-6133.9.3.253; FARLEY T, 1990, 6TH INT C AIDS SAN F; FIFE KH, 1988, 4TH INT C AIDS STOCK; FOX R, 1987, AIDS, V1, P241; FRAZER IH, 1988, MED J AUSTRALIA, V149, P365, DOI 10.5694/j.1326-5377.1988.tb120670.x; FUTTERMAN D, 1990, 6TH INT C AIDS SAN F; Gordis L, 1976, COMPLIANCE THERAPEUT, P51; GOTTLIEB NH, 1990, COGNITIVE THER RES, V14, P529, DOI 10.1007/BF01173362; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HAYNES RB, 1977, CLIN PHARMACOL THER, V22, P125; Haynes RB, 1976, COMPLIANCE THERAPEUT, P26; HOLMAN S, 1989, SEMIN PERINATOL, V13, P7; IRION O, 1990, 6TH INT C AIDS SAN F; IVERSON DC, 1989, HUMAN BEHAVIOR CANCE, P35; JACOBSBERG L, 1990, 6TH INT C AIDS SAN F; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; JOHNSTONE FD, 1990, BRIT MED J, V300, P23, DOI 10.1136/bmj.300.6716.23; JUDSON FN, 1983, LANCET, V2, P159; KAMENGA M, 1989, 5 INT C AIDS MONTR; KEFFELEW A, 1990, 6TH INT C AIDS SAN F; KIRAGU D, 1990, 6TH INT C AIDS SAN F; LINDAN C, 1990, 6TH INT C AIDS SAN F; Marlatt GA., 1985, RELAPSE PREVENTION; MARLINK RG, 1987, 3RD INT C AIDS WASH; MCALISTER A, 1987, TAKING CARE UNDERSTA, P14; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MCKUSICK L, 1990, AM J PUBLIC HEALTH, V80, P978, DOI 10.2105/AJPH.80.8.978; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; OSTROW DG, 1990, PSYCHIATRIC ASPECTS, P13; POWER R, 1988, BRIT J ADDICT, V83, P649; PROCHASKA JO, 1989, HUMAN BEHAV CANC RIS, P30; RAYMOND JS, 1989, HUMAN BEHAVIOR CANCE, P21; ROBERTSON JR, 1988, BRIT J ADDICT, V83, P387; ROGGENBURG L, 1990, 6TH INT C AIDS SAN F; ROSS MW, 1988, COMMUNITY HEALTH ST, V12, P322; RUGG D, 1991, 7TH INT C AIDS FLOR; SACKETT DL, 1979, COMPLIANCE HLTH CARE, P286; SCHECHTER MT, 1988, AM J PUBLIC HEALTH, V78, P1535, DOI 10.2105/AJPH.78.12.1535; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P1289, DOI 10.1001/jama.261.9.1289; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; SKIDMORE CA, 1989, BRIT J ADDICT, V84, P695; Slovic Paul, 1987, TAKING CARE UNDERSTA, V14, P28; STEMPEL RR, 1989, THESIS U CALIFORNIA; SUNDERLAND A, 1988, 4TH INT C AIDS STOCK; TICE J, 1990, 6TH INT C AIDS SAN F; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VANDENHOEK AJAR, 1990, AIDS, V4, P449, DOI 10.1097/00002030-199005000-00011; VANDENHOEK JAR, 1990, 6TH INT C AIDS SAN F; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1356; VANGRIENSVEN GJP, 1989, AM J EPIDEMIOL, V129, P596; VOGLER M, 1989, 5 INT C AIDS MONTR; WENGER NS, IN PRESS AM J PUBLIC; WIKTOR SZ, 1990, J ACQ IMMUN DEF SYND, V3, P62; WIZNIA A, 1989, 5 INT C AIDS MONTR; ZONES JS, 1986, 2ND INT C AIDS PAR; 1986, MMWR, V35, P284; 1984, MMWR, V33, P295; 1990, MMWR, V39, P137; 1990, 1990 CTR DIS CONTR A; 1990, EVALUATION HIV COUNS, P216	76	399	400	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2419	2429		10.1001/jama.266.17.2419	http://dx.doi.org/10.1001/jama.266.17.2419			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM790	1920748				2022-12-28	WOS:A1991GM79000030
J	HONIGMAN, B; LOWENSTEIN, SR; MOORE, EE; ROWEDER, K; PONS, P				HONIGMAN, B; LOWENSTEIN, SR; MOORE, EE; ROWEDER, K; PONS, P			THE ROLE OF THE PNEUMATIC ANTISHOCK GARMENT IN PENETRATING CARDIAC WOUNDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE SUPPORT; MAST SUIT; TRAUMA; TROUSERS; RESUSCITATION; EMERGENCY; TAMPONADE	Objective. - To determine the impact of the pneumatic antishock garment on survival in patients with cardiac wounds. Design. - A retrospective review of a 6.5-year experience in a population of patients with gunshot or stab wounds to the heart (N = 70). Setting. - The city and county of Denver, Colo, where all patients were transported by paramedic ambulances to Denver General Hospital, an urban, level 1 trauma center. Patients. - All patients were analyzed, including those transported to the emergency department with no vital signs at the trauma scene. Only patients with definite penetrating cardiac injuries were included. Methods. - Paramedic trip sheets and emergency department, operating room, in-hospital, and autopsy records were reviewed. Demographic, clinical outcome, and treatment data were collected. A multiple logistic regression model was developed to determine which characteristics and treatment variables were independently predictive of patient outcome. The ability of each independent variable to predict outcome was determined by calculating adjusted odds ratios (ORs) and 95% confidence intervals (Cls). Results. - Seventy patients (31 gunshot and 39 stab wounds) had a revised trauma score of 2.8 +/- 4.0 (mean +/- SD; range, 0-1 2; median, 0). Thirty-two (46%) had cardiac tamponade. Overall, 21 (30%) of the patients survived. In the logistic model, the presence of cardiac tamponade (OR, 9.1; 95% Cl, 1.5 to 56. 1) and a higher revised trauma score were associated with higher survival. Inflation of the pneumatic antishock garment was associated with sevenfold lower survival (adjusted OR, 0.14; 95% Cl, 0.02 to 0.86); the effect was negative across all trauma score groups. Conclusion. - Survival in patients with penetrating cardiac wounds is highly associated with anatomic and physiologic factors, while application of the pneumatic antishock garment appears to be detrimental.	UNIV COLORADO,HLTH SCI CTR,EMERGENCY MED RES CTR,DENVER,CO 80262; DENVER GEN HOSP,DEPT SURG,DENVER,CO 80204; DENVER GEN HOSP,DEPT EMERGENCY MED,DENVER,CO 80204	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; Denver Health Medical Center	HONIGMAN, B (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT SURG,EMERGENCY MED & TRAUMA SECT,4200 E 9TH AVE,DENVER,CO 80262, USA.							BICKELL WH, 1985, ANN EMERG MED, V14, P218, DOI 10.1016/S0196-0644(85)80443-1; BIVINS HG, 1982, ANN EMERG MED, V11, P409, DOI 10.1016/S0196-0644(82)80036-X; Carrasquilla C, 1972, Ann Thorac Surg, V13, P208; CHAMPION HR, 1988, TRAUMA; Civetta J M, 1976, JACEP, V5, P581, DOI 10.1016/S0361-1124(76)80216-X; COGBILL TH, 1983, J TRAUMA, V23, P453, DOI 10.1097/00005373-198306000-00002; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; DAVIS JW, 1981, ANN EMERG MED, V10, P185, DOI 10.1016/S0196-0644(81)80158-8; DEMETRIADES D, 1986, ANN SURG, V203, P315, DOI 10.1097/00000658-198603000-00018; IVATURY RR, 1988, J TRAUMA, V27, P1066; JACOBS LM, 1984, J TRAUMA, V24, P8, DOI 10.1097/00005373-198401000-00002; JONES EW, 1982, ARCH SURG-CHICAGO, V96, P671; KABACK KR, 1984, JAMA-J AM MED ASSOC, V252, P2598, DOI 10.1001/jama.252.18.2598; KARREL R, 1982, ANN EMERG MED, V11, P504; MACKERSIE RC, 1984, J TRAUMA, V24, P882, DOI 10.1097/00005373-198410000-00003; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MATTOX KL, 1986, J TRAUMA, V26, P779, DOI 10.1097/00005373-198609000-00002; MORENO C, 1986, J TRAUMA, V26, P821, DOI 10.1097/00005373-198609000-00007; PALAFOX BA, 1981, J TRAUMA, V21, P55, DOI 10.1097/00005373-198101000-00012; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; RANSOM K, 1978, J AM COLL EMERG PHYS, V7, P15; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SMITH JP, 1985, J TRAUMA, V25, P65, DOI 10.1097/00005373-198501000-00011; SUGG WL, 1968, J THORAC CARDIOV SUR, V56, P531, DOI 10.1016/S0022-5223(19)42812-2; TRINKLE JK, 1974, ANN THORAC SURG, V17, P230, DOI 10.1016/S0003-4975(10)65641-X; TRUNKEY DD, 1984, J TRAUMA, V24, P86, DOI 10.1097/00005373-198401000-00017; WECHSLER AS, 1974, J THORAC CARDIOVASC, V69, P847; 1985, INJURY AM CONTINUING	28	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2398	2401		10.1001/jama.266.17.2398	http://dx.doi.org/10.1001/jama.266.17.2398			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920746				2022-12-28	WOS:A1991GM79000026
J	MINKOFF, HL; DEHOVITZ, JA				MINKOFF, HL; DEHOVITZ, JA			CARE OF WOMEN INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PELVIC INFLAMMATORY DISEASE; PNEUMOCYSTIS-CARINII PNEUMONIA; PREGNANT-WOMEN; HIV INFECTION; AIDS; SYPHILIS; RISK; CANDIDIASIS; PROPHYLAXIS; ZIDOVUDINE	Objective. - To review current knowledge regarding human immunodeficiency virus (HIV) infection in women and to derive from that data standards of care. Data Sources. - Selective review of pertinent articles addressing cervical disease, pelvic inflammatory disease, sexually transmitted diseases, contraception, and pregnancy in HIV-infected women. A computer-assisted search was used to identify relevant articles on pharmacokinetics of drugs in women and oral contraceptive-drug interactions. Data Extraction. - Pertinent data were abstracted from case-control, cohort studies, clinical trials, and pharmacokinetic studies. Data Synthesis. - Few studies have been performed to define the clinical course of HIV infection in women. Gender-specific manifestations, such as cervical neoplasia, pelvic inflammatory disease, and vaginal moniliasis, appear to pursue a more aggressive course in HIV-infected women. Little is known about the pharmacokinetics of drugs for HIV and related infections. Oral contraceptives may alter the metabolism of some drugs used in HIV-infected women. An approach to the routine treatment of HIV-infected women is summarized. Conclusions. - Little is currently known regarding the natural course of HIV infection in women. Women infected with HIV should be followed up frequently with specific attention paid to the reproductive system. Additional studies should be conducted to determine the impact of HIV on gender-specific diseases.	SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,BROOKLYN,NY; SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,BROOKLYN,NY	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	MINKOFF, HL (corresponding author), SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,450 CLARKSON AVE,BOX 24,BROOKLYN,NY 11203, USA.							BACON JF, 1980, BRIT MED J, V280, P293, DOI 10.1136/bmj.280.6210.293; BAILEY K, 1985, OBSTET GYNECOL, V66, P211; BECKER MH, 1988, AM J PUBLIC HEALTH, V78, P394, DOI 10.2105/AJPH.78.4.394; BIGGAR RJ, 1989, AM J OBSTET GYNECOL, V161, P1239, DOI 10.1016/0002-9378(89)90674-1; CARPENTER CCJ, 1989, AM J MED, V86, P771, DOI 10.1016/0002-9343(89)90471-3; CARTER DE, 1973, CLIN PHARMACOL THER, V15, P22; CHAVKIN W, 1990, AM J PUBLIC HEALTH, V80, P483, DOI 10.2105/AJPH.80.4.483; COVINO JM, 1990, AM J OBSTET GYNECOL, V163, P116, DOI 10.1016/S0002-9378(11)90682-6; DESJARLAIS D, 1990, J ACQ IMMUN DEF SYND, V3, P1135; FEINGOLD AR, 1990, J ACQ IMMUN DEF SYND, V3, P896; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; GALL SA, 1977, SEMIN PERINATOL, V1, P119; GROSSMAN C, 1989, J STEROID BIOCHEM, V34, P241, DOI 10.1016/0022-4731(89)90088-5; GUAY DRP, 1987, THER DRUG MONIT, V9, P259, DOI 10.1097/00007691-198709000-00002; HARGER JH, 1989, OBSTET GYNECOL, V73, P367; Hatcher RA, 1990, CONTRACEPTIVE TECHNO; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; HOLLANDER H, 1991, MED MANAGEMENT AIDS, P93; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; HOOPER WD, 1990, CLIN PHARMACOL THER, V48, P633, DOI 10.1038/clpt.1990.207; IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K; KALLAND T, 1979, J NATL CANCER I, V63, P413; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; KNIGHT V, 1988, J INFECT DIS, V158, P443, DOI 10.1093/infdis/158.2.443; LAULEY TB, 1990, OBSTET GYNECOL, V76, P997; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MACDONALD KS, 1989, ANTIMICROB AGENTS CH, V33, P612, DOI 10.1128/AAC.33.5.612; MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X; MAIMAN M, 1991, OBSTET GYNECOL, V78, P84; MAIMAN M, 1988, JAMA-J AM MED ASSOC, V260, P2214, DOI 10.1001/jama.260.15.2214; MARTE C, 1990, 6TH INT C AIDS SAN F, V2, P2024; MATORRAS R, 1991, AM J OBSTET GYNECOL, V164, P42, DOI 10.1016/0002-9378(91)90620-7; MINKOFF H, 1991, AIDS CLIN CARE, V3, P33; MINKOFF HL, 1987, JAMA-J AM MED ASSOC, V258, P2714, DOI 10.1001/jama.258.19.2714; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P1111; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V162, P30, DOI 10.1016/0002-9378(90)90814-N; MONTGOMERY AB, 1987, LANCET, V2, P480; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOTYL MR, 1990, AM J CLIN PATHOL, V94, P84, DOI 10.1093/ajcp/94.1.84; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NAFZIGER AN, 1989, EUR J CLIN PHARMACOL, V37, P97; NANDA D, 1990, OBSTET GYN CLIN N AM, V17, P617; NOVELLO AC, 1991, JAMA-J AM MED ASSOC, V265, P1805; PETERSON HB, 1990, REV INFECT DIS, V12, pS656; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; Prange A.J., 1972, JAMA-J AM MED ASSOC, V219, P143; RHOADS JL, 1987, JAMA-J AM MED ASSOC, V257, P3105, DOI 10.1001/jama.257.22.3105; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAFRIN S, 1990, OBSTET GYNECOL, V75, P666; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3367; SENANAYAKE P, 1980, AM J OBSTET GYNECOL, V138, P852, DOI 10.1016/0002-9378(80)91070-4; SILVERMAN WA, 1956, PEDIATRICS, V18, P614; SKOLNICK JL, 1976, JAMA-J AM MED ASSOC, V236, P1382, DOI 10.1001/jama.236.12.1382; SOBEL JD, 1986, NEW ENGL J MED, V315, P1455, DOI 10.1056/NEJM198612043152305; SRIDAMA V, 1982, NEW ENGL J MED, V307, P352, DOI 10.1056/NEJM198208053070606; STHOEGER ZM, 1988, J IMMUNOL, V141, P91; TEICHMANN AT, 1990, AM J OBSTET GYNECOL, V163, P2208, DOI 10.1016/0002-9378(90)90563-M; TELZAK EE, 1990, REV INFECT DIS, V12, P380; TRAMONT EC, 1987, NEW ENGL J MED, V316, P1600, DOI 10.1056/NEJM198706183162510; VOGT MW, 1986, LANCET, V1, P535; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WOFSY CB, 1986, LANCET, V1, P527; 1989, RANDOMIZED TRIAL 3 A; 1985, MMWR, V34, P721; 1988, MMWR, V37, P600; 1987, PREVENTION HUMAN IMM, P1; 1990, MMWR, V39, P846; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1; 1991, HIV MED EVALUATION P	73	67	67	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2253	2258						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920725				2022-12-28	WOS:A1991GK66100034
J	CLINTON, JJ				CLINTON, JJ			OUTCOMES RESEARCH - A WAY TO IMPROVE MEDICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1991, JAMA-J AM MED ASSOC, V265, P1508	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2057	2057		10.1001/jama.266.15.2057	http://dx.doi.org/10.1001/jama.266.15.2057			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920687				2022-12-28	WOS:A1991GJ47400009
J	APPERLOO, AJ; DEZEEUW, D; SLUITER, HE; DEJONG, PE				APPERLOO, AJ; DEZEEUW, D; SLUITER, HE; DEJONG, PE			DIFFERENTIAL-EFFECTS OF ENALAPRIL AND ATENOLOL ON PROTEINURIA AND RENAL HEMODYNAMICS IN NONDIABETIC RENAL-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING ENZYME-INHIBITION; GLOMERULAR-FILTRATION RATE; NORMOTENSIVE PATIENTS; KIDNEY-FUNCTION; ACE INHIBITION; HYPERTENSION; CAPTOPRIL; NEPHROPATHY; MICROALBUMINURIA; FAILURE	Objective - To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin. Design - Prospective, double blind, randomised 16 week study after a pretreatment period of at least three weeks. Setting - Outpatient nephrology and hypertension unit. Patients - 27 patients with proteinuria (> 300 mg protein/day) of non-diabetic origin, moderately impaired renal function (creatinine clearance 30-90 ml/min), and a pretreatment diastolic blood pressure of > 80 mm Hg. Interventions - Treatment with enalapril (10 mg/day, adjusted between 5 and 40 mg, if necessary) or atenolol (50 mg/day, adjusted between 25 and 100 mg if necessary) titrated against a target fall in diastolic blood pressure to < 95 mm Hg or of > 10 mm Hg, or both. Main outcome measures - Blood pressure, renal haemodynamics, and urinary protein excretion. Results - No differences were detected between the two groups before treatment. The falls in systolic and diastolic blood pressures during treatment were not significantly different between both groups. Proteinuria fell slightly with atenolol but significantly more with enalapril (mean change -0.38 (95% confidence interval - 0.78 to 0.03) v -1.2 (-1.70 to -0.69) g/day respectively, p < 0.02) as did filtration fraction (mean change -1.8 (-2.9 to -0.7) v -3.8 (-4.9 to -2.8)% respectively. Serum potassium concentration increased with enalapril (mean change 0.63 (SD 0.51) v 0.19 (0.47) mmol/l, p < 0.05). Conclusions - Enalapril lowers proteinuria more than atenolol in patients with non-diabetic renal disease despite a similar blood pressure lowering effect of both drugs, and its antiproteinuric effect seems to be associated with the characteristic renal haemodynamic effect of angiotensin converting enzyme inhibitors.			APPERLOO, AJ (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT MED,DIV NEPHROL,9713 EZ GRONINGEN,NETHERLANDS.		de Zeeuw, Dick/E-9080-2014	de Zeeuw, Dick/0000-0003-3434-7777				ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; BABA T, 1989, DIABETOLOGIA, V32, P40; BEDOGNA V, 1990, KIDNEY INT, V38, P101, DOI 10.1038/ki.1990.173; BJORCK S, 1990, BMJ-BRIT MED J, V300, P904, DOI 10.1136/bmj.300.6729.904; DONKER AJM, 1977, NETH J MED, V20, P97; HALL JE, 1981, AM J PHYSIOL, V241, pR190, DOI 10.1152/ajpregu.1981.241.3.R190; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; HEEG JE, 1987, KIDNEY INT, V32, P78, DOI 10.1038/ki.1987.174; HEEG JE, IN PRESS KIDNEY INT; HERLITZ H, 1984, NEPHRON, V38, P253, DOI 10.1159/000183318; HOMMEL E, 1986, BMJ-BRIT MED J, V293, P467, DOI 10.1136/bmj.293.6545.467; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; LAGRUE G, 1987, NEPHRON, V46, P99, DOI 10.1159/000184318; MARRE M, 1987, BMJ-BRIT MED J, V294, P1448, DOI 10.1136/bmj.294.6585.1448; MIMRAN A, 1988, J HYPERTENS, V6, P919, DOI 10.1097/00004872-198811000-00011; REAMS GP, 1986, ARCH INTERN MED, V146, P2145, DOI 10.1001/archinte.146.11.2145; ROSMAN JB, 1984, LANCET, V2, P1291; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; WILLIAMS PS, 1988, Q J MED, V67, P343	19	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					821	824		10.1136/bmj.303.6806.821	http://dx.doi.org/10.1136/bmj.303.6806.821			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932973	Bronze, Green Published			2022-12-28	WOS:A1991GH94600023
J	MATSUOKA, M; NAGAWA, F; OKAZAKI, K; KINGSBURY, L; YOSHIDA, K; MULLER, U; LARUE, DT; WINER, JA; SAKANO, H				MATSUOKA, M; NAGAWA, F; OKAZAKI, K; KINGSBURY, L; YOSHIDA, K; MULLER, U; LARUE, DT; WINER, JA; SAKANO, H			DETECTION OF SOMATIC DNA RECOMBINATION IN THE TRANSGENIC MOUSE-BRAIN	SCIENCE			English	Article							HEAVY-CHAIN GENES; BETA-ACTIN GENE; NUCLEOTIDE-SEQUENCE; IMMUNE-SYSTEM; IMMUNOGLOBULIN; TRANSCRIPTION; SEGMENTS; ELEMENTS; NUCLEUS; REGION	A DNA construct containing the bacterial beta-galactosidase gene (lacZ) was used to study somatic DNA recombination in the transgenic mouse brain. Recombination-positive areas of the adult brain were stained blue with X-gal, a substrate of beta-galactosidase. Blue-colored cells appeared soon after birth, and continued to emerge in postnatal tissue. Staining was prominent in sensory as opposed to motor regions of the brain, and was present in more than 70 discrete areas of the nervous system. The possibility of DNA rearrangement is discussed with respect to the development of the central nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,IBARAKI 305,JAPAN; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	University of California System; University of California Berkeley; RIKEN	MATSUOKA, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720, USA.		Okazaki, Kenji/H-4393-2012	Matsuoka, Masao/0000-0002-0473-754X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018790, R01AI018790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18790] Funding Source: Medline; NINDS NIH HHS [NS16832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHUN JJM, 1989, CELL, V59, P189; DREYER WJ, 1965, P NATL ACAD SCI USA, V54, P864, DOI 10.1073/pnas.54.3.864; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HU H, 1986, BRAIN RES, V368, P201, DOI 10.1016/0006-8993(86)91064-4; Jerne N., 1967, NEUROSCIENCES STUDY, P200; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Neff WD, 1975, HDB SENSORY PHYSIOLO, P307; PARNES JR, 1987, IMMUNOL REV, V100, P109, DOI 10.1111/j.1600-065X.1987.tb00529.x; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Sarnat H. B., 1981, EVOLUTION NERVOUS SY, V2nd; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WINER JA, 1988, J COMP NEUROL, V274, P422, DOI 10.1002/cne.902740310; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	26	104	111	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					81	86		10.1126/science.1925563	http://dx.doi.org/10.1126/science.1925563			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925563				2022-12-28	WOS:A1991GH60500031
J	GARROW, J				GARROW, J			THE HEALTH OF THE NATION - RESPONSES - IMPORTANCE OF OBESITY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; BODY-WEIGHT; RISK FACTOR; OVERWEIGHT; TIME				GARROW, J (corresponding author), ST BARTHOLOMEWS HOSP,HUMAN NUTR,LONDON EC1A 7BE,ENGLAND.							BINGHAM S, 1991, BRIT MED J, V303, P353, DOI 10.1136/bmj.303.6798.353; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; Bush A., 1988, Journal of Human Nutrition and Dietetics, V1, P429, DOI 10.1111/j.1365-277X.1988.tb00216.x; DIXON AS, 1973, PRESCRIBERS J, V13, P41; DUBLIN LI, 1953, NEW ENGL J MED, V248, P971, DOI 10.1056/NEJM195306042482304; FORDE OH, 1986, ACTA MED SCAND, V219, P167; FRIEDMAN CI, 1985, CLIN OBSTET GYNECOL, V28, P645, DOI 10.1097/00003081-198528030-00019; GARFINKEL L, 1985, ANN INTERN MED, V103, P1034, DOI 10.7326/0003-4819-103-6-1034; Garrow J.S., 1988, OBESITY RELATED DISE; GARROW JS, 1991, BRIT MED J, V302, P803, DOI 10.1136/bmj.302.6780.803; GARROW JS, IN PRESS OVERWEIGHT; Gregory F., 1990, DIETARY NUTR SURVEY; HALL A, 1989, NEW ZEAL MED J, V102, P134; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; HUBERT HB, 1986, ANNU REV PUBL HEALTH, V7, P493, DOI 10.1146/annurev.pu.07.050186.002425; JEANRENAUD B, 1991, PROG OBES R, P409; KEYS A, 1972, ANN INTERN MED, V77, P15, DOI 10.7326/0003-4819-77-1-15; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NOMURA F, 1986, INT J OBESITY, V10, P349; PENTECOST BL, 1991, MED ASPECTS EXERCISE; REUBEN A, 1985, CLIN SCI, V69, P71, DOI 10.1042/cs0690071; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; SHAPER AG, 1988, CORONARY HEART DISEA; Sims E A, 1973, Recent Prog Horm Res, V29, P457; SONNEHOLM S, 1986, BRIT MED J, V292, P586, DOI 10.1136/bmj.292.6520.586; 1991, CM1523	27	59	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					704	706		10.1136/bmj.303.6804.704	http://dx.doi.org/10.1136/bmj.303.6804.704			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1912920	Bronze, Green Published			2022-12-28	WOS:A1991GG98000028
J	RICHET, E; VIDALINGIGLIARDI, D; RAIBAUD, O				RICHET, E; VIDALINGIGLIARDI, D; RAIBAUD, O			A NEW MECHANISM FOR COACTIVATION OF TRANSCRIPTION INITIATION - REPOSITIONING OF AN ACTIVATOR TRIGGERED BY THE BINDING OF A 2ND ACTIVATOR	CELL			English	Article							ESCHERICHIA-COLI; SUPERCOILED DNA; MALT PRODUCT; PROMOTERS; PROTEIN; OPERON; MUTATIONS; REGION; CRP; EXPRESSION	The cAMP receptor protein (CRP) and MalT, the maltose regulon activator, synergistically activate transcription from the E. coli malKp promoter. The malKp regulatory region comprises two series of MalT-binding sites separated by three CRP-binding sites. By combining genetic and biochemical studies, we demonstrate that the promoter-proximal region contains two overlapping sets of three MalT-binding sites. Occupation of the higher affinity set of sites, which occurs in the absence of CRP, does not lead to malKp activation. In contrast, in the presence of CRP, MalT binds to the lower affinity set of sites and triggers transcription initiation because, unlike the high affinity set, the low affinity set of sites is properly positioned with respect to the Pribnow box. The CRP effect requires the malKp-distal MalT-binding sites. The synergistic action of MalT and CRP therefore relies on MalT repositioning via the formation of a nucleoprotein structure involving the entire regulatory region.			RICHET, E (corresponding author), INST PASTEUR,UNITE GENET MOLEC,CNRS,URA 1149,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AIBA H, 1981, J BIOL CHEM, V256, P1905; BEDOUELLE H, 1983, J MOL BIOL, V170, P861, DOI 10.1016/S0022-2836(83)80192-2; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BUC H, 1987, RNA POLYMERASE REGUL, P115; CHAPON C, 1985, J BACTERIOL, V164, P639, DOI 10.1128/JB.164.2.639-645.1985; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DEBARBOUILLE M, 1982, MOL GEN GENET, V185, P88, DOI 10.1007/BF00333795; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; EISMANN ER, 1990, J MOL BIOL, V213, P763, DOI 10.1016/S0022-2836(05)80262-1; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GUTIERREZ C, 1985, BIOCHIMIE, V67, P145, DOI 10.1016/S0300-9084(85)80241-8; GUTIERREZ C, 1984, J MOL BIOL, V177, P69, DOI 10.1016/0022-2836(84)90058-5; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LICHENSTEIN HS, 1987, J BACTERIOL, V169, P811, DOI 10.1128/jb.169.2.811-822.1987; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOBELL RB, 1991, J MOL BIOL, V218, P45, DOI 10.1016/0022-2836(91)90872-4; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; Miller J.H., 1972, EXPT MOL GENETICS; RAIBAUD O, 1983, J MOL BIOL, V163, P395, DOI 10.1016/0022-2836(83)90065-7; RAIBAUD O, 1985, J BACTERIOL, V161, P1201, DOI 10.1128/JB.161.3.1201-1208.1985; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; RICHET E, 1991, J MOL BIOL, V218, P529; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; VALENTINHANSEN P, 1982, EMBO J, V1, P317, DOI 10.1002/j.1460-2075.1982.tb01167.x; VALENTINHANSEN P, 1991, MOL MICROBIOL, V5, P433, DOI 10.1111/j.1365-2958.1991.tb02126.x; VIDALINGIGLIARDI D, 1991, P NATL ACAD SCI USA, V88, P229, DOI 10.1073/pnas.88.1.229; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P5919, DOI 10.1093/nar/13.16.5919; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; VIDALINGIGLIARDI D, 1985, NUCLEIC ACIDS RES, V13, P1163, DOI 10.1093/nar/13.4.1163	44	80	81	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1185	1195		10.1016/0092-8674(91)90041-V	http://dx.doi.org/10.1016/0092-8674(91)90041-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913806				2022-12-28	WOS:A1991GG55200013
J	LYNOE, N; SANDLUND, M; DAHLQVIST, G; JACOBSSON, L				LYNOE, N; SANDLUND, M; DAHLQVIST, G; JACOBSSON, L			INFORMED CONSENT - STUDY OF QUALITY OF INFORMATION GIVEN TO PARTICIPANTS IN A CLINICAL-TRIAL	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether the participants in a clinical trial had perceived adequate information about the trial according to the guidelines of the Declaration of Helsinki. Design - About 18 months after the end of a gynaecological clinical trial the participants received a questionnaire by post, which focused on the quality of the information given to them before entering the trial. Neither researchers nor participants were aware in advance that the trial would become the subject of this follow up investigation. Setting - Eight different centres in Sweden. Subjects - 43 women out of the 53 who completed the trial (mean (range) age 23 (16 to 35) years) returned the questionnaire. Main outcome measures - Adequacy of the information (based on requirements of the Declaration of Helsinki) to enable the following: understanding of the aims of the study; awareness of what participation meant; and awareness of the possibility of withdrawing from participation at any time. Motives for agreeing to participate, and a subjective evaluation of the given information were also recorded. Results - All but one of the participants had been aware that they were taking part in a research project. Five women stated that they had not been aware that a second laparoscopy was performed only for research reasons. Seven women reported that they had not been aware of the meaning of participating in the project and 17 that they had had no information about the possibility of withdrawing from the study whenever they wanted. In the subjective rating 22 women considered the information given as good or very good. There was a systematic variation in the quality of the given information among the eight centres. Conclusion - Although all but one of the participants had been aware that they were taking part in a clinical trial, the quality of the information understood and recalled by participants varied, and in many cases clearly did not meet the guidelines of the Declaration of Helsinki. Variations among centres in participants' perception of information suggest that deficiencies in perception may be caused by informers rather than the participants.	KAROLINSKA INST,SACHS CHILDRENS HOSP,DEPT PEDIAT,S-10401 STOCKHOLM 60,SWEDEN; UMEA UNIV,DEPT PSYCHIAT,S-90185 UMEA,SWEDEN	Karolinska Institutet; Umea University	LYNOE, N (corresponding author), UMEA UNIV,DEPT SOCIAL MED,S-90185 UMEA,SWEDEN.							APPELBAUM PS, 1982, ARCH GEN PSYCHIAT, V39, P951; Beauchamp T., 1982, CONT ISSUES BIOETHIC; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; FADEN JRR, 1986, HIST THEORY INFORMED; Gray B, 1975, HUMAN SUBJECTS MED E; LYNOE N, 1987, LAKARTIDNINGEN, V84, P3246; Silva Mary Cipriano, 1988, IRB, V10, P1, DOI 10.2307/3564101; SIMES RJ, 1986, BRIT MED J, V293, P1065, DOI 10.1136/bmj.293.6554.1065; STANLEY B, 1984, JAMA-J AM MED ASSOC, V252, P1302, DOI 10.1001/jama.252.10.1302; TAUB HA, 1980, GERONTOLOGIST, V20, P686, DOI 10.1093/geront/20.6.686; WESTROM L, 1986, BEHANDLING AKUT AGGL	11	186	191	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					610	613		10.1136/bmj.303.6803.610	http://dx.doi.org/10.1136/bmj.303.6803.610			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1932901	Bronze, Green Published			2022-12-28	WOS:A1991GF67500020
J	REID, GS; ROBERTSON, AJ; BISSETT, C; SMITH, J; WAUGH, N; HALKERSTON, R				REID, GS; ROBERTSON, AJ; BISSETT, C; SMITH, J; WAUGH, N; HALKERSTON, R			CERVICAL SCREENING IN PERTH AND KINROSS SINCE INTRODUCTION OF THE NEW CONTRACT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine changes in the cervical screening service since the introduction of the new general practitioner contract on 1 April 1990. Design-Analysis of computerised records of cervical screening both before and after introduction of the new contract. Setting-General practices in Perth and Kinross Unit, Tayside. Patients-A total of 30 071 women aged 21-60 on 26 general practitioner partnership lists. Main outcome measures-Percentage average of target population for cervical screening in each practice for first three quarters on introduction of the contract. Results-Perth and Kinross Unit completed a computerised cervical screening call programme in July 1989, which produced an increase from 71% to 78% in the mean percentage of women aged 20-60 who had had cervical smear tests within 5.5 years. Six months after the introduction of the new general practitioner contract the mean population coverage was increased to 85% in women aged 21-60 and only four practices had not attained the 80% upper target compared with 10 on 1 April 1990. Detailed examination of randomly selected practices immediately before the new contract was introduced showed an average artificial list inflation of 4.3% in health board records when compared with practice records, a hysterectomy rate of 6.2%, and an additional 3% of women who were considered to be ineligible for smear testing due to putative virginity or illness or infirmity, or both. There was a considerable shift away from use of well woman clinics (2.7% of smears in 1990 compared with 5.6% in 1988) for taking cervical smears, potentially threatening the long term viability of the clinics. Conclusion-The introduction of the new contract for general practitioners has brought about a further sustained increase in population coverage for cervical screening in a small Scottish unit with a stable population, well motivated general practitioners, and a fully integrated computerised call and recall system based on the community health index. To optimise the screening service revision of the targets levels is necessary.	PERTH ROYAL INFIRM,DEPT PATHOL,PERTH PH1 1NX,SCOTLAND; TAYSIDE HLTH BOARD,DEPT PUBL HLTH MED,DUNDEE,SCOTLAND; MARYFIELD HOSP,E COAST SCOTLAND COMP CONSORTIUM,DUNDEE,SCOTLAND									CHAMBERLAIN J, 1984, BRIT MED J, V289, P853, DOI 10.1136/bmj.289.6449.853; CHOMET J, 1990, BRIT MED J, V300, P1504, DOI 10.1136/bmj.300.6738.1504; GEMMELL J, 1990, BRIT J OBSTET GYNAEC, V97, P58, DOI 10.1111/j.1471-0528.1990.tb01717.x; Robertson A J, 1990, Cytopathology, V1, P3, DOI 10.1111/j.1365-2303.1990.tb00320.x; SEFTON C, 1990, PULSE            DEC, P41; SHROFF KJ, 1988, BRIT MED J, V297, P1317, DOI 10.1136/bmj.297.6659.1317; WAUGH NR, 1990, BRIT MED J, V301, P238, DOI 10.1136/bmj.301.6745.238; 1986, STATEMENT FEES ALLOW; 1985, CERVICAL CANCER SCRE; 1985, LANCET, V2, P363; 1988, CERVICAL CANCER SCRE; 1988, HLTH B EDINB, V46, P146; 1990, STATEMENT FEES ALLOW, P57	13	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					447	450		10.1136/bmj.303.6800.447	http://dx.doi.org/10.1136/bmj.303.6800.447			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912838	Green Published, Bronze			2022-12-28	WOS:A1991GC46500018
J	PATON, CR				PATON, CR			THE HEALTH-SERVICE AND THE GENERAL-ELECTION	BRITISH MEDICAL JOURNAL			English	Article											PATON, CR (corresponding author), UNIV KEELE,CTR HLTH PLANNING & MANAGEMENT,STAFFORDSHIRE ST5 5SP,ENGLAND.							1991, EL9194 NHS MAN EX; 1991, CMND1523	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					405	407		10.1136/bmj.303.6799.405	http://dx.doi.org/10.1136/bmj.303.6799.405			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB599	1912810	Green Published, Bronze			2022-12-28	WOS:A1991GB59900021
J	WEEKS, JC; TIERNEY, MR; WEINSTEIN, MC				WEEKS, JC; TIERNEY, MR; WEINSTEIN, MC			COST-EFFECTIVENESS OF PROPHYLACTIC INTRAVENOUS IMMUNE GLOBULIN IN CHRONIC LYMPHOCYTIC-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNOGLOBULIN REPLACEMENT THERAPY	Background. A recent randomized controlled trial of intravenous immune globulin in patients with chronic lymphocytic leukemia and hypogammaglobulinemia demonstrated a statistically significant reduction in the rate of bacterial infections among patients who received intravenous immune globulin. We used decision-analysis techniques to determine whether prophylactic intravenous immune globulin is likely to result in an overall clinical benefit to patients who receive this treatment and to examine its cost effectiveness. Methods. We constructed a model to compare two strategies: treatment with intravenous immune globulin at a dose of 400 mg per kilogram of body weight every three weeks and no immune globulin therapy. Baseline estimates of the efficacy of intravenous immune globulin were derived from the published results of the randomized trial. The costs of treatment, complications, and infections were estimated on the basis of component costs. Health outcomes were measured in terms of gains in quality-adjusted life expectancy. Results. Intravenous immune globulin therapy can result in a loss of quality-adjusted life expectancy when the inconvenience of treatment is taken into account. If the inconvenience of treatment is not considered, therapy results in a gain of 0.8 quality-adjusted day per patient per year of therapy at a cost of $6 million per quality-adjusted life-year gained. Conclusions. Decision-analysis modeling may be applied to the results of randomized controlled trials to assess the potential clinical and financial effects of adopting the intervention in medical practice. In the case of intravenous immune globulin therapy in patients with chronic lymphocytic leukemia and hypogammaglobulinemia, this type of analysis suggests that treatment might not result in improved quality or length of life and that it is extraordinarily expensive in comparison with other treatments generally accepted as cost effective.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health								BERKMAN SA, 1990, ANN INTERN MED, V112, P278, DOI 10.7326/0003-4819-112-4-278; BESA EC, 1988, AM J MED, V84, P691, DOI 10.1016/0002-9343(88)90106-4; BESA EC, 1984, AM J MED, V76, P209, DOI 10.1016/0002-9343(84)90344-9; BOELAERT J, 1987, 27TH ANN INT C ANT A, P264; BOTTINO GG, 1988, NEW YORK STATE J MED, V88, P597; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; BUNCH C, 1988, NOUV REV FR HEMATOL, V30, P419; CHAPEL H, 1988, CLIN EXP IMMUNOL, V73, P160; CHAPEL HM, 1987, SEMIN HEMATOL, V24, P291; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8; GOLDMAN L, 1991, HARRISONS PRINCIPLES, P11; GRIFFITHS H, 1989, BLOOD, V73, P366; HOLLENBERG J, 1989, SMLTREE VERSION 29; LEVER AML, 1987, CLIN EXP IMMUNOL, V67, P441; MORRELL A, 1988, PEDIATR INFECT DI S5, V7, pS87; PIROFSKY B, 1986, REV INFECT DIS, V9, P232; PIROFSKY B, 1986, REV INFECT DIS S4, V8, pS449; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; ROZMAN C, 1984, BLOOD, V64, P642; SILBER R, 1990, HEMATOLOGY, P1005; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P184; 1990, JAMA-J AM MED ASSOC, V264, P3189; 1988, NEW ENGL J MED, V319, P902; 1983, VITAL HLTH STATIS 13, V74	27	148	150	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1991	325	2					81	86		10.1056/NEJM199107113250202	http://dx.doi.org/10.1056/NEJM199107113250202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV522	1904989				2022-12-28	WOS:A1991FV52200002
J	SMITH, DW; FRANKEL, LR; MATHERS, LH; TANG, ATS; ARIAGNO, RL; PROBER, CG				SMITH, DW; FRANKEL, LR; MATHERS, LH; TANG, ATS; ARIAGNO, RL; PROBER, CG			A CONTROLLED TRIAL OF AEROSOLIZED RIBAVIRIN IN INFANTS RECEIVING MECHANICAL VENTILATION FOR SEVERE RESPIRATORY SYNCYTIAL VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPECTRUM ANTIVIRAL ACTIVITY; VIRAL-INFECTION; BRONCHIOLITIS; DISEASE; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE; VIRAZOLE	Background. Although the antiviral agent ribavirin improves the course of lower respiratory tract disease in spontaneously breathing infants with respiratory syncytial virus infection, it is not known whether ribavirin can benefit infants with severe respiratory syncytial virus disease who require mechanical ventilation. Methods. We conducted a randomized, double-blind, placebo-controlled evaluation of ribavirin (20 mg per milliliter) administered continuously in aerosolized form to infants receiving mechanical ventilation for respiratory failure that was caused by documented respiratory syncytial virus infection. Results. Of the 28 infants (mean [+/- SD] age, 1.4 +/- 1.7 months) enrolled, 7 had underlying diseases predisposing them to severe infection (mean age, 3.0 +/- 2.6 months), and 21 were previously normal (mean age, 0.8 +/- 0.9 month). Among the 14 infants who received ribavirin, the mean duration of mechanical ventilation was 4.9 days (as compared with 9.9 days among the 14 who received placebo; P = 0.01), and the mean length of supplemental oxygen use was 8.7 days (as compared with 13.5 days; P = 0.01). The mean length of the hospital stay was 13.3 days after treatment with ribavirin and 15.0 with placebo (P = 0.04). When only the 21 previously normal infants were considered, the mean length of the hospital stay was 9.0 days for the ribavirin recipients and 15.3 days for those who received placebo (P = 0.005). Conclusions. In infants who require mechanical ventilation because of severe respiratory syncytial virus infection, treatment with aerosolized ribavirin decreases the duration of mechanical ventilation, oxygen treatment, and the hospital stay.	STANFORD UNIV, MED CTR, SCH MED, DIV INTENS CARE, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DIV INFECT DIS, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DIV NEONATAL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT PEDIAT, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University			Ariagno, Ronald/ABG-5884-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000081] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00081] Funding Source: Medline; NIAID NIH HHS [AI 008844] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1987, PEDIATRICS, V79, P475; BARRY W, 1986, ARCH DIS CHILD, V61, P593, DOI 10.1136/adc.61.6.593; CONRAD DA, 1987, PEDIATR INFECT DIS J, V6, P152, DOI 10.1097/00006454-198702000-00003; EDELSON PJ, 1990, PEDIATR INFECT DIS J, V9, pS71, DOI 10.1097/00006454-199009001-00002; FRANKEL LR, 1987, CRIT CARE MED, V15, P1051, DOI 10.1097/00003246-198711000-00012; FRANKEL LR, 1986, PEDIATR PULM, V2, P307, DOI 10.1002/ppul.1950020511; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; HALL CB, 1985, JAMA-J AM MED ASSOC, V254, P3047, DOI 10.1001/jama.254.21.3047; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; HUFFMAN JH, 1973, ANTIMICROB AGENTS CH, V3, P235, DOI 10.1128/AAC.3.2.235; KWONG MS, 1985, PEDIATRICS, V76, P585; MANSELL A, 1972, J APPL PHYSIOL, V33, P711, DOI 10.1152/jappl.1972.33.6.711; RODRIGUEZ WJ, 1987, PEDIATR INFECT DIS J, V6, P159, DOI 10.1097/00006454-198702000-00004; ROSENFELD W, 1988, BRONCHOPULMONARY DYS, P366; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; TABER LH, 1983, PEDIATRICS, V72, P613; WALD ER, 1988, J PEDIATR-US, V112, P154, DOI 10.1016/S0022-3476(88)80143-4; WITKOWSKI JT, 1972, J MED CHEM, V15, P1150, DOI 10.1021/jm00281a014; 1986, VIRAZOLE	19	200	220	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					24	29		10.1056/NEJM199107043250105	http://dx.doi.org/10.1056/NEJM199107043250105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1904551				2022-12-28	WOS:A1991FU34200005
J	FINBERG, RW; WAHL, SM; ALLEN, JB; SOMAN, G; STROM, TB; MURPHY, JR; NICHOLS, JC				FINBERG, RW; WAHL, SM; ALLEN, JB; SOMAN, G; STROM, TB; MURPHY, JR; NICHOLS, JC			SELECTIVE ELIMINATION OF HIV-1-INFECTED CELLS WITH AN INTERLEUKIN-2 RECEPTOR SPECIFIC CYTOTOXIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CELLS; FUSION PROTEIN; DIPHTHERIA-TOXIN; ENVELOPE GLYCOPROTEIN; LYMPHOCYTES; ACTIVATION; ENTRY; MONOCYTES; CD4	Infection by human immunodeficiency virus type 1 (HIV-1) is associated with cellular activation and expression of the interleukin-2 (IL-2) receptor. A genetically engineered fusion toxin, DAB486 IL-2, that contains the enzymatic site and translocation domain of diphtheria toxin and the receptor binding domain of IL-2 specifically kills cells that express high-affinity IL-2 receptors. This toxin selectively eliminated the HIV-1-infected cells from mixed cultures of infected and uninfected cells and inhibited production of viral proteins and infectious virus. Thus, cellular activation antigens present a target for early antiviral intervention.	SERAGEN,HOPKINTON,MA 01748; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NIDR,IMMUNOL LAB,BETHESDA,MD 20892; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,THORNDIKE LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; BOSTON UNIV MED,BOSTON UNIV HOSP,BOSTON,MA 02118	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University	FINBERG, RW (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,INFECT DIS LAB,BOSTON,MA 02115, USA.		Finberg, Robert W/E-3323-2010					ALLEN JB, 1990, J CLIN INVEST, V85, P192, DOI 10.1172/JCI114412; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FINBERG RW, UNPUB; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GEYER SJ, 1989, 5TH INT C AIDS INT A, P636; GOWDA SD, 1989, J IMMUNOL, V142, P773; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; KIRKMAN RL, 1989, TRANSPLANTATION, V47, P327, DOI 10.1097/00007890-198902000-00028; KIYOKAWA T, 1989, CANCER RES, V49, P4042; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LEMAISTRE F, 1990, BLOOD, V76, pA314; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1688, DOI 10.1002/art.1780331112; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; Nichols Johanna, UNPUB; PANKEWYCZ O, 1989, TRANSPLANTATION, V47, P318, DOI 10.1097/00007890-198902000-00026; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97, DOI 10.1128/JCM.25.1.97-99.1987; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL SM, 1989, J IMMUNOL, V142, P3553; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WOODWORTH T, 1991, 4TH INT C HUM RETR M; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	49	52	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1703	1705		10.1126/science.1904628	http://dx.doi.org/10.1126/science.1904628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1904628				2022-12-28	WOS:A1991FT11400045
J	WILSON, DK; RUDOLPH, FB; QUIOCHO, FA				WILSON, DK; RUDOLPH, FB; QUIOCHO, FA			ATOMIC-STRUCTURE OF ADENOSINE-DEAMINASE COMPLEXED WITH A TRANSITION-STATE ANALOG - UNDERSTANDING CATALYSIS AND IMMUNODEFICIENCY MUTATIONS	SCIENCE			English	Article							POINT MUTATION; XANTHINE-OXIDASE; ESCHERICHIA-COLI; INHIBITORS; PROTEIN; BINDING; IDENTIFICATION; EXPRESSION; TRANSPORT; CRYSTALLOGRAPHY	The crystal structure of a murine adenosine deaminase complexed with 6-hydroxyl-1,6-dihydropurine ribonucleoside, a nearly ideal transition-state analog, has been determined and refined at 2.4 angstrom resolution. The structure is folded as an eight-stranded parallel alpha/beta-barrel with a deep pocket at the beta-barrel COOH-terminal end wherein the inhibitor and a zinc are bound and completely sequestered. The presence of the zinc cofactor and the precise structure of the bound analog were not previously known. The 6R isomer of the analog is very tightly held in place by the coordination of the 6-hydroxyl to the zinc and the formation of nine hydrogen bonds. On the basis of the structure of the complex a stereoselective addition-elimination or S(N)2 mechanism of the enzyme is proposed with the zinc atom and the Glu and Asp residues playing key roles. A molecular explanation of a hereditary disease caused by several point mutations of an enzyme is also presented.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005	Baylor University; Howard Hughes Medical Institute; Rice University					NATIONAL CANCER INSTITUTE [R01CA014030] Funding Source: NIH RePORTER; NCI NIH HHS [CA14030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; AKESON AL, 1987, P NATL ACAD SCI USA, V84, P5947, DOI 10.1073/pnas.84.16.5947; AKESON AL, 1989, J CELL BIOCHEM, V39, P217, DOI 10.1002/jcb.240390302; AKESON AL, 1988, J BIOL CHEM, V263, P16291; ASHTON D, 1987, EUR J PHARMACOL, V142, P403, DOI 10.1016/0014-2999(87)90079-3; BONTHRON DT, 1985, J CLIN INVEST, V76, P894, DOI 10.1172/JCI112050; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2187, DOI 10.1016/0006-2952(75)90051-9; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; COOPER BT, UNPUB; COWAN MJ, 1983, P NATL ACAD SCI USA, V83, P1089; DAWICKI DD, 1988, BIOCHEM PHARMACOL, V37, P621, DOI 10.1016/0006-2952(88)90134-7; EVANS BE, 1973, BIOCHEMISTRY-US, V12, P392, DOI 10.1021/bi00727a005; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GAN TE, 1987, BLOOD, V69, P1376; GLAZER RI, 1980, CANCER CHEMOTH PHARM, V4, P227; GROSS RL, 1980, PHYSIOL REV, V60, P188, DOI 10.1152/physrev.1980.60.1.188; HAMPTON A, 1972, BIOCHEMISTRY-US, V11, P4736, DOI 10.1021/bi00775a016; Harrison MP., UNPUB; HIRSCHHORN R, 1989, J CLIN INVEST, V83, P497, DOI 10.1172/JCI113909; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; IKEHARA M, 1974, BIOCHIM BIOPHYS ACTA, V338, P512, DOI 10.1016/0304-4165(74)90313-4; IKEHARA M, 1972, BIOCHIM BIOPHYS ACTA, V11, P4736; JONES W, 1989, BIOCHEMISTRY-US, V28, P12242; KANNO H, 1988, JPN J EXP MED, V58, P1; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P8450, DOI 10.1021/bi00399a063; KURZ LC, 1983, BIOCHEMISTRY-US, V22, P382, DOI 10.1021/bi00271a023; KURZ LC, 1980, BIOCHEMISTRY-US, V19, P1616; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LOLIS E, 1990, ANNU REV BIOCHEM, V59, P597, DOI 10.1146/annurev.bi.59.070190.003121; MAQUIRE MH, 1971, EUR J BIOCHEM, V23, P22; MARTIN DW, 1981, ANNU REV BIOCHEM, V50, P845, DOI 10.1146/annurev.bi.50.070181.004213; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mcilwain H., 1983, CENTRAL NERVOUS SYST, P3; MILLER DM, 1983, J BIOL CHEM, V258, P3665; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P3386, DOI 10.1021/bi00768a011; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; RENOUF JA, 1989, CLIN CHEM, V35, P1478; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAWA T, 1967, J ANTIBIOT, V20, P317; SCHRAMM VL, 1985, BIOCHEMISTRY-US, V24, P641, DOI 10.1021/bi00324a016; VALERIO D, 1986, EMBO J, V5, P113, DOI 10.1002/j.1460-2075.1986.tb04184.x; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS PM, 1987, BIOCHEMISTRY-US, V26, P7378, DOI 10.1021/bi00397a027; WILSON DJ, UNPUB; WILSON DK, 1988, J MOL BIOL, V200, P613, DOI 10.1016/0022-2836(88)90549-9; WOLFENDEN R, 1967, J BIOL CHEM, V242, P977; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V8, P2412, DOI 10.1021/bi00834a024; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V16, P5071; WOO PWK, 1974, J HETEROCYCLIC CHEM, V11, P641, DOI 10.1002/jhet.5570110438; YEUNG CY, 1985, J BIOL CHEM, V260, P299; ZIELKE CL, 1971, ENZYMES, V4, P47	60	454	464	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1278	1284		10.1126/science.1925539	http://dx.doi.org/10.1126/science.1925539			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925539				2022-12-28	WOS:A1991FN85700031
J	BARDWELL, VJ; WICKENS, M; BIENROTH, S; KELLER, W; SPROAT, BS; LAMOND, AI				BARDWELL, VJ; WICKENS, M; BIENROTH, S; KELLER, W; SPROAT, BS; LAMOND, AI			SITE-DIRECTED RIBOSE METHYLATION IDENTIFIES 2'-OH GROUPS IN POLYADENYLATION SUBSTRATES CRITICAL FOR AAUAAA RECOGNITION AND POLY(A) ADDITION	CELL			English	Article							RNA INTERACTIONS; CLEAVAGE; INVITRO; POLYMERASE; SNRNP; OLIGONUCLEOTIDES; SEQUENCE	The importance of sugar contacts for the sequence-specific recognition that occurs during polyadenylation of mRNAs was investigated with chemically synthesized substrates containing 2'-O-CH3 groups at selected riboses. An RNA (5'-CUGCAAUAAACAAGUUAA-3') with 2'-O-CH3 ribose at each nucleotide except for the AAUAAA sequence and 3'-terminal adenosine was efficiently polyadenylated in vitro. Methylation of single riboses within AAUAAA inhibited both poly(A) addition and binding of the specificity factor, but the magnitude of inhibition varied greatly at different nucleotides. Nucleotides that showed sensitivity to base substitutions did not necessarily show sensitivity to ribose methylation, and vice versa. The data indicate that the specificity factor interacts with AAUAAA through RNA-protein contacts involving essential recognition of both sugars and bases at different nucleotide positions.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,MOLEC BIOL PROGRAM,MADISON,WI 53706; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Basel; European Molecular Biology Laboratory (EMBL)				Lamond, Angus/0000-0001-6204-6045	NIGMS NIH HHS [GM31892, GM00521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031892, K04GM000521, R37GM031892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P295, DOI 10.1128/MCB.10.1.295; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BOBST AM, 1969, J MOL BIOL, V46, P221, DOI 10.1016/0022-2836(69)90418-5; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HINGERTY B, 1974, BIOCHEM BIOPH RES CO, V61, P875, DOI 10.1016/0006-291X(74)90237-X; HOLMES KC, 1980, TRENDS BIOCHEM SCI, V5, P4, DOI 10.1016/S0968-0004(80)80066-1; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; LESLIE AGW, 1978, J MOL BIOL, V119, P399, DOI 10.1016/0022-2836(78)90222-X; Maniatis T., 1982, MOL CLONING; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; WAHLE E, 1991, IN PRESS J BIOL CHEM; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIGLEY PL, 1990, MOL CELL BIOL, V10, P1705, DOI 10.1128/MCB.10.4.1705; ZARKOWER D, 1987, EMBO J, V6, P177, DOI 10.1002/j.1460-2075.1987.tb04736.x; ZMUDZKA B, 1969, BIOCHEM BIOPH RES CO, V37, P895, DOI 10.1016/0006-291X(69)90215-0	28	60	60	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					125	133		10.1016/0092-8674(91)90414-T	http://dx.doi.org/10.1016/0092-8674(91)90414-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1901516				2022-12-28	WOS:A1991FF77300015
J	RAUB, W				RAUB, W			THERAPY APPEARS SAFE, EFFECTIVE AGAINST SPONTANEOUS ANIMAL TUMORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, J NATL CANCER I, V83, P18	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-28	WOS:A1991FD65900003
J	WALSH, BW; SCHIFF, I; ROSNER, B; GREENBERG, L; RAVNIKAR, V; SACKS, FM				WALSH, BW; SCHIFF, I; ROSNER, B; GREENBERG, L; RAVNIKAR, V; SACKS, FM			EFFECTS OF POSTMENOPAUSAL ESTROGEN REPLACEMENT ON THE CONCENTRATIONS AND METABOLISM OF PLASMA-LIPOPROTEINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; POST-MENOPAUSAL WOMEN; APOLIPOPROTEIN-B; HEART-DISEASE; TRIGLYCERIDE KINETICS; SERUM-LIPOPROTEINS; LONG-TERM; ESTRADIOL; HORMONE; CHOLESTEROL	Background. Postmenopausal estrogen-replacement therapy may reduce the risk of cardiovascular disease, and this beneficial effect may be mediated in part by favorable changes in plasma lipid levels. However, the effects on plasma lipoprotein levels of postmenopausal estrogens in the low doses currently used have not been precisely quantified, and the mechanism of these effects is unknown. Methods. We conducted two randomized, double-blind crossover studies in healthy postmenopausal women who had normal lipid values at base line. In study 1, 31 women received placebo and conjugated estrogens at two doses (0.625 mg and 1.25 mg per day), each treatment for three months. In study 2, nine women received placebo, oral micronized estradiol (2 mg per day), and transdermal estradiol (0.1 mg twice a week), each treatment for six weeks. The metabolism of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) was measured by endogenously labeling their protein component, apolipoprotein B. Results. In study 1, the conjugated estrogens at doses of 0.625 mg per day and 1.25 mg per day decreased the mean LDL cholesterol level by 15 percent (95 percent confidence interval, 11 to 19 percent; P < 0.0001) and 19 percent (95 percent confidence interval, 15 to 23 percent; P < 0.0001), respectively; increased the HDL cholesterol level by 16 percent (95 percent confidence interval, 12 to 20 percent; P < 0.0001) and 18 percent (95 percent confidence interval, 14 to 22 percent; P < 0.0001), respectively; and increased VLDL triglyceride levels by 24 percent (95 percent confidence interval, 8 to 40 percent; P < 0.003) and 42 percent (95 percent confidence interval, 26 to 58 percent; P < 0.0001), respectively. In study 2, oral estradiol increased the mean concentration of large VLDL apolipoprotein B by 30 +/- 10 percent (P = 0.05) by increasing its production rate by 82 +/- 18 percent P < 0.01). Most of this additional large VLDL was cleared directly from the circulation and was not converted to small VLDL or LDL. Oral estradiol reduced LDL cholesterol concentrations by 14 +/- 3 percent (P < 0.005), because LDL catabolism increased by 36 +/- 7 percent (P < 0.005). The oral estradiol increased the HDL cholesterol level by 15 +/- 2 percent (P < 0.0001). Transdermal estradiol had no effect. Conclusions. The postmenopausal use of oral estrogens in low doses favorably alters LDL and HDL levels that may protect women against atherosclerosis, while minimizing potentially adverse effects on triglyceride levels. The decrease in LDL levels results from accelerated LDL catabolism; the increase in triglyceride levels results from increased production of large, triglyceride-rich VLDL.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CLIN EPIDEMIOL & BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT GYNECOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CLIN RES CTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034980] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-02635] Funding Source: Medline; NHLBI NIH HHS [HL-34980] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachorik P S, 1986, Methods Enzymol, V129, P78; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; CRYER DR, 1986, J LIPID RES, V27, P508; EGUSA G, 1983, J LIPID RES, V24, P1261; ERIKSSON M, 1989, J CLIN INVEST, V84, P802, DOI 10.1172/JCI114239; GLUECK CJ, 1975, METABOLISM, V24, P537, DOI 10.1016/0026-0495(75)90078-5; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KISSEBAH AH, 1973, HORM METAB RES, V5, P184, DOI 10.1055/s-0028-1093969; KLETZKY OA, 1975, AM J OBSTET GYNECOL, V121, P688, DOI 10.1016/0002-9378(75)90474-3; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LOBO RA, 1980, AM J OBSTET GYNECOL, V138, P714, DOI 10.1016/0002-9378(80)90094-0; MANDEL FP, 1983, J CLIN ENDOCR METAB, V57, P133, DOI 10.1210/jcem-57-1-133; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MASHCHAK CA, 1982, AM J OBSTET GYNECOL, V144, P511, DOI 10.1016/0002-9378(82)90218-6; MILLER KW, 1984, J BIOL CHEM, V259, P5277; OHTA T, 1988, J LIPID RES, V29, P721; OHTA T, 1989, ARTERIOSCLEROSIS, V9, P90, DOI 10.1161/01.ATV.9.1.90; PACKARD CJ, 1984, J CLIN INVEST, V74, P2178, DOI 10.1172/JCI111644; PUCHOIS P, 1987, ATHEROSCLEROSIS, V68, P35, DOI 10.1016/0021-9150(87)90091-8; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSNER B, 1989, J AM STAT ASSOC, V84, P373, DOI 10.2307/2289920; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P189; ROSS RK, 1981, LANCET, V1, P858; ROSS RK, 1988, AM J PUBLIC HEALTH, V78, P516, DOI 10.2105/AJPH.78.5.516; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SHARF M, 1985, GYNECOL OBSTET INVES, V19, P207, DOI 10.1159/000299035; SIMONS LA, 1983, J LIPID RES, V24, P192; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; TASKINEN MR, 1987, LIPOPROTEIN LIPASE, P201; TIKKANEN MJ, 1985, FEBS LETT, V181, P160, DOI 10.1016/0014-5793(85)81134-0; VAITUKAITIS JL, 1973, J CLIN ENDOCR METAB, V37, P653, DOI 10.1210/jcem-37-5-653; VELDHUIS JD, 1985, ENDOCRINOLOGY, V117, P1321, DOI 10.1210/endo-117-4-1321; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WINDLER EET, 1980, J BIOL CHEM, V255, P464; WOLFE BM, 1989, J CLIN INVEST, V83, P40, DOI 10.1172/JCI113882; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0; NIH801527 DIV HEART, V1; 1988, SAS USERS GUIDE STAT	46	1055	1084	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1196	1204		10.1056/NEJM199110243251702	http://dx.doi.org/10.1056/NEJM199110243251702			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922206				2022-12-28	WOS:A1991GL28200002
J	SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV				SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV			THE 1ST STEP IN VISION - FEMTOSECOND ISOMERIZATION OF RHODOPSIN	SCIENCE			English	Article							PICOSECOND LASER PHOTOLYSIS; CIS-TRANS ISOMERIZATION; ABSORPTION-SPECTRA; ROOM-TEMPERATURE; BATHORHODOPSIN; DYNAMICS; PHOTORHODOPSIN	The kinetics of the primary event in vision have been resolved with the use of femtosecond optical measurement techniques. The 11-cis retinal prosthetic group of rhodopsin is excited with a 35-femtosecond pump pulse at 500 nanometers, and the transient changes in absorption are measured between 450 and 580 nanometers with a 10-femtosecond probe pulse. Within 200 femtoseconds, an increased absorption is observed between 540 and 580 nanometers, indicating the formation of photoproduct on this time scale. These measurements demonstrate that the first step in vision, the 11-cis --> 11-trans torsional isomerization of the rhodopsin chromophore, is essentially complete in only 200 femtoseconds.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	SCHOENLEIN, RW (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720, USA.		Schoenlein, Robert W/D-1301-2014; Peteanu, Linda/O-5581-2017	Schoenlein, Robert W/0000-0002-6066-7566; Peteanu, Linda/0000-0003-0075-6521	NATIONAL EYE INSTITUTE [R01EY002051, T32EY007043, R37EY002051] Funding Source: NIH RePORTER; NEI NIH HHS [T32EY07043, EY 02051] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIRGE RR, 1980, J AM CHEM SOC, V102, P2195, DOI 10.1021/ja00527a008; BIRGE RR, 1990, ANNU REV PHYS CHEM, V41, P683, DOI 10.1146/annurev.pc.41.100190.003343; BIRGE RW, COMMUNICATION; BUSCH GE, 1972, P NATL ACAD SCI USA, V69, P2802, DOI 10.1073/pnas.69.10.2802; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; DOUKAS AG, 1984, P NATL ACAD SCI-BIOL, V81, P4790, DOI 10.1073/pnas.81.15.4790; EYRING G, 1980, BIOCHEMISTRY-US, V19, P2410, DOI 10.1021/bi00552a020; FHAYWARD G, 1981, SCIENCE, V211, P942; FORK RL, 1987, OPT LETT, V12, P483, DOI 10.1364/OL.12.000483; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; HURLEY J, 1977, PURE APPL CHEM, V49, P341; KANDORI H, 1989, BIOPHYS J, V56, P453, DOI 10.1016/S0006-3495(89)82692-X; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; MONGER TG, 1979, BIOPHYS J, V27, P105, DOI 10.1016/S0006-3495(79)85205-4; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P254; POLLARD WT, 1990, CHEM PHYS LETT, V168, P239, DOI 10.1016/0009-2614(90)85603-A; POLLARD WT, 1990, J CHEM PHYS, V92, P4012, DOI 10.1063/1.457815; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SHANK CV, 1986, SCIENCE, V233, P1276, DOI 10.1126/science.233.4770.1276; SHICHIDA Y, 1984, PHOTOBIOCH PHOTOBIOP, V7, P221; SPALINK JD, 1983, P NATL ACAD SCI-BIOL, V80, P1887, DOI 10.1073/pnas.80.7.1887; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WEISS RM, 1979, J AM CHEM SOC, V101, P6131, DOI 10.1021/ja00514a051; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	25	710	721	2	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					412	415		10.1126/science.1925597	http://dx.doi.org/10.1126/science.1925597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925597				2022-12-28	WOS:A1991GK72900043
J	KOSMAN, D; IP, YT; LEVINE, M; ARORA, K				KOSMAN, D; IP, YT; LEVINE, M; ARORA, K			ESTABLISHMENT OF THE MESODERM-NEUROECTODERM BOUNDARY IN THE DROSOPHILA EMBRYO	SCIENCE			English	Article							SCUTE GENE-COMPLEX; SINGLE-MINDED GENE; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; NERVOUS-SYSTEM; EXPRESSION; PROTEIN; MELANOGASTER; CELLS; NEUROGENESIS	A gradient of the maternal morphogen dorsal establishes asymmetric patterns of gene expression along the dorsal-ventral axis of early embryos and activates the regulatory genes twist and snail, which are responsible for the differentiation of the ventral mesoderm. Expression of snail is restricted to the presumptive mesoderm, and the sharp lateral limits of this expression help to define the mesoderm-neuroectoderm boundary by repressing the expression of regulatory genes that are responsible for the differentiation of the neuroectoderm. The snail gene encodes a zinc finger protein, and neuroectodermal genes that are normally restricted to ventral-lateral regions of early embryos are expressed throughout ventral regions of snail- mutants. The formation of the sharp snail border involves dosage-sensitive interactions between dorsal and twist, which encode regulatory proteins that are related to the mammalian transcription factors NF-kB and MyoD, respectively.			KOSMAN, D (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093, USA.			Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM 46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERGA A, 1991, DEVELOPMENT, V111, P983; ALONSON MC, 1988, EMBO J, V7, P2588; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IP YT, 1991, CELL, V64, P439; KOSMAN D, UNPUB; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Rushlow C, 1990, Semin Cell Biol, V1, P137; SIMPSON P, 1983, GENETICS, V105, P615; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	30	205	206	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					118	122		10.1126/science.1925551	http://dx.doi.org/10.1126/science.1925551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925551				2022-12-28	WOS:A1991GH60500043
J	GALIONE, A; LEE, HC; BUSA, WB				GALIONE, A; LEE, HC; BUSA, WB			CA2+-INDUCED CA2+ RELEASE IN SEA-URCHIN EGG HOMOGENATES - MODULATION BY CYCLIC ADP-RIBOSE	SCIENCE			English	Article							MUSCLE RYANODINE RECEPTOR; INOSITOL TRISPHOSPHATE; CALCIUM RELEASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CHROMAFFIN CELLS; XENOPUS-LAEVIS; CA-2+ RELEASE; FERTILIZATION	Calcium-induced calcium release (CICR) may function widely in calcium-mediated cell signaling, but has been most thoroughly characterized in muscle cells. In a homogenate of sea urchin eggs, which display transients in the intracellular free calcium concentration ([Ca2+]i) during fertilization and anaphase, addition of Ca2+ triggered CICR. Ca2+ release was also induced by the CICR modulators ryanodine and caffeine. Responses to both Ca2+ and CICR modulators (but not Ca2+ release mediated by inositol 1,4,5-trisphosphate) were inhibited by procaine and ruthenium red, inhibitors of CICR. Intact eggs also displayed transients of [Ca2+]i when microinjected with ryanodine. Cyclic ADP-ribose, a metabolite with potent Ca2+-releasing properties, appears to act by way of the CICR mechanism and may thus be an endogenous modulator of CICR. A CICR mechanism is present in these nonmuscle cells as is assumed in various models of intracellular Ca2+ wave propagation.	UNIV MINNESOTA, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	GALIONE, A (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.		Lee, Hon Cheung/C-4329-2009; Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD022879, R29HD022879] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22879, HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DARGE PJ, 1989, CELL REGUL, V1, P279; EISEN A, 1984, J CELL BIOL, V99, P1878, DOI 10.1083/jcb.99.5.1878; EISEN A, 1984, J CELL BIOL, V99, P1647, DOI 10.1083/jcb.99.5.1647; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FUJIWARA A, 1990, DEV GROWTH DIFFER, V32, P303; GALIONE A, UNPUB; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; JAFFE LF, 1990, NATO ADV SCI I H-CEL, V45, P389; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LEE HC, 1989, J BIOL CHEM, V264, P1608; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PALADE P, 1983, J BIOL CHEM, V258, P8098; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RODGERS MT, UNPUB; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THAYER SA, 1988, MOL PHARMACOL, V34, P664; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALSETH TF, J CELL BIOL, V111, pA467; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1985, BIOL FERTILIZATION, V3, P167	39	577	585	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1143	1146		10.1126/science.1909457	http://dx.doi.org/10.1126/science.1909457			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1909457				2022-12-28	WOS:A1991GD80800034
J	WANG, H; KAVANAUGH, MP; NORTH, RA; KABAT, D				WANG, H; KAVANAUGH, MP; NORTH, RA; KABAT, D			CELL-SURFACE RECEPTOR FOR ECOTROPIC MURINE RETROVIRUSES IS A BASIC-AMINO-ACID TRANSPORTER	NATURE			English	Article							ENVELOPE GLYCOPROTEIN; LEUKEMIA VIRUSES; SACCHAROMYCES-CEREVISIAE; GENE; INTERFERENCE; MEMBRANE; ERYTHROLEUKEMIA; EXPRESSION; INFECTION; PROTEINS	THE complementary DNA sequence encoding the cell-surface receptor for ecotropic host-range murine retroviruses (ecoR) shows that it contains 622 amino acids and 14 hydrophobic potentially membrane-spanning sequences 1. Because this receptor occurs on many or all murine cells 2 and is probably essential for viability of cultured fibroblasts 3, its normal function might be to transport an essential metabolite. We expressed ecoR in Xenopus laevis oocytes by injecting RNA transcribed from the cloned cDNA. These oocytes specifically bound the gp70 envelope glycoprotein from an ecotropic murine leukaemia virus. An inward current was recorded electrophysiologically when a mixture of amino-acids was applied: this resulted from a stereoselective, saturable uptake of lysine, arginine and ornithine; it was independent of sodium and not substantially altered by gp70. Cysteine and homoserine were also taken up, but sodium was necessary for their transport. These properties of ecoR correspond to those of the y+ amino-acid transporter 4-6. Our results demonstrate the subversion of a ubiquitous cell membrane protein, in this case a basic amino acid transporter, for use as a retroviral receptor.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University	WANG, H (corresponding author), OREGON HLTH SCI UNIV, DEPT BIOCHEM, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022					ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; CHRISTENSEN HN, 1966, J BIOL CHEM, V241, P5542; CHRISTENSEN HN, 1969, P NATL ACAD SCI USA, V63, P948, DOI 10.1073/pnas.63.3.948; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; DELARCO J, 1976, CELL, V8, P365, DOI 10.1016/0092-8674(76)90148-3; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; HANDELIN BL, 1985, VIROLOGY, V140, P183, DOI 10.1016/0042-6822(85)90458-1; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KABAT D, 1989, VIROLOGY, V171, P467, DOI 10.1016/0042-6822(89)90616-8; KLEINERMAN ES, 1987, J IMMUNOL, V139, P2329; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; McGrath M S, 1980, Contemp Top Immunobiol, V11, P157; MITANI M, 1987, P NATL ACAD SCI USA, V84, P237, DOI 10.1073/pnas.84.1.237; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; SZUREK PF, 1988, J VIROL, V62, P357, DOI 10.1128/JVI.62.1.357-360.1988; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; WEISS R, 1984, RNA TUMOR VIRUSES, P209; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443	31	395	402	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					729	731		10.1038/352729a0	http://dx.doi.org/10.1038/352729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908564				2022-12-28	WOS:A1991GC06400063
J	BAICHWAL, VR; PARK, A; TJIAN, R				BAICHWAL, VR; PARK, A; TJIAN, R			V-SRC AND EJ RAS ALLEVIATE REPRESSION OF C-JUN BY A CELL-SPECIFIC INHIBITOR	NATURE			English	Article							PROTO-ONCOGENE; FIBROBLASTS; AP-1; GENE; TPA; TRANSCRIPTION	THE AP-1 family of transcription factors, which includes the proto-oncogene products c-Jun and c-Fos 1, controls the stimulation of cellular genes by growth factors and the expression of oncogenes, including src and ras 2-8. Transcriptional activation by c-Jun is regulated by a cell-type-specific inhibitor that represses the activity of a transcriptional activation domain (A1) of c-Jun by operating through the adjacent negative regulatory region (delta) (refs 9-11). Here we show that cotransfection of the src or ras oncogene enhances the transcriptional activity of a GAL4:c-Jun hybrid that includes the delta-A1 region of c-Jun, suggesting that the DNA binding and dimerization domain of c-Jun is not required for stimulation by Src or Ras. Moreover, induction of c-Jun activity by Src and Ras occurs in cell lines containing the c-Jun inhibitor but not in a cell line lacking it. The region in c-Jun essential for the stimulatory action of these oncogenes maps to domain A1. These findings suggest the existence of signal-transduction pathways that result in an increase in transcriptional activity of c-Jun and AP-1 by disrupting the c-Jun:inhibitor interaction.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	BAICHWAL, VR (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1989, CELL, V59, P909; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	17	84	88	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					165	168		10.1038/352165a0	http://dx.doi.org/10.1038/352165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1906140				2022-12-28	WOS:A1991FW09700060
J	BENATAR, SR				BENATAR, SR			MEDICINE AND HEALTH-CARE IN SOUTH-AFRICA - 5 YEARS LATER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OCCUPATIONAL-HEALTH; PERSONAL VIEW; AIDS EPIDEMIC; SERVICES; EXPENDITURE; APARTHEID; HOSPITALS; SELECTION; PATTERNS; STUDENTS		GROOTE SCHUUR HOSP, CAPE TOWN 7925, SOUTH AFRICA	University of Cape Town	BENATAR, SR (corresponding author), UNIV CAPE TOWN, DEPT MED, CAPE TOWN 7925, SOUTH AFRICA.							ANDERSSON N, 1988, SOC SCI MED, V27, P667, DOI 10.1016/0277-9536(87)90327-3; [Anonymous], 1987, AFRICAN PERSPECTIVES; Benatar S R, 1987, SA J Contin Med Educ, V5, P17; BENATAR SR, 1989, S AFR MED J, V76, P43; BENATAR SR, 1987, S AFR MED J, V72, P307; BENATAR SR, 1988, S AFR MED J, V73, P449; BENATAR SR, 1990, S AFR MED J, V77, P441; BENATAR SR, 1986, NEW ENGL J MED, V315, P527, DOI 10.1056/NEJM198608213150829; BENATAR SR, 1991, S AFR J SCI, V87, P4; BLOOM JB, 1986, BLACK S AFRICA DISIN; BOTHA JL, 1988, SOC SCI MED, V26, P845, DOI 10.1016/0277-9536(88)90177-3; BRINK AJ, 1988, S AFR MED J, V73, P203; BROOMBERG J, 1990, S AFR MED J, V78, P139; BROOMBERG J, 1990, S AFR MED J, V78, P130; BROOMBERG J, 1991, S AFR MED J, V79, P415; BROOMBERG J, IN PRESS FEB WORKSH; DEBEER C, 1990, S AFR MED J, V78, P144; DEBEER C, 1990, 21 U WITW CTR STUD H; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; GOOSEN G, 1989, 6 U CAP TOWN CTR AFR; ITYAVYAR DA, 1988, SOC SCI MED, V27, P1223, DOI 10.1016/0277-9536(88)90352-8; KANEBERMAN JDL, 1990, S AFR MED J, V78, P154; KEET MP, 1990, S AFR MED J, V78, P591; KIRSCH RE, 1988, ACTA JURIDICA, P1; KLOPPER JML, 1988, S AFR MED J, V74, P319; MCINTYRE DE, 1990, S AFR MED J, V78, P125; MITCHELL G, 1990, S AFR MED J, V78, P316; MITCHELL G, 1988, S AFR MED J, V73, P291; MOGOBA S, 1988, SANCTIONS ALTERNATIV; MYERS JE, 1989, AM J PUBLIC HEALTH, V79, P216, DOI 10.2105/AJPH.79.2.216; Navarro V., 1986, CRISIS HLTH MED SOCI; ORKIN M, 1989, SANCTIONS APARTHEID; RETIEF FP, 1987, NEW ENGL J MED, V316, P349; RISPEL LC, 1990, P S JOHANNESBURG; RUTKOVE SB, 1990, S AFR MED J, V77, P476; Sagan L. A., 1987, HLTH NATIONS TRUE CA; SAVAGE M, 1990, CRITICAL CHOICES S A, P147; SCHALL R, 1990, S AFR MED J, V78, P507; SCHOUB BD, 1990, S AFR MED J, V77, P613; SEEDAT YK, 1990, S AFR MED J, V78, P2; Steele Shelby, 1990, CONTENT OUR CHARACTE; STREBEL PM, 1990, S AFR MED J, V78, P408; SUMMERFIELD D, 1989, LANCET, V2, P551; TAYLOR SP, 1987, S AFR MED J, V72, P802; Trostle James, 1986, ANTHR EPIDEMIOLOGY I, P59; WILSON F, 1989, UPROOTING POVERTY S; YACH D, 1988, S AFR MED J, V73, P232; YACH D, 1988, SOC SCI MED, V27, P683, DOI 10.1016/0277-9536(87)90328-5; ZWARENSTEIN M, 1988, NATIONAL HLTH SERVIC; ZWARENSTEIN MF, 1990, S AFR MED J, V77, P448; ZWARENSTEIN MF, 1990, S AFR MED J, V77, P435; ZWI A, 1988, SOC SCI MED, V27, P691, DOI 10.1016/0277-9536(87)90329-7; ZWI A, 1988, SOC SCI MED, V27, P661, DOI 10.1016/0277-9536(87)90326-1; ZWI AB, 1987, SOC SCI MED, V25, P649, DOI 10.1016/0277-9536(87)90092-X; 1987, S AFR MED J, V71, P601; 1990, LANCET, V335, P1249; 1990, S AFR MED J, V77, pR7; 1990, S AFR MED J, V77, P225; 1989, HLTH TRENDS S AFRICA; 1988, S AFR MED J, V74, P252; 1990, LANCET, V335, P885; 1989, SUBSAHARAN AFRICA CR; 1990, AFRICA S SAHARA 1991	63	26	26	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					30	36		10.1056/NEJM199107043250106	http://dx.doi.org/10.1056/NEJM199107043250106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	1904552				2022-12-28	WOS:A1991FU34200006
J	MUSHLIN, AI; BLACK, ER; CONNOLLY, CA; BUONACCORSO, KM; EBERLY, SW				MUSHLIN, AI; BLACK, ER; CONNOLLY, CA; BUONACCORSO, KM; EBERLY, SW			THE NECESSARY LENGTH OF HOSPITAL STAY FOR CHRONIC PULMONARY-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Objective. - To determine the necessary length of stay for patients admitted to the hospital with an exacerbation of chronic pulmonary disease and to compare this with the length of stay assigned by the diagnosis related group system. Design. - A cohort of patients were followed up prospectively after hospital admission to determine when complications, critical incidents, and the need for monitoring occurred. The medically derived necessary lengths of stay were statistically compared with the lengths of stay assigned by the diagnosis related group. Clinical factors were used to predict long vs short necessary lengths of stay. Setting. - Two acute care hospitals: one was the principal and the other a major community teaching hospital. Patients. - A consecutive sample of 83 patients who were 45 years of age or older and who required admission for treatment of chronic pulmonary disease. Main Outcome Measures. - The occurrence and time of complications, critical interventions, and monitoring. Results. - After 6 days in the hospital, 90% of patients were free of complications or the need for monitoring. However, 16 days elapsed before 90% of patients had been discharged from the hospital. The length of stay that was considered necessary for care averaged 6.9 days; the actual mean length of stay was 8.7 days. The correlation between each patient's ideal length of stay and the length of stay assigned by the diagnosis related group was low and was not statistically significant. Three clinical variables at the time of admission (high PCO2 levels, symptoms that were present for more than 1 day, and antibiotic treatment) were associated with the need for longer hospital stays. Conclusions. - The medically required length of stay for patients with an exacerbation of chronic pulmonary disease was between 6 and 7 days, on average. This length of stay, which was based on clinical events, differs from the length of stay that was calculated as a statistical norm by the diagnosis related group system. Clinical characteristics may help to identify patients who require a longer length of stay.	UNIV ROCHESTER,SCH MED & DENT,DEPT COMMUNITY & PREVENT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOSTAT,ROCHESTER,NY 14642; STRONG MEM HOSP,OFF CLIN PRACTICE EVALUAT,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester	MUSHLIN, AI (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642, USA.				AHRQ HHS [HS 05386] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; FITZGERALD JF, 1987, JAMA-J AM MED ASSOC, V258, P218; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HORN SD, 1985, NEW ENGL J MED, V313, P20, DOI 10.1056/NEJM198507043130105; Mushlin A I, 1985, QRB Qual Rev Bull, V11, P378; Ryan B. F., 1985, MINITAB HDB; 1988, ROCHESTER AREA HOSPI; 1977, US DHEW NIH771248; 1983, SOCIAL SECURITY AMEN; 1980, US DHEW NIH812019	11	72	74	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					80	83						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	1904506				2022-12-28	WOS:A1991FT93400031
J	POWERS, S; GONZALES, E; CHRISTENSEN, T; CUBERT, J; BROEK, D				POWERS, S; GONZALES, E; CHRISTENSEN, T; CUBERT, J; BROEK, D			FUNCTIONAL CLONING OF BUD5, A CDC25-RELATED GENE FROM SACCHAROMYCES-CEREVISIAE THAT CAN SUPPRESS A DOMINANT-NEGATIVE RAS2 MUTANT	CELL			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; CDC25 GENE; CATALYTIC SUBUNITS; BUDDING YEAST; WILD-TYPE; ACTIVATION; SEQUENCE; DNA	By searching for genes that behave like CDC25 of S. cerevisiae in their ability to counteract a dominant-negative RAS2 mutant in a wild-type RAS-dependent manner, we have isolated a CDC25-like homolog, BUD5. BUD5 is tightly linked to the MAT locus. Although overexpressed BUD5 cannot substitute for CDC25 function, we present evidence that its gene product can bind to the guanine nucleotide binding-deficient RAS2val19ala22 gene product and thereby counteract its dominant-negative effect. We propose that BUD5 is a member of a family of CDC25-related genes that encode activators of RAS and RAS-like proteins.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California	POWERS, S (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Powers, Scott/0000-0003-2769-1932	NCI NIH HHS [CA50261] Funding Source: Medline; NIGMS NIH HHS [GM41258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BURNE HR, 1990, NATURE, V348, P125; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARTEGANI E, 1984, EUR J BIOCHEM, V144, P205, DOI 10.1111/j.1432-1033.1984.tb08450.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WEST M, 1990, FEBS LETT, V259, P2465; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0	29	93	95	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1225	1231		10.1016/0092-8674(91)90017-S	http://dx.doi.org/10.1016/0092-8674(91)90017-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905982				2022-12-28	WOS:A1991FU89900014
J	RUBINFELD, B; MUNEMITSU, S; CLARK, R; CONROY, L; WATT, K; CROSIER, WJ; MCCORMICK, F; POLAKIS, P				RUBINFELD, B; MUNEMITSU, S; CLARK, R; CONROY, L; WATT, K; CROSIER, WJ; MCCORMICK, F; POLAKIS, P			MOLECULAR-CLONING OF A GTPASE ACTIVATING PROTEIN-SPECIFIC FOR THE KREV-1 PROTEIN P21RAP1	CELL			English	Article							RAS-RELATED PROTEIN; BINDING-PROTEINS; HUMAN-PLATELETS; SUPPRESSOR ACTIVITY; KINASE SUBSTRATE; EFFECTOR DOMAIN; POINT MUTATIONS; RAS-P21 GTPASE; GENE-PRODUCT; BOVINE BRAIN	The rap1/Krev-1 gene encodes a ras-related protein that suppresses transformation by ras oncogenes. We have purified an 88 kd GTPase activating protein (GAP), specific for the rap1/Krev-1 gene product, from bovine brain. Based on partial amino acid sequences obtained from this protein, a 3.3 kb cDNA was isolated f rom a human brain library. Expression of the cDNA in insect Sf9 cells resulted in high level production of an 85-95 kd rap1GAP that specifically stimulated the GTPase activity of p2l(rap1). The complete deduced amino acid sequence is not homologous to any known protein sequences, including GAPs specific for p2l(ras). Northern and Western blotting analysis indicate that raplGAP is not ubiquitously expressed and appears most abundant in fetal tissues and certain tumor cell lines, particularly the Wilms' kidney tumor, SK-NEP-1, and the melanoma, SK-MEL-3, cell lines.			RUBINFELD, B (corresponding author), CETUS CORP,1400 53RD ST,EMERYVILLE,CA 94608, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775	NCI NIH HHS [CA51992-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1990, J BIOL CHEM, V265, P7104; HAUBRUCK H, 1991, J CELL BIOCH B S, V15, P138; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Maniatis T., 1982, MOL CLONING; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MIAORELLA B, 1988, BIOTECHNOLOGY, V6, P1506; MULCAHY LS, 1985, NATURE, V313, P2541; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SANDERS DA, 1990, CELL GROWTH DIFFER, V1, P251; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Summers MD, 1987, TEXAS AGR EXPT STATI; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	55	240	250	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1033	1042		10.1016/0092-8674(91)90555-D	http://dx.doi.org/10.1016/0092-8674(91)90555-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1904317				2022-12-28	WOS:A1991FR04700014
J	STOVER, CK; DELACRUZ, VF; FUERST, TR; BURLEIN, JE; BENSON, LA; BENNETT, LT; BANSAL, GP; YOUNG, JF; LEE, MH; HATFULL, GF; SNAPPER, SB; BARLETTA, RG; JACOBS, WR; BLOOM, BR				STOVER, CK; DELACRUZ, VF; FUERST, TR; BURLEIN, JE; BENSON, LA; BENNETT, LT; BANSAL, GP; YOUNG, JF; LEE, MH; HATFULL, GF; SNAPPER, SB; BARLETTA, RG; JACOBS, WR; BLOOM, BR			NEW USE OF BCG FOR RECOMBINANT VACCINES	NATURE			English	Article							ESCHERICHIA-COLI; STRESS PROTEINS; LYMPHOCYTES-T; INVIVO; MYCOBACTERIA; EXPRESSION; SEQUENCE; TUBERCULOSIS; CLONING; OPERON	BCG, a live attenuated tubercle bacillus, is the most widely used vaccine in the world and is also a useful vaccine vehicle for delivering protective antigens of multiple pathogens. Extrachromosomal and integrative expression vectors carrying the regulatory sequences for major BCG heat-shock proteins have been developed to allow expression of foreign antigens in BCG. These recombinant BCG strains can elicit long-lasting humoral and cellular immune responses to foreign antigens in mice.	UNIV PITTSBURGH, DIV BIOL SCI, PITTSBURGH, PA 15260 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	STOVER, CK (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.		Barletta, Raul G./V-9053-2019	Jacobs, William/0000-0003-3321-3080; Stover, Charles/0000-0002-7406-1696; Lee, Mong-Hong/0000-0001-8675-8215				[Anonymous], 1927, VACCINATION PREVENTI; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; AUSUBEL FM, 1987, CURR PROTOCOLS MOL B; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CERRONE MC, 1991, INFECT IMMUN, V59, P79, DOI 10.1128/IAI.59.1.79-90.1991; CONVIT, 1982, INT J LEPROSY, V50, P514; CONVIT J, 1987, LANCET, V1, P401; CURRY RC, 1987, J IMMUNOL METHODS, V104, P137, DOI 10.1016/0022-1759(87)90497-2; CURTISS R, 1989, IMMUNOL INVEST, V18, P583, DOI 10.3109/08820138909112265; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; HALPERN JL, 1990, INFECT IMMUN, V58, P1004, DOI 10.1128/IAI.58.4.1004-1009.1990; HART P D, 1974, Infection and Immunity, V10, P742; HENDERSON RH, 1989, ANN NY ACAD SCI, V569, P45; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; LAMB JR, 1982, J IMMUNOL, V129, P1465; LATHIGRA R, IN PRESS MOL MICROBI; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; LOTTE, 1988, B INT UNION TB LUNG, V63, P47; MILSTIEN JB, 1989, WHOEPIGEN893 DOC; MULLER I, 1987, INFECT IMMUN, V55, P2037; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; RAUZIER J, 1988, GENE, V71, P315, DOI 10.1016/0378-1119(88)90048-0; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHERLE PA, 1986, J EXP MED, V164, P1114, DOI 10.1084/jem.164.4.1114; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; STOVER CK, 1990, INFECT IMMUN, V58, P1360, DOI 10.1128/IAI.58.5.1360-1368.1990; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988; WALSH JA, 1986, STRATEGIES PRIMARY H, P1; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401; 1990, STATE WORLDS CHILDRE	37	1239	1456	4	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	1991	351	6326					456	460		10.1038/351456a0	http://dx.doi.org/10.1038/351456a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1904554	Bronze			2022-12-28	WOS:A1991FP75800046
J	KASLOW, DC; ISAACS, SN; QUAKYI, IA; GWADZ, RW; MOSS, B; KEISTER, DB				KASLOW, DC; ISAACS, SN; QUAKYI, IA; GWADZ, RW; MOSS, B; KEISTER, DB			INDUCTION OF PLASMODIUM-FALCIPARUM TRANSMISSION-BLOCKING ANTIBODIES BY RECOMBINANT VACCINIA VIRUS	SCIENCE			English	Article							SEXUAL STAGES; EXPRESSION; ANTIGENS; SURFACE	Many candidate antigens of malaria vaccines have limited immunological recognition. One exception is Pfs25, a cysteine-rich, 25-kilodalton sexual stage surface protein of Plasmodium falciparum. Pfs25 is a target of monoclonal antibodies that block transmission of malaria from vertebrate host to mosquito vector. The surface of mammalian cells infected with a recombinant vaccinia virus that expressed Pfs25 specifically bound transmission-blocking monoclonal antibodies. Furthermore, major histocompatibility complex-disparate congenic mouse strains immunized with recombinant Pfs25 elicited transmission-blocking antibodies, demonstrating that the capacity to develop transmission-blocking antibodies is not genetically restricted in mice. Live recombinant viruses may provide an inexpensive, easily administered alternative to subunit vaccines prepared from purified recombinant proteins to block transmission of malaria in developing countries.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KASLOW, DC (corresponding author), NIAID,PARASIT DIS LAB,BETHESDA,MD 20892, USA.		Isaacs, Stuart/HGA-3405-2022	Moss, Bernard/0000-0002-2154-8564				ANDREW ME, 1989, IMMUNOL CELL BIOL, V67, P331, DOI 10.1038/icb.1989.48; CARTER R, 1988, PROG ALLERGY, V41, P193; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; GOOD MF, 1988, SCIENCE, V242, P574, DOI 10.1126/science.2902690; ISAACS S, UNPUB; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KASLOW DC, UNPUB; LANGFORD CJ, 1986, MOL CELL BIOL, V6, P3191, DOI 10.1128/MCB.6.9.3191; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; PONNUDURAI T, 1987, T ROY SOC TROP MED H, V81, P491, DOI 10.1016/0035-9203(87)90172-6; QUAKYI I, UNPUB; QUAKYI IA, 1987, J IMMUNOL, V139, P4213; QUAKYI IA, 1980, TROP MED PARASITOL, V42, P325; SADOFF J, COMMUNICATION; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460	16	70	74	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1310	1313		10.1126/science.1925544	http://dx.doi.org/10.1126/science.1925544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925544				2022-12-28	WOS:A1991FN85700041
J	WILSON, TE; FAHRNER, TJ; JOHNSTON, M; MILBRANDT, J				WILSON, TE; FAHRNER, TJ; JOHNSTON, M; MILBRANDT, J			IDENTIFICATION OF THE DNA-BINDING SITE FOR NGFI-B BY GENETIC SELECTION IN YEAST	SCIENCE			English	Article							HORMONE RECEPTOR SUPERFAMILY; COUP TRANSCRIPTION FACTOR; SEQUENCE-ANALYSIS; ACTIVATOR PROTEIN; MAMMALIAN-CELLS; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; INDUCIBLE MEMBER; GAMMA-SUBUNIT; II GENE	An in vivo selection system for isolating targets of DNA binding proteins in yeast was developed and used to identify the DNA binding site for the NGFI-B protein, a member of the steroid-thyroid hormone receptor superfamily. The feasibility of the technique was verified by selecting DNA fragments that contained binding sites for GCN4, a well-characterized yeast transcriptional activator. The DNA binding domain of NGFI-B, expressed as part of a LexA-NGFI-B-GAL4 chimeric activator, was then used to isolate a rat genomic DNA fragment that contained an NGFI-B binding site. The NGFI-B response element (NBRE) is similar to but functionally distinct from elements recognized by the estrogen and thyroid hormone receptors and the hormone receptor-like proteins COUP-TF, CF1, and H-2RIIBP. Cotransfection experiments in mammalian cells demonstrated that NGFI-B can activate transcription from the NBRE with or without its putative ligand binding domain.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	MILBRANDT, J (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110, USA.		Johnston, Mark/R-6156-2019; Johnston, Mark/K-3543-2019	Johnston, Mark/0000-0002-4932-7229; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001018] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712] Funding Source: Medline; NINDS NIH HHS [NS01018] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; BALCKHART BD, 1986, J BIOL CHEM, V261, P15364; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHAPLIN DD, 1986, P NATL ACAD SCI USA, V83, P9601, DOI 10.1073/pnas.83.24.9601; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; CROWDER CM, 1988, MOL CELL BIOL, V8, P5257, DOI 10.1128/MCB.8.12.5257; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GLASS CK, 1988, CELL, V54, P321; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LORCH Y, 1985, J MOL BIOL, V186, P821, DOI 10.1016/0022-2836(85)90400-0; MILLBRANDT J, 1988, NEURON, V1, P183; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OSUMI T, 1987, J BIOL CHEM, V262, P8138; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; SASAKI H, 1985, GENE, V37, P191; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SHERMAN F, 1986, LABORATORY COURSE MA; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON T, UNPUB; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; [No title captured]	54	503	520	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1296	1300		10.1126/science.1925541	http://dx.doi.org/10.1126/science.1925541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925541				2022-12-28	WOS:A1991FN85700036
J	TODD, JS; SEEKINS, SV; KIRCHBAUM, JA; HARVEY, LK				TODD, JS; SEEKINS, SV; KIRCHBAUM, JA; HARVEY, LK			HEALTH ACCESS AMERICA - STRENGTHENING THE UNITED-STATES HEALTH-CARE SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Although Americans remain generally satisfied with the health care provided to them, sufficient access to high-quality, affordable health care for citizens without health care insurance has become an increasing problem in the last decade. Using the policy development process of the American Medical Association, Health Access America was conceived by the Association to improve access to affordable, high-quality health care. The proposal consists of six fundamental principles and 16 key points. This article specifically focuses on the five points that, if enacted into law, would improve access to health care for Americans who are, for various reasons, without health insurance.			TODD, JS (corresponding author), AMER MED ASSOC,515 N STATE ST,CHICAGO,IL 60610, USA.							BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; Donham C S, 1990, Health Care Financ Rev, V11, P169; NELSON C, 1990, CURRENT POPULATI P70, V17; TAYLOR H, 1989, OCT PHARM MAN ASS PU; 1990, MINIMUM BENEFITS PAC; 1978, REPORT NATIONAL COMM; 1987, HLTH POLICY AGENDA A; 1990, HLTH ACCESS AM AMA P; 1990, STATISTICAL ABSTRACT; 1988, HLTH INSURANCE RISK, P5	10	35	35	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2503	2506						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK903	1902268				2022-12-28	WOS:A1991FK90300021
J	EZEKOWITZ, RAB; WILLIAMS, DJ; KOZIEL, H; ARMSTRONG, MYK; WARNER, A; RICHARDS, FF; ROSE, RM				EZEKOWITZ, RAB; WILLIAMS, DJ; KOZIEL, H; ARMSTRONG, MYK; WARNER, A; RICHARDS, FF; ROSE, RM			UPTAKE OF PNEUMOCYSTIS-CARINII MEDIATED BY THE MACROPHAGE MANNOSE RECEPTOR	NATURE			English	Article							INVITRO; ZYMOSAN; PHAGOCYTOSIS	HUMAN exposure to Pneumocystis carinii is common 1,2 but, in the absence of acquired 3 or genetic 4 dysfunction of either cellular or humoral immunity, exposure rarely leads to illness. Although alveolar macrophages can degrade P. carinii 5,6, macrophage receptors involved in P. carinii recognition have not been clearly defined. Characterization of a predominant surface glycoprotein of the high mannose type 7,8 led us to investigate the role of the macrophage mannose receptor in this process. We report here that binding and uptake of cultured rat P. carinii by human and rat alveolar macrophages is reduced by 90% in the presence of competitive inhibitors of mannose receptor activity and by adherence of alveolar macrophages to mannan-coated surfaces. Further, only those COS cells transfected with the human macrophage mannose receptor complementary DNA that express surface mannose receptors bind and ingest P. carinii. These studies establish that the macrophage mannose receptor is sufficient for uptake of P. carinii and emphasize the role of the alveolar macrophage in first-line host defence against P. carinii.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MACARTHUR CTR MOLE PARASITOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT INTERNAL MED, PULM & CRIT CARE SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DIV PULM & CRIT CARE MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT RESP BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	EZEKOWITZ, RAB (corresponding author), CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA.							ARMSTRONG MYK, 1989, J PROTOZOOL, V36, pS24, DOI 10.1111/j.1550-7408.1989.tb05816.x; BERTON G, 1983, IMMUNOLOGY, V49, P705; EZEKOWITZ RAB, 1985, J CLIN INVEST, V76, P2368, DOI 10.1172/JCI112249; EZEKOWITZ RAB, 1988, J CELL SCI, P121; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; EZEKOWITZ RAB, 1989, NAT IMMUN, P15; HARMSEN AG, 1990, J EXP MED, V172, P937, DOI 10.1084/jem.172.3.937; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; MASUR H, 1978, J EXP MED, V147, P157, DOI 10.1084/jem.147.1.157; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MEUWISSEN JHET, 1977, J INFECT DIS, V136, P43, DOI 10.1093/infdis/136.1.43; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; NAKAMURA Y, 1989, J PROTOZOOL, V36, pS58, DOI 10.1111/j.1550-7408.1989.tb05832.x; PIFER LL, 1978, PEDIATRICS, V61, P35; POTTRATZ ST, 1990, J CLIN INVEST, V86, P1678, DOI 10.1172/JCI114891; POTTRATZ ST, 1990, J CLIN INVEST, V85, P351, DOI 10.1172/JCI114445; RADDING JA, 1989, INFECT IMMUN, V57, P2149, DOI 10.1128/IAI.57.7.2149-2157.1989; SHELLITO J, 1990, J CLIN INVEST, V85, P1686, DOI 10.1172/JCI114621; SUNG SSJ, 1983, J CELL BIOL, V96, P160, DOI 10.1083/jcb.96.1.160; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; VONBEHREN LA, 1978, AM REV RESPIR DIS, V118, P1051	21	374	379	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					155	158		10.1038/351155a0	http://dx.doi.org/10.1038/351155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903183				2022-12-28	WOS:A1991FL03500054
J	GRUMBACH, K; LEE, PR				GRUMBACH, K; LEE, PR			HOW MANY PHYSICIANS CAN WE AFFORD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; HEALTH-CARE; COST; DOCTORS; WILL	We project physician costs for the year 2000 under several alternative scenarios, using different assumptions about the future supply of physicians and gross income (or expenditures) per physician. The supply of active, posttraining patient-care physicians is projected to increase from a ratio of 144 per 100 000 population in 1986 to 176 per 100 000 in 2000. Depending on whether expenditures per physician increase at the rate of the consumer price index, the gross national product, or the historical 1982 through 1987 expenditure trends, there will be an additional cost (in constant 1986 dollars) of $21 billion, $30 billion, or $40 billion, respectively, compared with projected physician costs under a scenario of a constant physician-to-population ratio. The disproportionate growth of costs for practice overhead will pose a particular problem for efforts to restrain inflation of expenditures per physician.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Grumbach, Kevin/L-9222-2016					[Anonymous], 1987, Health Care Financ Rev, V8, P1; BARER ML, 1988, MILBANK Q, V66, P1, DOI 10.2307/3349985; CLARE L, 1987, HLTH AFF, V6, P90; DAVIES NE, 1990, JAMA-J AM MED ASSOC, V263, P73, DOI 10.1001/jama.263.1.73; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GINZBERG E, 1989, HEALTH AFFAIR, V8, P84, DOI 10.1377/hlthaff.8.2.84; GINZBERG E, 1984, COMING PHYSICIAN SUR; GONZALEZ AL, 1988, SOCIOECONOMIC CHARAC; HARRIS JE, 1986, HLTH AFF, V5, P31; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; IGLEHART JK, 1985, JAMA-J AM MED ASSOC, V254, P1785, DOI 10.1001/jama.254.13.1785; KIRKMANLIFF BL, 1990, J HEALTH POLIT POLIC, V15, P69, DOI 10.1215/03616878-15-1-69; KLETKE PR, 1990, AM J PUBLIC HEALTH, V80, P300, DOI 10.2105/AJPH.80.3.300; LUFT HS, 1986, HLTH AFF, V5, P32; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; Owens A, 1990, Med Econ, V67, P90; RACHLIS M, 1990, MAY PEW HLTH POL PRO; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; RICE T, 1984, ADV HLTH EC HLTH SER, P5; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; SCHWARTZ WB, 1990, JAMA-J AM MED ASSOC, V263, P557; SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405; SLOAN FA, 1983, JAMA-J AM MED ASSOC, V249, P766, DOI 10.1001/jama.249.6.766; TARLOV AR, 1990, JAMA-J AM MED ASSOC, V263, P571; TARLOV AR, 1983, NEW ENGL J MED, V308, P1235, DOI 10.1056/NEJM198305193082028; WEINER JP, 1989, HEALTH AFFAIR, V8, P173, DOI 10.1377/hlthaff.8.4.173; 1981, DHHS HRA81651 DEP HL; [No title captured]; 1988, DHHS HRSPOD881 DEP H; 1989, PHYSICIAN PAYMENT RE; [No title captured]	32	56	56	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2369	2372						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ955	1901922				2022-12-28	WOS:A1991FJ95500032
J	HADORN, DC				HADORN, DC			SETTING HEALTH-CARE PRIORITIES IN OREGON - COST-EFFECTIVENESS MEETS THE RULE OF RESCUE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION	The Oregon Health Services Commission recently completed work on its principal charge: creation of a prioritized list of health care services, ranging from the most important to the least important. Oregon's draft priority list was criticized because it seemed to favor minor treatments over lifesaving ones. This reaction reflects a fundamental and irreconcilable conflict between cost-effectiveness analysis and the powerful human proclivity to rescue endangered life: the "Rule of Rescue." Oregon's final priority list was generated without reference to costs and is, therefore, more intuitively sensible than the initial list. However, the utility of the final list is limited by its lack of specificity with regard to conditions and treatments. An alternative approach for setting health care priorities would circumvent the Rule of Rescue by carefully defining necessary indications for treatment. Such an approach might be applied to Oregon's final list in order to achieve better specificity.	UNIV COLORADO,CTR HLTH ETH & POLICY,DENVER,CO 80202	University of Colorado System; University of Colorado Denver	HADORN, DC (corresponding author), RAND CORP,DEPT SOCIAL POLICY,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90406, USA.				AHRQ HHS [T32 HS 00007] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; BOISAUBIN EV, 1988, JAMA-J AM MED ASSOC, V259, P1375; BROOK RH, 1986, ISSUES SCI TECHNOL, V3, P68; CALLAHAN D, 1990, NEW ENGL J MED, V322, P1810, DOI 10.1056/NEJM199006213222511; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P782, DOI 10.1001/jama.265.6.782; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P786; GOEL V, 1989, CAN MED ASSOC J, V140, P389; HADORN D, 1991, SOC SCI MED, V52, P773; HADORN DC, 1991, APR DES FAIR REAS BA; HADORN DC, IN PRESS HASTINGS CT; Jonsen A R, 1986, Law Med Health Care, V14, P172; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MORELL V, 1990, SCIENCE, V249, P468, DOI 10.1126/science.2382125; Rawls J., 1971, THEORY JUSTICE; SCANLON W, 1975, J PHILOS, V19, P655; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; 1983, SECURING ACCESS HLTH, P1; 1990, HLTH TECHNOLOGY ASSE	20	376	377	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2218	2225		10.1001/jama.265.17.2218	http://dx.doi.org/10.1001/jama.265.17.2218			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	1901610				2022-12-28	WOS:A1991FH87700034
J	JOHNSON, HA				JOHNSON, HA			DIMINISHING RETURNS ON THE ROAD TO DIAGNOSTIC CERTAINTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMATION	In the quest for diagnostic certainty, one can be led into a false sense of accomplishment by the results of sensitive, specific, and well-executed diagnostic tests that provide little or no diagnostic information. This is a consequence of the fact that as one approaches diagnostic certainty the useful information returned by diagnostic tests and observations approaches zero. This can be demonstrated by calculating the quantity of useful information provided by a test in a given clinical environment as one approaches certainty of diagnosis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University								DALLMAN PR, 1981, J PEDIATR, V93, P376; HERLITZ J, 1984, CLIN CARDIOL, V7, P433, DOI 10.1002/clc.4960070803; JOHNSON HA, 1989, ANN CLIN LAB SCI, V19, P323; JOHNSON HA, 1987, Q REV BIOL, V62, P141, DOI 10.1086/415403; JOHNSON HA, 1970, SCIENCE, V168, P1545, DOI 10.1126/science.168.3939.1545; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; SILK AD, 1989, NEW ENGL J MED, V320, P1272; Szilard L, 1929, Z PHYS, V53, P840, DOI 10.1007/BF01341281; [No title captured]	9	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2229	2231		10.1001/jama.265.17.2229	http://dx.doi.org/10.1001/jama.265.17.2229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	1901611				2022-12-28	WOS:A1991FH87700036
J	FOOTE, A; ERFURT, JC				FOOTE, A; ERFURT, JC			THE BENEFIT TO COST RATIO OF WORK-SITE BLOOD-PRESSURE CONTROL PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE COSTS; HYPERTENSION; PROMOTION; TRIAL	Reduction in the cost of health care claims among hypertensive employees was examined over a 4-year period after exposure to a 3-year blood pressure control program, to see whether work-site monitoring and counseling produced a subsequent benefit. Hypertensive employees at three experimental sites (N = 183 to 367 subjects) were compared with subjects at a control site (N = 169) who had received no postscreening follow-up or monitoring, and with matched normotensive employees. The cost of subsequent health care claims for hypertensive employees at the experimental sites was lower than claims for those at the control site, but there was no significant difference across the sites in claims for normotensive employees. After adjusting to a standard 1982 dollar, the data showed from $1.89 to $2.72 in reduced health care claims per dollar spent operating the hypertension control program.			FOOTE, A (corresponding author), UNIV MICHIGAN,INST LABOR & IND RELAT,WORKER HLTH PROGRAM,1111 E CATHERINE,ANN ARBOR,MI 48109, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028929] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL28929] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1979, PREV MED, V8, P123; ALDERMAN MH, 1976, B NEW YORK ACAD MED, V52, P697; ALDERMAN MH, 1983, HYPERTENSION S5, V5, P138; BLY JL, 1986, JAMA-J AM MED ASSOC, V256, P3235, DOI 10.1001/jama.256.23.3235; ERFURT JC, 1984, J OCCUP ENVIRON MED, V26, P892, DOI 10.1097/00043764-198412000-00007; ERFURT JC, 1990, J OCCUP ENVIRON MED, V32, P513, DOI 10.1097/00043764-199006000-00007; ERFURT JC, 1982, PB83113399; FIELDING JE, 1982, J OCCUP ENVIRON MED, V24, P907; FOOTE A, 1983, NEW ENGL J MED, V308, P809, DOI 10.1056/NEJM198304073081404; GIBBS JO, 1985, J OCCUP ENVIRON MED, V27, P826, DOI 10.1097/00043764-198511000-00016; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; LOGAN AG, 1979, LANCET, V2, P1175; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106; 1970, JAMA-J AM MED ASSOC, V212, P1143; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1982, NEW ENGL J MED, V307, P976; 1980, LANCET, V1, P1261; 1979, JAMA-J AM MED ASSOC, V242, P2562	18	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1283	1286		10.1001/jama.265.10.1283	http://dx.doi.org/10.1001/jama.265.10.1283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1899894				2022-12-28	WOS:A1991FA51100023
J	ESSEX, B; BATE, J				ESSEX, B; BATE, J			AUDIT IN GENERAL-PRACTICE BY A RECEPTIONIST - A FEASIBILITY STUDY	BRITISH MEDICAL JOURNAL			English	Article							QUALITY	Objective - To examine whether audit can be done cost effectively by a practice's receptionist. Design - The practice set goals for various aspects of care, and forms were devised for the receptionist to collect, analyse, and present data to assess whether these goals had been achieved in the previous year. Setting - Six doctor practice in south London looking after 11 500 patients. Main outcome measures - Ability of receptionist to present data showing the level of attainment of the practice's goals; time spent on audit by receptionist each week. Results - The practice set goals for immunisation; follow up of patients with abnormal cervical smears; frequency of recording of blood pressure and smoking habit; screening of patients over 75; care of diabetic patients and patients with serious mental illness; antenatal care; variations in workload; and availability of appointments. The receptionist was able to audit all these tasks in four hours a week; this increased her job satisfaction and extended her skills. A small amount of regular supervision was necessary - roughly 30 minutes a week in the first year of the study and 30 minutes a fortnight in the second - to ensure accuracy and deal with any difficulties that arose. Conclusion - The method developed enabled a receptionist to audit aspects of the practice cost effectively. There is great scope for enlarging the conventional role of the receptionist.			ESSEX, B (corresponding author), SYDENHAM GREEN HLTH CTR,LONDON SE26 4TG,ENGLAND.							BOSANQUET N, 1989, J ROY COLL GEN PRACT, V39, P88; BUCKLEY EG, 1989, J ROY COLL GEN PRACT, V39, P309; DIFFORD F, 1990, BRIT MED J, V300, P92, DOI 10.1136/bmj.300.6717.92; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; MARINKER M, 1990, BMJ; PENDLETON D, 1986, PURSUIT QUALITY; SHAW CD, 1989, BRIT MED J, V299, P498, DOI 10.1136/bmj.299.6697.498; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; WHALEN M, 1989, PRACTICE RECEPTIONIS; 1990, EURO REPORTS STUDIES, V94	10	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					573	576		10.1136/bmj.302.6776.573	http://dx.doi.org/10.1136/bmj.302.6776.573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	1902382	Bronze, Green Published			2022-12-28	WOS:A1991FB93600024
J	RUPPERSBERG, JP; FRANK, R; PONGS, O; STOCKER, M				RUPPERSBERG, JP; FRANK, R; PONGS, O; STOCKER, M			CLONED NEURONAL IK(A) CHANNELS REOPEN DURING RECOVERY FROM INACTIVATION	NATURE			English	Article							POTASSIUM CHANNELS; DIVERSITY	THE kinetic behaviour and functional role of potassium ion (K+) channels mediating a fast-inactivating K+ current (I(K)(A)) has been widely discussed 1. Activating in the subthreshold range of excitation, I(K)(A) channels are assumed to reduce the excitatory effect of depolarizing membrane currents in a time-dependent manner. Here we report that I(K)(A) channels not only open in response to a depolarization but open again after repolarization of the membrane. Although the current in response to the depolarization is rapidly inactivating, the current elicited by repolarization declines slowly and produces long-lasting after hyperpolarizations under current-clamp conditions. This implies an additional physiological role for I(K)(A) channels, particularly those that activate positive to the threshold of excitation. The underlying biophysical mechanism was studied by fast-application of peptides corresponding to the N-terminal end of the I(K)(A) channel proteins. It was found to be a voltage-dependent release of the inactivation gate.	ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY; RUHR UNIV BOCHUM,LEHRSTUHL BIOCHEM,W-4300 BOCHUM,GERMANY	Ruprecht Karls University Heidelberg; Ruhr University Bochum	RUPPERSBERG, JP (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.		Stocker, Martin/C-1844-2008					CASTRO B, 1977, J CHEM RES, V182, P2118; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1984, NEUROSCIENCE, V127, P267; LANCASTER B, 1986, J PHYSIOL-LONDON, V389, P187; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	14	133	135	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					657	660		10.1038/353657a0	http://dx.doi.org/10.1038/353657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922383				2022-12-28	WOS:A1991GK67200069
J	DAVIDSON, HW; REID, PA; LANZAVECCHIA, A; WATTS, C				DAVIDSON, HW; REID, PA; LANZAVECCHIA, A; WATTS, C			PROCESSED ANTIGEN BINDS TO NEWLY SYNTHESIZED MHC CLASS II MOLECULES IN ANTIGEN-SPECIFIC LYMPHOCYTES-B	CELL			English	Article							RESTRICTED T-CELLS; INVARIANT CHAIN; PRESENTING CELLS; HLA-DR; TRANSFERRIN RECEPTOR; PEPTIDE COMPLEXES; PROTEIN ANTIGENS; VIRAL PEPTIDES; BREFELDIN-A; ALPHA-CHAIN	We describe the direct detection of radiolabeled antigen fragments bound to class II MHC molecules following immunoglobulin-mediated endocytosis and processing of native antigen in B lymphoblastoid cells. Tris-Tricine SDS gels revealed six distinct iodinated processing products that could be detected on class II MHC 1 hr after antigen endocytosis and persisted for at least 20 hr. These physiological processed antigen-class II complexes were remarkably stable, as judged by the fact that class II-alpha-beta dimers, which remain associated in SDS, became labeled with the same set of processed peptides. Using a lectin-binding assay, we show that these physiological processing products bind to the newly maturing population of MHC molecules rather than binding to the preexisting cell surface population; in contrast, an exogenous peptide binds predominantly to the latter population. A direct T cell-independent assay for processed peptide-MHC complex formation should facilitate additional studies on the exogenous antigen processing pathway.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND		DAVIDSON, HW (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.			Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; Cresswell P, 1990, Semin Immunol, V2, P273; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DAVIS JE, 1990, J IMMUNOL, V144, P990; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEMOTZ S, 1989, J IMMUNOL, V142, P394; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARDING CV, 1989, J IMMUNOL, V142, P12; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEE JM, 1990, J IMMUNOL, V144, P1829; LEE P, 1988, J IMMUNOL, V140, P1063; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHY P, 1990, J IMMUNOL, V145, P1350; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, J IMMUNOL, V143, P1265; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P95; VANBLEEK GM, 1990, NATURE, V348, P213; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Watts C, 1990, Semin Immunol, V2, P247; WATTS C, 1989, COLD SH Q B, V54, P345; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WEBER DA, 1990, J MOL CELL IMMUNOL, V4, P255; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	75	180	180	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					105	116		10.1016/0092-8674(91)90575-J	http://dx.doi.org/10.1016/0092-8674(91)90575-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913812				2022-12-28	WOS:A1991GJ32000010
J	OLUBODUN, JOB; JAIYESIMI, AEA; FAKOYA, EA; OLASODE, OA				OLUBODUN, JOB; JAIYESIMI, AEA; FAKOYA, EA; OLASODE, OA			MALNUTRITION IN PRISONERS ADMITTED TO A MEDICAL WARD IN A DEVELOPING COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article									OGUN STATE UNIV,TEACHING HOSP,DEPT MED,PMB,SHAGAMU 2001,NIGERIA				Olasode, Olayinka/AAL-6831-2020					BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BURGESS RC, 1956, LANCET, V2, P411; OLUBODUN JOB, IN PRESS TROP GEOGR; SMITH R, 1984, BRIT MED J, V288, P995, DOI 10.1136/bmj.288.6422.995; WATERLOW JC, 1972, BRIT MED J, V3, P566, DOI 10.1136/bmj.3.5826.566	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					693	694		10.1136/bmj.303.6804.693	http://dx.doi.org/10.1136/bmj.303.6804.693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG980	1912916	Bronze, Green Published			2022-12-28	WOS:A1991GG98000022
J	DRUBIN, DG				DRUBIN, DG			DEVELOPMENT OF CELL POLARITY IN BUDDING YEAST	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; CDC24 GENE; MORPHOGENESIS; CDC42; MICROTUBULES; PROTEIN; CYCLE				DRUBIN, DG (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BABA M, 1989, J CELL SCI, V94, P207; Barnes G, 1990, CURR OPIN CELL BIOL, V2, P109, DOI 10.1016/S0955-0674(05)80040-7; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CHANT J, 1991, CELL, V65; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FORD SK, 1991, IN PRESS DEV GENET; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; HASEK J, 1987, J GEN MICROBIOL, V133, P3355; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; JACKSON CL, 1990, MOL CELL BIOL, V10, P2202, DOI 10.1128/MCB.10.5.2202; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIM HB, 1991, J CELL BIOL, V112, P535, DOI 10.1083/jcb.112.4.535; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KROPF DL, 1988, SCIENCE, V239, P187, DOI 10.1126/science.3336780; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; OHYA Y, 1991, IN PRESS J BIOL CHEM; Pringle J. R., 1986, YEAST CELL BIOL, P47; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHNEPF E, 1986, ANNU REV PLANT PHYS, V37, P23, DOI 10.1146/annurev.arplant.37.1.23; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SNYDER M, 1991, IN PRESS J CELL BIOL	28	224	225	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1093	1096		10.1016/0092-8674(91)90001-F	http://dx.doi.org/10.1016/0092-8674(91)90001-F			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905977				2022-12-28	WOS:A1991FU89900001
J	NAGAFUCHI, A; TAKEICHI, M; TSUKITA, S				NAGAFUCHI, A; TAKEICHI, M; TSUKITA, S			THE 102 KD CADHERIN-ASSOCIATED PROTEIN - SIMILARITY TO VINCULIN AND POSTTRANSCRIPTIONAL REGULATION OF EXPRESSION	CELL			English	Article							CELL-ADHESION MOLECULES; ADHERENS JUNCTIONS; MICROFILAMENT BUNDLES; FUNCTIONAL DOMAINS; CYTOPLASMIC DOMAIN; XENOPUS EMBRYOS; SORTING-OUT; GENE FAMILY; UVOMORULIN; CDNA	The E-cadherin cell adhesion molecule is associated with cytoplasmic polypeptides, and this association is essential for its cell-binding function. Using isolated adherens junctions of the liver, we purified a 102 kd protein that can associate with E-cadherin (CAP102) and isolated cDNAs encoding this protein. Sequence analysis of the cDNAs revealed that this protein has a similarity to vinculin. L cells not expressing endogenous cadherin express the mRNA for CAP102 but have only a trace amount of CAP102 protein. Introducing exogenous E-cadherin into these cells, however, induced a high expression of CAP102 protein without affecting the amount of its mRNA, suggesting that there is a posttranscriptional regulatory mechanism for this molecule. The same effect was observed by introducing N- or P-cadherin into L cells.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	NAGAFUCHI, A (corresponding author), NATL INST PHYSIOL SCI,DEPT INFORMAT PHYSIOL,OKAZAKI 444,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; Earle WR, 1943, J NATL CANCER I, V4, P165; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HOLTON JL, 1990, J CELL SCI, V97, P239; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; Maniatis T, 1989, DECONTAMINATION DILU; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; MOLONYMILAM L, 1985, J MOL BIOL, V184, P543; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OTTO JJ, 1990, CELL MOTIL CYTOSKEL, V16, P1, DOI 10.1002/cm.970160102; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, IN PRESS COLD SPRING; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; TSUKITA S, 1990, CELL STRUCT FUNCT, V15, P7, DOI 10.1247/csf.15.7; VESTWEBER D, 1984, CELL DIFFER DEV, V15, P269, DOI 10.1016/0045-6039(84)90084-8; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441; WELLER PA, 1990, P NATL ACAD SCI USA, V87, P5667, DOI 10.1073/pnas.87.15.5667; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085	53	504	521	2	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					849	857		10.1016/0092-8674(91)90392-C	http://dx.doi.org/10.1016/0092-8674(91)90392-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904011				2022-12-28	WOS:A1991FP51600015
J	SIEGEL, JM; NIENHUIS, R; FAHRINGER, HM; PAUL, R; SHIROMANI, P; DEMENT, WC; MIGNOT, E; CHIU, C				SIEGEL, JM; NIENHUIS, R; FAHRINGER, HM; PAUL, R; SHIROMANI, P; DEMENT, WC; MIGNOT, E; CHIU, C			NEURONAL-ACTIVITY IN NARCOLEPSY - IDENTIFICATION OF CATAPLEXY-RELATED CELLS IN THE MEDIAL MEDULLA	SCIENCE			English	Article							RETICULAR-FORMATION NEURONS; LOWER BRAIN-STEM; UNRESTRAINED CAT; REM-SLEEP; CHOLINE-ACETYLTRANSFERASE; BEHAVIORAL ORGANIZATION; PONTINE TEGMENTUM; MOVEMENTS; ATONIA; PROJECTIONS	Narcolepsy is a neurological disorder characterized by sleepiness and episodes of cataplexy. Cataplexy is an abrupt loss of muscle tone, most often triggered by sudden, strong emotions. A subset of cells in the medial medulla of the narcoleptic dog discharged at high rates only in cataplexy and rapid eye movement (REM) sleep. These cells were noncholinergic and were localized to ventromedial and caudal portions of the nucleus magnocellularis. The localization and discharge pattern of these cells indicate that cataplexy results from a triggering in waking of the neurons responsible for the suppression of muscle tone in REM sleep. However, most medullary cells were inactive during cataplexy but were active during REM sleep. These data demonstrate that cataplexy is a distinct behavioral state, differing from other sleep and waking states in its pattern of brainstem neuronal activity.	VET AFFAIRS MED CTR,DEPT PSYCHIAT,SAN DIEGO,CA; STANFORD UNIV,MED CTR,SCH MED,DEPT PSYCHIAT,STANFORD,CA 94305; UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SIEGEL, JM (corresponding author), VET AFFAIRS MED CTR,SEPULVEDA,CA 91343, USA.			Chiu, Charles/0000-0003-2915-2094	NHLBI NIH HHS [R01 HL041370, HL41370, R37 HL041370] Funding Source: Medline; NIMH NIH HHS [R01 MH064109] Funding Source: Medline; NINDS NIH HHS [P50 NS023724, NS23724, NS14610, R37 NS014610, R01 NS014610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL041370, R01HL041370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS023724, R01NS014610, R37NS014610, P50NS023724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH MS, 1989, SLEEP, V12, P254, DOI 10.1093/sleep/12.3.254; Baker TL, 1985, BRAIN MECH SLEEP, P199; BILLIARD M, 1985, ANN CLIN RES, V17, P220; CHASE MH, 1989, J NEUROSCI, V9, P743; CHASE MH, 1983, INT REV NEUROBIOL, V24, P213, DOI 10.1016/S0074-7742(08)60223-8; FORT P, 1990, CR ACAD SCI III-VIE, V311, P205; GUILLEMINAULT C, 1988, LANCET, V2, P511; GUILLEMINAULT C, 1976, NARCOLEPSY, P125; HENLEY K, 1974, ACTA NEUROBIOL EXP, V34, P215; Honda Y, 1984, FOLIA PSYCHIATR NEUR, V38, P360; JANKOWSKA E, 1968, ARCH ITAL BIOL, V106, P124; JOUVET M, 1965, CR SOC BIOL, V159, P895; KILDUFF TS, 1986, SLEEP, V9, P102, DOI 10.1093/sleep/9.1.102; LAI YY, 1988, J NEUROSCI, V8, P4790; LAI YY, 1989, SOC NEUR ABSTR, V17, P391; Lim R. K. S., 1960, STEREOTAXIC ATLAS DO; MCGINTY DJ, 1976, SCIENCE, V193, P240; MIGNOT E, 1989, BRAIN RES, V500, P1; MITLER MM, 1987, PSYCHIAT CLIN N AM, V10, P593; MITLER MM, 1974, EXP NEUROL, V45, P332, DOI 10.1016/0014-4886(74)90122-8; MORALES FR, 1982, SLEEP RES, V11, P26; MORI S, 1987, PROG NEUROBIOL, V28, P161, DOI 10.1016/0301-0082(87)90010-4; NETICK A, 1977, BRAIN RES, V120, P197, DOI 10.1016/0006-8993(77)90900-3; RECHTSCHAFFEN A, 1963, ELECTROEN CLIN NEURO, V15, P599, DOI 10.1016/0013-4694(63)90032-4; SAKAI K, 1990, BRAIN RES BULL, V24, P437, DOI 10.1016/0361-9230(90)90098-K; Sakai K., 1980, RETICULAR FORMATION, P427; SCHENKEL E, 1989, NEUROSCI LETT, V98, P159, DOI 10.1016/0304-3940(89)90503-X; SHIROMANI PJ, 1990, BRAIN RES, V517, P224, DOI 10.1016/0006-8993(90)91030-K; SHIROMANI PJ, 1988, SLEEP, V11, P1; Siegel J., UNPUB; SIEGEL JM, 1979, EXP NEUROL, V65, P691, DOI 10.1016/0014-4886(79)90055-4; SIEGEL JM, 1978, SCIENCE, V199, P207; SIEGEL JM, 1979, BRAIN RES REV, V1, P69, DOI 10.1016/0165-0173(79)90017-1; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P696, DOI 10.1152/jn.1983.50.3.696; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P717, DOI 10.1152/jn.1983.50.3.717; SIEGEL JM, 1979, BRAIN RES, V179, P49, DOI 10.1016/0006-8993(79)90488-8; SUZUKI SS, 1989, BRAIN RES, V484, P78, DOI 10.1016/0006-8993(89)90350-8; TOHYAMA M, 1979, BRAIN RES, V173, P383, DOI 10.1016/0006-8993(79)90237-3; VINCENT SR, 1987, BRAIN RES BULL, V18, P371, DOI 10.1016/0361-9230(87)90015-3	39	110	111	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1315	1318		10.1126/science.1925546	http://dx.doi.org/10.1126/science.1925546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925546	Green Accepted			2022-12-28	WOS:A1991FN85700043
J	MUSS, HB; CASE, LD; RICHARDS, F; WHITE, DR; COOPER, R; CRUZ, JM; POWELL, BL; SPURR, CL; CAPIZZI, RL				MUSS, HB; CASE, LD; RICHARDS, F; WHITE, DR; COOPER, R; CRUZ, JM; POWELL, BL; SPURR, CL; CAPIZZI, RL			INTERRUPTED VERSUS CONTINUOUS CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHWEST ONCOLOGY GROUP; SHORT-TERM; 5-FLUOROURACIL CAF; RANDOMIZED TRIAL; DRUG-THERAPY; ADRIAMYCIN; CYCLOPHOSPHAMIDE; METHOTREXATE; COMBINATION; QUALITY	Background. Chemotherapy for metastatic breast cancer is palliative, and the optimal duration of therapy is unknown. We designed a trial to determine whether continuous treatment is superior to stopping treatment after a brief induction period and resuming treatment when the disease progresses. Methods. We treated 250 women with metastatic breast cancer with six courses of cyclophosphamide, doxorubicin, and fluorouracil given every three weeks. At the completion of this induction period, women whose disease either regressed or remained stable were randomly assigned to receive either continued treatment with cyclophosphamide, methotrexate, and fluorouracil (maintenance therapy) or no further treatment (observation) followed by treatment with cyclophosphamide, methotrexate, and fluorouracil when disease progression became evident (reinduction). Results. The combined rate of complete and partial response after initial therapy was 30 percent (71 of 233 patients who could be evaluated; 95 percent confidence interval, 25 percent to 37 percent). In another 42 percent (98 patients), the disease remained stable. A total of 145 patients were randomized. Seventy-one were randomly assigned to the maintenance-therapy group, and 74 to the observation group. The median time to progression was 9.4 months for patients in the maintenance-therapy group and 3.2 months for patients in the observation group (P < 0.001). After reinduction therapy, the median time to progression was 3.5 months. The median length of survival from the time of initial therapy was 14.8 months for all 250 patients; it was 21.1 months for the 71 patients in the maintenance-therapy group and 19.6 months for the 74 patients in the observation group (P = 0.67). Maintenance therapy was the most important determinant of the time before progression (P < 0.001), but it was not associated with prolonged survival. The changes in performance status were similar in the patients in both groups, but nausea, vomiting, and mucositis were significantly more frequent in the maintenance-therapy group. Conclusions. In patients with breast cancer who received induction chemotherapy for 18 weeks, subsequent continuous chemotherapy was associated with a significant prolongation of the time before progression as compared with those receiving no further therapy; overall survival, however, was not significantly different in the two groups.			MUSS, HB (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.				NATIONAL CANCER INSTITUTE [U10CA045808, P30CA012197, U10CA037378] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45808, CA-12197, CA-37378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMANN FR, 1987, CANCER, V59, P239, DOI 10.1002/1097-0142(19870115)59:2<239::AID-CNCR2820590211>3.0.CO;2-C; AISNER J, 1987, J CLIN ONCOL, V5, P1523, DOI 10.1200/JCO.1987.5.10.1523; BENNETT JM, 1988, J CLIN ONCOL, V6, P1611, DOI 10.1200/JCO.1988.6.10.1611; BONADONNA G, 1986, NATL CANCER I MONOGR, V1, P45; BUCKNER JC, 1989, BREAST CANCER RES TR, V13, P135, DOI 10.1007/BF01806525; BULL JM, 1978, CANCER, V41, P1649, DOI 10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DONOVAN K, 1989, J CLIN ONCOL, V7, P959, DOI 10.1200/JCO.1989.7.7.959; FALKSON G, 1985, CANCER, V56, P219, DOI 10.1002/1097-0142(19850715)56:2<219::AID-CNCR2820560202>3.0.CO;2-Q; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; FREI E, 1985, CANCER RES, V45, P6523; GARBER JE, 1989, HEMATOL ONCOL CLIN N, V3, P807, DOI 10.1016/S0889-8588(18)30532-X; HARRIS AL, 1990, LANCET, V335, P186, DOI 10.1016/0140-6736(90)90277-C; HAYES DF, 1987, J CLIN ONCOL, V5, P1497, DOI 10.1200/JCO.1987.5.10.1497; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; HENDERSON IC, 1986, NATL CANCER I MONOGR, V1, P95; HORTOBAGYI GN, 1987, J CLIN ONCOL, V5, P354, DOI 10.1200/JCO.1987.5.3.354; KORN EL, 1986, STAT MED, V5, P255, DOI 10.1002/sim.4780050306; MOINPOUR CM, 1989, J NATL CANCER I, V81, P485, DOI 10.1093/jnci/81.7.485; MUSS HB, 1978, CANCER, V42, P2141, DOI 10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3; NEMOTO T, 1982, CANCER, V49, P1988, DOI 10.1002/1097-0142(19820515)49:10<1988::AID-CNCR2820491007>3.0.CO;2-L; PETRU E, 1986, WIEN KLIN WOCHENSCHR, V98, P790; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SMALLEY RV, 1983, BREAST CANCER RES TR, V3, P209, DOI 10.1007/BF01803563; TORMEY DC, 1985, BREAST CANCER RES TR, V5, P177, DOI 10.1007/BF01805992; TRANUM B, 1978, CANCER, V41, P2078, DOI 10.1002/1097-0142(197806)41:6<2078::AID-CNCR2820410602>3.0.CO;2-Q; TRANUM BL, 1982, CANCER, V49, P835, DOI 10.1002/1097-0142(19820301)49:5<835::AID-CNCR2820490502>3.0.CO;2-Z; VOGEL CL, 1984, J CLIN ONCOL, V2, P643, DOI 10.1200/JCO.1984.2.6.643; 1988, J CLIN ONCOL, V6, P976; 1988, J CLIN ONCOL, V6, P679	30	162	164	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1342	1348		10.1056/NEJM199111073251904	http://dx.doi.org/10.1056/NEJM199111073251904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922236	Bronze			2022-12-28	WOS:A1991GN47000004
J	LOPEZ, AJ; OKEEFE, P; MORRISSEY, M; PICKLEMAN, J				LOPEZ, AJ; OKEEFE, P; MORRISSEY, M; PICKLEMAN, J			CEFTRIAXONE-INDUCED CHOLELITHIASIS	ANNALS OF INTERNAL MEDICINE			English	Note							BILIARY PSEUDOLITHIASIS; CALCIUM-CEFTRIAXONE; SLUDGE; CHILDREN; THERAPY		LOYOLA UNIV, MED CTR, INFECT DIS SECT, 2160 S 1ST AVE, MAYWOOD, IL 60153 USA	Loyola University Chicago								HEIMDUTHOY KL, 1990, ANTIMICROB AGENTS CH, V34, P1146, DOI 10.1128/AAC.34.6.1146; LEE SP, 1990, PEDIATR INFECT DIS J, V9, P422, DOI 10.1097/00006454-199006000-00011; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; MEYBOOM RHB, 1988, BRIT MED J, V297, P858, DOI 10.1136/bmj.297.6652.858; PIGRAU C, 1989, LANCET, V2, P165; SCHAAD UB, 1986, PEDIATR INFECT DIS J, V5, P708, DOI 10.1097/00006454-198611000-00026; SCHAAD UB, 1990, NEW ENGL J MED, V322, P141, DOI 10.1056/NEJM199001183220301; SCHAAD UB, 1988, LANCET, V2, P1411; SHIFFMAN ML, 1990, GASTROENTEROLOGY, V99, P1772, DOI 10.1016/0016-5085(90)90486-K; XIA Y, 1990, GASTROENTEROLOGY, V99, P454, DOI 10.1016/0016-5085(90)91029-6	10	48	48	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					712	714		10.7326/0003-4819-115-9-712	http://dx.doi.org/10.7326/0003-4819-115-9-712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929040				2022-12-28	WOS:A1991GL69700009
J	FARESE, RV; BIGLIERI, EG; SHACKLETON, CHL; IRONY, I; GOMEZFONTES, R				FARESE, RV; BIGLIERI, EG; SHACKLETON, CHL; IRONY, I; GOMEZFONTES, R			LICORICE-INDUCED HYPERMINERALOCORTICOIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							11-BETA-HYDROXYSTEROID DEHYDROGENASE; MINERALOCORTICOID RECEPTOR; LIQUORICE		CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA; SAN FRANCISCO GEN HOSP,MED CTR,GEN CLIN RES CTR,SAN FRANCISCO,CA 94110	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; San Francisco General Hospital Medical Center					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK006415, R01DK034400] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00083] Funding Source: Medline; NIDDK NIH HHS [DK06415, DK34400] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMANINI D, 1983, CLIN ENDOCRINOL, V19, P609, DOI 10.1111/j.1365-2265.1983.tb00038.x; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BIGLIERI EG, 1966, J CLIN ENDOCR METAB, V26, P553, DOI 10.1210/jcem-26-5-553; BORST JGG, 1953, LANCET, V1, P657; CARD WI, 1953, LANCET, V1, P663; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; EPSTEIN MT, 1978, J CLIN ENDOCR METAB, V47, P397, DOI 10.1210/jcem-47-2-397; EPSTEIN MT, 1977, BRIT MED J, V1, P209, DOI 10.1136/bmj.1.6055.209; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; KATER CE, 1989, ENDOCR REV, V10, P149, DOI 10.1210/edrv-10-2-149; MONDER C, 1986, J CLIN ENDOCR METAB, V63, P550, DOI 10.1210/jcem-63-3-550; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; SHACKLETON C H L, 1990, P297; SHACKLETON CHL, 1990, ENDOCRINE HYPERTENSI, P155; STEWART PM, 1987, LANCET, V2, P821; STOCKIGT JR, 1971, CIRC RES          S2, V28, P175	17	200	202	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1223	1227		10.1056/NEJM199110243251706	http://dx.doi.org/10.1056/NEJM199110243251706			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922210				2022-12-28	WOS:A1991GL28200006
J	HASSOUN, PM; MARK, EJ; GUTTENTAG, AR; MARK, EJ; PINEDA, AE; SYSTROM, DM				HASSOUN, PM; MARK, EJ; GUTTENTAG, AR; MARK, EJ; PINEDA, AE; SYSTROM, DM			A 27-YEAR-OLD MAN WITH AIDS, A COUGH, FEVER, AND PULMONARY-INFILTRATES - ACUTE PULMONARY HISTOPLASMOSIS - (ACQUIRED-IMMUNODEFICIENCY-SYNDROME)	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							IMMUNE-DEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; NON-HODGKINS LYMPHOMA; NONTUBERCULOUS MYCOBACTERIAL INFECTION; BLOOD-INSTITUTE WORKSHOP; KAPOSIS SARCOMA; VIRUS-INFECTION; HOMOSEXUAL MEN; OPPORTUNISTIC INFECTIONS; BRONCHOALVEOLAR LAVAGE		TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts University	HASSOUN, PM (corresponding author), NEW ENGLAND MED CTR HOSP,BOSTON,MA 02111, USA.							ANKOBIAH WA, 1990, NEW YORK STATE J MED, V90, P234; [Anonymous], 1982, MMWR-MORBID MORTAL W; BACH MC, 1988, AM J MED, V85, P274, DOI 10.1016/0002-9343(88)90561-X; BIGBY TD, 1986, AM REV RESPIR DIS, V133, P515; BLOOM EJ, 1986, JAMA-J AM MED ASSOC, V256, P491; BONNER JR, 1984, ARCH INTERN MED, V144, P2178, DOI 10.1001/archinte.144.11.2178; BROADDUS C, 1985, ANN INTERN MED, V102, P747, DOI 10.7326/0003-4819-102-6-747; BRONNIMANN DA, 1987, ANN INTERN MED, V106, P372, DOI 10.7326/0003-4819-106-3-372; CATTERALL JR, 1986, AM REV RESPIR DIS, V133, P704; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; COHEN AJ, 1986, ANN INTERN MED, V104, P175, DOI 10.7326/0003-4819-104-2-175; COUVREUR J, 1975, REV FR MAL RESPIR, V3, P525; DENNING DW, 1991, NEW ENGL J MED, V324, P654, DOI 10.1056/NEJM199103073241003; ENGELBERG LA, 1984, AM REV RESPIR DIS, V130, P689; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; FLEMING AF, 1990, T ROY SOC TROP MED H, V84, P1, DOI 10.1016/0035-9203(90)90446-L; GILL PS, 1989, AM J MED, V87, P57, DOI 10.1016/S0002-9343(89)80483-8; GOLD JWM, 1988, CLIN CHEST MED, V9, P377; Grant I H, 1988, Infect Dis Clin North Am, V2, P457; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HEITZMAN ER, 1990, RADIOLOGY, V177, P347, DOI 10.1148/radiology.177.2.2217767; HERD AM, 1990, CAN MED ASSOC J, V143, P1329; HOPEWELL PC, 1988, J INFECT DIS, V157, P1115, DOI 10.1093/infdis/157.6.1115; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HUANG CT, 1987, ARCH INTERN MED, V147, P1181, DOI 10.1001/archinte.147.6.1181; JACOBSON MA, 1988, CLIN CHEST MED, V9, P443; JAGADHA V, 1985, AM J CLIN PATHOL, V84, P598, DOI 10.1093/ajcp/84.5.598; Johnson F B, 1987, Mil Med, V152, pM73; JOHNSON PC, 1988, AM J MED, V85, P152, DOI 10.1016/S0002-9343(88)80334-6; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KAUFFMAN CA, 1978, AM J MED, V64, P923, DOI 10.1016/0002-9343(78)90445-X; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; KRAMER MR, 1990, SOUTHERN MED J, V83, P1226, DOI 10.1097/00007611-199010000-00024; KURTIN PJ, 1990, AM J CLIN PATHOL, V93, P367, DOI 10.1093/ajcp/93.3.367; LEVINE AM, 1984, ANN INTERN MED, V100, P7, DOI 10.7326/0003-4819-100-1-7; MAAYAN S, 1987, AM J MED, V83, P945, DOI 10.1016/0002-9343(87)90656-5; MACHER AM, 1983, ANN INTERN MED, V99, P782, DOI 10.7326/0003-4819-99-6-782; MANDELL W, 1986, AM J MED, V81, P974, DOI 10.1016/0002-9343(86)90390-6; MARINELLI DL, 1986, RADIOLOGY, V160, P77, DOI 10.1148/radiology.160.1.3715048; MARTIN RA, 1989, J FAM PRACTICE, V29, P628; MASUR H, 1986, ANN INTERN MED, V104, P41, DOI 10.7326/0003-4819-104-1-41; MEDURI GU, 1986, AM J MED, V81, P11, DOI 10.1016/0002-9343(86)90175-0; MILLERCATCHPOLE R, 1989, MODERN PATHOL, V2, P277; Minamoto G, 1988, Infect Dis Clin North Am, V2, P447; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1582, DOI 10.1164/ajrccm/141.6.1582; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1356, DOI 10.1164/ajrccm/141.5_Pt_1.1356; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; NAIDICH DP, 1989, CHEST, V96, P723, DOI 10.1378/chest.96.4.723; NIEDT GW, 1985, ARCH PATHOL LAB MED, V109, P727; OGNIBENE FP, 1985, ANN INTERN MED, V102, P471, DOI 10.7326/0003-4819-102-4-471; PHILLIPS SC, 1981, NEW ENGL J MED, V305, P603, DOI 10.1056/NEJM198109103051102; PITCHENIK AE, 1988, CLIN CHEST MED, V9, P425; PITCHENIK AE, 1986, AM REV RESPIR DIS, V133, P226; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; POLISH LB, 1989, CHEST, V96, P1321, DOI 10.1378/chest.96.6.1321; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; PROSMANNE O, 1984, J CAN ASSOC RADIOL, V35, P186; REMALEY AT, 1990, CLIN CHEM, V36, P1992; REYNOLDS RJ, 1984, AM REV RESPIR DIS, V130, P317; SALZMAN SH, 1988, CHEST, V93, P916, DOI 10.1378/chest.93.5.916; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SHEPP DH, 1985, ANN INTERN MED, V103, P218, DOI 10.7326/0003-4819-103-2-218; SIVIT CJ, 1987, AM J ROENTGENOL, V148, P25, DOI 10.2214/ajr.148.1.25; SMITH E, 1989, SCAND J INFECT DIS, V21, P573, DOI 10.3109/00365548909037887; STERN RG, 1984, AM J ROENTGENOL, V142, P689, DOI 10.2214/ajr.142.4.689; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; SUSTER B, 1986, RADIOLOGY, V161, P87, DOI 10.1148/radiology.161.1.3489955; TOMITA T, 1988, HUM PATHOL, V19, P438, DOI 10.1016/S0046-8177(88)80494-5; TOURANI JM, 1985, LANCET, V1, P989; VIETZKE WM, 1968, CANCER-AM CANCER SOC, V21, P816, DOI 10.1002/1097-0142(196805)21:5<816::AID-CNCR2820210506>3.0.CO;2-#; WALLACE JM, 1987, CHEST, V92, P198, DOI 10.1378/chest.92.2.198; WASSER LS, 1989, CHEST, V96, P693, DOI 10.1378/chest.96.3.693; WHEAT LJ, 1984, ARCH INTERN MED, V144, P2147, DOI 10.1001/archinte.144.11.2147; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WHITE S, 1985, CHEST, V87, P486, DOI 10.1378/chest.87.4.486; WIGGINTON JM, 1989, MED HYPOTHESES, V30, P65, DOI 10.1016/0306-9877(89)90128-X; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; ZAMAN MK, 1988, AM REV RESPIR DIS, V137, P796, DOI 10.1164/ajrccm/137.4.796; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; 1991, NEW ENGL J MED, V325, P949; 1986, MMWR, V35, P757	86	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1228	1239						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922211				2022-12-28	WOS:A1991GL28200007
J	TELFER, JC; RUDD, CE				TELFER, JC; RUDD, CE			A 32-KD GTP-BINDING PROTEIN ASSOCIATED WITH THE CD4-P56LCK AND CD8-P56LCK T-CELL RECEPTOR COMPLEXES	SCIENCE			English	Article							TYROSINE KINASE P56LCK; HUMAN LYMPHOCYTES-T; PHOSPHOLIPASE-C; CROSS-LINKING; ACTIVATION; CD4; RAS; POLYPEPTIDES; PRODUCT	The guanosine triphosphate (GTP)-binding proteins include signal-transducing heterotrimeric G proteins (for example, G(s), G(i)), smaller GTP-binding proteins that function in protein sorting, and the oncogenic protein p21(ras). The T cell receptor complexes CD4-p56lck and CD8-p56lck were found to include a 32- to 33-kilodalton phosphoprotein (p32) that was recognized by an antiserum to a consensus GTP-binding region in G proteins. Immununoprecipitated CD4 and CD8 complexes bound GTP and hydrolyzed it to guanosine diphosphate (GDP). The p32 protein was covalently linked to [alpha-P-32]GTP by ultraviolet photoaffinity labeling. These results demonstrate an interaction between T cell receptor complexes and an intracellular GTP-binding protein.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 				ANDERSON P, 1987, J IMMUNOL, V139, P678; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DISANTO JP, 1987, LEUCOCYTE TYPING 3 W, P210; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HARNETT MM, 1988, IMMUNOL TODAY, V9, P315, DOI 10.1016/0167-5699(88)91325-4; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PESSAMORIKAWA T, 1990, J IMMUNOL, V144, P2690; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDD CE, 1985, J BIOL CHEM, V260, P1927; SCHMIDT RE, 1985, NATURE, V318, P289, DOI 10.1038/318289a0; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TELFER J, UNPUB; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VIELLETTE A, 1988, CELL, V55, P301; WANG P, 1989, J BIOCHEM-TOKYO, V105, P461, DOI 10.1093/oxfordjournals.jbchem.a122687; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	30	70	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1991	254	5030					439	441		10.1126/science.1925604	http://dx.doi.org/10.1126/science.1925604			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925604				2022-12-28	WOS:A1991GK72900052
J	FRANCO, B; GUIOLI, S; PRAGLIOLA, A; INCERTI, B; BARDONI, B; TONLORENZI, R; CARROZZO, R; MAESTRINI, E; PIERETTI, M; TAILLONMILLER, P; BROWN, CJ; WILLARD, HF; LAWRENCE, C; PERSICO, MG; CAMERINO, G; BALLABIO, A				FRANCO, B; GUIOLI, S; PRAGLIOLA, A; INCERTI, B; BARDONI, B; TONLORENZI, R; CARROZZO, R; MAESTRINI, E; PIERETTI, M; TAILLONMILLER, P; BROWN, CJ; WILLARD, HF; LAWRENCE, C; PERSICO, MG; CAMERINO, G; BALLABIO, A			A GENE DELETED IN KALLMANNS SYNDROME SHARES HOMOLOGY WITH NEURAL CELL-ADHESION AND AXONAL PATH-FINDING MOLECULES	NATURE			English	Article							AMINO-ACID-SEQUENCE; SYNDROME HYPOGONADOTROPIC HYPOGONADISM; HUMAN X-CHROMOSOME; DISTAL SHORT ARM; IMMUNOGLOBULIN SUPERFAMILY; STEROID SULFATASE; TYROSINE KINASE; MESSENGER-RNA; Y-CHROMOSOME; CDNA CLONE	Kallmann's syndrome (clinically characterized by hypogonadotropic hypogonadism and inability to smell) is caused by a defect in the migration of olfactory neurons, and neurons producing hypothalamic gonadotropin-releasing hormone. A gene has now been isolated from the critical region on Xp22.3 to which the syndrome locus has been assigned: this gene escapes X inactivation, has a homologue on the Y chromosome, and shows an unusual pattern of conservation across species. The predicted protein has significant similarities with proteins involved in neural cell adhesion and axonal pathfinding, as well as with protein kinases and phosphatases, which suggests that this gene could have a specific role in neuronal migration.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; INST G GASLINI,GENOA,ITALY; NAPLES UNIV,DEPT PEDIAT,I-80138 NAPLES,ITALY; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; WASHINGTON UNIV,SCH MED,CTR GENET MED,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305; IST BIOCHIM GENET EVOLUZION ST,PAVIA,ITALY	Baylor College of Medicine; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Naples Federico II; Baylor College of Medicine; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Washington University (WUSTL); Stanford University			Brown, Carolyn J/A-5159-2014; BALLABIO, Andrea/AAL-2672-2020; Maestrini, Elena/K-7508-2012; Bardoni, Barbara/F-9918-2013; Tonlorenzi, Rossana/AAN-2241-2020; FRANCO, Brunella/S-2882-2018	Brown, Carolyn J/0000-0002-8959-0101; BALLABIO, Andrea/0000-0003-1381-4604; Maestrini, Elena/0000-0001-5924-3179; Tonlorenzi, Rossana/0000-0002-6060-8208; Guioli, Silvana/0000-0002-4920-7745; FRANCO, Brunella/0000-0001-5588-4569; Bardoni, Barbara/0000-0001-6411-1517				BALLABIO A, 1989, ANN HUM GENET, V53, P9, DOI 10.1111/j.1469-1809.1989.tb01117.x; BALLABIO A, 1986, HUM GENET, V72, P237, DOI 10.1007/BF00291885; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; BARDONI B, 1988, Genomics, V3, P32, DOI 10.1016/0888-7543(88)90155-3; BASLER K, 1988, CELL, V54, P299; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRESLOW EA, 1979, REV BIOCH, V48, P251; BROWN CJ, 1991, NATURE, V349, P882; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEAR TN, 1988, CANCER RES, V48, P5203; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRENTH J, 1980, J BIOL CHEM, V255, P2652; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FISHER EH, 1991, SCIENCE, V253, P401; FRASER N, 1987, DEVELOPMENT, V101, P127; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; HERMANUSSEN M, 1985, CLIN GENET, V28, P106; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KATO I, 1979, FED PROC, V38, P832; KEITGES E, 1985, NATURE, V315, P226, DOI 10.1038/315226a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIPKIN VM, 1989, FEBS LETT, V254, P69, DOI 10.1016/0014-5793(89)81011-7; MEITINGER T, 1990, AM J HUM GENET, V47, P664; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; PIERETTI M, 1991, NUCLEIC ACIDS RES, V19, P2795, DOI 10.1093/nar/19.10.2795; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; ROSS MT, 1990, GENOMICS, V6, P528, DOI 10.1016/0888-7543(90)90482-A; Sambrook J, 1989, MOL CLONING LABORATO; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SHAPIRO LJ, 1979, SCIENCE, V204, P1224, DOI 10.1126/science.156396; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; SUNOHARA N, 1986, ANN NEUROL, V19, P174, DOI 10.1002/ana.410190211; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; WEGENKE JD, 1975, CLIN GENET, V7, P368; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	60	682	694	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					529	536		10.1038/353529a0	http://dx.doi.org/10.1038/353529a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922361				2022-12-28	WOS:A1991GJ64300057
J	CAMPBELL, DA; RADFORD, JMC; BURTON, P				CAMPBELL, DA; RADFORD, JMC; BURTON, P			UNEMPLOYMENT RATES - AN ALTERNATIVE TO THE JARMAN INDEX	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMALL AREA STATISTICS; DEPRIVATION; MORTALITY; HEALTH; INEQUALITIES; ENGLAND	Objective - To compare the Jarman index with alternative deprivation measures with regard to its usefulness to district health authorities as an indicator of need at small area level. Design - The Jarman index (UPA (8)), Townsend's index of material deprivation, the Scottish Development Department's index, the Department of the Environment's basic index, and unemployment rates were compared in respect of their correlation with measures of morbidity by electoral ward in a typical English district health authority. Measures of morbidity comprised standardised mortality ratios, admission rates (standardised and non-standardised), and permanent sickness rates. Spearman rank correlation coefficients were calculated for each combination of measures and were then ranked for each of the deprivation indices. Setting - The 59 electoral wards of the Central Nottinghamshire Health Authority. Results - The Jarman index consistently ranked lower in respect of its correlation with measures of morbidity than did the other deprivation measures. Current unemployment rates correlated well with morbidity measures, in particular with hospital admission rates, with correlations ranging from 0.669 to 0.830 for average and standardised all age admission rates. Conclusions - The Jarman index seems to be the least appropriate of these indices for health authority use. Unemployment rate merits further consideration as a simple, up to date marker for deprivation and consequent need for health service provision.	RANSOM HOSP, CENT NOTTINGHAMSHIRE HLTH AUTHOR, DEPT PUBL HLTH MED, MANSFIELD NG21 0ER, ENGLAND; UNIV LEICESTER, DEPT COMMUNITY HLTH, LEICESTER LE1 7RH, ENGLAND	University of Leicester			Burton, Paul R/H-7527-2016					Black D., 1980, INEQUALITIES HLTH; BLAND M, 1987, INTRO MED STATISTICS; BRENNER MH, 1979, LANCET, V2, P568; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; Carstairs V, 1981, Community Med, V3, P4, DOI 10.1007/BF02549432; CARSTAIRS V, 1989, BRIT MED J, V299, P1462, DOI 10.1136/bmj.299.6713.1462-a; CARSTAIRS V, 1989, COMMUNITY MED, V11, P364; CHARLTON J, 1985, BMJ-BRIT MED J, V290, P1715; CROMBIE IK, 1989, BRIT HEART J, V61, P172; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; DUGUID G, 1983, AREAS SPECIAL NEED S; HART N, 1986, J ROY STAT SOC A STA, V149, P228, DOI 10.2307/2981554; HUTCHINSON A, 1989, BRIT MED J, V299, P1142, DOI 10.1136/bmj.299.6708.1142; IRVING D, 1983, IDENTIFICATION UNDER; LEAVEY R, 1985, BRIT MED J, V291, P709, DOI 10.1136/bmj.291.6497.709; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; PISSARIDES C, 1990, 12 CTR EC PERF DISC; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; THUNHURST C, 1985, STATISTICIAN, V34, P93; TONSEND P, 1985, INT J HEALTH SERV, V15, P637, DOI 10.2190/AN09-8R52-UE6B-VWUU; Townsend PP., 1988, HLTH DEPRIVATION INE; WEST P, 1988, SOC SCI MED, V27, P291, DOI 10.1016/0277-9536(88)90262-6; Whitehead M., 1987, HLTH DIVIDE INEQUALI; YUEN P, 1989, BRIT MED J, V298, P1212, DOI 10.1136/bmj.298.6682.1212; 1991, EMPLOYMENT GAZETTE, V99, P175; 1990, POPULATION B NOTTING; 1991, EMPLOYMENT B NOTTING; 1983, 2 DEP ENV INF NOT; 1990, H A ANN PUBLIC HLTH; 1988, FINAL REPORT NHS MAN	32	69	71	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1991	303	6805					750	755		10.1136/bmj.303.6805.750	http://dx.doi.org/10.1136/bmj.303.6805.750			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932935	Green Published, Bronze			2022-12-28	WOS:A1991GG98100020
J	OSLER, K				OSLER, K			EMPLOYMENT EXPERIENCES OF VOCATIONALLY TRAINED DOCTORS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS	Objectives - To investigate the expectations and employment experiences of male and female doctors who completed vocational training in East Anglia during 1981-7 and to examine the factors which had influenced those who had changed direction early in their careers. Design - Survey conducted by confidential postal questionnaire. Setting - Britain. Subjects - 281 doctors, 233 (83%) of whom responded. Main outcome measures - Ideal choice of work on completion of vocational training; present employment; factors which had restricted present choice of work; factors associated with reported satisfaction with job. Results - 77/83 (93%) men and 130/150 (87%) women had hoped to work in general practice (p = 0.75). A smaller proportion of women (71%; 106) than men (89%; 74) were in general practice posts (p < 0.01); only 6% (nine) of women were on maternity leave or caring for children without paid employment. More women than men were working in medical jobs other than general practice (18% (27) women v 4% (three) men; p < 0.01). 44/91 (49%) women with children had achieved their employment goals compared with 47/59 (80%) women without children and 55/71 (78%) men with children. 87% (72/83) of men and 65% (98/150) of women had achieved the status of principal (p < 0.01). 162/193 (84%) doctors who had worked in general practice reported satisfaction with their jobs. Dissatisfaction was linked with doing a job different from that hoped for and with perceiving that the share of practice income did not accurately reflect their share of the practice workload. Conclusions - Steps need to be taken to retain women in general practice, including a statutory part time pay allowance and incentives for practices to allow flexible working hours for doctors with young children.			OSLER, K (corresponding author), GOLDINGS,GOLDINGS LANE,LEISTON IP16 4EB,SUFFOLK,ENGLAND.							Allen, 1988, DOCTORS THEIR CAREER; BROWN JM, 1983, BMJ, V286, P353; BUCHAN J, 1990, 199 I MANP STUD REP; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; HOOPER J, 1989, J ROY COLL GEN PRACT, V39, P400; NORTH MA, 1985, J ROY COLL GEN PRACT, V35, P29; WAKEFORD RE, 1989, J ROY COLL GEN PRACT, V39, P91; WARREN VJ, 1989, J ROY SOC MED, V82, P528, DOI 10.1177/014107688908200907; 1989, GENERAL PRACTICE NAT	9	12	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					762	764		10.1136/bmj.303.6805.762	http://dx.doi.org/10.1136/bmj.303.6805.762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932939	Bronze, Green Published			2022-12-28	WOS:A1991GG98100024
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			THE DUNDEE CORONARY RISK-DISK FOR MANAGEMENT OF CHANGE IN RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							SCOTTISH-HEART-HEALTH; DISEASE-PREVENTION-PROJECT; CHOLESTEROL; MORTALITY	Objective - To devise a simplified system for grading and monitoring modifiable coronary risk in primary care, to be used with an action plan. Methods - The risk equation came from 5203 men aged 40-59 in the United Kingdom heart disease prevention project, who had 331 coronary events over five years; the population rank (reading 1-100) was obtained by scoring 10359 participants in the Scottish heart health study. Calculation of rank was embodied in the Dundee coronary risk-disk; the formula was tested against the Whitehall study; disk and action plan were evaluated in primary care. Results - The system measures modifiable coronary risk from smoking, blood pressure, and blood cholesterol concentration by a sex and age related rank running from 1 (high risk, priority action) to 100 (low risk, general advice). The formula predicted outcome acceptably in the Whitehall study and is built into a circular slide rule. Only eight (11%) of 76 general practitioners and practice nurses surveyed already used risk factor scores. After evaluation most thought they should use one and proposed to incorporate the Dundee coronary risk-disk and the associated action plan into their routines. Conclusion - The Dundee coronary risk-disk readout of Dundee rank, standardised on a scale of 1 to 100 by age and sex, is a simple, valid means of assessing and monitoring modifiable coronary risk. It puts single risk factors (such as cholesterol concentration) in perspective and can aid selective testing. Understood by medical staff and patients, it should improve the efficiency and effectiveness of the high risk approach to coronary prevention.			TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							CHAMBLESS LE, 1990, STAT MED, V9, P385, DOI 10.1002/sim.4780090410; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; JARRETT RJ, 1982, BRIT MED J, V285, P535, DOI 10.1136/bmj.285.6341.535; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; ROSE G, 1983, LANCET, V1, P1062; Shaper A G, 1987, Health Trends, V19, P37; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; THORSEN RD, 1979, PREV MED, V8, P548, DOI 10.1016/0091-7435(79)90330-X; TUNSTALLPEDOE H, 1989, BMJ-BRIT MED J, V298, P1593, DOI 10.1136/bmj.298.6688.1593; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; 1989, BMJ, V298, P694; 1991, BMJ, V303, P748; 1988, J CLIN EPIDEMIOL, V41, P105; 1991, BMJ, V302, P1057; [No title captured]	17	117	119	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					744	747		10.1136/bmj.303.6805.744	http://dx.doi.org/10.1136/bmj.303.6805.744			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932933	Green Published, Bronze			2022-12-28	WOS:A1991GG98100018
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			THE HEALTH OF THE NATION - RESPONSES - CORONARY HEART-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article											TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CARDIOVASC EPIDEMIOL UNIT, DUNDEE DD1 9SY, SCOTLAND.							Gregory F., 1990, DIETARY NUTR SURVEY; ROSE G, 1983, EUR HEART J, V4, P141; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1990, HLTH UPDATE, V1; 1985, PROMOTING HLTH PREVE; 1990, WHO TECH REP SER, P797; 1989, 208 NAT AUD OFF HOUS; 1984, CORONARY HEART DISEA; 1989, WORLDWIDE MONITORING; 1990, WORLD HLTH STATISTIC; 1989, 26TH HOUS COMM COMM; 1988, ACTION UK 1984 1987; 1991, CM1523; 1991, DEP HLTH REPORT HLTH, V4	16	19	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					701	704		10.1136/bmj.303.6804.701	http://dx.doi.org/10.1136/bmj.303.6804.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912919	Green Published, Bronze			2022-12-28	WOS:A1991GG98000027
J	HALL, MH				HALL, MH			HEALTH OF PREGNANT-WOMEN	BRITISH MEDICAL JOURNAL			English	Article											HALL, MH (corresponding author), ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND.							BANTA D, 1989, EFFECTIVE CARE PREGN, P1449; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERAL V, 1979, BRIT MED J, V2, P632, DOI 10.1136/bmj.2.6191.632; BRYCE R, 1989, EFFECTIVE CARE PREGN, P1313; Carstairs V., 1991, DEPRIVATION HLTH SCO; Chalmers I, 1989, EFFECTIVE CARE PREGN; FORREST CG, 1982, BRIT MED J, V285, P1475; FRANCOME C, 1986, ABORTION PRACTICE BR; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; HOLLAND WW, 1988, EUROPEAN COMMUNITY A; KLINE J, 1990, EARLY PREGNANCY FAIL, P240; MACFARLANE A, 1984, BIRTH COUNTS STATIST; Oakley Ann, 1990, MISCARRIAGE; TEMMERMAN M, 1991, EUR J OBSTET GYN R B, V39, P13; Townsend P., 1988, INEQUALITIES HLTH BL; 1991, REPORT UK 1985 7	16	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					460	462		10.1136/bmj.303.6800.460	http://dx.doi.org/10.1136/bmj.303.6800.460			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912841	Green Published, Bronze			2022-12-28	WOS:A1991GC46500021
J	WARD, RHR; CAPON, DJ; JETT, CM; MURTHY, KK; MORDENTI, J; LUCAS, C; FRIE, SW; PRINCE, AM; GREEN, JD; EICHBERG, JW				WARD, RHR; CAPON, DJ; JETT, CM; MURTHY, KK; MORDENTI, J; LUCAS, C; FRIE, SW; PRINCE, AM; GREEN, JD; EICHBERG, JW			PREVENTION OF HIV-1 IIIB INFECTION IN CHIMPANZEES BY CD4 IMMUNOADHESIN	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; TYPE-1; IMMUNIZATION	THE first step in infection by the human immunodeficiency virus (HIV) is the specific binding of gp120, the envelope glycoprotein of HIV, to its cellular receptor, CD4 (see ref. 1 for review). To inhibit this interaction, soluble CD4 analogues that compete for gp120 binding and block HIV infection in vitro have been developed 2-8. To determine whether these analogues can protect an uninfected individual from challenge with HIV, we used the chimpanzee model system of cell-free HIV infection. Chimpanzees are readily infected with the IIIB strain of HIV-1, becoming viraemic within about 4-6 weeks of challenge, although they do not develop the profound CD4+ T-cell depletion and immunodeficiency characteristic of HIV infection in humans 9. CD4 immunoadhesin (CD4-IgG), a chimaeric molecule consisting of the N-terminal two immunoglobulin-like regions of CD4 joined to the Fc region of human IgG1 (refs 8, 10), was selected as the CD4 analogue for testing because it has a longer half-life than CD4, contributed by the IgG Fc portion of the molecule. In humans, this difference results in a 25-fold increased concentration of CD4-IgG in the blood compared with recombinant CD4 (ref. 11). Here we report that pretreatment with CD4-IgG can prevent the infection of chimpanzees with HIV-1. The need for a preventative agent is particularly acute in perinatal HIV transmission. As recombinant CD4-IgG, like the parent IgG molecule, efficiently crosses the primate placenta 10, it may be possible to set up an immune state in a fetus before HIV transfer occurs, thus preventing infection.	CELL GENESYS INC,FOSTER CITY,CA 94404; SW FDN BIOMED RES,SAN ANTONIO,TX 78284; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	Cell Genesys Inc; Texas Biomedical Research Institute; New York Blood Center	WARD, RHR (corresponding author), GENENTECH INC,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ANDERSON KP, 1989, J INFECT DIS, V160, P960, DOI 10.1093/infdis/160.6.960; BERGER EA, 1988, P NATL ACAD SCI USA, V85, P2357, DOI 10.1073/pnas.85.7.2357; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERNARD N, 1990, NEW ENGL J MED, V323, P916; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON D, 1991, REV IMMUNOL, V9, P649; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EICHBERG JW, 1990, ANIMAL MODELS AIDS, P47; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; MARRIN LN, 1990, 8TH A S NONH PRIM MO; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MORDENTI J, IN PRESS PHARM RES; SAIKI RK, 1985, SCIENCE, V230, P487; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; THOMAS RM, 1989, B LOND MATH SOC, V21, P463, DOI 10.1112/blms/21.5.463; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0	23	59	68	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					434	436		10.1038/352434a0	http://dx.doi.org/10.1038/352434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1907354	Bronze			2022-12-28	WOS:A1991FZ34600066
J	KARA, CJ; GLIMCHER, LH				KARA, CJ; GLIMCHER, LH			INVIVO FOOTPRINTING OF MHC CLASS-II GENES - BARE PROMOTERS IN THE BARE LYMPHOCYTE SYNDROME	SCIENCE			English	Article							DR-ALPHA GENE; B-CELL VARIANT; HLA-DR; NUCLEOTIDE-SEQUENCE; CHAIN GENE; EXPRESSION; BINDING; PROTEIN; ENHANCER; HYBRIDS	Major histocompatibility complex (MHC) class II genes are coordinately regulated and show tissue-specific expression. With the use of in vivo footprinting, common promoter sites in these genes were found to be occupied only in cells that expressed the genes, in spite of the presence of the promoter binding proteins. In vivo analysis of mutant cell lines that exhibited coordinate loss of class II MHC expression, including several from individuals with bare lymphocyte syndrome, revealed two in vivo phenotypes. One suggests a defect in gene activation, whereas the other suggests a defect in promoter accessibility.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI021163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036864] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21163] Funding Source: Medline; NIGMS NIH HHS [GM36864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACCOLLA RS, 1985, P NATL ACAD SCI USA, V82, P5145, DOI 10.1073/pnas.82.15.5145; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1989, J IMMUNOL, V142, P1005; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; FINN PW, 1990, EMBO J, V9, P1543, DOI 10.1002/j.1460-2075.1990.tb08273.x; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GLADSTONE P, 1980, SOMAT CELL GENET, V6, P285, DOI 10.1007/BF01538802; Griscelli C, 1989, Immunodefic Rev, V1, P135; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KARA C, UNPUB; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X	29	175	176	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					709	712		10.1126/science.1902592	http://dx.doi.org/10.1126/science.1902592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902592				2022-12-28	WOS:A1991FK18500050
J	HASHIZUME, K; ICHIKAWA, K; SAKURAI, A; SUZUKI, S; TAKEDA, T; KOBAYASHI, M; MIYAMOTO, T; ARAI, M; NAGASAWA, T				HASHIZUME, K; ICHIKAWA, K; SAKURAI, A; SUZUKI, S; TAKEDA, T; KOBAYASHI, M; MIYAMOTO, T; ARAI, M; NAGASAWA, T			ADMINISTRATION OF THYROXINE IN TREATED GRAVES-DISEASE - EFFECTS ON THE LEVEL OF ANTIBODIES TO THYROID-STIMULATING HORMONE RECEPTORS AND ON THE RISK OF RECURRENCE OF HYPERTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-MEDIATED-IMMUNITY; 3',5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE; HASHIMOTOS THYROIDITIS; THYROTROPIN RECEPTOR; ANTITHYROID DRUGS; HYPER-THYROIDISM; PLASMA-MEMBRANES; LYMPHOCYTES-T; INHIBITION; THERAPY	Background. Antibodies to thyroid-stimulating hormone (TSH) receptors that stimulate the thyroid gland cause hyperthyroidism in patients with Graves' disease, and their production during antithyroid drug treatment is an important determinant of the course of the disease. One factor that might contribute to the persistent production of antibodies to TSH receptors is stimulation of the release of thyroid antigens by TSH during antithyroid drug therapy. We therefore studied the effect of the suppression of TSH secretion by thyroxine on the levels of antibodies to TSH receptors after thyroid hormone secretion had been normalized by methimazole. Methods and Results. The levels of antibodies to TSH receptors were measured during treatment with methimazole, either alone or in combination with thyroxine, in 109 patients with hyperthyroidism due to Graves' disease. The patients first received 30 mg of methimazole daily for six months. All were euthyroid after six months, and their mean (+/- SD) level of antibodies to TSH receptors decreased from 64 +/- 9 percent to 25 +/- 15 percent (P < 0.01; normal, 2.9 +/- 1.4 percent). Sixty patients then received 100-mu-g of thyroxine and 10 mg of methimazole and 49 received placebo and 10 mg of methimazole daily for one year. In the thyroxine-treated group, the mean serum thyroxine concentration increased from 108 +/- 16 nmol per liter to 145 +/- 11 nmol per liter (P < 0.01), and the level of antibodies to TSH receptors decreased from 28 +/- 10 percent to 10 +/- 3 percent after one month of combination therapy. In the patients who received placebo and methimazole, the mean serum thyroxine concentration decreased and the level of antibodies to TSH receptors did not change. Methimazole, but not thyroxine or placebo, was discontinued in each group 1 1/2 years after the beginning of treatment. The level of antibodies to TSH receptors further decreased (from 6.6 +/- 3.2 percent at the time methimazole was discontinued to 2.1 +/- 1.2 percent one year later) in the patients who continued to receive thyroxine, but it increased (from 9.1 +/- 4.8 percent to 17.3 +/- 5.8 percent during the same period) in the patients who received placebo. One patient in the thyroxine-treated group (1.7 percent) and 17 patients in the placebo group (34.7 percent) had recurrences of hyperthyroidism within three years after the discontinuation of methimazole. Conclusions. The administration of thyroxine during antithyroid drug treatment decreases both the production of antibodies to TSH receptors and the frequency of recurrence of hyperthyroidism.	SHINSHU UNIV,SCH MED,DEPT ENDOCRINOL,MATSUMOTO,NAGANO 390,JAPAN; SHINSHU UNIV,SCH MED,DEPT METAB,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University; Shinshu University	HASHIZUME, K (corresponding author), SHINSHU UNIV,SCH MED,DEPT GERIATR,MATSUMOTO,NAGANO 390,JAPAN.							ADAMS DD, 1974, J CLIN ENDOCR METAB, V39, P826, DOI 10.1210/jcem-39-5-826; ADAMS DD, 1967, J CLIN ENDOCR METAB, V27, P173, DOI 10.1210/jcem-27-2-173; AIZAWA T, 1990, AM J MED, V89, P175, DOI 10.1016/0002-9343(90)90296-P; AMINO N, 1975, METABOLISM, V24, P45, DOI 10.1016/0026-0495(75)90006-2; AOKI N, 1979, CLIN EXP IMMUNOL, V38, P523; BALLARD PL, 1984, J CLIN INVEST, V74, P898, DOI 10.1172/JCI111507; FENZI G, 1979, J CLIN ENDOCR METAB, V48, P572, DOI 10.1210/jcem-48-4-572; HASHIZUME K, 1978, J CLIN ENDOCR METAB, V46, P679, DOI 10.1210/jcem-46-4-679; HASHIZUME K, 1985, ENDOCRINOL JAPON, V32, P481; HASHIZUME K, 1980, ENDOCRINOLOGY, V106, P1463, DOI 10.1210/endo-106-5-1463; HASHIZUME K, 1979, ENDOCRINOLOGY, V104, P1739, DOI 10.1210/endo-104-6-1739; HASHIZUME K, 1986, ENDOCRINOL JAPON, V33, P81; HASHIZUME K, 1985, ENDOCRINOL JAPON, V32, P569; HASHIZUME K, 1984, 7TH P INT C END QUEB, P804; HERSHMAN JM, 1966, J CLIN ENDOCR METAB, V26, P803, DOI 10.1210/jcem-26-8-803; IWATANI Y, 1987, J CLIN ENDOCR METAB, V65, P853, DOI 10.1210/jcem-65-5-853; IWATANI Y, 1989, BIOMED PHARMACOTHER, V43, P593, DOI 10.1016/0753-3322(89)90038-3; KUZUYA N, 1979, J CLIN ENDOCR METAB, V48, P706, DOI 10.1210/jcem-48-4-706; LAMKI L, 1973, J CLIN ENDOCR METAB, V36, P358, DOI 10.1210/jcem-36-2-358; MORI H, 1980, CLIN EXP IMMUNOL, V42, P33; MORI H, 1982, J CLIN ENDOCR METAB, V55, P399, DOI 10.1210/jcem-55-3-399; ONAYA T, 1973, J CLIN ENDOCR METAB, V36, P859, DOI 10.1210/jcem-36-5-859; REYNOLDS LR, 1979, ARCH INTERN MED, V139, P651, DOI 10.1001/archinte.139.6.651; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; SHEWRING G, 1982, CLIN ENDOCRINOL, V17, P409, DOI 10.1111/j.1365-2265.1982.tb01607.x; SHISHIBA Y, 1973, J CLIN ENDOCR METAB, V36, P517, DOI 10.1210/jcem-36-3-517; SLINGERLAND DW, 1979, JAMA-J AM MED ASSOC, V242, P2408, DOI 10.1001/jama.242.22.2408; SRIDAMA V, 1982, J CLIN ENDOCR METAB, V54, P316, DOI 10.1210/jcem-54-2-316; TAMAI H, 1980, ANN INTERN MED, V92, P488, DOI 10.7326/0003-4819-92-4-488; TOPLISS D, 1983, J CLIN ENDOCR METAB, V57, P700, DOI 10.1210/jcem-57-4-700; VOLPE R, 1986, CLIN ENDOCRINOL, V25, P453, DOI 10.1111/j.1365-2265.1986.tb01712.x; WARTOFSKY L, 1973, JAMA-J AM MED ASSOC, V226, P1083, DOI 10.1001/jama.226.9.1083; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WU B, 1973, Biology of the Neonate, V22, P161	35	206	213	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					947	953		10.1056/NEJM199104043241403	http://dx.doi.org/10.1056/NEJM199104043241403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	1900575				2022-12-28	WOS:A1991FE37600003
J	HE, JJ; QUIOCHO, FA				HE, JJ; QUIOCHO, FA			A NONCONSERVATIVE SERINE TO CYSTEINE MUTATION IN THE SULFATE-BINDING PROTEIN, A TRANSPORT RECEPTOR	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM	Serine 130 is one of seven residues that form a total of seven hydrogen bonds with the sulfate completely sequestered deep in the cleft between the two lobes of the bilobate sulfate-binding protein from Salmonella typhimurium. This residue has been replaced with Cys, Ala, and Gly by site-directed mutagenesis in an Escherichia coli expression system. Replacement with the isosteric Cys caused a 3200-fold decrease in the sulfate-binding activity relative to the wild-type activity, whereas replacement with Ala and Gly resulted in only 100- and 15-fold decreases, respectively. The effect of the Cys substitution is attributed largely to steric effect, whereas the Gly substitution more nearly reflects the loss of one hydrogen bond to the bound sulfate with a strength of only 1.6 kilocalories per mole.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR UNIV,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor University; Howard Hughes Medical Institute; Baylor University								AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; FREY MN, 1973, ACTA CRYSTALLOGR B, VB 29, P876, DOI 10.1107/S0567740873003481; FURLONG CE, 1987, CELLULAR MOL BIOL, P768; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; ISHIHARA H, 1980, J BIOL CHEM, V255, P4614; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; JACOBSON BL, IN PRESS J BIOL CHEM; KERR KA, 1975, ACTA CRYSTALLOGR B, V31, P2022, DOI 10.1107/S0567740875006772; KISTENMACHER TJ, 1974, ACTA CRYSTALLOGR B, V30, P2573, DOI 10.1107/S0567740874007618; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MCGRATH ME, 1989, BIOCHEMISTRY-US, V28, P9264, DOI 10.1021/bi00450a005; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; PARDEE AB, 1966, J BIOL CHEM, V241, P5886; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; POLGAR L, 1966, J AM CHEM SOC, V88, P153; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; SACK JS, UNPUB	19	176	183	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1479	1481		10.1126/science.1900953	http://dx.doi.org/10.1126/science.1900953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1900953				2022-12-28	WOS:A1991FC85300046
J	HAN, HQ; NICHOLS, RA; RUBIN, MR; BAHLER, M; GREENGARD, P				HAN, HQ; NICHOLS, RA; RUBIN, MR; BAHLER, M; GREENGARD, P			INDUCTION OF FORMATION OF PRESYNAPTIC TERMINALS IN NEUROBLASTOMA-CELLS BY SYNAPSIN-IIB	NATURE			English	Article							GLIOMA HYBRID-CELLS; PHOSPHOPROTEIN; PROTEIN-1	THE synapsins are a family of closely related phosphoproteins (termed synapsins Ia, Ib, IIa and IIb) associated with synaptic vesicles and implicated in the short-term regulation of neurotransmitter release from nerve endings 1-5. During development, expression of the synapsins correlates temporally with synapse formation 6, but there has been no direct evidence that they are involved in synaptogenesis. Here we report that overexpression of synapsin IIb in the neuroblastoma x glioma hybrid clonal cell line NG108-15 leads, during cell differentiation, to marked increases in the number of neuritic varicosities and in the numbers of small clear vesicles and large dense core vesicles per varicosity, as well as to the appearance of synapse-like cell-cell contacts. Thus, synapsin IIb may be involved in the regulation of synapse formation and, as a result, in long-term neuronal signalling.			HAN, HQ (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; CHANDLER CE, 1985, J CELL PHYSIOL, V125, P367, DOI 10.1002/jcp.1041250303; CZERNIK AJ, IN PRESS METH ENZYM; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; FURUYA S, 1983, TISSUE CELL, V15, P903, DOI 10.1016/0040-8166(83)90057-5; GRAY DB, 1990, J NEUROSCI, V10, P2687; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NESTLER EJ, 1982, SCIENCE, V217, P357, DOI 10.1126/science.6124039; NESTLER EJ, 1981, SCIENCE, V212, P1162, DOI 10.1126/science.6785886; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; ROMANO C, 1987, J NEUROSCI, V7, P1294; SAMBROOCK J, 1989, MOL CLONING LABORATO; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642	20	163	167	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					697	700		10.1038/349697a0	http://dx.doi.org/10.1038/349697a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1899916				2022-12-28	WOS:A1991EY62700048
J	MINOR, RL; SCOTT, BD; BROWN, DD; WINNIFORD, MD				MINOR, RL; SCOTT, BD; BROWN, DD; WINNIFORD, MD			COCAINE-INDUCED MYOCARDIAL-INFARCTION IN PATIENTS WITH NORMAL CORONARY-ARTERIES	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-DENSITY LIPOPROTEINS; RELAXING FACTOR; PULMONARY-EDEMA; NITRIC-OXIDE; ABUSE; SPASM; DISEASE; VASOCONSTRICTION; SMOKING; ATHEROSCLEROSIS	Objective: To review the reported cases of myocardial infarction temporally related to recreational and topical anesthetic use of cocaine, with special regard for underlying etiologic factors in patients subsequently found to have normal coronary arteries. Data Sources: Personal records of three cases and a comprehensive literature review using MEDLINE and supplemented by Index Medicus and the bibliographies of case reports. Data Synthesis: A total of 114 cases of cocaine-induced myocardial infarction were identified. The coronary anatomy was defined by angiography or autopsy in 92 patients, 38% of whom had normal coronary arteries. In these 35 patients (average age, 32; range, 21 to 60 years), myocardial infarction typically involved the anterior left ventricular wall (77%). Moderate cigarette smoking with one or fewer associated coronary risk factors was prevalent (68%). Focal coronary vasospasm was shown convincingly in only two cases. Intracoronary thrombus was initially found on 9 of 11 angiograms (82%) done within 12 hours of the myocardial infarction. Experimental evidence suggests that cocaine has direct and indirect sympathomimetic effects on vascular smooth muscle, attenuates endothelium vasodilator capacity, exerts a potent depressant effect on cardiac myocytes, and promotes atherogenesis. Conclusions: Cocaine-induced myocardial infarction in patients with normal coronary arteries probably involves adrenergically mediated increases in myocardial oxygen consumption, vasoconstriction of large epicardial arteries or small coronary resistance vessels, and coronary thrombosis. Accelerated atherosclerosis and impairment of endothelium vasodilator function may occur after chronic cocaine use.			MINOR, RL (corresponding author), UNIV IOWA HOSP & CLIN, DEPT MED, DIV CARDIOVASC, IOWA CITY, IA 52242 USA.			Brown, Donald/0000-0002-2740-2654	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008357, P50HL032295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-08357, HL-32295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCHER EK, 1988, AM J CARDIOL, V61, P939, DOI 10.1016/0002-9149(88)90384-0; BERTRAND ME, 1982, CIRCULATION, V65, P1299, DOI 10.1161/01.CIR.65.7.1299; BILLMAN GE, 1990, FASEB J, V4, P2469, DOI 10.1096/fasebj.4.8.2185973; BOAG F, 1985, POSTGRAD MED J, V61, P997, DOI 10.1136/pgmj.61.721.997; BROGAN W C, 1991, Journal of the American College of Cardiology, V17, p174A; CHIU YC, 1986, ARCH OTOLARYNGOL, V112, P988; CHOKSHI SK, 1989, ANN INTERN MED, V111, P1039, DOI 10.7326/0003-4819-111-12-1039; CHOKSHI SK, 1989, CIRCULATION S2, V80, P185; CHOKSHI SK, 1989, CIRCULATION S2, V80, P351; COLEMAN DL, 1982, WESTERN J MED, V136, P444; Cooke C T, 1988, Pathology, V20, P305; COOKE CT, 1988, PATHOLOGY, V20, P305; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; CUCCO RA, 1987, AM REV RESPIR DIS, V136, P179, DOI 10.1164/ajrccm/136.1.179; DAVIS JW, 1990, ADV EXP MED BIOL, V273, P107; DRESSLER FA, 1990, AM J CARDIOL, V65, P303, DOI 10.1016/0002-9149(90)90292-9; DREXLER H, 1989, CIRCULATION, V80, P466, DOI 10.1161/01.CIR.80.3.466; EICHHORN EJ, 1991, J AM COLL CARDIOL, V17, P43, DOI 10.1016/0735-1097(91)90702-B; FLORES ED, 1990, J AM COLL CARDIOL, V16, P74, DOI 10.1016/0735-1097(90)90459-3; FORSTERMANN U, 1988, CIRC RES, V62, P185, DOI 10.1161/01.RES.62.2.185; FRAKER TD, 1990, CIRCULATION, V81, P1012, DOI 10.1161/01.CIR.81.3.1012; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; GOULD L, 1985, NEW YORK STATE J MED, V85, P660; HADJIMILTIADES S, 1988, CATHETER CARDIO DIAG, V14, P33, DOI 10.1002/ccd.1810140107; HALE SL, 1989, AM HEART J, V118, P927, DOI 10.1016/0002-8703(89)90226-3; HALE SL, 1991, CIRCULATION, V83, P1437, DOI 10.1161/01.CIR.83.4.1437; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HAYES SN, 1991, AM HEART J, V121, P1639, DOI 10.1016/0002-8703(91)90007-5; HEISTAD DD, 1984, CIRC RES, V54, P711, DOI 10.1161/01.RES.54.6.711; HOFFMAN CK, 1989, RADIOLOGY, V172, P463, DOI 10.1148/radiology.172.2.2748827; HOLLIS TM, 1980, P SOC EXP BIOL MED, V165, P271; HOWARD RE, 1985, JAMA-J AM MED ASSOC, V254, P95, DOI 10.1001/jama.254.1.95; ISNER JM, 1990, J AM COLL CARDIOL, V15, P1104, DOI 10.1016/0735-1097(90)90249-O; ISNER JM, 1989, NEW ENGL J MED, V321, P1604, DOI 10.1056/NEJM198912073212309; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JOHNS ME, 1977, T AM ACAD OPHTHALMOL, V84, P969; KASKI JC, 1989, J AM COLL CARDIOL, V14, P1456, DOI 10.1016/0735-1097(89)90382-3; KLEIN LW, 1983, J AM COLL CARDIOL, V1, P421, DOI 10.1016/S0735-1097(83)80069-2; KOGAN MJ, 1977, ANAL CHEM, V49, P1965, DOI 10.1021/ac50021a020; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOLODGIE FD, 1991, J AM COLL CARDIOL, V17, P1553, DOI 10.1016/0735-1097(91)90646-Q; KOSSOWSKY WA, 1984, CHEST, V86, P729, DOI 10.1378/chest.86.5.729; KOSSOWSKY WA, 1989, CHEST, V96, P617, DOI 10.1378/chest.96.3.617; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAM D, 1988, AM HEART J, V115, P675, DOI 10.1016/0002-8703(88)90820-4; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; Littlewood S C, 1987, J La State Med Soc, V139, P15; LOPEZ JAG, 1989, CIRC RES, V65, P1078, DOI 10.1161/01.RES.65.4.1078; MAJID PA, 1990, AM J CARDIOL, V65, P812, DOI 10.1016/0002-9149(90)91396-N; MAOUAD J, 1984, AM J CARDIOL, V53, P354, DOI 10.1016/0002-9149(84)90464-8; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; MCPHERSON DD, 1987, NEW ENGL J MED, V316, P304, DOI 10.1056/NEJM198702053160604; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MITTLEMAN RE, 1987, J FORENSIC SCI, V32, P11; Moncada S, 1978, MECHANISMS VASODILAT, P107; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NADEMANEE K, 1989, ANN INTERN MED, V111, P876, DOI 10.7326/0003-4819-111-11-876; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PASTERNACK PF, 1985, AM J CARDIOL, V55, P847, DOI 10.1016/0002-9149(85)90172-9; PATEL R, 1988, CIRCULATION S2, V78, P436; PITTILO RM, 1990, ADV EXP MED BIOL, V273, P61; POLLIN W, 1985, JAMA-J AM MED ASSOC, V254, P98, DOI 10.1001/jama.254.1.98; QUILLEN J E, 1991, Journal of the American College of Cardiology, V17, p173A; RANDOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639; REZKALLA SH, 1990, AM HEART J, V120, P1403, DOI 10.1016/0002-8703(90)90255-V; RITCHIE JM, 1985, PHARMACOL BASIS THER, P309; ROD JL, 1987, AM J CARDIOL, V59, P161, DOI 10.1016/S0002-9149(87)80091-7; ROLLINGHER IM, 1986, CAN MED ASSOC J, V135, P45; RONGIONE A J, 1989, Journal of the American College of Cardiology, V13, p78A; RONGIONE AJ, 1988, CIRCULATION S2, V78, P436; RUBANYI GM, 1988, ENDOTHELIAL CELLS, P62; SCHACHNE JS, 1984, NEW ENGL J MED, V310, P1665; SCHNETZER GW, 1972, AM HEART J, V83, P552, DOI 10.1016/0002-8703(72)90048-8; SHEIKH KH, 1991, AM HEART J, V121, P1803, DOI 10.1016/0002-8703(91)90030-L; SIMPSON RW, 1986, ARCH PATHOL LAB MED, V110, P479; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; STENBERG RG, 1989, ARCH PATHOL LAB MED, V113, P521; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; TOBIS JM, 1991, CIRCULATION, V83, P913, DOI 10.1161/01.CIR.83.3.913; TOGNA G, 1985, HAEMOSTASIS, V15, P100; VALLADARES BK, 1987, HEART LUNG, V16, P456; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VARGAS R, 1988, CIRCULATION S2, V78, P222; VINCENT GM, 1983, NEW ENGL J MED, V309, P220, DOI 10.1056/NEJM198307283090406; VIRMANI R, 1988, AM HEART J, V115, P1068, DOI 10.1016/0002-8703(88)90078-6; VITA J A, 1990, Journal of the American College of Cardiology, V15, p158A; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; VITULLO JC, 1989, AM J PATHOL, V135, P85; WEBB RC, 1982, J PHARM PHARMACOL, V34, P134, DOI 10.1111/j.2042-7158.1982.tb04207.x; WEHBIE CS, 1987, SOUTHERN MED J, V80, P933, DOI 10.1097/00007611-198707000-00035; WEISS RJ, 1986, AM HEART J, V111, P793, DOI 10.1016/0002-8703(86)90120-1; WENGER NK, 1987, CARDIOVASC REV REP, V8, P52; WERNS SW, 1989, CIRCULATION, V79, P287, DOI 10.1161/01.CIR.79.2.287; WIENER RS, 1986, AM J MED, V81, P699, DOI 10.1016/0002-9343(86)90559-0; WILKINS CE, 1985, TEX HEART I J, V12, P385; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662; YOUNG D, 1947, AM HEART J, V34, P272, DOI 10.1016/0002-8703(47)90296-2; ZIMMERMAN FH, 1987, J AM COLL CARDIOL, V9, P964, DOI 10.1016/S0735-1097(87)80256-5	102	226	239	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					797	806		10.7326/0003-4819-115-10-797	http://dx.doi.org/10.7326/0003-4819-115-10-797			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929028				2022-12-28	WOS:A1991GP80000010
J	BARTSCH, P; MAGGIORINI, M; RITTER, M; NOTI, C; VOCK, P; OELZ, O				BARTSCH, P; MAGGIORINI, M; RITTER, M; NOTI, C; VOCK, P; OELZ, O			PREVENTION OF HIGH-ALTITUDE PULMONARY-EDEMA BY NIFEDIPINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MOUNTAIN-SICKNESS; PERMEABILITY; COAGULATION; RESPONSES; PRESSURE; HYPOXIA; ARTERY; LUNG	Background. Exaggerated pulmonary-artery pressure due to hypoxic vasoconstriction is considered an important pathogenetic factor in high-altitude pulmonary edema. We previously found that nifedipine lowered pulmonary-artery pressure and improved exercise performance, gas exchange, and the radiographic manifestations of disease in patients with high-altitude pulmonary edema. We therefore hypothesized that the prophylactic administration of nifedipine would prevent its recurrence. Methods. Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly (within 22 hours) from a low altitude to 4559 m and during the following three days at this altitude. Both the subjects and the investigators were blinded to the assigned treatment. The diagnosis of pulmonary edema was based on chest radiography. Pulmonary-artery pressure was measured by Doppler echocardiography and the difference between alveolar and arterial oxygen pressure was measured in simultaneously sampled arterial blood and end-expiratory air. Results. Seven of the 11 subjects who received placebo but only 1 of the 10 subjects who received nifedipine had pulmonary edema at 4559 m (P = 0.01). As compared with the subjects who received placebo, those who received nifedipine had a significantly lower mean (+/- SD) systolic pulmonary-artery pressure (41 +/- 8 vs. 53 +/- 16 mm Hg, P = 0.01), alveolar-arterial pressure gradient (6.6 +/- 3.8 vs. 11.8 +/- 4.4 mm Hg, P < 0.001), and symptom score of acute mountain sickness (2.0 +/- 0.7 vs. 3.9 +/- 1.9, P < 0.01) at 4559 m. Conclusions. The prophylactic administration of nifedipine is effective in lowering pulmonary-artery pressure and preventing high-altitude pulmonary edema in susceptible subjects. These findings support the concept that high pulmonary-artery pressure has an important role in the development of high-altitude pulmonary edema.	SWISS SCH SPORTS,RES INST,MAGGLINGER,SWITZERLAND; UNIV HOSP ZURICH,DEPT MED,CH-8091 ZURICH,SWITZERLAND; INSELSPITAL BERN,DEPT CARDIOL,CH-3010 BERN,SWITZERLAND; INSELSPITAL BERN,DEPT RADIOL,CH-3010 BERN,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern				Maggiorini, Marco/0000-0001-8180-2117				Antezana G, 1982, HIGH ALTITUDE PHYSL, P232; BARTSCH P, 1989, J APPL PHYSIOL, V67, P1336, DOI 10.1152/jappl.1989.67.4.1336; BARTSCH P, 1989, J APPL PHYSIOL, V66, P2136, DOI 10.1152/jappl.1989.66.5.2136; BARTSCH P, 1991, J APPL PHYSIOL, V71, P136; BARTSCH P, 1987, J APPL PHYSIOL, V63, P752, DOI 10.1152/jappl.1987.63.2.752; Bartsch P., 1990, HYPOXIA ADAPTATIONS, P241; FASULES JW, 1985, CIRCULATION, V72, P957, DOI 10.1161/01.CIR.72.5.957; HACKETT PH, 1986, JAMA-J AM MED ASSOC, V256, P36; HACKETT PH, 1980, NEW ENGL J MED, V302, P1070, DOI 10.1056/NEJM198005083021907; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1990, J WILDERNESS MED, V1, P3, DOI 10.1580/0953-9859-1.1.3; HACKETT PH, 1990, HYPOXIA ADAPTATIONS, P291; HATLE L, 1984, CARDIOLOGY INT PERSP, V2, P783; HOCHSTRASSER J, 1986, SCHWEIZ MED WSCHR, V116, P866; HOUSTON CS, 1960, NEW ENGL J MED, V263, P478, DOI 10.1056/NEJM196009082631003; HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759; HULTGREN HN, 1964, CIRCULATION, V29, P393, DOI 10.1161/01.CIR.29.3.393; HULTGREN HN, 1978, LUNG BIOL HLTH DISEA, V7, P437; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KAWASHIMA A, 1989, J APPL PHYSIOL, V67, P1982, DOI 10.1152/jappl.1989.67.5.1982; KOBAYASHI T, 1987, CHEST, V92, P814, DOI 10.1378/chest.92.5.814; KRONENBERG RS, 1971, J CLIN INVEST, V50, P827, DOI 10.1172/JCI106554; KUHLMANN J, 1986, TREATMENT CARDIOVASC, P120; KUHLMANN J, 1986, TREATMENT CARDIOVASC, P107; Lobenhoffer H., 1982, HIGH ALTITUDE PHYSL, P219; LUM H, 1989, J APPL PHYSIOL, V66, P1471, DOI 10.1152/jappl.1989.66.3.1471; MALO PE, 1986, PROSTAGLANDINS, V32, P221, DOI 10.1016/0090-6980(86)90127-9; OELZ O, 1989, LANCET, V2, P1241; OELZ O, 1991, LANCET, P556; PENALOZA D, 1969, AM J CARDIOL, V23, P369, DOI 10.1016/0002-9149(69)90517-7; RAMSCH KD, 1986, AM J NEPHROL, V6, P73, DOI 10.1159/000167224; REEVES JT, 1987, J APPL PHYSIOL, V63, P531, DOI 10.1152/jappl.1987.63.2.531; SCHOENE RB, 1985, CLIN CHEST MED, V6, P491; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; SIMONNEAU G, 1981, NEW ENGL J MED, V304, P1582, DOI 10.1056/NEJM198106253042606; SINGH I, 1965, LANCET, V1, P229; STAUB NC, 1980, NEW ENGL J MED, V302, P1085, DOI 10.1056/NEJM198005083021911; TOYOFUKU T, 1989, J CLIN INVEST, V83, P2063, DOI 10.1172/JCI114117; VOCK P, 1989, RADIOLOGY, V170, P661, DOI 10.1148/radiology.170.3.2916019; YAGI H, 1990, AM REV RESPIR DIS, V142, P796, DOI 10.1164/ajrccm/142.4.796; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657; 1981, LANCET, V1, P180	42	314	319	1	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1284	1289		10.1056/NEJM199110313251805	http://dx.doi.org/10.1056/NEJM199110313251805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922223				2022-12-28	WOS:A1991GM04100005
J	STERN, RS; WEISSMAN, JS; EPSTEIN, AM				STERN, RS; WEISSMAN, JS; EPSTEIN, AM			THE EMERGENCY DEPARTMENT AS A PATHWAY TO ADMISSION FOR POOR AND HIGH-COST PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALS; SYSTEMS; RATES; RISK	Background. - To determine the importance of the emergency department as the means of access to the hospital for the poor and the fiscal implications of providing these services, we examined the relationship between patients' socioeconomic status and admission via the emergency department. We also determined the association between entering the hospital via the emergency department and hospital resource use. Methods. - We conducted a study of 20 089 patients admitted to five Massachusetts hospitals (three community, two tertiary care) during a 6-month period. We determined the proportions of patients within various socioeconomic and disease groupings who entered through the emergency department. We compared length ot stay and charges for patients admitted through the emergency department with those for patients admitted through other routes. Results. - Overall, 51% of patients entered via the emergency department. Elderly patients (age > 65 years; odds ratio, 1.87) and patients with lower socioeconomic status as measured by income, occupation, and education (odds ratios, 2.38. 1.47, and 1.69, respectively) were more likely to enter the hospital via the emergency department than other patients. After adjustment for diagnosis related group, severity as measured by DRGSCALE, and socioeconomic status as measured by income. and excluding outliers, patients admitted via the emergency department stayed 27% longer and incurred 13% higher charges than other patients (P < .001). Conclusions. - Our data indicate that patients with lower socioeconomic status are more likely than other patients to use the emergency department as their means of access to the hospital and that patients admitted via the emergency department use far more resources than patients in the same diagnosis related group admitted by other means. Hospitals that make emergency department services more available may be more likely to hospitalize socioeconomically disadvantaged patients and may be at a substantial financial disadvantage under per-case reimbursement systems such as Medicare.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	STERN, RS (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT DERMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				AHRQ HHS [1 F32 HS00024] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDREN KG, 1987, SOC SCI MED, V25, P1121, DOI 10.1016/0277-9536(87)90353-4; BRESLOW NE, 1980, STATISTICAL METHODS, P1; CONKLIN JE, 1984, DRG REFINEMENT FEASI; CONKLIN JE, 1987, DRG REFINEMENT USING; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; HELLINGER FJ, 1985, INQUIRY-J HEALTH CAR, V22, P78; Melnick G A, 1989, Health Care Financ Rev, V10, P29; MUNOZ E, 1985, JAMA-J AM MED ASSOC, V254, P1763, DOI 10.1001/jama.254.13.1763; MUNOZ E, 1986, AM J PUBLIC HEALTH, V76, P696, DOI 10.2105/AJPH.76.6.696; MUNOZ E, 1989, J CARDIOVASC SURG, V30, P58; MUNOZ E, 1988, J THORAC CARDIOV SUR, V96, P376; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; SLOAN FA, 1988, AM J PUBLIC HEALTH, V78, P553, DOI 10.2105/AJPH.78.5.553; 1990, MEDICARES DISPROPORT; [No title captured]	15	94	94	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2238	2243		10.1001/jama.266.16.2238	http://dx.doi.org/10.1001/jama.266.16.2238			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920722				2022-12-28	WOS:A1991GK66100031
J	COLLEY, NJ; BAKER, EK; STAMNES, MA; ZUKER, CS				COLLEY, NJ; BAKER, EK; STAMNES, MA; ZUKER, CS			THE CYCLOPHILIN HOMOLOG NINAA IS REQUIRED IN THE SECRETORY PATHWAY	CELL			English	Article							CIS-TRANS-ISOMERASE; A-BINDING-PROTEIN; CRYSTALLOID ENDOPLASMIC-RETICULUM; CYCLOSPORIN-A; DROSOPHILA-MELANOGASTER; MESSENGER-RNA; NEUROSPORA-CRASSA; PERIPHERAL PHOTORECEPTORS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI	In Drosophila, the major rhodopsin Rh1 is synthesized in endoplasmic reticulum (ER)-bound ribosomes of the R1-R6 photoreceptor cells and is then transported to the rhabdomeres where it functions in phototransduction. Mutations in the cyclophilin homolog ninaA lead to a 90% reduction in Rh1 opsin. Cyclophilins have been shown to be peptidyl-prolyl cis-trans isomerases and have been implicated in catalyzing protein folding. We now show that mutations in the ninaA gene severely inhibit opsin transport from the ER, leading to dramatic accumulations of ER cisternae in the photoreceptor cells. These results demonstrate that ninaA functions in the ER. Interestingly, ninaA and Rh1 also colocalize to secretory vesicles, suggesting that Rh1 may require ninaA as it travels through the distal compartments of the secretory pathway. These results are discussed in relation to the possible role of cyclophilins in protein folding and intracellular protein trafficking.	UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,SAN DIEGO,CA 92103	University of California System; University of California San Diego; University of California System; University of California San Diego	COLLEY, NJ (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,SAN DIEGO,CA 92103, USA.			Stamnes, Mark/0000-0002-5869-7985	NEI NIH HHS [R01 EY008768] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON RGW, 1983, J CELL SCI, V63, P1; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BLEST AD, 1988, ADV INSECT PHYSIOL, V20, P1, DOI 10.1016/S0065-2806(08)60021-1; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BOREL JF, 1976, IMMUNOLOGY, V31, P631; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DECOUET HG, 1987, EUR J CELL BIOL, V44, P50; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRUGGE RJ, 1988, TRANSPL P, V20, P301; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEILER R, 1988, NATURE, V333, P737, DOI 10.1038/333737a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GRANELLIPIPERNO A, 1988, J EXP MED, V168, P1649, DOI 10.1084/jem.168.5.1649; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; HOHMAN R J, 1990, New Biologist, V2, P663; HUBER A, 1990, J BIOL CHEM, V265, P17906; HULTSCH T, 1990, J IMMUNOL, V144, P2659; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IWAI N, 1990, KIDNEY INT, V37, P1460, DOI 10.1038/ki.1990.136; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MINKE B, 1975, J COMP PHYSIOL, V98, P345, DOI 10.1007/BF00709805; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIGAL NH, 1990, BIOCHEM PHARMACOL, V40, P2201, DOI 10.1016/0006-2952(90)90712-T; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPIK G, 1991, J BIOL CHEM, V266, P10735; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STARK WS, 1988, J NEUROCYTOL, V17, P499, DOI 10.1007/BF01189805; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; STJULES RS, 1989, EXP EYE RES, V48, P653, DOI 10.1016/0014-4835(89)90007-9; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRENN G, 1989, J IMMUNOL, V142, P3796; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NUCLEIC ACIDS RES, V18, P190, DOI 10.1093/nar/18.1.190; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; ZUKER CS, 1988, CELL, V55, P475	79	303	305	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					255	263		10.1016/0092-8674(91)90177-Z	http://dx.doi.org/10.1016/0092-8674(91)90177-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913822				2022-12-28	WOS:A1991GL47000005
J	CARRELL, RW; EVANS, DL; STEIN, PE				CARRELL, RW; EVANS, DL; STEIN, PE			MOBILE REACTIVE CENTER OF SERPINS AND THE CONTROL OF THROMBOSIS	NATURE			English	Article							CRYSTAL-STRUCTURE; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL CHANGE; OVALBUMIN; ALPHA-1-ANTITRYPSIN; ABSENCE; MODEL	TWO protease inhibitors in human plasma play a key part in the control of thrombosis: antithrombin inhibits coagulation and the plasminogen activator inhibitor PAI-1 inhibits fibrinolysis, the dissolving of clots. Both inhibitors are members of the serpin family and both exist in the plasma in latent or inactive forms. We show here that the reactive centre of the serpins can adopt varying conformations and that mobility of the reactive centre is necessary for the function of antithrombin and its binding and activation by heparin; the identification of a new locked conformation explains the latent inactive state of PAI-1. This ability to vary conformation not only allows the modulation of inhibitory activity but also protects the circulating inhibitor against proteolytic attack. Together these findings explain the retention by the serpins of a large and unconstrained reactive centre as compared to the small fixed peptide loop of other families of serine protease inhibitors.			CARRELL, RW (corresponding author), UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUSTIN RC, 1991, FEBS LETT, V280, P254, DOI 10.1016/0014-5793(91)80305-M; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; CARRELL RW, 1986, NATURE, V322, P730; DEURAJKIZUK R, 1988, BLOOD, V72, P1518; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; KRESS LF, 1981, BIOCHEMISTRY-US, V20, P7432, DOI 10.1021/bi00529a017; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; PERRY DJ, 1991, FEBS LETT, V286, P2; POWELL LM, 1990, THESIS U NEWCASTLE U; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V14, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; VILLANUEVA GB, 1983, J BIOL CHEM, V258, P1010; WRIGHT HT, 1990, J MOL BIOL, V213, P518	21	292	299	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					576	578		10.1038/353576a0	http://dx.doi.org/10.1038/353576a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922367				2022-12-28	WOS:A1991GJ64300074
J	HARGREAVES, AD; LOGAN, RL; THOMSON, M; ELTON, RA; OLIVER, MF; RIEMERSMA, RA				HARGREAVES, AD; LOGAN, RL; THOMSON, M; ELTON, RA; OLIVER, MF; RIEMERSMA, RA			TOTAL CHOLESTEROL, LOW-DENSITY-LIPOPROTEIN CHOLESTEROL, AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND CORONARY HEART-DISEASE IN SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAJOR RISK FACTOR; MIDDLE-AGED MEN; SERUM-CHOLESTEROL; FRAMINGHAM	Objective - To investigate long term changes in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentrations and in measures of other risk factors for coronary heart disease and to assess their importance for the development of coronary heart disease in Scottish men. Design - Longitudinal study entailing follow up in 1988-9 of men investigated during a study in 1976. Setting - Edinburgh, Scotland. Subjects - 107 men from Edinburgh who had taken part in a comparative study of risk factors for heart disease with Swedish men in 1976 when aged 40. Intervention - The men were invited to attend a follow up clinic in 1988-9 for measurement of cholesterol concentrations and other risk factor measurements. Eighty three attended and 24 refused to or could not attend. Main outcome measures - Changes in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentrations, body weight, weight to height index, prevalence of smoking, and alcohol intake; number of coronary artery disease events. Results - Mean serum total cholesterol concentration increased over the 12 years mainly due to an increase in the low density lipoprotein cholesterol fraction (from 3.53 (SD 0.09) to 4.56 (0.11) mmol/l) despite a reduction in high density lipoprotein cholesterol concentration. Body weight and weight to height index increased. Fewer men smoked more than 15 cigarettes/day in 1988-9 than in 1976. Blood pressure remained stable and fasting triglyceride concentrations did not change. The frequency of corneal arcus doubled. Alcohol consumption decreased significantly. Eleven men developed clinical coronary heart disease. High low density lipoprotein and low high density lipoprotein cholesterol concentrations in 1976, but not total cholesterol concentration, significantly predicted coronary heart disease (p = 0.05). Almost all of the men who developed coronary heart disease were smokers (91% v 53%, p < 0.05). Conclusion - Over 12 years the lipid profile deteriorated significantly in this healthy cohort of young men. Smoking, a low high density lipoprotein concentration and a raised low density lipoprotein concentration were all associated with coronary heart disease in middle aged Scottish men, whereas there was no association for total cholesterol concentration. The findings have implications for screening programmes.	UNIV EDINBURGH, DEPT MED, EDINBURGH EH8 9XF, SCOTLAND; UNIV EDINBURGH, DEPT COMMUNITY MED, MED STAT UNIT, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	HARGREAVES, AD (corresponding author), UNIV EDINBURGH, DEPT CARDIOL, CARDIOVASC RES UNIT, EDINBURGH EH8 9XF, SCOTLAND.							CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLARK DA, 1967, AM J CLIN NUTR, V20, P743, DOI 10.1093/ajcn/20.7.743; CRIQUI MH, 1983, AM J EPIDEMIOL, V118, P52, DOI 10.1093/oxfordjournals.aje.a113616; ELFORD J, 1989, LANCET, V1, P343; GIDEZ LI, 1984, CLIN METABOLIC ASPEC, P415; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KEYS A, 1984, INT J EPIDEMIOL, V13, P428, DOI 10.1093/ije/13.4.428; KROMHOUT D, 1983, AM J CLIN NUTR, V38, P591, DOI 10.1093/ajcn/38.4.591; LOGAN RL, 1978, LANCET, V1, P949; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; OLIVER MF, 1975, EUR J CLIN INVEST, V5, P507, DOI 10.1111/j.1365-2362.1975.tb00483.x; POCOCK SJ, 1986, BMJ-BRIT MED J, V292, P515, DOI 10.1136/bmj.292.6519.515; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; THOMSON M, 1982, HUM NUTR-APPL NUTR, V36, P272; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; WOOD DA, 1987, LANCET, V1, P177; 1987, WORLD HLTH STAT Q, V40, P171	23	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1991	303	6804					678	681		10.1136/bmj.303.6804.678	http://dx.doi.org/10.1136/bmj.303.6804.678			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912914	Bronze, Green Published			2022-12-28	WOS:A1991GG98000019
J	BURKE, P; BAIN, J; ROBINSON, D; DUNLEAVEY, J				BURKE, P; BAIN, J; ROBINSON, D; DUNLEAVEY, J			ACUTE RED EAR IN CHILDREN - CONTROLLED TRIAL OF NON-ANTIBIOTIC TREATMENT IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							ACUTE OTITIS-MEDIA; CHILDHOOD OTALGIA; MYRINGOTOMY; AMOXYCILLIN; 3-DAY	Objective - To examine the efficacy and safety of conservative management of mild otitis media ("the acute red ear") in children. Design - Double blind placebo controlled trial. Setting - 17 group general practices (48 general practitioners) in Southampton, Bristol, and Portsmouth. Patients - 232 children aged 3-10 years with acute earache and at least one abnormal eardrum (114 allocated to receive antibiotic, 118 placebo). Interventions - Amoxycillin 125 mg three times a day for seven days or matching placebo; 100 ml paracetamol 120 mg/5 ml. Main outcome measures - Diary records of pain and crying, use of analgesic, eardrum signs, failure of treatment, tympanometry at one and three months, recurrence rate, and ear, nose, and throat referral rate over one year. Results - Treatment failure was eight times more likely in the placebo than the antibiotic group (14.4% v 1.7%, odds ratio 8.21, 95% confidence interval 1.94 to 34.7). Children in the placebo group showed a significantly higher incidence of fever on the day after entry (20% v 8%, p < 0.05), mean analgesic consumption (0.36 ml/h v 0.21 ml/h, difference 0.14, 95% confidence interval 0.07 to 0.23; p = 0.0022), mean duration of crying (1.44 days v 0.50 days, 0.94; 0.50 to 1.38; p < 0.001), and mean absence from school (1.96 days v 0.52 days, 1.45; 0.46 to 2.42; p = 0.0132). Differences in recorded pain were not significant. The prevalence of middle ear effusion at one or three months, as defined by tympanometry, was not significantly different, nor was there any difference in recurrence rate or in ear, nose, and throat referral rate in the follow up year. No characteristics could be identified which predicted an adverse outcome. Conclusions - Use of antibiotic improves short term outcome substantially and therefore continues to be an appropriate management policy.	UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6ST,ENGLAND	University of Southampton								ALTMAN DG, 1989, STATISTICS CONFIDENC; BAIN DJG, 1984, BRIT MED J, V288, P762, DOI 10.1136/bmj.288.6419.762; BAIN J, 1990, BMJ-BRIT MED J, V300, P1006, DOI 10.1136/bmj.300.6730.1006; BROWNING GG, 1990, BRIT MED J, V300, P1005, DOI 10.1136/bmj.300.6730.1005; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; DIAMANT M, 1974, ARCH OTOLARYNGOL, V100, P226; ENGELHARD D, 1989, LANCET, V2, P141; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; FRY J, 1958, BRIT MED J, V2, P883, DOI 10.1136/bmj.2.5101.883; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; JERGER J, 1970, ARCHIV OTOLARYNGOL, V92, P311; JONES R, 1986, J ROY COLL GEN PRACT, V36, P356; KALEIDA PH, 1991, PEDIATRICS, V87, P466; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; MILLS R, 1984, J ROY SOC MED, V77, P754, DOI 10.1177/014107688407700909; MILLS RP, 1984, BRIT MED J, V288, P1199, DOI 10.1136/bmj.288.6425.1199; MYGIND N, 1981, CLIN OTOLARYNGOL, V26, P5; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883; 1957, LANCET, V2, P510	22	130	129	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					558	562		10.1136/bmj.303.6802.558	http://dx.doi.org/10.1136/bmj.303.6802.558			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912887	Green Published, Bronze			2022-12-28	WOS:A1991GE94800025
J	BOVILL, EG; TERRIN, ML; STUMP, DC; BERKE, AD; FREDERICK, M; COLLEN, D; FEIT, F; GORE, JM; HILLIS, LD; LAMBREW, CT; LEIBOFF, R; MANN, KG; MARKIS, JE; PRATT, CM; SHARKEY, SW; SOPKO, G; TRACY, RP; CHESEBRO, JH				BOVILL, EG; TERRIN, ML; STUMP, DC; BERKE, AD; FREDERICK, M; COLLEN, D; FEIT, F; GORE, JM; HILLIS, LD; LAMBREW, CT; LEIBOFF, R; MANN, KG; MARKIS, JE; PRATT, CM; SHARKEY, SW; SOPKO, G; TRACY, RP; CHESEBRO, JH			HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							LEFT-VENTRICULAR FUNCTION; INTRAVENOUS STREPTOKINASE; REPERFUSION; SURVIVAL	Objectives: To assess the effects of invasive procedures, hemostatic and clinical variables, the timing of beta-blocker therapy, and the doses of recombinant plasminogen activator (rt-PA) on hemorrhagic events. Design: A multicenter, randomized, controlled trial. Setting: Hospitals participating in the Thrombolysis in Myocardial Infarction, Phase II trial (TIMI II). Interventions: Patients received rt-PA, heparin, and aspirin. The total dose of rt-PA was 150 mg for the first 520 patients and 100 mg for the remaining 2819 patients. Patients were randomly assigned to an invasive strategy (coronary arteriography with percutaneous angioplasty [if feasible] done routinely 18 to 48 hours after the start of thrombolytic therapy) or to a conservative strategy (coronary arteriography done for recurrent spontaneous or exercise-induced ischemia). Eligible patients were also randomly assigned to either immediate intravenous or deferred beta-blocker therapy. Measurements: Patients were monitored for hemorrhagic events during hospitalization. Main Results: In patients on the 100-mg rt-PA regimen, major and minor hemorrhagic events were more common among those assigned to the invasive than among those assigned to the conservative strategy (18.5% versus 12.8%, P < 0.001). Major or minor hemorrhagic events were associated with the extent of fibrinogen breakdown, peak rt-PA levels, thrombocytopenia, prolongation of the activated partial thromboplastin time (APTT) to more than 90 seconds, weight of 70 kg or less, female gender, and physical signs of cardiac decompensation. Immediate intravenous beta-blocker therapy had no important effect on hemorrhagic events when compared with delayed beta-blocker therapy. Intracranial hemorrhages were more frequent among patients treated with the 150-mg rt-PA dose than with the 100-mg rt-PA dose (2.1% versus 0.5%, P < 0.001). The extent of the plasmin-mediated hemostatic defect was also greater in patients receiving the 150-mg dose. Conclusions: Increased morbidity due to hemorrhagic complications is associated with an invasive management strategy in patients with acute myocardial infarction. Our findings show the complex interaction of several factors in the occurrence of hemorrhagic events during thrombolytic therapy.	UNIV VERMONT, BURLINGTON, VT 05405 USA; COLUMBIA UNIV, NEW YORK, NY 10027 USA; NYU, NEW YORK, NY 10003 USA; UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; MAINE MED CTR, PORTLAND, ME 04102 USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC 20052 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; NHLBI, BETHESDA, MD 20892 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	University of Vermont; Columbia University; New York University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Maine Medical Center; George Washington University; Harvard University; Harvard Medical School; Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic	BOVILL, EG (corresponding author), MARYLAND MED RES INST, TIMI COORDINATING CTR, 600 WYNDHURST AVE, BALTIMORE, MD 21210 USA.		Burkle, Frederick/AAE-5423-2020		NHLBI NIH HHS [HL38460, HL35058] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038460, P50HL035058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JL, 1988, J AM COLL CARDIOL, V11, P1153, DOI 10.1016/0735-1097(88)90276-8; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BOVILL E, 1987, BLOOD S, V760, pA1323; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; BRAUNWALD E, 1987, J AM COLL CARDIOL, V9, P467, DOI 10.1016/S0735-1097(87)80407-2; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CHAITMAN BR, 1989, J AM COLL CARDIOL, V14, P1159, DOI 10.1016/0735-1097(89)90410-5; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1986, CIRCULATION, V73, P511, DOI 10.1161/01.CIR.73.3.511; DIXON WJ, 1985, BMDP STATISTICAL SOF; Fleiss JL, 1981, STATISTICAL METHODS, P19; GARABEDIAN HD, 1986, AM J CARDIOL, V58, P673, DOI 10.1016/0002-9149(86)90336-X; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JAN KM, 1975, CIRCULATION, V51, P1079, DOI 10.1161/01.CIR.51.6.1079; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P122; KELTON J, 1991, PROGR HEMOSTASIS THR, V10, P1; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; MERSKEY C, 1969, P SOC EXP BIOL MED, V131, P871; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Snedecor G. W., 1967, STATISTICAL METHODS, P91; STUMP DC, 1988, THROMB HAEMOSTASIS, V59, P133; STUMP DC, 1989, CIRCULATION, V80, P1222, DOI 10.1161/01.CIR.80.5.1222; TRACY RP, 1988, BLOOD, V72, P1415; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILCOX RG, 1988, LANCET, V2, P525; 1990, LANCET, P65; 1985, SAS USERS GUIDE BASI	37	415	428	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					256	265		10.7326/0003-4819-115-4-256	http://dx.doi.org/10.7326/0003-4819-115-4-256			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1906692				2022-12-28	WOS:A1991GA76400003
J	LAI, KK; GANG, DL; ZAWACKI, JK; COOLEY, TP				LAI, KK; GANG, DL; ZAWACKI, JK; COOLEY, TP			FULMINANT HEPATIC-FAILURE ASSOCIATED WITH 2',3'-DIDEOXYINOSINE (DDI)	ANNALS OF INTERNAL MEDICINE			English	Note									BOSTON CITY HOSP, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston Medical Center; Boston University	LAI, KK (corresponding author), UNIV MASSACHUSETTS, SCH MED,MED CTR,DEPT MED,DIV INFECT DIS & IMMUNOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA.			Cooley, Timothy/0000-0002-3373-1569				CHAVESCARBALLO E, 1975, MAYO CLIN PROC, V50, P209; COOLEY TP, 1990, REV INFECT DIS, V12, pS552; GENEVE J, 1987, J PHARMACOL EXP THER, V242, P1133; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; PETERS RL, 1967, AM J SURG, V113, P622, DOI 10.1016/0002-9610(67)90308-X; POWELLJACKSON PR, 1984, GUT, V25, P673, DOI 10.1136/gut.25.6.673; SHERRATT HSA, 1986, TRENDS PHARMACOL SCI, V7, P186, DOI 10.1016/0165-6147(86)90310-X; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840	8	141	142	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					283	284		10.7326/0003-4819-115-4-283	http://dx.doi.org/10.7326/0003-4819-115-4-283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1906693				2022-12-28	WOS:A1991GA76400007
J	SEGEV, N				SEGEV, N			MEDIATION OF THE ATTACHMENT OR FUSION STEP IN VESICULAR TRANSPORT BY THE GTP-BINDING YPT1 PROTEIN	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; CHROMAFFIN GRANULES; SECRETORY VESICLES; GENE-PRODUCT; YEAST; MEMBRANE; RECONSTITUTION; COMPARTMENTS; INVITRO	The function of the guanosine triphosphate (GTP)-binding protein Ypt1 in regulating vesicular traffic was studied in a cell-free system that reconstitutes transport from the endoplasmic reticulum to the Golgi. Blocking the Ypt1 protein activity resulted in accumulation of vesicles that act as an intermediate passing between the two compartments. The Ypt1 protein was found on the outer side of these vesicles. The transport process is completed by fusion of these vesicles with the acceptor compartment, and Ypt1 protein activity was needed for this step. Thus, a specific GTP-binding protein is required for either attachment or fusion (or both) of secretory vesicles with the acceptor compartment during protein secretion.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637	University of Chicago	SEGEV, N (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637, USA.							BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; FISCHER, 1990, P NATL ACAD SCI USA, V87, P1988; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GALLWITZ D, 1983, NATURE, V306, P707; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JEDD G, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PADFIELD PJ, 1989, J CELL BIOL, V109, P299; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RUBINS J, 1989, J CELL BIOL, V109, P298; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, UNPUB; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WIDEY GM, 1989, J CELL BIOL, V109, P293; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	40	130	133	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 14	1991	252	5012					1553	1556		10.1126/science.1904626	http://dx.doi.org/10.1126/science.1904626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR040	1904626				2022-12-28	WOS:A1991FR04000049
J	HANNIGAN, GE; WILLIAMS, BRG				HANNIGAN, GE; WILLIAMS, BRG			SIGNAL TRANSDUCTION BY INTERFERON-ALPHA THROUGH ARACHIDONIC-ACID METABOLISM	SCIENCE			English	Article							INDUCED NUCLEAR FACTORS; SYNTHETASE GENE; PROMOTER ELEMENT; BINDING-PROTEIN; GROWTH-FACTOR; CELLS; ACTIVATION; EXPRESSION; ENHANCER; RAS	Molecular mechanisms that mediate signal transduction by growth inhibitory cytokines are poorly understood. Type I (alpha and beta) interferons (IFNs) are potent growth inhibitory cytokines whose biological activities depend on induced changes in gene expression. IFN-alpha induced the transient activation of phospholipase A2 in 3T3 fibroblasts and rapid hydrolysis of [H-3]arachidonic acid (AA) from prelabeled phospholipid pools. The phospholipase inhibitor, bromophenacyl bromide (BPB), specifically blocked IFN-induced binding of nuclear factors to a conserved, IFN-regulated enhancer element, the interferon-stimulated response element (ISRE). BPB also caused a dose-dependent inhibition of IFN-alpha-induced ISRE-dependent transcription in transient transfection assays. Specific inhibition of AA oxygenation by eicosatetraynoic acid prevented IFN-alpha induction of factor binding to the ISRE. Treatment of intact cells with inhibitors of fatty acid cyclooxygenase or lipoxygenase enzymes resulted in amplification of IFN-alpha-induced ISRE binding and gene expression. Thus, IFN-alpha-receptor-coupled AA hydrolysis may function in activation of latent transcription factors by IFN-alpha and provides a system for studying the role of AA metabolism in transduction of growth inhibitory signals.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Hannigan, Greg/A-5092-2009; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; CREAGAN ET, 1988, CANCER, V61, P1787, DOI 10.1002/1097-0142(19880501)61:9<1787::AID-CNCR2820610911>3.0.CO;2-Q; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FITZPATRICK FA, 1980, J IMMUNOL, V125, P431; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GARCIABLANCO MA, 1989, MOL CELL BIOL, V9, P1060, DOI 10.1128/MCB.9.3.1060; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HAMMARSTROM S, 1977, BIOCHIM BIOPHYS ACTA, V487, P517, DOI 10.1016/0005-2760(77)90221-1; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HANNIGAN GE, UNPUB; HONG SL, 1981, J BIOL CHEM, V256, P5215; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KIM B, 1989, SURGERY, V106, P248; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MILLS GB, 1985, 2 5A SYSTEM, P357; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4	34	156	157	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 11	1991	251	4990					204	207		10.1126/science.1898993	http://dx.doi.org/10.1126/science.1898993			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1898993				2022-12-28	WOS:A1991ET17300043
J	VEATCH, RM				VEATCH, RM			ROUTINE INQUIRY ABOUT ORGAN DONATION - AN ALTERNATIVE TO PRESUMED CONSENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											VEATCH, RM (corresponding author), KENNEDY INST ETH, WASHINGTON, DC 20057 USA.							CAPLAN AL, 1983, HASTINGS CENT REP, V13, P23, DOI 10.2307/3560741; DUKEMINI.J, 1968, NEW ENGL J MED, V279, P413, DOI 10.1056/NEJM196808222790807; Gerson William N, 1987, N Y Univ J Int Law Polit, V19, P1013; Matas A J, 1984, Theor Med, V5, P155, DOI 10.1007/BF00489488; MATAS AJ, 1986, POSITIVE APPROACHES, P37; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P1223, DOI 10.1001/jama.265.10.1223; SADLER AM, 1968, J AMER MED ASSOC, V206, P2501, DOI 10.1001/jama.1968.03150110049007; SPITAL A, 1991, NEW ENGL J MED, V325, P1243, DOI 10.1056/NEJM199110243251710; STARZL TE, 1984, JAMA-J AM MED ASSOC, V251, P1592; STUART FP, 1981, TRANSPLANTATION, V31, P238, DOI 10.1097/00007890-198104000-00002; VEATCH RM, 1989, DEATH DYING BIOL REV; 1991, UNOS UPDATE, V7, P19; 1986, TASK FORCE ORGAN TRA	13	46	46	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1246	1249		10.1056/NEJM199110243251711	http://dx.doi.org/10.1056/NEJM199110243251711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922213				2022-12-28	WOS:A1991GL28200011
J	ORTIZNAVARRETE, V; SEELIG, A; GERNOLD, M; FRENTZEL, S; KLOETZEL, PM; HAMMERLING, GJ				ORTIZNAVARRETE, V; SEELIG, A; GERNOLD, M; FRENTZEL, S; KLOETZEL, PM; HAMMERLING, GJ			SUBUNIT OF THE 20S PROTEASOME (MULTICATALYTIC PROTEINASE) ENCODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX	NATURE			English	Article							CLASS-II REGION; ANTIGEN PRESENTATION; CELLS; IDENTIFICATION; TRANSPORTERS; INTERFERON; GENE; EXPRESSION; PARTICLES; PATHWAY	CYTOTOXiC T lymphocytes recognize fragments (peptides) of protein antigens presented by major histocompatibility complex (MHC) class I molecules. In general, the peptides are derived from cytosolic proteins and are then transported to the endoplasmic reticulum where they assemble with the MHC class I heavy chains and beta-2-microglobulin to form stable and functional class I molecules 1-4. The proteases involved in the generation of these peptides are unknown. One candidate is the proteasome, a nonlysosomal proteinase complex abundantly present in the cytosol. Proteasomes have several proteolytically active sites and are complexes of high relative molecular mass (M(r) about 600K), consisting of about 20-30 subunits with M(r)s between 15 and 30K (refs 5-10). Here we show that at least one of these subunits is encoded by the mouse MHC in the region between the K locus and the MHC class II region, and inducible by interferon-gamma. This raises the intriguing possibility that the MHC encodes not only the MHC class I molecules themselves but also proteases involved in the formation of MHC-binding peptides.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; UNIV HEIDELBERG,ZMBH,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Ortiz-Navarrete, Vianney/H-1932-2016	Ortiz-Navarrete, Vianney/0000-0001-6546-9713				ARRIGO AP, 1987, J MOL EVOL, V25, P141, DOI 10.1007/BF02101756; CERUNDOLO V, 1990, NATURE, V345, P349; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALKENBURG PE, 1989, J BIOL CHEM, V264, P6660; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLOETZEL PM, 1987, MOL BIOL REP, V12, P223, DOI 10.1007/BF00356912; KLOETZEL PM, 1991, BIOMED BIOCHIM ACTA, V50, P451; KOCH N, 1982, J IMMUNOL, V128, P1155; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SEELIG A, IN PRESS BIOCH J; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UEMATSU Y, 1988, IMMUNOGENETICS, V27, P96, DOI 10.1007/BF00351082; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0	33	244	248	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					662	664		10.1038/353662a0	http://dx.doi.org/10.1038/353662a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922384				2022-12-28	WOS:A1991GK67200071
J	LIN, YS; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR				LIN, YS; HA, I; MALDONADO, E; REINBERG, D; GREEN, MR			BINDING OF GENERAL TRANSCRIPTION FACTOR TFIIB TO AN ACIDIC ACTIVATING REGION	NATURE			English	Article							RNA POLYMERASE-II; GAL4 DERIVATIVES; TATA-BOX; INITIATION; MECHANISM; CLONING; DOMAIN	A CENTRAL issue in eukaryotic transcriptional regulation is the mechanism by which promoter-specific transcription factors (activators) stimulate transcription. Two lines of evidence indicate that the general transcription factor TFIIB is a pivotal component in the mechanism by which an acidic activator functions. First, during assembly of the preinitiation complex TFIIB binding is a rate-limiting step enhanced by an acidic activator 1. Second, the TFIIB activity in a HeLa cell nuclear extract is specifically retained on a column containing an acidic activating region 1. But because our previous study monitored only TFIIB activity, it remains possible that the interaction between TFIIB and the acidic activating region is mediated through additional proteins, for example, those designated as adaptors 2, coactivators 3 or mediators 4,5. A complementary clone encoding TFIIB has recently been isolated and shown to encode a polypeptide of relative molecular mass 35,000 (ref. 6). Here we report that TFIIB expressed in and purified from Escherichia coli (recombinant TFIIB) binds directly to the potent acidic activating region of the herpes simplex virus-1 VP16 protein.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	LIN, YS (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.			Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764	19	340	349	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					569	571		10.1038/353569a0	http://dx.doi.org/10.1038/353569a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922364				2022-12-28	WOS:A1991GJ64300071
J	ANSSEAU, M; TROISFONTAINES, B; PAPART, P; VONFRENCKELL, R				ANSSEAU, M; TROISFONTAINES, B; PAPART, P; VONFRENCKELL, R			COMPULSIVE PERSONALITY AS PREDICTOR OF RESPONSE TO SEROTONINERGIC ANTIDEPRESSANTS	BRITISH MEDICAL JOURNAL			English	Article											ANSSEAU, M (corresponding author), CHU LIEGE,PSYCHIAT UNIT,DOMAINE UNIV SART TILMAN B35,B-4000 LIEGE,BELGIUM.							BENFIELD P, 1986, DRUGS, V32, P313, DOI 10.2165/00003495-198632040-00002; JENIKE MA, 1990, OBSESSIVE COMPULSIVE, P100; JOYCE PR, 1989, ARCH GEN PSYCHIAT, V46, P89; THASE ME, 1983, J AFFECT DISORDERS, V5, P267, DOI 10.1016/0165-0327(83)90050-2; 1980, DIAGNOSTIC STAITSTIC	5	41	41	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					760	761		10.1136/bmj.303.6805.760	http://dx.doi.org/10.1136/bmj.303.6805.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG981	1932937	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1991GG98100022
J	MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC				MADDEN, DR; GORGA, JC; STROMINGER, JL; WILEY, DC			THE STRUCTURE OF HLA-B27 REVEALS NONAMER SELF-PEPTIDES BOUND IN AN EXTENDED CONFORMATION	NATURE			English	Article							CLASS-I MOLECULES; DIRECT BINDING; HISTOCOMPATIBILITY ANTIGEN; VIRAL PEPTIDES; INTACT-CELLS; T-CELLS; INVITRO; RECOGNITION; PROTEIN; CHAINS	X-ray crystallography reveals electron density in the antigen-binding site of HLA-B27 that is an interpretable image of nonameric peptides in a largely extended conformation. Clear density exists for the main chain and several side chains and is consistent with the sequence of 11 nonameric self-peptides eluted from HLA-B27 (see accompanying article 1). Pockets in the antigen-binding cleft bind four side chains and the amino and carboxyl termini of the peptide.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	MADDEN, DR (corresponding author), HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, X PLOR MANUAL VERSIO; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CROWTHER RA, 1972, MOL REPLACEMENT METH; DORNMAIR K, 1991, P NATL ACAD SCI USA, V88, P1335, DOI 10.1073/pnas.88.4.1335; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GORGA JC, IN PRESS PROTEINS; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KHAN MA, 1987, ANKYLOSING SPONDYLIT, V1, P23; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LATTMAN EE, 1970, ACTA CRYSTALL B-STRU, VB 26, P1854, DOI 10.1107/S0567740870004995; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P227; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213	41	698	722	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					321	325		10.1038/353321a0	http://dx.doi.org/10.1038/353321a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922337				2022-12-28	WOS:A1991GG65400048
J	COSGROVE, D; GRAY, D; DIERICH, A; KAUFMAN, J; LEMEUR, M; BENOIST, C; MATHIS, D				COSGROVE, D; GRAY, D; DIERICH, A; KAUFMAN, J; LEMEUR, M; BENOIST, C; MATHIS, D			MICE LACKING MHC CLASS-II MOLECULES	CELL			English	Article							T-CELL-RECEPTOR; HISTOCOMPATIBILITY COMPLEX ANTIGEN; LYMPHOCYTE-B DEVELOPMENT; E-ALPHA-D; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; ACCESSORY CELLS; A-BETA; DIFFERENTIATION ANTIGENS	We have produced mice that lack major histocompatibility complex class II antigens, permitting us to evaluate the role of these molecules in diverse aspects of T and B cell differentiation. The mutant mice show near-complete elimination of CD4+ T lymphocytes from the spleen and lymph nodes; the few remaining CD4-positive cells are preferentially localized to B cell follicles. Surprisingly, substantial numbers of CD4 single-positive cells reside in the thymus; however, these are not mature thymocytes as we currently recognize them. B lymphocytes occur in normal numbers and are capable of terminal differentiation to plasma cells. Nevertheless, several aberrations in the B cell compartment are demonstrable: a lack of germinal centers, fewer IgM+IgD+ cells in certain individuals, reduced production of serum IgG1, and complete inability to respond to T-dependent antigens. In short, the class II-negative mice have confirmed some old ideas about lymphocyte differentiation, but have provided some surprises.	BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND		COSGROVE, D (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Gray, David/L-8295-2013	Gray, David/0000-0003-3785-4934; Kaufman, Jim/0000-0002-7216-8422				ACHAORBEA H, 1985, EUR J IMMUNOL, V15, P31, DOI 10.1002/eji.1830150107; ANDERSON GD, 1989, J IMMUNOL, V143, P3757; ANDERSON GD, 1989, J EXP MED, V170, P1003, DOI 10.1084/jem.170.3.1003; ASHIDA ER, 1987, P NATL ACAD SCI USA, V84, P3395, DOI 10.1073/pnas.84.10.3395; BECK BN, 1986, J IMMUNOL, V136, P2953; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOSWELL HS, 1980, J IMMUNOL, V125, P1340; BOSWELL HS, 1980, J EXP MED, V152, P1194, DOI 10.1084/jem.152.5.1194; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1986, EMBO J, V5, P2469, DOI 10.1002/j.1460-2075.1986.tb04523.x; BRUCE J, 1981, J IMMUNOL, V127, P2496; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Carbone F. R., 1989, Fundamental immunology., P541; CEBRA JJ, 1984, ANNU REV IMMUNOL, V2, P493, DOI 10.1146/annurev.immunol.2.1.493; CEREDIG R, 1987, P NATL ACAD SCI USA, V84, P8578, DOI 10.1073/pnas.84.23.8578; CHUSED TM, 1976, J IMMUNOL, V116, P1579; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; CRISPE IN, 1987, J IMMUNOL, V139, P3585; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EGERTON M, 1990, INT IMMUNOL, V2, P157, DOI 10.1093/intimm/2.2.157; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FULTZ MJ, 1982, J IMMUNOL, V129, P992; GERMAIN RN, 1986, NATURE, V320, P72, DOI 10.1038/320072a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; Griscelli C, 1989, Immunodefic Rev, V1, P135; GUTMAN GA, 1972, IMMUNOLOGY, V23, P465; Hardy R R, 1990, Semin Immunol, V2, P197; HASHIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P5883, DOI 10.1073/pnas.84.16.5883; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEINEN E, 1988, IMMUNOL TODAY, V9, P240, DOI 10.1016/0167-5699(88)91223-6; HERZENBERG LA, 1989, COLD SH Q B, V54, P219; HODES RJ, 1989, FUNDAMENTAL IMMUNOLO, P587; HOLUB M, 1989, IMMUNOLOGY NUDE MICE; HUGO P, 1991, EUR J IMMUNOL, V21, P835, DOI 10.1002/eji.1830210346; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KAUFMAN J, 1990, J IMMUNOL, V144, P2243; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KIMOTO M, 1989, IMMUNOLOGY, V67, P154; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; KRUISBEEK AM, 1983, J EXP MED, V157, P1932, DOI 10.1084/jem.157.6.1932; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAMERS MC, 1989, EUR J IMMUNOL, V19, P459, DOI 10.1002/eji.1830190308; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LARHAMMAR D, 1985, J BIOL CHEM, V260, P4111; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LEMEUR M, 1985, NATURE, V316, P38, DOI 10.1038/316038a0; LESLEY J, 1988, CELL IMMUNOL, V112, P40, DOI 10.1016/0008-8749(88)90274-2; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LYNCH F, 1989, EUR J IMMUNOL, V19, P223, DOI 10.1002/eji.1830190202; MACPHAIL S, 1987, J IMMUNOL, V139, P4007; MACPHAIL S, 1988, P NATL ACAD SCI USA, V85, P5205, DOI 10.1073/pnas.85.14.5205; MALISSEN B, 1986, P NATL ACAD SCI USA, V83, P3958, DOI 10.1073/pnas.83.11.3958; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MATSUBAYASHI Y, 1989, IMMUNOBIOLOGY, V180, P33, DOI 10.1016/S0171-2985(89)80028-2; MATSUMOTO K, 1989, EUR J IMMUNOL, V19, P1203, DOI 10.1002/eji.1830190708; MATSUNAGA M, 1990, J EXP MED, V171, P577, DOI 10.1084/jem.171.2.577; MCCARTHY SA, 1988, NATURE, V336, P76, DOI 10.1038/336076a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MIESCHER GC, 1987, J IMMUNOL, V138, P1959; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOND JJ, 1987, IMMUNOL REV, V99, P105, DOI 10.1111/j.1600-065X.1987.tb01174.x; MORRISSEY PJ, 1981, J IMMUNOL, V127, P1345; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NIKOLICZUGIC J, 1990, INT IMMUNOL, V2, P135, DOI 10.1093/intimm/2.2.135; OZATO K, 1980, J IMMUNOL, V124, P533; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PIERRES A, 1984, J IMMUNOL, V132, P2775; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; QUILL H, 1986, J IMMUNOL, V136, P3351; RELLAHAN BL, 1991, J EXP MED, V173, P503, DOI 10.1084/jem.173.2.503; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; Robinson M. A., 1989, Fundamental immunology., P489; ROUSE RV, 1982, J IMMUNOL, V128, P2243; SANT AJ, 1987, P NATL ACAD SCI USA, V84, P8065, DOI 10.1073/pnas.84.22.8065; SANT AJ, 1989, CELL, V57, P797, DOI 10.1016/0092-8674(89)90794-0; SCHUURMAN HJ, 1985, HUM IMMUNOL, V13, P69, DOI 10.1016/0198-8859(85)90014-X; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPENCER JS, 1989, J EXP MED, V169, P625, DOI 10.1084/jem.169.3.625; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VELARDI A, 1985, BLOOD, V65, P149; VELARDI A, 1986, J CLIN IMMUNOL, V6, P205, DOI 10.1007/BF00918700; VELARDI A, 1986, J IMMUNOL, V137, P2808; VERNACHIO J, 1989, J IMMUNOL, V142, P48; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WU L, 1990, INT IMMUNOL, V2, P51, DOI 10.1093/intimm/2.1.51; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	118	776	801	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1051	1066		10.1016/0092-8674(91)90448-8	http://dx.doi.org/10.1016/0092-8674(91)90448-8			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1909605				2022-12-28	WOS:A1991GE46000021
J	GHODSE, B; RAWAF, S				GHODSE, B; RAWAF, S			EXTRACONTRACTUAL REFERRALS IN 1ST 3 MONTHS OF NHS REFORMS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe the extracontractual referrals of residents of Merton and Sutton Health Authority during the first three months of the NHS reforms in terms of the nature of the referral (elective or emergency), the specialty referred to, and the source of and reason for referral. Design - Descriptive analysis of all extracontractual referrals submitted to the health authority between 1 April and 30 June 1991. Setting - Merton and Sutton Health Authority. Results - 247 extracontractual referrals were notified to Merton and Sutton Health Authority; 83 invoices for emergency treatment and 109 elective referrals were authorised at a total cost of 190 000 pounds. Of the elective referrals, 59 were to ear, nose, and throat; orthopaedic; or general surgery departments. Local general practitioners made only two thirds of the elective referrals, at least 15 of which were made at the patient's request. Four admissions accounted for a quarter of the total cost of the emergency admissions. Conclusions - Extracontractual referrals are unpredictable in terms of both their number and their cost. They provide a necessary safeguard for patient and general practitioner choice at the price of a considerable administrative workload. The fact that these referrals are income generating for providers means that additional safeguards may be necessary to prevent abuse of the system.	MERTON & SUTTON HLTH AUTHOR,PUBL HLTH,MITCHAM CR4 4TP,SURREY,ENGLAND					Rawaf, Salman/0000-0001-7191-2355				BEECHAM L, 1991, BRIT MED J, V302, P1108; DRUMMOND M, 1990, BRIT MED J, V301, P1288, DOI 10.1136/bmj.301.6764.1288; TUCKER WFG, 1991, BRIT MED J, V302, P117, DOI 10.1136/bmj.302.6768.117-c; 1990, FDL9034 DEP HLTH CIR; 1989, CMND555	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					497	499		10.1136/bmj.303.6801.497	http://dx.doi.org/10.1136/bmj.303.6801.497			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912859	Bronze, Green Published			2022-12-28	WOS:A1991GD80400016
J	MAHALANABIS, D				MAHALANABIS, D			BREAST-FEEDING AND VITAMIN-A-DEFICIENCY AMONG CHILDREN ATTENDING A DIARRHEA TREATMENT CENTER IN BANGLADESH - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							XEROPHTHALMIA; MORTALITY; MOTHERS; RISK	Objective - To determine the effect of breast feeding on the risk of xerophthalmia in children aged 6 months to 3 years attending a diarrhoea treatment centre in Bangladesh. Design - Case-control study based on stratified analysis (Mantel-Haenszel) and multivariate analysis (logistic regression) of data from a treatment centre based surveillance system. Setting - A large diarrhoea treatment centre in Dhaka, Bangladesh. Patients - 2687 children aged 6 months to 3 years representing a 4% systematic sample of all children in this age group treated yearly at the centre over three consecutive years. 66 of the children were cases of xerophthalmia (that is, they had Bitot's spots or corneal lesions or night blindness or night blindness plus conjunctival xerosis or any combination of these) and the remaining 2621 did not have signs or symptoms of vitamin A deficiency. This second group served as controls. Main outcome measure - Xerophthalmia and breast fed at onset of diarrhoea or presentation. Results - The odds ratio relating breast feeding to vitamin A deficiency after adjustment for a large number of confounding variables (0.26 (95% confidence interval 0.14 to 0.49); p < 0.001) reflected a 74% reduction in the risk of vitamin A deficiency among breast fed children. The estimated reduction of risk did not decline with age, and some 49% of children aged 24-35 months were still being breast fed. The odds ratio relating breast feeding to xerophthalmia in the third year of life (0.35 (95% confidence interval 0.35 to 0.86) reflected a 65% reduced risk of vitamin A deficiency. Other important risk factors or prognostic indicators for xerophthalmia as identified by multivariate analysis were recent measles, prolonged diarrhoea, severe protein energy malnutrition, and poor socioeconomic state. Conclusions - These results indicate that breast feeding was associated with a substantial reduction of the risk of vitamin A deficiency extending to the third year of life and support the recommendation that mothers in developing countries should be advised to breast feed for as long as possible.			MAHALANABIS, D (corresponding author), INT CTR DIARRHOEL DIS RES,DIV CLIN SCI,POB 128,DHAKA,BANGLADESH.							Becroft T C, 1967, Med J Aust, V2, P810; BRAKOHIAPA LA, 1988, LANCET, V2, P416; BROSS I, 1954, BIOMETRICS, V10, P478, DOI 10.2307/3001619; BROWN KH, 1982, AM J CLIN NUTR, V36, P878, DOI 10.1093/ajcn/36.5.878; COHEN N, 1985, SOC SCI MED, V21, P1269, DOI 10.1016/0277-9536(85)90276-X; DUALEH K A, 1989, Food and Nutrition Bulletin, V11, P43; GEBREMEDHIN M, 1976, AM J CLIN NUTR, V29, P441, DOI 10.1093/ajcn/29.4.441; HABTE D, 1989, 13 P NAT S INT VIT A, P7; MANTEL N, 1959, J NATL CANCER I, V22, P719; NEWELL DJ, 1963, BIOMETRICS, V19, P187, DOI 10.2307/2527585; ROY SK, 1984, J TROP MED HYG, V87, P11; ROY SK, 1989, VITAMIN A DEFICIENCY, P107; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P137; SINHA DP, 1973, LANCET, V2, P228; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1983, LANCET, V2, P585; SOMMER A, 1977, GUIDELINES ERADICATI, P1; STOLL BJ, 1985, J TROP PEDIATRICS, V31, P36, DOI 10.1093/tropej/31.1.36; STOLL BJ, 1982, BRIT MED J, V285, P1185, DOI 10.1136/bmj.285.6349.1185; TARWOTJO I, 1982, AM J CLIN NUTR, V35, P574, DOI 10.1093/ajcn/35.3.574; VANSTEENBERGEN WM, 1981, J TROP PEDIATRICS, V27, P155, DOI 10.1093/tropej/27.3.155; Vis H L, 1981, Assignment Child, V55-56, P183; WEST KP, 1986, AM J CLIN NUTR, V44, P690; 1985, BANGLADESH NATIONAL; 1976, WHO TECH REP SER, V590, P35	25	40	40	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					493	496		10.1136/bmj.303.6801.493	http://dx.doi.org/10.1136/bmj.303.6801.493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912858	Green Published, Bronze			2022-12-28	WOS:A1991GD80400015
J	RUPPERSBERG, JP; STOCKER, M; PONGS, O; HEINEMANN, SH; FRANK, R; KOENEN, M				RUPPERSBERG, JP; STOCKER, M; PONGS, O; HEINEMANN, SH; FRANK, R; KOENEN, M			REGULATION OF FAST INACTIVATION OF CLONED MAMMALIAN IK(A) CHANNELS BY CYSTEINE OXIDATION	NATURE			English	Article							DELAYED RECTIFIER PROPERTIES; BRAIN POTASSIUM-CHANNEL; RAT-BRAIN; EXPRESSION; CLONING; FAMILY; APLYSIA; MEMBER; CDNA	MODULATION of neuronal excitability by regulation of K+ channels potentially plays a part in short-term memory 1 but has not yet been studied at the molecular level. Regulation of K+ channels by protein phosphorylation 2-5 and oxygen 6 has been described for various tissues and cell types; regulation of fast-inactivating K+ channels mediating I(K)(A) currents has not yet been described. Functional expression of cloned mammalian K+ channels 7-13 has provided a tool for studying their regulation at the molecular level. We report here that fast-inactivating K+ currents mediated by cloned K+ channel subunits derived from mammalian brain expressed in Xenopus oocytes are regulated by the reducing agent glutathione. This type of regulation may have a role in vivo to link metabolism to excitability and to regulate excitability in specific membrane areas of mammalian neurons.	MAX PLANCK INST BIOPHYS CHEM, MEMBRANBIOPHYS ABT, W-3400 GOTTINGEN, GERMANY; ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY; RUHR UNIV BOCHUM, LEHRSTUHL BIOCHEM, W-4600 BOCHUM, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg; Ruhr University Bochum	RUPPERSBERG, JP (corresponding author), MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY.		Stocker, Martin/C-1844-2008	Heinemann, Stefan H./0000-0002-4144-0251				ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; ALKON DL, 1982, SCIENCE, V215, P693, DOI 10.1126/science.7058334; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CASTRO B, 1977, J CHEM RES, V182, P2118; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; FRANK R, 1988, MODERN METHODS PROTE, V3; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STOCKER M, 1990, P NATL ACAD SCI USA, V87, P8903, DOI 10.1073/pnas.87.22.8903; STOCKER M, IN PRESS P R SOC L B; STRONG JA, 1986, J NEUROSCI, V6, P814; STUHMER W, 1988, FEBS LETT, V242, P199, DOI 10.1016/0014-5793(88)81015-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	25	442	448	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					711	714		10.1038/352711a0	http://dx.doi.org/10.1038/352711a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1908562				2022-12-28	WOS:A1991GC06400057
J	OCONNOR, GT; PLUME, SK; OLMSTEAD, EM; COFFIN, LH; MORTON, JR; MALONEY, CT; NOWICKI, ER; TRYZELAAR, JF; HERNANDEZ, F; ADRIAN, L; CASEY, KJ; SOULE, DN; MARRIN, CAS; NUGENT, WC; CHARLESWORTH, DC; CLOUGH, R; KATZ, S; LEAVITT, BJ; WENNBERG, JE				OCONNOR, GT; PLUME, SK; OLMSTEAD, EM; COFFIN, LH; MORTON, JR; MALONEY, CT; NOWICKI, ER; TRYZELAAR, JF; HERNANDEZ, F; ADRIAN, L; CASEY, KJ; SOULE, DN; MARRIN, CAS; NUGENT, WC; CHARLESWORTH, DC; CLOUGH, R; KATZ, S; LEAVITT, BJ; WENNBERG, JE			A REGIONAL PROSPECTIVE-STUDY OF IN-HOSPITAL MORTALITY ASSOCIATED WITH CORONARY-ARTERY BYPASS-GRAFTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; SURGERY; RISK; QUALITY; SEVERITY; ILLNESS; RATES	Objective.-A prospective regional study was conducted to determine if the observed differences in in-hospital mortality rates associated with coronary artery bypass grafting (CABG) are solely the result of differences in patient case mix. Design.-Regional prospective cohort study Data including patient demographic and historical data, body surface area, cardiac catheterization results, priority of surgery, comorbidity, and status at hospital discharge were collected. This study presents data for 3055 CABG patients between July 1, 1987, and April 15, 1989. Setting.-This study includes data from all surgeons performing cardiothoracic surgery in Maine, New Hampshire, and Vermont; the data were collected from five regional medical centers. Patients.-Data were collected from all consecutive isolated CABG surgery patients during the study period. Main Outcome Measures.-Crude and adjusted in-hospital mortality rates associated with CABG. Main Results.-The overall crude in-hospital mortality rate for isolated CABG was 4.3%. The rate varied among centers (range, 3.1% to 6.3%) and among surgeons (range, 1.9% to 9.2%). Predictors of in-hospital mortality included increased age, female gender, small body surface area, greater comorbidity, reoperation, poorer cardiac function as indicated by a lower ejection fraction, increased left ventricular end diastolic pressure, and emergent or urgent surgery. After adjusting for the effects of potentially confounding variables, substantial and statistically significant variability was observed among medical centers (P = .021) and among surgeons (P = .025). Conclusion.-We conclude that the observed differences in in-hospital mortality rates among institutions and among surgeons in northern New England are not solely the result of differences in case mix as described by these variables and may reflect differences in currently unknown aspects of patient care. Understanding this variation requires a detailed understanding of the processes of care.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT SURG,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,CTR EVALUAT CLIN SCI,HANOVER,NH 03756; MED CTR HOSP VERMONT,DEPT SURG,BURLINGTON,VT 05401; MAINE MED CTR,DEPT SURG,PORTLAND,ME 04102; CATHOLIC MED CTR,DEPT SURG,MANCHESTER,NH; EASTERN MAINE MED CTR,DEPT SURG,BANGOR,ME 04401; MAINE MED ASSESSMENT PROGRAM,AUGUSTA,ME	Dartmouth College; Dartmouth College; Dartmouth College; University of Vermont Medical Center; Maine Medical Center; Eastern Maine Medical Center	OCONNOR, GT (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT MED,CLIN RES SECT,2 MAYNARD ST,HANOVER,NH 03756, USA.				NATIONAL LIBRARY OF MEDICINE [R29LM004667] Funding Source: NIH RePORTER; NLM NIH HHS [R29-LM-04667-02] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cornfield J, 1961, B INT STAT I, V38, P97; DAVIS PK, 1989, ANN THORAC SURG, V47, P493, DOI 10.1016/0003-4975(89)90422-0; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HENNEKENS CH, 1973, STATISTICAL METHODS, P92; JUNOD FL, 1987, ANN THORAC SURG, V43, P59, DOI 10.1016/S0003-4975(10)60167-1; Keller R B, 1990, Qual Assur Health Care, V2, P69; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; LOOP DF, 1975, J THORAC CARDIOVASC, V69, P40; MILLER DC, 1978, SURGERY, V84, P848; NAUNHEIM KS, 1988, J AM COLL CARDIOL, V11, P494, DOI 10.1016/0735-1097(88)91522-7; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; PARSONNET V, 1989, CIRCULATION, V79, P3; PIERPONT GL, 1985, J THORAC CARDIOV SUR, V89, P673; Principal Investigators of CASS and Associates, 1981, CIRCULATION S1, V63, pI1; ROOS LL, 1989, SOCIOECONOMICS SURGE, P258; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; 1986, CONFRONTING REGIONAL; 1988, ANN THORAC SURG, V46, P348; 1987, AGENDA CHANGE UPDATE, P1; 1986, STATISTICAL ANAL SYS; 1989, CURRENT POPULATION R; 1987, DHHS01002 PUBL	31	340	345	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					803	809		10.1001/jama.266.6.803	http://dx.doi.org/10.1001/jama.266.6.803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1907669				2022-12-28	WOS:A1991GA07300031
J	DIEKMANN, D; BRILL, S; GARRETT, MD; TOTTY, N; HSUAN, J; MONFRIES, C; HALL, C; LIM, L; HALL, A				DIEKMANN, D; BRILL, S; GARRETT, MD; TOTTY, N; HSUAN, J; MONFRIES, C; HALL, C; LIM, L; HALL, A			BCR ENCODES A GTPASE-ACTIVATING PROTEIN FOR P21RAC	NATURE			English	Article							RAS P21; GENE-PRODUCT; ESCHERICHIA-COLI; GAP; LEUKEMIA; DOMAIN; CELLS; CDNA; IDENTIFICATION; INTERACTS	MORE than thirty small guanine nucleotide-binding proteins related to the ras-encoded oncoprotein, termed Ras or p21ras, are known 1. They regulate many fundamental processes in all eukaryotic cells, such as growth, vesicle traffic and cytoskeletal organization. GTPase-activating proteins (GAPs) accelerate the intrinsic rate of GTP hydrolysis of Ras-related proteins, leading to down-regulation of the active GTP-bound form 2. For p21ras, two GAP proteins are known, rasGAP and the neurofibromatosis (NF1) gene product 2-5. There is evidence that rasGAP may also be a target protein for regulation by Ras and be involved in downstream signalling 6-8. We have purified a GAP protein for p21rho, which is involved in the regulation of the actin cytoskeleton 9. Partial sequencing of rhoGAP reveals significant homology with the product of the bcr (breakpoint cluster region) gene, the translocation breakpoint in Philadelphia chromosome-positive chronic myeloid leukaemias. We show here that the carboxy-terminal domains of the bcr-encoded protein (Bcr) and of a Bcr-related protein, n-chimaerin, are both GAP proteins for the Ras-related GTP-binding protein, p21rac. This result suggests that Bcr could be a target for regulation by Rac and has important new implications for the role of bcr translocations in leukaemia.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; INST NEUROL,LONDON WC1 1PJ,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; University College London			Hall, Christine/C-8390-2009; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Tapon, Dagmar/0000-0003-3837-4764				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMSON RB, 1989, ONCOGENE, V4, P243; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GARRETT MD, IN PRESS BIOCH J; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P636; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LI WJ, 1989, ONCOGENE, V4, P127; LIFSHITZ B, 1988, ONCOGENE, V2, P113; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OTSU M, 1991, CELL, V65, P1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	29	413	424	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					400	402		10.1038/351400a0	http://dx.doi.org/10.1038/351400a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1903516				2022-12-28	WOS:A1991FN85600056
J	HARDING, CV; COLLINS, DS; SLOT, JW; GEUZE, HJ; UNANUE, ER				HARDING, CV; COLLINS, DS; SLOT, JW; GEUZE, HJ; UNANUE, ER			LIPOSOME-ENCAPSULATED ANTIGENS ARE PROCESSED IN LYSOSOMES, RECYCLED, AND PRESENTED TO T-CELLS	CELL			English	Article							PH-SENSITIVE LIPOSOMES; MACROPHAGE ENDOSOMES; PINOCYTOSED FLUID; PROTEIN; ENDOCYTOSIS; EXCHANGE; MEMBRANE; BINDING; PEPTIDE; IA	Antigen processing required intracellular antigen catabolism to generate immunogenic peptides that bind to class II MHC molecules (MHC-II) for presentation to T-cells. We now provide direct evidence that these peptides are produced within dense lysosomes, as opposed to earlier endocytic compartments. The protein antigen hen egg lysozyme was targeted to endosomes or lysosomes by encapsulating it in liposomes of different membrane composition. Acid-sensitive liposomes released their contents in early endosomes, whereas acid-resistant liposomes sequestered their contents from potential endosomal processing events and released their contents only after delivery to lysosomes. Antigen encapsulated in acid-resistant liposomes was processed in a chloroquine-sensitive manner and presented more efficiently than soluble antigen or antigen encapsulated in acid-sensitive liposomes. Thus, peptides may be recycled from lysosomes, transported to endosomes to bind MHC-II, and then expressed at the cell surface.	STATE UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Utrecht University	HARDING, CV (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA.							ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; ALLEN PM, 1984, J IMMUNOL, V132, P1077; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BUCKMASTER MJ, 1987, CELL BIOL INT REP, V11, P501, DOI 10.1016/0309-1651(87)90011-7; COLLINS D, 1989, BIOCHIM BIOPHYS ACTA, V987, P47, DOI 10.1016/0005-2736(89)90453-7; CONNOR J, 1984, P NATL ACAD SCI-BIOL, V81, P1715, DOI 10.1073/pnas.81.6.1715; DALEKE DL, 1990, BIOCHIM BIOPHYS ACTA, V1024, P352, DOI 10.1016/0005-2736(90)90365-U; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; DUZGUNES N, 1985, BIOCHEMISTRY-US, V24, P3091, DOI 10.1021/bi00334a004; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1990, EUR J IMMUNOL, V20, P323, DOI 10.1002/eji.1830200214; HARDING CV, 1989, J IMMUNOL, V142, P12; LEYVACOBIAN F, 1988, J IMMUNOL, V141, P1445; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MAYORGA LS, 1989, J BIOL CHEM, V264, P5392; MONTE PD, 1989, J IMMUNOL, V142, P1437; MULLER WA, 1983, J CELL BIOL, V96, P29, DOI 10.1083/jcb.96.1.29; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRUCK O, 1981, BIOCHEMISTRY-US, V23, P1532; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025	32	258	264	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	1991	64	2					393	401		10.1016/0092-8674(91)90647-H	http://dx.doi.org/10.1016/0092-8674(91)90647-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1899049				2022-12-28	WOS:A1991EV33600015
J	GOLUB, HL				GOLUB, HL			A RESPONSE FROM TOKOS-MEDICAL-CORPORATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											GOLUB, HL (corresponding author), TOKOS MED CORP,CAMBRIDGE,MA 02141, USA.							KOSASA TS, 1990, OBSTET GYNECOL, V76, pS71; MORRISON JC, 1990, OBSTET GYNECOL, V76, pS76; MORRISON JC, 1989, INT J GYNECOL OBSTET, V28, P127, DOI 10.1016/0020-7292(89)90471-2; MOU SM, 1991, AM J OBSTET GYNECOL, V165, P858, DOI 10.1016/0002-9378(91)90429-U	4	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1377	1378		10.1056/NEJM199111073251913	http://dx.doi.org/10.1056/NEJM199111073251913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922243				2022-12-28	WOS:A1991GN47000013
J	CELLO, JP; GRENDELL, JH; BASUK, P; SIMON, D; WEISS, L; WITTNER, M; ROOD, RP; WILCOX, CM; FORSMARK, CE; READ, AE; SATOW, JA; WEIKEL, CS; BEAUMONT, C				CELLO, JP; GRENDELL, JH; BASUK, P; SIMON, D; WEISS, L; WITTNER, M; ROOD, RP; WILCOX, CM; FORSMARK, CE; READ, AE; SATOW, JA; WEIKEL, CS; BEAUMONT, C			EFFECT OF OCTREOTIDE ON REFRACTORY AIDS-ASSOCIATED DIARRHEA - A PROSPECTIVE, MULTICENTER CLINICAL-TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; SOMATOSTATIN ANALOG SMS-201-995; SMS 201-995; CRYPTOSPORIDIAL DIARRHEA; EFFICACY; THERAPY; PATIENT; TUMORS; HIV	Objective: To determine the efficacy and safety of octreotide for treatment of refractory, profuse diarrhea in patients with the acquired immunodeficiency syndrome (AIDS). Design: A prospective, open-label study. Setting: Inpatient metabolic units of four university medical centers. Patients: Fifty-one patients infected with human immunodeficiency virus (HIV) who had uncontrolled diarrhea (greater-than-or-equal-to 500-mL liquid stool per day) despite treatment with maximally tolerable doses of antidiarrheal medications. Intervention: After initial baseline studies, patients received octreotide, 50-mu-g every 8 hours for 48 hours. If stool volume was not reduced to < 250 mL/d, the dose of octreotide was increased stepwise to 100, 250, and 500-mu-g. Main Results: Fifty men and one woman (mean age, 36.3 +/- 1.1 years) entered and completed the 28-day protocol (14 days of inpatient therapy and 14 days of outpatient therapy). Stool frequency and volume decreased significantly (6.5 +/- 0.5 stools per day on day 0 compared with 3.8 +/- 0.3 stools per day on day 21 [P < 0.001] and 1604 +/- 180 mL/d on day 0 compared with 1084 +/- 162 mL/d on day 14 [P < 0.001], respectively). Twenty-one patients (41.2%) were considered to be partial or complete responders (reduction in daily stool volume by greater-than-or-equal-to 50% of initial collections or reduction to less-than-or-equal-to 250 mL/d). Of the 21 responders, 14 (67%) had no identifiable pathogens at initial screening compared with 9 of 30 (30%) nonresponders (P < 0.01). Conclusion: Patients with AIDS-associated refractory watery diarrhea, especially those without identifiable pathogens, may respond favorably to subcutaneously administered octreotide. This drug deserves further study in a randomized, placebo-controlled trial.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD 21205 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	University of California System; University of California San Francisco; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Albert Einstein College of Medicine					NCRR NIH HHS [RR00035, RR-00083, MO1-RR00827] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083, M01RR000827] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANTONY MA, 1988, DIGEST DIS SCI, V33, P1141, DOI 10.1007/BF01535791; CLOTET B, 1989, AIDS, V3, P857, DOI 10.1097/00002030-198912000-00016; COOK DJ, 1988, ANN INTERN MED, V108, P708, DOI 10.7326/0003-4819-108-5-708; FUESSL HS, 1989, KLIN WOCHENSCHR, V67, P452, DOI 10.1007/BF01725142; GROSMAN I, 1990, AM J GASTROENTEROL, V85, P1061; JOHNSTON DG, 1986, AM J MED, V81, P88, DOI 10.1016/0002-9343(86)90589-9; KATZ MD, 1988, DRUG INTEL CLIN PHAR, V22, P134, DOI 10.1177/106002808802200206; KVOLS LK, 1986, AM J MED, V81, P49, DOI 10.1016/0002-9343(86)90584-X; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LONDONG W, 1989, GASTROENTEROLOGY, V96, P713; ROBINSON EN, 1988, ANN INTERN MED, V109, P680, DOI 10.7326/0003-4819-109-8-680; RUFF MR, 1987, FEBS LETT, V211, P17, DOI 10.1016/0014-5793(87)81265-6; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; VINIK AI, 1986, AM J MED, V81, P23, DOI 10.1016/0002-9343(86)90582-6; WILLIAMS ST, 1989, AM J SURG, V157, P459, DOI 10.1016/0002-9610(89)90634-X	16	115	117	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					705	710		10.7326/0003-4819-115-9-705	http://dx.doi.org/10.7326/0003-4819-115-9-705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929038				2022-12-28	WOS:A1991GL69700007
J	LEGOUIS, R; HARDELIN, JP; LEVILLIERS, J; CLAVERIE, JM; COMPAIN, S; WUNDERLE, V; MILLASSEAU, P; LEPASLIER, D; COHEN, D; CATERINA, D; BOUGUELERET, L; DELEMARREVANDEWAAL, H; LUTFALLA, G; WEISSENBACH, J; PETIT, C				LEGOUIS, R; HARDELIN, JP; LEVILLIERS, J; CLAVERIE, JM; COMPAIN, S; WUNDERLE, V; MILLASSEAU, P; LEPASLIER, D; COHEN, D; CATERINA, D; BOUGUELERET, L; DELEMARREVANDEWAAL, H; LUTFALLA, G; WEISSENBACH, J; PETIT, C			THE CANDIDATE GENE FOR THE X-LINKED KALLMANN SYNDROME ENCODES A PROTEIN RELATED TO ADHESION MOLECULES	CELL			English	Article							STEROID SULFATASE GENE; AMINO-ACID-SEQUENCE; DISTAL SHORT ARM; IMMUNOGLOBULIN SUPERFAMILY; HYPOGONADOTROPIC HYPOGONADISM; Y-CHROMOSOME; FIBRONECTIN; MEMBER; DELETIONS; BINDING	Kallmann syndrome associates hypogonadotropic hypogonadism and anosmia and is probably due to a defect in the embryonic migration of olfactory and GnRH-synthesizing neurons. The Kallmann gene had been localized to Xp22.3. In this study 67 kb of genomic DNA, corresponding to a deletion interval containing at least part of the Kallmann gene, were sequenced. Two candidate exons, identified by multiparameter computer programs, were found in a cDNA encoding a protein of 679 amino acids. This candidate gene (ADMLX) is interrupted in its 3' coding region in the Kallmann patient, in which the proximal end of the KAL deletion interval was previously defined. A 5' end deletion was detected in another Kallmann patient. The predicted protein sequence shows homologies with the fibronectin type III repeat. ADMLX thus encodes a putative adhesion molecule, consistent with the defect of embryonic neuronal migration.	NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20892 USA; GENETHON, F-91002 EVRY, FRANCE; CEPH, F-75010 PARIS, FRANCE; FREE UNIV AMSTERDAM HOSP, DEPT PAEDIAT, 1007 MB AMSTERDAM, NETHERLANDS; CNRS, UNITE ONCOL VIRALE, F-94801 VILLEJUIF, FRANCE	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Centre National de la Recherche Scientifique (CNRS)	LEGOUIS, R (corresponding author), INST PASTEUR, CNRS, URA 1445, UNITE GENET MOLEC HUMAINE, F-75724 PARIS 15, FRANCE.		Legouis, Renaud/G-9088-2014; Claverie, Jean Michel/Z-2183-2019; Lutfalla, Georges/AAW-9386-2021; Claverie, Jean-Michel/AAG-4889-2019; Legouis, Renaud/S-1250-2017	Claverie, Jean-Michel/0000-0003-1424-0315; Legouis, Renaud/0000-0002-2699-2584; Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BALLABIO A, 1987, HUM GENET, V77, P338, DOI 10.1007/BF00291422; BELLANNECHANTELOT C, 1991, NUCLEIC ACIDS RES, V19, P505, DOI 10.1093/nar/19.3.505; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOGUSKI M, 1991, IN PRESS PROTEIN ENG; BOULOUX PM, 1991, IN PRESS NUCL ACIDS; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHAUSSAIN JL, 1988, HORM RES, V29, P202, DOI 10.1159/000181003; CLAVERIE JM, 1990, METHOD ENZYMOL, V183, P237; COULSON A, 1988, GENOME ANAL PRACTICA, P25; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; De Morster G, 1954, SCHWEIZ ARCH NEUROL, V74, P309; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; FISCHER G, 1986, J NEUROSCI, V6, P605; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GRUMET M, 1991, J CELL BIOL, V113, P399; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOWLEY PM, 1979, J BIOL CHEM, V254, P4876; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; Jones J R, 1976, Obstet Gynecol Annu, V5, P443; JONES PCT, 1966, NATURE, V212, P365, DOI 10.1038/212365a0; JUAN AMD, 1856, SIGLO MED, V211; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KLEIN P, 1986, BIOPOLYMERS, V25, P1659, DOI 10.1002/bip.360250909; KLINGMULLER D, 1987, J CLIN ENDOCR METAB, V65, P581, DOI 10.1210/jcem-65-3-581; KNOWLTON RG, 1989, NUCLEIC ACIDS RES, V17, P423, DOI 10.1093/nar/17.1.423; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MALES JL, 1973, ARCH INTERN MED, V131, P501, DOI 10.1001/archinte.131.4.501; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; McKusick VA, 1990, MENDELIAN INHERITANC; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; Pearson AA, 1941, J COMP NEUROL, V75, P39, DOI 10.1002/cne.900750104; PETIT C, 1990, GENOMICS, V6, P651, DOI 10.1016/0888-7543(90)90500-T; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PETIT C, 1990, P NATL ACAD SCI USA, V87, P3680, DOI 10.1073/pnas.87.10.3680; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; RONNEKLEIV OK, 1990, ENDOCRINOLOGY, V126, P498, DOI 10.1210/endo-126-1-498; RUEGG MA, 1989, EMBO J, V8, P55, DOI 10.1002/j.1460-2075.1989.tb03348.x; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Sambrook J, 1989, MOL CLONING LABORATO; SANTEN RJ, 1973, J CLIN ENDOCR METAB, V36, P47, DOI 10.1210/jcem-36-1-47; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAPIRO LJ, 1985, ADV HUM GENET, V14, P331; SPARKES RS, 1968, ARCH INTERN MED, V121, P534, DOI 10.1001/archinte.121.6.534; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TIEPOLO L, 1980, HUM GENET, V54, P205, DOI 10.1007/BF00278973; Ulrich A., 1985, NATURE, V313, P756; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEGENKE JD, 1975, CLIN GENET, V7, P368; WEISSENBACH J, 1989, CYTOGENET CELL GENET, V51, P438, DOI 10.1159/000132802; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	86	565	579	1	34	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					423	435		10.1016/0092-8674(91)90193-3	http://dx.doi.org/10.1016/0092-8674(91)90193-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913827				2022-12-28	WOS:A1991GL47000021
J	LEVY, F; GABATHULER, R; LARSSON, R; KVIST, S				LEVY, F; GABATHULER, R; LARSSON, R; KVIST, S			ATP IS REQUIRED FOR INVITRO ASSEMBLY OF MHC CLASS-I ANTIGENS BUT NOT FOR TRANSFER OF PEPTIDES ACROSS THE ER MEMBRANE	CELL			English	Article							TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CHAIN BINDING-PROTEIN; HLA-B ANTIGENS; H-2-DEFICIENT LYMPHOMA VARIANTS; ENDOPLASMIC-RETICULUM; INFLUENZA NUCLEOPROTEIN; LYMPHOBLASTOID CELLS; MULTIDRUG RESISTANCE; SYNTHETIC PEPTIDES	We have translated the HLA-B27 heavy chain in vitro and studied its assembly with beta-2-microglobulin and peptide in microsomes from human cells. The assembly process requires ATP. However, the translocation of peptide across the endoplasmic reticulum (ER) membrane does not require ATP, and binding of biotinylated peptide to BiP, an ER luminal protein, occurs after ATP depletion. Proteinase K treatment of the microsomes does not block peptide translocation. Thus, ATP is required in the lumen of the ER for efficient assembly to occur. Microsomes prepared from Raji and T1 cells show similar levels of assembly, whereas assembly in T2 microsomes is 10-fold lower. This difference remains after peptide stimulation of assembly. The inefficient assembly in T2 microsomes is not due to impaired peptide translocation across the ER membrane, as no difference was found compared with microsomes from T1 cells. Instead, the defect seems to reside in the lumen of the ER.			LEVY, F (corresponding author), LUDWIG INST CANC RES,BOX 60202,S-10401 STOCKHOLM,SWEDEN.							ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BARINAGA M, 1990, SCIENCE, V250, P1657, DOI 10.1126/science.2270477; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KETTLUN AM, 1982, PHYTOCHEMISTRY, V21, P551, DOI 10.1016/0031-9422(82)83139-7; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PARHAM P, 1990, NATURE, V346, P793, DOI 10.1038/346793a0; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; SIMON SM, 1991, CELL, V65, P671; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TRAVERSOCORI A, 1970, ARCH BIOCHEM BIOPHYS, V137, P133, DOI 10.1016/0003-9861(70)90420-0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	70	94	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					265	274		10.1016/0092-8674(91)90178-2	http://dx.doi.org/10.1016/0092-8674(91)90178-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913823				2022-12-28	WOS:A1991GL47000006
J	MURRELL, J; FARLOW, M; GHETTI, B; BENSON, MD				MURRELL, J; FARLOW, M; GHETTI, B; BENSON, MD			A MUTATION IN THE AMYLOID PRECURSOR PROTEIN ASSOCIATED WITH HEREDITARY ALZHEIMERS-DISEASE	SCIENCE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; PRION PROTEIN; CYSTATIN-C; GENE; INHIBITOR; CDNA; LINKAGE; VARIANT; LOCUS	Alzheimer's disease is a form of localized amyloidosis characterized by cerebral cortical amyloid plaques, neurofibrillary tangles, and amyloid deposits within the walls of leptomeningeal vessels. Although most cases of Alzheimer's disease are sporadic, kindreds with autosomal-dominant inheritance of the syndrome suggest that a single mutation may be important in pathogenesis. Direct sequencing of DNA from a family with autopsy-proven Alzheimer's disease revealed a single amino acid substitution (Phe for Val) in the transmembrane domain of the amyloid precursor protein. This mutation correlates with the presence of Alzheimer's disease in all patients in this study, and may be the inherited factor causing both amyloid fibril formation and dementia.	INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; VET AFFAIRS RICHARD L ROUDEBUSH MED CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center					NCRR NIH HHS [RR-00750] Funding Source: Medline; NIA NIH HHS [U24 AG021886] Funding Source: Medline; PHS HHS [34881, 42111] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U24AG021886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benson MD, 1989, METABOLIC BASIS INHE, P2439; CHRISTMANSON L, 1990, AMYLOID AMYLOIDOSIS, P635; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771; MURRELL JN, UNPUB; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NICHOLS WC, 1990, GENOMICS, V8, P318, DOI 10.1016/0888-7543(90)90288-6; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VITEK MP, 1988, MOL BRAIN RES, V4, P121, DOI 10.1016/0169-328X(88)90004-6; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	28	988	1089	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					97	99		10.1126/science.1925564	http://dx.doi.org/10.1126/science.1925564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925564				2022-12-28	WOS:A1991GH60500036
J	PADMORE, R; CAO, L; KLECKNER, N				PADMORE, R; CAO, L; KLECKNER, N			TEMPORAL COMPARISON OF RECOMBINATION AND SYNAPTONEMAL COMPLEX-FORMATION DURING MEIOSIS IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER FEMALES; MEIOTIC GENE CONVERSION; DOUBLE-STRAND BREAKS; CHROMOSOME SYNAPSIS; WILD-TYPE; INITIATION SITE; CROSSING-OVER; CELL-CYCLE; SEGREGATION	In synchronous cultures of S. cerevisiae undergoing meiosis, an early event in the meiotic recombination pathway, site-specific double strand breaks (DSBs), occurs early in prophase, in some instances well before tripartite synaptonemal complex (SC) begins to form. This observation, together with previous results, supports the view that events involving DSBs are required for SC formation. We discuss the possibility that the mitotic pathway for recombinational repair of DSBs served as the primordial mechanism for connecting homologous chromosomes during the evolution of meiosis. DSBs disappear during the period when tripartite SC structure is forming and elongating (zygotene); presumably, they are converted to another type of recombination intermediate. Neither DSBs nor mature recombinant molecules are present when SCs are full length (pachytene). Mature reciprocally recombinant molecules arise at the end of or just after pachytene. We suggest that the SC might coordinate recombinant maturation with other events of meiosis.			PADMORE, R (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338	NIGMS NIH HHS [GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; BAILEY NTJ, 1981, STATISTICAL METHODS, P24; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BORTS RH, 1984, COLD SPRING HARB SYM, V49, P67, DOI 10.1101/SQB.1984.049.01.010; Bridges CB, 1925, GENETICS, V10, P418; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CARPENTER ATC, 1981, CHROMOSOMA, V83, P59, DOI 10.1007/BF00286016; CARPENTER ATC, 1979, GENETICS, V92, P511; CARPENTER ATC, 1975, P NATL ACAD SCI USA, V72, P3186, DOI 10.1073/pnas.72.8.3186; COMINGS DE, 1970, NATURE, V227, P451, DOI 10.1038/227451a0; COMINGS DE, 1971, NATURE, V233, P48, DOI 10.1038/233048a0; DAVIDOW LS, 1984, GENETICS, V106, P165; DONAHUE TF, 1982, GENE, V18, P47, DOI 10.1016/0378-1119(82)90055-5; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; FINK GR, 1984, NATURE, V310, P728, DOI 10.1038/310728a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HENDERSON SA, 1970, ANNU REV GENET, V4, P295, DOI 10.1146/annurev.ge.04.120170.001455; HOLLIDAY R, 1977, PHILOS T R SOC B, V277, P359, DOI 10.1098/rstb.1977.0024; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HORESH O, 1979, CHROMOSOMA, V75, P101, DOI 10.1007/BF00330628; Howard-Flanders P, 1968, Adv Biol Med Phys, V12, P299; HOWARDFL.P, 1968, ANNU REV BIOCHEM, V37, P175, DOI 10.1146/annurev.bi.37.070168.001135; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JACKSON JA, 1985, GENETICS, V109, P303; JONES G H, 1987, P213; JONES GH, 1984, CONTROLLING EVENTS M, P293; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KING JS, 1990, GENETICS, V126, P1127; King R. C., 1970, Int. Rev. Cytol., V28, P125, DOI 10.1016/S0074-7696(08)62542-5; KLECKNER N, 1991, IN PRESS COLD SPRING, V56; KOLODKIN AL, 1986, CELL, V46, P733, DOI 10.1016/0092-8674(86)90349-1; KUROIWA T, 1984, EXP CELL RES, V153, P259, DOI 10.1016/0014-4827(84)90469-5; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAGUIRE MP, 1977, PHILOS T R SOC B, V277, P245, DOI 10.1098/rstb.1977.0015; MOENS PB, 1971, J CELL BIOL, V50, P344, DOI 10.1083/jcb.50.2.344; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; MOSES MJ, 1969, GENETICS, V61, P41; MOSES MJ, 1984, CONTROLLING EVENTS M, P245; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OLSON LW, 1978, MOL GEN GENET, V166, P151, DOI 10.1007/BF00285917; PERKINS DD, 1949, GENETICS, V34, P607; PETERSON JB, 1976, J CELL SCI, V22, P219; PETES TD, 1991, IN PRESS MOL BIOL YE; RASMUSSEN SW, 1986, CARLSBERG RES COMMUN, V51, P401, DOI 10.1007/BF02907315; RASMUSSEN SW, 1984, CONTROLLING EVENTS M, P271; RESNICK M A, 1987, P157; Rhoades MM., 1968, REPLICATION RECOMBIN, P229; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROMAN H, 1990, GENETICS, V124, P7; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; Sherman F., 1983, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; SOLARI AJ, 1970, CHROMOSOMA, V31, P217, DOI 10.1007/BF00326080; SOLARI AJ, 1981, INT CELL BIOL 1980 1, P178; STERN H, 1987, P303; STERN H, 1975, P NATL ACAD SCI USA, V72, P961, DOI 10.1073/pnas.72.3.961; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; UEKI K, 1981, J GEN APPL MICROBIOL, V27, P1, DOI 10.2323/jgam.27.1; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WILDENBERG J, 1970, GENETICS, V66, P291; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; ZICKLER D, 1975, CHROMOSOMA, V50, P1; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; ZOLAN ME, 1988, GENETICS, V120, P379	88	389	392	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1239	1256		10.1016/0092-8674(91)90046-2	http://dx.doi.org/10.1016/0092-8674(91)90046-2			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913808				2022-12-28	WOS:A1991GG55200018
J	MCDONALD, CC; STEWART, HJ				MCDONALD, CC; STEWART, HJ			FATAL MYOCARDIAL-INFARCTION IN THE SCOTTISH ADJUVANT TAMOXIFEN TRIAL	BRITISH MEDICAL JOURNAL			English	Article							NEGATIVE BREAST-CANCER; CLINICAL-TRIAL; WOMEN; THERAPY; BONE; ESTROGENS; DENSITY	Objective-To investigate the incidence of fatal myocardial infarction in women in the two randomised arms of the Scottish adjuvant tamoxifen trial. Design-Retrospective review of hospital notes to determine with the greatest possible certainty women who had died of an acute myocardial infarction. Setting-Scottish Cancer Trials Office, the University of Edinburgh. Patients-1070 postmenopausal women with operable breast cancer who were randomised to receive either adjuvant tamoxifen for five years or until relapse (539 patients) or tamoxifen for at least six weeks on the confirmation of first recurrence (531 patients). Main outcome measures-Incidence of fatal myocardial infarction in women with no known or suspected systemic cancer. Results-Of the 200 women who died in the adjuvant tamoxifen arm of the trial, 44 were free of cancer at death and 10 of these died of myocardial infarction. In the observation arm 251 women died, of whom 61 showed no evidence of systemic cancer and 25 had a fatal myocardial infarction. The incidence of fatal myocardial infarction in the two groups was significantly different (chi-2 = 6.88, p = 0.0087). Conclusion-Tamoxifen given for at least five years as adjuvant therapy for breast cancer seems to have a cardioprotective oestrogen-like effect in postmenopausal women.			MCDONALD, CC (corresponding author), UNIV EDINBURGH,MRC,SCOTTISH CANC TRIALS OFF,TEVIOT PL,EDINBURGH EH8 9AG,SCOTLAND.							BERTELLI G, 1988, BREAST CANCER RES TR, V12, P307, DOI 10.1007/BF01811244; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; CALEFFI M, 1988, J ENDOCRINOL, V119, P335, DOI 10.1677/joe.0.1190335; COLE MP, 1971, BRIT J CANCER, V25, P270, DOI 10.1038/bjc.1971.33; DAHAN R, 1985, LANCET, V1, P638; FISHER B, 1987, ANN INTERN MED, V106, P649, DOI 10.7326/0003-4819-106-5-649; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; JORDAN VC, 1988, CANCER INVEST, V6, P5; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; OSBORNE CK, 1985, CANCER RES, V45, P584; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STEWART HJ, 1980, EUR J CANCER, V16, P83; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; 1987, LANCET, V2, P171; 1988, NEW ENGL J MED, V319, P1681	21	323	330	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					435	437		10.1136/bmj.303.6800.435	http://dx.doi.org/10.1136/bmj.303.6800.435			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912833	Bronze, Green Published			2022-12-28	WOS:A1991GC46500013
J	LLOYD, A; YANCHEVA, N; WASYLYK, B				LLOYD, A; YANCHEVA, N; WASYLYK, B			TRANSFORMATION SUPPRESSOR ACTIVITY OF A JUN TRANSCRIPTION FACTOR LACKING ITS ACTIVATION DOMAIN	NATURE			English	Article							C-JUN; GENE; EXPRESSION; CELLS	THE oncoprotein c-Jun is thought to be a mediator of ras transformation as both its synthesis and activity as a transcription factor are stimulated by ras expression 1,2. But c-Jun co-operates with ras in transformation assays 3, suggesting that they act along different pathways (reviewed in ref. 4). Here we show by means of a dominant-negative mutated transcription factor that c-Jun potentially in conjunction with other factors that interact with it is necessary for transformation by ras. The mutant Jun lacks an activation domain and blocks stimulation of transcription by several oncoproteins, including Ras, v-Src, polyoma middle T, c-Jun and c-Fos, as well as by the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). The inhibition is specific for motifs that bind Jun: activation of an NF-kappa B/Rel motif is not affected. This Jun mutant acts as an anti-oncogene in ras-transformed cells, generating non-transformed revertants that have acquired anchorage and density-dependent growth, as well as reduced tumorigenicity in vivo. Mutants of other transcription factors designed to inhibit transformation will enable us to study their role in signal transduction.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Kane S E, 1990, Semin Cancer Biol, V1, P127; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SCHNEIKERT J, 1991, NUCLEIC ACIDS RES, V19, P783, DOI 10.1093/nar/19.4.783; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	17	181	184	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					632	638		10.1038/352635a0	http://dx.doi.org/10.1038/352635a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1907719				2022-12-28	WOS:A1991GB21100060
J	HUNTLEY, ME; LOPEZ, MDG; KARL, DM				HUNTLEY, ME; LOPEZ, MDG; KARL, DM			TOP PREDATORS IN THE SOUTHERN-OCEAN - A MAJOR LEAK IN THE BIOLOGICAL CARBON PUMP	SCIENCE			English	Article							MARGINAL ICE-ZONE; PHYTOPLANKTON GROWTH; WEDDELL SEA; AUTUMN	Primary productivity in the Southern Ocean is approximately 3.5 gigatons of carbon per year, which accounts for nearly 15 percent of the global total. The presence of high concentrations of nitrate in Antarctic waters suggests that it might be possible to increase primary production significantly and thereby alleviate the net accumulation of atmospheric carbon dioxide. An analysis of the food web for these waters implies that the Southern Ocean may be remarkably inefficient as a carbon sink. This inefficiency is caused by the large flux of carbon respired to the atmosphere by air-breathing birds and mammals, dominant predators in the unusually simple food web of Antarctic waters. These top predators may transfer into the atmosphere as much as 20 to 25 percent of photosynthetically fixed carbon.	UNIV HAWAII,SCH OCEAN & EARTH SCI & TECHNOL,HONOLULU,HI 96822	University of Hawaii System	HUNTLEY, ME (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.		Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				BERGER WH, 1989, PRODUCTIVITY OCEAN P, P1; BROWN SG, 1984, ANTARCT ECOL, V2, P717; Conover R.J., 1978, Marine Ecology (London), V4, P221; CONOVER RJ, IN PRESS J MAR SYSTE; COTA GF, 1990, DEEP-SEA RES, V37, P1145, DOI 10.1016/0198-0149(90)90056-2; CROXALL JP, 1984, ANTARCT ECOL, V2, P533; DUCKLOW H, 1988, PROTOZOA THEIR ROLE, P431; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; Everson I., 1984, ANTARCT ECOL, V1, P783; Gordon AL, 1982, SO OCEAN ATLAS; HUMPHREYS WF, 1979, J ANIM ECOL, V48, P427, DOI 10.2307/4171; HUNTLEY ME, IN PRESS DEEP SEA RE; KARL DM, IN PRESS DEEP SEA RE; KARL DM, 1990, DEEP-SEA RES, V37, P1145; Kawamura A., 1970, Scient. Rep. Whales Res. Inst., Tokyo, VNo. 22, P127; Knox G. A., 1970, ANTARCT ECOL, V1, P69; LANCELOT C, 1989, BELGIAN SCI RES PROG, V1; Laws R.M., 1984, P621; LAWS RM, 1985, AM SCI, V73, P26; LWAS RM, 1984, ANTARCTIC ECOLOGY, V2; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; Ricklefs RE, 1973, ECOLOGY; Romankevich E. A., 1984, GEOCHEMISTRY ORGANIC; SMETACEK V, COMMUNICATION; SMITH WO, 1990, LIMNOL OCEANOGR, V35, P809, DOI 10.4319/lo.1990.35.4.0809; SMITH WO, 1988, ANTARCTIC OCEAN RESO, P131, DOI DOI 10.1007/978-3-642-73724-4_10; Sundquist E.T., 1985, GEOPHYS MONOGR SER, V32, P5; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; VERNET M, IN PRESS ANTARCT J U; VEZINA AF, 1989, MAR ECOL-PROG SER, V42, P269	32	87	88	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					64	66		10.1126/science.1905841	http://dx.doi.org/10.1126/science.1905841			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905841				2022-12-28	WOS:A1991FV17700033
J	WOOLHOUSE, MEJ; TAYLOR, P; MATANHIRE, D; CHANDIWANA, SK				WOOLHOUSE, MEJ; TAYLOR, P; MATANHIRE, D; CHANDIWANA, SK			ACQUIRED-IMMUNITY AND EPIDEMIOLOGY OF SCHISTOSOMA-HAEMATOBIUM	NATURE			English	Article							HIGHVELD REGION; MANSONI; INFECTION; RESISTANCE; RESPONSES; DYNAMICS; MICE; SCHOOLCHILDREN; TRANSMISSION; REINFECTION	HUMAN immune responses to schistosome infection have been characterized in detail 1-5. But there has been controversy 6 over the relative importance of ecological factors (variation in exposure to infection) and immunological factors (acquired immunity) in determining the relationships between levels of infection and age typically found in areas where infection is endemic 7,8. Independent effects of exposure and age on the rates of reinfection with Schistosoma haematobium after chemotherapy have been demonstrated in the Gambia 9 and Zimbabwe 8. This age effect could be the result of acquired immunity to infection. Indeed, allowing for variation in exposure and age, low rates of reinfection in the Gambia are correlated with high amounts of specific IgE antibodies 10 -human IgE can kill S. mansoni schistosomulae in vitro 11. Further, animals can acquire immunologically mediated resistance to S. mansoni infection 12,14, although nonimmunological factors could also be involved 15. Acquisition of this immunity seems to be related to the cumulative effects of repeated infection and provides only partial protection 12,13,16. These characteristics are consistent with immuno-epidemiological data for both S. mansoni and S. haematobium infections of humans 4,17. We have now analysed age-prevalence data for human infection with S. haematobium, and find patterns of variation that are indeed consistent with the epidemiological effects of acquired immunity predicted by mathematical models.	UNIV ZIMBABWE,TRAINING CTR WATER & SANITAT,HARARE,ZIMBABWE; BLAIR RES LAB,HARARE,ZIMBABWE	University of Zimbabwe	WOOLHOUSE, MEJ (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.							ANDERSON JG, 1987, MUTAGENESIS, V2, P279, DOI 10.1093/mutage/2.4.279; ANDERSON RM, 1985, NATURE, V315, P493, DOI 10.1038/315493a0; BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8; BUTTERWORTH AE, 1987, PARASITOL TODAY, V3, P11, DOI 10.1016/0169-4758(87)90091-3; BUTTERWORTH AE, 1987, PARASITOLOGY, V94, P281, DOI 10.1017/S0031182000053956; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CHANDIWANA SK, 1988, TROP MED PARASITOL, V39, P187; CHANDIWANA SK, 1987, SOC SCI MED, V25, P495, DOI 10.1016/0277-9536(87)90173-0; CHANDIWANA SK, 1991, PARASITOLOGY, V102, P73, DOI 10.1017/S0031182000060364; Clarke V D, 1966, Cent Afr J Med, V12, P1; CROMBIE JA, 1985, NATURE, V315, P491, DOI 10.1038/315491a0; DEAN DA, 1983, EXP PARASITOL, V55, P1, DOI 10.1016/0014-4894(83)90002-4; DOENHOFF MJ, 1986, T ROY SOC TROP MED H, V80, P503, DOI 10.1016/0035-9203(86)90126-4; DUNNE DW, 1988, EUR J IMMUNOL, V18, P123, DOI 10.1002/eji.1830180119; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; Hagan P., 1987, The biology of schistosomes. From genes to latrines, P295; HAGAN P, 1987, T ROY SOC TROP MED H, V81, P938, DOI 10.1016/0035-9203(87)90359-2; JAMES SL, 1985, PARASITOLOGY, V91, P301, DOI 10.1017/S0031182000057395; PEARCE EJ, 1983, PARASITOLOGY, V87, P465, DOI 10.1017/S0031182000082998; SMITHERS SR, 1967, T ROY SOC TROP MED H, V61, P517, DOI 10.1016/0035-9203(67)90102-2; STURROCK RF, 1983, T ROY SOC TROP MED H, V77, P363, DOI 10.1016/0035-9203(83)90166-9; TAYLOR P, 1990, ACTA TROP, V47, P91, DOI 10.1016/0001-706X(90)90071-7; TAYLOR P, IN PRESS COMMUNITY B; Wilkins H.A., 1987, P379; WILKINS HA, 1984, T ROY SOC TROP MED H, V78, P216, DOI 10.1016/0035-9203(84)90281-5; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WILSON RA, 1990, PARASITOL TODAY, V6, P354, DOI 10.1016/0169-4758(90)90414-Y	27	133	133	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					757	759		10.1038/351757a0	http://dx.doi.org/10.1038/351757a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1905786				2022-12-28	WOS:A1991FU20100068
J	MCDONALD, JH; KREITMAN, M				MCDONALD, JH; KREITMAN, M			ADAPTIVE PROTEIN EVOLUTION AT THE ADH LOCUS IN DROSOPHILA	NATURE			English	Article							ALCOHOL-DEHYDROGENASE; STRANDED-DNA; MELANOGASTER	PROTEINS often differ in amino-acid sequence across species. This difference has evolved by the accumulation of neutral mutations by random drift, the fixation of adaptive mutations by selection, or a mixture of the two. Here we propose a simple statistical test of the neutral protein evolution hypothesis based on a comparison of the number of amino-acid replacement substitutions to synonymous substitutions in the coding region of a locus. If the observed substitutions are neutral, the ratio of replacement to synonymous fixed differences between species should be the same as the ratio of replacement to synonymous polymorphisms within species. DNA sequence data on the Adh locus (encoding alcohol dehydrogenase, EC 1.1.1.1) in three species in the Drosophila melanogaster species subgroup do not fit this expectation; instead, there are more fixed replacement differences between species than expected. We suggest that these excess replacement substitutions result from adaptive fixation of selectively advantageous mutations.			MCDONALD, JH (corresponding author), PRINCETON UNIV,DEPT ECOL & EVOLUT BIOL,PRINCETON,NJ 08544, USA.		Weinstock, George M/C-6314-2013	Weinstock, George M/0000-0002-2997-4592				BODMER M, 1984, NATURE, V309, P425, DOI 10.1038/309425a0; COHN VH, 1988, MOL BIOL EVOL, V5, P154; COLLET C, 1988, J MOL EVOL, V27, P142, DOI 10.1007/BF02138374; HALDANE J. B. S., 1957, JOUR GENETICS, V55, P511, DOI 10.1007/BF02984069; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; KREITMAN M, 1991, GENETICS, V127, P565; LEWONTIN RC, 1985, ANNU REV GENET, V19, P81, DOI 10.1146/annurev.ge.19.120185.000501; Nei M., 1987, MOL EVOLUTIONARY GEN; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SMITH JM, 1968, ANTURE, V219, P1114; Sokal R. R, 1981, BIOMETRY; SVED JA, 1968, AM NAT, V102, P283, DOI 10.1086/282542; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	15	2503	2537	4	260	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					652	654		10.1038/351652a0	http://dx.doi.org/10.1038/351652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1904993				2022-12-28	WOS:A1991FT11200066
J	SIMON, SM; BLOBEL, G				SIMON, SM; BLOBEL, G			A PROTEIN-CONDUCTING CHANNEL IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; NUCLEAR-ENVELOPE PERMEABILITY; IMMUNOGLOBULIN LIGHT-CHAINS; NASCENT POLYPEPTIDES; ROUGH MICROSOMES; MEMBRANE; TRANSLOCATION; SEQUENCE; PREPROLACTIN; RECEPTOR	The existence of a protein-conducting channel in the endoplasmic reticulum membrane was demonstrated by electrophysiological techniques. Pancreatic rough microsome (RM) vesicles were fused to one side (cis) of a planar lipid bilayer separating two aqueous compartments of 50 mM salt. This exposed the cytoplasmic surface of the RMs, with its attached ribosomes, to the cis chamber. Addition of 100-mu-M puromycin to the cis side caused a large increase in membrane conductance, presumably the result of puromycin-induced clearance of nascent protein chains from the lumen of protein-conducting channels. When puromycin was added at low concentrations (0.33-mu-M), single channels of 220 pS were observed. These closed when the salt concentration was raised to levels at which ribosomes detach from the membrane (150-400 mM), indicating that the attached ribosome keeps the channel in an open conformation. A mechanism for a complete cycle of opening and closing of the protein-conducting channel is suggested.			SIMON, SM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224				ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193; BRECHER AS, 1969, BIOCHEM J, V112, P335, DOI 10.1042/bj1120335; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORNELL DG, 1989, BIOCHEMISTRY-US, V28, P2789, DOI 10.1021/bi00433a008; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; HERSH LB, 1981, J NEUROCHEM, V36, P1594, DOI 10.1111/j.1471-4159.1981.tb00605.x; HEYER EJ, 1976, J GEN PHYSIOL, V67, P703, DOI 10.1085/jgp.67.6.703; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JIANG LW, 1986, J CELL BIOL, V102, P853, DOI 10.1083/jcb.102.3.853; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; MARCHAIS D, 1979, J PHYSIOL-LONDON, V297, P9, DOI 10.1113/jphysiol.1979.sp013025; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MILSTEIN C, 1972, NATURE-NEW BIOL, V239, P117, DOI 10.1038/newbio239117a0; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; MUELLER P, 1969, LABORATORY TECHNIQUE, P141; MULLINS LJ, 1959, J GEN PHYSIOL, V42, P817, DOI 10.1085/jgp.42.4.817; NESMEYANOVA MA, 1989, FEBS LETT, V257, P203, DOI 10.1016/0014-5793(89)81534-0; NILES WD, 1987, J GEN PHYSIOL, V90, P703, DOI 10.1085/jgp.90.5.703; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; Pestka S, 1974, Methods Enzymol, V30, P261; PETERS R, 1983, J BIOL CHEM, V258, P1427; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SABATINI DD, 1970, J CELL BIOL, V45, P146, DOI 10.1083/jcb.45.1.146; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHWARZ W, 1977, BIOPHYS J, V20, P343, DOI 10.1016/S0006-3495(77)85554-9; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; SUSZKIW JB, 1970, BIOCHEMISTRY-US, V9, P4008, DOI 10.1021/bi00822a021; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANHELDEN D, 1977, NATURE, V269, P711, DOI 10.1038/269711a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2; YAMAMOTO Y, 1990, BIOCHEMISTRY-US, V29, P8998, DOI 10.1021/bi00490a017; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	72	526	545	3	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					371	380		10.1016/0092-8674(91)90455-8	http://dx.doi.org/10.1016/0092-8674(91)90455-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1902142				2022-12-28	WOS:A1991FK18200004
J	BAILLY, E; MCCAFFREY, M; TOUCHOT, N; ZAHRAOUI, A; GOUD, B; BORNENS, M				BAILLY, E; MCCAFFREY, M; TOUCHOT, N; ZAHRAOUI, A; GOUD, B; BORNENS, M			PHOSPHORYLATION OF 2 SMALL GTP-BINDING PROTEINS OF THE RAB FAMILY BY P34CDC2	NATURE			English	Article							VESICULAR STOMATITIS-VIRUS; SYNTHESIZED G-PROTEIN; CONTROL GENE CDC2+; YPT1 PROTEIN; YEAST; SECRETION; MEMBRANE; MITOSIS; PRODUCT; ACTIVATION	ENTRY of a cell into mitosis induces a series of structural and functional changes including arrest of intracellular transport 1-4. Knowledge of how the mitotic cycle is driven progressed substantially with the identification of the p34cdc2 protein kinase as a subunit of maturation-promoting factor 5-7, the universal regulating component of the mitotic cycle 8. Activation of the kinase at the onset of mitosis 9 is thought to trigger the important mitotic events by phosphorylating key proteins 10. Small guanine nucleotide-binding proteins have been implicated in regulating transport pathways. For instance, two small Ras-related GTP-binding proteins, Sec4p and Ypt1p, control distinct stages of the secretory pathway in budding yeast 11-15. The GTP-binding proteins of the Rab family in rats and humans 16,17 display strong homologies with Sec4p and Ypt1p, and might therefore also be involved in regulating intracellular transport. Indeed, distinct Rab proteins are located in the exocytotic and endocytotic compartments 18-21. Interruption of vesicular transport during mitosis might involve modification of these proteins. We now present biochemical evidence for a mitosis-specific p34cdc2 phosphorylation of Rab1Ap and Rab4p. By contrast, Rab2p and Rab6p are not phosphorylated. We also show that the distribution of Rab1Ap and Rab4p between cytosolic and membrane-bound forms is different in interphase and mitotic cells. This may provide a clue to the mechanism by which phosphorylation could affect membrane traffic during mitosis.	INST PASTEUR,CNRS,URA 361,UNITE GENET SOMAT,F-75724 PARIS,FRANCE; FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	BAILLY, E (corresponding author), CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE.		Goud, Bruno/GWC-4807-2022					BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; FISCHER, 1990, P NATL ACAD SCI USA, V87, P1988; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LANGAN TA, 1982, J BIOL CHEM, V257, P4835; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MOLENAAR CMT, 1988, EMBO J, V7, P1167; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VANDERSLUIJS P, IN PRESS P NATN ACAD; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WARREN G, 1983, J CELL BIOL, V97, P1623, DOI 10.1083/jcb.97.5.1623; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	34	142	148	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					715	718		10.1038/350715a0	http://dx.doi.org/10.1038/350715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1902553				2022-12-28	WOS:A1991FJ13000063
J	EDDY, DM				EDDY, DM			WHAT CARE IS ESSENTIAL - WHAT SERVICES ARE BASIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									DUKE UNIV,DURHAM,NC 27706	Duke University								CALLAHAN D, 1990, WHAT KIND LIFE LIMIT, P191; EDDY D, 1990, JAMA-J AM MED ASSOC, V264, P105; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1169; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1165; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1170; Rawls J., 1971, THEORY JUSTICE; 1990, CALL ACTION, P61	9	46	46	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					782	&		10.1001/jama.265.6.782	http://dx.doi.org/10.1001/jama.265.6.782			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1899277				2022-12-28	WOS:A1991EW47900034
J	GAHRTON, G; TURA, S; LJUNGMAN, P; BELANGER, C; BRANDT, L; CAVO, M; FACON, T; GRANENA, A; GORE, M; GRATWOHL, A; LOWENBERG, B; NIKOSKELAINEN, J; REIFFERS, JJ; SAMSON, D; VERDONCK, L; VOLIN, L				GAHRTON, G; TURA, S; LJUNGMAN, P; BELANGER, C; BRANDT, L; CAVO, M; FACON, T; GRANENA, A; GORE, M; GRATWOHL, A; LOWENBERG, B; NIKOSKELAINEN, J; REIFFERS, JJ; SAMSON, D; VERDONCK, L; VOLIN, L			ALLOGENEIC BONE-MARROW TRANSPLANTATION IN MULTIPLE-MYELOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; TOTAL-BODY IRRADIATION; 1ST REMISSION; GRAFT; MELPHALAN; SURVIVAL	Background and Methods. In contrast to autologous bone marrow transplants for hematologic cancers, allogeneic transplants contain no tumor cells that might cause a relapse. We report the results of such allogeneic bone marrow transplantation using HLA-compatible sibling donors in 90 patients with multiple myeloma performed in 26 European centers between 1983 and 1989. Results. At the time of the most recent follow-up, 79 months after the start of the study, 47 patients were alive and 43 were dead. The rate of complete remission after bone marrow transplantation was 43 percent for all patients and 58 percent for the patients who had engraftment. The actuarial survival at 76 months was 40 percent. The median duration of relapse-free survival among patients who were in complete remission after bone marrow transplantation was 48 months. The stage of the disease at diagnosis and the number of treatment regimens tried before bone marrow transplantation were predictive of the likelihood of complete remission after engraftment. There were trends toward longer survival among patients who were responsive to treatment before bone marrow transplantation, patients with Stage I disease at diagnosis, and patients who had received only first-line treatment before transplantation, as compared with those who were not responsive, those with Stage II or III disease at diagnosis, and those who had received three or more lines of treatment, but the differences in these factors were not statistically significant. Two post-transplantation factors predicted better long-term survival: complete remission after engraftment and grade I graft-versus-host disease, rather than grade II, III, or IV. Conclusions. Allogeneic bone marrow transplantation with the use of HLA-matched sibling donors appears to be a promising method of treatment for some patients with multiple myeloma.	KAROLINSKA INST, S-14186 HUDDINGE, SWEDEN; HOSP SAN ORSOLA, DEPT HEMATOL, BOLOGNA, ITALY; HOP COCHIN, DEPT HEMATOL, F-75674 PARIS 14, FRANCE; HOSP CLAUDE HURIEZ, SERV MALAD SANG, LILLE, FRANCE; CLIN HOSP BARCELONA, SCH HEMATOL, BARCELONA, SPAIN; ROYAL MARSDEN HOSP, INST CANC RES, LONDON, ENGLAND; UNIV HOSP BASEL, DEPT INTERNAL MED, DIV HEMATOL, CH-4031 BASEL, SWITZERLAND; DR DANIEL DENHOED CANC CTR, ROTTERDAM, NETHERLANDS; UNIV TURKU, DEPT MED, SF-20500 TURKU 50, FINLAND; CTR FRANCOIS MAGENDIE, SERV MALAD SANG, PESSAC, FRANCE; CHARING CROSS HOSP, DEPT HAEMATOL, LONDON W6 8RP, ENGLAND; STATE UNIV UTRECHT HOSP, DEPT HEMATOL, 3511 GV UTRECHT, NETHERLANDS; UNIV HELSINKI, DEPT MED 3, SF-00100 HELSINKI 10, FINLAND	Karolinska Institutet; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Basel; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Turku; CHU Bordeaux; Imperial College London; Utrecht University; Utrecht University Medical Center; University of Helsinki	GAHRTON, G (corresponding author), HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN.		CAVO, MICHELE/AAK-8274-2020	CAVO, MICHELE/0000-0003-4514-3227				ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; ALEXANIAN R, 1991, AM J CLIN ONCOL-CANC, V14, P188, DOI 10.1097/00000421-199106000-00003; ANDERSON K, 1989, BLOOD S, V474, pA202; ANDERSON KC, 1991, BLOOD, V77, P712; APPERLEY JF, 1988, BRIT J HAEMATOL, V69, P239, DOI 10.1111/j.1365-2141.1988.tb07628.x; BARLOGIE B, 1987, BLOOD, V70, P869; BARLOGIE B, 1986, BLOOD, V67, P1298; BARLOGIE B, 1991, BONE MARROW TRANSPL, V7, P71; BUCKNER CD, 1989, EUR J HAEMATOL, V43, P186; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; FERMAND JP, 1989, BLOOD, V73, P20; FRIEDENBERG WR, 1991, AM J HEMATOL, V36, P171, DOI 10.1002/ajh.2830360303; GAHRTON G, 1989, BONE MARROW TRANSPL, V4, P4; GAHRTON G, 1989, EUR J HAEMATOL, V43, P182; GAHRTON G, 1988, HEMATOL ONCOL, V6, P181, DOI 10.1002/hon.2900060219; GAHRTON G, 1986, ACTA MED SCAND, V219, P523; GAHRTON G, 1990, Bone Marrow Transplantation, V5, P2; GOBBI M, 1989, EUR J HAEMATOL, V43, P176; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOLDSTONE AH, 1986, BRIT J HAEMATOL, V64, P529, DOI 10.1111/j.1365-2141.1986.tb02209.x; GORIN NC, 1990, BLOOD, V75, P1606; HOROWITZ MM, 1990, BLOOD, V75, P555; JAGANNATH S, 1990, BLOOD, V76, P1860; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; LOWENBERG B, 1984, CANCER, V54, P2840, DOI 10.1002/1097-0142(19841215)54:12<2840::AID-CNCR2820541204>3.0.CO;2-4; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MCELWAIN TJ, 1983, LANCET, V2, P822; MELLSTEDT H, 1989, EUR J HAEMATOL, V43, P124; OSTERBORG A, 1989, EUR J HAEMATOL, V43, P54; PALVA IP, 1990, EUR J HAEMATOL, V44, P120; REECE DE, 1989, BLOOD S, V74, pA202; REIFFERS J, 1989, LANCET, V2, P1336; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P296, DOI 10.1111/j.1365-2141.1989.tb07705.x; SELBY PJ, 1987, BRIT J HAEMATOL, V66, P55, DOI 10.1111/j.1365-2141.1987.tb06890.x; SPORN JR, 1986, SEMIN ONCOL, V13, P318; THOMAS ED, 1977, BLOOD, V49, P511; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1986, SCAND J HAEMATOL, V36, P176; VENTURA GJ, 1990, BONE MARROW TRANSPL, V5, P265; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; YEAGER AM, 1986, NEW ENGL J MED, V315, P141, DOI 10.1056/NEJM198607173150301	41	344	355	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1267	1273		10.1056/NEJM199110313251802	http://dx.doi.org/10.1056/NEJM199110313251802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922221	Green Published			2022-12-28	WOS:A1991GM04100002
J	REPRESA, J; LEON, Y; MINER, C; GIRALDEZ, F				REPRESA, J; LEON, Y; MINER, C; GIRALDEZ, F			THE INT-2 PROTOONCOGENE IS RESPONSIBLE FOR INDUCTION OF THE INNER-EAR	NATURE			English	Article							CHICK-EMBRYO; SEQUENCE	THE int-2 proto-oncogene encodes several products related to the fibroblast growth factor (FGF) family 1,2. FGFs have been associated with mesoderm induction in the amphibian embryo 2,3 and int-2 has a distinct pattern of expression throughout development in vertebrates 4,5. But evidence for a function of int-2 in embryo-genesis has been lacking. In the mouse embryo, int-2 transcripts have been detected in the rhombencephalon at a developmental stage where classical experiments showed that the induction of the inner ear occurs 6,7. This raises the possibility that int-2 may constitute a signal for the induction of the otic vesicle, the primordium of the inner ear. We provide direct evidence for this view by showing that (1) the formation of the otic vesicle is inhibited by antisense oligonucleotides targeted to the secreted form of int-2, and by antibodies against int-2 oncoproteins, and (2) basic FGF (bFGF) can mimic the inductive signal in the absence of the rhombencephalon.	FAC MED VALLADOLID,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN; FAC MED VALLADOLID,DEPT CIENCIAS MORFOL,E-47005 VALLADOLID,SPAIN				Leon, Yolanda/ABG-6797-2020; Giraldez, Fernando/C-9821-2014	Leon Alvarez, Yolanda/0000-0002-4536-8373				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALVAREZ IS, 1990, ANAT RECORD, V228, P315, DOI 10.1002/ar.1092280311; DODGSON JB, 1983, J BIOL CHEM, V258, P2685; GIRALDEZ F, 1987, DEVELOPMENT, V100, P271; Gospodarowicz D, 1990, Curr Top Dev Biol, V24, P57, DOI 10.1016/S0070-2153(08)60084-8; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; REPRESA J, 1990, DEVELOPMENT, V110, P1081; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Waddington CH, 1937, J EXP BIOL, V14, P232; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	14	163	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					561	563		10.1038/353561a0	http://dx.doi.org/10.1038/353561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922362				2022-12-28	WOS:A1991GJ64300068
J	BLACKWELL, CC; JAMES, VS; DAVIDSON, S; WYLD, R; BRETTLE, RP; ROBERTSON, RJ; WEIR, DM				BLACKWELL, CC; JAMES, VS; DAVIDSON, S; WYLD, R; BRETTLE, RP; ROBERTSON, RJ; WEIR, DM			SECRETOR STATUS AND HETEROSEXUAL TRANSMISSION OF HIV	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP EDINBURGH,INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; MUIRHOUSE MED GRP,EDINBURGH,SCOTLAND		BLACKWELL, CC (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELL C C, 1989, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V47, P341, DOI 10.1016/0378-1097(89)90256-5; BLACKWELL CC, 1989, P ROYAL COLLEGE PHYS, V19, P129; RAZA MW, 1991, BMJ-BRIT MED J, V303, P815, DOI 10.1136/bmj.303.6806.815; 1989, BMJ, V298, P411	4	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					825	826		10.1136/bmj.303.6806.825-a	http://dx.doi.org/10.1136/bmj.303.6806.825-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH946	1932975	Green Published, Bronze			2022-12-28	WOS:A1991GH94600026
J	RICHARDS, C				RICHARDS, C			GENERAL-PRACTICE AS A CAREER	BRITISH MEDICAL JOURNAL			English	Editorial Material											RICHARDS, C (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,HLTH CARE EVALUAT,BRISTOL BS8 2PR,ENGLAND.							ALLEN I, 1988, ANY ROOM TOP STUDY D; BAIN J, 1991, BRIT MED J, V302, P1183, DOI 10.1136/bmj.302.6786.1183; Branthwaite A, 1988, 38 ROYAL COLL GEN PR; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; GLASMAN D, 1991, HLTH SERVICE J  0815, P3; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; ILIFFE S, 1991, BRIT MED J, V302, P1584, DOI 10.1136/bmj.302.6792.1584; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932; LEONARD P, 1991, AUDIT NEWSLETTER ROY, V2, P1; MORRELL DC, 1991, BMJ-BRIT MED J, V302, P1313, DOI 10.1136/bmj.302.6788.1313; ODONNELL M, 1986, DOCTOR DOCTOR; RICHARDS C, 1989, 78 KING EDW HOSP FUN; SAVAGE R, 1991, BR J GEN PRACT, V41, P309; TAYLOR A, 1991, GENERAL PRACTIT 0906, P1; 1988, MANAGEMENT FAMILY PR	15	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					827	828		10.1136/bmj.303.6806.827	http://dx.doi.org/10.1136/bmj.303.6806.827			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932976	Green Published, Bronze			2022-12-28	WOS:A1991GH94600027
J	GALLAGHER, G; MACKAY, I				GALLAGHER, G; MACKAY, I			DOCTORS AND DROPS	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS HOSP,LONDON W6 8RP,ENGLAND	Imperial College London								CHALTON R, 1985, BRIT MED J, V291, P788, DOI 10.1136/bmj.291.6498.788; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202	2	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					761	761		10.1136/bmj.303.6805.761	http://dx.doi.org/10.1136/bmj.303.6805.761			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932938	Green Published, Bronze			2022-12-28	WOS:A1991GG98100023
J	HOPKINS, A				HOPKINS, A			FOR DEBATE - GUIDELINES FOR THE MANAGEMENT OF CONVULSIONS WITH FEVER	BRITISH MEDICAL JOURNAL			English	Article							FEBRILE CONVULSIONS; VALPROATE; CHILDREN; SEIZURES; THERAPY				HOPKINS, A (corresponding author), ROYAL COLL PHYS,RES UNIT,REGENTS PK,LONDON NW1 4LE,ENGLAND.							ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; BERG AT, 1990, J PEDIATR-US, V116, P329, DOI 10.1016/S0022-3476(05)82816-1; HORWITZ SJ, 1980, ANN NEUROL, V7, P524, DOI 10.1002/ana.410070605; KNUDSEN FU, 1985, ARCH DIS CHILD, V60, P1045, DOI 10.1136/adc.60.11.1045; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; NEWTON RW, 1988, ARCH DIS CHILD, V63, P1189, DOI 10.1136/adc.63.10.1189; NICOLL A, 1989, BRIT PAEDIATRIC ASS; PORTER RJ, 1981, FEBRILE SEIZURES, P107; SCHEFFNER D, 1988, EPILEPSIA, V29, P530, DOI 10.1111/j.1528-1157.1988.tb03757.x; STEELE RW, 1970, J PEDIATR-US, V77, P824, DOI 10.1016/S0022-3476(70)80242-6	10	52	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					634	636						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932910				2022-12-28	WOS:A1991GF67500030
J	MARMOT, M; BRUNNER, E				MARMOT, M; BRUNNER, E			ALCOHOL AND CARDIOVASCULAR-DISEASE - THE STATUS OF THE U-SHAPED CURVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; CONSUMPTION; DEATH; RISK; MEN; DRINKING				MARMOT, M (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.		Brunner, Eric/H-2114-2011; Marmot, M G/Y-3920-2019	Brunner, Eric/0000-0002-0595-4474; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AENDERSON P, 1988, BMJ-BRIT MED J, V297, P824; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; CASTELLI WP, 1977, LANCET, V2, P153; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; DEAN G, 1977, 14 TOB RES COUNC P 1; DEBUSK RF, 1986, NEW ENGL J MED, V314, P161, DOI 10.1056/NEJM198601163140307; DUFFY JC, 1982, PSYCHOL REP, V50, P125, DOI 10.2466/pr0.1982.50.1.125; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, CIRCULATION, V81, P720; KLATSKY AL, 1979, ALCOHOL CLIN EXP RES, V3, P33, DOI 10.1111/j.1530-0277.1979.tb04764.x; KLATSKY AL, 1989, CIRCULATION, V80, P611; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KOZAREVIC D, 1983, INT J EPIDEMIOL, V12, P145, DOI 10.1093/ije/12.2.145; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MILLER GJ, 1990, INT J EPIDEMIOL, V19, P923, DOI 10.1093/ije/19.4.923; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSS RK, 1981, LANCET, V1, P858; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SISCOVICK DS, 1986, AM J EPIDEMIOL, V123, P490, DOI 10.1093/oxfordjournals.aje.a114265; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1988, LANCET, V2, P1292	37	318	322	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 7	1991	303	6802					565	568		10.1136/bmj.303.6802.565	http://dx.doi.org/10.1136/bmj.303.6802.565			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912889	Green Published, Bronze			2022-12-28	WOS:A1991GE94800027
J	WILLIAMS, CJ				WILLIAMS, CJ			CANCER	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY				WILLIAMS, CJ (corresponding author), ROYAL S HANS HOSP,MED ONCOL UNIT,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Doll R, 1981, THE CAUSES OF CANCER; FINK K, 1968, PUBLIC HLTH REP, V63, P479; GRAY JAM, 1991, BREAST CANCER SCREEN; GUZICK DS, 1978, AM J PUBLIC HEALTH, V68, P125, DOI 10.2105/AJPH.68.2.125; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; ROBERTS MM, 1989, BRIT MED J, V299, P1153, DOI 10.1136/bmj.299.6708.1153; RODGERS A, 1991, BRIT MED J, V302, P411, DOI 10.1136/bmj.302.6773.411-b; SKRABANEK P, 1985, LANCET, V2, P318; TUYNS AJ, 1977, B CANCER, V64, P45; WALD N, 1991, BRIT MED J, V302, P845, DOI 10.1136/bmj.302.6780.845; 1988, LANCET, V2, P41; 1991, HLTH NATION; 1987, TECHNICAL B AM COLLE, V105; 1982, TRENDS CANCER SURVIV	15	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					516	517		10.1136/bmj.303.6801.516	http://dx.doi.org/10.1136/bmj.303.6801.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912867	Bronze, Green Published			2022-12-28	WOS:A1991GD80400024
J	EVANS, JG				EVANS, JG			THE HEALTH OF THE NATION - RESPONSES - CHALLENGE OF AGING	BRITISH MEDICAL JOURNAL			English	Article							LIFE				EVANS, JG (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DIV GERIATR MED,OXFORD OX2 6HE,ENGLAND.							ACLAND H, 1854, MEMOIR CHOLERA OXFOR; BEAGLEHOLE R, 1991, BRIT MED J, V303, P69, DOI 10.1136/bmj.303.6794.69; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P1126, DOI 10.2105/AJPH.74.10.1126; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; EVANS JG, 1982, NEUROLOGICAL DISORDE, P1; EVANS JG, 1986, STROKE EPIDEMIOLOGIC, P33; FAIRWEATHER DS, 1991, METABOLIC MOL BASIS, V1, P213; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KHAW KT, 1990, AGE AGEING, V19, P277, DOI 10.1093/ageing/19.5.277; Rees J L, 1982, Community Med, V4, P100, DOI 10.1007/BF02548823; 1988, SURVEY DISABILITY GR; 1991, CM1523	14	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					408	409		10.1136/bmj.303.6799.408	http://dx.doi.org/10.1136/bmj.303.6799.408			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB599	1912811	Bronze, Green Published			2022-12-28	WOS:A1991GB59900023
J	MCCLURKIN, JW; OPTICAN, LM; RICHMOND, BJ; GAWNE, TJ				MCCLURKIN, JW; OPTICAN, LM; RICHMOND, BJ; GAWNE, TJ			CONCURRENT PROCESSING AND COMPLEXITY OF TEMPORALLY ENCODED NEURONAL MESSAGES IN VISUAL-PERCEPTION	SCIENCE			English	Article							TWO-DIMENSIONAL PATTERNS; SINGLE UNITS; CORTEX; STREAMS	The intrinsic neuronal code that carries visual information and the perceptual mechanism for decoding that information are not known. However, multivariate statistics and information theory show that neurons in four visual areas simultaneously carry multiple, stimulus-related messages by utilizing multiplexed temporal codes. The complexity of these temporal messages increases progressively across the visual system, yet the temporal codes overlap in time. Thus, visual perception may depend on the concurrent processing of multiplexed temporal messages from all visual areas.	NIMH, NEUROPSYCHOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	MCCLURKIN, JW (corresponding author), NEI, SENSORIMOTOR RES LAB, BETHESDA, MD 20892 USA.							Ahmed N., 1975, ORTHOGONAL TRANSFORM, P86; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; COBURN KL, 1990, BEHAV NEUROSCI, V104, P62, DOI 10.1037/0735-7044.104.1.62; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; MCCLURKIN JW, IN PRESS J NEUROPHYS; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; OPTICAN LM, 1987, J NEUROPHYSIOL, V57, P162, DOI 10.1152/jn.1987.57.1.162; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; RICHMOND BJ, 1988, SOC NEUR ABSTR, V14, P308; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Uttal W.R., 1973, PSYCHOBIOLOGY SENSOR; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	14	100	100	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					675	677		10.1126/science.1908118	http://dx.doi.org/10.1126/science.1908118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1908118				2022-12-28	WOS:A1991GA30400042
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			FOS-JUN HETERODIMERS AND JUN HOMODIMERS BEND DNA IN OPPOSITE ORIENTATIONS - IMPLICATIONS FOR TRANSCRIPTION FACTOR COOPERATIVITY	CELL			English	Article							INTEGRATION HOST FACTOR; LEUCINE ZIPPER; FACTOR AP-1; PROTEIN COMPLEXES; BINDING; SITE; REPLICATION; ELECTROPHORESIS; RECOGNITION; ACTIVATION	Association of Fos and Jun with the AP-1 site results in a conformational change in the basic amino acid regions that constitute the DNA-binding domain. We show that Fos and Jun induce a corresponding alteration in the conformation of the DNA helix. Circular permutation analysis indicated that both Fos-Jun heterodimers and Jun homodimers induce flexure at the AP-1 site. Phasing analysis demonstrated that Fos-Jun heterodimers and Jun homodimers induce DNA bends that are directed in opposite orientations. Fos-Jun heterodimers bend DNA toward the major groove, whereas Jun homodimers bend DNA toward the minor groove. Fos and Jun peptides encompassing the dimerization and DNA-binding domains bend DNA in the same orientations as the full-length proteins. However, additional regions of both proteins influence the magnitude of the DNA bend angle. Thus, despite the amino acid sequence similarity in the basic region Fos-Jun heterodimers and Jun homodimers form topologically distinct DNA-protein complexes.			KERPPOLA, TK (corresponding author), ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110, USA.		Curran, Tom/F-5234-2018; Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Kerppola, Tom/AAG-4457-2022; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1991, IN PRESS TRANSCRIPTI; DEVARGAS LM, 1991, P NATL ACAD SCI USA, V88, P588, DOI 10.1073/pnas.88.2.588; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; RYSECK RP, 1991, ONCOGENE, V6, P533; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	56	296	297	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					317	326		10.1016/0092-8674(91)90621-5	http://dx.doi.org/10.1016/0092-8674(91)90621-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1906785				2022-12-28	WOS:A1991FY71200012
J	VERBY, JE; NEWELL, JP; ANDRESEN, SA; SWENTKO, WM				VERBY, JE; NEWELL, JP; ANDRESEN, SA; SWENTKO, WM			CHANGING THE MEDICAL-SCHOOL CURRICULUM TO IMPROVE PATIENT ACCESS TO PRIMARY CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; PROGRAM	The problems of access to health care by the underinsured demand a systematic response. One of the critical components of that response is medical curriculum reform, with the intent to graduate adequate numbers of physicians to do primary care, to work with the underinsured and the uninsured, and to practice in rural areas. One state, Minnesota, has developed a unique response to these needs, demonstrating problem solving very much in keeping with many of the recommendations in the literature. Highlighted in this article is the University of Minnesota's Rural Physician Associate Program, a predoctoral curriculum innovation functioning for 20 years to help resolve the issue of physician maldistribution in the state. The Rural Physician Associate Program provides students with many of the skills needed to provide primary care, it is cost-effective, and it has brought a number of benefits to the participating communities.	SO ILLINOIS UNIV,SCH MED,DEPT FAMILY MED,SPRINGFIELD,IL 62708; UNIV MINNESOTA,SCH MED,RURAL PHYSICIAN ASSOCIATE PROGRAM,MINNEAPOLIS,MN 55455	Southern Illinois University System; Southern Illinois University; University of Minnesota System; University of Minnesota Twin Cities	VERBY, JE (corresponding author), UNIV MINNESOTA,SCH MED,DEPT FAMILY PRACTICE & COMMUNITY HLTH,BOX 81 UMHC,MINNEAPOLIS,MN 55455, USA.							ADKINS RJ, 1987, J MED EDUC, V62, P810; BENJAMIN WW, 1989, NEW ENGL J MED, V321, P1191, DOI 10.1056/NEJM198910263211711; BLOOM SW, 1988, J HEALTH SOC BEHAV, V29, P294, DOI 10.2307/2136864; Brazeau N K, 1990, Fam Med, V22, P350; CULLISON S, 1976, JAMA-J AM MED ASSOC, V235, P502, DOI 10.1001/jama.235.5.502; ENGLE CE, 1989, ANN COMMUNITY ORIENT, V2, P85; Ernst R L, 1984, Med Care Rev, V41, P1, DOI 10.1177/107755878404100101; FLEXNER A, 1910, CARNEGIE F ADV TEACH, V4; FREYMANN JG, 1989, J GEN INTERN MED, V4, P313, DOI 10.1007/BF02597404; Head R E, 1989, Fam Med, V21, P187; KAUFMAN A, 1989, ACAD MED, V64, P285, DOI 10.1097/00001888-198906000-00001; KRALEWSKI J, 1989, HLTH INSURANCE COVER; MASON HR, 1975, JAMA-J AM MED ASSOC, V233, P49; MENNIN SP, 1989, ANN COMMUNITY ORIENT, V2, P101; RAPPLEYE WC, 1932, MED ED FINAL REPORT; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; Starr P, 1982, SOCIAL TRANSFORMATIO; VERBY JE, 1988, J MED EDUC, V63, P427; VERBY JE, 1976, JAMA-J AM MED ASSOC, V236, P2413; VERBY JE, 1983, FAM PRACT, V2, P151; 1986, US BUREAU CENSUS P25, V997; 1984, J MED ED 2, V59, P1; 1990, AAMC WEEKLY REP 1221, V4, P2; 1990, AAMC WEEKLY REP 0315, V4, P1; 1988, HLTH AFF S, V7, P1; 1989, P J MACY F NATIONAL	26	90	90	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					110	113		10.1001/jama.266.1.110	http://dx.doi.org/10.1001/jama.266.1.110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT934	1904505				2022-12-28	WOS:A1991FT93400037
J	SANTOSHAM, M; WOLFF, M; REID, R; HOHENBOKEN, M; BATEMAN, M; GOEPP, J; CORTESE, M; SACK, D; HILL, J; NEWCOMER, W; CAPRIOTTI, L; SMITH, J; OWEN, M; GAHAGAN, S; HU, D; KLING, R; LUKACS, L; ELLIS, RW; VELLA, PP; CALANDRA, G; MATTHEWS, H; AHONKHAI, V				SANTOSHAM, M; WOLFF, M; REID, R; HOHENBOKEN, M; BATEMAN, M; GOEPP, J; CORTESE, M; SACK, D; HILL, J; NEWCOMER, W; CAPRIOTTI, L; SMITH, J; OWEN, M; GAHAGAN, S; HU, D; KLING, R; LUKACS, L; ELLIS, RW; VELLA, PP; CALANDRA, G; MATTHEWS, H; AHONKHAI, V			THE EFFICACY IN NAVAJO INFANTS OF A CONJUGATE VACCINE CONSISTING OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE AND NEISSERIA-MENINGITIDIS OUTER-MEMBRANE PROTEIN COMPLEX	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-CHILDREN; UNITED-STATES; DISEASE; EPIDEMIOLOGY; IMMUNOGENICITY; INFECTIONS; ALASKA; TRIAL	Background and Methods. Several conjugate vaccines against Haemophilus influenzae type b have been developed in the search for one that induces protection even in young infants. We evaluated the safety and efficacy of a conjugate vaccine that links the H. influenzae type b capsular polysaccharide to the outer-membrane protein complex (OMPC) of Neisseria meningitidis serogroup B. We conducted a double-blind, placebo-controlled trial in Navajo infants, who are at high risk for systemic infections caused by H. influenzae type b. The infants were randomly assigned to receive the first dose of vaccine or placebo at 42 to 90 days of age and the second at 70 to 146 days of age. Results. Of the infants in the trial, 2588 were assigned to receive the vaccine and 2602 to receive placebo. The mean follow-up was 269 days in the vaccine group and 267 days in the placebo group. Before the age of 18 months, there was 1 systemic H. influenzae type b infection in the vaccine group, as compared with 22 in the placebo group (P < 0.001; point estimate of efficacy, 95 percent; 95 percent confidence interval, 72 to 99 percent). Of the 22 H. influenzae type b infections in the placebo group, 13 were meningitis. Among the children who received both doses, there was 1 H. influenzae type b infection in the vaccine group (n = 2056) and 14 in the placebo group (n = 2105) (P < 0.001; point estimate of efficacy, 93 percent; 95 percent confidence interval, 53 to 98 percent). The single infection in the vaccine group occurred at 151/2 months of age in an infant with osteomyelitis. Between the first and second doses there were no H. influenzae type b infections in the vaccine group and eight in the placebo group (P < 0.005; point estimate of efficacy, 100 percent; 95 percent confidence interval, 41 to 100 percent). Conclusions. The H. influenzae type b OMPC vaccine, administered at 2 and 4 months of age, is safe and induces a high rate of protection against invasive disease caused by H. influenzae type b in infants under the age of 18 months. Protection begins after the first dose.	NAVAJO AREA INDIAN HLTH SERV,WINDOW ROCK,AZ; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT PEDIAT,DIV PEDIAT INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; MERCK SHARP & DOHME LTD,W POINT,PA 19486	Johns Hopkins University; Johns Hopkins University; Merck & Company	SANTOSHAM, M (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR AMER INDIAN & ALASKAN NAT HLTH,DEPT INT HLTH,BALTIMORE,MD 21205, USA.			Gahagan, Sheila/0000-0002-1105-7323				BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; COULEHAN JL, 1984, PUBLIC HEALTH REP, V99, P404; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LETSON GW, 1988, PEDIATR INFECT DIS J, V7, P747, DOI 10.1097/00006454-198811000-00001; LOSONSKY GA, 1984, PEDIATR INFECT DIS J, V3, P539, DOI 10.1097/00006454-198411000-00012; MARBURG S, 1986, J AM CHEM SOC, V108, P5282, DOI 10.1021/ja00277a037; PRZYBOROWSKI J., 1939, BIOMETRIKA, V31, P313; SANTOSHAM M, 1991, PEDIATR INFECT DIS J, V10, P113, DOI 10.1097/00006454-199102000-00007; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SHAPIRO ED, 1989, J INFECT DIS, V160, P1064, DOI 10.1093/infdis/160.6.1064; SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005; SOOD SK, 1990, 30TH INT C ANT AG CH, P97; TODD JK, 1975, AM J DIS CHILD, V129, P607, DOI 10.1001/archpedi.1975.02120420047016; VELLA PP, 1990, PEDIATRICS, V85, P668; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17; WEINBERG GA, 1987, J PEDIATR-US, V111, P22, DOI 10.1016/S0022-3476(87)80336-0	19	259	260	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1767	1772		10.1056/NEJM199106203242503	http://dx.doi.org/10.1056/NEJM199106203242503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	1903846				2022-12-28	WOS:A1991FR68100003
J	HOSHIJIMA, K; INOUE, K; HIGUCHI, I; SAKAMOTO, H; SHIMURA, Y				HOSHIJIMA, K; INOUE, K; HIGUCHI, I; SAKAMOTO, H; SHIMURA, Y			CONTROL OF DOUBLESEX ALTERNATIVE SPLICING BY TRANSFORMER AND TRANSFORMER-2 IN DROSOPHILA	SCIENCE			English	Article							CHROMOSOMALLY MALE DROSOPHILA; GENE-PRODUCT LEADS; SEX DETERMINATION; FEMALE DIFFERENTIATION; ECTOPIC EXPRESSION; RNA; MELANOGASTER; PROTEIN; ENCODES; LOCUS	Sex-specific alternative processing of doublesex (dsx) precursor messenger RNA (pre-mRNA) regulates somatic sexual differentiation in Drosophila melanogaster. Cotransfection analyses in which the dsx gene and the female-specific transformer (tra) and transformer-2 (tra-2) complementary DNAs were expressed in Drosophila Kc cells revealed that female-specific splicing of the dsx transcript was positively regulated by the products of the tra and tra-2 genes. Furthermore, analyses of mutant constructs of dsx showed that a portion of the female-specific exon sequence was required for regulation of dsx pre-messenger RNA splicing.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Kyoto University								AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1988, GENE DEV, V2, P477, DOI 10.1101/gad.2.4.477; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELOTE JM, 1982, P NATL ACAD SCI-BIOL, V79, P1568, DOI 10.1073/pnas.79.5.1568; BELOTE JM, 1989, DEV GENET, V10, P143, DOI 10.1002/dvg.1020100304; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CLINE TW, 1985, ORIGIN EVOLUTION SEX, P301; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HOSHIJIMA K, UNPUB; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NOTHIGER R, 1985, TRENDS GENET, V1, P209, DOI 10.1016/0168-9525(85)90082-4; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAIKI RK, 1988, SCIENCE, V239, P427; SCHUPBACH T, 1982, DEV BIOL, V89, P117, DOI 10.1016/0012-1606(82)90300-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	23	252	260	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					833	836		10.1126/science.1902987	http://dx.doi.org/10.1126/science.1902987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1902987				2022-12-28	WOS:A1991FL12300043
J	MISBIN, RI				MISBIN, RI			PHYSICIANS AID IN DYING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ASSISTED SUICIDE; EUTHANASIA				MISBIN, RI (corresponding author), UNIV FLORIDA, GAINESVILLE, FL 32610 USA.							ALTMAN LK, 1991, NY TIMES        0724, pA10; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P151; BEAUCHAMP TL, PRINCIPLES BIOMEDICA, V127, P89; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT, P233; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Doerflinger R, 1989, Hastings Cent Rep, V19, P16, DOI 10.2307/3561965; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GIANELLI DM, 1991, WASHINGTON STATE PHY, P1; GIANELLI DM, 1991, AM MED NEWS     0107, P9; HECHINGER FM, 1991, NY TIMES        0124, pA22; HORAN DJ, 1980, DEATH DYING EUTHANAS, P127; JAKOBOVITS I, 1961, Harofe Haivri Heb Med J, V2, P242; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; ROSNER F, 1986, MODERN MED JEWISH ET, P189; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; THOMASMA DC, 1990, EUTHANASIA ETHICAL S; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WEIR RF, 1989, ABATING TREATMENT CR; WERTHAM F, 1980, DEATH DYING EUTHANAS, P610; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1988, JAMA-J AM MED ASSOC, V259, P272	25	37	37	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1307	1311		10.1056/NEJM199110313251811	http://dx.doi.org/10.1056/NEJM199110313251811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922229				2022-12-28	WOS:A1991GM04100011
J	COLLINSON, PO; RAMHAMADAMY, EM; GREENWOOD, TW; ROSALKI, SB				COLLINSON, PO; RAMHAMADAMY, EM; GREENWOOD, TW; ROSALKI, SB			RULING OUT ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							SEQUENTIAL ENZYME MEASUREMENTS; EARLY DIAGNOSIS		ROYAL FREE HOSP,LONDON,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	COLLINSON, PO (corresponding author), W MIDDLESEX UNIV HOSP,ISLEWORTH TW7 6AF,MIDDX,ENGLAND.							COLLINSON PO, 1988, ANN CLIN BIOCHEM, V25, P376, DOI 10.1177/000456328802500409; COLLINSON PO, 1989, J CLIN PATHOL, V42, P1126, DOI 10.1136/jcp.42.11.1126; COLLINSON PO, IN PRESS ANN CLIN BI; EAGLE KA, 1991, NEW ENGL J MED, V324, P1282, DOI 10.1056/NEJM199105023241811; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEUNG FY, 1991, ANN CLIN BIOCHEM, V28, P78, DOI 10.1177/000456329102800113; MULLEN PJ, 1990, BRIT MED J, V301, P1213; RAMHAMADANY EM, 1988, CLIN CHEM, V34, P1914; RUTTY G, 1989, ANN CLIN BIOCHEM, V26, P558, DOI 10.1177/000456328902600619; WU AHB, 1989, CLIN CHEM, V35, P1752	10	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1249	1249						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922214				2022-12-28	WOS:A1991GL28200012
J	CORBIN, V; MICHELSON, AM; ABMAYR, SM; NEEL, V; ALCAMO, E; MANIATIS, T; YOUNG, MW				CORBIN, V; MICHELSON, AM; ABMAYR, SM; NEEL, V; ALCAMO, E; MANIATIS, T; YOUNG, MW			A ROLE FOR THE DROSOPHILA NEUROGENIC GENES IN MESODERM DIFFERENTIATION	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; NEURONAL PRECURSOR CELLS; ACHAETE-SCUTE COMPLEX; EGF-LIKE REPEATS; NOTCH LOCUS; C-ELEGANS; MONONUCLEATED MYOBLASTS; TRANSLATIONAL CONTROL; NEURAL DEVELOPMENT; DIFFERENT PROTEINS	The neurogenic genes of Drosophila have long been known to regulate cell fate decisions in the developing ectoderm. In this paper we show that these genes also control mesoderm development. Embryonic cells that express the muscle-specific gene nautilus are overproduced in each of seven neurogenic mutants (Notch, Delta, Enhancer of split, big brain, mastermind, neuralized, and almondex), at the apparent expense of neighboring, nonexpressing mesodermal cells. The mesodermal defect does not appear to be a simple consequence of associated neural hypertrophy, suggesting that the neurogenic genes may function similarly and independently in establishing cell fates in both ectoderm and mesoderm. Altered patterns of beta-3-tubulin and myosin heavy chain gene expression in the mutants indicate a role for the neurogenic genes in development of most visceral and somatic muscles. We propose that the signal produced by the neurogenic genes is a general one, effective in both ectoderm and mesoderm.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Howard Hughes Medical Institute; Rockefeller University; Harvard University	CORBIN, V (corresponding author), ROCKEFELLER UNIV, GENET LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM029301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM5-25103, 5P01GM29301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BALL EE, 1985, J NEUROSCI, V5, P1808; BARAD M, 1988, EMBO J, V7, P2151, DOI 10.1002/j.1460-2075.1988.tb03054.x; BATE M, 1990, DEVELOPMENT, V110, P791; BETTLER D, 1991, DEV BIOL, V144, P436, DOI 10.1016/0012-1606(91)90436-7; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRAND M, 1988, ROUX ARCH DEV BIOL, V197, P457, DOI 10.1007/BF00385679; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPUZANO S, 1986, CELL, V44, P303, DOI 10.1016/0092-8674(86)90764-6; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; Cramer L., 1980, DROS INFORM SERV, V55, P197; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P173; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; EMERSON CP, 1975, J MOL BIOL, V93, P431, DOI 10.1016/0022-2836(75)90238-7; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIAALONSO L, 1986, ROUX ARCH DEV BIOL, V195, P259; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GASCH A, 1988, MOL GEN GENET, V211, P8, DOI 10.1007/BF00338387; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEISS D, 1988, DEVELOPMENT, V104, P525; LINDSLEY D, 1985, DROS INFO SERV, V62; LINDSLEY D, 1990, DROS INFO SERV, V68; Lindsley D.L., 1968, GENETIC VARIATIONS D; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORRIS GE, 1976, EXP CELL RES, V99, P106, DOI 10.1016/0014-4827(76)90685-6; MOSS PS, 1976, DEV BIOL, V48, P431, DOI 10.1016/0012-1606(76)90104-4; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; Poulson D. F., 1950, BIOL DROSOPHILA, P168; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; POULSON DF, 1945, AM NAT, V79, P340, DOI 10.1086/281269; PREISS A, 1988, EMBO J, V7, P3917, DOI 10.1002/j.1460-2075.1988.tb03278.x; PREISS JR, 1987, CELL, V51, P241; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHANNON MP, 1973, J EXP ZOOL, V183, P383, DOI 10.1002/jez.1401830312; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P55; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P445, DOI 10.1007/BF00375748; TROTTER JA, 1976, DEV BIOL, V49, P548, DOI 10.1016/0012-1606(76)90197-4; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VERTEL BM, 1976, DEV BIOL, V48, P438, DOI 10.1016/0012-1606(76)90105-6; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WRIGHT TRF, 1970, ADV GENET, V15, P261, DOI 10.1016/S0065-2660(08)60075-9; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	101	240	243	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					311	323		10.1016/0092-8674(91)90183-Y	http://dx.doi.org/10.1016/0092-8674(91)90183-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913825				2022-12-28	WOS:A1991GL47000011
J	EDDY, DM				EDDY, DM			OREGON METHODS - DID COST-EFFECTIVENESS ANALYSIS FAIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									DUKE UNIV,DURHAM,NC 27706	Duke University								EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P2399, DOI 10.1001/jama.265.18.2399; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3035	6	93	93	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2135	2141		10.1001/jama.266.15.2135	http://dx.doi.org/10.1001/jama.266.15.2135			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ474	1920704				2022-12-28	WOS:A1991GJ47400038
J	ROLPH, JE; KRAVITZ, RL; MCGUIGAN, K				ROLPH, JE; KRAVITZ, RL; MCGUIGAN, K			MALPRACTICE CLAIMS DATA AS A QUALITY IMPROVEMENT TOOL .2. IS TARGETING EFFECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAROTID ENDARTERECTOMY; HEALTH-CARE	Objective. - To evaluate the usefulness of malpractice claims data for identifying (1) physicians who are prone to negligent errors and (2) physician and hospital characteristics associated with particular kinds of errors. Design. - Retrospective review of physician malpractice claim records. Setting. - Large New Jersey physician malpractice insurer. Participants. - Physicians practicing obstetrics and gynecology, general surgery, anesthesiology, or radiology and covered by the insurance carrier for any portion of 1977 through 1989. Main Outcome Measures. - Claims were classified into 11 clinical error categories comprising three broad groups: patient management problems, technical performance problems, and staff coordination problems. Outcomes were expressed as per-physician frequency of claims due to negligence and proportion of claims associated with various types of errors. Results. - Using 5 years of claims history to predict long-term claims proneness was more accurate than chance alone by 57% in obstetrics and gynecology, 33% in general surgery, 11% in anesthesiology, and 15% in radiology. Cross-validated recursive partitioning showed that among physician characteristics, only specialty was predictive of physician error profiles. For physician claims arising in acute care hospitals, hospital size and location in addition to hospital services discriminated among different error profiles; the cross-validated accuracy of this method was 69% compared with 22% accuracy achieved by random prediction. Conclusion. - Use of physicians' malpractice claims histories to target individuals for education or sanctions is problematic because of the only modest predictive power of such claims histories.	UNIV CALIF LOS ANGELES,SCH MED,DIV GEN INTERNAL MED & HLTH SERV RES,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	ROLPH, JE (corresponding author), RAND CORP,HLTH PROGRAM,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90406, USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				AITKIN M, 1989, STATISTICAL MODELING; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Breiman L., 1984, CLASSIFICATION REGRE; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; BROOK RH, 1990, ANN INTERN MED, V113, P747, DOI 10.7326/0003-4819-113-10-747; CLARK LA, 1991, STATISTICAL MODELS S; DeGroot M.H., 2005, OPTIMAL STAT DECISIO; Deming EW., 1986, OUT CRISIS; GAIL MH, 1986, J NATL CANCER I, V76, P805; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HADORN D, 1991, IN PRESS STAT MED; JOHNSON ID, 1991, JAMA-J AM MED ASSOC, V265, P407, DOI 10.1001/jama.265.3.407; JOHNSON ID, 1991, JAMA-J AM MED ASSOC, V265, P410; KRAVITZ RL, 1991, JAMA-J AM MED ASSOC, V266, P2087, DOI 10.1001/jama.266.15.2087; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LAWLESS JF, 1987, CAN J STAT, V15, P209, DOI 10.2307/3314912; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; MELNICK G, R3601HCFA RAND CORP; NYE BF, 1988, J RISK INSUR, V150, P151; ROLPH JE, 1991, LAW CONTEMP PROBL, V54, P65; SANAZARO PJ, 1985, MED CARE, V23, P1097, DOI 10.1097/00005650-198509000-00007; SCHWARTZ WB, 1985, NEW ENGL J MED, V313, P157, DOI 10.1056/NEJM198507183130305; SCHWARTZ WB, 1989, JAMA-J AM MED ASSOC, V262, P1342, DOI 10.1001/jama.262.10.1342; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; 1988, MONITORING HLTH CARE; 1986, MEDICARE HOSPITAL MO, P5; 1982, ANN SURVEY HOSPITALS; 1990, NEW JERSEY RATE SCHE	28	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2093	2097		10.1001/jama.266.15.2093	http://dx.doi.org/10.1001/jama.266.15.2093			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920697				2022-12-28	WOS:A1991GJ47400029
J	SKARFORS, ET; SELINUS, KI; LITHELL, HO				SKARFORS, ET; SELINUS, KI; LITHELL, HO			RISK-FACTORS FOR DEVELOPING NON-INSULIN-DEPENDENT DIABETES - A 10 YEAR FOLLOW-UP OF MEN IN UPPSALA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PIMA-INDIANS; ESSENTIAL-HYPERTENSION; RESISTANCE; OBESITY; METABOLISM; MELLITUS; HISTORY; SODIUM	Objective - To analyse anthropometric and metabolic characteristics as risk factors for development of non-insulin dependent diabetes mellitus in middle aged normoglycaemic men. Design - Prospective population study based on data collected in a health survey and follow up 10 years later. Setting - Uppsala, a middle sized city in Sweden. Subjects - 2322 men aged 47-53, of whom 1860 attended the follow up 7-14 years later, at which time they were aged 56-64. Main outcome measures - Incidence of non-insulin dependent diabetes. Results - In a multivariate logistic regression analysis, variations of 1 SD from the mean of the group that remained euglycaemic were used to calculate odds ratios and 95% confidence intervals. Blood glucose concentration 60 minutes after the start of an intravenous glucose tolerance test (odds ratio = 5.93, 95% confidence interval 3.05 to 11.5), fasting serum insulin concentration (2.12, 1.54 to 2.93), acute insulin increment at an intravenous glucose tolerance test (1.71, 1.21 to 2.43), body mass index (1.41, 1.01 to 1.97), and systolic blood pressure (1.23, 0.97 to 1.56) were independent predictors of diabetes. In addition, the use of antihypertensive drugs at follow up (selective or unselective beta-blocking agents, thiazides, or hydralazine) was an independent risk factor (1.70, 1.11 to 2.60). Conclusions - Metabolic and anthropometric characteristics associated with or reflecting insulin resistance as well as a poor acute insulin response to glucose challenge were important predictors of future diabetes in middle aged men. Antihypertensive drugs were found to constitute a further, iatrogenic risk factor.			SKARFORS, ET (corresponding author), UNIV UPPSALA,DEPT GERIATR,S-75012 UPPSALA,SWEDEN.							BARNETT AH, 1982, SERONO S, V47, P225; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BOBERG J, 1976, SCAND J CLIN LAB INV, V36, P145, DOI 10.3109/00365517609055241; BURSTEIN M, 1960, CLIN CHIM ACTA, V5, P609, DOI 10.1016/0009-8981(60)90075-9; CERASI E, 1967, DIABETES, V16, P615, DOI 10.2337/diab.16.9.615; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P278, DOI 10.1530/acta.0.0550278; COLLEN MF, 1969, ARCH INTERN MED, V123, P664, DOI 10.1001/archinte.123.6.664; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DIXON WJ, 1981, BMDP STATISTICAL SOF, P330; EDWARDS DAW, 1955, BRIT J NUTR, V9, P133, DOI 10.1079/BJN19550021; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HAFFNER SM, 1989, DIABETES S2, V38, pA92; HARVALD B, 1963, ACTA MED SCAND, V173, P459; HEDSTRAND H, 1975, SCAND J CLIN LAB INV, V35, P331, DOI 10.3109/00365517509095749; HESTRAND H, 1975, UPSALA J MED SCI S, V19, P28; HILTON PJ, 1986, NEW ENGL J MED, V314, P222, DOI 10.1056/NEJM198601233140407; IKKOS D, 1957, ACTA ENDOCRINOL-COP, V25, P312, DOI 10.1530/acta.0.0250312; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KNOWLER WC, 1989, DIABETES S2, V38, pA92; LEE ET, 1985, DIABETES CARE, V8, P107, DOI 10.2337/diacare.8.2.107; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LITHELL H, 1984, ACTA MED SCAND, V215, P403; LUFT R, 1981, DIABETES CARE, V4, P58, DOI 10.2337/diacare.4.1.58; LUNDGREN H, 1988, BRIT MED J, V297, P1512, DOI 10.1136/bmj.297.6662.1512; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; NAGULESPARAN M, 1979, DIABETES, V28, P980, DOI 10.2337/diabetes.28.11.980; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; OSULLIVAN JB, 1968, NEW ENGL J MED, V278, P1038, DOI 10.1056/NEJM196805092781904; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; RUSH RL, 1971, ADV AUTOMAT ANAL, V1, P503; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SAYEGH HAI, 1979, LANCET, V1, P431; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; WAHLBERG F, 1966, ACTA MED SCAND S453, V180, P22; 1979, DIABETES, V28, P1039; 1985, WHO TECH REP SER, V724, P183	44	172	174	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					755	760		10.1136/bmj.303.6805.755	http://dx.doi.org/10.1136/bmj.303.6805.755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932936	Bronze, Green Published			2022-12-28	WOS:A1991GG98100021
J	HOH, JH; LAL, R; JOHN, SA; REVEL, JP; ARNSDORF, MF				HOH, JH; LAL, R; JOHN, SA; REVEL, JP; ARNSDORF, MF			ATOMIC FORCE MICROSCOPY AND DISSECTION OF GAP-JUNCTIONS	SCIENCE			English	Article							PROTEIN; MEMBRANES; CELLS	An atomic force microscope (AFM) was used to study the structure of isolated hepatic gap junctions in phosphate-buffered saline (PBS). The thickness of these gap junctions appears to be 14.4 nanometers, close to the dimensions reported by electron microscopy (EM). When an increasing force is applied to the microscope tip, the top membrane of the gap junction can bc "dissected" away, leaving the extracellular domains of the bottom membrane exposed. When such "force dissection" is performed on samples both trypsinized and fixed with glutaraldehyde, the hexagonal array of gap junction hemichannels is revealed, with a center-to-center spacing of 9.1 nanometers.	UNIV CHICAGO,DEPT MED,CARDIOL SECT,CHICAGO,IL 60637; CALTECH,DIV BIOL,PASADENA,CA 91125	University of Chicago; California Institute of Technology			Hoh, Jan H./P-8695-2019	Hoh, Jan/0000-0003-3842-9454; John, Scott/0000-0002-1232-9140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL021788, R01HL037109] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07003] Funding Source: Medline; NHLBI NIH HHS [HL37109, R37 HL21788] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett, 1985, GAP JUNCTIONS, P5; BERNARDINI G, 1981, INVEST OPHTH VIS SCI, V21, P291; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUTT HJ, 1990, BIOPHYS J, V58, P1473, DOI 10.1016/S0006-3495(90)82492-9; DEWEY MM, 1962, SCIENCE, V137, P670, DOI 10.1126/science.137.3531.670-a; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; EDSTROM RD, 1990, BIOPHYS J, V58, P1437, DOI 10.1016/S0006-3495(90)82489-9; FINBOW M, 1980, P NATL ACAD SCI-BIOL, V77, P970, DOI 10.1073/pnas.77.2.970; FLAGGNEWTON J, 1979, SCIENCE, V205, P404, DOI 10.1126/science.377490; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GOULD SAC, 1990, J VAC SCI TECHNOL A, V8, P369, DOI 10.1116/1.576398; HENDERSON D, 1979, J MOL BIOL, V132, P193, DOI 10.1016/0022-2836(79)90391-7; HERTZBERG EL, 1988, MODERN CELL BIOL GAP; HIROKAWA N, 1982, CELL, V30, P395, DOI 10.1016/0092-8674(82)90237-9; KARRER HE, 1960, J BIOPHYS BIOCHEM CY, V8, P135, DOI 10.1083/jcb.8.1.135; LAIRD DW, 1990, J CELL SCI, V97, P109; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MANJUNATH CK, 1982, BIOCHEM J, V205, P189, DOI 10.1042/bj2050189; NICHOLSON BJ, 1981, P NATL ACAD SCI-BIOL, V78, P7594, DOI 10.1073/pnas.78.12.7594; REVEL JP, 1967, J CELL BIOL, V33, pC7, DOI 10.1083/jcb.33.3.C7; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; SOSINSKY GE, 1988, BIOPHYS J, V53, P709, DOI 10.1016/S0006-3495(88)83152-7; SOSINSKY GE, 1990, BIOPHYS J, V58, P1213, DOI 10.1016/S0006-3495(90)82462-0; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0	24	217	225	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1405	1408		10.1126/science.1910206	http://dx.doi.org/10.1126/science.1910206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1910206				2022-12-28	WOS:A1991GF85100037
J	DOUGLAS, AS; RAWLES, JM; ALEXANDER, E; ALLAN, TM				DOUGLAS, AS; RAWLES, JM; ALEXANDER, E; ALLAN, TM			WINTER PRESSURE ON HOSPITAL MEDICAL BEDS	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,SCH MED,WELLCOME RES LIB,ABERDEEN AB9 1FX,SCOTLAND; GRAMPIAN AREA HLTH BOARD,DEPT COMMUNITY MED,ABERDEEN,SCOTLAND	University of Aberdeen; University of Aberdeen	DOUGLAS, AS (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZB,SCOTLAND.							DOUGLAS AS, 1991, LANCET, P1393; QUETELET MA, 1842, TREATISE MAN DEV HIS, P34; Sothern R., 1972, PHYSIOL TEACH, V1, P1	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					508	509		10.1136/bmj.303.6801.508-a	http://dx.doi.org/10.1136/bmj.303.6801.508-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912863	Bronze, Green Published			2022-12-28	WOS:A1991GD80400020
J	CUNNINGHAM, BC; MULKERRIN, MG; WELLS, JA				CUNNINGHAM, BC; MULKERRIN, MG; WELLS, JA			DIMERIZATION OF HUMAN GROWTH-HORMONE BY ZINC	SCIENCE			English	Article							PITUITARY; PROLACTIN; RECEPTOR; PROTEIN	Size-exclusion chromatography and sedimentation equilibrium studies demonstrated that zinc ion (Zn 2+) induced the dimerization of human growth hormone (hGH). Scatchard analysis of Zn-65(2+) binding to hGH showed that two Zn+ ions associate per dimer of hGH in a cooperative fashion. Cobalt (II) can substitute for Zn2+ in the hormone dimer and gives a visible spectrum characteristic of cobalt coordinated in a tetrahedral fashion by oxygen- and nitrogen-containing ligands. Replacement of potential Zn2+ ligands (His 18, His 21, and Glu 174) in hGH with alanine weakened both Zn2+ binding and hGH dimer formation. The Zn+-hGH dimer was more stable than monomeric hGH to denaturation in guanidine-HCl. Formation of a Zn2+-hGH dimeric complex may be important for storage of hGH in secretory granules.	GENENTECH INC,DEPT PROT ENGN,SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ACKERS GK, 1965, P NATL ACAD SCI USA, V53, P342, DOI 10.1073/pnas.53.2.342; Bertini I, 1984, Adv Inorg Biochem, V6, P71; CUNNINGHAM BA, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAUGHADAY WF, 1985, TXB ENDOCRINOLOGY, P577; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; LABELLA F, 1973, BIOCHEM BIOPH RES CO, V52, P786, DOI 10.1016/0006-291X(73)91006-1; LEWIS UJ, 1984, ANNU REV PHYSIOL, V46, P33; LORENSON MY, 1983, J BIOL CHEM, V258, P8618; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; LOWMAN HB, UNPUB; MARTIN MT, 1989, INORG CHEM, V36, P27; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; ROOT AW, 1979, J NUTR, V109, P958, DOI 10.1093/jn/109.6.958; SHIRE SJ, IN PRESS BIOCHEMISTR; TAYLOR AL, 1969, J CLIN INVEST, V48, P2349, DOI 10.1172/JCI106201; THOMPSON RG, 1972, J CLIN INVEST, V51, P3193, DOI 10.1172/JCI107146; THORLACIUSUSSING O, 1987, NEUROENDOCRINOLOGY, V45, P233, DOI 10.1159/000124731; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	25	205	222	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					545	548		10.1126/science.1907025	http://dx.doi.org/10.1126/science.1907025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1907025				2022-12-28	WOS:A1991FZ34700033
J	KRAUZLIS, RJ; LISBERGER, SG				KRAUZLIS, RJ; LISBERGER, SG			VISUAL-MOTION COMMANDS FOR PURSUIT EYE-MOVEMENTS IN THE CEREBELLUM	SCIENCE			English	Article							HORSERADISH-PEROXIDASE; RHESUS-MONKEY; VESTIBULOOCULAR REFLEX; PRIMATE FLOCCULUS; PURKINJE-CELLS; PROJECTIONS; MACAQUE; TRANSPORT; RESPONSES; NUCLEI	Eye movements that follow a target (pursuit eye movements) facilitate high acuity visual perception of moving targets by transforming visual motion inputs into motor commands that match eye motion to target motion. The performance of pursuit eye movements requires the cerebellar flocculus, which processes both visual motion and oculomotor signals. Electrophysiological recordings from floccular Purkinje cells have allowed the identification of their firing patterns during generation of the image velocity and image acceleration signals used for pursuit. Analysis with a method based on a behavioral model converted the time-varying spike trains of floccular Purkinje cells into a description of the firing rate contributed by three visual motion signals and one oculomotor input. The flocculus encodes all the signals needed to guide pursuit.	UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KRAUZLIS, RJ (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK FDN CTR INTEGRAT NEUROSCI,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Richard, Krauzlis/0000-0002-1826-0447				BALABAN CD, 1981, NEUROSCI LETT, V27, P101, DOI 10.1016/0304-3940(81)90251-2; BRODAL P, 1982, J COMP NEUROL, V204, P44, DOI 10.1002/cne.902040106; BRODAL P, 1978, BRAIN, V101, P251, DOI 10.1093/brain/101.2.251; BRODAL P, 1979, NEUROSCIENCE, V4, P193, DOI 10.1016/0306-4522(79)90082-4; Gerrits NM, 1987, EXP BRAIN RES SUPPL, V17, P26; GLICKSTEIN M, 1980, J COMP NEUROL, V190, P209, DOI 10.1002/cne.901900202; GOLDREICH D, 1987, Society for Neuroscience Abstracts, V13, P170; GOLDREICH D, IN PRESS J NEUROPHYS; Krauzlis RJ, 1989, NEURAL COMPUT, V1, P116, DOI 10.1162/neco.1989.1.1.116; KRAUZLIS R J, 1987, Society for Neuroscience Abstracts, V13, P170; KRAUZLIS R J, 1988, Society for Neuroscience Abstracts, V14, P798; LANGER T, 1985, J COMP NEUROL, V235, P1, DOI 10.1002/cne.902350102; LANGER T, 1985, J COMP NEUROL, V235, P26, DOI 10.1002/cne.902350103; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; LISBERGER SG, 1988, SCIENCE, V242, P771, DOI 10.1126/science.3142040; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P733, DOI 10.1152/jn.1978.41.3.733; MILES FA, 1975, SCIENCE, V189, P1000, DOI 10.1126/science.1083068; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; MORRIS E J, 1985, Society for Neuroscience Abstracts, V11, P79; NODA H, 1909, J PHYSIOL-LONDON, V294, P349; Pearlmutter BA, 1989, NEURAL COMPUT, V1, P263, DOI 10.1162/neco.1989.1.2.263; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P326, DOI 10.1113/jphysiol.1961.sp006811; STONE LS, 1990, J NEUROPHYSIOL, V63, P1241, DOI 10.1152/jn.1990.63.5.1241; STONE LS, 1990, J NEUROPHYSIOL, V63, P1262, DOI 10.1152/jn.1990.63.5.1262; STONE LS, 1989, EXP BRAIN RES S, V17, P299; ZEE DS, 1981, J NEUROPHYSIOL, V46, P878, DOI 10.1152/jn.1981.46.4.878	26	34	34	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					568	571		10.1126/science.1907026	http://dx.doi.org/10.1126/science.1907026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1907026				2022-12-28	WOS:A1991FZ34700041
J	HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR				HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR			IDENTIFICATION OF THE ENVELOPE V3 LOOP AS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; CENTRAL NERVOUS-SYSTEM; T-CELL; MONONUCLEAR PHAGOCYTES; NEUTRALIZING DETERMINANT; AIDS PATIENTS; CD4 ANTIGEN; SOLUBLE CD4; INFECTION	Cells of the monocyte-macrophage lineage are targets for human immunodeficiency virus-1 (HIV-1) infection in vivo. However, many laboratory strains of HIV-l that efficiently infect transformed T cell lines replicate poorly in macrophages. A 20-amino acid sequence from the macrophage-tropic BaL isolate of HIV-1 was sufficient to confer macrophage tropism on HTLV-IIIB, a T cell line-tropic isolate. This small sequence element is in the V3 loop, the envelope domain that is the principal neutralizing determinant of HIV-1. Thus, the V3 loop not only serves as a target of the host immune response but is also pivotal in determining HIV-l tissue tropism.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT HISTOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lyerly, Herbert K/B-6528-2014; Lyerly, Herbert Kim/AAX-4925-2020	Lyerly, Herbert K/0000-0002-0063-4770; Lyerly, Herbert Kim/0000-0002-0063-4770				ANDERSEN KB, 1987, J GEN VIROL, V68, P2193, DOI 10.1099/0022-1317-68-8-2193; ANDERSEN KB, 1989, J GEN VIROL, V70, P1921, DOI 10.1099/0022-1317-70-7-1921; APPLEYARD G, 1985, J GEN VIROL, V66, P363, DOI 10.1099/0022-1317-66-2-363; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BOYLE TJ, UNPUB; Boyum A, 1968, SCAND J CLIN LAB I S, V97, P51; CAMERINI D, 1990, CELL, V60, P747, DOI 10.1016/0092-8674(90)90089-W; CHENGMAYER C, 1990, J VIROL, V64, P4390, DOI 10.1128/JVI.64.9.4390-4398.1990; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; CROWL R, 1985, CELL, V41, P979, DOI 10.1016/S0092-8674(85)80078-7; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EVANS LA, 1987, J IMMUNOL, V138, P3415; FENYO EM, 1988, J VIROL, V62, P4414; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KIM SY, 1990, J VIROL, V64, P5600, DOI 10.1128/JVI.64.11.5600-5604.1990; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nowell P.C, 1960, CANCER RES, V20, P562; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; OTSUKI K, 1981, ARCH VIROL, V70, P315, DOI 10.1007/BF01320246; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959; PERTOFT H, 1980, J IMMUNOL METHODS, V33, P221, DOI 10.1016/S0022-1759(80)80012-3; POMERANTZ RJ, 1991, J VIROL, V65, P1041, DOI 10.1128/JVI.65.2.1041-1045.1991; POTTS BJ, 1990, VIROLOGY, V175, P465, DOI 10.1016/0042-6822(90)90431-P; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TOTH TE, 1982, AM J VET RES, V43, P967; ULMER AJ, 1979, J IMMUNOL METHODS, V30, P1, DOI 10.1016/0022-1759(79)90268-0; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; YOSHIKURA H, 1981, VIROLOGY, V113, P503, DOI 10.1016/0042-6822(81)90178-1	66	806	844	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					71	74		10.1126/science.1905842	http://dx.doi.org/10.1126/science.1905842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1905842				2022-12-28	WOS:A1991FV17700036
J	VANOPSTAL, AJ; HEPP, K; HESS, BJM; STRAUMANN, D; HENN, V				VANOPSTAL, AJ; HEPP, K; HESS, BJM; STRAUMANN, D; HENN, V			2-DIMENSIONAL RATHER THAN 3-DIMENSIONAL REPRESENTATION OF SACCADES IN MONKEY SUPERIOR COLLICULUS	SCIENCE			English	Article							ALERT RHESUS-MONKEY; EYE-MOVEMENTS; OCULOMOTOR SYSTEM; LISTINGS LAW; STIMULATION; DEFICITS; NEURONS; COIL	Saccades are controlled by neurons in the brainstem reticular formation that receive input from the superior colliculus and cortex. Recently two quantitative models have been proposed for the role of the colliculus in the generation of three-dimensional eye movements. In order to test these models, three-dimensional eye movements were measured in the alert monkey to investigate whether the saccadic motor map of the superior colliculus is two-dimensional, representing retinal target vectors, or three-dimensional, representing three-dimensional motor error for the rotation of the eye. Electrical stimulation of the superior colliculus produced two-dimensional, not three-dimensional, eye movements. It is therefore concluded that the collicular motor map is two-dimensional.	UNIV HOSP ZURICH, DEPT NEUROL, CH-8091 ZURICH, SWITZERLAND; SWISS FED INST TECHNOL, DEPT PHYS, CH-8093 ZURICH, SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			van Opstal, John/D-1907-2010	van Opstal, John/0000-0001-5957-5712				ALBANO JE, 1982, J NEUROPHYSIOL, V48, P338, DOI 10.1152/jn.1982.48.2.338; FERMAN L, 1987, VISION RES, V27, P811, DOI 10.1016/0042-6989(87)90078-2; HAUSTEIN W, 1989, BIOL CYBERN, V60, P411, DOI 10.1007/BF00204696; HENN V, 1991, VESTIBULAR BRAIN STE; HEPP K, 1990, COMMUN MATH PHYS, V132, P285, DOI 10.1007/BF02278012; HEPP K, 1990, Society for Neuroscience Abstracts, V16, P1084; HEPP K, 1989, NEUROBIOLOGY SACCADI, P105; HESS BJM, 1990, VISION RES, V30, P597, DOI 10.1016/0042-6989(90)90070-2; HIKOSAKA O, 1986, EXP BRAIN RES, V61, P531; HIKOSAKA O, 1985, J NEUROPHYSIOL, V53, P266, DOI 10.1152/jn.1985.53.1.266; JAY MF, 1987, J NEUROPHYSIOL, V57, P35, DOI 10.1152/jn.1987.57.1.35; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; RAYBOURN MS, 1977, J NEUROPHYSIOL, V40, P861, DOI 10.1152/jn.1977.40.4.861; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHILLER PH, 1980, J NEUROPHYSIOL, V44, P1175, DOI 10.1152/jn.1980.44.6.1175; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; SCHILLER PH, 1972, J NEUROPHYSIOL, V35, P915, DOI 10.1152/jn.1972.35.6.915; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; SPARKS DL, 1980, BRAIN RES, V190, P39, DOI 10.1016/0006-8993(80)91158-0; STRAUMANN D, 1990, EUR J NEUROSCI, V3, P163; STRAUMANN D, IN PRESS EXP BRAIN R; TWEED D, 1988, Society for Neuroscience Abstracts, V14, P958; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1988, ANN NY ACAD SCI, V545, P128; TWEED DB, 1990, NEURAL NETWORKS, V3, P75, DOI 10.1016/0893-6080(90)90046-N; VANOPSTAL AJ, 1990, EXP BRAIN RES, V79, P299, DOI 10.1007/BF00608239; VANOPSTAL AJ, 1990, SOC NEUR ABSTR, V16, P1084; von Helmholtz H, 1896, HDB PHYSL OPTIK; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	30	91	92	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1313	1315		10.1126/science.1925545	http://dx.doi.org/10.1126/science.1925545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925545				2022-12-28	WOS:A1991FN85700042
J	CLARK, SJ; SAAG, MS; DECKER, WD; CAMPBELLHILL, S; ROBERSON, JL; VELDKAMP, PJ; KAPPES, JC; HAHN, BH; SHAW, GM				CLARK, SJ; SAAG, MS; DECKER, WD; CAMPBELLHILL, S; ROBERSON, JL; VELDKAMP, PJ; KAPPES, JC; HAHN, BH; SHAW, GM			HIGH TITERS OF CYTOPATHIC VIRUS IN PLASMA OF PATIENTS WITH SYMPTOMATIC PRIMARY HIV-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HTLV-III INFECTION; IMMUNE-DEFICIENCY SYNDROME; AIDS RETROVIRUS INFECTION; HOMOSEXUAL MEN; LYMPHADENOPATHY SYNDROME; NEEDLESTICK INJURY; BLOOD-TRANSFUSION; NATURAL-HISTORY; SEROCONVERSION	Background. Primary infection with the human immunodeficiency virus (HIV-1) frequently causes an acute, self-limited viral syndrome. To examine the relations among viral replication, the immune response of the host, and clinical illness during this initial phase of infection, we undertook a quantitative, molecular, and biologic analysis of infectious HIV-1 in the blood and plasma of three patients with symptomatic primary infection and of a sexual partner of one of them. Methods. During an eight-week period of primary infection, HIV-1 was cultured frequently in dilutions of plasma and peripheral-blood mononuclear cells (PBMC), and levels of HIV-1 antigen and antibody were determined sequentially by enzyme-linked immunosorbent assay and immunoblotting. Replication-competent HIV-1 proviruses were cloned and characterized biologically. Results. Six to 15 days after the onset of symptoms, high titers of infectious HIV-1 (from 10 to 10(3) tissue-culture-infective doses per milliliter of plasma) and viral p24 antigen were detected in the plasma of all three patients. These titers fell precipitously by day 27, and the decline coincided with an increase in the levels of antiviral antibodies and the resolution of symptoms. Sequential isolates of virus from plasma and PBMC obtained throughout the period of primary infection, as well as virus derived from two molecular proviral clones, were highly cytopathic for normal-donor PBMC and immortalized T cells, despite the marked reduction in the titers of virus in plasma. Conclusions. Primary, symptomatic HIV-1 infection is associated with high titers of cytopathic, replication-competent viral strains, and during such infection potential infectivity is enhanced. Effective control of HIV-1 replication during primary infection implies the activation of clinically important mechanisms of immune defense that merit further examination in relation to the development of antiviral therapy and vaccines.	UNIV ALABAMA, DEPT MED,DIV HEMATOL ONCOL,701 19TH ST S,LHRB 613, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, DIV INFECT DIS, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Hahn, Beatrice/0000-0002-9400-9887				ABB J, 1987, INFECTION, V15, P425, DOI 10.1007/BF01647221; ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; ALLAIN JP, 1986, LANCET, V2, P1233; [Anonymous], 1984, LANCET, V2, P1376; BALSLEV E, 1990, J CLIN PATHOL, V43, P201, DOI 10.1136/jcp.43.3.201; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERNARD E, 1990, AIDS, V4, P932, DOI 10.1097/00002030-199009000-00023; BIGGAR RJ, 1986, BRIT MED J, V293, P1210, DOI 10.1136/bmj.293.6556.1210; BOITEUX F, 1985, NEW ENGL J MED, V312, P648; BREHMERANDERSSON E, 1990, ACTA DERM-VENEREOL, V70, P85; BUCHANAN JG, 1986, NEW ZEAL MED J, V99, P405; CALABRESE LH, 1987, ANN INTERN MED, V107, P849, DOI 10.7326/0003-4819-107-6-849; CARNE CA, 1985, LANCET, V2, P1206; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CILLA G, 1988, AIDS, V2, P399, DOI 10.1097/00002030-198810000-00013; COLEBUNDERS R, 1988, AIDS, V2, P125, DOI 10.1097/00002030-198804000-00009; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELRIO C, 1990, REV INFECT DIS, V12, P282; DENNING DW, 1987, BRIT MED J, V294, P143, DOI 10.1136/bmj.294.6565.143; DENNING DW, 1987, CUTIS, V40, P171; ELDER G, 1986, LANCET, V2, P1275; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FENYO EM, 1988, J VIROL, V62, P4414; GAINES H, 1987, LANCET, V1, P1249; GAINES H, 1987, LANCET, V1, P1317; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GOLDMAN R, 1986, AM J MED, V81, P1122, DOI 10.1016/0002-9343(86)90434-1; GOUDSMIT J, 1986, LANCET, V2, P177; HAHN BH, 1985, P NATL ACAD SCI USA, V82, P4813, DOI 10.1073/pnas.82.14.4813; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HILLMAN RJ, 1990, J ACQ IMMUN DEF SYND, V3, P926; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; ISAKSSON B, 1988, J INFECT DIS, V158, P866, DOI 10.1093/infdis/158.4.866; KESSLER HA, 1987, JAMA-J AM MED ASSOC, V258, P1196; KIEFF ED, 1989, NEW ENGL J MED, V321, P454; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; LAGESTEHR J, 1985, LANCET, V2, P1361; LINDSKOV R, 1986, LANCET, V1, P447; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; NEISSONVERNANT C, 1986, LANCET, V2, P814; OKSENHENDLER E, 1986, NEW ENGL J MED, V315, P582; PAUL DA, 1987, J MED VIROL, V22, P357, DOI 10.1002/jmv.1890220408; PEDERSEN C, 1990, AIDS, V4, P523, DOI 10.1097/00002030-199006000-00005; PIETTE AM, 1986, LANCET, V1, P852; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; ROMERIL KR, 1985, NEW ZEAL MED J, V98, P401; RUSTIN MHA, 1986, J INFECTION, V12, P161, DOI 10.1016/S0163-4453(86)93683-2; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAAG MS, IN PRESS J INFECT DI; SAMUEL D, 1988, LANCET, V1, P1221; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SINICCO A, 1990, J ACQ IMMUN DEF SYND, V3, P260; STRAMER SL, 1989, JAMA-J AM MED ASSOC, V262, P64, DOI 10.1001/jama.262.1.64; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TINDALL B, 1989, AIDS, V3, P747, DOI 10.1097/00002030-198911000-00010; TUCKER J, 1985, LANCET, V1, P585; VALLE SL, 1987, SCAND J INFECT DIS, V19, P13, DOI 10.3109/00365548709032372; VITTECOQ D, 1986, LANCET, V1, P1280; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; WALL RA, 1987, LANCET, V1, P566; WANTZIN GRL, 1986, BRIT J DERMATOL, V115, P601, DOI 10.1111/j.1365-2133.1986.tb05771.x; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WHITE GC, 1986, LANCET, V1, P611; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961; 1990, MMWR, V39, P117; 1990, MMWR, V39, P110; 1990, MMWR, V39, P489	78	622	637	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					954	960		10.1056/NEJM199104043241404	http://dx.doi.org/10.1056/NEJM199104043241404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	1900576				2022-12-28	WOS:A1991FE37600004
J	OTTEN, GR; GERMAIN, RN				OTTEN, GR; GERMAIN, RN			SPLIT ANERGY IN A CD8+ T-CELL - RECEPTOR-DEPENDENT CYTOLYSIS IN THE ABSENCE OF INTERLEUKIN-2 PRODUCTION	SCIENCE			English	Article							LYMPHOCYTES-T; CLASS-I; ANTIGEN; CLONES; INDUCTION; ACTIVATION; RESPONSIVENESS; TOLERANCE; INVIVO; EVENTS	Engagement of the antigen-specific receptor (TCR) of CD4+ T lymphocytes without a second (costimulatory) signal prevents the subsequent production of interleukin-2 (IL-2) by these cells. Because IL-2 is a key immunoregulatory lymphokine and is also produced by a subset of CD8+ T cells that are able to kill target cells, the effect of engaging the TCR of one such clone in the absence of costimulatory signals was examined. The capacity for TCR-dependent IL-2 production was lost, indicating comparable costimulator-dependent signaling requirements for IL-2 production in CD4+ and CD8+ T cells. However, TCR-mediated cytotoxicity was not impaired, implying that costimulation is required for only certain TCR-dependent effector functions.			OTTEN, GR (corresponding author), NIAID,LYMPHOCYTE BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020					ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AZUMA T, 1989, J IMMUNOL, V143, P1; BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; HSI ED, 1989, J BIOL CHEM, V264, P10836; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATIS LA, 1985, J IMMUNOL, V135, P703; MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; QUILL H, 1987, J IMMUNOL, V138, P3704; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROOPENIAN DC, 1983, J IMMUNOL, V130, P542; ROSENBERG AS, 1988, J EXP MED, V168, P33, DOI 10.1084/jem.168.1.33; SCHWARTZ RH, 1989, COLD SH Q B, V54, P605; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; VITIELLO A, 1989, J IMMUNOL, V143, P1512; VONBOEHMER H, 1983, EUR J IMMUNOL, V13, P176, DOI 10.1002/eji.1830130216; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WIDMER MB, 1981, NATURE, V294, P750, DOI 10.1038/294750a0	27	211	219	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1228	1231		10.1126/science.1900952	http://dx.doi.org/10.1126/science.1900952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900952				2022-12-28	WOS:A1991FA69100040
J	LADIAS, JAA; KARATHANASIS, SK				LADIAS, JAA; KARATHANASIS, SK			REGULATION OF THE APOLIPOPROTEIN-A-I GENE BY ARP-1, A NOVEL MEMBER OF THE STEROID-RECEPTOR SUPERFAMILY	SCIENCE			English	Article							COUP TRANSCRIPTION FACTOR; MESSENGER-RNA; HORMONE RECEPTOR; THYROID-HORMONE; INVITRO TRANSCRIPTION; ESTROGEN-RECEPTOR; EXPRESSION; RAT; ELEMENT; BINDS	Apolipoprotein AI (apoAI) is a lipid-binding protein that participates in the transport of cholesterol and other lipids in the plasma. A complementary DNA clone for a protein that bound to regulatory elements of the apoAI gene was isolated. This protein, designed apoAI regulatory protein-1 (ARP-1), is a novel member of the steroid hormone receptor superfamily. ARP-1 bound to DNA as a dimer, and its dimerization domain was localized to the COOH-terminal region. ARP-1 also bound to a thyroid hormone-responsive element and to regulatory regions of the apoB, apoCIII, insulin, and ovalbumin genes. In cotransfection experiments, ARP-1 down-regulated the apoAI gene. The involvement of ARP-1 in the regulation of apoAI gene expression suggests that it may participate in lipid metabolism and cholesterol homeostasis.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	LADIAS, JAA (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,MOLEC & CELLULAR CARDIOL LAB,BOSTON,MA 02115, USA.							ARCHER TK, 1986, J BIOL CHEM, V261, P5067; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LADIAS JAA, UNPUB; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER JCE, 1983, P NATL ACAD SCI-BIOL, V80, P1511, DOI 10.1073/pnas.80.6.1511; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; REUE K, 1988, J BIOL CHEM, V263, P6857; REUE K, 1988, J BIOL CHEM, V263, P11452; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; STAELS B, 1989, J LIPID RES, V30, P1137; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677	41	378	400	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					561	565		10.1126/science.1899293	http://dx.doi.org/10.1126/science.1899293			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1899293				2022-12-28	WOS:A1991EV45900052
J	HANDSFIELD, HH; MCCORMACK, WM; HOOK, EW; DOUGLAS, JM; COVINO, JM; VERDON, MS; REICHART, CA; EHRET, JM				HANDSFIELD, HH; MCCORMACK, WM; HOOK, EW; DOUGLAS, JM; COVINO, JM; VERDON, MS; REICHART, CA; EHRET, JM			A COMPARISON OF SINGLE-DOSE CEFIXIME WITH CEFTRIAXONE AS TREATMENT FOR UNCOMPLICATED GONORRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUALLY-TRANSMITTED DISEASE; NEISSERIA-GONORRHOEAE; INVITRO ACTIVITY; ORAL CEFIXIME; RESISTANCE; INFECTIONS; PHARMACOKINETICS; AMOXICILLIN; PENICILLIN; GONOCOCCI	Background. Because of the widespread existence of Neisseria gonorrhoeae resistant to penicillin or tetracycline, ceftriaxone is now recommended for the treatment of gonorrhea. There is, however, a need for effective antibiotics that can be administered orally as an alternative to ceftriaxone, which requires intramuscular administration. Cefixime is an orally absorbed cephalosporin that is active against resistant gonococci and has pharmacokinetic activity suitable for single-dose administration. Methods and Results. In a randomized, unblinded multicenter study of 209 men and 124 women with uncomplicated gonorrhea, we compared three single-dose treatment regimens: 400 mg or 800 mg of cefixime, administered orally, and 250 mg of ceftriaxone administered intramuscularly. The overall cure rates were 96 percent for the 400-mg dose of cefixime (89 of 93 patients) (95 percent confidence interval, 93.5 to 97.8 percent); 98 percent for the 800-mg dose of cefixime (86 of 88 patients) (95 percent confidence interval, 94.6 to 100 percent); and 98 percent for ceftriaxone (92 of 94 patients) (95 percent confidence interval, 94.9 to 100 percent). The cure rates were similar in men and women, and pharyngeal infection was eradicated in 20 of 22 patients (91 percent). Thirty-nine percent of 303 pretreatment gonococcal isolates had one or more types of antimicrobial resistance; the efficacy of all three regimens was independent of the resistance pattern. Chlamydia trachomatis infection persisted in at least half the patients infected in each treatment group. All three regimens were well tolerated. Conclusions. In the treatment ot uncomplicated gonorrhea, a single dose of cefixime (400 or 800 mg) given orally appears to be as effective as the currently recommended regimen of ceftriaxone (250 mg given intramuscularly).	SUNY HLTH SCI CTR,BROOKLYN,NY; BALTIMORE CITY DEPT HLTH,BALTIMORE,MD; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218; DENVER DIS CONTROL SERV,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262; UNIV WASHINGTON,SEATTLE,WA 98195; NEW YORK DEPT HLTH,BROOKLYN,NY; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA 98104	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Johns Hopkins University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle								BADDOUR LM, 1989, ANTIMICROB AGENTS CH, V33, P801, DOI 10.1128/AAC.33.6.801; BOWIE WR, 1986, ANTIMICROB AGENTS CH, V30, P590, DOI 10.1128/AAC.30.4.590; BRITTAIN DC, 1985, CLIN PHARMACOL THER, V38, P590, DOI 10.1038/clpt.1985.229; Christ W, 1988, Rev Infect Dis, V10 Suppl 1, pS141; GUAY DRP, 1986, ANTIMICROB AGENTS CH, V30, P485, DOI 10.1128/AAC.30.3.485; HANDSFIELD HH, 1987, SEX TRANSM DIS, V14, P227, DOI 10.1097/00007435-198710000-00010; HANDSFIELD HH, 1982, NEW ENGL J MED, V306, P950, DOI 10.1056/NEJM198204223061602; ISON CA, 1990, GENITOURIN MED, V66, P351; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JAFFE HW, 1979, ANTIMICROB AGENTS CH, V15, P587, DOI 10.1128/AAC.15.4.587; JEPHCOTT AE, 1990, LANCET, V335, P165, DOI 10.1016/0140-6736(90)90035-4; JOYCE MP, 1988, 6TH INT PATH NEISS C; KNAPP JS, 1984, J INFECT DIS, V150, P44, DOI 10.1093/infdis/150.1.44; KUHLWEIN A, 1989, EUR J CLIN MICROBIOL, V8, P261, DOI 10.1007/BF01965274; MARTIN DH, 1991, 31ST INT C ANT AG CH; MEGRAN DW, 1990, ANTIMICROB AGENTS CH, V34, P355, DOI 10.1128/AAC.34.2.355; MORAN JS, 1990, REV INFECT DIS, V12, pS633; RICE RJ, 1986, JAMA-J AM MED ASSOC, V255, P1739, DOI 10.1001/jama.255.13.1739; SCHOENKNECHT FD, 1985, MANUAL CLIN MICROBIO, P1000; SCHWARCZ SK, 1990, JAMA-J AM MED ASSOC, V264, P1413, DOI 10.1001/jama.264.11.1413; Sparling P., 1990, SEXUALLY TRANSMITTED, P131; STEINGRIMSSON O, 1990, J ANTIMICROB CHEMOTH, V25, P109, DOI 10.1093/jac/25.suppl_A.109; STONE JW, 1989, J ANTIMICROB CHEMOTH, V23, P221, DOI 10.1093/jac/23.2.221; VELLERFORNASA C, 1987, GENITOURIN MED, V63, P214; WAGENVOORT JHT, 1986, EUR J CLIN MICROBIOL, V5, P685, DOI 10.1007/BF02013305; WOLFSON JS, 1989, REV INFECT DIS, V11, pS960; YEUNG KH, 1990, LANCET, V336, P759, DOI 10.1016/0140-6736(90)92261-F; 1989, MMWR, V38, P21; 1990, MMWR, V39, P293; 1991, DRUG TOPICS RED BOOK; 1990, MMWR, V39, P284	31	77	78	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1337	1341		10.1056/NEJM199111073251903	http://dx.doi.org/10.1056/NEJM199111073251903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922235	Bronze			2022-12-28	WOS:A1991GN47000003
J	LEVINE, DP; FROMM, BS; REDDY, BR				LEVINE, DP; FROMM, BS; REDDY, BR			SLOW RESPONSE TO VANCOMYCIN OR VANCOMYCIN PLUS RIFAMPIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS	ANNALS OF INTERNAL MEDICINE			English	Article							DETROIT-MEDICAL-CENTER; CLINICAL-SIGNIFICANCE; THERAPY; ADDICTS; PHARMACOKINETICS; BACTEREMIA; TOLERANCE; EFFICACY; INVIVO	Objective: To determine the median response time to therapy with vancomycin alone or with vancomycin plus rifampin in patients with methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. Design: Cohort analysis of a randomized study. Setting: University medical center. Patients: Forty-two consecutive patients with MRSA endocarditis were randomly assigned to receive either vancomycin (group I) or vancomycin plus rifampin (group II) for 28 days. Measurements: Clinical signs and symptoms were recorded, and blood cultures were obtained daily to determine the duration of bacteremia. Main Results: The median duration of bacteremia was 9 days (7 days for group I and 9 days for group II). The median duration of fever for all patients and for each treatment group was 7 days. Six patients failed therapy, including three patients who died 5, 6, and 9 days after therapy was started, respectively. The other three patients who failed therapy required valve surgery on days 2, 22, and 27, respectively. Although patients had sustained bacteremia, no unusual complications were seen in either treatment group, and most patients responded to continued antibiotic therapy. Conclusions: Slow clinical response is common among patients with MRSA endocarditis who are treated with vancomycin or vancomycin plus rifampin. Nevertheless, few complications appear to be related solely to this sustained bacteremia.	WAYNE STATE UNIV, SCH MED, DETROIT, MI 48201 USA	Wayne State University	LEVINE, DP (corresponding author), DETROIT RECEIVING HOSP & UNIV HLTH CTR, DEPT MED, ROOM 5Q-14, 4201 ST ANTOINE, DETROIT, MI 48201 USA.							BAYER AS, 1985, J INFECT DIS, V151, P157, DOI 10.1093/infdis/151.1.157; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHAMBERS HF, 1984, ANTIMICROB AGENTS CH, V26, P61, DOI 10.1128/AAC.26.1.61; FAVILLE RJ, 1978, JAMA-J AM MED ASSOC, V240, P1963, DOI 10.1001/jama.240.18.1963; GENGO FM, 1984, J ANTIMICROB CHEMOTH, V14, P619, DOI 10.1093/jac/14.6.619; GOPAL V, 1976, JAMA-J AM MED ASSOC, V236, P1604, DOI 10.1001/jama.236.14.1604; HANDWERGER S, 1985, REV INFECT DIS, V7, P368; KARCHMER AW, 1985, AM J MED, V78, P116, DOI 10.1016/0002-9343(85)90374-2; KAYE D, 1980, ANN INTERN MED, V93, P924, DOI 10.7326/0003-4819-93-6-924; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LEVINE DP, 1982, ANN INTERN MED, V97, P330, DOI 10.7326/0003-4819-97-3-330; LEVINE DP, 1986, REV INFECT DIS, V8, P374; MASSANARI RM, 1978, CHEST, V73, P371, DOI 10.1378/chest.73.3.371; RAJASHEKARAIAH KR, 1980, ANN INTERN MED, V93, P796, DOI 10.7326/0003-4819-93-6-796; REYMANN MT, 1978, AM J MED, V65, P729, DOI 10.1016/0002-9343(78)90790-8; ROTSCHAFER JC, 1982, ANTIMICROB AGENTS CH, V22, P391, DOI 10.1128/AAC.22.3.391; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227	19	454	463	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					674	680		10.7326/0003-4819-115-9-674	http://dx.doi.org/10.7326/0003-4819-115-9-674			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929035				2022-12-28	WOS:A1991GL69700002
J	STREMMEL, W; MEYERROSE, KW; NIEDERAU, C; HEFTER, H; KREUZPAINTNER, G; STROHMEYER, G				STREMMEL, W; MEYERROSE, KW; NIEDERAU, C; HEFTER, H; KREUZPAINTNER, G; STROHMEYER, G			WILSON DISEASE - CLINICAL PRESENTATION, TREATMENT, AND SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Review							TRIETHYLENE TETRAMINE DIHYDROCHLORIDE; COPPER; PENICILLAMINE; DIAGNOSIS; THERAPY; ZINC; DEFICIENCY; TRIENTINE	Objective: To evaluate the diagnostic features, clinical course, and overall long-term survival of patients with Wilson disease. Design: Retrospective cohort study with a mean follow-up period of 14.2 years. Setting: A university medical center and a community hospital. Patients: Fifty-one consecutive patients with Wilson disease were evaluated between 1957 and 1989. Interventions: Patients were treated with D-penicillamine (600 to 1800 mg/d). Two patients with end-stage liver disease had liver transplantation. Main Results: Initial symptoms occurred at a mean age of 15.5 years. At diagnosis, the most common neurologic signs were dysarthria, tremor, writing difficulties, and ataxia followed by hypersalivation and headache. Somatic symptoms included abdominal pain, hepatomegaly, splenomegaly, cirrhosis of the liver, and thrombocytopenia. The mean serum concentrations of ceruloplasmin and copper were 44 mg/L and 4.7-mu-mol/L, respectively. The mean basal urinary copper excretion was 5.5-mu-mol/d, and the mean hepatic copper concentration was 19.6-mu-mol/g dry weight. Free serum copper concentration (mean, 2.7-mu-mol/L) was a reliable indicator of disease and was useful in assessing the effectiveness of therapy (values < 1.6-mu-mol/L). Treatment with D-penicillamine improved most of the hematologic and neurologic abnormalities but had little effect on hepatomegaly and splenomegaly and did not reverse cirrhosis. Two patients died of fulminant hepatic failure during the observation period, whereas two others with end-stage liver disease had successful liver transplantation and remain asymptomatic. Long-term survival of patients with Wilson disease was similar to that of age- and sex-matched controls. Conclusion: Our results suggest that long-term treatment of patients with Wilson disease with D-penicillamine can relieve symptoms and improve prognosis.	UNIV HOSP DUSSELDORF, DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital				Stremmel, Wolfgang/0000-0002-8545-1753				Bachmann H, 1979, Psychiatr Neurol Med Psychol (Leipz), V31, P393; BONNETAMIR B, 1990, ANN HUM GENET, V54, P155, DOI 10.1111/j.1469-1809.1990.tb00372.x; BREWER GJ, 1987, P SOC EXP BIOL MED, V184, P446; BREWER GJ, 1983, ANN INTERN MED, V99, P314, DOI 10.7326/0003-4819-99-3-314; CZAJA MJ, 1987, J CLIN INVEST, V80, P1200, DOI 10.1172/JCI113180; EDWARDS CQ, 1979, CLIN GENET, V15, P311; FRYDMAN M, 1985, P NATL ACAD SCI USA, V82, P1819, DOI 10.1073/pnas.82.6.1819; GIBBS K, 1980, LANCET, V2, P538; HALVERSON PB, 1978, JAMA-J AM MED ASSOC, V240, P1870, DOI 10.1001/jama.240.17.1870; HOOGENRAAD TU, 1987, J NEUROL SCI, V77, P137, DOI 10.1016/0022-510X(87)90116-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KREUZPAINTER G, 1990, KLIN WOCHENSCHR, V68, P60; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; POPPER H, 1979, LANCET, V1, P1205; SCHEINBERG IH, 1987, NEW ENGL J MED, V317, P209, DOI 10.1056/NEJM198707233170405; SCHEINBERG IH, 1975, NEW ENGL J MED, V293, P1300, DOI 10.1056/NEJM197512182932507; STERNLIEB I, 1979, GASTROENTEROLOGY, V77, P138; STROHMEYER G, 1984, METABOLISM NUTRITION, P211; VANDENHAMER CJA, 1989, LANCET, V2, P442; WALSHE JM, 1956, AM J MED, V21, P487, DOI 10.1016/0002-9343(56)90066-3; WALSHE JM, 1977, Q J MED, V46, P73; WALSHE JM, 1982, LANCET, V1, P643; WALSHE JM, 1984, SEMIN LIVER DIS, V4, P252, DOI 10.1055/s-2008-1041775; WALSHE JM, 1988, LANCET, V2, P435; WALSHE JM, 1973, Q J MED, V42, P441; Walshe JM, 1986, ORPHAN DIS ORPHAN DR, P76; WESCH H, 1980, DEUT MED WOCHENSCHR, V105, P483, DOI 10.1055/s-2008-1070692	27	211	217	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					720	726		10.7326/0003-4819-115-9-720	http://dx.doi.org/10.7326/0003-4819-115-9-720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929042				2022-12-28	WOS:A1991GL69700011
J	KLEBER, HD				KLEBER, HD			TRACKING THE COCAINE EPIDEMIC - THE DRUG-ABUSE WARNING NETWORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KLEBER, HD (corresponding author), OFF NATL DRUG CONTROL POLICY,WASHINGTON,DC 20500, USA.							POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233	1	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2272	2273						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920728				2022-12-28	WOS:A1991GK66100038
J	KLEIN, ML				KLEIN, ML			MACULAR DEGENERATION - IS ASPIRIN A RISK FOR PROGRESSIVE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KLEIN, ML (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							KINGHAM JD, 1988, NEW ENGL J MED, V318, P1126; 1990, ARCH OPHTHALMOL-CHIC, V108, P825; 1986, ARCH OPHTHALMOL-CHIC, V104, P503	3	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2279	2279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920731				2022-12-28	WOS:A1991GK66100041
J	SAMUELS, B; GLANTZ, SA				SAMUELS, B; GLANTZ, SA			THE POLITICS OF LOCAL TOBACCO CONTROL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Until the nonsmokers' rights movement, tobacco control activity was at the federal or state levels, which is where the tobacco industry dominates. Since the appearance of the nonsmokers' rights movement, progress in tobacco control has occurred primarily at the local level. In response to the success of this movement, the tobacco industry has developed "smokers' rights" groups and other tactics to fight local legislation. Several recent local campaigns in California illustrate these tactics. Tobacco control forces follow many paths, from sitting on the sidelines to making a serious commitment to smoking control legislation. Despite the tobacco industry's superior financial resources, the outcome of proposed local tobacco control legislation appears to depend on how seriously the health advocates mobilize in support of the local legislation. When the health community makes a serious commitment of time and resources, it wins. When it fails to make such a commitment, the tobacco industry prevails, more by default than by its superior financial resources.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV CARDIOL,BOX 0124,ROOM 1186M,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARNOLD R, 1987, LOS ANGELES TIM 0403; BEGAY ME, 1991, U CALIFORNIA I HLTH, P55; BLOOM S, 1991, SACRAMENTO BEE  0419, pB1; CHAVEZ K, 1990, SACRAMENTO BEE  1201, pB1; DEMPSTER D, 1990, SACRAMENTO BEE  0912, pA1; FERREL D, 1990, LOS ANGELES TIM 1017, pA1; FERRIS J, 1991, CONTRA COSTA TI 0623; FITCH A, 1990, MUNICIPAL LEGISLATIV; FREEDMAN A, 1988, WALL ST J       0411; GALLUP G, 1989, GALLUP POLL     0416; GLANTZ SA, 1987, CIRCULATION, V76, P746, DOI 10.1161/01.CIR.76.4.746; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HAGER P, 1987, LOS ANGELES TIM 0521; HANAUER P, 1985, NEW YORK STATE J MED, V85, P369; HANAUER P, 1986, LEGISLATIVE APPROACH, P1; IFERGAN SJ, 1987, BEVERLY HILLS CO MAY; JACOBS C, 1991, LOS ANGELES BUS 1022; JOSON J, 1991, DAILY REV       0317, P1; KING J, 1991, CONTRA COSTA TI 0511, pA5; KONRAD W, 1990, BUSINESS WEEK   0806, P48; MATHEWS J, 1991, SACRAMENTO BEE  0422; MAXWELL JC, 1989, ADVERTISING AGE 1204; MORRIS P, 1990, INDEPENDENT MAJOR DO; PERTSCHUK M, 1989, MAJOR LOCAL SMOKING; Pritchard R., 1986, US TOBACCO CAND 0717, P86; REYNOLDS RJ, 1989, INDEPENDENT EXPENDIT; SAMUELS BE, 1991, U CALIFORNIA I HLTH; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; STUMBO B, 1986, LOS ANGELES TIM 0824, P11; STUMBO B, 1986, LOS ANGELES TIM 0824, P24; SYLVESTER K, 1989, GOVERNING        MAY, P34; TAYLOR P, 1984, SMOKE RING, P189; WARNER KE, 1989, AM J PUBLIC HEALTH, V79, P144, DOI 10.2105/AJPH.79.2.144; 1991, P MORRIS MAGAZINE, V6, P22; 1990, PRELIMINARY ANAL IMP; 1982, KERN COUNTY SMOKING; 1991, 1991 92 DIRECTORY LO, P195; 1986, HLTH CONSEQUENCES IN; 1991, SLO RESTAURANTS JOIN; 1978, PUBLIC ATTITUDES CIG; 1990, GENERAL PURPOSE RECI; 1990, US EPA600690006A PUB; 1987, CHOICE, V1, P4	43	106	107	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2110	2117		10.1001/jama.266.15.2110	http://dx.doi.org/10.1001/jama.266.15.2110			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GJ474	1920699				2022-12-28	WOS:A1991GJ47400032
J	YAMAMURA, M; UYEMURA, K; DEANS, RJ; WEINBERG, K; REA, TH; BLOOM, BR; MODLIN, RL				YAMAMURA, M; UYEMURA, K; DEANS, RJ; WEINBERG, K; REA, TH; BLOOM, BR; MODLIN, RL			DEFINING PROTECTIVE RESPONSES TO PATHOGENS - CYTOKINE PROFILES IN LEPROSY LESIONS	SCIENCE			English	Article							T-CELL SUBSETS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; RECIPROCAL EXPRESSION; SKIN-LESIONS; INTERLEUKIN-4; PROGRESSION; RESOLUTION; EXPANSION	The immunological mechanisms required to engender resistance have been defined in few infectious diseases of man, and the role of specific cytokines is unclear. Leprosy presents clinically as a spectrum in which resistance correlates with cell-mediated immunity to the pathogen. To assess in situ cytokine patterns, messenger RNA extracted from leprosy skin biopsy specimens was amplified by the polymerase chain reaction with 14 cytokine-specific primers. In lesions of the resistant form of the disease, messenger RNAs coding for interleukin-2 and interferon-gamma were most evident. In contrast, messenger RNAs for interleukin-4, interleukin-5, and interleukin-10 predominated in the multibacillary form. Thus, resistance and susceptibility were correlated with distinct patterns of cytokine production.	UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DERMATOL SECT,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90054; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of Southern California; Children's Hospital Los Angeles; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022553, R22AI022553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07118, AI 22553] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOLDI J, 1990, AM J PATHOL, V137, P749; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; COOPER CL, 1989, J EXP MED, V169, P1565, DOI 10.1084/jem.169.5.1565; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; MODLIN RL, 1984, J IMMUNOL, V132, P3085; MODLIN RL, 1983, CLIN EXP IMMUNOL, V53, P17; MODLIN RL, 1983, J AM ACAD DERMATOL, V8, P182, DOI 10.1016/S0190-9622(83)70021-6; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; MODLIN RL, 1986, NATURE, V322, P459, DOI 10.1038/322459a0; MODLIN RL, 1986, J IMMUNOL, V137, P2831; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; POND L, 1989, J IMMUNOL, V143, P4232; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; VANVOORHIS WC, 1982, NEW ENGL J MED, V307, P1593, DOI 10.1056/NEJM198212233072601	17	1175	1225	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					277	279		10.1126/science.1925582	http://dx.doi.org/10.1126/science.1925582			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925582				2022-12-28	WOS:A1991GJ64200036
J	KOELLE, MR; TALBOT, WS; SEGRAVES, WA; BENDER, MT; CHERBAS, P; HOGNESS, DS				KOELLE, MR; TALBOT, WS; SEGRAVES, WA; BENDER, MT; CHERBAS, P; HOGNESS, DS			THE DROSOPHILA ECR GENE ENCODES AN ECDYSONE RECEPTOR, A NEW MEMBER OF THE STEROID-RECEPTOR SUPERFAMILY	CELL			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; P-ELEMENT TRANSPOSASE; DNA-BINDING DOMAIN; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; ECDYSTEROID RECEPTORS; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; EARLY PUFF	The steroid hormone ecdysone triggers coordinate changes in Drosophila tissue development that result in metamorphosis. To advance our understanding of the genetic regulatory hierarchies controlling this tissue response, we have isolated and characterized a gene, EcR, for a new steroid receptor homolog and have shown that it encodes an ecdysone receptor. First, EcR protein binds active ecdysteroids and is antigenically indistinguishable from the ecdysone-binding protein previously observed in extracts of Drosophila cell lines and tissues. Second, EcR protein binds DNA with high specificity at ecdysone response elements. Third, ecdysone-responsive cultured cells express EcR, whereas ecdysone-resistant cells derived from them are deficient in EcR. Expression of EcR in such resistant cells by transfection restores their ability to respond to the hormone. As expected, EcR is nuclear and found in all ecdysone target tissues examined. Furthermore, the EcR gene is expressed at each developmental stage marked by a pulse of ecdysone.	STANFORD UNIV, MED CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	Stanford University; Indiana University System; Indiana University Bloomington	KOELLE, MR (corresponding author), STANFORD UNIV, MED CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ASHBURNER M, 1973, COLD SPRING HARB SYM, V38, P655; ASHBURNER M, 1976, INSECT DEV, P203; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BELYAEVA ES, 1987, CHROMOSOMA, V95, P295, DOI 10.1007/BF00294787; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BESTBELPOMME M, 1978, P NATL ACAD SCI USA, V75, P6102, DOI 10.1073/pnas.75.12.6102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BURTIS KC, 1985, THESIS STANFORD U ST; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAO AT, 1986, EMBO J, V5, P143, DOI 10.1002/j.1460-2075.1986.tb04188.x; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS L, 1980, ROUX ARCH DEV BIOL, V189, P1, DOI 10.1007/BF00848562; CHERBAS P, 1988, P NATL ACAD SCI USA, V85, P2096, DOI 10.1073/pnas.85.7.2096; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIBELLO PR, 1991, IN PRESS GENETICS; DINAN L, 1985, ARCH INSECT BIOCHEM, V2, P295, DOI 10.1002/arch.940020307; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GALCERAN J, 1990, NUCLEIC ACIDS RES, V18, P539, DOI 10.1093/nar/18.3.539; GATERMANN KB, 1988, BIOTECHNIQUES, V6, P951; GIETZ RD, 1985, DEV BIOL, V107, P142, DOI 10.1016/0012-1606(85)90383-5; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HANDLER AM, 1982, DEV BIOL, V93, P73, DOI 10.1016/0012-1606(82)90240-8; HANDLER AM, 1989, MOL CELL ENDOCRINOL, V63, P103, DOI 10.1016/0303-7207(89)90086-5; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; IRVINE KD, 1991, DEVELOPMENT, V111, P407; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KISS I, 1988, GENETICS, V118, P247; KOELLE MR, 1991, IN PRESS P NATL ACAD; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAMINSKY GP, 1980, P NATL ACAD SCI-BIOL, V77, P4175, DOI 10.1073/pnas.77.7.4175; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MAROY P, 1978, P NATL ACAD SCI USA, V75, P6035, DOI 10.1073/pnas.75.12.6035; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OSTERBUR DL, 1982, J CELL BIOCHEM, V20, P277, DOI 10.1002/jcb.240200307; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PRATT WB, 1988, J BIOL CHEM, V263, P267; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAGE BA, 1982, J BIOL CHEM, V257, P6373; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER I, 1978, GENETICS BIOL DROS A, V2, P265; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; STEVENS B, 1982, DEV BIOL, V94, P176, DOI 10.1016/0012-1606(82)90080-X; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YUND MA, 1978, P NATL ACAD SCI USA, V75, P6039, DOI 10.1073/pnas.75.12.6039; YUND MA, 1979, MOL CELL ENDOCRINOL, V14, P19, DOI 10.1016/0303-7207(79)90055-8; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	109	798	848	7	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					59	77		10.1016/0092-8674(91)90572-G	http://dx.doi.org/10.1016/0092-8674(91)90572-G			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913820				2022-12-28	WOS:A1991GJ32000007
J	GLYNNE, R; POWIS, SH; BECK, S; KELLY, A; KERR, LA; TROWSDALE, J				GLYNNE, R; POWIS, SH; BECK, S; KELLY, A; KERR, LA; TROWSDALE, J			A PROTEASOME-RELATED GENE BETWEEN THE 2 ABC TRANSPORTER LOCI IN THE CLASS-II REGION OF THE HUMAN MHC	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR-WEIGHT PROTEINASE; INFLUENZA NUCLEOPROTEIN; ANTIGEN PRESENTATION; T-CELLS; PURIFICATION; SEQUENCES; MACROPAIN; PATHWAY; LIVER	IT is now possible to paint a detailed picture of how cytoplasmic proteins are handled by the immune system 1-7. They are apparently degraded in the cytoplasm into peptides. These are then transported into the endoplasmic reticulum where they encounter class I major histocompatibility complex (MHC) molecules. Once loaded with peptide, the HLA molecules move through the Golgi apparatus to the cell membrane. Until recently, it had not been established how peptides without signal sequences cross the ER membrane. However, a number of papers have now described a pair of membrane transporter genes of the ABC (ATP-binding cassette) super-family which are attractive candidates for this function 8-12. Both transporter genes, which may encode two halves of a heterodimer, are situated in the class II region of the MHC. There is evidence that other putative components of the processing machinery, the LMPs (low molecular mass polypeptides), are also encoded in the MHC 13-15. Similarities between the properties of the LMPs and a large intracellular protease complex, called proteasome, have led to the suggestion that LMPs are involved in processing antigens 16. We have now identified a human gene with sequence homology to proteasome components. Remarkably, this gene maps between the two putative peptide transporter genes.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND	University of London; King's College London	GLYNNE, R (corresponding author), IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; AUSABEL FM, 1987, CURRENT PROTOCOLS MO; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1988, ARCH BIOCHEM BIOPHYS, V268, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERNBERG MJE, 1991, COMPUT APPL BIOSCI, V7, P257; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R	32	417	427	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					357	360		10.1038/353357a0	http://dx.doi.org/10.1038/353357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922342				2022-12-28	WOS:A1991GG65400063
J	CASTELLANO, AR; NETTLEMAN, MD				CASTELLANO, AR; NETTLEMAN, MD			COST AND BENEFIT OF SECONDARY PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; AIDS; PENTAMIDINE; PREVENTION	Objective.-To determine the relative cost and benefit of aerosolized pentamidine and the combination product of sulfamethoxazole and trimethoprim sulfate as secondary prophylaxis for Pneumocystis carinii pneumonia. Design.-A Markov-based cost-benefit analysis was performed. Drug efficacies, toxicities, and mortality rates were drawn from the current literature. Setting.-Hypothetical. Patient Population.-Patients infected with the human immunodeficiency virus who had had at least one episode of P carinii pneumonia. Interventions.-Regimen 1 required the use of aerosolized pentamidine as the sole first-line prophylactic agent in all patients. Regimen 2 required the use of sulfamethoxazole-trimethoprim in all patients who had no history of a toxic reaction to the drug; only patients with a history of toxic effects and those who developed toxic effects while receiving the drug would receive aerosolized pentamidine. Regimen 3 required that no secondary prophylaxis be given. Main Outcome Measures.-Net cost, median patient survival, and 5-year survival for each regimen and for regimens 1 and 2 compared with regimen 3. Main Results.-Regimen 2 was dominant, with a net cost of $6332 per patient and a median survival of 2.050 years. Compared with no prophylaxis, regimen 2 resulted in a savings of $16 503 per patient and a 0.696-year increase in median survival. Compared with regimen 1, regimen 2 resulted in a savings of $2904 and a 0.067-year increase in median survival. Conclusions.-Secondary prophylaxis for P carinii saves money and extends survival. Current data suggest that sulfamethoxazole-trimethoprim should be given whenever it can be tolerated. Use of aerosolized pentamidine as a first-line agent would result in a modest increase in cost and a decrease in life expectancy.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of Iowa								BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERNARD E, 1988, 4TH INT C AIDS STOCK, P420; BERNARD EM, 1987, CLIN RES, V35, pA468; BIRGITTE NJ, 1989, 5TH INT C AIDS MONTR, P296; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CLOTET B, 1990, 6TH INT C AIDS SAN F, P225; CONTE JE, 1988, 4TH INT C AIDS STOCK, P419; CORCKERY KJ, 1988, RESPIR CARE, V33, P676; CREIGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Friedberg G, 1988, J Palliat Care, V4, P38; GABIN SJ, 1988, 4TH INT C AIDS STOCK, P419; GOLDEN JA, 1989, LANCET, V1, P654; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; KAPLAN LD, 1985, CLIN RES, V33, pA406; KELLY J, 1990, 6TH INT C AIDS SAN F, P225; KEYES C, 1989, 5TH INT C AIDS MONTR, P295; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; LANG OS, 1989, 5TH INT C AIDS MONTR, P196; LEOUNG GS, 1988, 4TH INT C AIDS STOCK, P419; LEOUNG GS, 1989, 5TH INT C AIDS MONTR, P299; MASUR H, 1989, PRINCIPLES PRACTICE, P3; MEDINA I, 1987, 27TH INT C ANT AG CH, P261; METROKA CE, 1989, 5TH INT C AIDS MONTR, P196; MOON MW, 1989, 5TH INT C AIDS MONTR, P298; NETTLEMAN MD, 1988, INFECT CONT HOSP EP, V9, P88, DOI 10.2307/30144149; NIELSEN TL, 1990, 6TH INT C AIDS SAN F, P225; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHAFER RW, 1989, J ACQ IMMUN DEF SYND, V2, P389; SMITH DE, 1988, 4TH INT C AIDS STOCK, P418; STASZEWSKI S, 1989, 5TH INT C AIDS MONTR, P299; TORRES R, 1990, 6TH INT AIDS C SAN F, P223; TORRES RA, 1989, 5TH INT C AIDS MONTR, P299; VANGUNDY KP, 1988, 4TH INT C AIDS STOCK, P420; WEINKE T, 1988, 4TH INT C AIDS STOCK, P421; Weinstein MC, 1980, CLIN DECISION ANAL; WEISMAN J, 1989, 5TH INT C AIDS MONTR, P219; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WOFSY CB, 1987, REV INFECT DIS, V9, pS184; 1989, MMWR SS5, V38, P1	44	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					820	824		10.1001/jama.266.6.820	http://dx.doi.org/10.1001/jama.266.6.820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1907671				2022-12-28	WOS:A1991GA07300034
J	JAMES, DV; HAMILTON, LW				JAMES, DV; HAMILTON, LW			THE CLERKENWELL SCHEME - ASSESSING EFFICACY AND COST OF A PSYCHIATRIC LIAISON SERVICE TO A MAGISTRATES COURT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the efficacy of psychiatric liaison schemes to magistrates' courts in shortening the period that mentally ill accused people spend in custody between arrest, the provision of psychiatric reports, and admission to hospital under the Mental Health Act 1983 and to establish the direct costs of setting up such schemes. Design-A nine month prospective study of court referrals and concurrent analysis of prison records. Setting-An inner London magistrates' court (Clerkenwell) and a large remand prison (Brixton). Patients-Consecutive series of 80 remand prisoners receiving psychiatric assessment through a liaison scheme; 50 remand prisoners placed on hospital orders by magistrates' courts after being remanded to prison for reports; 364 psychiatric prisoners undergoing second opinion assessments at a remand prison; 520 offenders in a remand prison placed on hospital orders. Main outcome measures-Comparison of lengths of time spent in custody for different stages of the assessment and disposal process. Results-For the 50 remand prisoners assessed in prison the mean time from arrest to appearance in court with a psychiatric report was 33.7 days and from arrest to admission to hospital 50.8 days. For those examined in court under the liaison scheme the equivalent figures were 5.4 days (t = 12.63, p < 0.0001) and 8.7 days (t = 13.04, p < 0.0001). The number of hospital orders made at the court increased fourfold after the liaison scheme began. The additional direct costs of the scheme were negligible. Conclusion-Psychiatric liaison services to magistrates' courts can greatly reduce the length of time that offenders with mental disorders spend in custody. Such schemes may increase recognition of offenders suitable for admission to hospital. A scheme could be established in some areas within existing service provision.	BROADMOOR HOSP,CROWTHORNE RG11 7EG,BERKS,ENGLAND		JAMES, DV (corresponding author), ROYAL FREE HOSP,DEPT PSYCHIAT,LONDON NW3 2QG,ENGLAND.							BOWDEN P, 1978, BRIT J PSYCHIAT, V132, P332; FAULK M, 1975, MED SCI LAW, V15, P276, DOI 10.1177/002580247501500409; FENNELL P, 1991, CRIM LAW REV, P333; GIBBENS TCN, 1977, MED REMANDS CRIMINAL; HERBST KR, 1991, MENTALLY DISORDERED; Joseph P L, 1990, Health Trends, V22, P51; 1991, CMND1456; IN PRESS REPORT INNE; 1990, CMND1302; 1990, PROVISION MENTALLY D; 1990, HMP BRIXTON REPORT H	11	40	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					282	285		10.1136/bmj.303.6797.282	http://dx.doi.org/10.1136/bmj.303.6797.282			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1909597	Green Published, Bronze			2022-12-28	WOS:A1991FZ72100019
J	KARESS, RE; CHANG, XJ; EDWARDS, KA; KULKARNI, S; AGUILERA, I; KIEHART, DP				KARESS, RE; CHANG, XJ; EDWARDS, KA; KULKARNI, S; AGUILERA, I; KIEHART, DP			THE REGULATORY LIGHT CHAIN OF NONMUSCLE MYOSIN IS ENCODED BY SPAGHETTI-SQUASH, A GENE REQUIRED FOR CYTOKINESIS IN DROSOPHILA	CELL			English	Article							HEAVY-CHAIN; CELL-CYCLE; CHROMOSOME MOVEMENT; SEQUENCE-ANALYSIS; DICTYOSTELIUM; MELANOGASTER; INVITRO; MUSCLE; ACTIN; DISSECTION	Two independent approaches to understanding the molecular mechanism of cytokinesis have converged on the gene spaghetti-squash (sqh). A genetic screen for mitotic mutants identified sqh1, a mutation that disrupts cytokinesis, which was then cloned by transposon tagging. Independently, the gene that encodes the regulatory light chain of the biochemically defined nonmuscle myosin (MRLC-C) was also cloned. We show here that sqh encodes MRLC-C and that in sqh1 mutants, the level of stable light chain transcript is greatly reduced. Reversion by transposon excision or transformation with a wild-type copy of the sqh transcription unit rescues cytokinesis failure and other defects in sqh1. Vertebrate homologs of MRLC-C are phosphorylatable and regulate myosin activity in vitro. These studies provide genetic proof that MRLC-C is required for cytokinesis, suggest a role for the protein in regulating contractile ring function, and establish a genetic system to evaluate its function.	HARVARD UNIV, DEPT CELLULAR & DEV IMMUNOL, CAMBRIDGE, MA 02138 USA	Harvard University	KARESS, RE (corresponding author), NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA.		Aguilera, Isabel/K-2680-2017; Edwards, Kevin Andrew/GOE-3539-2022	Aguilera, Isabel/0000-0003-2165-4954; Edwards, Kevin Andrew/0000-0003-4721-5626; Karess, Roger/0000-0002-7299-0600	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037979, R01GM033830] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33830, GM37979] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1987, ANEUPLOIDY A; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; Conrad G. W., 1981, MITOSIS CYTOKINESIS, P365; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Engels W.R, 1989, MOBILE DNA, P437; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; HATZFELD J, 1975, CELL, V5, P123, DOI 10.1016/0092-8674(75)90020-3; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1982, J CELL BIOL, V94, P165, DOI 10.1083/jcb.94.1.165; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; KIEHART DP, 1990, ANN NY ACAD SCI, V582, P233; KITANISHIYUMURA T, 1989, CELL MOTIL CYTOSKEL, V12, P78, DOI 10.1002/cm.970120203; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RIPOLL P, 1987, BIOESSAYS, V7, P204, DOI 10.1002/bies.950070504; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SATTERWHITE L, 1990, ANN NY ACAD SCI, V582, P307; SCHROEDER T, 1989, ANN NY ACAD SCI, V582, P78; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Snedecor G.W., 1980, STAT METHODS, V7; SPUDICH JA, 1989, CELL REGUL, V1, P1; SUBBIAH S, 1989, J MOL BIOL, V209, P539, DOI 10.1016/0022-2836(89)90592-5; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZAVODNY P, 1988, NUCLEIC ACIDS RES, V16, P214	56	238	240	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1177	1189		10.1016/0092-8674(91)90013-O	http://dx.doi.org/10.1016/0092-8674(91)90013-O			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905980	hybrid			2022-12-28	WOS:A1991FU89900010
J	MILLER, K; SHIPMAN, M; TROWBRIDGE, IS; HOPKINS, CR				MILLER, K; SHIPMAN, M; TROWBRIDGE, IS; HOPKINS, CR			TRANSFERRIN RECEPTORS PROMOTE THE FORMATION OF CLATHRIN LATTICES	CELL			English	Article							COATED PIT FORMATION; MEDIATED ENDOCYTOSIS; CARCINOMA A431-CELLS; VESICLES; CELLS; INTERNALIZATION; FIBROBLASTS; MICROSCOPY; FLOW	Gold conjugates have been used to quantitate human transferrin receptors (hTfnRs) on transfected chick embryo fibroblasts. No relationship could be found between the number of hTfnRs and the number of clathrin-coated pits. However, hTfnRs are also associated with flat clathrin lattices that lie outside invaginated pits. With increasing levels of receptor expression, the density of hTfnRs within flat lattices increases, and at the highest levels of expression the total area of flat lattice increases up to 3-fold. These results show that increased receptor numbers can promote clathrin lattice growth and suggest that the recruitment of receptors like hTfnRs is an essential step in lattice construction. We conclude that the process of invagination, which gives rise to coated pits, is regulated separately.	SALK INST BIOL STUDIES,DEPT CANC BIOL,SAN DIEGO,CA 92138	Salk Institute	MILLER, K (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND.							BEAUMELLE BD, 1990, J CELL BIOL, V7111, P1811; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRETSCHER MS, 1983, COLD SPRING HARB SYM, V46, P707; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HOPKINS C, 1985, MOL MECHANISMS TRANS, P337; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HOPKINS CR, 1985, J CELL SCI S, V3, P173; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAUPIN P, 1983, J CELL BIOL, V96, P51, DOI 10.1083/jcb.96.1.51; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; NICOL A, 1987, EUR J CELL BIOL, V43, P348; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RUTTER G, 1985, European Journal of Cell Biology, V39, P443; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633	30	109	109	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					621	632		10.1016/0092-8674(91)90094-F	http://dx.doi.org/10.1016/0092-8674(91)90094-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1903330				2022-12-28	WOS:A1991FM03700012
J	SIMON, MI; STRATHMANN, MP; GAUTAM, N				SIMON, MI; STRATHMANN, MP; GAUTAM, N			DIVERSITY OF G-PROTEINS IN SIGNAL TRANSDUCTION	SCIENCE			English	Article							NUCLEOTIDE-BINDING-PROTEINS; BETA-GAMMA-SUBUNITS; NUCLEOSIDE-DIPHOSPHATE KINASE; STIMULATORY G-PROTEIN; MAMMALIAN G-PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; ADENYLYL CYCLASE; PERTUSSIS TOXIN; SACCHAROMYCES-CEREVISIAE	The heterotrimeric guanine nucleotide-binding proteins (G proteins) act as switches that regulate information processing circuits connecting cell surface receptors to a variety of effectors. The G proteins are present in all eukaryotic cells, and they control metabolic, humoral, neural, and developmental functions. More than a hundred different kinds of receptors and many different effectors have been described. The G proteins that coordinate receptor-effector activity are derived from a large gene family. At present, the family is known to contain at least sixteen different genes that encode the alpha subunit of the heterotrimer, four that encode beta subunits, and multiple genes encoding gamma subunits. Specific transient interactions between these components generate the pathways that modulate cellular responses to complex chemical signals.	WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	SIMON, MI (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							AMATRUDA T, IN PRESS P NATL ACAD; ASANO T, 1990, FEBS LETT, V266, P41, DOI 10.1016/0014-5793(90)81501-E; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BIRNBAUMER L, 1989, RECENT PROG HORM RES, V45, P121; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1989, PROTEINS, V6, P222, DOI 10.1002/prot.340060304; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; DERETIC D, 1987, J BIOL CHEM, V262, P10839; DESOUSA SM, 1989, J BIOL CHEM, V264, P18544; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOHLMAN H, IN PRESS ANN REV BIO; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; EVANS T, 1987, J BIOL CHEM, V262, P176; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOH JW, 1989, SCIENCE, V244, P980, DOI 10.1126/science.2543072; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HINTOND R, 1990, J NERUOSCI, V10, P2763; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HSU WH, 1990, J BIOL CHEM, V265, P11220; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; IM MJ, 1987, J RECEPTOR RES, V7, P17, DOI 10.3109/10799898709054977; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1984, J BIOL CHEM, V259, P3568; KAZIRO Y, 1988, COLD SPRING HARB SYM, V53, P209, DOI 10.1101/SQB.1988.053.01.027; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUMAGAI A, 1988, COLD SPRING HARB SYM, V53, P675, DOI 10.1101/SQB.1988.053.01.077; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LEVITZKI A, 1987, FEBS LETT, V211, P113, DOI 10.1016/0014-5793(87)81419-9; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAKUSOKA M, 1988, P NATL ACAD SCI USA, V85, P5384; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUMOTO K, 1988, COLD SPRING HARB SYM, V53, P567, DOI 10.1101/SQB.1988.053.01.065; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NEER EJ, 1988, J BIOL CHEM, V263, P8996; OHTSUKI K, 1986, BIOCHIM BIOPHYS ACTA, V882, P322, DOI 10.1016/0304-4165(86)90254-0; OKABE K, 1990, J BIOL CHEM, V265, P12854; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; POUYSSEGUR J, 1990, KAR INS NCS, P85; PROVOST NM, 1988, J BIOL CHEM, V263, P12070; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; RAYMOND JR, 1990, ADP RIBOSYLATING TOX, P163; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SCHMIDT CJ, 1989, CELL REGUL, V1, P125, DOI 10.1091/mbc.1.1.125; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STONE DE, 1990, MOL CELL BIOL, V10, P4439, DOI 10.1128/MCB.10.9.4439; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN M, UNPUB; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, IN PRESS NATURE; THAMBI NC, 1989, J BIOL CHEM, V264, P18552; UI M, 1990, ADP RIBOSYLATING TOX, P45; VOLTERRA A, 1988, P NATL ACAD SCI USA, V85, P7810, DOI 10.1073/pnas.85.20.7810; VONWEIZSACKER E, UNPUB; WALKER G, 1990, FASEB J, V4, P2924, DOI 10.1096/fasebj.4.11.2116341; WANG N, 1990, J BIOL CHEM, V265, P1239; WILKIE T, UNPUB; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; YATANI A, 1988, J BIOL CHEM, V263, P9887; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YOON JS, 1989, J BIOL CHEM, V264, P18536; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	141	1808	1885	3	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					802	808		10.1126/science.1902986	http://dx.doi.org/10.1126/science.1902986			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1902986				2022-12-28	WOS:A1991FL12300037
J	OGORMAN, S; FOX, DT; WAHL, GM				OGORMAN, S; FOX, DT; WAHL, GM			RECOMBINASE-MEDIATED GENE ACTIVATION AND SITE-SPECIFIC INTEGRATION IN MAMMALIAN-CELLS	SCIENCE			English	Article							FLP RECOMBINASE; YEAST PLASMID; HEAT-SHOCK; DNA; SEQUENCES; CIRCLE; GENOME	A binary system for gene activation and site-specific integration, based on the conditional recombination of transfected sequences mediated by the FLP recombinase from yeast, was implemented in mammalian cells. In several cell lines, FLP rapidly and precisely recombined copies of its specific target sequence to activate an otherwise silent beta-galactosidase reporter gene. Clones of marked cells were generated by excisional recombination within a chromosomally integrated copy of the silent reporter. By the reverse reaction, integration of transfected DNA was targeted to a specific chromosomal site. The results suggest that FLP could be used to mosaically activate or inactivate transgenes for analysis of vertebrate development, and to efficiently integrate transfected DNA at predetermined chromosomal locations.			OGORMAN, S (corresponding author), SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; DEWET J, 1987, MOL CELL BIOL, V72, P725; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OGORMAN S, UNPUB; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SAUER B, 1990, New Biologist, V2, P441; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X	25	439	618	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1351	1355		10.1126/science.1900642	http://dx.doi.org/10.1126/science.1900642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1900642				2022-12-28	WOS:A1991FB73300042
J	SHORVON, SD				SHORVON, SD			MEDICAL ASSESSMENT AND TREATMENT OF CHRONIC EPILEPSY	BRITISH MEDICAL JOURNAL			English	Review							TEMPORAL-LOBE EPILEPSY; PARTIAL SEIZURES; RESONANCE; DRUGS; PET; CT				SHORVON, SD (corresponding author), UNIV LONDON,NATL HOSP,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND.		Shorvon, Simon D/A-2019-2009	Shorvon, Simon/0000-0003-0313-2001				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1989, LANCET, V1, P532; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; BINNIE CD, 1987, EPILEPSY, P169; BRODIE MJ, 1988, BRIT MED J, V296, P1110, DOI 10.1136/bmj.296.6629.1110; CHADWICK DW, 1987, BRIT MED J, V294, P723, DOI 10.1136/bmj.294.6574.723; DUNCAN JS, 1990, EPILEPSIA, V31, P324, DOI 10.1111/j.1528-1157.1990.tb05383.x; DUNCAN R, 1990, J NEUROL NEUROSUR PS, V53, P11, DOI 10.1136/jnnp.53.1.11; ENGEL J, 1987, SURGICAL TREATMENT E; FRANCESCHI M, 1989, EPILEPSIA, V30, P540, DOI 10.1111/j.1528-1157.1989.tb05469.x; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; JABBARI B, 1986, ARCH NEUROL-CHICAGO, V43, P869, DOI 10.1001/archneur.1986.00520090009007; KUZNIECKY R, 1987, ANN NEUROL, V22, P341, DOI 10.1002/ana.410220310; LATACK JT, 1986, RADIOLOGY, V159, P159, DOI 10.1148/radiology.159.1.3081943; LESSER RP, 1986, ARCH NEUROL-CHICAGO, V43, P367, DOI 10.1001/archneur.1986.00520040049018; POLKEY CE, 1988, TXB EPILEPSY, P485; REYNOLDS EH, 1980, PHARMACOL THERAPEUT, V8, P217, DOI 10.1016/0163-7258(80)90047-9; REYNOLDS EH, 1981, EPILEPSIA, V22, P1, DOI 10.1111/j.1528-1157.1981.tb04327.x; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; Shorvon S.D., 1986, INTRACTABLE EPILEPSY, P13; SHORVON SD, 1988, TXB EPILEPSY, P611; SPERLING MR, 1986, ANN NEUROL, V20, P57, DOI 10.1002/ana.410200110; SUSSMAN NM, 1984, EPILEPSIA, V25, P649; THEODORE WH, 1986, NEUROLOGY, V36, P750, DOI 10.1212/WNL.36.6.750; WIESER HG, 1987, PRESURGICAL EVALUATI; 1989, LANCET, V2, P196; 1981, EPILEPSIA, V22, P480; 1985, EPILEPSIA, V26, P268; [No title captured]; [No title captured]; 1989, LANCET, V2, P485	31	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					363	366		10.1136/bmj.302.6773.363	http://dx.doi.org/10.1136/bmj.302.6773.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1900724	Bronze, Green Published			2022-12-28	WOS:A1991EX85800005
J	LOBO, PJ; POWLES, RL; HANRAHAN, A; REYNOLDS, DK				LOBO, PJ; POWLES, RL; HANRAHAN, A; REYNOLDS, DK			ACUTE MYELOBLASTIC-LEUKEMIA - A MODEL FOR ASSESSING VALUE FOR MONEY FOR NEW TREATMENT PROGRAMS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure the effects of changes in treatment of acute myeloblastic leukaemia that may give better value for money. Design-Retrospective analysis of patients' notes to identify items of management costing money; prospective costing of these items. The Medical Research Council acute myeloblastic leukaemia 9 trial was used to identify the amount and distribution of these costs when either one or two courses of induction treatment were required to obtain complete remission. These findings were then extrapolated to four published international controlled trials using similarly intense treatment and in which the number of courses of treatment required for complete remission was stated, to compare British costs for treatment with idarubicin and daunorubicin, both in combination with cytarabine. Setting-Leukaemia unit, Royal Marsden Hospital, London. Subjects-Data on 10 patients receiving intensive induction treatment for acute myeloblastic leukaemia were used to identify 160 items of cost in four broad groups: general (including accommodation), diagnostic, supportive treatment, and cytotoxic chemotherapy. One newly treated patient was prospectively assessed over one month, including a time and motion study, to cost these items; then costs for 268 patients from the MRC trial receiving moderate induction chemotherapy including daunorubicin were assessed, and costs for treatment of 522 patients in the four international studies comparing daunorubicin with idarubicin were analysed. Main outcome measures-Cost effectiveness was measured as the overall cost to obtain complete remission in untreated patients with acute myeloblastic leukaemia after treatment with idarubicin or daunorubicin. Results-The 160 costed items were measured for their sensitivity in varying the total cost of treatment, this being assessed within Britain in other district general and private hospitals to measure the extremes of cost of these items. Overall, idarubicin, although more expensive, showed a substantial saving (1477 pounds per patient) in total hospital costs, more than offsetting the increased cost (607 pounds) of the new treatment, an overall saving of 870 pounds per patient (5%). Conclusion-Approaches modelling cost effectiveness may be an essential part of planning new programmes of treatment in the future. This method can be used to estimate the cost effectiveness of the treatments in different environments and countries where costs may vary widely.	ROYAL MARSDEN HOSP, LEUKAEMIA UNIT, SUTTON SM2 5PT, SURREY, ENGLAND; FARMITALIA CARLO ERBA LTD, DEPT MED, ST ALBANS, HERTS, ENGLAND; ROYAL MARSDEN HOSP, DEPT FINANCE, SUTTON SM2 5PT, SURREY, ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust								BERMAN E, 1989, SEMIN ONCOL, V16, P30; PETTI MC, 1989, SEMIN ONCOL, V16, P10; POWLES RL, 1980, LANCET, V1, P1047; VOGLER WR, 1989, SEMIN ONCOL, V16, P21; WIERNIK PH, 1989, SEMIN ONCOL, V16, P25	5	23	23	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	1991	302	6772					323	326		10.1136/bmj.302.6772.323	http://dx.doi.org/10.1136/bmj.302.6772.323			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	1900453	Bronze, Green Published			2022-12-28	WOS:A1991EX56900022
J	JAVITT, JC; MCBEAN, AM; NICHOLSON, GA; BABISH, JD; WARREN, JL; KRAKAUER, H				JAVITT, JC; MCBEAN, AM; NICHOLSON, GA; BABISH, JD; WARREN, JL; KRAKAUER, H			UNDERTREATMENT OF GLAUCOMA AMONG BLACK-AMERICANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-ANGLE GLAUCOMA; ARGON-LASER TRABECULOPLASTY; FOLLOW-UP; RETINOPATHY; POPULATION; BLINDNESS; WHITES; CARE	Background. Cross-sectional studies and those using national data sets estimate that glaucoma-related blindness is between six and eight times more common among black Americans than among whites. Community-based studies have found that glaucoma is four to six times more prevalent among blacks. It is not known why blacks with glaucoma are more likely to become blind than whites with glaucoma. Methods. To investigate the possibility that under-treatment of glaucoma is an important factor contributing to this higher rate of blindness, we studied the population-based rates of incisional and laser surgery tor open-angle glaucoma among blacks and whites in a 5 percent random sample of Medicare claims for 1986 through 1988. Results. For all U.S. census divisions combined, the rate of surgery for glaucoma among black Medicare beneficiaries was 2.2 times higher than the rate among white beneficiaries (95 percent confidence interval, 2.1 to 2.3). We calculated an expected rate of treatment among blacks on the basis of the rate of treatment among whites and the assumption that glaucoma is four times more prevalent among blacks - a conservative estimate. The observed rate of glaucoma surgery among blacks was 45 percent lower than the expected rate we calculated, which may in part account for the excess rate of blindness among blacks. The magnitude of this difference in treatment rates varied from 29 percent in the Middle Atlantic states to 50 percent in the South Atlantic states. Conclusions. Older black Americans are not receiving potentially sight-saving care for open-angle glaucoma at the same rate as older white Americans.	GEORGETOWN UNIV,DEPT COMMUNITY & FAMILY MED,PROGRAM TECHNOL ASSESSMENT,WASHINGTON,DC 20057; HLTH CARE FINANCING ADM,BUR HLTH STAND QUAL,OFF PROGRAM ASSESSMENT,BALTIMORE,MD; HLTH CARE FINANCING ADM,OFF RES,BALTIMORE,MD	Georgetown University	JAVITT, JC (corresponding author), CTR SIGHT,WORTHEN CTR EYE CARE RES,3800 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006758, R24RR006758] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R21EY007744, R01EY008805] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR0 6758] Funding Source: Medline; NEI NIH HHS [R01 EY08805, R21 EY07744] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], HCFA COMMON PROCEDUR; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DASBACH EJ, 1991, MED CARE, V29, P20, DOI 10.1097/00005650-199101000-00003; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FISHER E, IN PRESS AM J PUBLIC; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HILLER R, 1975, AM J OPHTHALMOL, V80, P62, DOI 10.1016/0002-9394(75)90870-3; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565; JAVITT JC, 1990, OPHTHALMOLOGY, V97, P483, DOI 10.1016/S0161-6420(90)32573-3; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; KAHN HA, 1973, DHEW NIH73427 NAT EY; KRUPIN T, 1986, OPHTHALMOLOGY, V93, P811; Lave J, 1983, Health Care Financ Rev, V5, P93; LESKE MC, 1989, BRIT J OPHTHALMOL, V73, P365, DOI 10.1136/bjo.73.5.365; MARTIN MJ, 1985, AM J OPHTHALMOL, V99, P383, DOI 10.1016/0002-9394(85)90001-7; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; MAYER WJ, 1989, AM J PUBLIC HEALTH, V79, P772, DOI 10.2105/AJPH.79.6.772; MILLER RD, 1981, OPHTHALMIC SURG LAS, V12, P46; PODGOR MJ, 1983, AM J EPIDEMIOL, V118, P206, DOI 10.1093/oxfordjournals.aje.a113628; ROBERTS J, 1977, VITAL HLTH STATI 201, V11; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; SCHWARTZ AL, 1985, ARCH OPHTHALMOL-CHIC, V103, P1482; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WELSH NH, 1972, BRIT J OPHTHALMOL, V56, P32, DOI 10.1136/bjo.56.1.32; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; 1977, CPT4 AM MED ASS; 1986, INT CLASSIFICATION D; 1990, HCFA03301 HLTH CAR F, V2	33	98	99	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1418	1422		10.1056/NEJM199111143252005	http://dx.doi.org/10.1056/NEJM199111143252005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP524	1922253	Bronze			2022-12-28	WOS:A1991GP52400005
J	KODISH, E; LANTOS, J; STOCKING, C; SINGER, PA; SIEGLER, M; JOHNSON, FL				KODISH, E; LANTOS, J; STOCKING, C; SINGER, PA; SIEGLER, M; JOHNSON, FL			BONE-MARROW TRANSPLANTATION FOR SICKLE-CELL DISEASE - A STUDY OF PARENTS DECISIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							APLASTIC-ANEMIA; CHILDREN; SURVIVAL; MORTALITY; LEUKEMIA; QUALITY; CANCER; LIFE	Background. Bone marrow transplantation has been shown to cure sickle cell disease, but it carries a 15 percent mortality risk. To determine whether parents would accept this risk to cure their children of sickle cell disease, we interviewed parents of children with sickle cell disease who were being followed in a university hospital clinic. Methods. We assessed parents' attitudes by using questions based on the standard reference-gamble paradigm. After we gave them descriptions of bone marrow transplantation and graft-versus-host disease (GVHD), the parents were presented with a series of hypothetical situations. In the first situation, bone marrow transplantation was described as offering certain (100 percent) survival with cure of sickle cell disease. In subsequent descriptions, the mortality rate associated with bone marrow transplantation was increased by 5 percent increments. The parents indicated the highest mortality risk at which they would consent to the procedure in order to cure their children. Results. In order to obtain a cure for their children, 36 of 67 parents (54 percent) were willing to accept some risk of short-term mortality, 25 of 67 (37 percent) were willing to accept at least the 15 percent short-term mortality risk we estimate to be the current figure for bone marrow transplantation, and 8 of 67 (12 percent) were willing to accept a short-term mortality risk of 50 percent or more. Nine parents (13 percent) said they would accept both a mortality risk of 15 percent or more and an additional 15 percent risk of GVHD. The parents' decisions were not related to the clinical severity of their children's illness. Conclusions. At current rates of mortality and morbidity with bone marrow transplantation, a substantial minority of the parents of children with sickle cell disease may consent to bone marrow transplantation for their children. Parental attitudes should be factored into decisions about whether to off er bone marrow transplantation to children with sickle cell disease.	UNIV TORONTO,CTR BIOETH,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV CHICAGO,PRITZKER SCH MED,CTR CLIN MED ETH,CHICAGO,IL 60637; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Chicago; University of Toronto	KODISH, E (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT PEDIAT,BOX 97,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							BEUTLER E, 1983, HEMATOLOGY, P583; BRIGGS NC, 1986, TRANSFUSION, V26, P324, DOI 10.1046/j.1537-2995.1986.26486262738.x; DURBIN M, 1988, PEDIATRICS, V82, P774; FORMAN SJ, 1990, HEMATOL ONCOL CLIN N, V4, P517, DOI 10.1016/S0889-8588(18)30476-3; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4; Galimberti M, 1989, Prog Clin Biol Res, V309, P223; HARTH SC, 1990, BRIT MED J, V300, P1372, DOI 10.1136/bmj.300.6736.1372; JOHNSON FL, 1984, NEW ENGL J MED, V311, P780, DOI 10.1056/NEJM198409203111207; JOHNSON FL, 1985, AM J PEDIAT HEMATOL, V7, P254; KODISH E, 1990, CLIN RES, V38, P694; LEIKIN SL, 1989, PEDIATRICS, V84, P500; LOCASCIULLI A, 1990, BONE MARROW TRANSPL, V6, P211; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MCGLAVE P, 1990, SEMIN HEMATOL, V27, P23; MCNEIL BJ, 1978, NEW ENGL J MED, V299, P1397, DOI 10.1056/NEJM197812212992506; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; OR R, 1988, HEMOGLOBIN, V12, P609, DOI 10.3109/03630268808991651; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1987, HEMATOLOGY INFANCY C, P655; SARNAIK SA, 1982, AM J PEDIAT HEMATOL, V4, P386; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; STORB R, 1984, SEMIN HEMATOL, V21, P27; VERMYLEN C, 1988, LANCET, V1, P1427; 1986, ETHICS REGULATION CL, P1; 29TH WORLD MED ASS T; 1983, FED REGISTER, V48, P9814	27	106	106	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1349	1353		10.1056/NEJM199111073251905	http://dx.doi.org/10.1056/NEJM199111073251905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922237	Bronze			2022-12-28	WOS:A1991GN47000005
J	COTTON, RGH; MALCOLM, ADB				COTTON, RGH; MALCOLM, ADB			MUTATION DETECTION	NATURE			English	Article							SICKLE-CELL-ANEMIA; POLYMERASE CHAIN-REACTION; DNA; HYBRIDIZATION; AMPLIFICATION; DIAGNOSIS; CYTOSINE; THYMINE; ALLELE; GENE		CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6 8RF, ENGLAND	Imperial College London	COTTON, RGH (corresponding author), ROYAL CHILDRENS HOSP, MURDOCH INST RES BIRTH DEFECTS, FLEMINGTON RD, PARKVILLE, VIC 3052, AUSTRALIA.							BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; COTTON RGH, 1989, NUCLEIC ACIDS RES, V17, P4223, DOI 10.1093/nar/17.11.4223; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COTTON RGH, 1989, BIOCHEM J, V263, P1; GANGULY A, 1990, NUCLEIC ACIDS RES, V18, P3933, DOI 10.1093/nar/18.13.3933; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GROMPE M, 1989, P NATL ACAD SCI USA, V86, P5888, DOI 10.1073/pnas.86.15.5888; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KAN YW, 1978, LANCET, V2, P910; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; ROSENTHAL A, 1990, NUCLEIC ACIDS RES, V18, P3095, DOI 10.1093/nar/18.10.3095; SCHOFIELD JP, 1989, NUCLEIC ACIDS RES, V17, P9498, DOI 10.1093/nar/17.22.9498; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	16	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	1991	353	6344					582	583		10.1038/353582a0	http://dx.doi.org/10.1038/353582a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922369				2022-12-28	WOS:A1991GJ64300076
J	KELLY, AP; MONACO, JJ; CHO, SG; TROWSDALE, J				KELLY, AP; MONACO, JJ; CHO, SG; TROWSDALE, J			A NEW HUMAN HLA CLASS-II-RELATED LOCUS, DM	NATURE			English	Article							DQ-SUBREGION; CHAIN GENE; MHC; MOLECULES; SEQUENCE; DISTINCT; REGION; BETA	HLA CLASS II molecules have a crucial role in the immune response to antigens. We have isolated two new class II-like complementary DNA sequences, RING6 and RING7, which map between the HLA-DNA and -DOB loci. They are novel members of the immunoglobulin gene family which may have diverged before the duplications that gave rise to the main class II loci. The RING6 and RING7 genes seem to encode alpha- and beta-chains of a previously undiscovered class II-related protein.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	Virginia Commonwealth University	KELLY, AP (corresponding author), IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BLANCK G, 1988, J IMMUNOL, V141, P1734; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; GUESSOW D, 1987, J IMMUNOL, V139, P3122; HANSON IM, 1991, IMMUNOGENETICS, V34, P5, DOI 10.1007/BF00212306; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; KELLY A, 1985, NUCLEIC ACIDS RES, V13, P1607, DOI 10.1093/nar/13.5.1607; KLEIN J, 1986, NATURAL HIST MAJOR H; LINDAHL KF, 1989, COLD SH Q B, V54, P563; OSULLIVAN DM, 1986, P NATL ACAD SCI USA, V83, P4484, DOI 10.1073/pnas.83.12.4484; RAGOUSSIS J, 1991, P NATL ACAD SCI USA, V88, P3753, DOI 10.1073/pnas.88.9.3753; Sambrook J, 1989, MOL CLONING LABORATO; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0	18	254	265	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					571	573		10.1038/353571a0	http://dx.doi.org/10.1038/353571a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922365				2022-12-28	WOS:A1991GJ64300072
J	ANDERSON, P				ANDERSON, P			THE HEALTH OF THE NATION - RESPONSES - ALCOHOL AS A KEY AREA	BRITISH MEDICAL JOURNAL			English	Article							CONSUMPTION				ANDERSON, P (corresponding author), CHURCHILL HOSP,HLTH EDUC,AUTHOR PRIMARY HLTH CARE UNIT,OXFORD OX3 7LJ,ENGLAND.							ANDERSON P, 1988, BRIT MED J, V297, P824, DOI 10.1136/bmj.297.6652.824; ANDERSON P, IN PRESS J R SOC MED; ANDERSON P, 1991, MANAGEMENT DRINKING; DRUMMOND DC, 1990, LANCET, V7336, P915; GIESBRECHT N, 1989, RES ACTION COMMUNITY; GLIKSMAN L, 1987, 82 ADD RES F INT DOC; GODDARD E, 1991, DRINKING ENGLAND WAL; KENDELL RE, 1984, ALCOHOL ALCOHOLISM, V19, P271; KENDELL RE, 1983, BRIT J ADDICT, V78, P365; KREITMAN N, 1986, BRIT J ADDICT, V81, P353; MANN RE, 1988, BRIT J ADDICT, V83, P683; MAYNARD A, 1990, PREVENTING ALCOHOL T, V1; OSTERBERG E, 1980, ALCOHOL POLICY MEASU; POTAMIANOS G, 1986, LANCET, V2, P797; ROBINSON D, 1989, CONTROLLING LEGAL AD; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; SPRING JA, 1977, NATURE, V270, P567, DOI 10.1038/270567a0; 1990, SOCIAL TRENDS, V20; 1986, REPORTS GENERAL PRAC, V24; 1975, GENERAL HOUSEHOLD SU; 1982, ALCOHOL POLICIES 197; 1991, ALCOHOL PUBLIC HLTH; 1987, GREAT GROWING EVIL M; 1986, ALCOHOL OUR FAVOURIT; 1991, CM1523	26	24	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					766	769		10.1136/bmj.303.6805.766	http://dx.doi.org/10.1136/bmj.303.6805.766			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG981	1932941	Bronze, Green Published			2022-12-28	WOS:A1991GG98100026
J	GILLILAND, EL; WOLFE, JHN				GILLILAND, EL; WOLFE, JHN			ABC OF VASCULAR DISEASES - LEG ULCERS	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	GILLILAND, EL (corresponding author), N YORK GEN HOSP,N YORK M2K 1E1,ONTARIO,CANADA.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					776	779		10.1136/bmj.303.6805.776	http://dx.doi.org/10.1136/bmj.303.6805.776			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932945	Bronze, Green Published			2022-12-28	WOS:A1991GG98100030
J	LAURANCE, J				LAURANCE, J			THE NEW NHS - 6 MONTHS ON THE FREEMAN-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					765	766		10.1136/bmj.303.6805.765	http://dx.doi.org/10.1136/bmj.303.6805.765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932940	Bronze, Green Published			2022-12-28	WOS:A1991GG98100025
J	GRUSBY, MJ; JOHNSON, RS; PAPAIOANNOU, VE; GLIMCHER, LH				GRUSBY, MJ; JOHNSON, RS; PAPAIOANNOU, VE; GLIMCHER, LH			DEPLETION OF CD4+ T-CELLS IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENT MICE	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; GERM-LINE TRANSMISSION; HOMOLOGOUS RECOMBINATION; POSITIVE SELECTION; GENE-EXPRESSION; PHENOTYPE; ANTIGENS; RECEPTOR	The maturation of T cells in the thymus is dependent on the expression of major histocompatibility complex (MHC) molecules. By disruption of the MHC class II A-beta-b gene in embryonic stem cells, mice were generated that lack cell surface expression of class II molecules. These MHC class II-deficient mice were depleted of mature CD4+ T cells and were deficient in cell-mediated immune responses. These results provide genetic evidence that class II molecules are required for the maturation and function of mature CD4+ T cells.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED & VET MED, DEPT PATHOL, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	NIAID NIH HHS [AI21569] Funding Source: Medline; NICHD NIH HHS [HD27295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021569, R01AI021569] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, UNPUB; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GERMAIN R, COMMUNICATION; GRUSBY M, UNPUB; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LARHAMMAR D, 1983, CELL, V34, P179, DOI 10.1016/0092-8674(83)90148-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	27	635	646	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1991	253	5026					1417	1420		10.1126/science.1910207	http://dx.doi.org/10.1126/science.1910207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1910207				2022-12-28	WOS:A1991GF85100041
J	KION, TA; HOFFMANN, GW				KION, TA; HOFFMANN, GW			ANTI-HIV AND ANTI-ANTI-MHC ANTIBODIES IN ALLOIMMUNE AND AUTOIMMUNE MICE	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS HIV; IMMUNE-SYSTEM; AIDS; CD4; INFECTION; IDENTIFICATION; PATHOGENESIS; DISEASE; BINDING	Alloimmune mice (mice that have been exposed to cells from another murine strain) were shown to make antibodies against gp120 and p24 of human immunodeficiency virus (HIV, and mice of the autoimmune strains MRL-lpr/lpr and MRL-+/+ made antibodies against gp120. This is surprising because the mice were not exposed to HIV. Furthermore, anti-anti-MHC antibodies (molecules that have shapes similar to those of major histocompatibility complex molecules) were detected in both alloimmune sera and MRL mice. These results are discussed in the context of a possible role for allogeneic stimuli in the pathogenesis of acquired immunodeficiency syndrome, as suggested by an idiotypic network model.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PHYS,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								ANDRIEU JM, 1986, AIDS RES HUM RETROV, V2, P163, DOI 10.1089/aid.1.1986.2.163; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DIAMOND DC, 1988, J IMMUNOL, V141, P3715; FORSYTH RB, 1990, J IMMUNOL, V145, P215; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HABESHAW JA, 1989, J ACQ IMMUN DEF SYND, V2, P457; HOFFMANN GW, 1986, J IMMUNOL, V137, P61; HOFFMANN GW, 1991, P NATL ACAD SCI USA, V88, P3060, DOI 10.1073/pnas.88.8.3060; HOFFMANN GW, 1988, SEMIOTICS CELLULAR C, P257; Hsu D H, 1989, Int Immunol, V1, P197, DOI 10.1093/intimm/1.2.197; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; KION TA, UNPUB; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SHEARER GM, 1983, NEW ENGL J MED, V308, P223, DOI 10.1056/NEJM198301273080415; THOMAS Y, 1983, IMMUNOL REV, V74, P113, DOI 10.1111/j.1600-065X.1983.tb01086.x; VEGA MA, 1990, NATURE, V345, P26, DOI 10.1038/345026a0; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; YOUNG JAT, 1988, NATURE, V333, P215, DOI 10.1038/333215c0; ZIEGLER JL, 1986, CLIN IMMUNOL IMMUNOP, V41, P305, DOI 10.1016/0090-1229(86)90001-2	21	130	142	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1138	1140		10.1126/science.1909456	http://dx.doi.org/10.1126/science.1909456			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1909456				2022-12-28	WOS:A1991GD80800032
J	HUSSEY, RM; CLARKE, CA				HUSSEY, RM; CLARKE, CA			DEATHS FROM RH HEMOLYTIC-DISEASE IN ENGLAND AND WALES IN 1988 AND 1989	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,DEPT GENET & MICROBIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool	HUSSEY, RM (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,POB 147,LIVERPOOL L69 3BX,ENGLAND.							CLARKE CA, 1989, J ROY COLL PHYS LOND, V23, P181; THOMSON A, 1990, LANCET, V336, P1147, DOI 10.1016/0140-6736(90)92767-C; 1956, VITAL STATISTICS U A, V2	3	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					445	446		10.1136/bmj.303.6800.445	http://dx.doi.org/10.1136/bmj.303.6800.445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912836	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1991GC46500016
J	ODOWD, TC; WILSON, AD				ODOWD, TC; WILSON, AD			THE FUTURE OF GENERAL-PRACTICE - SET MENUS AND CLINICAL FREEDOM .7.	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; CARE				ODOWD, TC (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							ANDERSON CM, 1988, BRIT MED J, V297, P113, DOI 10.1136/bmj.297.6641.113; BABER NS, 1984, BRIT MED J, V289, P1431, DOI 10.1136/bmj.289.6456.1431; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; FOX TF, 1951, LANCET, V2, P115; GOL R, 1990, BR J GEN PRACT, V40, P361; GOL R, 1988, J R COLL GEN PRACT, V38, P10; HAMPTON JR, 1983, BRIT MED J, V287, P1237, DOI 10.1136/bmj.287.6401.1237; HOFFENBERG R, 1987, ROCK CARLING FELLOWS, P14; LEITCH D, 1989, BRIT MED J, V298, P1615, DOI 10.1136/bmj.298.6688.1615; LICHTENSTEIN MJ, 1985, J ROY COLL GEN PRACT, V35, P516; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MANT D, 1990, BMJ-BRIT MED J, V300, P1053, DOI 10.1136/bmj.300.6731.1053; MORRELL DC, 1991, BMJ-BRIT MED J, V302, P1313, DOI 10.1136/bmj.302.6788.1313; NICOLL A, 1986, LANCET, V1, P606; PETRIE JC, 1987, BRIT MED J, V294, P919, DOI 10.1136/bmj.294.6577.919; ROBERTS CJ, 1985, LANCET, V1, P89; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; STERN D, 1986, J ROY COLL GEN PRACT, V36, P549; 1991, BUILDING YOUR OWN FU; 1985, QUALITY PRACTICE POL, V2	22	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					450	452		10.1136/bmj.303.6800.450	http://dx.doi.org/10.1136/bmj.303.6800.450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912839	Green Published, Bronze			2022-12-28	WOS:A1991GC46500019
J	PLESS, IB				PLESS, IB			ACCIDENT PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							INJURIES; EPIDEMIOLOGY				PLESS, IB (corresponding author), MCGILL UNIV,PAEDIAT EPIDEMIOL & HLTH,MONTREAL H3A 2T5,QUEBEC,CANADA.							BAKER SP, 1984, INJURY FACT BOOK; Fingerhut L A, 1989, Vital Health Stat 3, P1; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; LANGLEY JD, 1988, ACCIDENT ANAL PREV, V20, P1, DOI 10.1016/0001-4575(88)90009-7; MCDERMOTT FT, 1991, MED J AUSTRALIA, V154, P156, DOI 10.5694/j.1326-5377.1991.tb121017.x; PLESS IB, 1987, J SOC ISSUES, V43, P87, DOI 10.1111/j.1540-4560.1987.tb01297.x; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; Robertson L.S., 1983, INJURIES CAUSES CONT; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Waller JA., 1985, INJURY CONTROL GUIDE; 1991, HLTH NATION; 1989, AM J PREV MED, V5, P5; 1990, REPORT ACTION ACCIDE; 1979, DHEW PHS7955071A PUB	14	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					462	464		10.1136/bmj.303.6800.462	http://dx.doi.org/10.1136/bmj.303.6800.462			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912842	Bronze, Green Published			2022-12-28	WOS:A1991GC46500022
J	GUNN, J; MADEN, A; SWINTON, M				GUNN, J; MADEN, A; SWINTON, M			TREATMENT NEEDS OF PRISONERS WITH PSYCHIATRIC-DISORDERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the prevalence of psychiatric disorder and the treatment needs of sentenced prisoners in England and Wales. Design-Population survey based on a 5% sample of men serving prison sentences. Setting-Sixteen prisons for adult males and nine institutions for male young offenders representative of all prisons in prison type, security levels, and length of sentences. Subjects-406 young offenders and 1478 adult men, 404 and 1365 of whom agreed to be interviewed. Main outcome measures-History of psychiatric disorder, clinical diagnosis of psychiatrist, and required treatment. Results-652 (37%) men had psychiatric disorders diagnosed, of whom 15 (0.8%) had organic disorders, 34 (2%) psychosis, 105 (6%) neurosis, 177 (10%) personality disorder, and 407 (23%) substance misuse. 52 (3%) were judged to require transfer to hospital for psychiatric treatment, 96 (5%) required treatment in a therapeutic community setting, and a further 176 (10%) required further psychiatric assessment or treatment within prison. Conclusions-By extrapolation the sentenced prison population includes over 700 men with psychosis, and around 1100 who would warrant transfer to hospital for psychiatric treatment. Provision of secure treatment facilities, particularly long term medium secure units, needs to be improved. Services for people with personality, sexual, and substance misuse disorders should be developed in both prisons and the health service.	INST PSYCHIAT,DEPT FORENS PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London								BENTLEY C, 1990, BRIT MED J, V301, P501, DOI 10.1136/bmj.301.6751.501; BLUGLASS RA, 1966, PSYCHIATRIC STUDY SC; CHEADLE J, 1982, SENTENCED MENTALLY I; COID JW, 1988, BRIT MED J, V296, P1779, DOI 10.1136/bmj.296.6639.1779; DOOLEY E, 1990, BRIT J PSYCHIAT, V156, P40, DOI 10.1192/bjp.156.1.40; GENDERS E, 1989, GRENDON STUDY THERAP; GOLDBERG DP, 1970, BRIT J PREV SOC MED, V24, P18; GROUNDS A, 1991, BRIT J CRIMINOL, V31, P54, DOI 10.1093/oxfordjournals.bjc.a048085; GUNN J, 1978, PSYCHIATRIC ASPECTS; Guze SB, 1976, CRIMINALITY PSYCHIAT; MADEN A, 1991, BRIT MED J, V302, P880, DOI 10.1136/bmj.302.6781.880; Roper W. F., 1950, BRIT J DELINQUENCY, V1, P15; ROPER WF, 1950, BRIT J DELINQUENCY, V1, P243; TAYLOR PJ, 1984, BRIT MED J, V288, P1945, DOI 10.1136/bmj.288.6435.1945; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0; 1989, PRISON STATISTICS EN; 1978, MENTAL DISORDERS GLO; 1986, LANCET, V2, P24; 1974, CMND5698; 1974, HLTH SERVICE CIRCULA; IN PRESS MENTALLY DI; 1990, CMND555	22	189	194	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					338	341		10.1136/bmj.303.6798.338	http://dx.doi.org/10.1136/bmj.303.6798.338			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912775	Bronze, Green Published			2022-12-28	WOS:A1991GA60600020
J	JEANNEL, D; TUPPIN, P; BRUCKER, G; DANIS, M; GENTILINI, M				JEANNEL, D; TUPPIN, P; BRUCKER, G; DANIS, M; GENTILINI, M			IMPORTED AND AUTOCHTHONOUS KALA-AZAR IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article							VISCERAL LEISHMANIASIS; DISEASE	Objective - To study the epidemiological, clinical, and biological features of imported and autochthonous kala-azar in France. Design-Prospective survey of all patients in France with kala-azar diagnosed over the two years 1986-7. Information was obtained from parasitology laboratories in regional hospitals and all hospital laboratories and haematology departments capable of diagnosing leishmaniasis in the south of France. Setting-107 public hospitals in France. Patients-89 patients with kala-azar. Interventions-All patients were treated with drugs. In the first instance meglumine antimonate was given to all but two patients. Main outcome measures-Prevalence of the various clinical and biological features of kala-azar; proportion of patients with HIV infection. Results-Half (44) of the patients were children under 8 years old. Seventy patients acquired the disease in France. Imported kala-azar was acquired mainly in Mediterranean countries (9/18 cases). Only 46 (52%) of the patients had all three of the classic associated clinical features of fever, splenomegaly, and hepatomegaly. Anaemia was the commonest biological sign, and the association of the four usual biological signs-anaemia, leucopenia, thrombocytopenia, and hypergammaglobulinaemia -was present in only 14 (33%) of the children under 8 and 26 (60%) adults. Fourteen of the patients over 8 years old were infected with HIV. Conclusion-Doctors must be aware of kala-azar in Mediterranean areas, especially as patients often present without the characteristic features and the disease affects young children preferentially.	INST HLTH & DEV,NATL CTR IMPORTED DIS,F-75270 PARIS,FRANCE; HOP LA PITIE SALPETRIERE,DEPT TROP DIS & PARASITOL,F-75651 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite								BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BRYCESON ADM, 1985, T ROY SOC TROP MED H, V79, P705, DOI 10.1016/0035-9203(85)90199-3; HEILMANN K, 1971, DEUT MED WOCHENSCHR, V96, P36, DOI 10.1055/s-0028-1108196; HILL FGH, 1975, BRIT MED J, V3, P334; JEANNEL D, 1989, LANCET, V2, P804, DOI 10.1016/S0140-6736(89)90868-4; KILLICKKENDRICK R, 1984, ANN PARASIT HUM COMP, V59, P555, DOI 10.1051/parasite/1984596555; KINMOND S, 1989, LANCET, V2, P325, DOI 10.1016/S0140-6736(89)90502-3; MONTALBAN C, 1987, J INFECTION, V15, P247, DOI 10.1016/S0163-4453(87)92728-9; NEVA FA, 1990, NEW ENGL J MED, V322, P55, DOI 10.1056/NEJM199001043220111; OGUNKOLADE BW, 1988, VET PARASITOL, V28, P33, DOI 10.1016/0304-4017(88)90016-7; PUGIN P, 1968, SCHWEIZ MED WOCHENSC, V93, P1320; QUILICI M, 1987, ANN PEDIATR-PARIS, V34, P369; ROCHA H, 1979, PRINCIPLES PRACTICE, P2210; WHEATLEY T, 1983, J INFECTION, V7, P166, DOI 10.1016/S0163-4453(83)90716-8; 1984, WHO TECH REP SER, V701; 1987, B EPIDEMIOLOGIQUE HE, V7, P3	16	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					336	338		10.1136/bmj.303.6798.336	http://dx.doi.org/10.1136/bmj.303.6798.336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912774	Green Published, Bronze			2022-12-28	WOS:A1991GA60600019
J	SOLOMON, A; WEISS, DT; KATTINE, AA				SOLOMON, A; WEISS, DT; KATTINE, AA			NEPHROTOXIC POTENTIAL OF BENCE-JONES PROTEINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIGHT-CHAIN DEPOSITION; MOLECULAR-WEIGHT PROTEINS; MULTIPLE-MYELOMA; ISOELECTRIC POINT; RENAL-FAILURE; LYMPHOPLASMACYTIC DISORDERS; AMYLOID DEPOSITS; BETA-FIBRILLOSES; CAST NEPHROPATHY; RAT	Background. The renal manifestations of diseases associated with the production of monoclonal light chains - myeloma (cast) nephropathy, light-chain deposition disease, and amyloidosis AL - result from the deposition of certain Bence Jones proteins as tubular casts, basement-membrane precipitates, or fibrils, respectively. For unknown reasons, the severity of the renal manifestations of these diseases varies greatly from patient to patient. We employed an experimental in vivo model to determine the pathologic importance of various Bence Jones proteins. Methods. Mice were injected intraperitoneally with 300 mg of Bence Jones protein from 40 patients with multiple myeloma or amyloidosis AL and killed 48 hours later. The mouse kidneys were examined by light and electron microscopy, and light-chain deposits were identified immunohistochemically with highly specific antihuman lightchain antiserum. Results. Of the 40 different human Bence Jones proteins studied, 26 were deposited in the mouse kidneys predominantly as tubular casts, basement-membrane precipitates, or crystals; no light-chain deposits were detected in the kidneys of the mice that received the other 14 Bence Jones proteins. Of the 18 patients for whom renal tissue was available for study, the findings in 14 were comparable to those in the mice. Furthermore, the proteins obtained from 22 of the 27 patients whose serum creatinine concentrations equaled or exceeded 168-mu-mol per liter (1.9 mg per deciliter) were deposited in the mouse kidneys, whereas protein deposition occurred after the injection of proteins from only 4 of the 13 patients with serum creatinine concentrations below 168-mu-mol per liter. The repeated injection of Bence Jones proteins from two patients who had amyloidosis AL resulted in deposition of the protein in the mouse kidneys as amyloid. Conclusions. Particular Bence Jones proteins are primarily responsible for producing the distinctive types of protein deposition in renal tissue and the clinical manifestations that occur in patients with light-chain - associated diseases. This experimental model has potential value for the identification of nephrotoxic or amyloidogenic light chains.	UNIV TENNESSEE, MED CTR, GRAD SCH MED, DEPT PATHOL, KNOXVILLE, TN 37920 USA	University of Tennessee System; University of Tennessee Health Science Center	SOLOMON, A (corresponding author), UNIV TENNESSEE, MED CTR,GRAD SCH MED,DEPT MED, HUMAN IMMUNOL & CANC PROGRAM, 1924 ALCOA HWY, KNOXVILLE, TN 37920 USA.				NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER; NCI NIH HHS [CA-10056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1990, ARCH INTERN MED, V150, P1693; BUXBAUM J, 1986, J CLIN INVEST, V78, P798, DOI 10.1172/JCI112643; BUXBAUM JN, 1990, ANN INTERN MED, V112, P455, DOI 10.7326/0003-4819-76-3-112-6-455; Clyne D H, 1981, Contrib Nephrol, V24, P78; CLYNE DH, 1979, KIDNEY INT, V16, P345, DOI 10.1038/ki.1979.137; COOPER EH, 1984, J CLIN PATHOL, V37, P852, DOI 10.1136/jcp.37.8.852; COWARD RA, 1984, CLIN SCI, V66, P229, DOI 10.1042/cs0660229; FANG LST, 1985, KIDNEY INT, V27, P582, DOI 10.1038/ki.1985.50; GALLO G, 1989, SEMIN HEMATOL, V26, P234; GALLO GR, 1982, PATHOL ANNU, V17, P291; GANEVAL D, 1984, KIDNEY INT, V26, P1, DOI 10.1038/ki.1984.126; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; HILL GS, 1983, AM J KIDNEY DIS, V2, P423, DOI 10.1016/S0272-6386(83)80075-4; HILL GS, 1983, PATHOLOGY KIDNEY, V2, P993; JOHNS EA, 1986, J CLIN PATHOL, V39, P833, DOI 10.1136/jcp.39.8.833; JOHNSON WJ, 1990, ARCH INTERN MED, V150, P863, DOI 10.1001/archinte.150.4.863; KOSS MN, 1976, LAB INVEST, V34, P579; KYLE RA, 1989, ANNU REV MED, V40, P53; MELCION C, 1984, CLIN NEPHROL, V22, P138; NORDEN AGW, 1989, J CLIN PATHOL, V42, P59, DOI 10.1136/jcp.42.1.59; PALANT CE, 1986, AM J MED, V80, P98, DOI 10.1016/0002-9343(86)90055-0; PIRANI CL, 1982, CONTEMP ISS NEPHROL, V10, P287; PREUDHOMME JL, 1980, AM J MED, V69, P703, DOI 10.1016/0002-9343(80)90421-0; RANDALL RE, 1976, AM J MED, V60, P293, DOI 10.1016/0002-9343(76)90440-X; ROTA S, 1987, MEDICINE, V66, P126, DOI 10.1097/00005792-198703000-00004; SANDERS PW, 1987, KIDNEY INT, V32, P851, DOI 10.1038/ki.1987.286; SANDERS PW, 1988, J CLIN INVEST, V82, P2086, DOI 10.1172/JCI113830; SANDERS PW, 1990, J CLIN INVEST, V85, P570, DOI 10.1172/JCI114474; SMOLENS P, 1983, KIDNEY INT, V24, P192, DOI 10.1038/ki.1983.144; SMOLENS P, 1986, KIDNEY INT, V30, P874, DOI 10.1038/ki.1986.267; SOLLING K, 1984, ACTA MED SCAND, V216, P495; SOLOMON A, 1975, J CLIN INVEST, V55, P579, DOI 10.1172/JCI107965; SOLOMON A, 1986, SEMIN ONCOL, V13, P341; SOLOMON A, 1990, AM J PATHOL, V137, P855; SOLOMON A, 1982, J CLIN INVEST, V70, P453, DOI 10.1172/JCI110635; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; SOLOMON A, 1982, NEW ENGL J MED, V306, P605, DOI 10.1056/NEJM198203113061010; STURGILL BC, 1987, PATHOL ANNU, V22, P133; TUBBS RR, 1981, AM J MED, V71, P263, DOI 10.1016/0002-9343(81)90127-3; WEISS JH, 1981, KIDNEY INT, V20, P198, DOI 10.1038/ki.1981.122; WOCHNER RD, 1967, J EXP MED, V126, P207, DOI 10.1084/jem.126.2.207	42	219	223	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1845	1851		10.1056/NEJM199106273242603	http://dx.doi.org/10.1056/NEJM199106273242603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	1904132				2022-12-28	WOS:A1991FT58000003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SAFETY OF DENTAL AMALGAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-28	WOS:A1991FP63500006
J	SHUFORD, W; RAFF, HV; FINLEY, JW; ESSELSTYN, J; HARRIS, LJ				SHUFORD, W; RAFF, HV; FINLEY, JW; ESSELSTYN, J; HARRIS, LJ			EFFECT OF LIGHT CHAIN V-REGION DUPLICATION ON IGG OLIGOMERIZATION AND INVIVO EFFICACY	SCIENCE			English	Article							COMPLEMENT; IMMUNOGLOBULIN; ACTIVATION; ANTIBODIES; PROTECTION; PROTEINS	A human immunoglobulin G1 (IgG1) antibody oligomer was isolated from a transfected myeloma cell line that produced a monoclonal antibody to group B streptococci. Compared to the IgG1 monomer, the oligomer was significantly more effective at protecting neonatal rats from infection in vivo. The oligomer was also shown to cross the placenta and to be stable in neonatal rats. Immunochemical analysis and complementary DNA sequencing showed that the transfected cell line produced two distinct kappa light chains: a normal light chain (L(n)) with a molecular mass of 25 kilodaltons and a 37-kilodalton species (L37), the domain composition of which was variable-variable-constant (V-V-C). Cotransfection of vectors encoding the heavy chain and L37 resulted in production of oligomeric IgG.	BRISTOL MYERS,SQUIBB PHARMACEUT RES INST,DEPT MOLEC IMMUNOL,SEATTLE,WA 98121; BRISTOL MYERS,SQUIBB PHARMACEUT RES INST,DEPT IMMUNE SCI,SEATTLE,WA 98121	Bristol-Myers Squibb; Bristol-Myers Squibb								CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; ENGVALL E, 1972, J IMMUNOL, V109, P129; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; HAMES BD, 1981, GEL ELECTROPHORESIS, P30; HARLOW E, 1988, ANTIBODIES LAB MANUA, P391; JESKE DJ, 1984, FUNDAMENTAL IMMUNOLO, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN TR, 1988, J INFECT DIS, V157, P91, DOI 10.1093/infdis/157.1.91; MORRISON SL, 1989, ADV IMMUNOL, V44, P65; RAFF HV, 1988, J EXP MED, V168, P905, DOI 10.1084/jem.168.3.905; RAFF HV, 1990, J INFECT DIS, V163, P346; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P308; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; SHIGEOKA AO, 1984, J INFECT DIS, V150, P63, DOI 10.1093/infdis/150.1.63; SHUFORD W, UNPUB; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SMITH VH, UNPUB; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162	21	16	23	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					724	727		10.1126/science.1902593	http://dx.doi.org/10.1126/science.1902593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902593				2022-12-28	WOS:A1991FK18500055
J	ECHT, DS; LIEBSON, PR; MITCHELL, LB; PETERS, RW; OBIASMANNO, D; BARKER, AH; ARENSBERG, D; BAKER, A; FRIEDMAN, L; GREENE, HL; HUTHER, ML; RICHARDSON, DW				ECHT, DS; LIEBSON, PR; MITCHELL, LB; PETERS, RW; OBIASMANNO, D; BARKER, AH; ARENSBERG, D; BAKER, A; FRIEDMAN, L; GREENE, HL; HUTHER, ML; RICHARDSON, DW			MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR ARRHYTHMIAS; RISK-FACTORS; TACHYARRHYTHMIAS; TOCAINIDE; SUDDEN; EVENTS; BEATS; DEATH; DRUGS	Background and Methods. In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide or moricizine were randomly assigned to receive either active drug or placebo. The use of encainide and flecainide was discontinued because of excess mortality. We examined the mortality and morbidity after randomization to encainide or flecainide or their respective placebo. Results. Of 1498 patients, 857 were assigned to receive encainide or its placebo (432 to active drug and 425 to placebo) and 641 were assigned to receive flecainide or its placebo (323 to active drug and 318 to placebo). After a mean follow-up of 10 months, 89 patients had died: 59 of arrhythmia (43 receiving drug vs. 16 receiving placebo; P = 0.0004), 22 of nonarrhythmic cardiac causes (17 receiving drug vs. 5 receiving placebo; P = 0.01), and 8 of noncardiac causes (3 receiving drug vs. 5 receiving placebo). Almost all cardiac deaths not due to arrhythmia were attributed to acute myocardial infarction with shock (11 patients receiving drug and 3 receiving placebo) or to chronic congestive heart failure (4 receiving drug and 2 receiving placebo). There were no differences between the patients receiving active drug and those receiving placebo in the incidence of nonlethal disqualifying ventricular tachycardia, proarrhythmia, syncope, need for a permanent pacemaker, congestive heart failure, recurrent myocardial infarction, angina, or need for coronary-artery bypass grafting or angioplasty. Conclusions. There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide. Nonlethal events, however, were equally distributed between the active-drug and placebo groups. The mechanisms underlying the excess mortality during treatment with encainide or flecainide remain unknown.			ECHT, DS (corresponding author), CARDIAC ARRHYTHMIA SUPPRESS TRIAL, CTR COORDINATING, 1107 NE 45TH, RM 505, SEATTLE, WA 98105 USA.		Mitchell, L. Brent/AAJ-5076-2020	Patt, Mitchell/0000-0001-9696-4477				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, AM J CARDIOL, V61, P501; BASTIAN BC, 1980, AM HEART J, V100, P1017, DOI 10.1016/0002-8703(80)90207-0; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; CHAMBERLAIN DA, 1980, LANCET, V2, P1324; FAIN ES, 1986, CIRCULATION, V73, P1334, DOI 10.1161/01.CIR.73.6.1334; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; GOTTLIEB SH, 1987, CIRCULATION, V75, P792, DOI 10.1161/01.CIR.75.4.792; GREENE HL, 1989, AM J CARDIOL, V63, P393, DOI 10.1016/0002-9149(89)90306-8; HOCKINGS BEF, 1987, AM J CARDIOL, V60, P967, DOI 10.1016/0002-9149(87)90334-1; HOROWITZ LN, 1987, AM J CARDIOL, V59, pE45, DOI 10.1016/0002-9149(87)90201-3; HUGENHOLTZ PG, 1978, MANAGEMENT VENTRICUL, P572; Impact Research Group, 1984, J AM COLL CARDIOL, V4, P1148; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MORGANROTH J, 1986, J AM COLL CARDIOL, V8, P607, DOI 10.1016/S0735-1097(86)80190-5; MORGANROTH J, 1987, AM J CARDIOL, V59, pE32, DOI 10.1016/0002-9149(87)90199-8; MORGANROTH J, 1984, AM J CARDIOL, V53, pB89, DOI 10.1016/0002-9149(84)90509-5; MORGANROTH J, 1988, AM J CARDIOL, V62, P571; MORGANROTH J, 1990, AM J CARDIOL, V65, P40, DOI 10.1016/0002-9149(90)90023-T; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; PETER T, 1978, BRIT HEART J, V40, P1356; PLATIA EV, 1985, AM J CARDIOL, V55, P956, DOI 10.1016/0002-9149(85)90726-X; REIFFEL JA, 1985, PACE, V8, P369, DOI 10.1111/j.1540-8159.1985.tb05773.x; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; RUSKIN JN, 1989, NEW ENGL J MED, V321, P386, DOI 10.1056/NEJM198908103210608; RYDEN L, 1980, AM HEART J, V100, P1006, DOI 10.1016/0002-8703(80)90205-7; SOYKA LF, 1986, AM J CARDIOL, V58, pC96, DOI 10.1016/0002-9149(86)90111-6; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WOOSLEY RL, 1987, AM J CARDIOL, V59, pE19, DOI 10.1016/0002-9149(87)90197-4; 1986, AM J CARDIOL, V54, P91; 1971, LANCET, V2, P1055	32	2210	2272	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					781	788		10.1056/NEJM199103213241201	http://dx.doi.org/10.1056/NEJM199103213241201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1900101				2022-12-28	WOS:A1991FC44200001
J	NAKABEPPU, Y; NATHANS, D				NAKABEPPU, Y; NATHANS, D			A NATURALLY-OCCURRING TRUNCATED FORM OF FOSB THAT INHIBITS FOS JUN TRANSCRIPTIONAL ACTIVITY	CELL			English	Article							SERUM GROWTH-FACTORS; C-FOS; PROTO-ONCOGENE; MESSENGER-RNAS; FACTOR AP-1; AUTO-REGULATION; LEUCINE ZIPPER; 3T3 CELLS; GENE; EXPRESSION	Fos and Jun transcription factors are induced by a variety of extracellular signaling agents. We describe here an unusual member of the Fos family that is also induced, namely, a truncated form of FosB (DELTA-FosB) missing the C-terminal 101 amino acids of FosB. DELTA-FosB retains the dimerization and DNA-binding activities of FosB but has lost the ability in transfection assays to activate a promoter with an AP-1 site and to repress the c-fos promoter. Rather, DELTA-FosB inhibits gene activation by Jun or Jun + Fos and inhibits repression of the c-fos promoter by FosB or c-Fos, presumably by competing with full-length Fos proteins at the steps of dimerization with Jun and binding to DNA. In stimulated cells DELTA-FosB may act to limit the transcriptional effects of Fos and Jun proteins.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University	NAKABEPPU, Y (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X	NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [5 PO1 CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1989, GROWTH FACTORS DIFFE; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLE AJ, 1990, IN PRESS J NEUROCHEM; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GANTZ R, 1989, SCIENCE, V243, P1695; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARLOW E, 1988, ANTIBODIES LABORATOR; Higgins GM, 1931, ARCH PATHOL, V12, P186; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1991, MOL ASPECTS CELLULAR, V6; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Miller J.H., 1972, EXPT MOL GENETICS; MILLER R, 1984, NATURE, V312, P716; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swinyard E. A., 1972, EXPT MODELS EPILEPSY, P433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	68	419	427	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					751	759		10.1016/0092-8674(91)90504-R	http://dx.doi.org/10.1016/0092-8674(91)90504-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1900040				2022-12-28	WOS:A1991EZ47800010
J	BROOKS, R; MCGOVERN, BA; GARAN, H; RUSKIN, JN				BROOKS, R; MCGOVERN, BA; GARAN, H; RUSKIN, JN			CURRENT TREATMENT OF PATIENTS SURVIVING OUT-OF-HOSPITAL CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; MALIGNANT VENTRICULAR ARRHYTHMIAS; ACUTE MYOCARDIAL-INFARCTION; SIGNAL-AVERAGED ELECTROCARDIOGRAM; ANTIARRHYTHMIC DRUG EFFICACY; LONG-TERM SURVIVAL; SUDDEN-DEATH; FOLLOW-UP; CLINICAL CHARACTERISTICS	Most out-of-hospital cardiac arrests result from the sudden onset of a sustained ventricular arrhythmia in the absence of a new myocardial infarction. Individuals who survive cardiac arrest are at high risk for recurrent arrhythmias and sudden unexpected death. To prevent recurrent cardiac arrest, effective treatment must be provided during hospitalization after the initial episode. Caring for the survivor of cardiac arrest requires a detailed clinical investigation to define the underlying cardiac anatomy and left ventricular function and to elucidate the mechanism and characteristics of the patient's arrhythmia. Appropriate antiarrhythmic therapy, such as drugs or a nonpharmacological intervention (eg, implantable cardioverter-defibrillator), is then selected based on these considerations. In addition, ischemia is treated aggressively with beta-adrenergic blocking agents and, when appropriate, with surgical coronary artery revascularization.			BROOKS, R (corresponding author), MASSACHUSETTS GEN HOSP, CARDIAC UNIT, BOSTON, MA 02114 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1985, WHO TECH REP SER; BACH SM, 1989, J AM COLL CARDIOL, V13, P65; BELHASSEN B, 1987, CIRCULATION, V75, P809, DOI 10.1161/01.CIR.75.4.809; BENDITT DG, 1983, J AM COLL CARDIOL, V2, P418, DOI 10.1016/S0735-1097(83)80267-8; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BORGGREFE M, 1987, NONPHARMACOLOGICAL T, P109; BROOKS R, 1988, MEDICINE, V67, P271, DOI 10.1097/00005792-198809000-00001; BROOKS R, 1990, HEART DISEASE CLIN U, P193; COBB LA, 1975, CIRCULATION, V52, P223; COPELAND JG, 1984, CURRENT PROBLEMS DIA, P451; DAVIES MJ, 1981, BRIT HEART J, V45, P88; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DUBNER SJ, 1989, AM J CARDIOL, V64, P801, DOI 10.1016/0002-9149(89)90769-8; DUBUC M, 1989, J ELECTROPHYSIOL, V3, P81; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; ELDAR M, 1987, J AM COLL CARDIOL, V10, P600, DOI 10.1016/S0735-1097(87)80203-6; ELDAR M, 1987, J AM COLL CARDIOL, V10, P291, DOI 10.1016/S0735-1097(87)80010-4; FLEMING HA, 1986, ANN NY ACAD SCI, V465, P543, DOI 10.1111/j.1749-6632.1986.tb18531.x; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; FOGOROS RN, 1983, CIRCULATION, V68, P88, DOI 10.1161/01.CIR.68.1.88; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GALLAGHER JJ, 1984, TACHYCARDIAS MECHANI, P259; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOLDSTEIN S, 1981, CIRCULATION, V64, P977, DOI 10.1161/01.CIR.64.5.977; GOMES JA, 1987, J AM COLL CARDIOL, V10, P349; GRABOYS TB, 1982, AM J CARDIOL, V50, P437, DOI 10.1016/0002-9149(82)90307-1; GREENSPAN AM, 1985, AM J CARDIOL, V56, P277, DOI 10.1016/0002-9149(85)90850-1; HARGROVE WC, 1989, J THORAC CARDIOV SUR, V97, P923; HAYS LJ, 1989, AM HEART J, V118, P53, DOI 10.1016/0002-8703(89)90071-9; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HOHNLOSER SH, 1987, AM HEART J, V114, P1, DOI 10.1016/0002-8703(87)90299-7; HOLMES DR, 1986, CIRCULATION, V73, P1254, DOI 10.1161/01.CIR.73.6.1254; HOROWITZ LN, 1990, AM J CARDIOL, V65, pD41; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JENSEN G, 1975, CHEST, V67, P43, DOI 10.1378/chest.67.1.43; KANOVSKY MS, 1984, CIRCULATION, V70, P264, DOI 10.1161/01.CIR.70.2.264; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; KEMPF FC, 1984, AM J CARDIOL, V53, P1577, DOI 10.1016/0002-9149(84)90582-4; KILLIP T, 1985, CIRCULATION, V72, P102; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KRON IL, 1989, ANN THORAC SURG, V48, P85, DOI 10.1016/0003-4975(89)90185-9; KUCHAR DL, 1988, J AM COLL CARDIOL, V12, P982, DOI 10.1016/0735-1097(88)90465-2; KULLER LH, 1980, PROG CARDIOVASC DIS, V23, P1, DOI 10.1016/0033-0620(80)90002-X; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; LEMERY R, 1989, J AM COLL CARDIOL, V13, P911, DOI 10.1016/0735-1097(89)90235-0; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LIBERTHSON RR, 1979, CIRCULATION, V59, P748, DOI 10.1161/01.CIR.59.4.748; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; MANOLIS AS, 1989, AM HEART J, V118, P445, DOI 10.1016/0002-8703(89)90256-1; MARCHLINSKI FE, 1989, PACE, V12, P646; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MCLARAN CJ, 1987, BRIT HEART J, V58, P583; MEISSNER MD, 1988, AM J CARDIOL, V61, P1050, DOI 10.1016/0002-9149(88)90124-5; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MITCHELL LB, 1989, CIRCULATION, V80, P34, DOI 10.1161/01.CIR.80.1.34; MOOSVIAR, 1990, AM J CARDIOL, V65, P1192; MORADY F, 1983, AM HEART J, V106, P1306, DOI 10.1016/0002-8703(83)90038-8; MORADY F, 1983, AM J CARDIOL, V51, P85, DOI 10.1016/S0002-9149(83)80016-2; MORADY F, 1984, J AM COLL CARDIOL, V4, P39, DOI 10.1016/S0735-1097(84)80316-2; MORADY F, 1987, J AM COLL CARDIOL, V9, P1004, DOI 10.1016/S0735-1097(87)80300-5; MORALES AR, 1980, CIRCULATION, V62, P230, DOI 10.1161/01.CIR.62.2.230; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; MYERBURG RJ, 1989, J AM COLL CARDIOL, V14, P508, DOI 10.1016/0735-1097(89)90209-X; MYERBURG RJ, 1988, HEART DISEASE TXB CA, P742; NADEMANEE K, 1985, CIRCULATION, V72, P555, DOI 10.1161/01.CIR.72.3.555; PAUL T, 1990, AM J CARDIOL, V65, P318, DOI 10.1016/0002-9149(90)90295-C; PIONKOWSKI RS, 1983, ANN EMERG MED, V12, P733, DOI 10.1016/S0196-0644(83)80245-5; PLATIA EV, 1984, J AM COLL CARDIOL, V4, P493, DOI 10.1016/S0735-1097(84)80092-3; POLL DS, 1984, CIRCULATION, V70, P451, DOI 10.1161/01.CIR.70.3.451; POSER RF, 1985, AM HEART J, V110, P9, DOI 10.1016/0002-8703(85)90507-1; PRATT CM, 1983, J AM COLL CARDIOL, V2, P789, DOI 10.1016/S0735-1097(83)80224-1; REID PR, 1987, NONPHARMACOLOGICAL T, P477; RICKS WB, 1977, CIRCULATION, V56, P38, DOI 10.1161/01.CIR.56.1.38; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; ROY D, 1983, AM J CARDIOL, V52, P969, DOI 10.1016/0002-9149(83)90514-3; RUSKIN JN, 1980, NEW ENGL J MED, V303, P607, DOI 10.1056/NEJM198009113031103; RUSKIN JN, 1983, NEW ENGL J MED, V309, P1302, DOI 10.1056/NEJM198311243092107; SAKSENA S, 1988, JAMA-J AM MED ASSOC, V259, P69, DOI 10.1001/jama.259.1.69; SALERNO DM, 1987, AM J CARDIOL, V59, P84, DOI 10.1016/S0002-9149(87)80075-9; SCHAFFER WA, 1975, NEW ENGL J MED, V293, P259, DOI 10.1056/NEJM197508072930601; SCHWARTZ PJ, 1987, NON PHARM THERAPY TA, P143; SCHWARTZ PJ, 1986, MED MANAGEMENT CARDI, P153; SHARMA B, 1987, AM J CARDIOL, V59, P740, DOI 10.1016/0002-9149(87)91084-8; SKALE BT, 1986, AM J CARDIOL, V57, P113, DOI 10.1016/0002-9149(86)90962-8; SOMBERG JC, 1987, AM HEART J, V114, P18, DOI 10.1016/0002-8703(87)90301-2; STEVENSON LW, 1987, AM J MED, V83, P871, DOI 10.1016/0002-9343(87)90644-9; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; TAKARO T, 1976, CIRCULATION, V54, P107; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; TOPAZ O, 1989, AM HEART J, V118, P281, DOI 10.1016/0002-8703(89)90186-5; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; VIGNOLA PA, 1984, J AM COLL CARDIOL, V4, P812, DOI 10.1016/S0735-1097(84)80411-8; VISKIN S, 1990, AM HEART J, V120, P661, DOI 10.1016/0002-8703(90)90025-S; VOLPI A, 1989, AM J CARDIOL, V63, P1174, DOI 10.1016/0002-9149(89)90174-4; WALLER BF, 1987, MAYO CLIN PROC, V62, P634, DOI 10.1016/S0025-6196(12)62308-8; WAXMAN HL, 1983, CIRCULATION, V67, P30, DOI 10.1161/01.CIR.67.1.30; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEAVER WD, 1982, CIRCULATION, V66, P212, DOI 10.1161/01.CIR.66.1.212; WHITFORD EG, 1988, AM HEART J, V115, P360, DOI 10.1016/0002-8703(88)90482-6; WILBER DJ, 1987, CIRCULATION, V75, P146; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1976, AM J MED, V60, P961, DOI 10.1016/0002-9343(76)90567-2; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; 1985, FED  REG        1115, P50	114	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					762	768		10.1001/jama.265.6.762	http://dx.doi.org/10.1001/jama.265.6.762			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1899276				2022-12-28	WOS:A1991EW47900031
J	LEE, VMY; BALIN, BJ; OTVOS, L; TROJANOWSKI, JQ				LEE, VMY; BALIN, BJ; OTVOS, L; TROJANOWSKI, JQ			A68 - A MAJOR SUBUNIT OF PAIRED HELICAL FILAMENTS AND DERIVATIZED FORMS OF NORMAL-TAU	SCIENCE			English	Article							ALZHEIMERS-DISEASE; PROTEIN-TAU; NEUROFIBRILLARY TANGLES; MONOCLONAL-ANTIBODY; NERVOUS-SYSTEM; HUMAN-BRAIN; IDENTIFICATION; LOCALIZATION; ANTIGEN; MICROTUBULES	Putative Alzheimer disease (AD)-specific proteins (A68) were purified to homogeneity and shown to be major subunits of one form of paired helical filaments (PHFs). The amino acid sequence and immunological data indicate that the backbone of A68 is indistinguishable from that of the protein-tau (tau), but A68 could be distinguished from normal human-tau by the degree to which A68 was phosphorylated and by the specific residues in A 68 that served as phosphate acceptors. The larger apparent relative molecular mass (M(r)) of A68, compared to normal human-tau, was attributed to abnormal phosphorylation of A68 because enzymatic dephosphorylation of A68 reduced its M(r) to close to that of normal-tau. Moreover, the LysSerProVal motif in normal human-tau appeared to be an abnormal phosphorylation site in A68 because the Ser in this motif was a phosphate acceptor site in A68, but not in normal human-tau. Thus, the major subunits of a class of PHFs are A68 proteins and the excessive or inappropriate phosphorylation of normal-tau may change its apparent M(r), thus transforming-tau into A68.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	LEE, VMY (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.							ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; CHUI HC, 1989, ARCH NEUROL-CHICAGO, V46, P806, DOI 10.1001/archneur.1989.00520430102025; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P816; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P7384, DOI 10.1073/pnas.85.19.7384; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEE VY, UNPUB; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MCKEE AC, 1989, ANN NEUROL, V26, P652, DOI 10.1002/ana.410260511; MIYAKAWA T, 1989, VIRCHOWS ARCH B, V57, P267, DOI 10.1007/BF02899091; NUKINA N, 1988, NEUROSCI LETT, V87, P240, DOI 10.1016/0304-3940(88)90455-7; OTVOS L, 1989, INT J PEPT PROT RES, V34, P129; PRICE DL, 1989, BIOESSAYS, V10, P69, DOI 10.1002/bies.950100208; SCHMIDT ML, 1990, AM J PATHOL, V136, P1069; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; STERN RA, 1989, AM J PATHOL, V134, P973; Trojanowski J Q, 1990, Annu Rev Gerontol Geriatr, V10, P167; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Wischik CM, 1989, CURR OPIN CELL BIOL, V1, P115, DOI 10.1016/S0955-0674(89)80047-X; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN B, 1988, P NATL ACAD SCI USA, V85, P6202, DOI 10.1073/pnas.85.16.6202; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509	35	1333	1399	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					675	678		10.1126/science.1899488	http://dx.doi.org/10.1126/science.1899488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1899488				2022-12-28	WOS:A1991EW39900046
J	FEUERSTEIN, B; STREETEN, DHP				FEUERSTEIN, B; STREETEN, DHP			RECOVERY OF ADRENAL-FUNCTION AFTER FAILURE RESULTING FROM TRAUMATIC BILATERAL ADRENAL HEMORRHAGES	ANNALS OF INTERNAL MEDICINE			English	Note								After jumping from a 60-foot (18-m) building, a 32-year-old psychotic man sustained severe pelvic and femoral injuries and had hypotension associated with adrenal insufficiency caused by bilateral adrenal hemorrhages. Several months later he stopped steroid-replacement therapy without adverse effects. Adrenocorticotropic hormone (ACTH) administration was found to cause normal increases in plasma cortisol concentrations at 10 and 30 months after the initial trauma. This appears to be the first reported case of recovery of adrenal function after hemorrhage-induced adrenal insufficiency. Periodic evaluation of adrenal response to ACTH might be useful for patients who have had adrenal failure resulting from bilateral adrenal hemorrhages.	SUNY HLTH SCI CTR, 750 E ADAMS ST, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NCRR NIH HHS [RR229] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMADOR E, 1965, ANN INTERN MED, V63, P559, DOI 10.7326/0003-4819-63-4-559; ANDERSON KC, 1981, AM J HEMATOL, V11, P379, DOI 10.1002/ajh.2830110406; CHALMERS RA, 1981, LANCET, V2, P1196; CLARK OH, 1975, ANN SURG, V182, P124, DOI 10.1097/00000658-197508000-00007; FELLERMAN H, 1970, ANN INTERN MED, V73, P585, DOI 10.7326/0003-4819-73-4-585; RAO RH, 1989, ANN INTERN MED, V110, P227, DOI 10.7326/0003-4819-110-3-227; SEVITT S, 1955, J CLIN PATHOL, V8, P185, DOI 10.1136/jcp.8.3.185; SIU SCB, 1990, MAYO CLIN PROC, V65, P664, DOI 10.1016/S0025-6196(12)65129-5; SKELTON FR, 1955, P SOC EXP BIOL MED, V90, P342; XARLI VP, 1978, MEDICINE, V57, P211, DOI 10.1097/00005792-197805000-00002	10	22	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					785	786		10.7326/0003-4819-115-10-785	http://dx.doi.org/10.7326/0003-4819-115-10-785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929027				2022-12-28	WOS:A1991GP80000008
J	YIN, L				YIN, L			A RESPONSE FROM THE FDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											YIN, L (corresponding author), US FDA,ROCKVILLE,MD 20850, USA.								0	8	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1377	1377		10.1056/NEJM199111073251912	http://dx.doi.org/10.1056/NEJM199111073251912			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922242				2022-12-28	WOS:A1991GN47000012
J	SAUER, F; JACKLE, H				SAUER, F; JACKLE, H			CONCENTRATION-DEPENDENT TRANSCRIPTIONAL ACTIVATION OR REPRESSION BY KRUPPEL FROM A SINGLE BINDING-SITE	NATURE			English	Article							ALCOHOL-DEHYDROGENASE GENE; EARLY DROSOPHILA EMBRYO; ARAC PROTEIN; HUNCHBACK; PRODUCTS; KNIRPS; EXPRESSION; PROMOTERS; PATTERN; REGION	ONE of the gap class of segmentation genes 1, Kruppel (Kr), is required for normal thorax and abdominal development of the Drosophila embryo. Its gene product, a zinc-finger type protein 2, forms a bell-shape concentration gradient in a central position of the blastoderm 3-6. Genetic and molecular studies suggested that the Kr protein (KR) may act both as a positive and as a negative regulator of transcription on several other genes 3-9 of the zygotic segmentation hierarchy 1. We have examined the regulatory potential of Kr by a series of cotransfection experiments in the Drosophila Schneider cell line system. Different doses of Kr expression plasmid were tested for their ability to drive reporter gene expression mediated by a single 11-base pair KR in vitro binding site common to several putative Kr target genes 4-6,8-10. Our results show that low amounts of Kr expression plasmid lead to transcriptional activation, whereas high amounts result in repression. Distinct portions of KR other than the DNA-binding domain are required for gene activation and repression, suggesting that KR itself can act as a concentration-dependent positive and negative regulator of transcription.			SAUER, F (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,FASSBERG,W-3400 GOTTINGEN,GERMANY.							BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; GAUL U, 1988, THESUS U TUBINGEN; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOCH MM, IN PRESS EMBO J; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MANIATIS T, 1990, MOL CLONING; MARTIN K, 1986, P NATL ACAD SCI USA, V83, P3654, DOI 10.1073/pnas.83.11.3654; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PING Z, 1991, GENE DEV, V5, P254; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0	32	142	145	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 10	1991	353	6344					563	566		10.1038/353563a0	http://dx.doi.org/10.1038/353563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ643	1922363				2022-12-28	WOS:A1991GJ64300069
J	STOCUM, DL				STOCUM, DL			LIMB REGENERATION - A CALL TO ARMS (AND LEGS)	CELL			English	Review							RETINOIC-ACID; AXOLOTL LIMBS; VITAMIN-A; MONOCLONAL-ANTIBODY; AMBYSTOMA-MEXICANUM; POSITIONAL MEMORY; NEWT LIMB; CELLS; EXPRESSION; BLASTEMA				STOCUM, DL (corresponding author), INDIANA UNIV,SCH SCI,DEPT BIOL,INDIANAPOLIS,IN 46202, USA.							BOILLY B, 1991, DEV BIOL, V145, P302, DOI 10.1016/0012-1606(91)90128-P; BORGENS RB, 1982, SCIENCE, V217, P747, DOI 10.1126/science.7100922; BROWN R, 1991, DEVELOPMENT, V111, P489; CRAWFORD K, 1988, DEVELOPMENT, V102, P687; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEKETE DM, 1991, GLIA, V4, P214; FERRETTI P, 1989, DEV BIOL, V133, P415, DOI 10.1016/0012-1606(89)90045-6; GLOBUS M, 1980, DEV BIOL, V75, P358, DOI 10.1016/0012-1606(80)90169-4; GRIFFIN KJP, 1987, DEVELOPMENT, V101, P267; GRILLO HC, 1968, DEV BIOL, V17, P571, DOI 10.1016/0012-1606(68)90006-7; Hinterberger T J, 1990, Ontogenez, V21, P341; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KIM WS, 1986, DEV BIOL, V114, P170, DOI 10.1016/0012-1606(86)90393-3; KINTNER CR, 1985, J EMBRYOL EXP MORPH, V89, P37; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1985, TRENDS GENET, V1, P103, DOI 10.1016/0168-9525(85)90041-1; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MESCHER AL, 1976, J EXP ZOOL, V195, P117, DOI 10.1002/jez.1401950111; MUNEOKA K, 1982, NATURE, V298, P369, DOI 10.1038/298369a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; ONDA H, 1990, DEVELOPMENT, V108, P657; RAGSDALE CW, 1989, NATURE, V341, P654, DOI 10.1038/341654a0; SCADDING SR, 1988, CAN J ZOOL, V66, P879, DOI 10.1139/z88-130; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P19; Schmidt AJ, 1968, CELLULAR BIOL VERTEB; SESSIONS SK, 1988, J EXP ZOOL, V247, P39, DOI 10.1002/jez.1402470106; SINGER M, 1978, AM ZOOL, V18, P829; STOCUM DL, 1972, J EXP ZOOL, V181, P49, DOI 10.1002/jez.1401810106; STOCUM DL, 1991, IN PRESS SEMIN DEV B, V2; TASSAVA RA, 1982, DIFFERENTIATION, V22, P151, DOI 10.1111/j.1432-0436.1982.tb01242.x; TASSAVA RA, 1986, J EXP ZOOL, V239, P229, DOI 10.1002/jez.1402390210; TSCHUMI PA, 1957, J ANAT, V91, P149; UNTEMA CL, 1959, J EXP ZOOL, V140, P101; VAESSEN MJ, 1990, DEVELOPMENT, V110, P371	38	42	42	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					5	8		10.1016/0092-8674(91)90565-G	http://dx.doi.org/10.1016/0092-8674(91)90565-G			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913819				2022-12-28	WOS:A1991GJ32000002
J	HOBBS, JT				HOBBS, JT			ABC OF VASCULAR DISEASES - VARICOSE-VEINS	BRITISH MEDICAL JOURNAL			English	Article											HOBBS, JT (corresponding author), ST MARYS HOSP,LONDON,ENGLAND.								0	9	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					707	710		10.1136/bmj.303.6804.707	http://dx.doi.org/10.1136/bmj.303.6804.707			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912921	Green Published, Bronze			2022-12-28	WOS:A1991GG98000029
J	FALKOW, S				FALKOW, S			BACTERIAL ENTRY INTO EUKARYOTIC CELLS	CELL			English	Review							LISTERIA-MONOCYTOGENES; EPITHELIAL-CELLS; YERSINIA-ENTEROCOLITICA; MAMMALIAN-CELLS; LINE CACO-2; SALMONELLA; PHAGOCYTOSIS; PENETRATION; PROTEIN; GROWTH				FALKOW, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305, USA.							BARONDESS JJ, 1990, NATURE, V346, P871, DOI 10.1038/346871a0; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FINLAY BB, 1988, BIOCHIMIE, V70, P10891; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; MILLER VL, 1990, J BACTERIOL, V172, P1062, DOI 10.1128/jb.172.2.1062-1069.1990; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; PULKKINEN WS, 1991, J BACTERIOL, V173, P86, DOI 10.1128/jb.173.1.86-93.1991; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; WRIGHT SD, 1985, REV INFECT DIS, V7, P395; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016	25	154	160	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1099	1102		10.1016/0092-8674(91)90003-H	http://dx.doi.org/10.1016/0092-8674(91)90003-H			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905978				2022-12-28	WOS:A1991FU89900003
J	WALKER, MD				WALKER, MD			ACUTE SPINAL-CORD INJURY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							METHYLPREDNISOLONE				WALKER, MD (corresponding author), NINCDS,BETHESDA,MD 20892, USA.							BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; COLLINS WF, 1986, CENT NERV SYST TRAUM, V3, P316; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; STRIPLING TE, 1990, PARAPLEGIA NEWS  AUG, P50; Young W, 1985, CENTRAL NERVOUS SYST, P463	8	28	31	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1885	1887		10.1056/NEJM199106273242608	http://dx.doi.org/10.1056/NEJM199106273242608			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	1904134				2022-12-28	WOS:A1991FT58000008
J	ROYBAL, ER				ROYBAL, ER			THE UNITED-STATES HEALTH-ACT - COMPREHENSIVE REFORM FOR A CARING AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ROYBAL, ER (corresponding author), US HOUSE REPRESENTAT,SELECT COMM AGING,ROOM 712,HOB ANNEX 1,WASHINGTON,DC 20515, USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1991	265	19					2545	2548		10.1001/jama.265.19.2545	http://dx.doi.org/10.1001/jama.265.19.2545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK903	1902269				2022-12-28	WOS:A1991FK90300030
J	HILLMAN, AL; EISENBERG, JM; PAULY, MV; BLOOM, BS; GLICK, H; KINOSIAN, B; SCHWARTZ, JS				HILLMAN, AL; EISENBERG, JM; PAULY, MV; BLOOM, BS; GLICK, H; KINOSIAN, B; SCHWARTZ, JS			AVOIDING BIAS IN THE CONDUCT AND REPORTING OF COST-EFFECTIVENESS RESEARCH SPONSORED BY PHARMACEUTICAL COMPANIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BIOMEDICAL-RESEARCH; CLINICAL RESEARCH; ETHICS; INDUSTRY; DOCTORS		UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; ANGELL M, 1988, NEW ENGL J MED, V318, P1462, DOI 10.1056/NEJM198806023182210; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BLUMENTHAL D, 1986, NEW ENGL J MED, V314, P1621, DOI 10.1056/NEJM198606193142506; BRICKER EM, 1989, NEW ENGL J MED, V320, P1690, DOI 10.1056/NEJM198906223202511; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS T, 1978, CONT ISSUES BIOETHIC, P426; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; GOLDFINGER SE, 1990, ANN INTERN MED, V112, P624; HEALY B, 1988, NEW ENGL J MED, V319, P1058, DOI 10.1056/NEJM198810203191605; HEALY B, 1985, NEW ENGL J MED, V312, P1450, DOI 10.1056/NEJM198505303122210; KAHN CR, 1984, NEW ENGL J MED, V310, P257, DOI 10.1056/NEJM198401263100410; KIPPEN A, 1990, WASHINGTON MONTH OCT, P38; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; MILLER K, 1985, NEW ENGL J MED, V313, P54; MUSHER DM, 1986, NEW ENGL J MED, V315, P590; NOBEL JJ, 1990, JAMA-J AM MED ASSOC, V263, P1435, DOI 10.1001/jama.263.10.1435; PEART WS, 1980, LANCET, V2, P465; RAWLINS MD, 1984, LANCET, V2, P276; RELMAN AS, 1984, NEW ENGL J MED, V310, P1182, DOI 10.1056/NEJM198405033101809; RETSONK EL, 1979, NEW ENGL J MED, V1, P335; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; SIVARAJAN M, 1985, NEW ENGL J MED, V312, P1132; STROSS JK, 1987, J GEN INTERN MED, V2, P155, DOI 10.1007/BF02596142; WOOLF PK, 1987, JAMA-J AM MED ASSOC, V258, P3424, DOI 10.1001/jama.258.23.3424; 1990, JAMA-J AM MED ASSOC, V263, P2790; 1990, CLIN RES, V38, P239; 1986, J R COLL PHYSICIANS, V20, P235; 1984, ANN INTERN MED, V101, P263	35	196	198	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1362	1365		10.1056/NEJM199105093241911	http://dx.doi.org/10.1056/NEJM199105093241911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	1901959				2022-12-28	WOS:A1991FK18600011
J	ERRINGTON, RD; ASHBY, D; GORE, SM; ABRAMS, KR; MYINT, S; BONNETT, DE; BLAKE, SW; SAXTON, TE				ERRINGTON, RD; ASHBY, D; GORE, SM; ABRAMS, KR; MYINT, S; BONNETT, DE; BLAKE, SW; SAXTON, TE			HIGH-ENERGY NEUTRON TREATMENT FOR PELVIC CANCERS - STUDY STOPPED BECAUSE OF INCREASED MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIAL; CLINICAL-TRIALS; BLADDER-CANCER; THERAPY; RADIOTHERAPY; RTOG	Objective - To compare high energy fast neutron treatment with conventional megavoltage x ray treatment in the management of locally advanced pelvic carcinomas (of the cervix, bladder, prostate, and rectum). Design - Randomised study from February 1986; randomisation to neutron treatment or photon treatment was unstratified and in the ratio of 3 to 1 until January 1988, when randomisation was in the ratio 1 to 1 and stratified by site of tumour. Setting - Mersey regional radiotherapy centre at Clatterbridge Hospital, Wirral. Patients - 151 patients with locally advanced, non-metastatic pelvic cancer (27 cervical, 69 of the bladder, seven prostatic, and 48 of the rectum). Intervention - Randomisation to neutron treatment was stopped in February 1990. Main outcome measures - Patient survival and causes of death in relation to the development of metastatic disease and treatment related morbidity. Results - In the first phase of the trial 42 patients were randomised to neutron treatment and 14 to photon treatment, and in the second phase 48 to neutron treatment and 47 to photon treatment. The relative risk of mortality for photons compared with neutrons was 0.66 (95% confidence interval 0.40 to 1.10) after adjustment for site of tumour and other important prognostic factors. Short term and long term complications were similar in both groups. Conclusions - The trial was stopped because of the increased mortality in patients with cancer of the cervix, bladder, or rectum treated with neutrons.	UNIV LIVERPOOL,DEPT COMPUTAT MATH,LIVERPOOL L69 3BX,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND; UNIV LIVERPOOL,DEPT STAT,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; MRC Biostatistics Unit; University of Liverpool; University of Liverpool	ERRINGTON, RD (corresponding author), CLATTERBRIDGE HOSP,MERSEY REG CTR RADIOTHERAPY & ONCOL,MRC,CYCLOTRON UNIT,WIRRAL L63 4JY,ENGLAND.		Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567				ARMITAGE P, 1987, STATISTICAL METHODS, P460; BATTERMANN JJ, 1982, INT J RADIAT ONCOL, V8, P2159, DOI 10.1016/0360-3016(82)90562-4; BONNETT DE, 1988, BRIT J RADIOL, V61, P38, DOI 10.1259/0007-1285-61-721-38; COX DR, 1972, J R STAT SOC B, V34, P187; DUNCAN W, 1986, INT J RADIAT ONCOL, V12, P2085, DOI 10.1016/0360-3016(86)90006-4; DUNCAN W, 1985, INT J RADIAT ONCOL, V11, P2043, DOI 10.1016/0360-3016(85)90082-3; DUNCAN W, 1987, RADIOTHER ONCOL, V8, P191, DOI 10.1016/S0167-8140(87)80242-6; ELASHOFF JD, 1983, HEPATOLOGY, V73, P1031; FLEISS JL, 1981, STATISTICAL METHODS, P68; GRIFFIN T, 1986, B CANCER, V73, P582; GRIFFIN TW, 1988, INT J RADIAT ONCOL, V14, P583; LARAMORE GE, 1990, BRIT MED J, V301, P344, DOI 10.1136/bmj.301.6747.344; LARAMORE GE, 1985, INT J RADIAT ONCOL, V11, P1621, DOI 10.1016/0360-3016(85)90214-7; MACDOUGALL RH, 1990, BRIT MED J, V300, P1721, DOI 10.1136/bmj.300.6741.1721; MAOR MH, 1988, INT J RADIAT ONCOL, V14, P885, DOI 10.1016/0360-3016(88)90010-7; PETERS LJ, 1986, NUCL SCI APPL, V2, P243; POCOCK SJ, 1989, CONTROLLED CLIN TRIA, V10, P209; POINTON RS, 1985, BRIT J RADIOL, V58, P219, DOI 10.1259/0007-1285-58-687-219; WAMBERSIE A, 1986, B CANCER, V73, P546; ZINK S, 1989, AM J CLIN ONCOL-CANC, V12, P277, DOI 10.1097/00000421-198908000-00001	20	48	48	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1045	1051		10.1136/bmj.302.6784.1045	http://dx.doi.org/10.1136/bmj.302.6784.1045			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903663	Green Published, Bronze			2022-12-28	WOS:A1991FK56300020
J	AELONY, Y; KING, R; BOUTIN, C				AELONY, Y; KING, R; BOUTIN, C			THORACOSCOPIC TALC POUDRAGE PLEURODESIS FOR CHRONIC RECURRENT PLEURAL EFFUSIONS	ANNALS OF INTERNAL MEDICINE			English	Article							CORYNEBACTERIUM-PARVUM; SYMPTOMATIC TREATMENT; TETRACYCLINE; MESOTHELIOMA; DIAGNOSIS	Objective: To assess the effectiveness of thoracoscopic talc poudrage for the treatment of chronic pleural effusions. Design: Prospective evaluation. Setting: Kaiser-Permanente Hospital. Patients: Forty-seven consecutive patients with recalcitrant pleural effusions, referred for thoracoscopy. Intervention: Patients received general or local anesthesia; 42 had a 7-mm rigid thoracoscopic examination followed by insufflation of 5 mL of talc. Patients then had chest-tube drainage. Measurements: We recorded clinical characteristics, final diagnosis, procedure-related pain and morbidity, days of hospitalization, patient-reported degree of symptom relief, and chest roentgenographic results at 1, 3, and 12 months. All patients were followed for 16 months or until death. Main Results: Of 39 evaluable patients, all reported prolonged relief of effusion-related dyspnea. Radiographic results confirmed the elimination of pleural effusions in 34 patients (87%), including all 11 with benign conditions and 23 of 28 (82%) with malignancies. Treatment failed in three patients because of entrapped lung and in two patients with mesotheliomas whose effusions recurred more than a year after treatment. No procedure-related mortality or morbidity was found. Ambulatory patients required hospitalization for a mean of 3.9 days (range, 2 to 11 days). Mild pain was reported by some patients. The mean duration of chest-tube drainage was 2.7 days (range, 1 to 9 days). Patients with malignant disease lived an average of 12.4 months (range, 1 to 61 months) after the procedure. Conclusions: Thoracoscopic talc poudrage is an effective pleural sclerosing technique and is relatively painless.	HOP CONCEPTION, F-13386 MARSEILLE 5, FRANCE	Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	AELONY, Y (corresponding author), SO CALIF PERMANENTE MED GRP, DEPT INTERNAL MED, 25825 S VERMONT, HARBOR CITY, CA 90710 USA.							ANTONY VB, 1987, AM REV RESPIR DIS, V135, P775, DOI 10.1164/arrd.1987.135.4.775; BONIFACE E, 1989, REV MAL RESPIR, V6, P133; BOUTIN C, 1981, AM REV RESPIR DIS, V124, P588; Boutin C, 1991, PRACTICAL THORACOSCO; BOUTIN C, 1990, LUNG S, P1113; Boutin C, 1985, REV MAL RESPIR, V2, P374; BOUTIN C, 1985, PLEURA HLTH DISEASE; BRANDT HJ, 1985, ATLAS DIAGNOSTIC THO; CANTO A, 1985, MED CLIN-BARCELONA, V84, P806; CHRETIEN J, 1983, DISEASES PLEURA, P152; DAVIDSON AC, 1988, THORAX, V43, P327, DOI 10.1136/thx.43.4.327; DUNKEL TB, 1986, MINN MED, V69, P717; ELMES PC, 1976, Q J MED, V45, P427; FENTIMAN IS, 1987, CANCER TREAT REV, V14, P107, DOI 10.1016/0305-7372(87)90043-0; Frank W, 1989, Pneumologie, V43, P80; GAENSLER EA, 1964, NEW ENGL J MED, V270, P1319, DOI 10.1056/NEJM196406182702501; Gust R, 1989, Pneumologie, V43, P85; HAUPT GJ, 1960, JAMA-J AM MED ASSOC, V73, P173; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; JONES DP, 1989, CHEST S, V96, pS276; LADJIMI S, 1989, REV MAL RESPIR, V6, P147; LANDVATER L, 1988, CHEST, V93, P1196, DOI 10.1378/chest.93.6.1196; LANGE P, 1988, THORAX, V43, P559, DOI 10.1136/thx.43.7.559; LEAHY BC, 1985, EUR J RESPIR DIS, V66, P50; LIGHT RW, 1972, ANN INTERN MED, V77, P507, DOI 10.7326/0003-4819-77-4-507; LIGHT RW, 1983, PLEURAL DISEASES, P84; LIGHT RW, 1983, PLEURAL DISEASES, P86; LIGHT RW, 1983, PLEURAL DISEASES, P77; MARTINI N, 1975, CANCER, V35, P734, DOI 10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N; MUIR J F, 1987, American Review of Respiratory Disease, V135, pA244; NG TK, 1984, MED J AUSTRALIA, V140, P452, DOI 10.5694/j.1326-5377.1984.tb108157.x; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; ROSSI GA, 1987, AM REV RESPIR DIS, V135, P885, DOI 10.1164/arrd.1987.135.4.885; SHERMAN S, 1988, CHEST, V93, P533, DOI 10.1378/chest.93.3.533; SHERMAN S, 1987, SOUTH MED J, V80, P716, DOI 10.1097/00007611-198706000-00013; TSANG V, 1990, THORAX, V45, P369, DOI 10.1136/thx.45.5.369; TZENG E, 1990, CHEST, V98, P890, DOI 10.1378/chest.98.4.890; Viskum K, 1981, Poumon Coeur, V37, P25; WEISSBERG D, 1980, ANN THORAC SURG, V29, P205, DOI 10.1016/S0003-4975(10)61868-1; Weissberg D, 1981, Poumon Coeur, V37, P291; WOOTEN S A, 1987, American Review of Respiratory Disease, V135, pA245	41	74	75	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					778	782		10.7326/0003-4819-115-10-778	http://dx.doi.org/10.7326/0003-4819-115-10-778			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929026				2022-12-28	WOS:A1991GP80000006
J	SEGRAVES, RT				SEGRAVES, RT			REVERSING ANORGASMIA ASSOCIATED WITH SEROTONIN UPTAKE INHIBITORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							FLUOXETINE				SEGRAVES, RT (corresponding author), CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106, USA.							HERMAN JB, 1990, J CLIN PSYCHIAT, V51, P25; KLINE MD, 1989, AM J PSYCHIAT, V146, P804; MCCORMICK S, 1990, J CLIN PSYCHIAT, V51, P383; MOINTIERO WO, 1985, BRIT J PSYCHIAT, V151, P107; MOSHER JS, 1990, AM J PSYCHIAT, V147, P949; PRICE J, 1990, J CLIN PSYCHIAT, V51, P32; SEGRAVES RT, 1989, ARCH GEN PSYCHIAT, V46, P275; ZAJECKA J, 1991, J CLIN PSYCHIAT, V52, P66	8	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2279	2279						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920732				2022-12-28	WOS:A1991GK66100042
J	SEGRAVES, WA				SEGRAVES, WA			SOMETHING OLD, SOME THINGS NEW - THE STEROID-RECEPTOR SUPERFAMILY IN DROSOPHILA	CELL			English	Review							GENE SUPERFAMILY; MEMBER; PROTEIN; MELANOGASTER; SEGMENTATION; KNIRPS; FINGER; PUFF; 75B				SEGRAVES, WA (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,LA JOLLA,CA 92037, USA.							ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; KOELLE MR, 1991, CELL, V67, P1371; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PALLI SR, 1991, INSECT BIOCHEM, V21, P7, DOI 10.1016/0020-1790(91)90059-N; PERRIMON N, 1985, GENETICS, V111, P23; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; UEDA H, 1991, NUCLEIC ACIDS RES, V19, P3689, DOI 10.1093/nar/19.13.3689; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YAMAMOTO K, 1988, SCIENCE, V239, P916, DOI 10.1126/science.3124270	27	74	76	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					225	228		10.1016/0092-8674(91)90172-U	http://dx.doi.org/10.1016/0092-8674(91)90172-U			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913821				2022-12-28	WOS:A1991GL47000001
J	AIN, KB; REFETOFF, S; FEIN, HG; WEINTRAUB, BD				AIN, KB; REFETOFF, S; FEIN, HG; WEINTRAUB, BD			PSEUDOMALABSORPTION OF LEVOTHYROXINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							L-THYROXINE; MUNCHAUSENS SYNDROME; THYROID-HORMONE; TRIIODOTHYRONINE; HYPOTHYROIDISM; MALABSORPTION; ABSORPTION; CONVERSION; BYPASS	Objective. - The issue of patient compliance with pharmacological therapy vs malabsorption of medication was explored in the context of persistent hypothyroidism despite the administration of large doses of levothyroxine sodium. Design. - Retrospective case series. Setting. - Referred care in two large tertiary care centers. Patients. - Four patients, seen within two decades, with clinical and biochemical hypothyroidism while receiving levothyroxine, were evaluated for selective malabsorption of this hormone. Interventions. - Studies included serial measurements of thyroid hormone levels after a loading dose of levothyroxine or liothyronine sodium or evaluation with a double-labeled thyroxine tracer technique. Results were compared with studies of levothyroxine malabsorption in the medical literature. Results. - All patients were ultimately found to have normal (82% to 100%) absorption of oral levothyroxine. There was no evidence that malabsorption of levothyroxine can occur as an isolated abnormality. Conclusions. - Some patients exhibit a factitious disorder suggesting malabsorption of levothyroxine. When treating hypothyroidism, psychiatric issues may result in noncompliance with levothyroxine therapy.	NIDDKD, METAB CELLULAR & NUTR ENDOCRINOL BRANCH, BETHESDA, MD USA; NIDDKD, CLIN ENDOCRINOL BRANCH, BETHESDA, MD USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PEDIAT, CHICAGO, IL 60637 USA; WALTER REED ARMY MED CTR, DEPT CLIN PHYSIOL, WASHINGTON, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Chicago; University of Chicago; United States Department of Defense; United States Army; Walter Reed National Military Medical Center			Refetoff, Samuel/ABB-1263-2021; Ain, Kenneth/A-5179-2012	Refetoff, Samuel/0000-0003-0164-8231; Ain, Kenneth/0000-0002-2668-934X	NCRR NIH HHS [RR 00055] Funding Source: Medline; NIDDK NIH HHS [DK 15070] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015070, R01DK015070] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER R, 1951, LANCET, V260, P339; AZIZI F, 1979, ANN INTERN MED, V90, P941, DOI 10.7326/0003-4819-90-6-941; BANTLE JP, 1987, THYROID TODAY, V10, P1; BARBATO AL, 1977, BRIT J RADIOL, V50, P827, DOI 10.1259/0007-1285-50-599-827; BEVAN JS, 1986, INT J OBESITY, V10, P245; BHUGRA D, 1988, ACTA PSYCHIAT SCAND, V77, P497, DOI 10.1111/j.1600-0447.1988.tb05160.x; CHUNG SJ, 1967, AM J PHYSIOL, V212, P97, DOI 10.1152/ajplegacy.1967.212.1.97; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; GREENSTADT MA, 1982, HORMONE DRUGS, P534; HAYS MT, 1968, J CLIN ENDOCR METAB, V28, P749, DOI 10.1210/jcem-28-6-749; INADA M, 1975, J CLIN INVEST, V55, P1337, DOI 10.1172/JCI108053; Mani L S, 1985, Indian J Gastroenterol, V4, P239; NICOLOFF JT, 1972, J CLIN INVEST, V51, P473, DOI 10.1172/JCI106835; NORTHCUTT RC, 1969, J AMER MED ASSOC, V208, P1857; SARNE DH, 1990, J CLIN ENDOCR METAB, V70, P1305, DOI 10.1210/jcem-70-5-1305; SAWIN CT, 1984, ANN INTERN MED, V100, P641, DOI 10.7326/0003-4819-100-5-641; SHAFER N, 1980, NEW YORK STATE J MED, V80, P594; SMALLRIDGE RC, 1990, MIL MED, V155, P156, DOI 10.1093/milmed/155.4.156; STOCK JM, 1974, NEW ENGL J MED, V290, P529, DOI 10.1056/NEJM197403072901001; STONE E, 1984, J CLIN ENDOCR METAB, V59, P139, DOI 10.1210/jcem-59-1-139; SURKS MI, 1973, J CLIN INVEST, V52, P805, DOI 10.1172/JCI107244; SUZUKI Y, 1982, Folia Endocrinologica Japonica, V58, P1487; SYMONS RG, 1983, CLIN ENDOCRINOL, V19, P539, DOI 10.1111/j.1365-2265.1983.tb00029.x; VALENTE WA, 1981, J CLIN ENDOCR METAB, V53, P527, DOI 10.1210/jcem-53-3-527; VICK K, 1989, 24TH ANN AM SOC HOSP; WEINTRAUB BD, 1981, ANN INTERN MED, V95, P339, DOI 10.7326/0003-4819-95-3-339; WENZEL KW, 1986, DEUT MED WOCHENSCHR, V111, P1356, DOI 10.1055/s-2008-1068634; WENZEL KW, 1977, METABOLISM, V26, P1, DOI 10.1016/0026-0495(77)90121-4; WENZEL KW, 1974, J CLIN ENDOCR METAB, V38, P902, DOI 10.1210/jcem-38-5-902	29	70	72	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2118	2120		10.1001/jama.266.15.2118	http://dx.doi.org/10.1001/jama.266.15.2118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920700				2022-12-28	WOS:A1991GJ47400033
J	CHUAH, SY; CROWSON, CP; DRONFIELD, MW				CHUAH, SY; CROWSON, CP; DRONFIELD, MW			TOPICAL ANESTHESIA IN UPPER GASTROINTESTINAL ENDOSCOPY	BRITISH MEDICAL JOURNAL			English	Article							LIDOCAINE		PETERBOROUGH DIST GEN HOSP,DEPT MED,PETERBOROUGH PE3 6DA,ENGLAND									CANTOR DS, 1986, GASTROINTEST ENDOSC, V32, P339, DOI 10.1016/S0016-5107(86)71879-8; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; GORDON MJ, 1976, GASTROENTEROLOGY, V71, P564; ODONOHUE WJ, 1980, ARCH INTERN MED, V140, P1508, DOI 10.1001/archinte.140.11.1508	4	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					695	695		10.1136/bmj.303.6804.695	http://dx.doi.org/10.1136/bmj.303.6804.695			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912917	Green Published, Bronze			2022-12-28	WOS:A1991GG98000024
J	ODWYER, FG; DALTON, A; PEARCE, JB				ODWYER, FG; DALTON, A; PEARCE, JB			ADOLESCENT SELF HARM PATIENTS - AUDIT OF ASSESSMENT IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the assessment of adolescent self harm patients attending an accident and emergency department. Design - Retrospective assessment of case notes. Setting - Accident and emergency department, Leicester Royal Infirmary. Patients - 210 adolescent patients (aged 9-19 years) attending the department during 1 January 1989-31 December 1989 after deliberate self poisoning; records were available for 200. Main outcome measures - Numbers of admissions, discharges from department without either a psychiatric consultation or some form of follow up, and discharges with either of these; scoring of adequacy of psychiatric and social assessment by accident and emergency doctor. Results - 89 patients were admitted (mean score 5.1, excluding 22 patients too drowsy or unforthcoming for proper assessment), 80 were discharged without specific psychiatric consultation or other follow up (mean score 5.4), and 31 were discharged with psychiatric consultation or other follow up (mean score 9.1). The percentage of patients in each group whose assessment by the accident and emergency doctor was considered to be adequate or better than adequate over 10 headings ranged from 0%-40% for admitted patients, 0%-50% for those discharged without psychiatric assessment, and 0%-61% in the remaining group. Overall, in almost half (49%, 54/111) of all of those discharged documentation of the suicidal state was inadequate. Conclusion - The assessment of many adolescent self harm patients in this clinic was unsatisfactory. Implications - Doctors working in accident and emergency departments should be encouraged to liaise with child psychiatrists before discharging such patients.	CHILD & FAMILY PSYCHIAT SERV,LEICESTER,ENGLAND	University of Leicester	ODWYER, FG (corresponding author), LEICESTER ROYAL INFIRM,DEPT ACCID & EMERGENCY,LEICESTER LE1 5WW,ENGLAND.							BANCROFT JH, 1975, J PREVENTIVE SOCIAL, V29, P170; BLACK D, 1988, J ROY SOC MED, V81, P97, DOI 10.1177/014107688808100216; BLACK M, 1982, B ROYAL COLLEGE PSYC, V6, P182; BURTON P, 1990, BRIT MED J, V300, P1695, DOI 10.1136/bmj.300.6741.1695; HAWTON K, 1982, BRIT J PSYCHIAT, V141, P166, DOI 10.1192/bjp.141.2.166; HAWTON K, 1976, SUICIDE ATTEMPTED SU, P124; KIERNAN WES, 1976, BRIT J PSYCHIAT, V129, P167, DOI 10.1192/bjp.129.2.167; OTTO V, 1972, ACTA PSYCHIAT SCAND, V233, P7; OWENS D, 1990, J ROY COLL PHYS LOND, V24, P281; TAYLOR EA, 1984, BRIT J PSYCHIAT, V145, P127, DOI 10.1192/bjp.145.2.127	10	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					629	630		10.1136/bmj.303.6803.629	http://dx.doi.org/10.1136/bmj.303.6803.629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1932907	Bronze, Green Published			2022-12-28	WOS:A1991GF67500027
J	VANMIERT, M; THORNINGTON, RE; VANVELZEN, D				VANMIERT, M; THORNINGTON, RE; VANVELZEN, D			CARDIAC-ARREST AFTER MASSIVE ACUTE FAT-EMBOLISM	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP ALDER HEY,FETAL & INFANT PATHOL,LIVERPOOL L12 2AP,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								GURD A, 1984, CLIN ORTHOPAEDICS, V185, P69; GURD AR, 1974, J BONE JOINT SURG BR, VB 56, P408, DOI 10.1302/0301-620X.56B3.408; HAYLEY SR, 1983, ANAESTHESIA INTENSIV, V11, P162	3	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					396	397		10.1136/bmj.303.6799.396	http://dx.doi.org/10.1136/bmj.303.6799.396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB599	1912807	Bronze, Green Published			2022-12-28	WOS:A1991GB59900017
J	BIRD, AG; GORE, SM; LEIGHBROWN, AJ; CARTER, DC				BIRD, AG; GORE, SM; LEIGHBROWN, AJ; CARTER, DC			ESCAPE FROM COLLECTIVE DENIAL - HIV TRANSMISSION DURING SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD; AIDS		MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND; UNIV EDINBURGH,DIV BIOL SCI B,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ENVIRONM,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	MRC Biostatistics Unit; University of Edinburgh; Royal Infirmary of Edinburgh	BIRD, AG (corresponding author), ROYAL INFIRM,HIV IMMUNOL UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BERGLUND O, 1988, AIDS, V2, P51, DOI 10.1097/00002030-198802000-00009; BERKELMAN R, 1990, HIV HLTH CARE WORKER; DECLERCQ A, 1991, BRIT MED J, V302, P51, DOI 10.1136/bmj.302.6767.51; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1991, JAMA-J AM MED ASSOC, V265, P1845, DOI 10.1001/jama.265.14.1845; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LOT F, 1990, BEH, V49, P207; MANNING S, 1991, J MED DEF UNION, V2, P43; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SIMMONDS P, 1990, AIDS S1, V4, P577; WELCH J, 1989, LANCET, V1, P205; 1988, AIDS HIV INFECTED HE; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1989, MMWR S56, V1, P3; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	22	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					351	352		10.1136/bmj.303.6798.351	http://dx.doi.org/10.1136/bmj.303.6798.351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912780	Green Published, Bronze			2022-12-28	WOS:A1991GA60600026
J	DYNLACHT, BD; HOEY, T; TJIAN, R				DYNLACHT, BD; HOEY, T; TJIAN, R			ISOLATION OF COACTIVATORS ASSOCIATED WITH THE TATA-BINDING PROTEIN THAT MEDIATE TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							RNA POLYMERASE-II; ANTENNAPEDIA GENE-COMPLEX; FUNCTIONAL-ANALYSIS; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; DROSOPHILA; BOX; YEAST; INITIATION; DOMAINS	A key step in the regulation of transcription involves interactions between promoter-selective factors and various components of the transcriptional apparatus. Here we report the requirements for transcriptional activation directed by NTF-1, a developmentally regulated transcription factor in Drosophila. Reconstituted transcription with fractionated Drosophila basal factors reveals that activation by NTF-1 requires factors present in the endogenous TFIID fraction that are distinct from the purified TATA-binding protein (TBP). Glycerol gradient sedimentation and immunoprecipitation analyses indicate that TFIID is a multiprotein complex containing TBP and at least six tightly bound TBP-associated factors (TAFs). Preparations of TBP lacking TAFs after fractionation with denaturants no longer support activation by NTF-1 but retain basal level activity. Addition of immunopurified and renatured TAFs to free TBP restores the ability of NTF-1 to activate transcription without influencing basal transcription. These results suggest that one or more of the TAF polypeptides confer coactivator function.			DYNLACHT, BD (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DREIVER W, 1989, NATURE, V342, P149; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	40	606	622	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					563	576		10.1016/0092-8674(81)90019-2	http://dx.doi.org/10.1016/0092-8674(81)90019-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907890				2022-12-28	WOS:A1991GA94100017
J	WEEKS, KM; CROTHERS, DM				WEEKS, KM; CROTHERS, DM			RNA RECOGNITION BY TAT-DERIVED PEPTIDES - INTERACTION IN THE MAJOR GROOVE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE-SPECIFIC RECOGNITION; HIV-1 TAT; TRANS-ACTIVATION; MESSENGER-RNA; RESPONSIVE SEQUENCE; GENE-EXPRESSION; LOOP SEQUENCE; NUCLEIC-ACIDS; NASCENT RNA	Replication of human immunodeficiency virus requires binding of the viral Tat protein to its RNA target sequence TAR; peptides derived from Tat bind to a TAR "contact site" spanning 5 bp and a trinucleotide pyrimidine bulge. We find that high affinity binding requires a U residue in the bulge loop and 2 specific adjacent base pairs. Other bulged RNAs bind in a lower affinity nonspecific manner; sequence-specific binding requires a bulge loop of more than 1 nucleotide. Reaction with diethyl pyrocarbonate indicates that one effect of the bulge is to make the otherwise deep and narrow RNA major groove accessible. A model consistent with these data involves local distortion of A-form geometry at the bulge, which bends the helix and permits protein binding and interactive access in the RNA major groove.			WEEKS, KM (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021966, R37GM021966, P01GM039546] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39546, GM 21966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; Endo S, 1989, Virus Genes, V3, P99; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOUGEL M, 1987, J MOL BIOL, V198, P91, DOI 10.1016/0022-2836(87)90460-8; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MYERS G, 1990, HUMAN RETROVIRUSES A; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; SUSSMAN JL, 1976, SCIENCE, V192, P853, DOI 10.1126/science.775636; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; VANSTOLK BJ, 1984, J MOL BIOL, V180, P151, DOI 10.1016/0022-2836(84)90435-2; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011	48	337	345	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					577	588		10.1016/0092-8674(81)90020-9	http://dx.doi.org/10.1016/0092-8674(81)90020-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907891				2022-12-28	WOS:A1991GA94100018
J	AGRAWAL, NM; ROTH, S; GRAHAM, DY; WHITE, RH; GERMAIN, B; BROWN, JA; STROMATT, SC				AGRAWAL, NM; ROTH, S; GRAHAM, DY; WHITE, RH; GERMAIN, B; BROWN, JA; STROMATT, SC			MISOPROSTOL COMPARED WITH SUCRALFATE IN THE PREVENTION OF NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED GASTRIC-ULCER - A RANDOMIZED, CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							DOUBLE-BLIND; MUCOSAL DAMAGE; PLACEBO; INJURY; NSAID; COMPLICATIONS; GASTROPATHY; MECHANISMS; PROTECTION; SYMPTOMS	Objectives: To compare the efficacy and frequency of adverse experiences of misoprostol and sucralfate in the prevention of gastric ulcers in patients receiving nonsteroidal anti-inflammatory drug (NSAID) therapy. Design: A prospective, randomized, single-blind, multicenter trial. Patients: Patients with osteoarthritis receiving treatment with ibuprofen, piroxicam, or naproxen and experiencing abdominal pain were eligible. Interventions: Patients who were expected to receive at least 3 months of NSAID therapy and who did not have a gastric ulcer at the time of the initial screening endoscopy were randomized to receive misoprostol, 200-mu-g four times a day, or sucralfate, 1 g four times a day. A gastric ulcer was defined as a lesion of the gastric mucosa 0.3 cm or greater in diameter. Patients were followed clinically, and repeat endoscopies were performed after 4, 8, and 12 weeks. Main Measurement: The development of a gastric ulcer, which was regarded as a prophylaxis failure. Results: Two hundred fifty-three patients were evaluable for efficacy analysis. A gastric ulcer developed in 2 of the 122 (1.6%, 95% Cl, 0.3% to 6.4%) patients on misoprostol, compared with 21 of 131 patients on sucralfate (16%, Cl, 10.4% to 23.7%). The difference in ulcer rates was 14.4% (Cl, 10.4% to 19.5%; P < 0.001). Conclusion: In patients receiving chronic NSAID therapy for osteoarthritis, treatment with misoprostol for 3 months was associated with a significantly lower frequency of gastric ulcer formation, compared with treatment with sucralfate (P < 0.001).	ARIZONA ARTHRITIS RES & EDUC LTD, PHOENIX, AZ USA; BAYLOR UNIV, VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SACRAMENTO MED CTR, SACRAMENTO, CA 95817 USA; UNIV S FLORIDA, TAMPA, FL 33620 USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA; UNIV HLTH SCI CHICAGO MED SCH, N CHICAGO, IL 60064 USA	Baylor College of Medicine; Baylor University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Davis; University of California System; University of California Davis; State University System of Florida; University of South Florida; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Chicago Medical School	AGRAWAL, NM (corresponding author), TULANE UNIV, SCH MED, GASTROENTEROL SECT, 1430 TULANE AVE, NEW ORLEANS, LA 70112 USA.		Graham, David/AAL-2165-2021					ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; AGRAWAL NM, 1989, INT J CLIN PHARM RES, V9, P347; ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BUSSIERE JL, 1990, CLIN EXP RHEUMATOL, V8, pS4; CALDWELL JR, 1987, AM J MED, V83, P74, DOI 10.1016/0002-9343(87)90832-1; COHEN MM, 1989, GASTROENTEROLOGY, V96, P292, DOI 10.1016/0016-5085(89)91550-3; COLLINS PW, 1990, MED RES REV, V10, P149, DOI 10.1002/med.2610100202; DAJANI EZ, 1987, PROSTAG OTH LIPID M, V33, P117, DOI 10.1016/0090-6980(87)90054-2; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GEIS S, 1990, CLIN EXP RHEUMATOL, P4; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1988, AM J GASTROENTEROL, V83, P1081; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; HOLLANDER D, 1984, SCAND J GASTROENTERO, V19, P97; ISENBERG JI, 1986, DIGEST DIS SCI, V31, pS130, DOI 10.1007/BF01309337; KONTUREK SJ, 1986, GUT, V27, P1450, DOI 10.1136/gut.27.12.1450; LANZA F, 1988, AM J GASTROENTEROL, V83, P143; LANZA FL, 1989, AM J GASTROENTEROL, V84, P633; LANZA FL, 1988, GASTROENTEROLOGY, V95, P289, DOI 10.1016/0016-5085(88)90482-9; LIGUMSKY M, 1986, ISRAEL J MED SCI, V22, P801; MILLER TA, 1983, AM J PHYSIOL, V245, pG601, DOI 10.1152/ajpgi.1983.245.5.G601; ROTH S, 1989, ARCH INTERN MED, V149, P775, DOI 10.1001/archinte.149.4.775; ROTH SH, 1988, J RHEUMATOL, V15, P912; SATO N, 1987, AM J MED, V83, P15, DOI 10.1016/0002-9343(87)90573-0; STEM AI, 1986, AM J MED S6A, V86, P66; TARNAWSKI A, 1986, GASTROENTEROLOGY, V90, P893, DOI 10.1016/0016-5085(86)90865-6; WAISMAN Y, 1988, DIGESTION, V41, P78, DOI 10.1159/000199735; WALLACE JL, 1988, CAN J PHYSIOL PHARM, V66, P666, DOI 10.1139/y88-105; WILSON DE, 1986, DIGEST DIS SCI, V31, pS126, DOI 10.1007/BF01309336	29	158	160	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1991	115	3					195	200		10.7326/0003-4819-115-3-195	http://dx.doi.org/10.7326/0003-4819-115-3-195			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY152	1905501				2022-12-28	WOS:A1991FY15200006
J	STEPHANOPOULOS, G; VALLINO, JJ				STEPHANOPOULOS, G; VALLINO, JJ			NETWORK RIGIDITY AND METABOLIC ENGINEERING IN METABOLITE OVERPRODUCTION	SCIENCE			English	Article								In order to enhance the yield and productivity of metabolite production, researchers have focused almost exclusively on enzyme amplification or other modifications of the product pathway. However, overproduction of many metabolites requires significant redirection of flux distributions in the primary metabolism, which may not readily occur following product deregulation because metabolic pathways have evolved to exhibit control architectures that resist flux alterations at branch points. This problem can be addressed through the use of some general concepts of metabolic rigidity, which include a means for identifying and removing rigid branch points within an experimental framework.			STEPHANOPOULOS, G (corresponding author), MIT, DEPT CHEM ENGN, CAMBRIDGE, MA 02139 USA.		Vallino, Joseph/J-6177-2015	Vallino, Joseph/0000-0002-4184-4512				AIBA S, 1979, BIOTECHNOL BIOENG, V21, P1373, DOI 10.1002/bit.260210806; [Anonymous], ALLOSTERIC ENZYMES K; ATKINSON DE, 1989, CONTROL METABOLIC PR, P3; ATKINSON DE, 1977, CELLULAR ENERGY META, P193; BAILEY JE, 1990, ANN NY ACAD SCI, V589, P1, DOI 10.1111/j.1749-6632.1990.tb24230.x; BLUM JJ, 1982, BIOL REGULATION DE A, V3, P99; CARY JW, 1990, ANN NY ACAD SCI, V589, P67, DOI 10.1111/j.1749-6632.1990.tb24235.x; CHANCE B, 1960, J BIOL CHEM, V235, P2426; COLMAN B, 1976, PLANT SCI LETT, V6, P123, DOI 10.1016/0304-4211(76)90146-2; CREMER J, 1988, J GEN MICROBIOL, V134, P3221; DENHOLLANDER JA, 1986, BIOCHEMISTRY-US, V25, P212, DOI 10.1021/bi00349a030; FAZEL AM, 1980, ARCH BIOCHEM BIOPHYS, V200, P165, DOI 10.1016/0003-9861(80)90343-4; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; GARFINKEL D, 1981, TRENDS BIOCHEM SCI, V6, P69, DOI 10.1016/0968-0004(81)90025-6; GARFINKEL D, 1964, J BIOL CHEM, V239, P971; GROEN AK, 1988, BIOCHEM J, V253, P619, DOI 10.1042/bj2530619; HATCH MD, 1970, ANN REV PLANT PHYSIO, V21, P141, DOI 10.1146/annurev.pp.21.060170.001041; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HEINRICH R, 1977, PROG BIOPHYS MOL BIO, V32, P1; Herbert D., 1961, S SOC GEN MICROBIOL, V11, P391; HIGA AI, 1976, J GEN MICROBIOL, V93, P69, DOI 10.1099/00221287-93-1-69; Holms W H, 1987, Biochem Soc Symp, V54, P17; HOLMS WH, 1986, CURR TOP CELL REGUL, V28, P69; INBAR L, 1987, EUR J BIOCHEM, V162, P621, DOI 10.1111/j.1432-1033.1987.tb10684.x; Ingraham J.L., 1983, GROWTH BACTERIAL CEL, P87; JENSEN RA, 1969, J BIOL CHEM, V244, P2816; JOSHI A, 1990, J THEOR BIOL, V142, P41, DOI 10.1016/S0022-5193(05)80012-8; JOSHI A, 1989, J THEOR BIOL, V141, P515, DOI 10.1016/S0022-5193(89)80233-4; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KANE JF, 1970, J BIOL CHEM, V245, P2384; KELL DB, 1986, TRENDS BIOTECHNOL, V4, P137, DOI 10.1016/0167-7799(86)90163-0; KINOSHITA S, 1985, BIOL IND MICROORGANI, P115; KINOSHITA S, 1978, ECON MICROBIOL, V2, P209; KODAKI T, 1985, J BIOCHEM-TOKYO, V97, P533, DOI 10.1093/oxfordjournals.jbchem.a135088; KORNBERG H. L., 1966, ESSAYS BIOCHEM, V2, P1; KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; Lardy H, 1972, ENZYMES, P117; LIAO CL, 1971, J BACTERIOL, V106, P37, DOI 10.1128/JB.106.1.37-44.1971; LIAO JC, 1988, BIOTECHNOL BIOENG, V31, P869, DOI 10.1002/bit.260310815; LINDOW SE, 1989, SCIENCE, V244, P1300, DOI 10.1126/science.2660261; MAJEWSKI RA, 1985, BIOSYSTEMS, V18, P15, DOI 10.1016/0303-2647(85)90057-7; MAJEWSKI RA, 1990, BIOTECHNOL BIOENG, V36, P166, DOI 10.1002/bit.260360209; MENKEL E, 1989, APPL ENVIRON MICROB, V55, P684, DOI 10.1128/AEM.55.3.684-688.1989; MILLER AL, 1972, ARCH BIOCHEM BIOPHYS, V152, P531, DOI 10.1016/0003-9861(72)90248-2; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MORI M, 1986, AGR BIOL CHEM TOKYO, V50, P2605, DOI 10.1080/00021369.1986.10867781; MORI M, 1985, J BIOCHEM-TOKYO, V98, P1621, DOI 10.1093/oxfordjournals.jbchem.a135432; MORI M, 1987, AGR BIOL CHEM TOKYO, V51, P129, DOI 10.1080/00021369.1987.10868003; MORI M, 1985, J BIOCHEM-TOKYO, V97, P1119, DOI 10.1093/oxfordjournals.jbchem.a135156; Nakayama K, 1972, MICROBIAL PRODUCTION, P369; NIRANJAN SC, 1989, BIOTECHNOL BIOENG, V34, P496, DOI 10.1002/bit.260340409; OREGAN M, 1989, GENE, V77, P237, DOI 10.1016/0378-1119(89)90072-3; OWTTRIM GW, 1988, BIOCHEM CELL BIOL, V66, P93, DOI 10.1139/o88-012; OZAKI H, 1969, J BIOCHEM-TOKYO, V66, P297, DOI 10.1093/oxfordjournals.jbchem.a129148; PALSSON BO, 1985, J THEOR BIOL, V113, P261, DOI 10.1016/S0022-5193(85)80227-7; PAPOUTSAKIS ET, 1984, BIOTECHNOL BIOENG, V26, P174, DOI 10.1002/bit.260260210; REARDON KF, 1987, BIOTECHNOL PROGR, V3, P153, DOI 10.1002/btpr.5420030307; SANWAL BD, 1970, BACTERIOL REV, V34, P20, DOI 10.1128/MMBR.34.1.20-39.1970; SANWAL BD, 1966, J BIOL CHEM, V241, P4557; SANWAL BD, 1971, CURR TOP CELL REGUL, V3, P1; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P365, DOI 10.1016/S0022-5193(69)80026-3; SAVAGEAU MA, 1970, J THEOR BIOL, V26, P215, DOI 10.1016/S0022-5193(70)80013-3; SHIIO I, 1987, AGR BIOL CHEM TOKYO, V51, P2485; SHIIO I, 1984, AGR BIOL CHEM TOKYO, V48, P3091, DOI 10.1080/00021369.1984.10866644; SHIIO I, 1979, AGR BIOL CHEM TOKYO, V43, P2479, DOI 10.1080/00021369.1979.10863842; Stadtman E.R., 1970, ENZYMES, V1, P397; STEIN RB, 1979, J BIOL CHEM, V254, P385; STOUTHAMER AH, 1973, A VAN LEEUW J MICROB, V39, P545, DOI 10.1007/BF02578899; TOSAKA O, 1979, AGR BIOL CHEM TOKYO, V43, P265, DOI 10.1080/00021369.1979.10863453; TOSAKA O, 1985, AGR BIOL CHEM TOKYO, V49, P1305, DOI 10.1080/00021369.1985.10866916; TSAI SP, 1988, BIOTECHNOL BIOENG, V32, P713, DOI 10.1002/bit.260320517; TSAI SP, 1988, BIOTECHNOL PROGR, V4, P82, DOI 10.1002/btpr.5420040206; UMBARGER HE, 1969, ANNU REV BIOCHEM, V38, P323, DOI 10.1146/annurev.bi.38.070169.001543; Vallino J.J., 1990, FRONTIERS BIOPRARSSI, P205; Vallino J.J., 1991, THESIS MIT CAMBRIDGE; VALLINO JJ, 1987, ANN NY ACAD SCI, V506, P415, DOI 10.1111/j.1749-6632.1987.tb23838.x; WALSH K, 1985, J BIOL CHEM, V260, P8430; YAMAGUCHI K, 1986, AGR BIOL CHEM TOKYO, V50, P2453, DOI 10.1080/00021369.1986.10867786; YOKOTA A, 1988, AGR BIOL CHEM TOKYO, V52, P455; 1987, TRENDS BIOCHEM SCI, V12, P4; 1987, TRENDS BIOCHEM SCI, V12, P216	82	417	452	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	1991	252	5013					1675	1681		10.1126/science.1904627	http://dx.doi.org/10.1126/science.1904627			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1904627				2022-12-28	WOS:A1991FT11400039
J	KRAPF, R; BEELER, I; HERTNER, D; HULTER, HN				KRAPF, R; BEELER, I; HERTNER, D; HULTER, HN			CHRONIC RESPIRATORY ALKALOSIS - THE EFFECT OF SUSTAINED HYPERVENTILATION ON RENAL REGULATION OF ACID-BASE-EQUILIBRIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HYPOCAPNIA; RADIOIMMUNOASSAY; PLASMA; SERUM; H+	Background. In normal subjects, chronic hyperventilation lowers plasma bicarbonate concentration, primarily by inhibiting the urinary excretion of net acid. The quantitative relation between reduced arterial carbon dioxide tension (PaCO2) and the plasma bicarbonate concentration in the chronic steady state has not been studied in humans, however, and the laboratory criteria for the diagnosis of chronic respiratory alkalosis therefore remain undefined. We wished to provide such reference data for clinical use. Moreover, because chronic hyperventilation paradoxically lowers blood pH still further in dogs with metabolic acidosis, we desired to study the effect of chronic hypocapnia on the plasma bicarbonate concentration (and blood pH) in normal human subjects in whom acidosis had been induced with ammonium chloride. Methods. Under metabolic-balance conditions, we used altitude-induced hypobaric hypoxia to produce chronic hypocapnia in nine normal young men, five of whom received ammonium chloride daily to cause metabolic acidosis (the mean [+/- SE] steady-state plasma bicarbonate level in these five was 12.0 +/- 0.5 mmol per liter). Results. For each decrease of 1 mm Hg (0.13 kPa) in the PaCO2, the plasma bicarbonate concentration decreased by 0.41 mmol per liter in the subjects who started with a normal plasma bicarbonate concentration and by 0.42 mmol per liter in the subjects with acidosis. In contrast to the findings in previous studies of dogs, hypocapnia increased blood pH similarly in both groups; the blood hydrogen ion concentration decreased by about 0.4 nmol per liter for every decrease of 1 mm Hg (0.13 kPa) in PaCO2. Conclusions. These results provide reference data for the diagnosis of chronic respiratory alkalosis in humans. Although chronic hypocapnia decreased plasma bicarbonate levels similarly in normal subjects with acidosis and without acidosis, the percent reduction in PaCO2 was always greater than the corresponding percent reduction in the plasma bicarbonate concentration. Therefore, as was not true of the response in dogs, the subjects' blood pH always increased with hyperventilation, regardless of the initial plasma bicarbonate concentration.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,DIV NEPHROL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	KRAPF, R (corresponding author), INSELSPITAL BERN,DEPT MED,CH-3010 BERN,SWITZERLAND.							ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; ALTMAN PL, 1971, RESP CIRC, P12; ARBUS GS, 1969, NEW ENGL J MED, V280, P117, DOI 10.1056/NEJM196901162800301; BARKER ES, 1957, J CLIN INVEST, V36, P515, DOI 10.1172/JCI103449; BRACKETT NC, 1965, NEW ENGL J MED, V272, P6, DOI 10.1056/NEJM196501072720102; BRACKETT NC, 1969, NEW ENGL J MED, V280, P124, DOI 10.1056/NEJM196901162800302; BRAZEAU P, 1953, AM J PHYSIOL, V175, P33, DOI 10.1152/ajplegacy.1953.175.1.33; BURNELL JM, 1956, J CLIN INVEST, V35, P935, DOI 10.1172/JCI103352; COHEN JJ, 1976, J CLIN INVEST, V57, P1483, DOI 10.1172/JCI108418; COTLOVE E, 1961, CLIN CHEM, V7, P285; DEMPSEY JA, 1972, RESP PHYSIOL, V16, P213, DOI 10.1016/0034-5687(72)90052-7; DEMPSEY JA, 1974, J CLIN INVEST, V53, P1001; DICKINSON JG, 1987, BRIT MED J, V295, P1161, DOI 10.1136/bmj.295.6607.1161; DOUGLAS C. G., 1933, JOUR PHYSIOL, V78, P404, DOI 10.1113/jphysiol.1933.sp003012; DUGGAN J, 1982, CLIN CHEM, V28, P1407; FISHMAN AP, 1988, PULMONARY DISEASES D, V3; FORSTER HV, 1975, J APPL PHYSIOL, V38, P1067, DOI 10.1152/jappl.1975.38.6.1067; FORSTER HV, 1972, J APPL PHYSIOL, V32, P134, DOI 10.1152/jappl.1972.32.1.134; FORWAND SA, 1968, NEW ENGL J MED, V279, P839, DOI 10.1056/NEJM196810172791601; FOSTER LB, 1974, CLIN CHEM, V20, P365; GENNARI FJ, 1972, J CLIN INVEST, V51, P1722, DOI 10.1172/JCI106973; GIEBISCH G, 1955, J CLIN INVEST, V34, P231, DOI 10.1172/JCI103076; GLEDHILL N, 1975, KIDNEY INT, V8, P376, DOI 10.1038/ki.1975.130; GRIMBERT F, 1977, B EUR PHYSIOPATH RES, V13, P659; HELGER R, 1974, Z KLIN CHEM KLIN BIO, V12, P344; LOGSDON EE, 1960, ANN NY ACAD SCI, V87, P801, DOI 10.1111/j.1749-6632.1960.tb23237.x; MADIAS NE, 1977, J CLIN INVEST, V60, P1393, DOI 10.1172/JCI108900; MOSTELLAR ME, 1964, J CLIN INVEST, V43, P138, DOI 10.1172/JCI104888; OGIHARA T, 1977, J CLIN ENDOCR METAB, V45, P726, DOI 10.1210/jcem-45-4-726; RELMAN AS, 1953, J CLIN INVEST, V32, P972, DOI 10.1172/JCI102823; ROSENTHAL TB, 1948, J BIOL CHEM, V173, P25; SCHAMBELAN M, 1987, AM J PHYSIOL, V252, pE454, DOI 10.1152/ajpendo.1987.252.4.E454; SENDROY J, 1932, J BIOL CHEM, V106, P463; SEVERINGHAUS JW, 1956, J APPL PHYSIOL, V9, P197, DOI 10.1152/jappl.1956.9.2.197; SEVERINGHAUS JW, 1963, J APPL PHYSIOL, V18, P1155, DOI 10.1152/jappl.1963.18.6.1155; YOUNG DB, 1988, AM J PHYSIOL, V255, pF811, DOI 10.1152/ajprenal.1988.255.5.F811	36	94	95	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1394	1401		10.1056/NEJM199105163242003	http://dx.doi.org/10.1056/NEJM199105163242003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	1902283				2022-12-28	WOS:A1991FL12500003
J	WOOLHANDLER, S; HIMMELSTEIN, DU				WOOLHANDLER, S; HIMMELSTEIN, DU			THE DETERIORATING ADMINISTRATIVE EFFICIENCY OF THE UNITED-STATES HEALTH-CARE SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COST	Background and Methods. In 1983 the proportion of health care expenditures consumed by administration in the United States was 60 percent higher than in Canada and 97 percent higher than in Britain. To assess the effects of recent health policy initiatives on the administrative efficiency of health care, we examined four components of administrative costs in the United States and Canada for 1987: insurance overhead, hospital administration, nursing home administration, and physicians' billing and overhead expenses. Most data were provided by the two nations' federal health and statistics agencies, supplemented by state and provincial data and published sources. Because data on physicians' billing costs were limited, we estimated a range for these costs by two methods that rely on different sources of data. All figures are reported in 1987 U.S. dollars. Results. In 1987 health care administration cost between $96.8 billion and $120.4 billion in the United States, amounting to 19.3 to 24.1 percent of total spending on health care, or $400 to $497 per capita. In Canada, between 8.4 and 11.1 percent of health care spending ($117 to $156 per capita) was devoted to administration. Administrative costs in the United States increased 37 percent in real dollars between 1983 and 1987, whereas in Canada they declined. The proportion of health care spending consumed by administration is now at least 117 percent higher in the United States than in Canada and accounts for about half the total difference in health care spending between the two nations. If health care administration in the United States had been as efficient as in Canada, $69.0 billion to $83.2 billion would have been saved in 1987. Conclusions. The administrative structure of the U.S. healty care system is increasingly inefficient as compared with that of Canada's national health program. Recent health policies with the avowed goal of improving the efficiency of care have imposed substantial new bureaucratic costs and burdens.	CAMBRIDGE HOSP,DEPT MED,DIV SOCIAL & COMMUNITY MED,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,BOSTON,MA 02115; PUBL CITIZEN HLTH RES GRP,WASHINGTON,DC	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Harvard Medical School								BALLARD CL, 1985, NATL TAX J, V38, P125; BERRY CB, 1978, STUDY RESPONSES CANA; DICKENS C, 1896, STORIES CHRISTMAS NU; GERBER PC, 1990, PHYSICIANS MANAGE, V30, P32; GONZALEZ ML, 1989, SOCIOECONOMIC CHARAC; GUEST DB, 1985, LANCET, V2, P997; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; Kenkel P J, 1990, Mod Healthc, V20, P27; KENKEL PJ, 1990, MOD HEALTHCARE, V20, P32; Letsch S W, 1988, Health Care Financ Rev, V10, P109; MACEWAN A, 1982, REV RADICAL POL ECON, V14, P1; PARKER P, 1988, LANCET, V1, P1210; POULLIER JP, 1989, HLTH CARE FINANCING, V11, P111; REYNOLDS RA, 1983, SOCIOECONOMIC CHARAC; VAYDA E, 1989, Journal of Public Health Policy, V10, P359, DOI 10.2307/3342797; WOOLHANDLER S, 1988, INT J HEALTH SERV, V18, P393, DOI 10.2190/78J9-BWXL-Y6AL-45RA; 1988, CURRENT POPULATION S; 1989, MOD HEALTHCARE, V19, P32; 1989, 1988 89 ONT MIN HLTH; 1990, SUDOC GAOTHRD9016 US; 1988 1989 ZAHL BER; 1988, HOSPITAL STATISTICS; 1989, AGGREGATE LONG TERM; 1989, GESETZLICHE KRANKENV; 1989, AGGREGATE HOSPITAL F; 1981, STATISTICAL ABSTRACT; 1984, HOSPITAL STATISTICS; 1989, CANADIAN MED PROTECT; 1987, 1986 1987 REG ASS MA, P30; 1989, SMS REPORT, V3, P2; 1990, SUDOC GAOTHRD9042 US; 1986, 1985 86 SASK MED CAR; 1984, COMPENDIUM HLTH STAT; 1986, ANN STATISTICAL TABL, P3; 1989, MOD HEALTHCARE, V19, P64; 1990, BLUE CROSS BLUE SHIE; 1988, COST EFFECTS EXTENDI	37	261	262	2	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1253	1258		10.1056/NEJM199105023241805	http://dx.doi.org/10.1056/NEJM199105023241805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ823	1901623				2022-12-28	WOS:A1991FJ82300005
J	HENDEE, WR				HENDEE, WR			DRUG-ABUSE IN THE UNITED-STATES - STRATEGIES FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ALCOHOL; PROGRAMS	Efforts to curtail abuse of alcohol and other drugs concentrate on activities designed for supply-and-demand reduction. Many law enforcement and health officials agree that the reduction in supply of drugs cannot succeed as long as the demand for drugs for purposes of abuse occurs in a significant segment of society. Critical to reducing this demand is prevention. Only through an understanding of the correlates and risk factors associated with the use of alcohol and other drugs, along with the identification and implementation of sound strategies, can change occur. Although research has uncovered a considerable body of knowledge about the interplay of personal behavior, risk factors, and health in the prevention of substance abuse, many questions remain unanswered. Until those answers are known, efforts that have proven most effective need to be more widely emphasized.			HENDEE, WR (corresponding author), AMER MED ASSOC, SCI & TECHNOL GRP, 515 N STATE ST, CHICAGO, IL 60610 USA.							BACHMAN JG, 1988, J HEALTH SOC BEHAV, V29, P92, DOI 10.2307/2137183; Bandura A., 1977, SOCIAL LEARNING THEO, V1; BLUM RH, 1972, DREAM SELLERS; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BOTVIN GJ, 1990, ADDICT BEHAV, V15, P47, DOI 10.1016/0306-4603(90)90006-J; BOTVIN GJ, 1986, J SCHOOL HEALTH, V56, P369, DOI 10.1111/j.1746-1561.1986.tb05775.x; BRUNSWICK AF, 1979, YOUTH SOC, V11, P139, DOI 10.1177/0044118X7901100201; BUTYNSKI W, 1988, PUBLIC HEALTH REP, V103, P611; CLONINGER CR, 1983, J PSYCHIAT TREAT EV, V5, P487; COTTON NS, 1979, J STUD ALCOHOL, V40, P89, DOI 10.15288/jsa.1979.40.89; DESMOND DP, 1977, CONTEMP DRUG PROBL, V6, P41; FLAY BR, 1986, J SCHOOL HEALTH, V56, P402, DOI 10.1111/j.1746-1561.1986.tb05782.x; FLEMING JP, 1982, DRUG ALCOHOL DEPEN, V9, P285, DOI 10.1016/0376-8716(82)90068-0; GOLDSTEIN JW, 1977, AM J DRUG ALCOHOL AB, V4, P401, DOI 10.3109/00952997709002774; GOODSTADT MS, 1978, HEALTH EDUC QUART, V6, P263, DOI 10.1177/109019817800600301; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; Hawkins J D, 1985, NIDA Res Monogr, V56, P75; HEATH AC, 1989, J STUD ALCOHOL, V50, P38, DOI 10.15288/jsa.1989.50.38; HINDELANG MJ, 1973, SOC PROBL, V20, P471, DOI 10.1525/sp.1973.20.4.03a00070; Hirschi T., 2017, CAUSES DELINQUENCY; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; JESSOR R, 1975, J STUD ALCOHOL, V36, P27, DOI 10.15288/jsa.1975.36.27; JESSOR R, 1976, J CONSULT CLIN PSYCH, V44, P125; JESSOR R, 1977, PROBLEM BEHAVIOR PSY; JESSOR R, 1978, LONGITUDINAL RES DRU; JOHNSON CA, 1986, J SCHOOL HEALTH, V56, P364, DOI 10.1111/j.1746-1561.1986.tb05774.x; KANDEL DB, 1982, J AM ACAD CHILD PSY, V21, P328, DOI 10.1016/S0002-7138(09)60936-5; Kandel DB, 1978, LONGITUDINAL RES DRU, P73; Kandel DB, 1978, LONGITUDINAL RES DRU; KAUFMAN E, 1979, FAMILY THERAPY DRUG; KUMPFER KL, 1986, CHILDHOOD CHEM ABUSE; LEVY D, 1985, J PUBLIC POLICY MARK, V4, P47, DOI 10.1177/074391568500400104; LEVY D, 1983, J STUD ALCOHOL, V44, P929, DOI 10.15288/jsa.1983.44.929; LOEBER R, 1983, PSYCHOL BULL, V94, P68, DOI 10.1037/0033-2909.94.1.68; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; PENTZ MA, 1989, JAMA-J AM MED ASSOC, V261, P3259, DOI 10.1001/jama.261.22.3259; Robins L N, 1985, NIDA Res Monogr, V56, P178; ROBINS LN, 1978, PSYCHOL MED, V8, P611, DOI 10.1017/S0033291700018821; SCHMIDT W, 1981, BRIT J ADDICT, V76, P407; SCHONBERG S, 1988, SUBSTANCE ABUSE GUID; SWISHER JD, 1979, HDB DRUG ABUSE, P423; TOBLER NS, 1986, J DRUG ISSUES, V16, P537, DOI 10.1177/002204268601600405; 1989, SURGEON GENERALS WOR; 1990, 7TH US DEP HLTH HUM; 1987, DIAGNOSTIC STATISTIC; 1989, NATIONAL DRUG CONTRO; 1989, FED REG         0317, V54, P11278; 1990, NATIONAL DRUG CONTRO; 1988, CONTROLLING DRUG ABU; 1986, DRUG ABUSE DRUG ABUS, pCH2; 1982, NARINF19823 DIV NAR, P1	52	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2102	2107						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	1901609				2022-12-28	WOS:A1991FG90700029
J	GREEN, J; PASSMAN, LJ; WINTFELD, N				GREEN, J; PASSMAN, LJ; WINTFELD, N			ANALYZING HOSPITAL MORTALITY - THE CONSEQUENCES OF DIVERSITY IN PATIENT MIX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME; MEDICAL-CARE; PHYSICIANS; ILL	Consumers and payers increasingly demand data with which to evaluate health care providers. While publication of risk-adjusted hospital-specific death rates is one response, debate continues over whether higher than predicted mortality is a warning about quality of care or rather a reflection of a hospital's atypical patient population. To help inform this debate, we compared the characteristics of Medicare patients discharged from 187 hospitals that the Health Care Financing Administration (HCFA) had labeled "high-mortality outliers" with those of Medicare patients from 5373 hospitals not so designated. Hospitals were most likely to be flagged as high-mortality outliers by HCFA when they had large shares of very elderly patients (age greater-than-or-equal-to 85 years), patients with high-risk diagnoses, or patients requiring nursing home care. After adjustments were made to compensate for these biases, nearly half the hospitals flagged as outliers by HCFA were no longer so designated. Statistics purporting to measure effectiveness of care from hospital death rates should be modified to account for diversity in patient mix.	UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MED CTR,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	GREEN, J (corresponding author), NYU MED CTR,HLTH POLICY RES,550 1ST AVE,NEW YORK,NY 10016, USA.							BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BOWEN OR, 1987, HCFA01002 US DEP HLT; BOWEN OR, 1988, HCFA00651 US DEP HLT; DALY J, 1988, JAMA-J AM MED ASSOC, V260, P3617; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; GORDON WZ, 1985, J AM GERIATR SOC, V33, P519, DOI 10.1111/j.1532-5415.1985.tb04614.x; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HOPKINS JL, 1991, QRC ADVISOR, V7, P1; JENCKS SF, 1990, JAMA-J AM MED ASSOC, V263, P2679; KANE RL, 1983, MED CARE, V21, P1055, DOI 10.1097/00005650-198311000-00002; LEVY MR, 1984, WESTERN J MED, V140, P111; MALKIN S, 1976, CAN MED ASSOC J, V115, P129; MOTT PD, 1988, J AM GERIATR SOC, V36, P47, DOI 10.1111/j.1532-5415.1988.tb03433.x; NOYES R, 1977, J AM GERIATR SOC, V25, P470, DOI 10.1111/j.1532-5415.1977.tb00810.x; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROTH RM, 1985, AM FAM PHYSICIAN, V31, P131; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCHWARTZ DA, 1986, J AM GERIATR SOC, V34, P807, DOI 10.1111/j.1532-5415.1986.tb03986.x; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; SILVERMAN HA, 1990, HLTH CARE FINANC SPR, P99; SULLIVAN LW, 1989, HCFA00701 US DEP HLT; WAGNER L, 1990, MOD HEALTHCARE  1210, P20; WALSH S, 1988, EUR J SURG ONCOL, V14, P367; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; ZARIAN DA, 1989, J NATL MED ASSOC, V81, P373; 1990, DISCHARGES NURSING H; 1989, HOSP PEER REV, V14, P124; 1990, DISCHARGE DATA REV; 1990, PROGRAM NOTE MED TRE; 1989, RISK ADJUSTED 30 DAY; 1986, HCFA DATA PROFILES; 1989, HOSPITAL MORTALITY D; 1989, HE6189 PENNS HLTH CA, P1; 1988, GAOPEMD8829 US GEN A; 1988, 1988 AHA ANN SURVEY	38	67	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1849	1853						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1900894				2022-12-28	WOS:A1991FE86200026
J	ADELSTEIN, S; PRITCHARDBRISCOE, H; ANDERSON, TA; CROSBIE, J; GAMMON, G; LOBLAY, RH; BASTEN, A; GOODNOW, CC				ADELSTEIN, S; PRITCHARDBRISCOE, H; ANDERSON, TA; CROSBIE, J; GAMMON, G; LOBLAY, RH; BASTEN, A; GOODNOW, CC			INDUCTION OF SELF-TOLERANCE IN T-CELLS BUT NOT B-CELLS OF TRANSGENIC MICE EXPRESSING LITTLE SELF ANTIGEN	SCIENCE			English	Article							IMMUNOLOGICAL-TOLERANCE; LUPUS-ERYTHEMATOSUS; CLONAL ANALYSIS; LYMPHOCYTES-B; AUTOANTIBODIES; RECEPTOR; GENES; UNRESPONSIVENESS; DETERMINANT; SPECIFICITY	Self-tolerance to a transgene-encoded protein, hen egg lysozyme, was examined in the T and B cell repertoires of a series of lines of transgenic mice that expressed different serum concentrations of soluble lysozyme. T cells were tolerant in all lines in which lysozyme was expressed irrespective of the antigen concentration, whereas B cell tolerance did not occur when the serum lysozyme concentration was less than 1.5 nanograms per milliliter (0.1 nM). Induction of elevated transgene expression could restore B cell tolerance. These findings support the hypothesis that autoimmune disease may in some instances arise through a bypass of T cell tolerance.	UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL, LOS ANGELES, CA 90024 USA	University of Sydney; Centenary Institute; University of California System; University of California Los Angeles			Goodnow, Christopher C/V-8108-2018; Adelstein, Stephen/I-7936-2016	Goodnow, Christopher C/0000-0001-5296-6155; Adelstein, Stephen/0000-0001-7221-6298				ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ARNOLD B, 1990, IMMUNOL TODAY, V11, P69, DOI 10.1016/0167-5699(90)90026-6; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.immunol.7.1.513; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; GAMMON G, 1987, IMMUNOL REV, V98, P53; GOODNOW CC, 1989, COLD SPRING HARB SYM, V54, P907, DOI 10.1101/SQB.1989.054.01.106; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS DE, 1982, J EXP MED, V156, P567, DOI 10.1084/jem.156.2.567; IVERSON GM, 1972, EUR J IMMUNOL, V2, P195, DOI 10.1002/eji.1830020302; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCHEYZERWILLIAMS MG, 1988, J IMMUNOL, V141, P4118; MILLER JFAP, 1989, IMMUNOL REV, V107, P109, DOI 10.1111/j.1600-065X.1989.tb00005.x; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NELL LJ, 1989, J IMMUNOL, V142, P3063; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RAJEWSKY K, 1974, EUR J IMMUNOL, V4, P120, DOI 10.1002/eji.1830040211; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; REUTER R, 1986, P NATL ACAD SCI USA, V83, P8689, DOI 10.1073/pnas.83.22.8689; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SMITH RT, 1961, ADV IMMUNOL, V1, P67, DOI 10.1016/S0065-2776(08)60763-4; TERNYNCK T, 1986, IMMUNOL REV, V94, P99; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; Weigle W O, 1980, Adv Immunol, V30, P159; WHITELEY PJ, 1990, J IMMUNOL, V145, P1376; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	41	199	201	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1223	1225		10.1126/science.1900950	http://dx.doi.org/10.1126/science.1900950			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1900950				2022-12-28	WOS:A1991FA69100038
J	POLLOCK, DA; HOLMGREEN, P; LUI, KJ; KIRK, ML				POLLOCK, DA; HOLMGREEN, P; LUI, KJ; KIRK, ML			DISCREPANCIES IN THE REPORTED FREQUENCY OF COCAINE-RELATED DEATHS, UNITED-STATES, 1983 THROUGH 1988	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COUNTY; STATISTICS; PROGRAM; ABUSE	Objective. - To assess the validity of cocaine-related mortality data available from the principal federal sources of information about the frequency of drug abuse deaths in the United States: the national vital statistics system and the Drug Abuse Warning Network (DAWN). Design, Setting, and Participants. - We compared the number of cocaine-related deaths reported to national vital statistics and DAWN from 25 metropolitan areas during the years 1983 through 1988. We also compared cocaine-related mortality data reported to national vital statistics with data from all published forensic case series of cocaine-related deaths that occurred during the mid-1980s. Results. - During the 6-year study period, 75% more cocaine-related deaths were reported to DAWN (6057) than to national vital statistics (3466) from the 25 metropolitan areas that we studied. For individual metropolitan areas, the discrepancy between DAWN and vital statistics counts of cocaine-related deaths was as large as a sixfold difference. In six of the seven forensic case series identified in our literature search, the number of cocaine-related deaths exceeded the number of these deaths reported to vital statistics. The largest discrepancy was for cocaine-related deaths in New York, NY, during a 10-month period in 1986 for which 151 deaths were reported in a case series and seven deaths were reported to vital statistics. Conclusion. - Improvements in existing public health surveillance systems are needed for (1) full and accurate measurements of the lethal impact of drug abuse epidemics and (2) valid and comprehensive assessments of the effectiveness of national programs designed to prevent drug-related morbidity and mortality.			POLLOCK, DA (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,DIV INJURY CONTROL,ATLANTA,GA 30333, USA.							BACKENHEIMER MS, 1977, GUIDE INVESTIGATION, P1; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; BURLINGTON B, 1980, JAMA-J AM MED ASSOC, V243, P1036, DOI 10.1001/jama.1980.03300360012010; CHERUBIN CE, 1980, DRUGS RELATION DRUG, P173; Collins J., 1990, FEDERAL DRUG DATA NA; Cornwell P D, 1986, Med Leg Bull, V35, P1; FAGAN J, 1989, CONTEMP DRUG PROBL, V0016; FEATHERLY JW, 1989, CRACK COCAINE OVERVI; Goldstein P.J., 1989, CONTEMP DRUG PROBL, V16, P651; HEAGARTY MC, 1990, AJDC, V147, P756; HOOD I, 1990, J FORENSIC SCI, V35, P591; HOPKINS DD, 1989, AM J PUBLIC HEALTH, V79, P570, DOI 10.2105/AJPH.79.5.570; JAFFE J, 1989, DRUG ABUSE TREATMENT, pR9; JOHNSON BD, 1990, DRUGS CRIME, P9; KARCH SB, 1991, AM J FOREN MED PATH, V12, P1, DOI 10.1097/00000433-199103000-00001; KISSNER DG, 1987, AM REV RESPIR DIS, V136, P1250, DOI 10.1164/ajrccm/136.5.1250; Kozel N J, 1990, Bull Pan Am Health Organ, V24, P53; LETTIERI DJ, 1974, DRUG USE EPIDEMIOLOG, P159; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; MCKELWAY R, 1990, AM J PSYCHIAT, V147, P1667; MUSTO DF, 1987, AM DISEASE ORIGINS N; POIKOLAINEN K, 1981, BRIT J ADDICT, V76, P363; REAY DT, 1990, T ASSOC LIF, V73, P155; ROGERS JN, 1986, J FORENSIC SCI, V31, P1404; ROSENBERG HM, 1989, AM J PUBLIC HEALTH, V79, P563, DOI 10.2105/AJPH.79.5.563; SANDER R, 1985, J FORENSIC SCI, V30, P478; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; UNGERLEIDER JT, 1980, ARCH GEN PSYCHIAT, V37, P106; WETLI CV, 1987, COCAINE CLIN HDB, P33; 1990, DATA DRUG ABUSE WARN; 1984, DATA DRUG ABUSE WARN; 1990, HLTH PEOPLE 2000 NAT; 1987, DATA DRUG ABUSE WARN; 1990, WORKSHOP IMPROVING C; 1986, DATA DRUG ABUSE WARN; 1977, INT CLASSIFICATION D; 1985, DATA DRUG ABUSE WARN; 1988, DATA DRUG ABUSE WARN; 1989, DATA DRUG ABUSE WARN; 1983, VITAL STATISTICS MOR; 1987, DRUG ABUSE WARNING N; 1986, MED LETT DRUGS THER, V28, P69	42	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2233	2237		10.1001/jama.266.16.2233	http://dx.doi.org/10.1001/jama.266.16.2233			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920721				2022-12-28	WOS:A1991GK66100030
J	KHANKHOJE, M				KHANKHOJE, M			HER DAUGHTER, HER DOCTOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2067	2067						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920691				2022-12-28	WOS:A1991GJ47400013
J	MERRIAM, J; ASHBURNER, M; HARTL, DL; KAFATOS, FC				MERRIAM, J; ASHBURNER, M; HARTL, DL; KAFATOS, FC			TOWARD CLONING AND MAPPING THE GENOME OF DROSOPHILA	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; DEVELOPMENTALLY REGULATED GENES; YEAST ARTIFICIAL CHROMOSOMES; P-ELEMENT; DNA-MOLECULES; PHYSICAL MAP; INSERTIONAL MUTAGENESIS; MELANOGASTER GENOME; GEL-ELECTROPHORESIS; X-CHROMOSOME	An ultimate goal of Drosophila genetics is to identify and define the functions of all the genes in the organism. Traditional approaches based on the isolation of mutant genes have been extraordinary fruitful. Recent advances in the manipulation and analysis of large DNA fragments have made it possible to develop detailed molecular maps of the Drosophila genome as the initial steps in determining the complete DNA sequence.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; INST MOLEC BIOL & BIOTECHNOL,HERAKLION,GREECE; WASHINGTON UNIV,DEPT GENET,ST LOUIS,MO 63110; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	University of Cambridge; Washington University (WUSTL); Harvard University	MERRIAM, J (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.							Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; AJIOKA JW, 1991, CHROMOSOMA, V100, P495, DOI 10.1007/BF00352200; AKAM M, 1991, NATURE, V349, P282, DOI 10.1038/349282a0; ASHBURNER M, 1989, LABORATORY HDB; ASHBURNER M, 1991, INF SERV, V69; BELLEN HJ, 1990, J PHYSIOL-PARIS, V84, P33; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BLACKMAN RK, 1989, EMBO J, V8, P211, DOI 10.1002/j.1460-2075.1989.tb03366.x; BOUCHE JP, 1982, J MOL BIOL, V154, P21, DOI 10.1016/0022-2836(82)90414-4; Bridges CB, 1938, J HERED, V29, P11, DOI 10.1093/oxfordjournals.jhered.a104399; Bridges CB, 1935, J HERED, V26, P60, DOI 10.1093/oxfordjournals.jhered.a104022; BRIDGES CB, 1942, PUBL CARNEGIE I WASH, V552; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; COLLINS J, 1978, P NATL ACAD SCI USA, V75, P4242, DOI 10.1073/pnas.75.9.4242; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; DEVLIN RH, 1990, GENETICS, V125, P129; DIMITRI P, 1991, GENETICS, V127, P553; Dobzhansky T., 1937; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ENDOW SA, 1991, P NATL ACAD SCI USA, V88, P4424, DOI 10.1073/pnas.88.10.4424; FASANO L, 1991, CELL, V64, P63, DOI 10.1016/0092-8674(91)90209-H; Finnegan D J, 1986, Oxf Surv Eukaryot Genes, V3, P1; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; Goulding MD, 1989, CURR OPIN CELL BIOL, V1, P1088, DOI 10.1016/S0955-0674(89)80055-9; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; Hartl D., 1989, PRINCIPLES POPULATIO; HEALY MJ, 1988, MOL GEN GENET, V213, P63, DOI 10.1007/BF00333399; HEARN MG, 1991, GENETICS, V128, P785; Heitz E., 1934, Biologisches Zentralblatt Leipzig, V54, P588; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; ISING G, 1984, MOL GEN GENET, V196, P6, DOI 10.1007/BF00334085; JUDD BH, 1972, GENETICS, V71, P139; KAFATOS FC, 1991, TRENDS GENET, V7, P155, DOI 10.1016/0168-9525(91)90104-X; KAVENOFF R, 1973, CHROMOSOMA, V41, P1, DOI 10.1007/BF00284071; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lewontin RC, 1974, GENETIC BASIS EVOLUT; LINDSLEY DL, IN PRESS GENOME DROS; LINDSLEY DL, 1968, PUBLICATION CARNEGIE, V627; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; LOVERING R, 1991, GENETICS, V128, P357; MANNING JE, 1975, CELL, V4, P141, DOI 10.1016/0092-8674(75)90121-X; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MERRIAM J, 1990, GENETIC MAPS; MERRIAM J, 1986, DROS INFORM SERV, V63, P173; MIKLOS GLG, 1988, P NATL ACAD SCI USA, V85, P2051, DOI 10.1073/pnas.85.7.2051; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; Painter TS, 1933, SCIENCE, V78, P585, DOI 10.1126/science.78.2034.585; Painter TS, 1934, GENETICS, V19, P0175; Painter TS, 1934, J HERED, V25, P465, DOI 10.1093/oxfordjournals.jhered.a103862; PALAZZOLO MJ, IN PRESS P NATL ACAD; PARDUE ML, 1990, CHROMOSOMA, V100, P3, DOI 10.1007/BF00337597; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; RASCH EM, 1971, CHROMOSOMA, V33, P1, DOI 10.1007/BF00326379; ROBERTS DB, 1986, PRACTICAL APPROACH; ROSHBASH M, 1985, CELL, V43, P3; RUBIN GM, 1988, SCIENCE, V240, P1453, DOI 10.1126/science.3131880; RYKOWSKI MC, 1988, CELL, V54, P461, DOI 10.1016/0092-8674(88)90067-0; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SCALENGGHE F, 1981, CHROMOSOMA, V82, P805; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SIDENKIAMOS I, 1990, NUCLEIC ACIDS RES, V18, P6261, DOI 10.1093/nar/18.21.6261; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; SORSA V, 1988, CHROMOSOME MAPS DROS, V1; SPRADLING AC, 1981, ANNU REV GENET, V15, P219, DOI 10.1146/annurev.ge.15.120181.001251; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; Sturtevant Alfred, 1965, HIST GENETICS; TOMKIEL J, 1991, GENETICS, V128, P583; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WRIGHT C, 1991, NATURE, V350, P458, DOI 10.1038/350458a0; [No title captured]	87	76	76	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					221	225		10.1126/science.1925579	http://dx.doi.org/10.1126/science.1925579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925579				2022-12-28	WOS:A1991GJ64200028
J	PEARSON, PL; MAIDAK, B; CHIPPERFIELD, M; ROBBINS, R				PEARSON, PL; MAIDAK, B; CHIPPERFIELD, M; ROBBINS, R			THE HUMAN GENOME INITIATIVE - DO DATABASES REFLECT CURRENT PROGRESS	SCIENCE			English	Editorial Material							RECOMBINANT DNA TECHNIQUES; COMMITTEE; GENBANK				PEARSON, PL (corresponding author), JOHNS HOPKINS UNIV, SCH MED, WELCH LAB APPL RES ACAD INFORMAT, BALTIMORE, MD 21205 USA.		Chipperfield, Martyn/H-6359-2013	Chipperfield, Martyn/0000-0002-6803-4149				BRANSCOMB E, 1990, GENOMICS, V8, P3511; BURKS C, 1985, COMPUT APPL BIOSCI, V1, P225; BURKS C, 1990, METHOD ENZYMOL, V183, P3; CARRANO AV, 1989, GENOME, V31, P1059, DOI 10.1139/g89-182; CINKOSKY MJ, 1991, SCIENCE, V252, P1273, DOI 10.1126/science.1925538; Harnden DG, 1985, INT SYSTEM HUMAN CYT; KAHN P, 1990, METHOD ENZYMOL, V183, P23; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; PEARSON PL, 1987, CYTOGENET CELL GENET, V46, P390, DOI 10.1159/000132487; PEARSON PL, 1991, NUCLEIC ACIDS RES, V19, P2237, DOI 10.1093/nar/19.suppl.2237; SHOWS TB, 1987, CYTOGENET CELL GENET, V46, P11; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; STALLINGS RL, COMMUNICATION; STEPHENS JC, 1990, SCIENCE, V250, P237, DOI 10.1126/science.2218527; WILLARD HF, 1985, CYTOGENET CELL GENET, V40, P360, DOI 10.1159/000132180; 1990, US GENOME PROJECT 1S, P11	17	18	18	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1991	254	5029					214	215		10.1126/science.1925578	http://dx.doi.org/10.1126/science.1925578			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925578				2022-12-28	WOS:A1991GJ64200027
J	PTASHNE, M; EISEN, HN; CAIRNS, J; YANNOUTSOS, N				PTASHNE, M; EISEN, HN; CAIRNS, J; YANNOUTSOS, N			MORE VIEWS ON IMANISHI-KARI	NATURE			English	Discussion							HEAVY-CHAIN GENE; TRANSGENIC MICE; IMMUNOGLOBULIN		MIT,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Massachusetts Institute of Technology (MIT); Harvard University; Harvard T.H. Chan School of Public Health; MRC National Institute for Medical Research	PTASHNE, M (corresponding author), HARVARD UNIV,CAMBRIDGE,MA 02138, USA.							DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; EISEN HN, 1991, NATURE, V351, P343, DOI 10.1038/351343a0; IACOMINI, 1990, INT IMMUN, V3, P185; OTOOLE M, 1991, NATURE, V351, P180, DOI 10.1038/351180a0; RATH S, 1989, J IMMUNOL, V143, P2074; WEAVER D, 1986, CELL, V45, P247, DOI 10.1016/0092-8674(86)90389-2	6	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					101	102						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1906137				2022-12-28	WOS:A1991FW09700020
J	CHANT, J; CORRADO, K; PRINGLE, JR; HERSKOWITZ, I				CHANT, J; CORRADO, K; PRINGLE, JR; HERSKOWITZ, I			YEAST BUD5, ENCODING A PUTATIVE GDP-GTP EXCHANGE FACTOR, IS NECESSARY FOR BUD SITE SELECTION AND INTERACTS WITH BUD FORMATION GENE BEM1	CELL			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; CDC25 GENE; CELLULAR MORPHOGENESIS; BINDING PROTEINS; WILD-TYPE; RAS; ACTIN; PRODUCT; MUTANTS	Cells of the yeast S. cerevisiae choose bud sites in an axial or bipolar spatial pattern depending on their cell type. We have identified a gene, BUD5, that resembles BUD1 and BUD2 in being required for both patterns; bud5- mutants also exhibit random budding in all cell types. The BUD5 nucleotide sequence predicts a protein of 538 amino acids that has similarity to the S. cerevisiae CDC25 product, an activator of RAS proteins that catalyzes GDP-GTP exchange. Two potential targets of BUD5 are known: BUD1 (RSR1) and CDC42, proteins involved in bud site selection and bud formation, respectively, that have extensive similarity to RAS. We also show that BUD5 interacts functionally with a gene, BEM1, that is required for bud formation. This interaction provides further support for the view that products involved in bud site selection guide the positioning of a complex necessary for bud formation.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHANT, J (corresponding author), UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM31006, GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031006, R01GM031006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BANUETT F, 1987, J BACTERIOL, V169, P4076, DOI 10.1128/jb.169.9.4076-4085.1987; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENDER A, 1989, GENETICS, V121, P463; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CHANT J, 1991, CELL, V65; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANIEL J, 1987, MOL CELL BIOL, V7, P3857, DOI 10.1128/MCB.7.10.3857; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FINEGOLD AA, 1991, IN PRESS P NATL ACAD; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HERSKOWITZ IH, 1965, GENETICS; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LEVITZKI A, 1990, SCIENCE, V248, P794, DOI 10.1126/science.2188357; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Pringle J R, 1975, Methods Cell Biol, V11, P131, DOI 10.1016/S0091-679X(08)60320-9; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1987, METHOD ENZYMOL, V152, P481; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108; WILKINSON LE, 1974, EXP CELL RES, V89, P175, DOI 10.1016/0014-4827(74)90200-6	52	222	225	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1213	1224		10.1016/0092-8674(91)90016-R	http://dx.doi.org/10.1016/0092-8674(91)90016-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1905981	Green Published			2022-12-28	WOS:A1991FU89900013
J	VANLOHUIZEN, M; VERBEEK, S; SCHEIJEN, B; WIENTJENS, E; VANDERGULDEN, H; BERNS, A				VANLOHUIZEN, M; VERBEEK, S; SCHEIJEN, B; WIENTJENS, E; VANDERGULDEN, H; BERNS, A			IDENTIFICATION OF COOPERATING ONCOGENES IN E-MU-MYC TRANSGENIC MICE BY PROVIRUS TAGGING	CELL			English	Article							MURINE LEUKEMIA-VIRUS; T-CELL LYMPHOMAS; C-MYC; TRANSCRIPTION FACTOR; PUTATIVE ONCOGENE; NUCLEAR LOCATION; SACCHAROMYCES-CEREVISIAE; REGULATED EXPRESSION; V(D)J RECOMBINATION; VERTEBRATE NUCLEUS	Mo-MLV infection of E-mu-myc transgenic mice results in a dramatic acceleration of pre-B cell lymphomagenesis. We have used provirus tagging to identify genes that cooperate with the E-mu-myc transgene in B cell transformation. Here we report on the identification of four loci, pim-1, bmi-1, pal-1, and bla-1, which are occupied by proviruses in 35%, 35%, 28%, and 14% of the tumors, respectively. bmi-1, pal-1, and bla-1 represent novel common proviral insertion sites. The bmi-1 gene encodes a 324 amino acid protein with a predominantly nuclear localization. bmi-1 is highly conserved in evolution and contains several motifs frequently found in transcriptional regulators, including a new putative zinc finger motif. No genes have yet been assigned to pal-1 and bla-1. The distribution of proviruses over the four common insertion sites suggests that provirus tagging can be used not only to identify the cooperating oncogenes but also to assign these genes to distinct complementation groups in tumorigenesis.	UNIV AMSTERDAM,DEPT BIOCHEM,AMSTERDAM,NETHERLANDS	University of Amsterdam	VANLOHUIZEN, M (corresponding author), NETHERLANDS CANC INST,DIV MOLEC GENET,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BERG JM, 1987, COLD SPRING HARB SYM, V52, P579, DOI 10.1101/SQB.1987.052.01.066; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; COPELAND NG, 1991, TRENDS GENET, V7, P105; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; DAVIS BR, 1986, J VIROL, V60, P423, DOI 10.1128/JVI.60.2.423-430.1986; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DOMEN J, 1987, ONCOGENE RES, V1, P103; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; EVERETT RD, 1987, EMBO J, V6, P2069, DOI 10.1002/j.1460-2075.1987.tb02472.x; FRANKEL AD, 1988, CELL, V53, P675, DOI 10.1016/0092-8674(88)90083-9; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATTHEWS EA, 1989, INT J CANCER, V43, P1120, DOI 10.1002/ijc.2910430627; MCGINNIS W, 1984, CELL, V38, P675, DOI 10.1016/0092-8674(84)90262-9; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PATEL PI, 1986, MOL CELL BIOL, V6, P393, DOI 10.1128/MCB.6.2.393; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	79	671	706	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					737	752		10.1016/0092-8674(91)90382-9	http://dx.doi.org/10.1016/0092-8674(91)90382-9			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904008				2022-12-28	WOS:A1991FP51600005
J	EDDY, DM				EDDY, DM			OREGON PLAN - SHOULD IT BE APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2232, DOI 10.1001/jama.265.17.2232; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2505; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2498; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2140; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2501	8	36	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2439	&		10.1001/jama.266.17.2439	http://dx.doi.org/10.1001/jama.266.17.2439			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920751				2022-12-28	WOS:A1991GM79000034
J	BOYD, AS; NELDNER, KH				BOYD, AS; NELDNER, KH			PHOTOLOCALIZED VARICELLA IN AN ADULT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ZOSTER VIRUS				BOYD, AS (corresponding author), TEXAS TECH UNIV,HLTH SCI CTR,DEPT DERMATOL,LUBBOCK,TX 79430, USA.							ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; CASTROW FF, 1973, ARCH DERMATOL, V107, P628, DOI 10.1001/archderm.1973.01620190092026; FINDLAY GH, 1979, S AFR MED J, V55, P989; GILCHREST B, 1974, PEDIATRICS, V54, P136; GROSE C, 1978, INFECT IMMUN, V19, P199, DOI 10.1128/IAI.19.1.199-203.1978; PERNA JJ, 1987, J AM ACAD DERMATOL, V17, P473, DOI 10.1016/S0190-9622(87)70232-1	6	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2204	2204		10.1001/jama.266.16.2204	http://dx.doi.org/10.1001/jama.266.16.2204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920713				2022-12-28	WOS:A1991GK66100013
J	STEINGRIMSSON, E; PIGNONI, F; LIAW, GJ; LENGYEL, JA				STEINGRIMSSON, E; PIGNONI, F; LIAW, GJ; LENGYEL, JA			DUAL ROLE OF THE DROSOPHILA PATTERN GENE TAILLESS IN EMBRYONIC TERMINI	SCIENCE			English	Article							CROSS-REGULATORY INTERACTIONS; RECEPTOR TYROSINE KINASE; GAP GENES; TORSO; SEGMENTATION; REQUIREMENT; MUTATIONS; HUNCHBACK; ANTERIOR; PROTEIN	One of the first zygotically active genes required for formation of the terminal domains of the Drosophila embryo is tailless (tll). Expression of the tll gene is activated ectopically in gain-of-function mutants of the maternal terminal gene torso (tor); this suggests that tor normally activates the tll gene in the termini. Ectopic expression of tll under the control of an inducible promoter results in differentiation of ectopic terminal-specific structures, the Filzkorper, and leads to the activation of at least one gene, hunchback, that is required to form these structures. Ectopic expression of the tll gene also represses segmentation by repressing the gap genes Kruppel and knirps and probably also pair rule genes.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Steingrimsson, Eirikur/0000-0001-5826-7486	PHS HHS [09948] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1989, GENES EMBRYOS, P1; CAPMOSORTEGA JA, 1985, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; COULTER DE, 1988, GENE DEV, V2, P1812, DOI 10.1101/gad.2.12b.1812; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FOE VE, 1983, J CELL SCI, V61, P31; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JACKLE H, 1986, NATURE, V324, P668, DOI 10.1038/324668a0; KLINGER M, 1989, THESIS U TUBINGEN TU; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PIGNONI F, UNPUB; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; Wieschaus E., 1986, P199	37	100	100	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					418	421		10.1126/science.1925599	http://dx.doi.org/10.1126/science.1925599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925599				2022-12-28	WOS:A1991GK72900045
J	BLUMENTHAL, JA; SIEGEL, WC; APPELBAUM, M				BLUMENTHAL, JA; SIEGEL, WC; APPELBAUM, M			FAILURE OF EXERCISE TO REDUCE BLOOD-PRESSURE IN PATIENTS WITH MILD HYPERTENSION - RESULTS OF A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AEROBIC EXERCISE; PHYSICAL-ACTIVITY; ARTERIAL-HYPERTENSION; HIGH-INTENSITY; MEN; FITNESS; RESPONSES; STRESS	Objective. - To assess the effects of physical exercise training on blood pressure in patients with mild hypertension. Design. - Randomized controlled trial. Setting. - Hospital-based cardiac rehabilitation program. Patients. - Ninety-nine men and women with untreated mild hypertension (systolic blood pressure, 140 to 180 mm Hg; diastolic blood pressure, 90 to 105 mm Hg) were included in the volunteer sample. Interventions. - Subjects were randomly assigned to a 4-month program of aerobic exercise training, strength and flexibility training, or to a waiting list control group. Main Outcome Measures. - The main outcome measures were systolic and diastolic blood pressures measured four times with a random zero sphygmomanometer on 3 separate days in a clinic setting. Results. - After 4 months of exercise training, subjects in the aerobic exercise group did not exhibit greater reductions in blood pressure than subjects in the control group. We expected a differential decline of 5 mm Hg between the aerobic exercise and waiting list control groups and found a difference of -1.0 +/- 16 mm Hg and -1.2 +/- 10 mm Hg at alpha = .05 for systolic and diastolic blood pressure, respectively. Conclusions. - Moderate aerobic exercise alone should not be considered a replacement for pharmacologic therapy in nonobese patients with mild hypertension.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; NEW ENGLAND DEACONESS HOSP, DEPT MED, BOSTON, MA 02215 USA; VANDERBILT UNIV, GEORGE PEABODY COLL TEACHERS, DEPT PSYCHOL, NASHVILLE, TN 37203 USA	Duke University; Vanderbilt University; Vanderbilt University Peabody College	BLUMENTHAL, JA (corresponding author), DUKE UNIV, MED CTR, DEPT PSYCHIAT, BOX 3119, DURHAM, NC 27710 USA.				NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NHLBI NIH HHS [HL-30675, HL-43028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043028, R01HL030675] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN KL, 1956, ACTA MED SCAND, V153, P367; ASTRAND I, 1960, Acta Physiol Scand Suppl, V49, P1; BLAIR SN, 1984, JAMA-J AM MED ASSOC, V252, P487, DOI 10.1001/jama.252.4.487; BLUMENTHAL JA, 1990, AM J CARDIOL, V65, P93, DOI 10.1016/0002-9149(90)90032-V; BLUMENTHAL JA, 1988, AM J CARDIOL, V61, P26, DOI 10.1016/0002-9149(88)91298-2; BONANNO JA, 1974, AM J CARDIOL, V33, P760, DOI 10.1016/0002-9149(74)90218-5; BOYER JL, 1970, J AMER MED ASSOC, V211, P1668, DOI 10.1001/jama.211.10.1668; CADE R, 1984, AM J MED, V77, P785, DOI 10.1016/0002-9343(84)90513-8; CEDERHOLM J, 1986, ACTA MED SCAND, V219, P37; COOPER KH, 1976, JAMA-J AM MED ASSOC, V236, P166, DOI 10.1001/jama.236.2.166; CRIQUI MH, 1982, PREV MED, V11, P391, DOI 10.1016/0091-7435(82)90043-3; DUNCAN JJ, 1985, JAMA-J AM MED ASSOC, V254, P2609, DOI 10.1001/jama.254.18.2609; ERIKSSEN J, 1981, ACTA MED SCAND, P57; FRASER GE, 1983, CIRCULATION, V67, P405, DOI 10.1161/01.CIR.67.2.405; HAGBERG JM, 1983, AM J CARDIOL, V52, P763, DOI 10.1016/0002-9149(83)90412-5; HANSON JS, 1970, CIRC RES, V27, pI49; HICKEY N, 1975, BRIT MED J, V3, P507, DOI 10.1136/bmj.3.5982.507; HURLEY BF, 1984, MED SCI SPORT EXER, V16, P483, DOI 10.1249/00005768-198410000-00011; KENNEY WL, 1984, SPORTS MED, V1, P459, DOI 10.2165/00007256-198401060-00005; KIYONAGA A, 1985, HYPERTENSION, V7, P125, DOI 10.1161/01.HYP.7.1.125; KUKKONEN K, 1982, ANN CLIN RES, V14, P139; Leren P, 1975, Acta Med Scand Suppl, V588, P1; LIGHT KC, 1988, PSYCHOPHYSIOLOGY, V25, P107, DOI 10.1111/j.1469-8986.1988.tb00969.x; MARTIN JE, 1990, CIRCULATION, V81, P1560, DOI 10.1161/01.CIR.81.5.1560; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAFFENBARGER RS, 1968, AM J EPIDEMIOL, V88, P25, DOI 10.1093/oxfordjournals.aje.a120864; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PICKERING G, 1975, HYPERTENSION MANUAL; ROBERTS J, 1981, VITAL HLTH STAT 11, V221; ROMAN O, 1981, CARDIOLOGY, V67, P230, DOI 10.1159/000173248; ROSKIES E, 1986, HEALTH PSYCHOL, V5, P45, DOI 10.1037/0278-6133.5.1.45; Sannerstedt R, 1973, Clin Sci Mol Med Suppl, V45 Suppl 1, p145s; SEALS DR, 1984, MED SCI SPORT EXER, V16, P207; SIEGEL W C, 1991, Annals of Behavioral Medicine, V13, P23; SINYOR D, 1986, PSYCHOSOM MED, V48, P324, DOI 10.1097/00006842-198605000-00003; URATA H, 1987, HYPERTENSION, V9, P245, DOI 10.1161/01.HYP.9.3.245; VANHOOF R, 1989, AM J CARDIOL, V63, P945, DOI 10.1016/0002-9149(89)90145-8; WESTHEIM A, 1986, ACTA MED SCAND, P99; 1983, METROPOLITAN LIFE IN, V64, P2	39	149	150	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2098	2104		10.1001/jama.266.15.2098	http://dx.doi.org/10.1001/jama.266.15.2098			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920698				2022-12-28	WOS:A1991GJ47400030
J	HEALY, B				HEALY, B			CHEMOTHERAPY DURING CHILDHOOD DOES NOT ADVERSELY AFFECT OFFSPRING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, JAMA-J AM MED ASSOC, V325, P141	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-28	WOS:A1991GJ47400007
J	KELLEY, J; XU, QH				KELLEY, J; XU, QH			EXTREME SEXUAL DIMORPHISM IN A MIOCENE HOMINOID	NATURE			English	Article							BODY SIZE; EVOLUTION; VARIABILITY; MONKEYS; CHINA	SOME Miocene hominoids may have been extremely sexually dimorphic for body size, inferred from the apparent dimorphism of dental and gnathic remains 1-4. But this has never been demonstrated convincingly for any fossil species because of small sample sizes, uncertainties about the number of species in most fossil samples, and the inability to reliably sex individual specimens. Here we demonstrate a case of extreme dental dimorphism, and presumed body-size dimorphism, in a Miocene hominoid sample in which these limitations have been overcome. Lufengpithecus lufengensis from the late Miocene site of Lufeng, China, was more dimorphic than the most dimorphic living hominoid, the orangutan, and may have been more dimorphic than any living anthropoid.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912; ACAD SINICA,INST VERTEBRATE PALEONTOL & PALEOANTHROPOL,BEIJING 100044,PEOPLES R CHINA	Brown University; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS								DEMMENT MW, 1983, AFR J ECOL, V21, P219, DOI 10.1111/j.1365-2028.1983.tb00323.x; Fleagle J.G., 1984, P192; Fleagle JG, 1988, PRIMATE ADAPTATION E; JARMAN P, 1983, BIOL REV, V58, P485, DOI 10.1111/j.1469-185X.1983.tb00398.x; Jungers W.L., 1985, P345; KAY RF, 1988, AM J PHYS ANTHROPOL, V77, P385, DOI 10.1002/ajpa.1330770311; KAY RF, 1982, P NATL ACAD SCI-BIOL, V79, P209, DOI 10.1073/pnas.79.2.209; KELLEY J, 1989, AM J PRIMATOL, V18, P15, DOI 10.1002/ajp.1350180103; KELLEY J, 1986, J HUM EVOL, V15, P461, DOI 10.1016/S0047-2484(86)80028-8; KELLEY J, 1986, THESIS YALE U; Kelley J., 1986, COMP PRIMATE BIOL, P361; Leutenegger W., 1982, International Journal of Primatology, V3, P387, DOI 10.1007/BF02693740; LEUTENEGGER W, 1971, AM J PHYS ANTHROPOL, V35, P91, DOI 10.1002/ajpa.1330350111; LUCS PW, 1986, Z MORPHOL ANTHROPOL, V76, P253; Mahler P.E., 1973, METRIC VARIATION PON; Martin L.B., 1983, THESIS U LONDON; OXNARD CE, 1985, AM J PRIMATOL, V8, P127, DOI 10.1002/ajp.1350080205; Pickford M., 1986, HUM EVOL, V1, P111; PICKFORD M, 1986, HUM EVOL, V1, P77; PILBEAM D, 1986, AM ANTHROPOL, V88, P295, DOI 10.1525/aa.1986.88.2.02a00010; Pilbeam D. R., 1969, Bulletin of the Peabody Museum of Natural History, V31, P1; Plavcan J.M., 1990, THESIS DUKE U; POST D, 1978, AM J PHYS ANTHROPOL, V49, P533, DOI 10.1002/ajpa.1330490413; Shea B. T., 1986, HUM EVOL, V1, P97, DOI DOI 10.1007/BF02437489; Swindler DR, 1967, BABOON MED RES, VII, P133; SWINDLER DR, 1976, DETITION LIVING PRIM; WOOD BA, 1991, J HUM EVOL, V20, P291, DOI 10.1016/0047-2484(91)90012-K; WU R, 1983, NATURE, V306, P286; WU RK, 1983, AM J PRIMATOL, V5, P303, DOI 10.1002/ajp.1350050403; Wu Rukang, 1986, Acta Anthropologica Sinica, V5, P1; Wu Rukang, 1983, Acta Anthropologica Sinica, V2, P1; Xu Q, 1978, KEXUE TONGBAO, V9; XU QH, 1979, VERTEBRAT PALASIATIC, V17, P1	33	47	47	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1991	352	6331					151	153		10.1038/352151a0	http://dx.doi.org/10.1038/352151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FW097	1906139				2022-12-28	WOS:A1991FW09700054
J	IGLEHART, JK				IGLEHART, JK			GERMANY HEALTH-CARE SYSTEM .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ARNOLD M, 1982, MED PROFESSION FEDER; BRENNER G, IN PRESS HLTH AFF MI; DOHLER M, 1990, INT SOCIOLOGICAL ASS; GLASER WA, 1983, J HEALTH POLIT POLIC, V8, P352, DOI 10.1215/03616878-8-2-352; GLASER WA, IN PRESS HLTH INSURA; HURST JW, 1991, HLTH CARE FINANCE RE, V12, P75; IGLEHART JK, 1991, NEW ENGL J MED, V324, P506; KIRKMANLIFF BL, 1990, J HEALTH POLIT POLIC, V15, P69, DOI 10.1215/03616878-15-1-69; ORME M, 1990, EUR J CLIN PHARMACOL, V38, P101; REHER R, 1989, DRUG REFERENCE PRICE; RUBLEE DA, 1989, HEALTH AFFAIR, V8, P178, DOI 10.1377/hlthaff.8.3.178; SANDIER S, 1989, HLTH CARE FINANC R S, V10, P33; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; Schneider M, 1991, Health Care Financ Rev, V12, P87; SERMEUS G, 1989, DRUG PRICES DRUG LEG	15	36	36	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1750	1756		10.1056/NEJM199106133242428	http://dx.doi.org/10.1056/NEJM199106133242428			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ155	1903509				2022-12-28	WOS:A1991FQ15500032
J	KRUPNICK, AJ; PORTNEY, PR				KRUPNICK, AJ; PORTNEY, PR			CONTROLLING URBAN AIR-POLLUTION - A BENEFIT-COST ASSESSMENT	SCIENCE			English	Article							OZONE; QUALITY; EXPOSURE; EXERCISE	To help focus debate about the best use of society's resources, it is important to have estimates of the benefits and costs of further improvements in air quality. Such estimates are developed, with focus primarily on reductions in ground-level ozone resulting from the control of volatile organic compounds; to a lesser extent, particulate control also is considered. Proposed controls are evaluated for both the nation as a whole and for the Los Angeles metropolitan area, where violations of air quality standards are most frequent and severe. Subject to a number of uncertainties, the costs of proposed new controls are found to exceed the benefits, perhaps by a considerable margin.			KRUPNICK, AJ (corresponding author), RESOURCES FUTURE INC,WASHINGTON,DC 20036, USA.							ABBEY D, 1988, ANN M AIR POLLUTION; AVOL EL, 1984, JAPCA J AIR WASTE MA, V34, P804, DOI 10.1080/00022470.1984.10465814; BARRY BE, 1985, LAB INVEST, V53, P682; BARTLETT D, 1974, APPL PHYSL, V37, P92; CHAMEIDES WL, 1988, SCIENCE, V241, P1473, DOI 10.1126/science.3420404; DICKIE M, 1987, RECONCILING AVERTING; FEINSTEIN AR, 1988, SCIENCE, V242, P1257, DOI 10.1126/science.3057627; FISHER A, 1989, J POLICY ANAL MANAG, V8, P88, DOI 10.2307/3324426; Freeman A.M, 1979, BENEFITS ENV IMPROVE; Gramlich E. M, 1981, BENEFIT COST ANAL GO, P98; HALL JV, 1989, EC ASSESSMENT HLTH B; HARRISON D, 1988, EC IMPACTS DRAFT AIR; HAZILLA M, 1990, J POLIT ECON, V98, P853, DOI 10.1086/261709; HOLGUIN AH, 1984, AIR POLLUT CONTROL, P262; Kneese AV, 1984, MEASURING BENEFITS C; KNEESE AV, 1985, HDB NATURAL RESOURCE, P191; KRUPNICK AJ, 1990, J ENVIRON ECON MANAG, V18, P1, DOI 10.1016/0095-0696(90)90048-4; KRUPNICK AJ, 1987, ANAL SELECTED HLTH B; KRUPNICK AJ, 1990, COST EFFECTIVENESS E; KRUPNICK AJ, 1989, CATCHING OUR BREATH; KULLE TJ, 1985, AM REV RESPIR DIS, V132, P36; LINN W S, 1986, Toxicology and Industrial Health, V2, P99; LIPFERT FW, 1989, ENVIRON SCI TECHNOL, V23, P11; LIPFERT FW, 1989, ENV HLTH PERSPECT, V79, P3; LOEHMAN ET, 1979, J ENVIRON ECON MANAG, V6, P222, DOI 10.1016/0095-0696(79)90006-8; MCCONNELL VD, 1990, J ENVIRON MANAGE, V30, P1, DOI 10.1016/0301-4797(90)90033-S; MCDONNELL WF, 1983, J APPL PHYSIOL, V54, P1345, DOI 10.1152/jappl.1983.54.5.1345; NICHOLS A, 1990, BENEFITS 1989 AIR QU; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; PORTNEY PR, 1990, REG SCI URBAN ECON, V20, P407, DOI 10.1016/0166-0462(90)90019-Y; PORTNEY PR, 1990, J ECON PERSPECT, V4, P173, DOI 10.1257/jep.4.4.173; PORTNEY PR, 1986, J URBAN ECON, V20, P21, DOI 10.1016/0094-1190(86)90013-6; PORTNEY PR, 1988, ISSUES SCI TECHNOL, V4, P74; PORTNEY PR, 1990, PUBLIC POLICIES ENV, P68; Rowe R, 1986, BENEFITS AIR POLLUTI; Rowe R.D., 1985, EPA2300785010 EN RES; RUSSELL M, 1988, SCIENCE, V241, P1275, DOI 10.1126/science.3413490; SCHWARTZ J, 1989, JAPCA-INT J AIR POLL, V38, P158; SCHWARTZ J, 1985, EPA2300585006 PUBL; SEINFELD JH, 1988, JAPCA J AIR WASTE MA, V38, P616, DOI 10.1080/08940630.1988.10466404; TOLLEY G, 1986, VALUATION REDUCTIONS; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; 1991, EPA450491003 DOC; 1987, REV NATIONAL AMBIENT; 1990, EPA450490002 DOC; 1989, ATCHING OUR BREATH N; 1989, EPA REPORT CLEAN AIR; 1989, DRAFT 1988 AIR QUALI	48	71	71	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					522	528		10.1126/science.1902322	http://dx.doi.org/10.1126/science.1902322			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ127	1902322				2022-12-28	WOS:A1991FJ12700035
J	ROMEO, C; SEED, B				ROMEO, C; SEED, B			CELLULAR-IMMUNITY TO HIV ACTIVATED BY CD4 FUSED TO T-CELL OR FC RECEPTOR POLYPEPTIDES	CELL			English	Article							NATURAL-KILLER CELLS; RECOMBINANT SOLUBLE CD4; CLASS-II MHC; ANTIGEN RECEPTOR; ZETA-CHAIN; SURFACE EXPRESSION; MOLECULAR-CLONING; IMMUNODEFICIENCY VIRUS; TRANSFECTED CELLS; TRANS-ACTIVATOR	We describe functional simplified T cell and Fc receptor chimeras that are capable of directing CD8+ cytotoxic T lymphocytes (CTLs) to specifically recognize and lyse cells expressing HIV envelope proteins. Target cells bearing HLA-DR molecules are not recognized by CTL armed with the chimeras. The variety of cell types in which the native receptors are active suggests multiple possibilities for antiviral intervention through genetic means.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROMEO, C (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERKHOUT B, 1988, J BIOL CHEM, V263, P8528; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BOYLE DB, 1988, GENE, V65, P123, DOI 10.1016/0378-1119(88)90424-6; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; KUSTER H, 1990, J BIOL CHEM, V265, P6448; KUWANA Y, 1987, BIOCHEM BIOPH RES CO, V149, P960, DOI 10.1016/0006-291X(87)90502-X; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MERCEP M, 1988, SCIENCE, V242, P571, DOI 10.1126/science.2845582; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1990, SCI AM, V262, P62, DOI 10.1038/scientificamerican0590-62; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WATANABE M, 1989, NATURE, V337, P267, DOI 10.1038/337267a0; WEISS A, 1984, J IMMUNOL, V133, P123; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	69	354	400	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1037	1046		10.1016/0092-8674(91)90327-U	http://dx.doi.org/10.1016/0092-8674(91)90327-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900456				2022-12-28	WOS:A1991FA94000020
J	SEEMAN, H; TRAUBE, M				SEEMAN, H; TRAUBE, M			HICCUPS AND ACHALASIA	ANNALS OF INTERNAL MEDICINE			English	Note							GASTROESOPHAGEAL REFLUX		YALE UNIV, SCH MED, GASTROENTEROL UNIT, POB 3333, NEW HAVEN, CT 06510 USA	Yale University				traube, morris/0000-0002-7028-6695				FELDMAN M, 1988, AM J MED SCI, V295, P60, DOI 10.1097/00000441-198801000-00013; FISHER MJ, 1989, DIGEST DIS SCI, V34, P1277, DOI 10.1007/BF01537278; GLUCK M, 1986, ANN INTERN MED, V105, P219, DOI 10.7326/0003-4819-105-2-219; GOLDENBERG SP, 1991, GASTROENTEROLOGY, V101, P743, DOI 10.1016/0016-5085(91)90534-R; KAUFMANN HJ, 1982, GASTROENTEROLOGY, V82, P1443; LEWIS JH, 1985, J CLIN GASTROENTEROL, V7, P539, DOI 10.1097/00004836-198512000-00021; MARSHALL JB, 1990, AM J GASTROENTEROL, V85, P1172; SHAY SS, 1984, GASTROENTEROLOGY, V87, P204	8	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1991	115	9					711	712		10.7326/0003-4819-115-9-711	http://dx.doi.org/10.7326/0003-4819-115-9-711			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL697	1929039				2022-12-28	WOS:A1991GL69700008
J	CELIN, SE; BLUESTONE, CD; STEPHENSON, J; YILMAZ, HM; COLLINS, JJ				CELIN, SE; BLUESTONE, CD; STEPHENSON, J; YILMAZ, HM; COLLINS, JJ			BACTERIOLOGY OF ACUTE OTITIS-MEDIA IN ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILUS-INFLUENZAE; MIDDLE-EAR; CHEMOTHERAPY; CHILDREN	Objective. - The objective of this study was to determine the bacteriology of acute otitis media in adults. Although this has frequently been studied in children, no data have recently been reported from adults in the United States. Additionally, information on the prevalence of Haemophilus influenzae as a causative organism in acute otitis media in adults has not been available. Design. - Middle-ear aspirates for cultures were obtained by myringotomy from adults meeting entry criteria. Setting. - Emergency department, Eye and Ear Hospital of Pittsburgh, Pa. Patients. - Thirty-four patients (volunteer sample) met the eligibility requirements. Exclusion criteria included history of chronic otitis media, recent antibiotic therapy, immunosuppressive illnesses, or prior otologic surgery. Intervention. - Ten days of oral cefuroxime axetil (250 mg) was prescribed. Main Outcome Measures.-Patients were followed closely for at least 6 weeks. Aerobic and anaerobic cultures were incubated and evaluated per the scheduled protocol. Results. - Haemophilus influenzae and Streptococcus pneumoniae were grown on culture of specimens f rom nine and seven patients (26% and 21 %), respectively Twenty-two percent (2/9) of the H influenzae isolates and the single isolate of Moraxella catarrhalis produced beta-lactamase (9% overall). Conclusions. - The present results suggest that, as in children, amoxicillin would be an appropriate first-line agent for empiric therapy of acute otitis media in adults. Antimicrobials inactive against H influenzae (eg, penicillin V, cephalexin, erythromycin, or tetracyclines) are not appropriate for initial therapy. Antimicrobials with efficacy against organisms producing beta-lactamase, such as cefuroxime axetil, which was used to treat the study patients, do not appear to be required for routine initial therapy in adults. However, they would be appropriate when an organism producing beta-lactamase is isolated from the middle ear or when a patient fails to improve rapidly on amoxicillin therapy.	UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,DIV PEDIAT OTOLARYNGOL,PITTSBURGH,PA 15261; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT OTOLARYNGOL,MICROBIOL LAB,PITTSBURGH,PA; GLAXO INC,RES INST,DEPT CLIN RES,RES TRIANGLE PK,NC	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; GlaxoSmithKline								Bluestone, 1990, PEDIATRIC OTOLARYNGO, P320; BRANEFORSHELANDER P, 1975, SCAND J INFECT DIS, V7, P103, DOI 10.3109/inf.1975.7.issue-2.05; CHONMAITREE T, 1986, PEDIATRICS, V77, P698; DADSWELL JV, 1967, LANCET, V1, P243; DUDLEY JP, 1980, JAMA-J AM MED ASSOC, V243, P2328; HAUGSTEN P, 1980, J LARYNGOL OTOL, V94, P169, DOI 10.1017/S0022215100088630; HERBERTS G, 1971, PRACT-OTO-RHINO-LARY, V33, P191; HOWIE VM, 1970, PEDIATRICS, V45, P29; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KLEIN JO, 1980, ANN OTOL RHINOL LA S, V89, pS98; SCHWARTZ R, 1977, JAMA-J AM MED ASSOC, V238, P1032, DOI 10.1001/jama.238.10.1032; Schwartz R H, 1981, Am J Otolaryngol, V2, P19, DOI 10.1016/S0196-0709(81)80004-X; SHAMBAUGH GE, 1980, OTOLARYNGOLOGY, V2, P1448; STIERNBERG CM, 1986, OTOLARYNG HEAD NECK, V94, P648; SUGITA R, 1983, INT J PEDIATR OTORHI, V6, P135; SUGITA R, 1985, J LARYNGOL OTOL, V99, P629, DOI 10.1017/S0022215100097395; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; [No title captured]	18	32	33	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2249	2252		10.1001/jama.266.16.2249	http://dx.doi.org/10.1001/jama.266.16.2249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK661	1920724				2022-12-28	WOS:A1991GK66100033
J	SUTTER, TR; GUZMAN, K; DOLD, KM; GREENLEE, WF				SUTTER, TR; GUZMAN, K; DOLD, KM; GREENLEE, WF			TARGETS FOR DIOXIN - GENES FOR PLASMINOGEN-ACTIVATOR INHIBITOR-2 AND INTERLEUKIN-1-BETA	SCIENCE			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTORS; CDNA CLONING; CELL-LINE; C-FOS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; EXPRESSION; MOUSE; DIFFERENTIATION	Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD), a widespread environmental contaminant, may elicit its effects by altering gene expression in susceptible cells. Five TCDD-responsive complementary DNA clones were isolated from a human keratinocyte cell line. One of these clones encodes plasminogen activator inhibitor-2, a factor that influences growth and differentiation by regulating proteolysis of the extracellular matrix. Another encodes the cytokine interleukin-1-beta. Thus, TCDD alters the expression of growth regulatory genes and has effects similar to those of other tumor-promoting agents that affect both inflammation and differentiation.	CHEM IND INST TOXICOL,RES TRIANGLE PK,NC 27709									ABBOTT BD, 1989, TOXICOL APPL PHARM, V100, P119, DOI 10.1016/0041-008X(89)90096-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bailar J C 3rd, 1991, N Engl J Med, V324, P260, DOI 10.1056/NEJM199101243240409; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; Bravo R, 1990, Semin Cancer Biol, V1, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOK JC, 1987, ENVIRON HEALTH PERSP, V76, P71, DOI 10.2307/3430467; DINARELLO CA, 1989, B NEW YORK ACAD MED, V65, P80; DOLD KM, 1990, ANAL BIOCHEM, V184, P67, DOI 10.1016/0003-2697(90)90013-Y; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNIGAN DD, 1987, BIOTECHNIQUES, V5, P32; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; GOUGH M, 1988, RISK ANAL, V8, P337, DOI 10.1111/j.1539-6924.1988.tb00496.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HART DA, 1988, COMP BIOCHEM PHYS B, V90, P691, DOI 10.1016/0305-0491(88)90323-9; HUDSON LG, 1986, TOXICOL APPL PHARM, V82, P481, DOI 10.1016/0041-008X(86)90283-8; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; LAIHO M, 1989, CANCER RES, V49, P2533; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NISHIDA T, 1987, BIOCHEM BIOPH RES CO, V143, P345, DOI 10.1016/0006-291X(87)90671-1; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PHILLIPS CL, 1988, MOL ENDOCRINOL, V2, P641, DOI 10.1210/mend-2-7-641; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PRATT RM, 1984, TERATOGEN CARCIN MUT, V4, P427, DOI 10.1002/tcm.1770040505; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; SUTTER TR, UNPUB; Taylor J S, 1979, Ann N Y Acad Sci, V320, P295, DOI 10.1111/j.1749-6632.1979.tb13155.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YE RD, 1987, J BIOL CHEM, V262, P3718	55	305	312	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					415	418		10.1126/science.1925598	http://dx.doi.org/10.1126/science.1925598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925598				2022-12-28	WOS:A1991GK72900044
J	HEALY, B				HEALY, B			BONE-MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, ANN INTERN MED, V115, P13	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2054	2054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920686				2022-12-28	WOS:A1991GJ47400006
J	KRAVITZ, RL; ROLPH, JE; MCGUIGAN, K				KRAVITZ, RL; ROLPH, JE; MCGUIGAN, K			MALPRACTICE CLAIMS DATA AS A QUALITY IMPROVEMENT TOOL .1. EPIDEMIOLOGY OF ERROR IN 4 SPECIALTIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFESSIONAL LIABILITY; DIAGNOSTIC-RADIOLOGY; MEDICAL MALPRACTICE; ANESTHESIA; INJURY; CARE	Objective. - To identify potentially preventable sources of medical injury in obstetrics and gynecology, general surgery, anesthesiology, and radiology. Design. - Retrospective review of physician malpractice claim records. Setting. - Large New Jersey physician malpractice insurer. Participants. - Physicians practicing obstetrics and gynecology, general surgery, anesthesiology, and radiology and covered by the insurance carrier during any portion of 1977 through 1989. Main Outcome Measures. - Proportion of claims due to negligence associated with errors in (1) patient management, (2) technical performance, and (3) medical and nursing staff coordination and the clinical and financial consequences of such errors. Results. - Among 1371 claims ascribed to negligence, patient management errors were cited most frequently in all four specialties (48% to 75%) and, compared with performance and coordination problems, were generally associated with a higher frequency of serious injury and higher median payments. Coordination problems accounted for about 9% of claims. In obstetrics and gynecology, newborn delivery claims usually arose from management errors (57% to 68%), whereas gynecologic procedure claims were most often associated with performance errors (55% to 73%). Underperformance of cesarean section was cited more frequently than overperformance (31% vs 3%). General surgery claims were about equally divided between management and performance types regardless of procedure. Failure to perform appropriate diagnostic testing or monitoring was the main problem in 3% to 8% of claims. Conclusion. - Malpractice data can be used to identify problem-prone clinical processes and suggest interventions that may reduce negligence.	UNIV CALIF LOS ANGELES,SCH MED,DIV GEN INTERNAL MED & HLTH SERV RES,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	KRAVITZ, RL (corresponding author), RAND CORP,HLTH PROGRAM,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90406, USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				BERLIN L, 1977, RADIOLOGY, V123, P523, DOI 10.1148/123.2.523; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; DAHLEN RT, 1989, RADIOLOGY, V170, P277, DOI 10.1148/radiology.170.1.2909111; DAVIS DA, 1984, INT ANESTHESIOL CLIN, V22, P31, DOI 10.1097/00004311-198408000-00005; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; EICHHORN JH, 1989, ANESTHESIOLOGY, V70, P572, DOI 10.1097/00000542-198904000-00002; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; Garg M L, 1978, Leg Aspects Med Pract, V6, P25; HAMER MM, 1987, RADIOLOGY, V164, P263, DOI 10.1148/radiology.164.1.3588916; HERMAN PG, 1975, CHEST, V68, P278, DOI 10.1378/chest.68.3.278; Holder A R, 1972, JAMA, V222, P121; Julian T M, 1985, Am J Perinatol, V2, P320, DOI 10.1055/s-2007-999980; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEHMANN EL, 1975, NONPARAMETRICS; LEHR JL, 1976, RADIOLOGY, V118, P257, DOI 10.1148/118.2.257; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; MERRICK NJ, 1986, R32046CWFHF RAND COR; MILLS DH, 1963, JAMA-J AM MED ASSOC, V183, P1073; OGBURN PL, 1988, J REPROD MED, V33, P608; PEARSE WH, 1988, CLIN OBSTET GYNECOL, V31, P148; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; REYNOLDS RA, 1983, SOCIOECONOMIC CHARAC; ROLPH JE, 1991, JAMA-J AM MED ASSOC, V266, P2093, DOI 10.1001/jama.266.15.2093; SANDERS PS, 1987, MINN MED, V70, P708; SOLAZZI RW, 1984, INT ANESTHESIOL CLIN, V22, P43, DOI 10.1097/00004311-198408000-00006; TANCREDI LR, 1978, SCIENCE, V200, P879, DOI 10.1126/science.644329; Weinstein MC, 1980, CLIN DECISION ANAL; ZEITLIN GL, 1989, ANAESTHESIA, V44, P432, DOI 10.1111/j.1365-2044.1989.tb11347.x; 1985, DATA SHARING SYSTEM; 1980, MALPRACTICE CLAIMS 2; 1989, PIAA DATA SHARING RE; 1989, PHYSICIANS SURGEONS; 1985, PROFESSIONAL LIABILI; 1987, RISK PREVENTION MED; 1977, MED INSURANCE FEASIB; 1990, PATIENTS DOCTORS LAW; 1986, GAOHRD87021 PUBL; 1984, PROFESSIONAL LIABILI	38	74	74	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2087	2092		10.1001/jama.266.15.2087	http://dx.doi.org/10.1001/jama.266.15.2087			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920696				2022-12-28	WOS:A1991GJ47400028
J	HALPIN, SFS; YEOMAN, L; DUNDAS, DD				HALPIN, SFS; YEOMAN, L; DUNDAS, DD			RADIOGRAPHIC EXAMINATION OF THE LUMBAR SPINE IN A COMMUNITY-HOSPITAL - AN AUDIT OF CURRENT PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSTIC-RADIOLOGY; ROYAL-COLLEGE; GUIDELINES	Objective - To assess general practitioners' decisions to request lumbar spine radiographs according to the guidelines of the Royal College of Radiologists. Design - Prospective questionnaire survey of outpatients attending for lumbar spine radiography. Setting - London community hospital. Subjects - 100 consecutive adult outpatients attending for lumbar spine radiography at their general practitioner's request. Main outcome measures - Patient's history and clinical signs; radiological diagnosis; change in management of patients with significant radiological abnormality in response to the radiologist's report. Results - 60 patients were aged between 18 and 45, 27 (45%) of whom were women. Five patients were fully examined by their doctor before radiographs were requested, 76 were partially examined, and 19 were not examined. In 37 patients the examinations showed radiologically normal findings; 30 had radiologically significant disc or degenerative disease. Pain score and radiological diagnosis was not correlated (6.43 (range 1-10) for patients with significant disease v 6.14 (range 1-10) for those without, p > 0.05). There were no cases of malignancy or infection. One patient with radiologically significant disease was referred to a hospital specialist, and the management of only two such patients was altered by the report. 52 of the examinations should not have been requested if the guidelines had been strictly applied. Conclusions - There is a need to inform doctors of the efficacy of radiological examinations. An awareness of the college's guidelines among general practitioners should be actively promoted by radiologists.	BOLINGBROKE HOSP,DEPT RADIOL,LONDON SW11,ENGLAND									BUTT WP, 1989, CLIN RADIOL, V40, P6, DOI 10.1016/S0009-9260(89)80004-2; Edelstyn G A, 1967, Clin Radiol, V18, P158, DOI 10.1016/S0009-9260(67)80010-2; FOWKES FGR, 1987, CLIN RADIOL, V38, P45, DOI 10.1016/S0009-9260(87)80399-9; FOWKES FGR, 1984, LANCET, V2, P795; Her Majesty's Stationery Office, 1985, IONISING RAD REGULAT; KELEN GD, 1986, ANN EMERG MED, V15, P245, DOI 10.1016/S0196-0644(86)80556-X; NACHEMSON A, 1976, LUMBAR SPINE BACK PA, P355; PEARSON R, 1989, BRIT MED J, V299, P1175, DOI 10.1136/bmj.299.6709.1175; QUINET RJ, 1979, SEMIN ARTHRITIS RHEU, V8, P261, DOI 10.1016/0049-0172(79)90005-2; ROBERTS CJ, 1984, J ROY COLL PHYS LOND, V18, P62; ROBERTS CJ, 1981, LANCET, V2, P791; ROBERTS CJ, 1988, CLIN RADIOL, V39, P3, DOI 10.1016/S0009-9260(88)80325-8; RYAN M, 1991, RES MED PRACTICE VAR; WADDELL G, 1982, BRIT J HOSP MED, V28, P187; 1989, NRPBR227; 1990, PATIENT DOSE REDUCTI; 1987, NATIONAL RADIOLOGI S, V86; 1986, NRPBR200; 1990, MAKING BEST IMAGING; 1989, LIVING RAD; 1989, MAKING BEST USE DEP	21	40	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 5	1991	303	6806					813	815		10.1136/bmj.303.6806.813	http://dx.doi.org/10.1136/bmj.303.6806.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH946	1932970	Bronze, Green Published			2022-12-28	WOS:A1991GH94600020
J	GRENNINGLOH, G; REHM, EJ; GOODMAN, CS				GRENNINGLOH, G; REHM, EJ; GOODMAN, CS			GENETIC-ANALYSIS OF GROWTH CONE GUIDANCE IN DROSOPHILA - FASCICLIN-II FUNCTIONS AS A NEURONAL RECOGNITION MOLECULE	CELL			English	Article							CELL-ADHESION MOLECULE; GRASSHOPPER EMBRYOS; IMMUNOGLOBULIN SUPERFAMILY; AXON PATHWAYS; SELECTIVE FASCICULATION; MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; NCAM; PROTEINS; SEQUENCE	fascilin II (fas II), a member of the immunoglobulin superfamily, was previously characterized and cloned in grasshopper. To analyze the function of this molecule, we cloned the Drosophila fas II homolog and generated mutants in the gene. In both grasshopper and Drosophila, fasciclin II is expressed on the MP1 fascicle and a subset of other axon pathways. In fas II mutant Drosophila embryos, the CNS displays no gross phenotype, but the MP1 fascicle fails to develop. The MP1, dMP2, and vMP2 growth cones fail to recognize one another or other axons that normally join the MP1 pathway. During their normal period of axon outgrowth, these growth cones stall and do not join any other neighboring pathway. Thus, fasciclin II functions as a neuronal recognition molecule for the MP1 axon pathway. These studies serve as molecular confirmation for the existence of functional labels on specific axon pathways in the developing nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GRENNINGLOH, G (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.				NICHD NIH HHS [HD21294] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021294, R01HD021294] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BASTIANI MJ, 1985, TRENDS NEUROSCI, V8, P257, DOI 10.1016/0166-2236(85)90099-2; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1986, J NEUROSCI, V6, P3518; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOE CQ, 1986, J NEUROSCI, V6, P3552; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DULAC S, 1986, J NEUROSCI, V6, P3532; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HYNES RO, 1986, ANN REV CELL BIOL, V1, P67; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KUWADA JY, 1986, SCIENCE, V233, P740, DOI 10.1126/science.3738507; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RAPER JA, 1983, J NEUROSCI, V3, P20; RAPER JA, 1983, COLD SPRING HARB SYM, V48, P587, DOI 10.1101/SQB.1983.048.01.063; RAPER JA, 1984, J NEUROSCI, V4, P2329; RAPER JA, 1983, J NEUROSCI, V3, P31; ROBERTSON HM, 1988, GENETICS, V118, P461; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1987, NUCLEIC ACIDS RES, V15, P8621, DOI 10.1093/nar/15.21.8621; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SNOW PM, 1988, P NATL ACAD SCI USA, V85, P5291, DOI 10.1073/pnas.85.14.5291; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; THANOS S, 1984, P NATL ACAD SCI-BIOL, V81, P1906, DOI 10.1073/pnas.81.6.1906; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITLOCK KE, 1991, IN PRESS SOC NEUROSC; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	46	409	411	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					45	57		10.1016/0092-8674(91)90571-F	http://dx.doi.org/10.1016/0092-8674(91)90571-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913818				2022-12-28	WOS:A1991GJ32000006
J	ERVASTI, JM; CAMPBELL, KP				ERVASTI, JM; CAMPBELL, KP			MEMBRANE ORGANIZATION OF THE DYSTROPHIN-GLYCOPROTEIN COMPLEX	CELL			English	Article							RABBIT SKELETAL-MUSCLE; DUCHENNE MUSCULAR-DYSTROPHY; MOLECULE N-CAM; SARCOPLASMIC-RETICULUM; CELL-ADHESION; ULTRASTRUCTURAL-LOCALIZATION; 1,4-DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; PROTEINS; IDENTIFICATION	The stoichiometry, cellular location, glycosylation, and hydrophobic properties of the components in the dystrophin-glycoprotein complex were examined. The 156, 59, 50, 43, and 35 kd dystrophin-associated proteins each possess unique antigenic determinants, enrich quantitatively with dystrophin, and were localized to the skeletal muscle sarcolemma. The 156, 50, 43, and 35 kd dystrophin-associated proteins contained Asn-linked oligosaccharides. The 156 kd dystrophin-associated glycoprotein contained terminally sialylated Ser/Thr-linked oligosaccharides. Dystrophin, the 156 kd, and the 59 kd dystrophin-associated proteins were found to be peripheral membrane proteins, while the 50 kd, 43 kd, and 35 kd dystrophin-associated glycoproteins and the 25 kd dystrophin-associated protein were confirmed as integral membrane proteins. These results demonstrate that dystrophin and its 59 kd associated protein are cytoskeletal elements that are tightly linked to a 156 kd extracellular glycoprotein by way of a complex of transmembrane proteins.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa	ERVASTI, JM (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA.		Ervasti, James/AAZ-4786-2020; Pillay, Nischalan/F-9536-2012	Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1991, INT CONGR SER, P321; Carney S.L., 1986, CARBOHYDRATE ANAL, P97; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHANG HW, 1989, J BIOL CHEM, V264, P20831; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CULLEN MJ, 1990, PROC R SOC SER B-BIO, V240, P197, DOI 10.1098/rspb.1990.0034; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOLDEN KG, 1971, BIOCHEMISTRY-US, V10, P3105, DOI 10.1021/bi00792a019; JAY SD, 1991, J BIOL CHEM, V266, P3287; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JORGENSEN AO, 1990, J CELL BIOL, V110, P1173, DOI 10.1083/jcb.110.4.1173; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEBERER E, 1990, J BIOL CHEM, V265, P10118; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MOORE SE, 1987, J CELL BIOL, V105, P1377, DOI 10.1083/jcb.105.3.1377; MURAYAMA T, 1990, P JPN ACAD B-PHYS, V66, P96, DOI 10.2183/pjab.66.96; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P829; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SHARP AH, 1989, J BIOL CHEM, V264, P2816; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH FS, 1989, DEVELOPMENT, V105, P803; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZARAINHERZBERG A, 1988, J BIOL CHEM, V263, P4807; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	49	1127	1145	2	62	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 20	1991	66	6					1121	1131		10.1016/0092-8674(91)90035-W	http://dx.doi.org/10.1016/0092-8674(91)90035-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913804				2022-12-28	WOS:A1991GG55200007
J	WILLIFORD, WO				WILLIFORD, WO			PERIOPERATIVE TOTAL PARENTERAL-NUTRITION IN SURGICAL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. We undertook this study to test the hypothesis that perioperative total parenteral nutrition (TPN) decreases the incidence of serious complications after major abdominal or thoracic surgical procedures in malnourished patients. Methods. We studied 395 malnourished patients (99 percent of them male) who required laparotomy or noncardiac thoracotomy. They were randomly assigned to receive either TPN for 7 to 15 days before surgery and 3 days afterward (the TPN group) or no perioperative TPN (the control group). The patients were monitored for complications for 90 days after surgery. Results. The rates of major complications during the first 30 days after surgery in the two groups were similar (TPN group, 25.5 percent; control group, 24.6 percent), as were the overall 90-day mortality rates (13.4 percent and 10.5 percent, respectively). There were more infectious complications in the TPN group than in the controls (14.1 vs. 6.4 percent; P = 0.01; relative risk, 2.20; 95 percent confidence interval, 1.19 to 4.05), but slightly more noninfectious complications in the control group (16.7 vs. 22.2 percent; P = 0.20; relative risk, 0.75; 95 percent confidence interval, 0.50 to 1.13). The increased rate of infections was confined to patients categorized as either borderline or mildly malnourished, according to Subjective Global Assessment or an objective nutritional assessment, and these patients had no demonstrable benefit from TPN. In contrast, severely malnourished patients who received TPN had fewer noninfectious complications than controls (5 vs. 43 percent; P = 0.03; relative risk, 0.12; 95 percent confidence interval, 0.02 to 0.91), with no concomitant increase in infectious complications. Conclusions. The use of preoperative TPN should be limited to patients who are severely malnourished unless there are other specific indications.			WILLIFORD, WO (corresponding author), DEPT VET AFFAIRS MED CTR,MED RES SERV,COOPERAT STUDIES PROGRAM COORDINATING CTR,PERRY POINT,MD 21902, USA.							BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BUZBY GP, 1988, AM J CLIN NUTR, V47, P357, DOI 10.1093/ajcn/47.2.357; BUZBY GP, 1988, AM J CLIN NUTR, V47, P366, DOI 10.1093/ajcn/47.2.366; DEMPSEY DT, 1988, AM J CLIN NUTR, V47, P352, DOI 10.1093/ajcn/47.2.352; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; MULLER JM, 1986, WORLD J SURG, V10, P53; MULLER JM, 1982, LANCET, V1, P68	7	717	726	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					525	532						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1906987				2022-12-28	WOS:A1991GB44700001
J	HARRISON, PM; WENDON, JA; GIMSON, AES; ALEXANDER, GJM; WILLIAMS, R				HARRISON, PM; WENDON, JA; GIMSON, AES; ALEXANDER, GJM; WILLIAMS, R			IMPROVEMENT BY ACETYLCYSTEINE OF HEMODYNAMICS AND OXYGEN-TRANSPORT IN FULMINANT HEPATIC-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE HEART-FAILURE; CRITICALLY ILL PATIENTS; N-ACETYLCYSTEINE; RELAXING FACTOR; NITRIC-OXIDE; SEPTIC SHOCK; NITROGLYCERIN TOLERANCE; THERAPEUTIC GOALS; SURGICAL PATIENTS; CONSUMPTION	Background. When administered early after an overdose of acetaminophen, intravenous acetylcysteine prevents hepatic necrosis by replenishing reduced stores of glutathione. How acetylcysteine improves the survival of patients with established liver damage induced by acetaminophen, however, is unknown. This study was undertaken to determine whether the beneficial effect of acetylcysteine under such circumstances could be due to enhancement of oxygen delivery and consumption. Methods. We studied the effect of acetylcysteine on systemic hemodynamics and oxygen transport in 12 patients with acetaminophen-induced fulminant hepatic failure and 8 patients with acute liver failure from other causes. The acetylcysteine was given in a dose of 150 mg per kilogram of body weight in 250 ml of 5 percent dextrose over a period of 15 minutes and then in a dose of 50 mg per kilogram in 500 ml of 5 percent dextrose over a period of 4 hours; measurements were made before treatment began and after 30 minutes of the regimen. Results. In the patients with acetaminophen-induced liver failure, the infusion of acetylcysteine resulted in an increase in mean oxygen delivery from 856 to 975 ml per minute per square meter of body-surface area (P = 0.0036), due to an increase in the cardiac index from 5.6 to 6.7 liters per minute per square meter (P = 0.0021). Mean arterial pressure rose from 88 to 95 mm Hg (P = 0.0054) despite a decrease in systemic vascular resistance from 1296 to 1113 dyn . sec . cm-5 per square meter (P = 0.027). There was an increase in oxygen consumption from 127 to 184 ml per minute per square meter (P = 0.0007) associated with an increase in the oxygen-extraction ratio from 16 to 21 percent (P = 0.022). The effects in the patients with acute liver failure from other causes were similar. Conclusions. The increase in oxygen delivery and consumption in response to acetylcysteine may account for its beneficial effect on survival in patients with fulminant hepatic failure induced by acetaminophen.	KINGS COLL,SCH MED & DENT,DENMARK HILL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Harrison, Phillip M/D-5374-2009	opoku, anita/0000-0001-7243-8157				ASTIZ ME, 1987, CRIT CARE MED, V15, P26, DOI 10.1097/00003246-198701000-00005; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BIHARI D, 1985, CRIT CARE MED, V13, P1034, DOI 10.1097/00003246-198512000-00010; BIHARI D, 1985, J HEPATOL, V1, P405, DOI 10.1016/S0168-8278(85)80778-9; BIHARI DJ, 1986, SEMIN LIVER DIS, V6, P119, DOI 10.1055/s-2008-1040595; BIHARI DJ, 1987, SCAND J CLIN LAB INV, V188, P37; Burns H J, 1982, Ciba Found Symp, V87, P293, DOI 10.1002/9780470720691.ch16; EDWARDS JD, 1989, CRIT CARE MED, V17, P1098, DOI 10.1097/00003246-198911000-00002; EDWARDS JD, 1989, CRIT CARE MED, V17, P996, DOI 10.1097/00003246-198910000-00006; EKLUND A, 1988, EUR RESPIR J, V1, P832; FORMAN MB, 1988, CIRCULATION, V78, P202, DOI 10.1161/01.CIR.78.1.202; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HENRY PJ, 1989, J CARDIOVASC PHARM, V14, P31, DOI 10.1097/00005344-198907000-00007; HOROWITZ JD, 1983, CIRCULATION, V68, P1247, DOI 10.1161/01.CIR.68.6.1247; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P926; JENSEN T, 1988, APMIS, V96, P62, DOI 10.1111/j.1699-0463.1988.tb05269.x; KAUFMAN BS, 1984, CHEST, V85, P336, DOI 10.1378/chest.85.3.336; KEAYS RT, 1989, GUT, V30, pA1512; KHARAZMI A, 1988, INT J IMMUNOPHARMACO, V10, P39, DOI 10.1016/0192-0561(88)90148-8; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LUCHT WD, 1987, AM J MED SCI, V294, P161, DOI 10.1097/00000441-198709000-00006; MAY DC, 1987, NEW ENGL J MED, V317, P805, DOI 10.1056/NEJM198709243171305; MOHSENIFAR Z, 1987, CHEST, V92, P447, DOI 10.1378/chest.92.3.447; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NEEDLEMAN P, 1973, J PHARMACOL EXP THER, V187, P324; NEWMAN CM, 1990, BRIT J PHARMACOL, V99, P825, DOI 10.1111/j.1476-5381.1990.tb13014.x; OGRADY JG, 1988, GASTROENTEROLOGY, V94, P1186, DOI 10.1016/0016-5085(88)90011-X; PACKER M, 1987, NEW ENGL J MED, V317, P799, DOI 10.1056/NEJM198709243171304; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; ROBIN ED, 1980, AM REV RESPIR DIS, V122, P517; RUMACK BH, 1981, ARCH INTERN MED, V141, P380, DOI 10.1001/archinte.141.3.380; SARREL PM, 1990, LANCET, V336, P1030, DOI 10.1016/0140-6736(90)92490-9; Shoemaker W C, 1989, Prog Clin Biol Res, V308, P133; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1986, CRIT CARE MED, V14, P1032, DOI 10.1097/00003246-198612000-00008; STAMLER J, 1989, CIRC RES, V65, P789, DOI 10.1161/01.RES.65.3.789; TORRESI J, 1985, J CARDIOVASC PHARM, V7, P777, DOI 10.1097/00005344-198507000-00024; Trey C, 1970, Prog Liver Dis, V3, P282; WOLF YG, 1987, CRIT CARE MED, V15, P198, DOI 10.1097/00003246-198703000-00003	45	418	422	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1852	1857		10.1056/NEJM199106273242604	http://dx.doi.org/10.1056/NEJM199106273242604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	1904133	Bronze			2022-12-28	WOS:A1991FT58000004
J	CHAVEZ, GF; MULINARE, J; EDMONDS, LD				CHAVEZ, GF; MULINARE, J; EDMONDS, LD			EPIDEMIOLOGY OF RH HEMOLYTIC-DISEASE OF THE NEWBORN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE GLOBULIN; IMMUNOGLOBULIN UTILIZATION; RHESUS ISOIMMUNIZATION; PREVENTION; IDENTIFICATION; SURVEILLANCE; MANAGEMENT	Nationwide surveillance of Rh hemolytic disease of the newborn (RhHDN) indicates that, after a substantial decline in incidence, reported rates reached a plateau in the late 1970s. We conducted a study designed to validate RhHDN surveillance data, to obtain corrected incidence estimates, and to identify potential reasons for the reported plateau. We obtained data from the Birth Defects Monitoring Program, a national surveillance system that collects data from public and private hospitals participating voluntarily. We asked hospitals for copies of the medical records for all infants discharged with a code for RhHDN and for a sample of the medical records of infants discharged with a code for other and unspecified hemolytic disease during 1986. The estimated incidence rate of RhHDN was 10.6 per 10 000 total births, with some regional variations. Our findings indicate that, despite the availability of an effective preventive measure, RhHDN continues to contribute significantly to infant morbidity and mortality in the United States.	CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV BIRTH DEFECTS & DEV DISABIL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ADAMS MM, 1981, AM J PUBLIC HEALTH, V71, P1031, DOI 10.2105/AJPH.71.9.1031; ADAMS MM, 1984, AM J OBSTET GYNECOL, V149, P633, DOI 10.1016/0002-9378(84)90248-5; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC, P384; BOWMAN JM, 1983, CAN MED ASSOC J, V129, P343; BOWMAN JM, 1984, AM J OBSTET GYNECOL, V148, P1151, DOI 10.1016/0002-9378(84)90651-3; Bowman JM., 1978, PERINATAL CARE, V2, P24; Caiola G, 1984, Obstet Gynecol Surv, V39, P55, DOI 10.1097/00006254-198401000-00021; CLARKE CA, 1985, BRIT MED J, V291, P17, DOI 10.1136/bmj.291.6487.17; EDMONDS LD, 1981, INT J EPIDEMIOL, V10, P247, DOI 10.1093/ije/10.3.247; FREDA VJ, 1975, NEW ENGL J MED, V292, P1014, DOI 10.1056/NEJM197505082921906; FRIGOLETTO FD, 1979, CLIN PERINATOL, V6, P321, DOI 10.1016/S0095-5108(18)31150-3; GRIMES DA, 1983, SOUTHERN MED J, V76, P743, DOI 10.1097/00007611-198306000-00017; GRIMES DA, 1977, OBSTET GYNECOL, V50, P261; GRIMES DA, 1981, AM J OBSTET GYNECOL, V140, P246, DOI 10.1016/0002-9378(81)90268-4; HENRY G, 1976, OBSTET GYNECOL, V48, P557; HENSLEIGH PA, 1983, AM J OBSTET GYNECOL, V146, P749, DOI 10.1016/0002-9378(83)91071-2; KEITH L, 1978, PERINATAL CARE, V2, P37; KORNSTAD L, 1987, NIPH (National Institute of Public Health) Annals (Oslo), V10, P3; LIM OW, 1982, OBSTET GYNECOL, V59, P477; POLLACK W, 1978, PERINATAL CARE, V2, P8; WIBLEKANT J, 1983, CLIN PERINATOL, V10, P343, DOI 10.1016/S0095-5108(18)30970-9; WYSOWSKI DK, 1979, JAMA-J AM MED ASSOC, V242, P1376, DOI 10.1001/jama.242.13.1376; 1988, MONTHLY VITAL STATIS, V37; 1989, GUIDE CLIN PREVENTIV, P221; 1988, MMWR S5, V37, P1; 1981, MMWR, V30, P13; 1985, MMWR, V34, pSS1	27	95	99	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3270	3274		10.1001/jama.265.24.3270	http://dx.doi.org/10.1001/jama.265.24.3270			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1904504				2022-12-28	WOS:A1991FR83500033
J	ODONNELL, M				ODONNELL, M			BATTLE OF THE CLOTBUSTERS	BRITISH MEDICAL JOURNAL			English	Article																			0	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1259	1261		10.1136/bmj.302.6787.1259	http://dx.doi.org/10.1136/bmj.302.6787.1259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1904288	Bronze, Green Published			2022-12-28	WOS:A1991FP27200030
J	PHILP, I; MAWHINNEY, S; MUTCH, WJ				PHILP, I; MAWHINNEY, S; MUTCH, WJ			SETTING STANDARDS FOR LONG-TERM CARE OF THE ELDERLY IN HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,GERIATR MED,DUNDEE DD1 9SY,SCOTLAND	University of Dundee				philp, ian/0000-0002-3972-6496				DENHAM M, 1989, CARE ELDERLY, V1, P855; DONALDSON C, 1988, AGE AGEING, V17, P379, DOI 10.1093/ageing/17.6.379; Kane RA, 1987, LONG TERM CARE PRINC; PHILP I, IN PRESS INT J GERIA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1056	1056		10.1136/bmj.302.6784.1056	http://dx.doi.org/10.1136/bmj.302.6784.1056			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903665	Green Published, Bronze			2022-12-28	WOS:A1991FK56300023
J	DEISS, LP; KIMCHI, A				DEISS, LP; KIMCHI, A			A GENETIC TOOL USED TO IDENTIFY THIOREDOXIN AS A MEDIATOR OF A GROWTH INHIBITORY SIGNAL	SCIENCE			English	Article							TUMOR SUPPRESSOR GENES; EPSTEIN-BARR VIRUS; C-MYC SUPPRESSION; INTERFERON-GAMMA; TRANSFORMED PHENOTYPE; NECROSIS FACTOR; CDNA LIBRARIES; EXPRESSION; CLONING; CELLS	Loss of sensitivity to growth inhibitory polypeptides is likely to be one of the events that participates in the formation of some tumors and might be caused by inactivation or loss of the genetic elements that transduce these extracellular signals. The isolation of such a gene was achieved by randomly inactivating genes by an anti-sense complementary DNA expression library followed by direct selection for growth in the presence of an inhibitory polypeptide. Thus, a gene whose inactivation conveyed growth resistance to interferon-gamma (IFN-gamma) was isolated. Sequence analysis showed complete identity with human thioredoxin, a dithiol reducing agent, implicated here in the IFN-gamma-mediated growth arrest of HeLa cells.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BERNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN JM, 1990, P NATL ACAD SCI USA, V87, P5026, DOI 10.1073/pnas.87.13.5026; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DEISS LP, UNPUB; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DRINKWATER NR, 1986, P NATL ACAD SCI USA, V83, P3402, DOI 10.1073/pnas.83.10.3402; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1988, ONCOGENE, V2, P485; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINDLAY CA, 1989, CELL, V57, P1083; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IJZERMANS JNM, 1989, IMMUNOBIOLOGY, V179, P456, DOI 10.1016/S0171-2985(89)80049-X; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P521; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MIKKELSEN T, 1990, CELL GROWTH DIFFER, V1, P201; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STEG P S, 1988, Cancer Research, V48, P6550; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	53	185	203	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					117	120		10.1126/science.1901424	http://dx.doi.org/10.1126/science.1901424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1901424				2022-12-28	WOS:A1991FE95200047
J	REYNAUD, CA; MACKAY, CR; MULLER, RG; WEILL, JC				REYNAUD, CA; MACKAY, CR; MULLER, RG; WEILL, JC			SOMATIC GENERATION OF DIVERSITY IN A MAMMALIAN PRIMARY LYMPHOID ORGAN - THE SHEEP ILEAL PEYERS-PATCHES	CELL			English	Article							IMMUNE-RESPONSE; B-CELLS; VARIABLE REGION; CHICKEN; MATURATION; FABRICIUS; ANTIBODY; MUTATION; BURSA; LYMPHOCYTES	Ileal Peyer's patches (IPPs) in the sheep are composed of tightly packed follicles in which surface IgM-positive B cells proliferate and can be exported to the periphery. We report that the light chain rearrangement pattern in a single IPP follicle is much more restricted than in the entire tissue, which indicates that, as in the chicken bursa, ongoing rearrangement does not take place in this organ. Moreover, we show that B cells extensively diversify their antigen receptor while proliferating in IPP follicles. Sequencing of part of the V-lambda-locus indicates that this diversification is not achieved by gene conversion, but rather by untemplated somatic mutation and intense selective pressure. These results strongly imply that sheep IPPs behave as a bursa-equivalent, primary lymphoid organ of diversification and that somatic point hypermutation, which is known to proceed during secondary immune responses, can also generate an antibody repertoire.			REYNAUD, CA (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARCHER OK, 1963, NATURE, V200, P337, DOI 10.1038/200337a0; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRANDTZAEG P, 1989, IMMUNOL INVEST, V18, P29, DOI 10.3109/08820138909112225; CLAMAN HN, 1966, P SOC EXP BIOL MED, V122, P1167; COOPER GN, 1972, CONTEMP TOPICS IMMUN, V1, P49; COOPER MD, 1968, INT ARCH ALLER A IMM, V33, P65, DOI 10.1159/000229975; COOPER MD, 1965, NATURE, V205, P143, DOI 10.1038/205143a0; DUPASQUIER L, 1989, FUNDAMENTAL IMMUNOLO, P139; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; FICHTELIUS KE, 1968, LAB INVEST, V19, P339; FOLEY RC, 1989, J IMMUNOL, V142, P708; FRIEDBER.SH, 1974, J IMMUNOL, V113, P1477; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; GEARHART PJ, 1981, NATURE, V291, P29, DOI 10.1038/291029a0; GERBER HA, 1986, AUST J EXP BIOL MED, V64, P201, DOI 10.1038/icb.1986.22; Good R A, 1973, Harvey Lect, V67, P1; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HEIN WR, 1989, IMMUNOLOGY, V68, P365; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOOD L, 1967, COLD SPRING HARB SYM, V32, P133, DOI 10.1101/SQB.1967.032.01.021; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSVERK T, 1987, IMMUNOL CELL BIOL, V65, P251, DOI 10.1038/icb.1987.28; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MCCORMACK WT, 1989, GENE DEV, V3, P838, DOI 10.1101/gad.3.6.838; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MILLER JF, 1961, LANCET, V2, P748; MITCHELL GF, 1968, J EXP MED, V128, P821, DOI 10.1084/jem.128.4.821; OSMOND DG, 1974, CELL IMMUNOL, V13, P132, DOI 10.1016/0008-8749(74)90233-0; PINK JRL, 1987, CURR TOP MICROBIOL, V135, P57; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; REYNOLDS JD, 1983, EUR J IMMUNOL, V13, P627, DOI 10.1002/eji.1830130805; REYNOLDS JD, 1987, EUR J IMMUNOL, V17, P503, DOI 10.1002/eji.1830170411; REYNOLDS JD, 1986, J IMMUNOL, V136, P2005; REYNOLDS JD, 1984, EUR J IMMUNOL, V14, P1, DOI 10.1002/eji.1830140102; REYNOLDS JD, 1976, THESIS AUSTR NATIONA; SABLITZKY F, 1985, EMBO J, V4, P345, DOI 10.1002/j.1460-2075.1985.tb03635.x; Salami M. Al, 1985, Immunology of sheep, P19; SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; WABL M, 1987, IMMUNOL REV, V96, P90, DOI 10.1111/j.1600-065X.1987.tb00511.x; WARNER NL, 1962, AUST J EXP BIOL MED, V43, P373; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; WEILL JC, 1986, P NATL ACAD SCI USA, V83, P3336, DOI 10.1073/pnas.83.10.3336; WEILL JC, 1987, SCIENCE, V238, P1094, DOI 10.1126/science.3317827; WYSOCKI L, 1986, P NATL ACAD SCI USA, V83, P1847, DOI 10.1073/pnas.83.6.1847	55	240	241	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1991	64	5					995	1005		10.1016/0092-8674(91)90323-Q	http://dx.doi.org/10.1016/0092-8674(91)90323-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900459				2022-12-28	WOS:A1991FA94000016
J	GOLDMAN, L; WEINSTEIN, MC; GOLDMAN, PA; WILLIAMS, LW				GOLDMAN, L; WEINSTEIN, MC; GOLDMAN, PA; WILLIAMS, LW			COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; STAGE RENAL-DISEASE; 2 NATIONAL SURVEYS; SERUM-CHOLESTEROL; POLICY MODEL; RISK-FACTORS; MORTALITY; THERAPY; DIET; CHOLESTYRAMINE	To determine the cost-effectiveness of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (such as lovastatin) for the primary and secondary prevention of coronary heart disease, we used the Coronary Heart Disease Policy Model, a computer-simulated model that estimates the risk factor-specific annual incidence of coronary heart disease and the risk of recurrent coronary events in persons with prevalent coronary heart disease. When used for secondary prevention, 20 mg/d of lovastatin was estimated to save lives and save costs in younger men with cholesterol levels above 250 mg/dL (6.47 mmol/L) and to have a favorable cost-effectiveness ratio regardless of the cholesterol level except in young women with cholesterol levels below 250 mg/dL (6.47 mmol/L). Doses of 40 mg/d of lovastatin had favorable incremental cost-effectiveness ratios in men with cholesterol levels above 250 mg/dL (6.47 mmol/L). By comparison, primary prevention had favorable cost-effectiveness ratios only in selected subgroups based on cholesterol levels and other established risk factors. We conclude that current national recommendations regarding medication for secondary prevention are not as aggressive as our projections would suggest, while recommendations regarding the use of medications for primary prevention should consider the cost of medication as well as the risk factor profile of the individual patient.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	GOLDMAN, L (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV CLIN EPIDEMIOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [HS06258] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CORDAY E, 1989, J AM COLL CARDIOL, V13, P497, DOI 10.1016/0735-1097(89)90531-7; DAYTON S, 1969, CIRCULATION, V40, pII1; DRUMMOND MF, 1987, HEALTH POLICY, V7, P309, DOI 10.1016/0168-8510(87)90072-8; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HAVEL RJ, 1987, ANN INTERN MED, V107, P609, DOI 10.7326/0003-4819-107-5-609; HIMMELSTEIN DU, 1984, NEW ENGL J MED, V311, P1511, DOI 10.1056/NEJM198412063112311; HJERMANN I, 1981, LANCET, V2, P1303; HOEG JM, 1986, AM J CARDIOL, V57, P933, DOI 10.1016/0002-9149(86)90733-2; ILLINGWORTH DR, 1984, ANN INTERN MED, V101, P598, DOI 10.7326/0003-4819-101-5-598; KANNEL WB, 1990, AM J CARDIOL, V66, pB1, DOI 10.1016/0002-9149(90)90434-3; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; MANTELL G, 1990, AM J CARDIOL, V66, pB11, DOI 10.1016/0002-9149(90)90435-4; MARTENS LL, 1989, AM J MED, V87, pS54, DOI 10.1016/S0002-9343(89)80600-X; MARTENS LL, 1990, AM J CARDIOL, V65, pF27; MCGEE D, 1976, NIH761083 PUBL; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; PALUMBO PJ, 1989, JAMA-J AM MED ASSOC, V262, P91, DOI 10.1001/jama.262.1.91; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TOBERT JA, 1986, JAMA-J AM MED ASSOC, V256, P2829; TOSTESON ANA, 1990, AM J PUBLIC HEALTH, V80, P1481, DOI 10.2105/AJPH.80.12.1481; TSEVAT J, IN PRESS CIRCULATION; TURPEINEN O, 1979, CIRCULATION, V59, P1; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; 1973, SOME CHARACTERISTICS; 1989, LANCET, V1, P1423; 1971, BMJ, V4, P775; 1988, TECHNICAL APPENDICES; 1971, BMJ, V4, P767; 1981, VITAL STATISTICS U A, V2; 1982, CURRENT POPULATI P25, V922; 1982, CURRENT POPULATI P25, V917; 1988, JAMA-J AM MED ASSOC, V260, P359; 1987, NIH872703 US DEP HLT; 1984, CURRENT POPULATI P25, V949	63	305	305	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1145	1151		10.1001/jama.265.9.1145	http://dx.doi.org/10.1001/jama.265.9.1145			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1899896				2022-12-28	WOS:A1991EZ47400032
J	SHERRY, S; MARDER, VJ				SHERRY, S; MARDER, VJ			STREPTOKINASE AND RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR (RT-PA) ARE EQUALLY EFFECTIVE IN TREATING ACUTE MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Review						STREPTOKINASE; PLASMINOGEN ACTIVATOR, TISSUE-TYPE; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR, RECOMBINANT	LEFT-VENTRICULAR FUNCTION; INTRACORONARY FIBRINOLYTIC THERAPY; WASHINGTON RANDOMIZED TRIAL; ISCHEMIC CELL-DEATH; 12-MONTH FOLLOW-UP; INTRAVENOUS STREPTOKINASE; THROMBOLYTIC THERAPY; TIMI TRIAL; PHASE-I; CORONARY THROMBOLYSIS	In recent trials, patients with myocardial infarction who received either recombinant tissue-type plasminogen activator (rt-PA) or streptokinase showed essentially no difference in the amount of myocardial salvage, in mortality reduction, or in the incidence of bleeding complications. These findings thus failed to fulfill the expectation that rt-PA would be twice as effective as streptokinase as a thrombolytic agent. The basis for this mistaken prediction was an unfortunate overemphasis on an inadequate surrogate endpoint, namely, the patency or reperfusion rate at 90 minutes after the start of therapy. Using the 90-minute patency or reperfusion rate as an endpoint has several serious limitations. First, it is an observation made at only one point in time during a dynamic process that may change even during the infusion proper. Second, a single view at 90 minutes completely disregards the possibility of subsequent reocclusion which often occurs within 1 hour after treatment. Third, an image at 90 minutes is more a reflection of the speed of thrombolysis than of whether lysis will eventually occur; the pace of clot lysis depends on both the agent used and the age of the thrombus. Fourth, lysis at 90 minutes is o minimal relevance for myocardial salvage unless observed within the time frame when infarction size can be limited significantly, which is generally less than 4 hours between symptom onset and the time that reperfusion is accomplished. Fifth, a stable state of vessel patency is meaningful for mortality reduction even if stabilization occurs after completion of the infarction. Such "late," but lasting, patency is a critical component of the "open vessel" principle and explains, at least in part, the survival benefit that accrues to patients treated even 24 hours after the onset of symptoms. There is currently no evidence that rt-PA has a more beneficial effect on survival or function than does streptokinase or any other plasminogen activator used in treating acute myocardial infarction; nor is there any evidence that patients who receive rt-PA therapy show a decreased incidence of bleeding complications compared with those who receive streptokinase, despite the relative fibrinogen-sparing attribute of rt-PA. Given the poor predictive value of the 90-minute angiogram for ultimate clinical advantage of one agent over another, studies that are limited to this endpoint are of marginal use in evaluating treatment regimens used in mortality studies. The best evidence to date indicates that streptokinase and rt-PA are of equivalent value for survival after acute myocardial infarction, a conclusion that can be justifiably challenged only with a valid mortality study.	UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14642 USA; TEMPLE UNIV, HLTH SCI CTR, PHILADELPHIA, PA 19140 USA	University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON J L, 1990, Journal of the American College of Cardiology, V15, p218A; ANDERSON JL, 1988, J AM COLL CARDIOL, V11, P1153, DOI 10.1016/0735-1097(88)90276-8; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; ANDERSON JL, 1984, CIRCULATION, V70, P606, DOI 10.1161/01.CIR.70.4.606; ANDERSON JL, 1983, NEW ENGL J MED, V308, P1312, DOI 10.1056/NEJM198306023082202; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1974, JAMA, V229, P1606; ARMSTRONG PW, 1989, J AM COLL CARDIOL, V13, P1469, DOI 10.1016/0735-1097(89)90334-3; BASSAND J P, 1990, Journal of the American College of Cardiology, V15, p214A; BASSAND JP, 1987, AM J CARDIOL, V60, P435, DOI 10.1016/0002-9149(87)90281-5; BASSAND JP, 1989, J AM COLL CARDIOL, V13, P988, DOI 10.1016/0735-1097(89)90249-0; BAUGHMAN RA, 1987, TISSUE PLASMINOGEN A, P41; BETRIU A, 1982, CIRCULATION, V65, P1099, DOI 10.1161/01.CIR.65.6.1099; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; CALIFF RM, 1989, J AM COLL CARDIOL, V13, P1130, DOI 10.1016/0735-1097(89)90274-X; CARLSON SE, 1988, ARCH NEUROL-CHICAGO, V45, P1070, DOI 10.1001/archneur.1988.00520340024005; CERCEK B, 1987, AM J CARDIOL, V60, P214, DOI 10.1016/0002-9149(87)90216-5; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COLLEN D, 1984, CIRCULATION, V70, P1012, DOI 10.1161/01.CIR.70.6.1012; COLLEN D, 1990, ANN INTERN MED, V112, P529, DOI 10.7326/0003-4819-112-7-529; DALEN JE, 1988, AM J CARDIOL, V62, P179, DOI 10.1016/0002-9149(88)90208-1; DIEFENBACH C, 1988, AM J CARDIOL, V61, P966, DOI 10.1016/0002-9149(88)90107-5; DURAND P, 1987, CLIN CARDIOL, V10, P383, DOI 10.1002/clc.4960100704; EIGLER N, 1984, AM J CARDIOL, V54, P261, DOI 10.1016/0002-9149(84)90178-4; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; GANZ W, 1985, NEW ENGL J MED, V313, P1018; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; HELD AC, 1988, AM J CARDIOL, V62, P310, DOI 10.1016/0002-9149(88)90231-7; HOFFMANN JJML, 1987, DRUGS, V33, P242, DOI 10.2165/00003495-198700333-00045; HOGG KJ, 1990, LANCET, V335, P254, DOI 10.1016/0140-6736(90)90069-H; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; JOHNS JA, 1988, CIRCULATION, V78, P546, DOI 10.1161/01.CIR.78.3.546; KASE CS, 1990, ANN INTERN MED, V112, P17, DOI 10.7326/0003-4819-112-1-17; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KENNEDY JW, 1987, J AM COLL CARDIOL, V10, pB28, DOI 10.1016/S0735-1097(87)80425-4; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; KEREN A, 1990, J AM COLL CARDIOL, V15, P790, DOI 10.1016/0735-1097(90)90275-T; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; KHAJA F, 1983, NEW ENGL J MED, V308, P1305, DOI 10.1056/NEJM198306023082201; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; MAGNANI B, 1989, J AM COLL CARDIOL, V13, P19, DOI 10.1016/0735-1097(89)90543-3; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1512, DOI 10.1056/NEJM198806093182306; MARDER VJ, 1979, ANN INTERN MED, V90, P802, DOI 10.7326/0003-4819-90-5-802; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; MARINO P, 1989, J AM COLL CARDIOL, V14, P1149, DOI 10.1016/0735-1097(89)90409-9; MARTIN GV, 1988, CIRCULATION, V78, P258, DOI 10.1161/01.CIR.78.2.258; MATHEY DG, 1985, AM J CARDIOL, V55, P878, DOI 10.1016/0002-9149(85)90710-6; MATHEY DG, 1987, AM J MED, V83, P26, DOI 10.1016/0002-9343(87)90884-9; MENTZER RL, 1986, AM J CARDIOL, V57, P1220, DOI 10.1016/0002-9149(86)90192-X; MEYER J, 1989, LANCET, V1, P863; MONASSIER JP, 1987, DRUGS, V33, P247, DOI 10.2165/00003495-198700333-00046; NEUHAUS KL, 1988, J AM COLL CARDIOL, V12, P581, DOI 10.1016/S0735-1097(88)80040-8; OROURKE M, 1988, CIRCULATION, V77, P1311, DOI 10.1161/01.CIR.77.6.1311; PACOURET G, 1989, CIRCULATION S2, V80, P40; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; REIMER KA, 1979, LAB INVEST, V40, P633; RELMAN AS, 1985, NEW ENGL J MED, V312, P915, DOI 10.1056/NEJM198504043121409; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; RITCHIE JL, 1984, CIRCULATION, V70, P867, DOI 10.1161/01.CIR.70.5.867; SCHREIBER TL, 1986, AM J CARDIOL, V58, P47, DOI 10.1016/0002-9149(86)90239-0; SCHRODER R, 1989, AM J CARDIOL, V64, P878, DOI 10.1016/0002-9149(89)90835-7; SCHRODER R, 1988, NEW ENGL J MED, V318, P381; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; SHERRY S, 1988, AM J CARDIOL, V61, P1344, DOI 10.1016/0002-9149(88)91181-2; SHERRY S, 1985, NEW ENGL J MED, V313, P1014, DOI 10.1056/NEJM198510173131609; SHERRY S, 1987, AM J MED, V83, P31, DOI 10.1016/0002-9343(87)90885-0; SHERRY S, 1987, AM J CARDIOL, V59, P984, DOI 10.1016/0002-9149(87)91139-8; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; SIX AJ, 1990, AM J CARDIOL, V65, P119, DOI 10.1016/0002-9149(90)90071-8; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; SWAN HJC, 1983, NEW ENGL J MED, V308, P1354, DOI 10.1056/NEJM198306023082209; TAVAZZI L, 1989, LANCET, V2, P182; THOMPSON PL, 1988, LANCET, V1, P203; TOPOL EJ, 1989, J AM COLL CARDIOL, V13, P1477, DOI 10.1016/0735-1097(89)90335-5; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, P1173, DOI 10.1016/S0735-1097(87)80114-6; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, LANCET, V1, P1147; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; VERSTRAETE M, 1981, ACTA MED SCAND, P7; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WHITE HD, 1990, LANCET, V336, P297, DOI 10.1016/0140-6736(90)91818-U; WHITE HD, 1989, NEW ENGL J MED, V320, P817, DOI 10.1056/NEJM198903303201301; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1973, CIRCULATION S2, V47, P108; 1979, NEW ENGL J MED, V30, P797	92	58	58	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					417	423		10.7326/0003-4819-114-5-417	http://dx.doi.org/10.7326/0003-4819-114-5-417			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1899546				2022-12-28	WOS:A1991EZ17400011
J	LAZARD, D; ZUPKO, K; PORIA, Y; NEF, P; LAZAROVITS, J; HORN, S; KHEN, M; LANCET, D				LAZARD, D; ZUPKO, K; PORIA, Y; NEF, P; LAZAROVITS, J; HORN, S; KHEN, M; LANCET, D			ODORANT SIGNAL TERMINATION BY OLFACTORY UDP GLUCURONOSYL TRANSFERASE	NATURE			English	Article							SENSITIVE ADENYLATE-CYCLASE; RAT; CYTOCHROME-P-450; ASSAY; IDENTIFICATION; PURIFICATION; LOCALIZATION; STIMULATION; EPITHELIUM; RECEPTION	THE onset of olfactory transduction has been extensively studied 1-7, but considerably less is known about the molecular basis of olfactory signal termination 6,8,9. It has been suggested that the highly active cytochrome P450 monooxygenases of olfactory neuroepithelium 10-12 are termination enzymes 5,8,11,12, a notion supported by the identification and molecular cloning of olfactory-specific cytochrome P450s (refs. 13-16). But as reactions catalysed by cytochrome P450 (refs 17, 18) often do not significantly alter volatility, lipophilicity or odour properties 9,11, cytochrome P450 may not be solely responsible for olfactory signal termination. In liver and other tissues, drug hydroxylation by cytochrome P450 is frequently followed by phase II biotransformation, for example by UDP glucuronosyl transferase (UGT), resulting in a major change of solubility and chemical properties 19. We report here the molecular cloning and expression of an olfactory-specific UGT. The olfactory enzyme, but not the one in liver microsomes, shows preference for odorants over standard UGT substrates. Furthermore, glucuronic acid conjugation abolishes the ability of odorants 1,20 to stimulate olfactory adenylyl cyclase. This, together with the known broad spectrum of drug-detoxification enzymes 17,19, supports a role for olfactory UGT in terminating diverse odorant signals.	WEIZMANN INST SCI,DEPT MEMBRANE RES,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; CRAWFORD JM, 1988, AM J PHYSIOL, V255, P121; DAHL AR, 1982, SCIENCE, V216, P57, DOI 10.1126/science.7063870; DAHL AR, 1988, MOL NEUROBIOLOGY OLF; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; Fenaroli G., 1975, FENAROLIS HDB FLAVOR, V2; FOSTER JR, 1986, BIOCHEM PHARMACOL, V35, P4543, DOI 10.1016/0006-2952(86)90777-X; GANDER JE, 1980, PHARMACOL THERAPEUT, V10, P191, DOI 10.1016/0163-7258(80)90081-9; GETCHELL TV, 1984, PROG NEUROBIOL, V23, P317, DOI 10.1016/0301-0082(84)90008-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JENNER J, 1988, Drug Metabolism and Drug Interactions, V6, P123; LANCET D, 1987, TRENDS BIOCHEM SCI, V12, P63, DOI 10.1016/0968-0004(87)90032-6; LANCET D, 1988, COLD SPRING HARB SYM, V53, P343, DOI 10.1101/SQB.1988.053.01.041; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LAZARD D, 1989, BIOCHIM BIOPHYS ACTA, V1013, P68, DOI 10.1016/0167-4889(89)90129-8; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; MACKENZIE PI, 1987, J BIOL CHEM, V262, P9744; MACKENZIE PI, 1989, CLIN EXP PHARMACOL P, V16, P501, DOI 10.1111/j.1440-1681.1989.tb01595.x; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; NEF P, 1990, J BIOL CHEM, V265, P2903; PACE U, 1986, P NATL ACAD SCI USA, V83, P4947, DOI 10.1073/pnas.83.13.4947; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PFEUFFER E, 1989, J BIOL CHEM, V264, P18803; REED RR, 1990, CELL, V60, P1, DOI 10.1016/0092-8674(90)90706-K; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHEPHERD SRP, 1989, BIOCHEM J, V259, P617, DOI 10.1042/bj2590617; SHIPLEY MT, 1985, BRAIN RES BULL, V15, P129, DOI 10.1016/0361-9230(85)90129-7; SHIRLEY SG, 1986, BIOCHEM J, V240, P605, DOI 10.1042/bj2400605; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SNYDER SH, 1989, TRENDS NEUROSCI, V12, P35, DOI 10.1016/0166-2236(89)90154-9; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; TALAMO BR, 1989, NATURE, V337, P736, DOI 10.1038/337736a0; VOIGT JM, 1985, CANCER LETT, V27, P241, DOI 10.1016/0304-3835(85)90180-6; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	38	192	193	2	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					790	793		10.1038/349790a0	http://dx.doi.org/10.1038/349790a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1900353				2022-12-28	WOS:A1991EZ66600056
J	XIAO, H; PERISIC, O; LIS, JT				XIAO, H; PERISIC, O; LIS, JT			COOPERATIVE BINDING OF DROSOPHILA HEAT-SHOCK FACTOR TO ARRAYS OF A CONSERVED 5 BP UNIT	CELL			English	Article							HSP 70 GENE; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; DNA-BINDING; CONSENSUS SEQUENCE; ACTIVATOR PROTEIN; ELEMENTS; YEAST; MELANOGASTER; EXPRESSION	Drosophila heat shock factor (HSF) exists as a multimer in solution and when bound to its regulatory element (HSE). We have previously reported evidence that subunits of HSF associate to form homotrimers and that each subunit contacts a conserved 5 bp DNA sequence repeated within an HSE. Here we show that HSF binding is highly cooperative at two distinct levels: between subunits of the HSF multimer, and between multimers. The binding of HSF to one of a pair of adjacent trimeric binding sites facilitates HSF binding to the second by over 2000-fold. This cooperativity is particularly important in binding HSF at 37-degrees-C, and could account for the requirement for multiple binding sites in vivo and, in part, for the differential expression of heat shock genes.			XIAO, H (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.			Perisic, Olga/0000-0002-3842-2896	NIGMS NIH HHS [GM25232] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025232, R01GM025232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; AMIN J, 1985, MOL CELL BIOL, V5, P197, DOI 10.1128/MCB.5.1.197; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Ptashne M., 1986, A GENETIC SWITCH; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF R, 1988, SCIENCE, V240, P127, DOI 10.1126/science.3353710; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WEI R, 1986, NUCLEIC ACIDS RES, V14, P8183, DOI 10.1093/nar/14.20.8183; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	36	215	220	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					585	593		10.1016/0092-8674(91)90242-Q	http://dx.doi.org/10.1016/0092-8674(91)90242-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1899357	hybrid			2022-12-28	WOS:A1991EX36100014
J	SIANI, A; STRAZZULLO, P; GIACCO, A; PACIONI, D; CELENTANO, E; MANCINI, M				SIANI, A; STRAZZULLO, P; GIACCO, A; PACIONI, D; CELENTANO, E; MANCINI, M			INCREASING THE DIETARY POTASSIUM INTAKE REDUCES THE NEED FOR ANTIHYPERTENSIVE MEDICATION	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; SPONTANEOUSLY HYPERTENSIVE RATS; LOW-SODIUM DIET; BLOOD-PRESSURE; MILD HYPERTENSION; SUPPLEMENTATION; CHLORIDE; MEN; THERAPY; FIBER	Objective: To determine whether an increase in dietary potassium intake from natural foods reduces the need for antihypertensive medication in patients with essential hypertension. Design: Randomized, controlled trial with 1-year follow-up. Setting: Hypertension outpatient clinic of a university hospital. Patients: Fifty-four patients with well-controlled hypertension, 47 of whom completed 1 year of follow-up. Intervention: Patients were randomly assigned to one of two groups and were given dietary advice aimed at selectively increasing potassium intake (group 1) or at keeping their customary diet unchanged (group 2). During a 1-year follow-up period, drug therapy was reduced in stepwise fashion, according to a fixed protocol, provided that blood pressure remained below 160/95 mm Hg. Main Results: Potassium intake was checked monthly by referring to 3-day food records and by measuring 24-hour urinary potassium excretion. Potassium intake increased in group 1 but did not change in group 2 (P < 0.001). No change was observed in either urinary sodium excretion or in body weight. After 1 year, the average drug consumption (number of pills per day) relative to that at baseline was 24% in group 1 (95% Cl, 15% to 32%) and 60% in group 2 (Cl, 44% to 76%) (P < 0.001). By the end of the study, blood pressure could be controlled using less than 50% of the initial therapy in 81 % of the patients in group 1 (Cl, 66% to 96%) compared with 29% of the patients in group 2 (Cl, 10% to 48%) (P = 0.001). Patients in group 1 ended the study with a lower number of reported symptoms compared with patients in the control group (P < 0.001). Conclusion: Increasing the dietary potassium intake from natural foods is a feasible and effective measure to reduce antihypertensive drug treatment.	NAPLES UNIV, SCH MED 2, DEPT INTERNAL MED & METAB DIS, VIA S PANSINI 5, I-80131 NAPLES, ITALY	University of Naples Federico II			Siani, Alfonso/B-7925-2015; Celentano, Egidio/AAC-8984-2022	Celentano, Egidio/0000-0002-3193-5699				BARDEN A, 1988, CLIN SCI, V75, P527, DOI 10.1042/cs0750527; CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011; CAPPUCCIO FP, 1985, BRIT MED J, V291, P235, DOI 10.1136/bmj.291.6490.235; ELLIOTT P, 1988, BRIT MED J, V297, P319; FIDANZA F, 1981, TABELLE COMPOSIZIONE; FINNERTY FA, 1984, AM J CARDIOL, V53, P1304, DOI 10.1016/0002-9149(84)90084-5; FUJITA T, 1983, KIDNEY INT, V24, P731, DOI 10.1038/ki.1983.220; FUJITA T, 1984, HYPERTENSION, V6, P184, DOI 10.1161/01.HYP.6.2_Pt_1.184; GOTO A, 1981, HYPERTENSION, V3, P128; GRIMM RH, 1990, NEW ENGL J MED, V322, P569, DOI 10.1056/NEJM199003013220901; IIMURA O, 1981, CLIN SCI, V61, pS77, DOI 10.1042/cs061077s; KAPLAN NM, 1985, NEW ENGL J MED, V312, P746, DOI 10.1056/NEJM198503213121203; KRISHNA GG, 1990, J AM SOC NEPHROL, V1, P43; KRISHNA GG, 1989, NEW ENGL J MED, V320, P1177, DOI 10.1056/NEJM198905043201804; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; MACGREGOR GA, 1982, LANCET, V2, P567; MARGETTS BM, 1987, CLIN SCI, V72, P343, DOI 10.1042/cs0720343; PATKI PS, 1990, BMJ-BRIT MED J, V301, P351; PRESCOTT SL, 1988, CLIN SCI, V74, P665, DOI 10.1042/cs0740665; PUSKA P, 1983, LANCET, V1, P1; REBELLO T, 1983, AM J CLIN NUTR, V38, P84, DOI 10.1093/ajcn/38.1.84; SIANI A, 1987, BMJ-BRIT MED J, V294, P1453, DOI 10.1136/bmj.294.6585.1453; SMITH SJ, 1985, BMJ-BRIT MED J, V290, P110, DOI 10.1136/bmj.290.6462.110; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STRAZZULLO P, 1986, J HYPERTENS, V4, P407, DOI 10.1097/00004872-198608000-00003; SUGDEN AL, 1987, HYPERTENSION, V9, P571, DOI 10.1161/01.HYP.9.6.571; SUZUKI H, 1981, HYPERTENSION, V3, P566, DOI 10.1161/01.HYP.3.5.566; SVETKEY LP, 1987, HYPERTENSION, V9, P444, DOI 10.1161/01.HYP.9.5.444; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; YOUNG JB, 1982, J CHRON DIS, V35, P879, DOI 10.1016/0021-9681(82)90118-7	30	103	108	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					753	759		10.7326/0003-4819-115-10-753	http://dx.doi.org/10.7326/0003-4819-115-10-753			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929022				2022-12-28	WOS:A1991GP80000001
J	OELLER, PW; WONG, LM; TAYLOR, LP; PIKE, DA; THEOLOGIS, A				OELLER, PW; WONG, LM; TAYLOR, LP; PIKE, DA; THEOLOGIS, A			REVERSIBLE INHIBITION OF TOMATO FRUIT SENESCENCE BY ANTISENSE RNA	SCIENCE			English	Article							ETHYLENE BIOSYNTHESIS; GENE-EXPRESSION; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; POLYGALACTURONASE; PLANTS	Ethylene controls fruit ripening. Expression of antisense RNA to the rate-limiting enzyme in the biosynthetic pathway of ethylene, 1-aminocyclopropane-1-carboxylate synthase, inhibits fruit ripening in tomato plants. Administration of exogenous ethylene or propylene reverses the inhibitory effect. This result demonstrates that ethylene is the trigger and not the by-product of ripening and raises the prospect that the life-span of plant tissues can be extended, thereby preventing spoilage.	UNIV CALIF BERKELEY,USDA,CTR PLANT GENE EXPRESS,ALBANY,CA 94710	United States Department of Agriculture (USDA); University of California System; University of California Berkeley					NIGMS NIH HHS [GM-35447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT AB, 1989, BIOTECHNOLOGY FOOD Q, P167; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BIALE JACOB B., 1960, ADVANCES IN FOOD RES, V10, P293; BIALE JB, 1981, RECENT ADV BIOCH FRU, P1, DOI DOI 10.1111/J.1365-313X.2007.03170.X; BURG SP, 1965, SCIENCE, V148, P1190, DOI 10.1126/science.148.3674.1190; BURG SP, 1962, PLANT PHYSIOL, V37, P179, DOI 10.1104/pp.37.2.179; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHRISTOFFERSEN RE, 1982, PLANTA, V155, P52, DOI 10.1007/BF00402931; DELLAPENNA D, 1986, P NATL ACAD SCI USA, V83, P6420, DOI 10.1073/pnas.83.17.6420; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOLLIDAY R, 1988, PERSPECT BIOL MED, V32, P109; KENDE H, 1981, PLANTA, V151, P476, DOI 10.1007/BF00386542; KENDE H, 1989, PLANT PHYSIOL, V91, P1, DOI 10.1104/pp.91.1.1; KIDD F, 1945, PLANT PHYSIOL, V20, P467, DOI 10.1104/pp.20.4.467; LATIES GG, 1987, MOL BIOL PLANT GROWT, V44, P107; LINCOLN JE, 1987, P NATL ACAD SCI USA, V84, P2793, DOI 10.1073/pnas.84.9.2793; LYONS JM, 1964, AM SOC HORTIC SCI J, V84, P491; MCMURCHIE EJ, 1972, NATURE, V237, P235, DOI 10.1038/237235a0; OW DW, 1987, P NATL ACAD SCI USA, V84, P4870, DOI 10.1073/pnas.84.14.4870; ROTTMAN WH, IN PRESS J MOL BIOL; Sambrook J., 1989, MOL CLONING; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; VARNER JE, 1961, ANNU REV PLANT PHYS, V12, P245, DOI 10.1146/annurev.pp.12.060161.001333; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YOSHII H, 1982, PLANT CELL PHYSIOL, V23, P639	26	573	694	3	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					437	439		10.1126/science.1925603	http://dx.doi.org/10.1126/science.1925603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1925603				2022-12-28	WOS:A1991GK72900051
J	SCHIRO, JA; CHAN, BMC; ROSWIT, WT; KASSNER, PD; PENTLAND, AP; HEMLER, ME; EISEN, AZ; KUPPER, TS				SCHIRO, JA; CHAN, BMC; ROSWIT, WT; KASSNER, PD; PENTLAND, AP; HEMLER, ME; EISEN, AZ; KUPPER, TS			INTEGRIN-ALPHA-2-BETA-1 (VLA-2) MEDIATES REORGANIZATION AND CONTRACTION OF COLLAGEN MATRICES BY HUMAN-CELLS	CELL			English	Article							FIBRONECTIN RECEPTOR EXPRESSION; FIBROBLAST TRACTION; SURFACE RECEPTORS; INTEGRIN; ADHESION; BINDING; MORPHOGENESIS; GLYCOPROTEIN; LATTICES; HOMOLOGY	The capacity of cells to organize and contract collagen fibrils is fundamental to processes as diverse as embryogenesis and wound healing. We analyzed different beta-1 integrins on diploid fibroblasts for their role in modifying the tertiary structure of collagen matrices. Using monoclonal antibodies that block the interaction of integrins with their ligands, evidence was obtained that alpha-2-beta-1 integrin is required for the contraction of a type I collagen matrix. Further supporting the role of alpha-2-beta-1, cell lines expressing minimal levels of this integrin uniformly failed to contract collagen matrices. In addition, transfection of a full-length alpha-2 cDNA into one such cell line led to enhanced cell surface expression of alpha-2-beta-1 and conferred the de novo capacity to contract collagen matrices.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	SCHIRO, JA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110, USA.		Kupper, Thomas/O-4962-2019	Kassner, Paul/0000-0002-1471-1191	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025082, R37AI025082, R29AI025082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040124, R37AR012129, R01AR012129] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25082] Funding Source: Medline; NIAMS NIH HHS [AR 12129, AR 40124] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUVOIS B, 1987, CELL BIOCHEM FUNCT, V5, P281, DOI 10.1002/cbf.290050407; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CLARK RAF, 1990, J INVEST DERMATOL, V94, pS128, DOI 10.1111/1523-1747.ep12876104; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; EISEN AZ, 1987, J INVEST DERMATOL, V88, P741, DOI 10.1111/1523-1747.ep12470412; GRINNELL F, 1984, J CELL SCI, V66, P51; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; GULLBERG D, 1990, EXP CELL RES, V190, P254, DOI 10.1016/0014-4827(90)90194-F; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NAIDET C, 1987, NATURE, V325, P348, DOI 10.1038/325348a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINBERG BM, 1980, J CELL BIOL, V87, P304, DOI 10.1083/jcb.87.1.304; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	30	356	362	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					403	410		10.1016/0092-8674(91)90191-Z	http://dx.doi.org/10.1016/0092-8674(91)90191-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1913826				2022-12-28	WOS:A1991GL47000019
J	REISER, SJ				REISER, SJ			ADMINISTRATIVE CASE ROUNDS - INSTITUTIONAL POLICIES AND LEADERS CAST IN A DIFFERENT LIGHT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											REISER, SJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,PROGRAM HUMANITIES & TECHNOL HLTH CARE,POB 20708,HOUSTON,TX 77225, USA.							BULGER RE, 1990, INTEGRITY HLTH CARE; Drucker, 1992, MANAGING NONPROFIT O; Huber P.W., 1991, LIABILITY MAZE IMPAC; REISER SJ, 1991, ANN INTERN MED, V114, P902, DOI 10.7326/0003-4819-114-10-902; RICH C, IN PRESS PRAGMATISM; WALTON M, 1990, DEMING MANAGEMENT WO	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	1991	266	15					2127	2128		10.1001/jama.266.15.2127	http://dx.doi.org/10.1001/jama.266.15.2127			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ474	1920702				2022-12-28	WOS:A1991GJ47400035
J	BELLET, PS; MALONEY, MJ				BELLET, PS; MALONEY, MJ			THE IMPORTANCE OF EMPATHY AS AN INTERVIEWING SKILL IN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CHILDRENS HOSP MED CTR,DEPT PSYCHIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,CINCINNATI,OH 45221	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati								ARING CD, 1958, JAMA-J AM MED ASSOC, V167, P448, DOI 10.1001/jama.1958.02990210034008; BERGER DM, 1987, CLIN EMPATHY; BOOK HE, 1991, AM J PSYCHOTHER, V45, P21, DOI 10.1176/appi.psychotherapy.1991.45.1.21; COUSINS N, 1985, NEW ENGL J MED, V313, P1422, DOI 10.1056/NEJM198511283132227; COUSINS N, 1982, JAMA-J AM MED ASSOC, V248, P210; ENGEL GL, 1973, ANN INTERN MED, V78, P587, DOI 10.7326/0003-4819-78-4-587; GREENSON RR, 1960, INT J PSYCHOANAL, V41, P418; HAVENS L, 1978, PSYCHIATRY, V41, P336, DOI 10.1080/00332747.1978.11023993; KOHUT H, 1982, INT J PSYCHOANAL, V63, P395; KORSCH BM, 1971, AM J DIS CHILD, V121, P110, DOI 10.1001/archpedi.1971.02100130064006; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; POOLE AD, 1979, SOC SCI MED-MED SOC, VA13, P37, DOI 10.1016/0271-7123(79)90006-3; SZALITA AB, 1976, PSYCHIATRY, V39, P142, DOI 10.1080/00332747.1976.11023884	13	145	147	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1831	1832		10.1001/jama.266.13.1831	http://dx.doi.org/10.1001/jama.266.13.1831			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG551	1909761				2022-12-28	WOS:A1991GG55100038
J	BROWN, MG; DRISCOLL, J; MONACO, JJ				BROWN, MG; DRISCOLL, J; MONACO, JJ			STRUCTURAL AND SEROLOGICAL SIMILARITY OF MHC-LINKED LMP AND PROTEASOME (MULTICATALYTIC PROTEINASE) COMPLEXES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; MAMMALIAN-CELLS; SKELETAL-MUSCLE; UBIQUITIN; TRANSPORTERS; ANTIGENS; GENE	MAJOR histocompatibility complex (MHC) class I molecules associate with peptides derived from endogenously synthesized antigens. Cytotoxic T-lymphocytes can thus scan class I molecules and bound peptide on the surface of cells for foreign antigenic determinants. Recent evidence 1,2 demonstrates that the products of trans-acting, non-class I genes in the class II region of the MHC are required in the class I antigen-processing pathway. There are genes (called HAM1 and HAM2 in the mouse) in this region that encode proteins postulated to be involved in the transport of peptide fragments into the endoplasmic reticulum for association with newly synthesized class I molecules 2-5. But, the mechanism by which such peptide fragments are produced remains a mystery. At least two genes encoding subunits of the low-molecular mass polypeptide (LMP) complex are tightly linked to the HAM1 and HAM2 genes. We show that the LMP complex is closely related to the proteasome (multicatalytic proteinase complex), an intracellular protein complex that has multiple proteolytic activities 6,7. We speculate that the LMP complex may have a role in MHC class I antigen processing, and therefore that the MHC contains a cluster of genes required for distinct functions in the antigen processing pathway.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	BROWN, MG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298, USA.		Brown, Michael G/AAX-5569-2021	Brown, Michael G/0000-0003-2872-7685; Driscoll, James/0000-0001-8364-0617				ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; MARTINEZ CK, IN PRESS NATURE, V353; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x	22	307	311	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					355	357		10.1038/353355a0	http://dx.doi.org/10.1038/353355a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922341				2022-12-28	WOS:A1991GG65400062
J	HOWARD, AJ; DUNKIN, KT; MUSSER, JM; PALMER, SR				HOWARD, AJ; DUNKIN, KT; MUSSER, JM; PALMER, SR			EPIDEMIOLOGY OF HAEMOPHILUS-INFLUENZAE TYPE-B INVASIVE DISEASE IN WALES	BRITISH MEDICAL JOURNAL			English	Article							MEMBRANE PROTEIN SUBTYPES; 10 YEARS EXPERIENCE; HEMOPHILUS-INFLUENZAE; BACTERIAL-MENINGITIS; CONJUGATE VACCINES; CHILDREN; POPULATION; AMPICILLIN; PREVENTION; RESISTANCE	Objective-To investigate the epidemiology of invasive disease due to Haemophilus influenzae type b, the clones responsible, and the antibiotic resistance of the isolates. Design-Prospective population based analysis of clinical and epidemiological data collected for Gwynedd during 1980-90 and in the whole of Wales during 1988-90. Setting-19 hospitals in Wales; all medical microbiology laboratories in Wales participated. Patients-82 patients with confirmed invasive infections caused by H influenzae type b in Gwynedd during 1980-90 and 207 in Wales during 1988-90. Main outcome measures-Clinical and epidemiological measures; analysis of the clonal types of the isolates based on the electrophoretic mobilities of 17 metabolic enzymes; and antibiotic resistance. Results-The annual incidence of H influenzae type b infections in Gwynedd was 3.2 cases/100 000 and in Wales was 2.5 cases/100 000. Most cases occurred in children aged under 5 years, the highest annual incidence being in those aged under 1 (84.6/100 000 and 56.9/100 000 in Wales). The cumulative risk of acquiring H influenzae type b disease by the fifth birthday was one in 456 in Gwynedd and one in 578 in Wales. Fifteen per cent of cases in Gwynedd and 7% of those in Wales occurred in adults. Predominant clinical conditions were meningitis in children and pneumonia in adults. In Gwynedd 2/70 (3%) children and 5/12 (42%) adults died. Long term neurological sequelae occurred in 8% (4/48) of children who survived haemophilus meningitis. Children presenting with infection were usually the youngest members of their family. No secondary household cases were identified. 100 of 128 (78%) strains were of a single clone, electrophoretic type 12.5, and 4/207 (1.9%) isolates from Wales were resistant to both ampicillin and chloramphenicol. Conclusions-The annual rate of infection in children aged under 5 in four Welsh counties was 12-44% higher than that previously published for the United Kingdom. The study emphasises the potential value of a vaccine effective in early infancy and provides baseline data to assess its efficacy after its introduction. Alternatives to ampicillin and chloramphenicol should be used as first line, empirical treatment for severe infections that might be caused by H influenzae type b in Wales.	PENN STATE UNIV,INST MOLEC EVOLUT GENET,UNIVERSITY PK,PA 16802; COMMUNICABLE DIS SURVEILLANCE CTR,WELSH UNIT,CARDIFF CF4 3QX,WALES	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	HOWARD, AJ (corresponding author), GWYNEDD HOSP,DEPT MED MICROBIOL,BANGOR LL57 2PW,WALES.				PHS HHS [A1 24332] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARENKAMP SJ, 1983, J INFECT DIS, V148, P1127, DOI 10.1093/infdis/148.6.1127; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; CAMPBELL H, 1990, PEDIATRICS, V86, P102; Cartwright K A, 1991, CDR (Lond Engl Rev), V1, pR2; DAVEY PG, 1982, J HYG-CAMBRIDGE, V88, P383, DOI 10.1017/S002217240007025X; DELRIO MDA, 1983, LANCET, V1, P1241; DYAS A, 1986, J INFECTION, V13, P179, DOI 10.1016/S0163-4453(86)93093-8; FEIGIN RD, 1976, J PEDIATR-US, V88, P542, DOI 10.1016/S0022-3476(76)80002-9; GOLDACRE MJ, 1976, LANCET, V1, P28; GRANOFF DM, 1986, J INFECT DIS, V153, P448, DOI 10.1093/infdis/153.3.448; GUNN BA, 1974, LANCET, V2, P845; HAMPTON CM, 1983, J CLIN MICROBIOL, V18, P596, DOI 10.1128/JCM.18.3.596-600.1983; HOWARD AJ, 1988, J ANTIMICROB CHEMOTH, V21, P251, DOI 10.1093/jac/21.2.251; MACHKA K, 1988, EUR J CLIN MICROBIOL, V7, P14, DOI 10.1007/BF01962165; MAKELA PH, 1990, PEDIATRICS, V85, P651; MUSSER JM, 1985, P NATL ACAD SCI USA, V82, P5078, DOI 10.1073/pnas.82.15.5078; MUSSER JM, 1990, REV INFECT DIS, V12, P75; SELL SHW, 1972, PEDIATRICS, V49, P206; SPROLES ET, 1969, J PEDIATR-US, V75, P782, DOI 10.1016/S0022-3476(69)80300-8; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; TAKALA AK, 1990, 30TH INT C ANT AG CH, P187; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; TEJANI A, 1982, DEV MED CHILD NEUROL, V24, P338; THOMAS WJ, 1974, LANCET, V1, P313; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WARD JI, 1979, NEW ENGL J MED, V301, P122, DOI 10.1056/NEJM197907193010302; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; WILLIAMS GT, 1989, ARCH DIS CHILD, V64, P517; 1985, DIGEST WELSH STATIST; 1989, DIGEST WELSH STATIST; 1984, PEDIATRICS, V74, P301	32	45	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					441	445		10.1136/bmj.303.6800.441	http://dx.doi.org/10.1136/bmj.303.6800.441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912835	Green Published, Bronze			2022-12-28	WOS:A1991GC46500015
J	SEURI, M				SEURI, M			RISK OF APPENDECTOMY IN OCCUPATIONS ENTAILING CONTACT WITH PIGS	BRITISH MEDICAL JOURNAL			English	Article							YERSINIA; INFECTION				SEURI, M (corresponding author), UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,POB 1627,SF-70211 KUOPIO,FINLAND.							ASPLUND K, 1990, ACTA VET SCAND, V31, P39; ATTWOOD SEA, 1987, LANCET, V1, P529; ATTWOOD SEA, 1989, BRIT J SURG, V76, P499, DOI 10.1002/bjs.1800760523; MERILAHTIPALO R, 1991, SCAND J INFECT DIS, V23, P55, DOI 10.3109/00365549109023375; TERTTI R, 1984, J INFECT DIS, V149, P245, DOI 10.1093/infdis/149.2.245	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					345	346		10.1136/bmj.303.6798.345-a	http://dx.doi.org/10.1136/bmj.303.6798.345-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GA606	1912777	Green Published, Bronze			2022-12-28	WOS:A1991GA60600023
J	RUOHOLA, H; BREMER, KA; BAKER, D; SWEDLOW, JR; JAN, LY; JAN, YN				RUOHOLA, H; BREMER, KA; BAKER, D; SWEDLOW, JR; JAN, LY; JAN, YN			ROLE OF NEUROGENIC GENES IN ESTABLISHMENT OF FOLLICLE CELL FATE AND OOCYTE POLARITY DURING OOGENESIS IN DROSOPHILA	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NOTCH LOCUS; C-ELEGANS; ANTEROPOSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; BICOID RNA; MELANOGASTER; PATTERN	Oogenesis in Drosophila involves specification of both germ cells and the surrounding somatic follicle cells, as well as the determination of oocyte polarity. We found that two neurogenic genes, Notch and Delta, are required in oogenesis. These genes encode membrane proteins with epidermal growth factor repeats and are essential in the decision of an embryonic ectodermal cell to take on the fate of neuroblast or epidermoblast. In oogenesis, mutation in either gene leads to an excess of posterior follicle cells, a cell fate change reminiscent of the hyperplasia of neuroblasts seen in neurogenic mutant embryos. Furthermore, the Notch mutation in somatic cells causes mislocalization of bicoid in the oocyte. These results suggest that the neurogenic genes Notch and Delta are involved in both follicle cell development and the establishment of anterior-posterior polarity in the oocyte.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD GRP BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	RUOHOLA, H (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Swedlow, Jason/0000-0002-2198-1958; Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; BUSSON D, 1983, GENETICS, V105, P309; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPOSORTEGA JA, 1991, IN PRESS ANN REV NEU; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DELACONCHA A, 1988, GENETICS, V118, P499; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EPHRUSSI A, 1991, IN PRESS CELL, V66; FASANO L, 1988, DEVELOPMENT, V104, P245; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HAENLIN M, 1990, DEVELOPMENT, V110, P905; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; King R. C., 1970, OVARIAN DEV DROSOPHI; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOCH EA, 1969, Z ZELLFORSCH MIK ANA, V102, P129, DOI 10.1007/BF00336421; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MAHOWALD AP, 1978, GENET BIOL DROSOPHIL, P141; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIESCHAUS E, 1980, DEV NEUROBIOLOGY DRO, P85; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	329	330	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					433	449		10.1016/0092-8674(81)90008-8	http://dx.doi.org/10.1016/0092-8674(81)90008-8			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1907889				2022-12-28	WOS:A1991GA94100006
J	FROMHERZ, P; OFFENHAUSSER, A; VETTER, T; WEIS, J				FROMHERZ, P; OFFENHAUSSER, A; VETTER, T; WEIS, J			A NEURON-SILICON JUNCTION - A RETZIUS CELL OF THE LEECH ON AN INSULATED-GATE FIELD-EFFECT TRANSISTOR	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; MICROELECTRODE ARRAY; PLANAR; POTENTIALS; CULTURE; INVITRO	An identified neuron of the leech, a Retzius cell, has been attached to the open gate of a p-channel field-effect transistor. Action potentials, spontaneous or stimulated, modulate directly the source-drain current in silicon. The electronic signals match the shape of the action potential. The average voltage on the gate was up to 25 percent of the intracellular voltage change. Occasionally weak signals that resemble the first derivative of the action potential were observed. The junctions can be described by a model that includes capacitive coupling of the plasma membrane and the gate oxide and that accounts for variable resistance of the seal.			FROMHERZ, P (corresponding author), UNIV ULM,BIOPHYS ABT,W-7900 ULM,GERMANY.		Offenhäusser, Andreas/E-7990-2012	Offenhäusser, Andreas/0000-0001-6143-2702				BERGVELD P, 1976, IEEE T BIO-MED ENG, V23, P136, DOI 10.1109/TBME.1976.324574; DIETZEL ID, 1986, J PHYSIOL-LONDON, V372, P191, DOI 10.1113/jphysiol.1986.sp016004; DRAKE KL, 1988, IEEE T BIO-MED ENG, V35, P719, DOI 10.1109/10.7273; GROSS GW, 1977, NEUROSCI LETT, V6, P101, DOI 10.1016/0304-3940(77)90003-9; JOBLING DT, 1981, MED BIOL ENG COMPUT, V19, P553, DOI 10.1007/BF02442768; KUPERSTEIN M, 1985, NEUROSCIENCE, V15, P703, DOI 10.1016/0306-4522(85)90072-7; NOVAK JL, 1986, IEEE T BIO-MED ENG, V33, P196, DOI 10.1109/TBME.1986.325891; PARSONS TD, 1989, BIOPHYS J, V56, P213, DOI 10.1016/S0006-3495(89)82666-9; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; REGEHR WG, 1988, IEEE T BIO-MED ENG, V35, P1023, DOI 10.1109/10.8687; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; TAKAHASHI K, 1984, SENSOR ACTUATOR, V5, P89, DOI 10.1016/0250-6874(84)87009-2; Wolf S., 1986, PROCESS TECHNOL INT, V1, P199	13	451	469	0	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1290	1293		10.1126/science.1925540	http://dx.doi.org/10.1126/science.1925540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925540				2022-12-28	WOS:A1991FN85700034
J	GODDARD, J; BLOOM, SR; FRACKOWIAK, RSJ; PUSEY, CD; MACDERMOT, J; LIDDLE, PF				GODDARD, J; BLOOM, SR; FRACKOWIAK, RSJ; PUSEY, CD; MACDERMOT, J; LIDDLE, PF			HAMMERSMITH STAFF ROUNDS - LITHIUM INTOXICATION	BRITISH MEDICAL JOURNAL			English	Discussion											GODDARD, J (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0HS,ENGLAND.		Frackowiak, Richard S/I-1809-2013; Frackowiak, Richard/H-4383-2011; Liddle, Peter/AAU-7939-2020	Frackowiak, Richard/0000-0002-3151-822X; 				APTE SN, 1983, ANN NEUROL, V13, P453, DOI 10.1002/ana.410130414; BENNET WM, 1986, KIDNEY, V1, P1449; CADE JFJ, 1949, MED J AUSTRALIA, V36, P349; GODINICH MJ, 1990, KIDNEY INT S28, V37, pS52; HANSEN EK, 1978, Q J MED, V186, P123; KINCAIDSMITH P, 1979, LANCET, V2, P700; LANGE C, 1897, HOSPITALSTIDENDE, V5, P21; LESLIE KO, 1980, J NEUROPATH EXP NEUR, V39, P370, DOI 10.1097/00005072-198005000-00108; MYERS UB, 1980, KIDNEY INT, V18, P607; SIMARD M, 1989, ARCH INTERN MED, V149, P36, DOI 10.1001/archinte.149.1.36; WALDMEIER P C, 1990, Pharmacology and Toxicology Supplement, V66, P121	11	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1267	1269		10.1136/bmj.302.6787.1267	http://dx.doi.org/10.1136/bmj.302.6787.1267			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1904289	Green Published, Bronze			2022-12-28	WOS:A1991FP27200032
J	DUMLER, JS				DUMLER, JS			FATAL ROCKY-MOUNTAIN-SPOTTED-FEVER IN MARYLAND 1901	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University								Badger LF, 1931, PUBLIC HEALTH REP, V46, P463, DOI 10.2307/4579958; DUMLER JS, 1990, AM J CLIN PATHOL, V93, P410, DOI 10.1093/ajcp/93.3.410; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; Lillie RD, 1931, PUBLIC HEALTH REP, V46, P2840, DOI 10.2307/4580261; Ricketts HT, 1906, J AMER MED ASSOC, V47, P33; WOODWARD TE, 1973, J INFECT DIS, V127, P583, DOI 10.1093/infdis/127.5.583; 1988, MMWR, V38, P513	7	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					718	718		10.1001/jama.265.6.718	http://dx.doi.org/10.1001/jama.265.6.718			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1899275				2022-12-28	WOS:A1991EW47900011
J	BUCHSBAUM, DG; BUCHANAN, RG; CENTOR, RM; SCHNOLL, SH; LAWTON, MJ				BUCHSBAUM, DG; BUCHANAN, RG; CENTOR, RM; SCHNOLL, SH; LAWTON, MJ			SCREENING FOR ALCOHOL-ABUSE USING CAGE SCORES AND LIKELIHOOD RATIOS	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-MAINTENANCE-ORGANIZATION; DIAGNOSTIC INTERVIEW SCHEDULE; GENERAL-PRACTICE; QUESTIONNAIRE; RECOGNITION; PREVALENCE; CONSUMPTION; POPULATION; VALIDATION; SERVICES	Objective: To assess the performance of the CAGE (acronym referring to four questions, see below) questionnaire in discriminating between medicine outpatients with and without an alcohol abuse or dependence disorder. Design: A cross-sectional design of a sample of consecutive patients who received both the alcohol module of the diagnostic interview schedule and the CAGE (Cut down, Annoyed, Guilty, Eye-opener) screening questionnaire. Setting: The outpatient medical practice of an urban university teaching hospital. Patients: All patients 18 years or older who signed a consent form approved by the university's institutional review board. Measurement: Calculation of the sensitivity, specificity, receiver operating characteristic (ROC) curve, and likelihood ratio for CAGE Scores of 0 to 4. Results: Thirty-six percent of the sample group met criteria for a history of alcohol abuse or dependence. A CAGE score of 2 or more was associated with a sensitivitY and specificity of 74% and 91%. The calculated area under the ROC curve was 0.89, whereas the likelihood ratios for CAGE scores of 0 to 4 were 0.14, 1.5, 4.5, 13, and 100, respectively. These ratios were associated with posterior probabilities for an abuse or dependence disorder of 7%, 46%, 72%, 88%, and 98%, respectively. Conclusion: Clinicians can improve their ability to estimate a patient's risk for an alcohol abuse or dependence disorder using likelihood ratios for CAGE scores.			BUCHSBAUM, DG (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, BOX 102, RICHMOND, VA 23298 USA.							BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BUCHSBAUM DG, 1991, ALCOHOL ALCOHOLISM, V26, P215, DOI 10.1093/oxfordjournals.alcalc.a045103; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CENTOR RM, 1989, 13TH P ANN S COMP AP; CLEARY PD, 1988, AM J MED, V85, P466; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; Ford D E, 1990, J Gen Intern Med, V5, pS37, DOI 10.1007/BF02600839; GART JJ, 1988, BIOMETRICS, V44, P323, DOI 10.2307/2531848; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; HELZER JE, 1987, ARCH GEN PSYCHIAT, V44, P1069; HOLDER HD, 1986, JAMA-J AM MED ASSOC, V256, P1456, DOI 10.1001/jama.256.11.1456; HSIAO JK, 1989, ARCH GEN PSYCHIAT, V46, P664; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; PUDDEY IB, 1987, LANCET, V1, P647; REIFF S, 1981, ALCOHOL CLIN EXP RES, V5, P559, DOI 10.1111/j.1530-0277.1981.tb05361.x; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINSON KS, 1987, CLIN RES, V35, pA92; ROGHMANN KJ, 1981, J STUD ALCOHOL, V42, P312, DOI 10.15288/jsa.1981.42.312; SCHWARTZ WB, 1981, NEW ENGL J MED, V305, P917, DOI 10.1056/NEJM198110153051604; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; WALLACE P, 1985, BRIT MED J, V290, P1949, DOI 10.1136/bmj.290.6486.1949; 1987, DIAGNOSTIC STATISTIC	30	264	264	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					774	777		10.7326/0003-4819-115-10-774	http://dx.doi.org/10.7326/0003-4819-115-10-774			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1929025				2022-12-28	WOS:A1991GP80000005
J	DANILA, RN; MACDONALD, KL; RHAME, FS; MOEN, ME; REIER, DO; LETOURNEAU, JC; SHEEHAN, MK; ARMSTRONG, J; BENDER, ME; OSTERHOLM, MT				DANILA, RN; MACDONALD, KL; RHAME, FS; MOEN, ME; REIER, DO; LETOURNEAU, JC; SHEEHAN, MK; ARMSTRONG, J; BENDER, ME; OSTERHOLM, MT			A LOOK-BACK INVESTIGATION OF PATIENTS OF AN HIV-INFECTED PHYSICIAN - PUBLIC-HEALTH IMPLICATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXAMINATION GLOVES; LATEX; VINYL; SURGEON; AIDS; TRANSMISSION; INDIVIDUALS; VIRUSES; BLOOD; RISK	Background. Transmission of the human immunodeficiency virus (HIV) to five patients receiving care from an HIV-infected dentist in Florida has recently been reported. Current data indicate that the risk of HIV transmission from health care workers to patients is extremely low. Despite this low risk. programs to notify patients of past exposure to an HIV-infected health care worker are being conducted with increasing frequency. Methods. We recently conducted an investigation of all the patients cared for by an HIV-infected family physician during a period when he had severe dermatitis caused by Mycobacterium marinum on his hands and forearms. After reviewing the patients' records, we notified 336 patients who had undergone one or more procedures (digital examination of a body cavity or vaginal delivery) placing them at potentially increased risk of HIV infection. The patients were offered tests for HIV infection and counseling. Results. Of the 336 patients, 325 (97 percent) had negative tests for HIV antibody, 3 (1 percent) refused testing, 1 (< 1 percent) died of a cause unrelated to HIV infection before notification, and the HIV-antibody status of 7 (2 percent) remained unknown. The direct and indirect public health costs of this investigation were approximately $130,000. Conclusions. The results of this investigation raise important questions about the risk of HIV transmission from health care workers to patients and the usefulness of HIV look-back programs, particularly in the light of recently published recommendations from the Centers for Disease Control. We propose that before a look-back investigation is undertaken, there should be a clearly identifiable risk of transmission of the infection, substantially higher than the risk requiring limitation of an HIV-infected health care worker's practice prospectively.	MINNESOTA DEPT HLTH, DIV DIS PREVENT & CONTROL, AIDS STD PREVENT SERV SECT, MINNEAPOLIS, MN 55440 USA; UNIV MINNESOTA HOSP & CLIN, MINNEAPOLIS, MN 55455 USA	Minnesota Department of Health (MHD); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital	DANILA, RN (corresponding author), MINNESOTA DEPT HLTH, DIV DIS PREVENT & CONTROL, ACUTE DIS EPIDEMIOL SECT, 717 SE DELAWARE ST, MINNEAPOLIS, MN 55440 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARMSTRONG FP, 1987, MIL MED, V152, P414; Comer R W, 1991, J Dent Educ, V55, P187; DALGLEISH AG, 1988, BRIT J SURG, V75, P171, DOI 10.1002/bjs.1800750229; DEGROOTKOSOLCHAROEN J, 1989, AM J INFECT CONTROL, V17, P196, DOI 10.1016/0196-6553(89)90128-4; DICKEY NW, 1991, JAMA-J AM MED ASSOC, V265, P2338, DOI 10.1001/jama.1991.03460180043023; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; KORNIEWICZ DM, 1990, J CLIN MICROBIOL, V28, P787, DOI 10.1128/JCM.28.4.787-788.1990; KOTILAINEN HR, 1989, ARCH INTERN MED, V149, P2749, DOI 10.1001/archinte.149.12.2749; MAKULOWICH GS, 1991, AIDS PATIENT CARE, V5, P143; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P1661; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SACKS JJ, 1986, NEW ENGL J MED, V314, P1190; STAVER S, 1991, AM MED NEWS     0610, P38; STAVER S, 1991, AM MED NEWS     0610, P3; STEIMER KS, 1986, J VIROL, V58, P9, DOI 10.1128/JVI.58.1.9-16.1986; STEIMER KS, 1986, VIROLOGY, V150, P283, DOI 10.1016/0042-6822(86)90289-8; VALKIRS GE, 1985, CLIN CHEM, V31, P1427; ZBITNEW A, 1989, J ACQ IMMUN DEF SYND, V2, P201; ZECKHAUSER RJ, 1990, SCIENCE, V248, P559, DOI 10.1126/science.2333509; 1986, MMWR, V35, P237; 1991, MMWR, V40, P33; 1991, AM DENTAL ASS POLICY; 1988, J AM DENT ASSOC, V116, P614; 1988, J AM DENT ASSOC, V116, P241; 1989, AM J INFECT CONTROL, V17, pA24; 1987, MMWR, V36, P1; 1986, MMWR, V35, P221; 1989, MMWR, V38, P1; 1990, MMWR, V39, P489; 1991, MMWR, V40, P377; 1990, CONTROL HOSP EPIDEMI, V11, P647; 1991, MMWR, V40, P21	38	64	64	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1406	1411		10.1056/NEJM199111143252003	http://dx.doi.org/10.1056/NEJM199111143252003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922251				2022-12-28	WOS:A1991GP52400003
J	BEUTLER, E				BEUTLER, E			CURRENT CONCEPTS - GAUCHERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; MEDIATED GENE-TRANSFER; ACID BETA-GLUCOSIDASE; HUMAN GLUCOCEREBROSIDASE; REPLACEMENT THERAPY; SPLENECTOMY; MUTATIONS; ENZYME; CELLS; POLYMORPHISM				BEUTLER, E (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036639] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIDDK NIH HHS [DK36639] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; ASHKENAZI A, 1986, EUR J PEDIATR, V145, P138, DOI 10.1007/BF00441877; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BELCHETZ PE, 1977, LANCET, V2, P116; BEUTLER E, 1990, BLOOD, V76, P646; BEUTLER E, 1977, WESTERN J MED, V126, P46; BEUTLER E, 1990, CLIN CHIM ACTA, V194, P161, DOI 10.1016/0009-8981(90)90130-K; BEUTLER E, 1977, P NATL ACAD SCI USA, V74, P4620, DOI 10.1073/pnas.74.10.4620; BEUTLER E, 1991, BLOOD, V78, P1183; BEUTLER E, 1988, BLOOD REV, V2, P59, DOI 10.1016/0268-960X(88)90009-4; BEUTLER E, 1979, GENETIC DISEASES ASH, P157; BEUTLER E, IN PRESS P NATL ACAD; BEUTLER E, IN PRESS N ENGL J ME; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; BRADY RO, 1965, J BIOL CHEM, V240, P39; CHANGLO M, 1967, AM J MED SCI, V254, P303, DOI 10.1097/00000441-196709000-00005; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; ERIKSON A, 1990, ACTA PAEDIATR SCAND, V79, P680, DOI 10.1111/j.1651-2227.1990.tb11535.x; EYAL N, 1990, GENE, V96, P277, DOI 10.1016/0378-1119(90)90264-R; FINK JK, 1990, P NATL ACAD SCI USA, V87, P2334, DOI 10.1073/pnas.87.6.2334; FLESHNER PR, 1991, AM J SURG, V161, P69, DOI 10.1016/0002-9610(91)90363-I; FURBISH FS, 1978, BIOCHEM BIOPH RES CO, V81, P1047, DOI 10.1016/0006-291X(78)91456-0; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GINSBURG SJ, 1973, J PEDIATR-US, V82, P1046, DOI 10.1016/S0022-3476(73)80441-X; Grabowski G A, 1982, Prog Clin Biol Res, V95, P573; GRABOWSKI GA, 1985, AM J HUM GENET, V37, P499; HOBBS JR, 1987, LANCET, V1, P1111; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; ISELIUS L, 1989, ACTA PAEDIATR SCAND, V78, P592, DOI 10.1111/j.1651-2227.1989.tb17942.x; KOHN DB, 1991, HUM GENE THER, V2, P101, DOI 10.1089/hum.1991.2.2-101; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; Lee R E, 1982, Prog Clin Biol Res, V95, P177; LIEBERMAN J, 1976, NEW ENGL J MED, V294, P1442, DOI 10.1056/NEJM197606242942609; Martin B M, 1989, Adv Pediatr, V36, P277; MASUNO M, 1990, HUM GENET, V84, P203; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; RAPPEPORT JM, 1984, NEW ENGL J MED, V311, P84, DOI 10.1056/NEJM198407123110203; ROBINSON DB, 1980, CLIN CHEM, V26, P371; ROTTER JI, 1987, NATURE, V329, P289, DOI 10.1038/329289a0; SAMAMA G, 1989, PRESSE MED, V18, P1078; SCHNEIDER EL, 1977, AM J MED, V63, P475, DOI 10.1016/0002-9343(77)90288-1; SHAFITZAGARDO B, 1981, AM J HUM GENET, V33, P564; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; SORGE J, 1985, P NATL ACAD SCI USA, V82, P7289, DOI 10.1073/pnas.82.21.7289; SORGE J, 1987, P NATL ACAD SCI USA, V84, P906, DOI 10.1073/pnas.84.4.906; STOWENS DW, 1985, MEDICINE, V64, P310, DOI 10.1097/00005792-198509000-00003; YOSIPOVITCH Z, 1990, ISRAEL J MED SCI, V26, P593; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1990, AM J HUM GENET, V46, P902; ZIMRAN A, 1990, J CLIN INVEST, V85, P219, DOI 10.1172/JCI114415; ZIMRAN A, IN PRESS AM J HUM GE; ZIMRAN A, IN PRESS N ENGL J ME; 1991, FDA MED B, V21, P6	54	134	145	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 7	1991	325	19					1354	1360						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN470	1922238				2022-12-28	WOS:A1991GN47000006
J	VANGIJN, J; ALGRA, A; KAPPELLE, J; KOUDSTAAL, PJ; VANLATUM, LJ				VANGIJN, J; ALGRA, A; KAPPELLE, J; KOUDSTAAL, PJ; VANLATUM, LJ		DUTCH TIA TRIAL STUDY GRP	A COMPARISON OF 2 DOSES OF ASPIRIN (30 MG VS 283 MG A DAY) IN PATIENTS AFTER A TRANSIENT ISCHEMIC ATTACK OR MINOR ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLATELET CYCLOOXYGENASE INHIBITION; PREGNANCY-INDUCED HYPERTENSION; INTEROBSERVER AGREEMENT; CLINICAL-TRIALS; BLEEDING-TIME; THROMBOXANE; PHARMACOLOGY; ACETYLATION; HANDICAP	Background. Aspirin is known to improve the outcome of patients who have had a cerebral transient ischemic attack, but the optimal dose of aspirin remains uncertain. Experimental evidence indicates that 30 mg of aspirin daily alters platelet aggregation more favorably than the 300-mg dose currently used in patients after transient ischemic attack or minor ischemic stroke. Methods. We assessed the effects of two doses of a water-soluble preparation of acetylsalicylic acid, or aspirin (30 mg vs. 283 mg a day), on the occurrence of death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction in a double-blind, randomized, controlled clinical trial in patients who had had a transient ischemic attack or minor stroke. A total of 3131 patients participated in the study. The mean follow-up was 2.6 years. Results. In the group assigned to receive 30 mg of aspirin, the frequency of death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction was 228 of 1555 (14.7 percent), as compared with 240 of 1576 (15.2 percent) in the group assigned to receive 283 mg. The age- and sex-adjusted hazard ratio for the group receiving the lower dose was 0.91 (95 percent confidence interval, 0.76 to 1.09). There were slightly fewer major bleeding complications in the 30-mg group than in the 283-mg group (40 vs. 53), and significantly fewer reports of minor bleeding (49 vs. 84). Fewer patients receiving 30 mg of aspirin reported gastrointestinal symptoms (164 vs. 179) and other adverse effects (73 vs. 90). Conclusions. Our data indicate that 30 mg of aspirin daily is no less effective in the prevention of vascular events than a 283-mg dose in patients with a transient ischemic attack or minor stroke, and has fewer adverse effects.	UNIV HOSP ROTTERDAM, ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; UNIV UTRECHT, UTRECHT, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Utrecht University	VANGIJN, J (corresponding author), UNIV HOSP UTRECHT, DEPT NEUROL, POB 85500, NL-3508 GA UTRECHT, NETHERLANDS.		van Gijn, Jan/A-9444-2008					[Anonymous], 1987, Lancet, V2, P1351; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P316; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1988, Stroke, V19, P512; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; COX DR, 1972, J R STAT SOC B, V34, P187; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; GASPARI F, 1987, J CLIN INVEST, V79, P1788, DOI 10.1172/JCI113020; GREENBERG H, 1987, AM J CARDIOL, V59, P1057, DOI 10.1016/0002-9149(87)90848-4; KALLMAN R, 1987, THROMB RES, V45, P355, DOI 10.1016/0049-3848(87)90224-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; PATRONO C, 1989, TRENDS PHARMACOL SCI, V10, P453, DOI 10.1016/S0165-6147(89)80010-0; PATRONO C, 1985, CIRCULATION, V72, P1177, DOI 10.1161/01.CIR.72.6.1177; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PEDERSEN AK, 1985, CIRCULATION, V72, P1164, DOI 10.1161/01.CIR.72.6.1164; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RAGHOEBAR M, 1986, BIOPHARM DRUG DISPOS, V7, P183, DOI 10.1002/bdd.2510070209; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WALLENBURG HCS, 1986, LANCET, V1, P1; 1990, LANCET, P827; 1990, STATISTICS EPIDEMIOL	27	592	598	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1261	1266		10.1056/nejm199110313251801	http://dx.doi.org/10.1056/nejm199110313251801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922220				2022-12-28	WOS:A1991GM04100001
J	BUERSTEDDE, JM; TAKEDA, S				BUERSTEDDE, JM; TAKEDA, S			INCREASED RATIO OF TARGETED TO RANDOM INTEGRATION AFTER TRANSFECTION OF CHICKEN B-CELL LINES	CELL			English	Article							LIGHT-CHAIN GENE; BETA-ACTIN GENE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; OVALBUMIN GENE; NUCLEOTIDE-SEQUENCE; DNA-SEQUENCES; STEM-CELLS; EXPRESSION; REGION	Constructs of four different genetic loci were transfected into the avian leukosis virus-induced chicken B cell line DT40, which continues diversification of its rearranged light chain immunoglobulin gene by gene conversion. Analysis of stable transfectants revealed an unexpectedly high frequency of targeted integration into the homologous gene loci of DT40. Transcriptional activity of the target gene locus is not required, since a construct of the untranscribed ovalbumin gene also integrated predominantly by homologous recombination. A construct derived from the beta-actin locus was transfected into other chicken cell lines to determine the cell type specificity of the phenomenon. Targeted integration still occurred at high frequency in two other B cell lines that do not have the gene conversion activity. However, the ratios of targeted to random integration were reduced by at least one order of magnitude in three non-B cell lines.			BUERSTEDDE, JM (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.			Takeda, Shunichi/0000-0002-7924-7991				ADAIR GM, 1989, P NATL ACAD SCI USA, V86, P4574, DOI 10.1073/pnas.86.12.4574; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BEUG H, 1982, J CELL PHYSIOL, P195; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CALNEK BW, 1981, INFECT IMMUN, V34, P483, DOI 10.1128/IAI.34.2.483-491.1981; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CHANG XB, 1987, P NATL ACAD SCI USA, V84, P4959, DOI 10.1073/pnas.84.14.4959; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; HEILIG R, 1982, J MOL BIOL, V156, P1, DOI 10.1016/0022-2836(82)90455-7; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; KIM S, 1990, MOL CELL BIOL, V10, P3224, DOI 10.1128/MCB.10.6.3224; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; LAI EC, 1980, P NATL ACAD SCI-BIOL, V77, P244, DOI 10.1073/pnas.77.1.244; MANSIKKA A, 1990, P NATL ACAD SCI USA, V87, P9416, DOI 10.1073/pnas.87.23.9416; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIYAZAKI J, 1989, GENE, V79, P269; MOSCOVICI C, 1982, EXPRESSION DIFFERENT; OMALLEY BW, 1974, SCIENCE, V183, P610, DOI 10.1126/science.183.4125.610; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294; WOO SLC, 1981, BIOCHEMISTRY-US, V20, P6437, DOI 10.1021/bi00525a024; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	34	467	482	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					179	188		10.1016/0092-8674(91)90581-I	http://dx.doi.org/10.1016/0092-8674(91)90581-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913816				2022-12-28	WOS:A1991GJ32000016
J	MARTIN, K; HELENIUS, A				MARTIN, K; HELENIUS, A			NUCLEAR TRANSPORT OF INFLUENZA-VIRUS RIBONUCLEOPROTEINS - THE VIRAL MATRIX PROTEIN (M1) PROMOTES EXPORT AND INHIBITS IMPORT	CELL			English	Article							MESSENGER-RNA; A VIRUS; MONOCLONAL-ANTIBODIES; INFECTED-CELLS; MEDIATED TRANSLOCATION; XENOPUS OOCYTES; KINASE-C; NUCLEOPROTEIN; SEQUENCE; BINDING	Because influenza virus replicates in the nucleus and buds from the plasma membrane, its ribonucleoproteins (RNPs) must undergo bidirectional transport across the nuclear membrane. Export from the nucleus to the cytoplasm was found to depend on the viral matrix protein (M1). M1 associated with newly assembled viral RNPs (vRNPs) in the nucleus and escorted them to the cytoplasm through the nuclear pores. In contrast, during entry of the virus into a new host cell, M1 protein dissociated from the RNPs, allowing them to enter the nucleus. Amantadine, an antiviral agent that induces an early block in influenza A infection, was found to block the dissociation event and thereby to prevent import of incoming RNPs into the nucleus. Together, these results showed that M1 modulates the directionality of vRNP transport into and out of the nucleus.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University	MARTIN, K (corresponding author), YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA.				NIAID NIH HHS [AI18599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018599, R01AI018599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADSHAW GL, 1989, J VIROL, V63, P1704, DOI 10.1128/JVI.63.4.1704-1714.1989; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOPPIN PW, 1975, INFLUENZA VIRUSES IN, P15; COMPANS PM, 1975, COMPREHENSIVE VIROLO, P179; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FLAWITH JWF, 1979, J GEN VIROL, V45, P527, DOI 10.1099/0022-1317-45-2-527; FRANKLIN RM, 1959, VIROLOGY, V8, P293, DOI 10.1016/0042-6822(59)90031-5; Goldfarb DS, 1989, CURR OPIN CELL BIOL, V1, P441, DOI 10.1016/0955-0674(89)90003-3; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAY AJ, 1975, NEGATIVE STRAND VIRU, P635; HEGGENESS MH, 1982, VIROLOGY, V118, P466, DOI 10.1016/0042-6822(82)90367-1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HSU MT, 1987, P NATL ACAD SCI USA, V84, P8140, DOI 10.1073/pnas.84.22.8140; INGLIS SC, 1984, J GEN VIROL, V65, P153, DOI 10.1099/0022-1317-65-1-153; JONES IM, 1986, EMBO J, V5, P2371, DOI 10.1002/j.1460-2075.1986.tb04506.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAWAKAMI K, 1983, J BIOCHEM-TOKYO, V93, P989, DOI 10.1093/oxfordjournals.jbchem.a134254; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KISTNER O, 1989, J GEN VIROL, V70, P2421, DOI 10.1099/0022-1317-70-9-2421; KRUG RM, 1989, INFLUENZA VIRUSES, P89; KUROKAWA M, 1990, J GEN VIROL, V71, P2149, DOI 10.1099/0022-1317-71-9-2149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MURTI KG, 1988, VIROLOGY, V164, P562, DOI 10.1016/0042-6822(88)90574-0; NATH ST, 1990, MOL CELL BIOL, V10, P4139, DOI 10.1128/MCB.10.8.4139; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PALESE P, 1977, CELL, V10, P1, DOI 10.1016/0092-8674(77)90133-7; PATTERSON S, 1988, J GEN VIROL, V69, P1859, DOI 10.1099/0022-1317-69-8-1859; REES PJ, 1981, J GEN VIROL, V53, P125, DOI 10.1099/0022-1317-53-1-125; REES PJ, 1982, J GEN VIROL, V59, P403, DOI 10.1099/0022-1317-59-2-403; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIGG RJ, 1989, J GEN VIROL, V70, P2097, DOI 10.1099/0022-1317-70-8-2097; RITCHEY MB, 1977, J VIROL, V21, P1196, DOI 10.1128/JVI.21.3.1196-1204.1977; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; RUIGROK RWH, 1989, VIROLOGY, V173, P311, DOI 10.1016/0042-6822(89)90248-1; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKEHEL JJ, 1971, VIROLOGY, V44, P396, DOI 10.1016/0042-6822(71)90270-4; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VANWYKE KL, 1980, J VIROL, V35, P24, DOI 10.1128/JVI.35.1.24-30.1980; VANWYKE KL, 1981, J VIROL, V39, P313, DOI 10.1128/JVI.39.1.313-317.1981; WINTER G, 1980, NUCLEIC ACIDS RES, V8, P1965, DOI 10.1093/nar/8.9.1965; WINTER G, 1981, VIROLOGY, V114, P423, DOI 10.1016/0042-6822(81)90223-3; YE ZP, 1989, J VIROL, V63, P3586, DOI 10.1128/JVI.63.9.3586-3594.1989; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	78	490	510	4	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					117	130		10.1016/0092-8674(91)90576-K	http://dx.doi.org/10.1016/0092-8674(91)90576-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913813				2022-12-28	WOS:A1991GJ32000011
J	FIRTHCOZENS, J; VENNING, P				FIRTHCOZENS, J; VENNING, P			AUDIT OFFICERS - WHAT ARE THEY UP TO	BRITISH MEDICAL JOURNAL			English	Article									NW REG HLTH AUTHOR,MANCHESTER M60 7LP,ENGLAND		FIRTHCOZENS, J (corresponding author), YORKSHIRE REG HLTH AUTHOR,QUEENS BLDG,PK PARADE,HARROGATE HG1 5AH,YORKS,ENGLAND.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					631	632		10.1136/bmj.303.6803.631	http://dx.doi.org/10.1136/bmj.303.6803.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932908	Bronze, Green Published			2022-12-28	WOS:A1991GF67500028
J	NOAH, ND				NOAH, ND			COMMUNICABLE DISEASES OTHER THAN AIDS	BRITISH MEDICAL JOURNAL			English	Article							OUTBREAK				NOAH, ND (corresponding author), KINGS COLL,SCH MED & DENT,DEPT PUBL HLTH & EPIDEMIOL,LONDON SE5 9PJ,ENGLAND.							BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; HELLER D, 1986, BRIT MED J, V292, P1726, DOI 10.1136/bmj.292.6537.1726; OMAHONY MC, 1990, EPIDEMIOL INFECT, V104, P361, DOI 10.1017/S0950268800047385; 1988, BROADCASTING HOUSE L; 1988, HOSPITAL INFECTION C; 1990, MICROBIOLOGICAL SAFE; 1991, HLTH NATION; 1991, UK LEVELS HLTH 1ST R	8	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					639	640		10.1136/bmj.303.6803.639	http://dx.doi.org/10.1136/bmj.303.6803.639			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932912	Green Published, Bronze			2022-12-28	WOS:A1991GF67500032
J	JOHNSON, AM				JOHNSON, AM			HIV AND AIDS	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, AM (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ADES AE, 1991, LANCET, P1562; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; DUNNELL K, 1991, POPULATION TRENDS, V64, P38; JOHNSON AM, 1989, AIDS, V3, P135, DOI 10.1097/00002030-198903000-00003; JOHNSON AM, 1989, PHILOS T R SOC LOND, V325, P115; MCGINNIS JM, 1985, OXFORD TXB PUBLIC HL, P385; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; WODAK A, 1990, AIDS (London), V4, pS105; 1988, REPORT; 1988, AIDS STRATEGIC MONIT; 1980, PROMOTING HLTH PERVE; 1988, MMWR, V37, P565; 1990, MMWR, V39, P54; 1990, NEW CASES NHS GENITO; 1991, UK LEVELS HLTH; 1991, HLTH NATION; 1990, MMWR, V40, P41; 1990, DHHS PHS9050212 PUBL; 1979, DHEW PHS7955071 PUBL; 1991, 1 PUBL HLTH LAB SERV, pR69	20	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					573	576		10.1136/bmj.303.6802.573	http://dx.doi.org/10.1136/bmj.303.6802.573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912891	Bronze, Green Published			2022-12-28	WOS:A1991GE94800030
J	FITZPATRICK, MM; SHAH, V; TROMPETER, RS; DILLON, MJ; BARRATT, TM				FITZPATRICK, MM; SHAH, V; TROMPETER, RS; DILLON, MJ; BARRATT, TM			LONG-TERM RENAL OUTCOME OF CHILDHOOD HEMOLYTIC UREMIC SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOLYTIC-UREMIC SYNDROME; PROGNOSTIC FEATURES; ESCHERICHIA-COLI	Objective - To evaluate the long term outcome of renal function in infants and children after diarrhoea associated haemolytic uraemic syndrome. Setting - The Hospital for Sick Children, Great Ormond Street, and the Royal Free Hospital, London. Subjects - 103 children with the syndrome who presented between 1966 and 1985; 88 attended for follow up investigations (40 male, 48 female) with a mean age 11.6 (range 5.2-22.6) years and a mean duration of follow up of 8.5 (range 5.1-21.3) years. Main outcome measures - Blood pressure, ratio of early morning urine albumin to creatinine concentration, glomerular filtration rate, and plasma renin activity. Results - The mean (SD) systolic blood pressure standard deviation score was 0.38 (0.67) and diastolic blood pressure SD score was 0.10 (0.76). The geometric mean ratio of overnight urine albumin to creatinine concentration was 1.27 (range 0.03-48.2), significantly higher than the value observed in 77 normal children (0.32 (0.05-1.95), p < 0.0001). Glomerular filtration rate estimated from the plasma clearance of chromium-51 EDTA was 95.1 (22.7) ml/min/1.73 m2 surface area, and 16 children had a rate of less-than-or-equal-to 80 ml/min/1.73 m2. Significant negative correlations were found between glomerular filtration rate and urinary albumin to creatinine ratio (r = -0.41, p < 0.0001) and glomerular filtration rate and systolic blood pressure SD score (r = -0.48, p < 0.0001). A significant positive correlation was found between urinary albumin to creatinine ratio and systolic blood pressure SD score (r = 0.25, p = 0.02). Conclusions - After an acute episode of diarrhoea associated haemolytic uraemic syndrome 31% (27/88) of children had an increased albumin excretion, 18% (16/88) had a reduced glomerular filtration rate and 10% (9/88) had both, in association with a higher systolic blood pressure, indicating considerable residual nephropathy in this group.	INST CHILD HLTH, MED LAB, LONDON WC1N 1EH, ENGLAND	University of London; University College London	FITZPATRICK, MM (corresponding author), INST CHILD HLTH, DEPT PAEDIAT NEPHROL, LONDON WC1N 1EH, ENGLAND.							[Anonymous], 1987, PEDIATRICS, V79, P1; CHANTLER C, 1972, ARCH DIS CHILD, V47, P613, DOI 10.1136/adc.47.254.613; COAD NAG, 1991, CLIN NEPHROL, V35, P10; DILLON MJ, 1975, J CLIN PATHOL, V28, P625, DOI 10.1136/jcp.28.8.625; DONCKERWOLCKE RA, 1979, PAEDIATRICIAN, V8, P378; GASSER C, 1955, Schweiz Med Wochenschr, V85, P905; GIANANTONIO CA, 1973, NEPHRON, V11, P174; GIBB DM, 1990, THESIS U BRISTOL BRI; HABIB R, 1982, ADV NEPHROL, V14, P109; KAPLAN BS, 1971, J PEDIATR-US, V78, P420, DOI 10.1016/S0022-3476(71)80221-4; KAPLAN BS, 1977, CLIN NEPHROL, V8, P495; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; LEVIN M, 1984, ARCH DIS CHILD, V59, P397, DOI 10.1136/adc.59.5.397; Levin M, 1989, Adv Pediatr Infect Dis, V4, P51; LOIRAT C, 1984, ACTA PAEDIATR SCAND, V73, P505, DOI 10.1111/j.1651-2227.1984.tb09962.x; LONDE S, 1985, PEDIATRICS, V76, P460; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MILFORD DV, 1990, ARCH DIS CHILD, V65, P716, DOI 10.1136/adc.65.7.716; MILFORD DV, 1991, J PEDIATR-US, V118, P191, DOI 10.1016/S0022-3476(05)80481-0; MUAKA PBK, 1981, EUR J PEDIATR, V136, P237; PERELSTEIN EM, 1990, ARCH DIS CHILD, V65, P728, DOI 10.1136/adc.65.7.728; SIENIAWSKA M, 1990, PEDIATR NEPHROL, V4, P213, DOI 10.1007/BF00857656; TROMPETER RS, 1983, ARCH DIS CHILD, V58, P101, DOI 10.1136/adc.58.2.101; VANDYCK M, 1988, CLIN NEPHROL, V29, P109; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; WRIGHT BM, 1970, LANCET, V1, P337	26	83	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1991	303	6801					489	492		10.1136/bmj.303.6801.489	http://dx.doi.org/10.1136/bmj.303.6801.489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912857	Green Published, Bronze			2022-12-28	WOS:A1991GD80400014
J	MEYNAAR, IA; VANTWOUT, JW; VANDENBROUCKE, JP; VANFURTH, R				MEYNAAR, IA; VANTWOUT, JW; VANDENBROUCKE, JP; VANFURTH, R			USE OF INFLUENZA VACCINE IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV,DEPT INFECT DIS,HOSP BLDG 1,CS-P,POB 9600,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC			Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				FRANK JW, 1985, CAN MED ASSOC J, V132, P371; HOFSTRA ML, 1990, HUISARTS WET, V33, P429; MCKINNEY WP, 1989, AM J PUBLIC HEALTH, V79, P1422, DOI 10.2105/AJPH.79.10.1422; NICHOLSON KG, 1990, BRIT MED J, V301, P617, DOI 10.1136/bmj.301.6753.617; 1990, VACCINATIE TEGEN INF	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					508	508		10.1136/bmj.303.6801.508	http://dx.doi.org/10.1136/bmj.303.6801.508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912862	Bronze, Green Published			2022-12-28	WOS:A1991GD80400019
J	WILLIAMSON, JD				WILLIAMSON, JD			DEALING WITH EXTRACONTRACTUAL REFERRALS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe the mechanism established by Richmond, Twickenham, and Roehampton Health Authority to manage extracontractual referral requests made on behalf of its resident population and to examine its working in the first three months of the new arrangements. Design - Description of the procedures for managing extracontractual referrals and the decisions made on requests submitted to the district health authority between 1 April and 30 June 1991. Results - 235 requests were submitted, 79 for emergency care. 156 requests were clearly for elective treatments and, of these, 61 were ultimately refused, 20 because the district health authority was not liable to pay. Of the remaining 41, 17 were appealed successfully and three unsuccessfully. More than half of the elective extracontractual referrals correctly submitted were to either orthopaedics, general surgery, oral surgery, gynaecology, or plastic surgery. Overall, the district health authority approved three quarters of the requests for which it would be financially liable; this was the predicted workload for the period. Conclusions - The management of extracontractual referral requests is complex and time consuming for clinicians and managers alike. Patient choice is clearly being limited to some extent, but this is necessary if the number of requests is not to exceed the levels on which funding is based.			WILLIAMSON, JD (corresponding author), QUEEN MARYS UNIV HOSP,RICHMOND TWICKENHAM & ROEHAMPTON HLTH AUTHOR,LONDON SW15 5PN,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					499	504		10.1136/bmj.303.6801.499	http://dx.doi.org/10.1136/bmj.303.6801.499			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912860	Green Published, Bronze			2022-12-28	WOS:A1991GD80400017
J	MUGFORD, M; BANFIELD, P; OHANLON, M				MUGFORD, M; BANFIELD, P; OHANLON, M			EFFECTS OF FEEDBACK OF INFORMATION ON CLINICAL-PRACTICE - A REVIEW	BRITISH MEDICAL JOURNAL			English	Review							CONTINUING MEDICAL-EDUCATION; CESAREAN-SECTION RATES; TEST-ORDERING BEHAVIOR; DIAGNOSTIC-TESTS; RANDOMIZED TRIAL; GENERAL-PRACTITIONERS; PHYSICIAN EDUCATION; QUALITY ASSURANCE; COST AUDITS; SELF-AUDIT	Objective - To establish what is known about the role of feedback of statistical information in changing clinical practice. Design - Review of 36 studies of interventions entailing the use of statistical information for audit or practice review, which used a formal research design. Subjects - Papers identified from computer searches of medical and health service management publications, of which 36 describing studies of interventions designed to influence clinical care and including information feedback from clinical or administrative data systems were reviewed. Main outcome measures - Evidence for effect of information feedback on change in clinical practice. Results - Information feedback was most likely to influence clinical practice if it was part of strategy to target decision makers who had already agreed to review their practice. A more direct effect was discernable if the information was presented close to the time of decision making. The questions of the optimum layout and quantity of information were not addressed; the 36 papers were insufficient for defining good formats for information to be used for audit or quality assurance. Conclusions - Given the cost of information processing and the current emphasis on closing the audit loop in the health services, it is important that the use of information in the audit process should be critically evaluated.	ST MARYS HOSP,SCH MED,DEPT OBSTET,LONDON W2 1PG,ENGLAND	Imperial College London	MUGFORD, M (corresponding author), RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.							ANDERSON CM, 1988, BRIT MED J, V297, P113, DOI 10.1136/bmj.297.6641.113; Barr A, 1986, Hosp Health Serv Rev, V82, P70; Braham R L, 1987, Health Care Manage Rev, V12, P11; CHASSIN MR, 1986, JAMA-J AM MED ASSOC, V256, P1012, DOI 10.1001/jama.256.8.1012; COHEN DI, 1982, MED CARE, V20, P286, DOI 10.1097/00005650-198203000-00005; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; CUMMINGS KM, 1982, MED CARE, V20, P293, DOI 10.1097/00005650-198203000-00006; DOMENIGHETTI G, 1988, LANCET, V2, P1470; DYCK FJ, 1977, NEW ENGL J MED, V296, P1326, DOI 10.1056/NEJM197706092962306; EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; EVANS CE, 1986, JAMA-J AM MED ASSOC, V255, P501; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; FINN AF, 1988, JAMA-J AM MED ASSOC, V259, P2549, DOI 10.1001/jama.259.17.2549; FOWKES FGR, 1985, MED EDUC, V19, P113, DOI 10.1111/j.1365-2923.1985.tb01150.x; FOWKES FGR, 1985, 57 KINGS FUND PROJ P; GLEICHER N, 1984, JAMA-J AM MED ASSOC, V252, P3273; GRANT GB, 1985, LANCET, V1, P1030; GRIVELL AR, 1981, CLIN CHEM, V27, P1717; GROSSMAN RM, 1983, MED CARE, V21, P783, DOI 10.1097/00005650-198308000-00003; HARRIS CM, 1984, 24 OCC PAP; HEMMINKI E, 1976, DRUG INTEL CLIN PHAR, V10, P321, DOI 10.1177/106002807601000603; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; LINN BS, 1980, JAMA-J AM MED ASSOC, V244, P565, DOI 10.1001/jama.244.6.565; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; LONG MJ, 1983, MED CARE, V21, P243, DOI 10.1097/00005650-198302000-00011; MACDONALDROSS M, 1977, AV COMMUN REV, V25, P359; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MITCHELL MW, 1985, J ROY COLL PHYS LOND, V19, P251; Morgan M, 1978, QRB Qual Rev Bull, V4, P33; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; NELSON AR, 1976, NEW ENGL J MED, V295, P617, DOI 10.1056/NEJM197609092951111; NORTON PG, 1985, J FAM PRACTICE, V21, P289; PARRINO TA, 1989, AM J MED, V86, P442, DOI 10.1016/0002-9343(89)90343-4; POP P, 1989, J ROY COLL GEN PRACT, V39, P507; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; Schlager D D, 1983, J Med Syst, V7, P137, DOI 10.1007/BF00995120; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; SHAW CD, 1980, BRIT MED J, V280, P1314, DOI 10.1136/bmj.280.6227.1314; SHAW CD, 1980, BRIT MED J, V280, P1256, DOI 10.1136/bmj.280.6226.1256; SHAW CD, 1980, BRIT MED J, V280, P1443, DOI 10.1136/bmj.280.6229.1443; SHAW CD, 1980, BRIT MED J, V280, P1509, DOI 10.1136/bmj.280.6230.1509; SHAW CD, 1980, BRIT MED J, V280, P1361, DOI 10.1136/bmj.280.6228.1361; SIBLEY JC, 1982, NEW ENGL J MED, V306, P511, DOI 10.1056/NEJM198203043060904; SUNDERLAND R, 1985, ARCH DIS CHILD, V60, P593, DOI 10.1136/adc.60.6.593; SWOR RA, 1990, ANN EMERG MED, V19, P286, DOI 10.1016/S0196-0644(05)82048-7; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WEINGARTEN MA, 1989, FAM PRACT, V6, P120, DOI 10.1093/fampra/6.2.120; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; WENNBERG JE, 1977, PEDIATRICS, V59, P821; WHITESIDE ME, 1987, HOSP FORMUL, V22, P561; WHITESIDE ME, 1987, HOSPITAL FORMULARY, V22, P568; WHITESIDE ME, 1987, HOSPITAL FORMULARY, V22, P566; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005; WILLIAMS RL, 1983, AM J PUBLIC HEALTH, V73, P863, DOI 10.2105/AJPH.73.8.863; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; Wynick D, 1985, Health Trends, V17, P24; 1991, DOH HC912 DEP HLTH; 1983, RJR124334 MERS REG H	60	227	230	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1991	303	6799					398	402		10.1136/bmj.303.6799.398	http://dx.doi.org/10.1136/bmj.303.6799.398			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB599	1912809	Bronze, Green Published			2022-12-28	WOS:A1991GB59900019
J	WASHBURN, JO; MERCER, DR; ANDERSON, JR				WASHBURN, JO; MERCER, DR; ANDERSON, JR			REGULATORY ROLE OF PARASITES - IMPACT ON HOST POPULATION SHIFTS WITH RESOURCE AVAILABILITY	SCIENCE			English	Article							LAMBORNELLA-CLARKI CILIOPHORA; AEDES-SIERRENSIS DIPTERA; CALIFORNIA TREEHOLES; MOSQUITO; CILIATE; TETRAHYMENIDAE; CULICIDAE	Effects of infections by the ciliate Lambornella clarki on larval populations of its mosquito host Aedes sierrensis were examined in laboratory and field studies. When host populations developed with sufficient food, mortality from parasites was additive and reduced the number of emerging mosquitoes. For food-limited populations, mortality was compensatory or depensatory; emerging adults were as or more abundant with higher average fitness than those from uninfected control populations. When nutrients were scarce, parasitic infections relaxed larval competition and increased per capita food by reducing host abundance. Food limitation altered larval feeding behavior, reducing horizontal transmission and subsequent mortality from parasitism.			WASHBURN, JO (corresponding author), UNIV CALIF BERKELEY, DEPT ENTOMOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020245] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20245] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUDELOSILVA F, 1984, AM J TROP MED HYG, V33, P1267, DOI 10.4269/ajtmh.1984.33.1267; ANDERSON RM, 1979, NATURE, V279, P150, DOI 10.1038/279150a0; ANDERSON RM, 1978, J ANIM ECOL, V47, P219, DOI 10.2307/3933; CARPENTER SR, 1982, OIKOS, V39, P17, DOI 10.2307/3544526; CARPENTER SR, 1983, ECOLOGY, V64, P219, DOI 10.2307/1937068; CLARK TB, 1976, J INVERTEBR PATHOL, V28, P341, DOI 10.1016/0022-2011(76)90009-4; CORLISS JO, 1976, T AM MICROSC SOC, V95, P725, DOI 10.2307/3225400; EGERTER DE, 1985, J INVERTEBR PATHOL, V46, P296, DOI 10.1016/0022-2011(85)90072-2; EGERTER DE, 1986, P NATL ACAD SCI USA, V83, P7335, DOI 10.1073/pnas.83.19.7335; Esch G. W., 1990, PARASITE COMMUNITIES; Hassell M. P, 1982, POPULATION BIOL INFE, P15; Hawley W.A., 1985, P167; HAWLEY WA, 1985, J ANIM ECOL, V54, P955, DOI 10.2307/4389; Holmes J.C., 1982, Life Sciences Research Report, P37; Lounibos L. P., 1985, ECOLOGY MOSQUITOES; SCOTT ME, 1989, PROTOZOOL TODAY, V5, P179; Washburn J., UNPUB; WASHBURN JO, 1988, SCIENCE, V240, P1193, DOI 10.1126/science.3131877; WASHBURN JO, 1986, J INVERTEBR PATHOL, V48, P296, DOI 10.1016/0022-2011(86)90058-3; WASHBURN JO, 1989, J MED ENTOMOL, V26, P173, DOI 10.1093/jmedent/26.3.173; WASHBURN JO, IN PRESS J INVERT PA; WOODWARD DL, 1988, B SOC VECTOR ECOL, V13, P1	22	79	80	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					185	188		10.1126/science.1906637	http://dx.doi.org/10.1126/science.1906637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1906637				2022-12-28	WOS:A1991FW16000033
J	STEWART, WW; FEDER, N				STEWART, WW; FEDER, N			ANALYSIS OF A WHISTLE-BLOWING	NATURE			English	Editorial Material							IMMUNOGLOBULIN GENE; EXPRESSION; ANTIBODY				STEWART, WW (corresponding author), NIH,BETHESDA,MD 20892, USA.							GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; KUNG JT, 1981, J IMMUNOL, V127, P873; VELARDI A, 1984, J IMMUNOL, V133, P2323; WEAVER D, 1986, CELL, V45, P247, DOI 10.1016/0092-8674(86)90389-2	4	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					687	691		10.1038/351687a0	http://dx.doi.org/10.1038/351687a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1905785				2022-12-28	WOS:A1991FU20100029
J	SHON, KJ; KIM, YG; COLNAGO, LA; OPELLA, SJ				SHON, KJ; KIM, YG; COLNAGO, LA; OPELLA, SJ			NMR-STUDIES OF THE STRUCTURE AND DYNAMICS OF MEMBRANE-BOUND BACTERIOPHAGE-PFL COAT PROTEIN	SCIENCE			English	Article							N-15 CHEMICAL-SHIFT; PHOTOSYNTHETIC REACTION CENTER; SOLID-STATE; SPECTROSCOPY; BACTERIORHODOPSIN; RESOLUTION; MICELLES; TENSORS; MODEL	Filamentous bacteriophage coat protein undergoes a remarkable structural transition during the viral assembly process as it is transferred from the membrane environment of the cell, where it spans the phospholipid bilayer, to the newly extruded virus particles. Nuclear magnetic resonance (NMR) studies show the membrane-bound form of the 46-residue Pfl coat protein to be surprisingly complex with five distinct regions. The secondary structure consists of a long hydrophobic helix (residues 19 to 42) that spans the bilayer and a short amphipathic helix (residues 6 to 13) parallel to the plane of the bilayer. The NH2-terminus (residues 1 to 5), the COOH-terminus (residues 43 to 46), and residues 14 to 18 connecting the two helices are mobile. By comparing the structure and dynamics of the membrane-bound coat protein with that of the viral form as determined by NMR and neutron diffraction, essential features of assembly process can be identified.	UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Colnago, Luiz Alberto/E-9693-2012	Colnago, Luiz Alberto/0000-0002-9516-9022	NCRR NIH HHS [RR-02301] Funding Source: Medline; NIAID NIH HHS [AI20770-06] Funding Source: Medline; NIGMS NIH HHS [GM34343-06] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020770] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOGUSKY MJ, 1985, BIOCHEM BIOPH RES CO, V127, P540, DOI 10.1016/S0006-291X(85)80193-5; BOGUSKY MJ, 1987, J MAGN RESON, V72, P186, DOI 10.1016/0022-2364(87)90187-9; BOWERS JL, 1988, BIOCHEMISTRY-US, V27, P5156, DOI 10.1021/bi00414a031; CHIRLIAN LE, 1990, ADV MAGN RESON, V14, P183; COLNAGO LA, 1986, BIOMOLECULAR STEREOD, V3, P147; CROSS TA, 1980, BIOCHEM BIOPH RES CO, V92, P478, DOI 10.1016/0006-291X(80)90358-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; HARBISON GS, 1984, J MAGN RESON, V60, P79, DOI 10.1016/0022-2364(84)90027-1; HARTZELL CJ, 1987, J AM CHEM SOC, V109, P5967; HENRY GD, 1990, BIOCHEMISTRY-US, V29, P6303, DOI 10.1021/bi00478a027; KENIRY MA, 1984, NATURE, V307, P383, DOI 10.1038/307383a0; LEO GC, 1987, BIOCHEMISTRY-US, V26, P854, DOI 10.1021/bi00377a029; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; OAS TG, 1987, J AM CHEM SOC, V109, P5962, DOI 10.1021/ja00254a011; Opella S J, 1986, Methods Enzymol, V131, P327; OPELLA SJ, 1987, Q REV BIOPHYS, V19, P7, DOI 10.1017/S0033583500004017; OPELLA SJ, 1989, METHOD ENZYMOL, V176, P242; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; ROWITCH DH, 1987, J MOL BIOL, V195, P873, DOI 10.1016/0022-2836(87)90491-8; SCHIKSNIS RA, 1987, BIOCHEMISTRY-US, V26, P1373, DOI 10.1021/bi00379a025; SHON K, 1989, J MAGN RESON, V82, P193, DOI 10.1016/0022-2364(89)90182-0; SHON K, UNPUB; TENG Q, 1989, J MAGN RESON, V85, P439, DOI 10.1016/0022-2364(89)90235-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	25	152	152	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1303	1304		10.1126/science.1925542	http://dx.doi.org/10.1126/science.1925542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925542				2022-12-28	WOS:A1991FN85700038
J	TATTERSALL, R; GREGORY, R; SELBY, C; KERR, D; HELLER, S				TATTERSALL, R; GREGORY, R; SELBY, C; KERR, D; HELLER, S			COURSE OF BRITTLE DIABETES - 12-YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIA; IDDM	Objective - To determine the course of brittle diabetes. Design - 12 year follow up of patients identified in 1977-9 as having brittle diabetes; retrospective review of the case notes. Setting - Nottingham health district. Subjects - 25 brittle diabetic patients were identified in 1979-9; 11 (five men) had three or more admissions with ketoacidosis between June 1977 and 1979 and 14 (eight men) had three or more attendances at the accident and emergency department with hypoglycaemia in 1978. Two controls from our diabetic register were matched to each patient for age, sex, and duration of diabetes. Main outcome measures - Frequency of ketoacidosis and severe hypoglycaemia in the 12 years after ascertainment; diabetic control and complications in 1988-90; retrospective attribution of the cause of brittleness. Results - Patients with recurrent ketoacidosis had had a median (range) of 28 (8-67) episodes. One man died of a cerebral tumour but five of the surviving nine patients had not been admitted in the past two years, although diabetic control remained poor (median haemoglobin A1 concentration 14%). Seven patients had pure hypoglycaemic brittleness, and five had also had eight or more admissions with ketoacidosis (mixed brittleness). Two died of uraemia within a year after ascertainment and two others in hypoglycaemic coma seven and 12 years later. Brittle diabetes was in most cases related to a specific situation, usually unhappiness at home or school. Conclusions - Brittle diabetes is often episodic and almost always related to stressful life circumstances. Once the underlying cause is removed it tends to improve. Recurrent hypoglycaemic brittleness of psychological origin has a poor prognosis.			TATTERSALL, R (corresponding author), UNIV NOTTINGHAM HOSP,DEPT DIABET,NOTTINGHAM NG7 2UH,ENGLAND.			Heller, Simon/0000-0002-2425-9565				AMBLER J, 1983, CLIN CHEM, V29, P340; [Anonymous], 1968, CLIN DIABETES MELLIT, V15, P307; BRINK SJ, 1986, JAMA-J AM MED ASSOC, V255, P617; CHAPMAN J, 1988, DIABETIC MED, V5, P659, DOI 10.1111/j.1464-5491.1988.tb01075.x; CLAUSENSJOBOM N, 1989, DIABETOLOGIA, V32, P818; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; FARBEROW NL, 1970, PSYCHOL REP, V27, P935, DOI 10.2466/pr0.1970.27.3.935; FLEXNER CW, 1984, AM J MED, V76, P691, DOI 10.1016/0002-9343(84)90297-3; GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; GRIFFITH DNW, 1989, DIABETIC MED, V6, P440, DOI 10.1111/j.1464-5491.1989.tb01201.x; HARDY KJ, 1991, DIABETIC MED, V8, P69, DOI 10.1111/j.1464-5491.1991.tb01518.x; HEDLEY AJ, 1982, BRIT MED J, V285, P509, DOI 10.1136/bmj.285.6340.509-a; JONES RB, 1983, METHOD INFORM MED, V22, P4; O'Brien I A, 1985, Diabet Med, V2, P392; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; SCHADE DS, 1985, DIABETES CARE, V8, P12, DOI 10.2337/diacare.8.1.12; SCHULER G, 1989, DIABETES RES CLIN PR, V6, P145, DOI 10.1016/0168-8227(89)90119-8; TATTERSALL R, 1977, CLIN ENDOCRINOL META, V6, P403, DOI 10.1016/S0300-595X(77)80045-5; TATTERSALL RB, 1985, BMJ, V291, P55; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13; Woodyatt RT., 1934, TXB MED AM AUTHORS, V3rd ed, P628; 1988, DIABETES CARE, V11, P669	23	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1240	1243		10.1136/bmj.302.6787.1240	http://dx.doi.org/10.1136/bmj.302.6787.1240			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1904287	Green Published, Bronze			2022-12-28	WOS:A1991FP27200022
J	CHAPDELAINE, Y; BONEN, L				CHAPDELAINE, Y; BONEN, L			THE WHEAT MITOCHONDRIAL GENE FOR SUBUNIT-I OF THE NADH DEHYDROGENASE COMPLEX - A TRANSSPLICING MODEL FOR THIS GENE-IN-PIECES	CELL			English	Article							REVEALS EXTENSIVE HOMOLOGIES; RNA SECONDARY STRUCTURE; PLANT-MITOCHONDRIA; RIBOSOMAL PROTEIN-S12; MARCHANTIA-POLYMORPHA; SEQUENCE-ANALYSIS; READING FRAME; DNA-SEQUENCE; INTRONS; CHLOROPLAST	The nad1 gene encoding subunit I of the respiratory chain NADH dehydrogenase is fragmented into five unique-copy coding segments that are scattered over at least 40 kb and interspersed with other genes in the wheat mitochondrial genome. The nad1 segments are flanked by sequences with group II intron features, and transcript analysis demonstrates the presence of correctly spliced mRNAs. RNA editing occurs at sites asymmetrically distributed along the wheat nad1 coding region, and the initiation codon is created by RNA editing. The unusual organization of the wheat nad1 gene is attributed to mitochondrial DNA rearrangements within introns, and a trans-splicing model involving secondary structural interactions between group II-like intron pieces is proposed for its expression.			CHAPDELAINE, Y (corresponding author), UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; BONEN L, 1988, GENE, V73, P47, DOI 10.1016/0378-1119(88)90311-3; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CUMMINGS DJ, 1988, CURR GENET, V14, P253, DOI 10.1007/BF00376746; DANDEKAR T, 1990, NUCLEIC ACIDS RES, V18, P4719, DOI 10.1093/nar/18.16.4719; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HERRIN DL, 1988, J BIOL CHEM, V262, P14601; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HILDEBRAND M, 1988, P NATL ACAD SCI USA, V85, P372, DOI 10.1073/pnas.85.2.372; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P10025, DOI 10.1093/nar/16.21.10025; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LANG BF, 1985, J MOL BIOL, V184, P353, DOI 10.1016/0022-2836(85)90286-4; LEJEUNE B, 1988, VARIABILITE GENETIQU, P201; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; LONSDALE DM, 1989, COMPR TREAT, V15, P229; MAKAROFF CA, 1987, NUCLEIC ACIDS RES, V15, P5141, DOI 10.1093/nar/15.13.5141; Maniatis T., 1982, MOL CLONING; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMELZER C, 1986, CELL, V46, P57; SMALL I, 1989, CELL, V58, P69, DOI 10.1016/0092-8674(89)90403-0; STERN DB, 1986, CURR GENET, V10, P857, DOI 10.1007/BF00418532; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WILSON AJ, 1984, PLANT CELL REP, V3, P237, DOI 10.1007/BF00269301; WISSINGER B, 1991, CELL, V65; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	50	179	188	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					465	472		10.1016/0092-8674(91)90464-A	http://dx.doi.org/10.1016/0092-8674(91)90464-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1902143				2022-12-28	WOS:A1991FK18200013
J	POTTS, JT				POTTS, JT			NIH CONFERENCE - DIAGNOSIS AND MANAGEMENT OF ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM - CONSENUS DEVELOPMENT CONFERENCE STATEMENT	ANNALS OF INTERNAL MEDICINE			English	Article								Endocrinologists, surgeons, radiologists, epidemiologists, and primary health care providers convened to address both indications for surgery in asymptomatic patients with hyperparathyroidism as well as how patients who do not have surgery should be monitored and managed to minimize the risk for complications. The National Institutes of Health Consensus Development Conference Panel concluded that a diagnosis of hyperparathyroidism is established by showing persistent hypercalcemia and an elevated serum parathyroid hormone concentration; that the current and acceptable treatment for hyperparathyroidism is surgery; that the diagnosis of hyperparathyroidism in an asymptomatic patient does not in all cases mandate referral for surgery; that conscientious surveillance may be justified in patients whose calcium levels are only mildly elevated and whose renal and bone status are close to normal; and that preoperative localization in patients without previous neck operation is rarely indicated and has not proved to be cost effective.			POTTS, JT (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, BOSTON, MA 02114 USA.			Schlechte, Janet/0000-0002-4089-0445				1990, CONS DEV C STAT OCT	1	353	362	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					593	597		10.7326/0003-4819-114-7-593	http://dx.doi.org/10.7326/0003-4819-114-7-593			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1900404				2022-12-28	WOS:A1991FD66100013
J	BIGRIGG, MA; READ, MD				BIGRIGG, MA; READ, MD			MANAGEMENT OF WOMEN REFERRED TO EARLY-PREGNANCY ASSESSMENT UNIT - CARE AND COST-EFFECTIVENESS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the efficiency of an early pregnancy assessment unit in the care of women with bleeding or pain in early pregnancy. Design - Analysis of women attending in the first year of the unit's operation and in the six months immediately before its introduction. Setting - Early pregnancy assessment unit in a district general hospital serving a population of 310 000. Patients - 1141 women referred with bleeding or pain in early pregnancy. Main outcome measures - Length of stay in hospital required for diagnosis and treatment. Results - Before the unit was established the mean admission time was one and a half (range half to three) days for women who required no treatment and three (one and a half to five) days in women requiring evacuation of uterus. These times were reduced to two hours as an outpatient and one day respectively for most women after the unit was established . Between 318 and 505 women were estimated to have been saved from unnecessary admission and 233 had their stay reduced; the associated saving was between 95 000 pounds and 120 000 pounds in one year. Conclusions - The early pregnancy assessment unit improved the quality of care and also produced considerable savings in financial and staff resources.	GLOUCESTER ROYAL HOSP,OBSTET & GYNAECOL,GLOUCESTER GL1 3NN,ENGLAND									BUCK N, 1989, REPORT CONFIDENTIAL; 1982, MATERNITY CARE ACT 1; 1982, REPORT ROYAL COLLEGE; 1990, QUALITY MED CARE	4	86	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					577	579		10.1136/bmj.302.6776.577	http://dx.doi.org/10.1136/bmj.302.6776.577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	1902383	Green Published, Bronze			2022-12-28	WOS:A1991FB93600025
J	MOLLER, HU; THYGESEN, K; KRUIT, PJ				MOLLER, HU; THYGESEN, K; KRUIT, PJ			CORNEAL DEPOSITS ASSOCIATED WITH FLECAINIDE	BRITISH MEDICAL JOURNAL			English	Article									AARHUS KOMMUNE HOSP,DEPT INTERNAL MED,DIV CARDIOL,DK-8000 AARHUS,DENMARK; DIACONESSENHUIS,DEPT OPHTHALMOL,2334 CK LEIDEN,NETHERLANDS	Aarhus University	MOLLER, HU (corresponding author), AARHUS KOMMUNE HOSP,DEPT OPHTHALMOL,DK-8000 AARHUS,DENMARK.							BRON AJ, 1973, T OPHTHAL SOC UK, V93, P455; CHEW E, 1982, CAN J OPHTHALMOL, V17, P96; CLEMETT R S, 1982, Transactions of the Ophthalmological Society of New Zealand, V34, P52; Gentzkow GD, 1984, AM J CARDIOL, V53, p101B; PILGER IS, 1983, ANN OPHTHALMOL, V15, P1076	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					506	507		10.1136/bmj.302.6775.506	http://dx.doi.org/10.1136/bmj.302.6775.506			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	1901500	Bronze, Green Published			2022-12-28	WOS:A1991FB05500021
J	CROSTON, GE; KERRIGAN, LA; LIRA, LM; MARSHAK, DR; KADONAGA, JT				CROSTON, GE; KERRIGAN, LA; LIRA, LM; MARSHAK, DR; KADONAGA, JT			SEQUENCE-SPECIFIC ANTIREPRESSION OF HISTONE HL-MEDIATED INHIBITION OF BASAL RNA POLYMERASE-II TRANSCRIPTION	SCIENCE			English	Article							HIGHER-ORDER STRUCTURE; DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; CHROMATIN STRUCTURE; INVITRO TRANSCRIPTION; FUNCTIONAL STEPS; NUCLEOSOMES; GENE; INITIATION; YEAST	To understand the principles of control and selectivity in gene expression, the biochemical mechanisms by which promoter- and enhancer-binding factors regulate transcription by RNA polymerase II were analyzed. A general observed repressor of transcription was purified and identified as histone H-1. Since many aspects of H-1 binding to naked DNA resemble its interaction with chromatin, purified H-1 bound to naked DNA was used as a model for the repressed state of the DNA template. Three sequence-specific transcription factors, Spl, GAL4-VP16, and GAGA factor, were shown to counteract H-1-mediated repression (antirepression). In addition, Spl and GAL4-VP16, but not the GAGA factor, activated transcription in the absence of H-1. Therefore, true activation and antirepression appear to be distinct activities of sequence-specific factors. Furthermore, transcription antirepression by GAL4-VP16 was sustained for several rounds of transcription. These findings, together with previous studies on H-1, suggest that H-1 participates in repression of the genome in the ground state and that sequence-specific transcription factors induce selected genes by a combination of true activation and release of basal repression that is mediated at least in part by H-1.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cold Spring Harbor Laboratory								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CARTWRIGHT IL, 1987, EMBO J, V6, P3097, DOI 10.1002/j.1460-2075.1987.tb02618.x; CARTWRIGHT IL, 1982, NUCLEIC ACIDS RES, V10, P5835, DOI 10.1093/nar/10.19.5835; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; CROSTON GE, UNPUB; DEBERNARDIN W, 1986, J MOL BIOL, V189, P503, DOI 10.1016/0022-2836(86)90320-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GOLDBERG ML, 1979, THESIS STANFORD U; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMAKAKA RT, IN PRESS P NATL ACAD; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUMAR NM, 1980, NUCLEIC ACIDS RES, V8, P3535, DOI 10.1093/nar/8.16.3535; LAYBOURN PJ, UNPUB; LENNARD AC, 1985, EMBO J, V4, P3455, DOI 10.1002/j.1460-2075.1985.tb04104.x; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY TJ, 1986, NUCLEIC ACIDS RES, V14, P5563, DOI 10.1093/nar/14.13.5563; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SCHLISSEL MS, 1989, EMBO J, V8, P527; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; THOMAS JO, 1980, EUR J BIOCHEM, V112, P501; van Holde K.E., 1988, CHROMATIN; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WOLFFE A P, 1990, New Biologist, V2, P211; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	67	344	347	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 8	1991	251	4994					643	649		10.1126/science.1899487	http://dx.doi.org/10.1126/science.1899487			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1899487				2022-12-28	WOS:A1991EW39900037
J	CHEINGSONGPOPOV, R; PANAGIOTIDI, C; BOWCOCK, S; ARONSTAM, A; WADSWORTH, J; WEBER, J				CHEINGSONGPOPOV, R; PANAGIOTIDI, C; BOWCOCK, S; ARONSTAM, A; WADSWORTH, J; WEBER, J			RELATION BETWEEN HUMORAL RESPONSES TO HIV GAG AND ENV PROTEINS AT SEROCONVERSION AND CLINICAL OUTCOME OF HIV-INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHADENOPATHY-ASSOCIATED VIRUS; RETROVIRUSES HTLV-III; T-LYMPHOTROPIC VIRUS; ANTIBODY-RESPONSE; HOMOSEXUAL MEN; CORE ANTIBODIES; AIDS; ANTIGEN; RISK	Objective - To study the contribution of the humoral response to HIV-1 at seroconversion to disease outcome after 84 months. Design - A retrospective longitudinal study. Setting - Two haemophilia centres in the United Kingdom. Patients - 88 Haemophiliac patients infected with HIV-1 for whom sera were available from before seroconversion and in whom clinical follow up data were available. Results - Kaplan-Meier survival analysis showed a significant difference between a high titre (> 1600 p24 antibody response at seroconversion and prolonged time before the development of HIV related disease (p = 0.0008). In contrast, higher titres of antibody to gp120 at seroconversion (> 25 600) correlated with more rapid clinical deterioration (p = 0.025). Conclusions - The first humoral response to HIV proteins at seroconversion is associated with clinical outcome; patients with an initial low titre antibody response to the gagp24 protein have a significantly faster rate of progression to CDC stage IV disease. Patients with a high titre p24 antibody response progress to AIDS more slowly, and these data provide an explanation why p24 antigenaemia is not universally detected in patients with AIDS. It is unclear whether the association between a strong initial p24 antibody response and slower progression of HIV disease is causal and if so whether it is due to viral or host factors.	LORD MAYOR TRELOAR HOSP & COLL, TRELOAR HAEMOPHILIA CTR, ALTON, HANTS, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0HS, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT MED, INFECT DIS UNIT, LONDON W12 0HS, ENGLAND	Imperial College London; Imperial College London; Imperial College London								ALLAIN JP, 1986, LANCET, V2, P1233; BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291; BIGGAR RJ, 1985, BRIT MED J, V291, P997, DOI 10.1136/bmj.291.6501.997; BRUNVEZINET F, 1984, LANCET, V1, P1253; CHEINGSONGPOPOV R, 1990, AIDS RES HUM RETROV, V6, P1099, DOI 10.1089/aid.1990.6.1099; CHEINGSONGPOPOV R, 1984, LANCET, V2, P477; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1987, J INFECT DIS, V155, P1113, DOI 10.1093/infdis/155.6.1113; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FORSTER SM, 1987, AIDS, V1, P235; GAINES H, 1987, LANCET, V1, P1249; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LANGE JMA, 1986, BRIT MED J, V292, P228, DOI 10.1136/bmj.292.6515.228; LANGE JMA, 1987, AIDS, V1, P15; LANGE JMA, 1986, BRIT MED J, V293, P1459, DOI 10.1136/bmj.293.6560.1459; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; NAYLOR PH, 1987, P NATL ACAD SCI USA, V84, P2951, DOI 10.1073/pnas.84.9.2951; PAN LZ, 1987, J INFECT DIS, V155, P626, DOI 10.1093/infdis/155.4.626; PAPSIDERO LD, 1989, J VIROL, V63, P267, DOI 10.1128/JVI.63.1.267-272.1989; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; RANKI A, 1987, LANCET, V2, P589; ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHUPBACH J, 1985, NEW ENGL J MED, V312, P265, DOI 10.1056/NEJM198501313120502; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SICILIANO RF, 1988, CELL, V54, P561; SIMMONDS P, 1988, BRIT MED J, V296, P593, DOI 10.1136/bmj.296.6622.593; STEEL CM, 1988, LANCET, V1, P1185; STEIMER KS, 1986, VIROLOGY, V150, P283, DOI 10.1016/0042-6822(86)90289-8; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TSIQUAYE KN, 1988, AIDS, V2, P41, DOI 10.1097/00002030-198802000-00007; WEBER J, 1989, HUMAN RETROVIRUSES, P207; WEBER JN, 1987, LANCET, V1, P119, DOI 10.1016/S0140-6736(87)91964-7; 1986, ANN INTERN MED, V105, P234	39	75	76	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 5	1991	302	6767					23	26		10.1136/bmj.302.6767.23	http://dx.doi.org/10.1136/bmj.302.6767.23			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1899349	Green Published, Bronze			2022-12-28	WOS:A1991ER37200020
J	HEALY, B				HEALY, B			RESULTS OF RADIAL KERATOTOMY EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, OPHTHALMOLOGY, V98, P1164	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2341	2341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM790	1920737				2022-12-28	WOS:A1991GM79000007
J	STLOUIS, ME; CONWAY, GA; HAYMAN, CR; MILLER, C; PETERSEN, LR; DONDERO, TJ				STLOUIS, ME; CONWAY, GA; HAYMAN, CR; MILLER, C; PETERSEN, LR; DONDERO, TJ			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN DISADVANTAGED ADOLESCENTS - FINDINGS FROM THE UNITED-STATES-JOB-CORPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILITARY SERVICE; SEROPREVALENCE; APPLICANTS; EPIDEMIC; RISK	Objective. - To describe the human immunodeficiency virus (HIV) epidemic among socially and educationally disadvantaged young persons in the United States. Design. - We analyzed demographic and geographic findings from the screening of Job Corps students for antibody to HIV. Setting. - The Job Corps is a federal training program for disadvantaged, out-of-school youth. Population Screened. - Residential students aged 16 to 21 years who entered the Job Corps from October 1987 through February 1990. Main Outcome Measure. - Rates of observed HIV infection in entering students, stratified by demographic and geographic features. Results. - Of 137 209 Job Corps students screened, 488 were HIV seropositive (3.6 per 1000), a seroprevalence rate higher than that among military applicants of the same age. Overall seroprevalence was slightly higher in male (3.7 per 1000) than in female (3.2 per 1000) Job Corps students, but among those students aged 16 and 17 years, seroprevalence was higher among females (2.3 per 1000) than among males (1.5 per 1000) (P < .05). For students aged 16 to 21 years, seroprevalence increased with year of age: 1.8 per 1000 per year for males and 0.7 per 1 000 per year for females. Among those aged 21 years, HIV prevalence was 8.9 per 1000. For black and Hispanic students from large Northeastern cities, seroprevalence increased by 4.3 per 1000 per year of age and reached 24.8 per 1000 (one of 40) in students aged 21 years. However, among students from rural areas and small towns, HIV seroprevalence was disproportionately high in the Southeast. Compared with recently described US patients with the acquired immunodeficiency syndrome, HIV-infected students who entered the Job Corps were much more likely to be female. Conclusions. - These findings show that disadvantaged, out-of-school adolescents are at high risk for HIV infection. The screening results identified surprisingly high seroprevalence in the southeastern United States and demonstrated a marked shift in the HIV epidemic to young women. Controlling the HIV epidemic among teenagers must include interventions that will reach adolescents early and outside of the formal educational system.	CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,HIV SEROEPIDEMIOL BRANCH,1600 CLIFTON RD,ATLANTA,GA 30333; US DEPT LABOR,EMPLOYMENT AND TRAINING ADM,OFF JOB CORPS,WASHINGTON,DC 20210	Centers for Disease Control & Prevention - USA; United States Department of Labor								BELL T, 1984, SEXUALLY TRANSMITTED, P73; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; EDLIN B, 1991, 7TH INT C AIDS FLOR, V2; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; GAYLE HD, 1990, NEW ENGL J MED, V323, P1538, DOI 10.1056/NEJM199011293232206; HEIN K, 1989, J PEDIATR-US, V114, P144, DOI 10.1016/S0022-3476(89)80622-5; KOMINSKI R, 1990, DEMOGRAPHY, V27, P303, DOI 10.2307/2061455; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; WENDELL D, 1990, 6TH INT C AIDS SAN F; 1990, MMWR, V39, P385; 1990, AIDS 2ND DECADE, P147; 1990, JOB CORPS BRIEF PROG; 1990, HIV AIDS SURVEILLANC, P1; 1989, SAS STAT USERS GUIDE, V2, P1351; 1990, MMWR, V39, P395; 1989, MMWR, V38, P1; 1988, SEXUALLY TRANSMITTED	21	106	106	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	1991	266	17					2387	2391		10.1001/jama.266.17.2387	http://dx.doi.org/10.1001/jama.266.17.2387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GM790	1920745				2022-12-28	WOS:A1991GM79000024
J	BARRERA, JM; BRUGUERA, M; ERCILLA, G; SANCHEZTAPIAS, JM; GIL, MP; GIL, C; COSTA, J; GELABERT, A; RODES, J; CASTILLO, R				BARRERA, JM; BRUGUERA, M; ERCILLA, G; SANCHEZTAPIAS, JM; GIL, MP; GIL, C; COSTA, J; GELABERT, A; RODES, J; CASTILLO, R			INCIDENCE OF NON-A, NON-B HEPATITIS AFTER SCREENING BLOOD-DONORS FOR ANTIBODIES TO HEPATITIS-C VIRUS AND SURROGATE MARKERS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, VIRAL, NON-A, NON-B; HEPATITIS-C VIRUS; HEPATITIS ANTIBODIES; BLOOD DONORS; BLOOD TRANSFUSION	TRANSFUSION-TRANSMITTED VIRUSES; CORE ANTIGEN; RECIPIENTS; EPIDEMIOLOGY; INFECTIVITY; AGENTS; ASSAY	Objective: To compare the effect of screening blood donors for antibodies to hepatitis C virus (anti-HCV) on the incidence of non-A, non-B hepatitis in recipients with that of screening blood donors for antibodies to hepatitis B core antigen (anti-HBc) and elevated alanine aminotransferase levels. Design: Cohort analysis of serum samples from donors and recipients. Recipients were followed for 12 months to determine the occurrence of non-A, non-B hepatitis. Setting: The blood-transmitted viruses unit and the liver unit of a university teaching hospital. Subjects: A total of 250 patients who had open heart surgery and their 3142 blood donors. Measurements: Donor sera were tested for anti-HCV by enzyme-linked immunosorbent assay (ELISA) and, in the event of a positive result, by recombinant immunoblot assay (RIBA). Antibodies to anti-HBc and serum alanine aminotransferase (ALT) levels were also measured. Measurements of anti-HCV and ALT activity in recipients were done before transfusion and at regular intervals during follow-up. Main Results: Of the 250 transfusion recipients, 40 developed non-A, non-B hepatitis. Of the 3142 donors, 70 were positive for anti-HCV by ELISA, 440 were positive for anti-HBc, and 177 had alanine aminotransferase levels between 0.67 and 1.33-mu-kat/L. The sensitivity (87%), specificity (89%), positive predictive value (59%), and negative predictive value (97%) of blood-donor screening were higher for anti-HCV than for anti-HBc (82%, 36%, 21%, and 91%, respectively) and for elevated alanine aminotransferase levels (65%, 70%, 29%, and 91%, respectively). The expected number of donors excluded because of the presence of anti-HCV was considerably smaller than that of donors with positive results for surrogate markers of hepatitis. Conclusions: Screening blood donors for the presence of anti-HCV is more accurate than screening for surrogate markers (anti-HBc and ALT) and protects more effectively against post-transfusion non-A, non-B hepatitis.	UNIV BARCELONA, HOSP CLIN & PROVINCIAL, VILLARROEL 170, E-08036 BARCELONA, SPAIN	University of Barcelona				Gil, M. Pilar/0000-0002-6281-0282; Gil, Cristina/0000-0002-2692-8814				AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; BARRERA JM, 1987, MED CLIN-BARCELONA, V89, P759; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HOLLINGER FB, 1980, J INFECT DIS, V142, P400, DOI 10.1093/infdis/142.3.400; HOYOS M, 1989, HEPATOLOGY, V9, P449, DOI 10.1002/hep.1840090318; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VANDERPOEL CL, 1989, LANCET, V2, P297	21	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					596	600		10.7326/0003-4819-115-8-596	http://dx.doi.org/10.7326/0003-4819-115-8-596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1909848				2022-12-28	WOS:A1991GJ90200003
J	STEHLING, MK; TURNER, R; MANSFIELD, P				STEHLING, MK; TURNER, R; MANSFIELD, P			ECHO-PLANAR IMAGING - MAGNETIC-RESONANCE-IMAGING IN A FRACTION OF A SECOND	SCIENCE			English	Article							INTRAVOXEL INCOHERENT MOTION; CENTRAL-NERVOUS-SYSTEM; HUMAN FETUS INUTERO; HUMAN-BRAIN MOTION; CEREBROSPINAL-FLUID; FLASH MRI; HUMAN-HEART; FLIP-ANGLE; NMR; DIFFUSION	Progress has recently been made in implementing magnetic resonance imaging (MRI) techniques that can be used to obtain images in a fraction of a second rather than in minutes. Echo-planar imaging (EPI) uses only one nuclear spin excitation per image and lends itself to a variety of critical medical and scientific applications. Among these are evaluation of cardiac function in real time, mapping of water diffusion and temperature in tissue, mapping of organ blood pool and perfusion, functional imaging of the central nervous system, depiction of blood and cerebrospinal fluid flow dynamics, and movie imaging of the mobile fetus in utero. Through shortened patient examination times, higher patient throughput, and lower cost per MRI examination, EPI may become a powerful tool for early diagnosis of some common and potentially treatable diseases such as ischemic heart disease, stroke, and cancer.	SIEMENS AG,W-8520 ERLANGEN,GERMANY; NIH,CARDIAC ENERGET LAB,BETHESDA,MD 20892; UNIV NOTTINGHAM,DEPT PHYS,NOTTINGHAM NG7 2RD,ENGLAND	Siemens AG; Siemens Germany; National Institutes of Health (NIH) - USA; University of Nottingham	STEHLING, MK (corresponding author), FRIEDRICH ALEXANDER UNIV ERLANGEN,DEPT CARDIOL,W-8520 ERLANGEN,GERMANY.		Turner, Robert/C-1820-2008	Turner, Robert/0000-0001-5055-9644				ADSON MA, 1983, AM J ROENTGENOL, V140, P695, DOI 10.2214/ajr.140.4.695; AHN CB, 1986, IEEE T MED IMAGING, V5, P2, DOI 10.1109/TMI.1986.4307732; ATKINSON DJ, 1988, 7TH ANN M SOC MAGN R, P137; AVRAM HE, 1988, 7 ANN M SOC MAGN RES, P980; AXEL L, 1984, AM J ROENTGENOL, V143, P1157, DOI 10.2214/ajr.143.6.1157; BAILES DR, 1985, J COMPUT ASSIST TOMO, V9, P835, DOI 10.1097/00004728-198507010-00039; BELLIVEAU JW, 1991, 9TH ANN M SOC MAGN R, P202; BLOCH F, 1946, PHYS REV, V69, P127, DOI 10.1103/PhysRev.69.127; BOURLAND JD, 1990, 9TH P SMRM ANN M, P1157; BRADLEY WG, 1986, RADIOLOGY, V159, P611, DOI 10.1148/radiology.159.3.3704142; BRADLEY WG, 1985, RADIOLOGY, V156, P93, DOI 10.1148/radiology.156.1.4001426; BRYANT DJ, 1984, J COMPUT ASSIST TOMO, V8, P588, DOI 10.1097/00004728-198408000-00002; BUDINGER TF, 1990, 9TH ANN M SOC MAGN R, P276; CHAPMAN B, 1987, MAGNET RESON MED, V5, P246, DOI 10.1002/mrm.1910050305; CHENEVERT TL, 1990, RADIOLOGY, V177, P401, DOI 10.1148/radiology.177.2.2217776; CHIEN D, 1990, MAGN RESON IMAGING, V8, P829, DOI 10.1016/0730-725X(90)90022-T; CHIEN D, 1991, JMRI-J MAGN RESON IM, V1, P63, DOI 10.1002/jmri.1880010108; CHRISPIN A, 1986, PEDIATR RADIOL, V16, P293, DOI 10.1007/BF02386865; COHEN MS, 1990, MAGNET RESON MED, V14, P409, DOI 10.1002/mrm.1910140226; CROOKS LE, 1988, RADIOLOGY, V166, P157, DOI 10.1148/radiology.166.1.3336674; DAMADIAN R, 1971, SCIENCE, V171, P1151, DOI 10.1126/science.171.3976.1151; DELANNOY J, 1990, MED PHYS, V17, P855, DOI 10.1118/1.596477; DINSMORE R, 1990, CLIN MAGNETIC RESONA, pCH27; DOYLE M, 1986, LANCET, V2, P682; EDELSTEIN WA, 1980, PHYS MED BIOL, V25, P751, DOI 10.1088/0031-9155/25/4/017; EHMAN LR, 1985, AM J ROENTGENOL, V143, P1175; FEINBERG DA, 1990, MAGNET RESON MED, V13, P162, DOI 10.1002/mrm.1910130116; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; FEINBERG DA, 1985, MAGNET RESON MED, V2, P555, DOI 10.1002/mrm.1910020606; FEINER LF, 1980, APPL PHYS, V22, P257, DOI 10.1007/BF00899875; FERRUCCI JT, 1986, AM J ROENTGENOL, V147, P1103, DOI 10.2214/ajr.147.6.1103; FIRMIN DN, 1989, MAGN RESON MED, V12, P316, DOI 10.1002/mrm.1910120304; FISCHER H, 1989, 75TH ANN M RAD SOC N, P276; FRAHM J, 1990, MAGNET RESON MED, V13, P150, DOI 10.1002/mrm.1910130114; GARROWAY AN, 1974, J PHYS C SOLID STATE, V7, pL457, DOI 10.1088/0022-3719/7/24/006; HAACKE E M, 1986, Magnetic Resonance Imaging, V4, P359, DOI 10.1016/0730-725X(86)91046-5; HAACKE EM, 1990, AM J ROENTGENOL, V155, P951, DOI 10.2214/ajr.155.5.2120964; HAASE A, 1990, MAGN RESON MED, V13, P77, DOI 10.1002/mrm.1910130109; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; HENDRICK R E, 1984, Magnetic Resonance Imaging, V2, P193, DOI 10.1016/0730-725X(84)90005-5; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; HIGUCHI N, 1990, 9TH ANN M SOC MAGN R, P638; HOWSEMAN AM, 1988, BRIT J RADIOL, V61, P822, DOI 10.1259/0007-1285-61-729-822; JOHNSON G, 1985, J MAGN RESON, V63, P14, DOI 10.1016/0022-2364(85)90149-0; KANTOR HL, 1988, 7TH ANN M SOC MAGN R, P246; KAUFMAN L, 1983, CIRCULATION, V67, P251, DOI 10.1161/01.CIR.67.2.251; KIM JH, 1986, 5TH ANN M SOC MAGN R, P659; KING KF, 1984, MED PHYS, V11, P1, DOI 10.1118/1.595470; KOMIYAMA M, 1987, AM J NEURORADIOL, V8, P65; KOSE K, 1990, 9TH ANN M SOC MAGN R, P168; KRESTEL E, 1990, IAMGING SYSTEMS MED; KUCHARCZYK W, 1986, RADIOLOGY, V161, P761, DOI 10.1148/radiology.161.3.3786729; KUMAR A, 1975, J MAGN RESON, V18, P69, DOI 10.1016/0022-2364(75)90224-3; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1991, J COMPUT ASSIST TOMO, V15, P19, DOI 10.1097/00004728-199101000-00002; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; LEBIHAN D, 1989, RADIOLOGY, V171, P853, DOI 10.1148/radiology.171.3.2717764; LEWIS CE, 1986, RADIOLOGY, V160, P803, DOI 10.1148/radiology.160.3.3737921; LJUNGGREN S, 1983, J MAGN RESON, V54, P338, DOI 10.1016/0022-2364(83)90060-4; MACOVSKI A, 1985, MAGNET RESON MED, V2, P29, DOI 10.1002/mrm.1910020105; Macovski A, 1986, P INT SOC MAGN RESON, V1986, P156; MANSFIELD P, 1975, PHYS REV B, V12, P3618, DOI 10.1103/PhysRevB.12.3618; MANSFIELD P, 1990, PHILOS T R SOC A, V333, P495, DOI 10.1098/rsta.1990.0177; MANSFIELD P, 1990, BRIT J RADIOL, V63, P833, DOI 10.1259/0007-1285-63-755-833; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MANSFIELD P, 1987, J MAGN RESON, V72, P211, DOI 10.1016/0022-2364(87)90283-6; MANSFIELD P, 1973, J PHYS C SOLID STATE, V6, pL422, DOI 10.1088/0022-3719/6/22/007; Mansfield P., 1982, NMR IMAGING BIOMEDIC; MERBOLDT KD, 1989, MAGNET RESON MED, V9, P423, DOI 10.1002/mrm.1910090316; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; MOONEN CTW, 1989, RADIOLOGY, V171, P853; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; OCALLAGHAN C, 1987, ANN RADIOL, V30, P470; ORDIDGE RJ, 1990, MAGNET RESON MED, V16, P238, DOI 10.1002/mrm.1910160205; ORDIDGE RJ, 1989, 8TH P SMRM ANN M, P889; PATRONAS N, 1991, NEURORADIOLOGY S, V33, P267; PATTANY PM, 1987, J COMPUT ASSIST TOMO, V11, P369, DOI 10.1097/00004728-198705000-00001; PURCELL EM, 1946, PHYS REV, V69, P37, DOI 10.1103/PhysRev.69.37; Radon J., 1917, BER SAECHS AKAD WISS, V69, P262, DOI DOI 10.1109/TMI.1986.4307775; REILLY JP, 1989, MED BIOL ENG COMPUT, V27, P101, DOI 10.1007/BF02446217; ROSEN B R, 1989, Magnetic Resonance Quarterly, V5, P263; ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211; RUBIN JB, 1987, AM J ROENTGENOL, V148, P973, DOI 10.2214/ajr.148.5.973; RZEDZIAN RR, 1987, AM J ROENTGENOL, V149, P245, DOI 10.2214/ajr.149.2.245; RZEDZIAN RR, 1987, 6TH P SMRM ANN M, P229; SAINI S, 1986, AM J ROENTGENOL, V147, P357, DOI 10.2214/ajr.147.2.357; SINGER JR, 1959, SCIENCE, V130, P1652, DOI 10.1126/science.130.3389.1652; STARK DD, 1985, AM J ROENTGENOL, V145, P213, DOI 10.2214/ajr.145.2.213; STEHLING MJ, 1989, RADIOLOGY, V170, P257, DOI 10.1148/radiology.170.1.2909106; STEHLING MK, 1989, LANCET, V2, P157; STEHLING MK, 1990, BRIT J RADIOL, V63, P430, DOI 10.1259/0007-1285-63-750-430; STEHLING MK, 1991, BRIT J RADIOL, V64, P89, DOI 10.1259/0007-1285-64-758-89; STEHLING MK, 1989, RADIOLOGY, V171, P41, DOI 10.1148/radiology.171.1.2928545; STEHLING MK, 1990, MAGNET RESON MED, V13, P314, DOI 10.1002/mrm.1910130214; STEHLING MK, 1990, MAGNET RESON MED, V13, P514, DOI 10.1002/mrm.1910130320; STEHLING MK, 1989, 8TH P ANN M SMRM AMS, P358; STEHLING MK, IN PRESS RADIOLOGY; STEHLING MK, 1990, 8TH ANN M SOC MAGN R, P101; STEHLING MK, IN PRESS AM J ROENTG; STEHLING MK, 1988, EUROPEAN C NMR MED B, P64; STEHLING MK, 1988, EUROPEAN C NMR MED B, P258; STEHLING MK, 1990, 8TH ANN M SOC MAGN R, P50; STEHLING MK, 1989, 75TH ANN M RAD SOC N, P337; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; TURNER R, 1990, RADIOLOGY, V177, P407, DOI 10.1148/radiology.177.2.2217777; TURNER R, 1986, J PHYS E SCI INSTRUM, V19, P876, DOI 10.1088/0022-3735/19/10/023; TURNER R, 1988, J PHYS E SCI INSTRUM, V21, P948, DOI 10.1088/0022-3735/21/10/008; TWIEG DB, 1983, MED PHYS, V10, P610, DOI 10.1118/1.595331; WAUGH JS, 1970, J MOL SPECTROSC, V35, P298, DOI 10.1016/0022-2852(70)90205-5; WEDEEN VJ, 1990, 9TH ANN M SOC MAGN R, P164; WEHRLI FW, 1984, J COMPUT ASSIST TOMO, V8, P369, DOI 10.1097/00004728-198406000-00001; WHITE D, 1990, 9TH P SMRM ANN M NEW, P57; WILKE N, IN PRESS RADIOLOGY; WINKLER ML, 1988, RADIOLOGY, V166, P17, DOI 10.1148/radiology.166.1.3275967; WOOD ML, 1985, MED PHYS, V12, P143, DOI 10.1118/1.595782; YOUNG IR, 1986, J COMPUT ASSIST TOMO, V10, P271, DOI 10.1097/00004728-198603000-00020; YOUNG IR, 1982, J COMPUT ASSIST TOMO, V6, P1, DOI 10.1097/00004728-198202000-00001; [No title captured]; [No title captured]; [No title captured]	124	432	449	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					43	50		10.1126/science.1925560	http://dx.doi.org/10.1126/science.1925560			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925560				2022-12-28	WOS:A1991GH60500026
J	JOHNSTON, MA; HUGHES, DA; AZMY, AF				JOHNSTON, MA; HUGHES, DA; AZMY, AF			LESSON OF THE WEEK - LATE COMPLICATIONS OF UNDETECTED URETHRAL STRICTURE AFTER CARDIAC-SURGERY IN A CHILD	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HOSP SICK CHILDREN,DEPT PAEDIAT SURG & NEPHROL,GLASGOW G3 8SJ,SCOTLAND	University of Glasgow								ALLEN TD, 1978, J UROLOGY, V119, P247, DOI 10.1016/S0022-5347(17)57447-9; GRIFFITHS DJ, 1984, BRIT J UROL, V56, P474; PRABHU S, 1985, J PEDIATR SURG, V20, P69, DOI 10.1016/S0022-3468(85)80396-1; RUTUU M, 1982, LANCET, V1, P218; SUTHERLAND PD, 1982, LANCET, V1, P622; WALSH A, 1982, LANCET, V1, P392	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1991	303	6805					772	773		10.1136/bmj.303.6805.772	http://dx.doi.org/10.1136/bmj.303.6805.772			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932943	Green Published, Bronze			2022-12-28	WOS:A1991GG98100028
J	VONAHSEN, U; DAVIES, J; SCHROEDER, R				VONAHSEN, U; DAVIES, J; SCHROEDER, R			ANTIBIOTIC INHIBITION OF GROUP-I RIBOZYME FUNCTION	NATURE			English	Article							CATALYTIC CORE; RIBOSOMAL-RNA; BINDING-SITE; INTRONS; BACTERIOPHAGE-T4; SEQUENCE; PROTEIN	THE discovery of catalytically active RNA has provided the basis for the evolutionary concept of an RNA world. It has been proposed that during evolution the functions of ancient catalytic RNA were modulated by low molecular weight effectors, related to antibiotics, present in the primordial soup. Antibiotics and RNA may have coevolved in the formation of the modern ribosome 1. Here we report that a set of aminoglycoside antibiotics, which are known to interact with the decoding region of the 16S ribosomal RNA of Escherichia coli 2-4, inhibit the second step of splicing of the T4 phage-derived td intron. Thus catalytic RNA seems to interact not only with a mononucleotide 5 and an amino acid 6, but also with another class of biomolecules, the sugars. Splicing of other group I introns but not group II introns was inhibited. The similarity in affinity and specificity of these antibiotics for group I introns and rRNAs may result from recognition of evolutionarily conserved structures.	INST PASTEUR,UNITE GENIE MICROBIOL,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VONAHSEN, U (corresponding author), UNIV VIENNA,INST MIKROBIOL & GENET,ALTHANSTR 14,A-1090 VIENNA,AUSTRIA.							AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BENVENISTE R, 1973, ANTIMICROB AGENTS CH, V4, P2402; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CUNDLIFFE E, 1990, RIBOSOME, P479; DAVIES J, 1990, MOL MICROBIOL, V4, P1227, DOI 10.1111/j.1365-2958.1990.tb00701.x; DAVIES JE, 1983, BIOCH GENETIC REGULA, P329; EHRENMAN K, 1986, P NATL ACAD SCI USA, V83, P5875, DOI 10.1073/pnas.83.16.5875; GALE EF, 1966, BIOCH STUDIES ANTIMI, P1; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; VONAHSEN U, 1990, NATURE, V346, P801; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1990, NATURE, V342, P349	23	233	244	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					368	370		10.1038/353368a0	http://dx.doi.org/10.1038/353368a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922343				2022-12-28	WOS:A1991GG65400066
J	SHAMANSKI, FL; ORRWEAVER, TL				SHAMANSKI, FL; ORRWEAVER, TL			THE DROSOPHILA PLUTONIUM AND PAN GU GENES REGULATE ENTRY INTO S-PHASE AT FERTILIZATION	CELL			English	Article							PROTO-ONCOGENE PRODUCT; CELL-CYCLE; EARLY EMBRYOGENESIS; DNA-REPLICATION; XENOPUS-LAEVIS; MELANOGASTER; EGGS; DIVISION; NUCLEAR; MUTATION	Mutations in the Drosophila maternal genes plutonium (plu) and pan gu (png) have the striking phenotype that DNA replication initiates in unfertilized eggs. Fertilized eggs from plu or png mutant mothers also have a mutant phenotype; DNA replication is uncoupled from nuclear division, resulting in giant, polyploid nuclei. Analysis of multiple alleles of these genes indicates that their wild-type function is required to maintain repression of DNA replication until fertilization. The phenotype of two png alleles suggests that this gene also may play a direct role in coupling S phase and mitosis during the early cleavage divisions. We describe genetic interactions among png, plu, and the previously identified gene gnu that demonstrate these three genes regulate the same process.	WHITEHEAD INST,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute	SHAMANSKI, FL (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL CANCER INSTITUTE [T32CA009541] Funding Source: NIH RePORTER; NCI NIH HHS [CA09541-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLEN HJ, 1988, ROUX ARCH DEV BIOL, V197, P258, DOI 10.1007/BF00380019; BERG CA, 1991, GENETICS, V127, P515; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DECICCO DV, 1984, CELL, V38, P45, DOI 10.1016/0092-8674(84)90525-7; DIXON WJ, 1951, INTRO STATISTICAL AN; DOANE WW, 1960, SCIENCE, V132, P677, DOI 10.1126/science.132.3428.677; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GONZALEZ C, 1990, J CELL SCI, V96, P605; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LIN HF, 1991, CELL, V64, P49, DOI 10.1016/0092-8674(91)90208-G; LINDREN BW, 1978, PROBABILITY STATISTI; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MCKNIGHT SL, 1976, CELL, V8, P305, DOI 10.1016/0092-8674(76)90014-3; Mohler D., 1984, DROSOPHILA INFORMATI, V60, P236; MOHLER JD, 1977, GENETICS, V85, P259; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; ORRWEAVER TL, 1986, MOL CELL BIOL, V6, P4624, DOI 10.1128/MCB.6.12.4624; PERRIMON N, 1989, GENETICS, V121, P333; PICARD A, 1987, NATURE, V327, P170, DOI 10.1038/327170a0; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SANDER K, 1985, BIOL FERTILIZATION, V2, P409; SCHUPBACH T, 1989, GENETICS, V121, P101; SHELLENBARGER DL, 1978, MUTAT RES, V52, P395, DOI 10.1016/0027-5107(78)90178-1; Sokal Robert R., 1969, BIOMETRY; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; ZALOKAR M, 1975, DEV BIOL, V47, P419, DOI 10.1016/0012-1606(75)90295-X	51	87	87	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1289	1300		10.1016/0092-8674(91)90050-9	http://dx.doi.org/10.1016/0092-8674(91)90050-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913810				2022-12-28	WOS:A1991GG55200022
J	LAVERICK, MD; CROAL, SA; MOLLAN, RAB				LAVERICK, MD; CROAL, SA; MOLLAN, RAB			ORTHOPEDIC SURGEONS AND THROMBOPROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article							DEEP VENOUS THROMBOSIS; TOTAL HIP-REPLACEMENT; VEIN THROMBOSIS; PREVENTION; THROMBOEMBOLISM; COMPRESSION; STOCKINGS; HEPARIN	Objective - To assess attitudes to the use of thromboprophylaxis among orthopaedic surgeons in the United Kingdom. Design and subjects - Single page postal questionnaire to all 926 active orthopaedic surgeons who are members of the British Orthopaedic Association. Results - The response rate was 70% (659 surgeons), of whom 595 (90%) used some form of prophylaxis. Most (548; 83%) used drugs but 47 (7%) used only elasticated stockings. A history of thromboembolic disease, hip surgery, and obesity was seen as the main risk factor. Ineffectiveness was the principal reason for not using prophylaxis. Conclusions - Most orthopaedic surgeons use regimens of thromboprophylaxis, though many of these are of limited value. Improvements in the efficacy and safety of prophylactic agents, combined with ease of administration, would increase the use of such agents and make orthopaedic surgery safer for the patient.			LAVERICK, MD (corresponding author), QUEENS UNIV BELFAST,MUSGRAVE PK HOSP,DEPT ORTHOPAED SURG,BELFAST BT9 7JB,NORTH IRELAND.							BEISAW NE, 1988, J BONE JOINT SURG AM, V70A, P2, DOI 10.2106/00004623-198870010-00002; BRENKEL I, 1989, BRIT J HOSP MED, V42, P282; CHRISMAN OD, 1976, J BONE JOINT SURG AM, V58, P918, DOI 10.2106/00004623-197658070-00003; COTTON LT, 1977, SURGERY, V81, P228; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; JOHNSON R, 1986, CLIN ORTHOPAEDICS, V211, P151; Ljungstrom K G, 1988, Acta Chir Scand Suppl, V543, P26; NICOLAIDES AN, 1983, SURGERY, V94, P21; PLANES A, 1986, HAEMOSTASIS, V16, P152; PLANES A, 1990, J BONE JOINT SURG BR, V72, P9, DOI 10.1302/0301-620X.72B1.2298803; SALZMAN EW, 1976, J BONE JOINT SURG AM, V58, P903, DOI 10.2106/00004623-197658070-00001; SCURR JH, 1988, BRIT MED J, V297, P28, DOI 10.1136/bmj.297.6640.28; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; TORNGREN S, 1980, BRIT J SURG, V67, P482, DOI 10.1002/bjs.1800670710; WHITEHOUSE G, 1987, BRIT MED J, V295, P801, DOI 10.1136/bmj.295.6602.801; WOLFE JHN, 1987, BMJ, V295, P1365; 1986, JAMA-J AM MED ASSOC, V256, P744	18	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					549	550		10.1136/bmj.303.6802.549	http://dx.doi.org/10.1136/bmj.303.6802.549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE948	1912884	Bronze, Green Published			2022-12-28	WOS:A1991GE94800021
J	TAYLOR, D				TAYLOR, D			FUNDING FAMILY HEALTH-SERVICES	BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, D (corresponding author), KINGS FUND INST,HLTH POLICY ANAL,LONDON NW1 7NF,ENGLAND.							CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; Hudson B., 1991, HLTH SERVICE J  0704, P30; HURST JW, 1991, HLTH CARE SYSTEMS TR, P71; JONSSON B, 1991, HLTH CARE SYSTEMS TR, P87; TAYLOR D, 1991, DEV PRIMARY CARE OPP; TAYLOR DG, 1984, UNDERSTANDING NHS 19; WIENER JP, 1990, GP BUDGET HOLDING UK; 1991, BUILDING YOUR OWN FU	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1991	303	6802					562	564		10.1136/bmj.303.6802.562	http://dx.doi.org/10.1136/bmj.303.6802.562			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE948	1912888	Bronze, Green Published			2022-12-28	WOS:A1991GE94800026
J	HULL, D				HULL, D			THE HEALTH OF THE NATION - RESPONSES - CHILDRENS HEALTH	BRITISH MEDICAL JOURNAL			English	Article											HULL, D (corresponding author), QUEENS MED CTR,DEPT CHILD HLTH,NOTTINGHAM NG7 2UH,ENGLAND.							1988, DAY PRACTICE INFANT; 1991, CM1523; 1991, SOCIAL TRENDS, V21	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					514	516		10.1136/bmj.303.6801.514	http://dx.doi.org/10.1136/bmj.303.6801.514			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD804	1912866	Green Published, Bronze			2022-12-28	WOS:A1991GD80400023
J	REULER, JB; BALAZS, JR				REULER, JB; BALAZS, JR			PORTABLE MEDICAL RECORD FOR THE HOMELESS MENTALLY-ILL	BRITISH MEDICAL JOURNAL			English	Article									E LONDON HOMELESS HLTH PROJECT,LONDON,ENGLAND; VET AFFAIRS MED CTR,GEN MED SECT,PORTLAND,OR	US Department of Veterans Affairs; Veterans Health Administration (VHA)								BALDRY M, 1986, BRIT MED J, V292, P596, DOI 10.1136/bmj.292.6520.596; PARROTT J, 1988, J ROY SOC MED, V81, P520, DOI 10.1177/014107688808100908; PRIEST RG, 1986, B ROYAL COLLEGE PSYC, V10, P185; ROTH LH, 1980, AM J PSYCHIAT, V137, P592; 1987, PRIMARY HLTH CARE HO	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1991	303	6800					446	446		10.1136/bmj.303.6800.446	http://dx.doi.org/10.1136/bmj.303.6800.446			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC465	1912837	Green Published, Bronze			2022-12-28	WOS:A1991GC46500017
J	QUON, D; WANG, Y; CATALANO, R; SCARDINA, JM; MURAKAMI, K; CORDELL, B				QUON, D; WANG, Y; CATALANO, R; SCARDINA, JM; MURAKAMI, K; CORDELL, B			FORMATION OF BETA-AMYLOID PROTEIN DEPOSITS IN BRAINS OF TRANSGENIC MICE	NATURE			English	Article							PRECURSOR MESSENGER-RNA; ALZHEIMERS-DISEASE; DIFFERENTIAL EXPRESSION; SENILE PLAQUES; RAT-BRAIN; ANTIBODY; NEURONS; CORTEX; GENE; DNA	DEPOSITS of beta-amyloid are one of the main pathological characteristics of Alzheimer's disease. The beta-amyloid peptide constituent (relative molecular mass 4,200) of the deposits is derived from the beta-amyloid precursor protein (beta-APP) which is expressed in several different isoforms 1-6. The two most prevalent beta-APP isoforms are distinguished by either the presence (beta-APP751) or absence (beta-APP695) of a Kunitz serine protease inhibitor domain. Changes in the abundance of different beta-APP messenger RNAs in brains of Alzheimer's disease victims have been widely reported 7-12. Although these results have been controversial, most evidence favours an increase in the mRNAs encoding protease inhibitor-containing isoforms of beta-APP and it is proposed that this change contributes to beta-amyloid formation 9-12. We have now produced an imbalance in the normal neuronal ratio of beta-APP isoforms by preparing transgenic mice expressing additional beta-APP751 under the control of a neural-specific promoter. The cortical and hippocampal brain regions of the transgenic mice display extracellular beta-amyloid immunoreactive deposits varying in size (< 5-50-mu-m) and abundance. These results suggest that one mechanism of beta-amyloid formation may involve a disruption of the normal ratio of neuronal beta-APP isoform expression and support a direct relationship between increased expression of Kunitz inhibitor-bearing beta-APP isoforms and beta-amyloid deposition.	CALIF BIOTECHNOL INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043									ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; BUGIANI O, 1989, NEUROSCI LETT, V103, P263, DOI 10.1016/0304-3940(89)90110-9; EKLUND J, 1976, ANIM PROD, V22, P127, DOI 10.1017/S0003356100035509; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; IKEDA S, 1989, LAB INVEST, V60, P113; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MURPHY GM, 1990, PROG NEURO-PSYCHOPH, V14, P309, DOI 10.1016/0278-5846(90)90019-D; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TAKIO K, 1989, BIOCHEM BIOPH RES CO, V160, P1296, DOI 10.1016/S0006-291X(89)80144-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591	30	357	402	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					239	241		10.1038/352239a0	http://dx.doi.org/10.1038/352239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1906990				2022-12-28	WOS:A1991FX18500065
J	ZHENG, YX; JUNG, MK; OAKLEY, BR				ZHENG, YX; JUNG, MK; OAKLEY, BR			GAMMA-TUBULIN IS PRESENT IN DROSOPHILA-MELANOGASTER AND HOMO-SAPIENS AND IS ASSOCIATED WITH THE CENTROSOME	CELL			English	Article							ASPERGILLUS-NIDULANS; INDIVIDUAL MICROTUBULES; PERICENTRIOLAR MATERIAL; DYNAMIC INSTABILITY; INVITRO; CELLS; POLARITY; POLYMERIZATION; MICROSCOPY; SPINDLE	The mipA gene of A. nidulans encodes a newly discovered member of the tubulin superfamily of proteins, gamma-tubulin. In A. nidulans, gamma-tubulin is essential for nuclear division and microtubule assembly and is associated with the spindle pole body, the fungal microtubule organizing center. By low stringency hybridizations we have cloned cDNAs from D. melanogaster and H. sapiens, the predicted products of which share more than 66% amino acid identity with A. nidulans gamma-tubulin. Gamma-Tubulin-specific antibodies stained centrosomes of Drosophila, human, and mouse cell lines. Staining was most intense in prophase through metaphase when microtubule assembly from centrosomes was maximal. These results demonstrate that gamma-tubulin genes are present and expressed in humans and flies; they suggest that gamma-tubulin may be a universal component of microtubule organizing centers; and they are consistent with an earlier hypothesis that gamma-tubulin is a minus-end nucleator of microtubule assembly.			ZHENG, YX (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.			Oakley, Berl/0000-0002-3046-8240				BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BERGEN LG, 1980, J CELL BIOL, V84, P141, DOI 10.1083/jcb.84.1.141; EUTENEUER U, 1981, J CELL BIOL, V89, P338, DOI 10.1083/jcb.89.2.338; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; HARLOW E, 1988, ANTIBODIES LABORATOR; HEIDEMANN SR, 1980, J CELL BIOL, V87, P152, DOI 10.1083/jcb.87.1.152; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; MCGILL M, 1975, J CELL BIOL, V67, P188; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OAKLEY CE, 1987, GENE, V53, P293, DOI 10.1016/0378-1119(87)90019-9; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Pickett-Heaps J.D., 1969, CYTOBIOS, V3, P257; ROBBINS E, 1968, J CELL BIOL, V36, P329, DOI 10.1083/jcb.36.2.329; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SNYDER JA, 1975, J CELL BIOL, V67, P744, DOI 10.1083/jcb.67.3.744; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELZER BR, 1979, J CELL BIOL, V81, P484, DOI 10.1083/jcb.81.3.484; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WEIL CF, 1986, MOL CELL BIOL, V6, P2963, DOI 10.1128/MCB.6.8.2963; WEISENBERG RC, 1975, J CELL BIOL, V64, P146, DOI 10.1083/jcb.64.1.146	23	389	396	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					817	823		10.1016/0092-8674(91)90389-G	http://dx.doi.org/10.1016/0092-8674(91)90389-G			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904010				2022-12-28	WOS:A1991FP51600012
J	RAUB, W				RAUB, W			PREDICTORS OF TYPE-II DIABETES IDENTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1990, ANN INTERN MED, V113, P909	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-28	WOS:A1991FD65900005
J	ROSE, EH; ALEDORT, LM				ROSE, EH; ALEDORT, LM			NASAL SPRAY DESMOPRESSIN (DDAVP) FOR MILD HEMOPHILIA-A AND VONWILLEBRAND DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							BIOLOGICAL RESPONSE; VASOPRESSIN; INTRANASAL; HYPONATREMIA; SEIZURES	Objective: To evaluate the effect of a nasal spray preparation of desmopressin (DDAVP) on levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as the length of bleeding time in patients with mild hemophilia A and von Willebrand disease; to determine whether effective hemostatic levels can be attained; and to compare the effect of this spray with that of standard intravenous desmopressin treatment. Design: Before-and-after trial in patients known to respond to intravenous desmopressin. Setting: Regional, comprehensive, hemophilia diagnosis and treatment center. Patients: A total of 22 patients, including 11 patients with von Willebrand disease, 8 patients with mild hemophilia A, and 3 symptomatic hemophilia carriers. Interventions: Patients were infused with desmopressin, 0.3-mu-g/kg body weight. At least 1 week later, they were taught to self-administer desmopressin nasal spray, 150-mu-g to each nostril. Measurements: In patients with hemophilia, the level of factor VIII activity was measured; in patients with von Willebrand disease, levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as bleeding time were measured before and after each administration of desmopressin. Main Results: Desmopressin, when administered intravenously or intranasally, elevated levels of factor VIII, ristocetin cofactor, and von Willebrand antigen in both mildly hemophiliac patients and patients with von Willebrand disease when compared with baseline measures (P < 0.05). Factor VIII levels adequate for hemostasis were achieved by 82% of the hemophiliac patients. An abnormal bleeding time was corrected in the majority (62%) of patients with von Willebrand disease. Conclusion: A nasal spray preparation of desmopressin apparently was effective both in treating bleeding episodes and when used prophylactically for minor surgical procedures in several patients.	CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL030567] Funding Source: NIH RePORTER; NCI NIH HHS [MCB-360001-04-01] Funding Source: Medline; NHLBI NIH HHS [HL-30567-02] Funding Source: Medline; PHS HHS [000217-01-2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DELAFUENTE B, 1985, ANN INTERN MED, V103, P6, DOI 10.7326/0003-4819-103-1-6; DESIO L, 1985, THROMB HAEMOSTASIS, V54, P387; HARRIS AS, 1988, J PHARM SCI-US, V77, P337, DOI 10.1002/jps.2600770412; HARRIS AS, 1986, J PHARM SCI, V75, P1085, DOI 10.1002/jps.2600751113; Heinisch O., 1963, PREIS S BIOM J, V1965, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; KOHLER M, 1984, KLIN WOCHENSCHR, V62, P543, DOI 10.1007/BF01727749; KOHLER M, 1986, THROMB HAEMOSTASIS, V55, P108; LETHAGEN S, 1990, BLUT, V60, P187, DOI 10.1007/BF01720274; LETHAGEN S, 1987, THROMB HAEMOSTASIS, V58, P1033; MANNUCCI PM, 1977, LANCET, V1, P869; MANNUCCI PM, 1987, THROMB HAEMOSTASIS, V58, P1037; MARIANA G, 1984, CLIN LAB HAEMATOL, V6, P229; SHEPHERD LL, 1989, J PEDIATR-US, V114, P470, DOI 10.1016/S0022-3476(89)80575-X; SMITH TJ, 1989, AM J HEMATOL, V31, P199, DOI 10.1002/ajh.2830310310; WARRIER AI, 1983, J PEDIATR-US, V102, P228, DOI 10.1016/S0022-3476(83)80526-5; [No title captured]	16	94	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					563	568		10.7326/0003-4819-114-7-563	http://dx.doi.org/10.7326/0003-4819-114-7-563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1900403				2022-12-28	WOS:A1991FD66100007
J	AUWERX, J; SASSONECORSI, P				AUWERX, J; SASSONECORSI, P			IP-1 - A DOMINANT INHIBITOR OF FOS/JUN WHOSE ACTIVITY IS MODULATED BY PHOSPHORYLATION	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CELLULAR FOS PROTEINS; DNA-BINDING PROTEINS; PROTO-ONCOGENE FOS; C-FOS; TRANSCRIPTION FACTOR; LEUCINE ZIPPER; JUN ENCODES; KINASE-C; AP-1	Transcription factor AP-1 is inducible by phorbol esters and thus could be considered to be one final target of the protein kinase C signal transduction pathway. AP-1 consists of the products of the fos and jun oncogenes, which associate as dimers to bind TPA-responsive promoter elements (TRE) efficiently. We show that AP-1 activity is modulated by an inhibitory protein (IP-1), present both in the nucleus and cytoplasm of several cell types. IP-1 specifically blocks DNA binding of AP-1 from nuclear extracts and of in vitro synthesized Fos/Jun proteins. It is a labile protein of 30-40 kd, which exerts its activity only in the nonphosphorylated form. Block of IP-1 function is obtained by PKA-mediated phosphorylation, possibly suggesting a cross talk mechanism at transcriptional level. Competition experiments with synthetic peptides suggest that IP-1 could interact with Fos and/or Jun leucine zippers. We speculate that IP-1 might act as a transcriptional antioncogene.			AUWERX, J (corresponding author), FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Sassone-Corsi, Paolo/H-6182-2011	Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	52	226	229	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					983	993		10.1016/0092-8674(91)90322-P	http://dx.doi.org/10.1016/0092-8674(91)90322-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900458				2022-12-28	WOS:A1991FA94000015
J	PRIOR, TI; FITZGERALD, DJ; PASTAN, I				PRIOR, TI; FITZGERALD, DJ; PASTAN, I			BARNASE TOXIN - A NEW CHIMERIC TOXIN COMPOSED OF PSEUDOMONAS EXOTOXIN-A AND BARNASE	CELL			English	Article							GENOMIC SEQUENCES; ESCHERICHIA-COLI; BARSTAR; CELLS; RIBONUCLEASE; IMMUNOTOXINS; AERUGINOSA; EXPRESSION; ANTIBODY; PROTEINS	We have constructed a chimeric toxin composed of Pseudomonas exotoxin A (PE) and the extracellular ribonuclease of Bacillus amyloliquefaciens, barnase. The chimeric protein, termed PE-Bar, reacted with both anti-PE and anti-barnase antisera and had both ADP ribosylation and ribonuclease activities. The chimeric toxin was cytotoxic to the murine fibroblast cell line L929 and to a murine hybridoma resistant to PE. A mutant form of PE-Bar lacking ADP-ribosylating activity was still cytotoxic to L929 cells. Because treatment of cells prelabeled with [H-3]uridine resulted in a decrease in their RNA content, we conclude that this cytotoxic effect was due to the ribonuclease activity of barnase molecules that had been translocated to the cytosol. It is now possible to construct chimeric toxins with two or more enzymatic activities that can be delivered to the cytosol of the target cells.			PRIOR, TI (corresponding author), NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FITZGERALD D, 1989, J NATL CANCER I, V81, P1455, DOI 10.1093/jnci/81.19.1455; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; HARTLEY RW, 1973, J BIOL CHEM, V248, P5624; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KONDO T, 1988, J BIOL CHEM, V263, P9470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; PADDON CJ, 1986, GENE, V40, P231, DOI DOI 10.1016/0378-1119(85)90045-9; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PASTAN I, 1989, J BIOL CHEM, V264, P15157; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SMEATON JR, 1967, BIOCHIM BIOPHYS ACTA, V145, P547, DOI 10.1016/0005-2787(67)90115-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLINGHAM MC, 1987, P NATL ACAD SCI USA, V84, P2474, DOI 10.1073/pnas.84.8.2474	26	64	77	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					1017	1023		10.1016/0092-8674(91)90325-S	http://dx.doi.org/10.1016/0092-8674(91)90325-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900455				2022-12-28	WOS:A1991FA94000018
J	KENDRICK, T; SIBBALD, B; BURNS, T; FREELING, P				KENDRICK, T; SIBBALD, B; BURNS, T; FREELING, P			ROLE OF GENERAL-PRACTITIONERS IN CARE OF LONG-TERM MENTALLY-ILL PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY CARE; PSYCHIATRISTS; CLINICS	Objective - To assess general practitioners' involvement with long term mentally ill patients and attitudes towards their care. Design - Postal questionnaire survey. Setting - General practices in South West Thames region. Subjects - 507 general practitioners, 369 (73%) of whom returned the questionnaire. Main outcome measures - The number of adult long term mentally ill patients whom general practitioners estimate they have on their lists and general practitioners' willingness to take responsibility for them. Results - 110 respondents had noticed an effect of the discharge of adult long term mentally ill patients on their practices. Most (225) respondents estimated that they had 10 or fewer such patients each on their lists. Having higher numbers was significantly associated with practising in Greater London or within three miles of a large mental hospital and having contact with a psychiatrist visiting the practice. 333 general practitioners would agree to share the care of long term mentally ill patients with the psychiatrist by taking responsibility for the patients' physical problems. Only 59 would agree to act as a key worker, 308 preferring the community psychiatric nurse to do it. Only nine had specific practice policies for looking after long term mentally ill patients and 287 agreed that such patients often come to their general practitioner's attention only when there is a crisis. Conclusions - The uneven distribution of long term mentally ill patients suggests that community psychiatric resources might be better targeted at those practices with higher numbers of such patients. Most general practitioners seem to be receptive to a shared care plan where the consultant takes responsibility for monitoring psychiatric health with the community nurse as key worker. The lack of practice policies for reviewing the care of long term mentally ill patients must limit general practitioners' ability to prevent crises developing in their care.	ST GEORGE HOSP,SCH MED,DEPT PSYCHIAT,LONDON SW17 0RE,ENGLAND	St Georges University London	KENDRICK, T (corresponding author), ST GEORGE HOSP,SCH MED,DEPT GEN PRACTICE,LONDON SW17 0RE,ENGLAND.		Kendrick, Tony/H-8558-2014	Kendrick, Tony/0000-0003-1618-9381				BROWN RMA, 1988, BRIT J PSYCHIAT, V153, P168, DOI 10.1192/bjp.153.2.168; BRUGHA TS, 1989, BRIT J PSYCHIAT, V155, P777, DOI 10.1192/bjp.155.6.777; GROVES T, 1990, BRIT MED J, V300, P1128, DOI 10.1136/bmj.300.6732.1128; MITCHELL ARK, 1985, BRIT J PSYCHIAT, V147, P371, DOI 10.1192/bjp.147.4.371; MURPHY E, 1987, BRIT MED J, V295, P1505, DOI 10.1136/bmj.295.6612.1505-a; REGIER DA, 1985, PSYCHOL MED, V15, P265, DOI 10.1017/S0033291700023540; SHEPHERD M, 1989, BRIT MED J, V299, P666, DOI 10.1136/bmj.299.6700.666; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; STRATHDEE G, 1988, FAM PRACT, V5, P111, DOI 10.1093/fampra/5.2.111; STRATHDEE G, 1984, J ROY COLL GEN PRACT, V34, P615; THORNICROFT G, 1988, BRIT J PSYCHIAT, V153, P257, DOI 10.1192/S0007125000222502; TYRER P, 1984, BRIT J PSYCHIAT, V145, P9, DOI 10.1192/bjp.145.1.9; 1990, COMMENTS WORKING PAR; 1989, GOOD PRACTICE DISCHA	14	78	79	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					508	510		10.1136/bmj.302.6775.508	http://dx.doi.org/10.1136/bmj.302.6775.508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	1901501	Bronze, Green Published			2022-12-28	WOS:A1991FB05500023
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SHILEY HEART-VALVE PHYSICIAN AND PATIENT NOTIFICATION PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					847	847		10.1001/jama.265.7.847	http://dx.doi.org/10.1001/jama.265.7.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1899454				2022-12-28	WOS:A1991EX58700011
J	GRAY, WA; CAPONE, RJ; MOST, AS				GRAY, WA; CAPONE, RJ; MOST, AS			UNSUCCESSFUL EMERGENCY MEDICAL RESUSCITATION - ARE CONTINUED EFFORTS IN THE EMERGENCY DEPARTMENT JUSTIFIED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY RESUSCITATION; SURVIVAL; DEATH; DEFIBRILLATION; EXPERIENCE; OUTCOMES; CPR	Background. The majority of attempts to resuscitate victims of prehospital cardiopulmonary arrest are unsuccessful, and patients are frequently transported to the emergency department for further resuscitation efforts. We evaluated the efficacy and costs of continued hospital resuscitation for patients in whom resuscitation efforts outside the hospital have failed. Methods. We reviewed the records of 185 patients presenting to our emergency department after an initially unsuccessful, but ongoing, resuscitation for a prehospital arrest (cardiac, respiratory, or both) by an emergency medical team. Prehospital and hospital characteristics of treatment for the arrest were identified, and the patients' outcomes in the emergency room were ascertained. The hospital course and the hospital costs for the patients who were revived were determined. Results. Over a 19-month period, only 16 of the 185 patients (9 percent) were successfully resuscitated in the emergency department and admitted to the hospital. A shorter duration of prehospital resuscitation was the only characteristic of the resuscitation associated with an improved outcome in the emergency department. No patient survived until hospital discharge, and all but one were comatose throughout hospitalization. The mean stay in the hospital was 12.6 days (range, 1 to 132), with an average of 2.3 days (range, 1 to 11) in an intensive care unit. The total hospital cost for the 16 patients admitted was $180,908 (range per patient, $1,984 to $95,144). Conclusions. In general, continued resuscitation efforts in the emergency department tor victims of cardiopulmonary arrest in whom prehospital resuscitation has tailed are not worthwhile, and they consume precious institutional and economic resources without gain.	BROWN UNIV,PROGRAM MED,PROVIDENCE,RI 02912; UNIV ROCHESTER,MED CTR,DIV CARDIOL,ROCHESTER,NY 14642	Brown University; University of Rochester	GRAY, WA (corresponding author), RHODE ISL HOSP,DIV CARDIOL,593 EDDY ST,PROVIDENCE,RI 02903, USA.							APRAHAMIAN C, 1986, ANN EMERG MED, V15, P445, DOI 10.1016/S0196-0644(86)80185-8; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EINARSSON O, 1989, J INTERN MED, V225, P129, DOI 10.1111/j.1365-2796.1989.tb00052.x; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; Hallstorm AP, 1983, EMERG HLTH SERV Q, V1, P41; HALLSTROM AP, 1985, CRIT CARE MED, V13, P927, DOI 10.1097/00003246-198511000-00019; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; McIntyre KM, 1983, TXB ADV CARDIAC LIFE; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SAPHIR R, 1968, MEDICINE, V47, P73, DOI 10.1097/00005792-196801000-00004; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; Talbott J., 1965, FUNDAMENTALS CARDIOP, P1; THOMPSON RG, 1979, ANN INTERN MED, V90, P437; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; TRESCH DD, 1981, ARCH INTERN MED, V141, P1154, DOI 10.1001/archinte.141.9.1154; TWEED WA, 1984, CAN MED ASSOC J, V131, P429; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1983, EUTHANASIA AIDING SU; 1980, JAMA-J AM MED ASSOC, V24, P453	36	202	204	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 14	1991	325	20					1393	1398		10.1056/NEJM199111143252001	http://dx.doi.org/10.1056/NEJM199111143252001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP524	1922249				2022-12-28	WOS:A1991GP52400001
J	LAPUMA, J; STOCKING, CB; LAVOIE, D; DARLING, CA				LAPUMA, J; STOCKING, CB; LAVOIE, D; DARLING, CA			WHEN PHYSICIANS TREAT MEMBERS OF THEIR OWN FAMILIES - PRACTICES IN A COMMUNITY-HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Little is known about the circumstances under which physicians care for family members. We sought to examine current practice and, in particular, to learn how often family members request medical care or treatment, whether physicians accede to such requests, and what concerns, if any, physicians have about caring for their family members. Methods. In late 1990 we distributed a pretested, structured questionnaire to all members of the active medical staff (physicians with M.D. or D.O. degrees) of a large suburban community teaching hospital. Of 691 eligible members of the medical staff, 465 physicians responded. Results. Of the 465 respondents, 461 (99 percent) reported requests from family members for medical advice, diagnosis, or treatment. A total of 386 (83 percent of the respondents) had prescribed medication for a family member, 372 (80 percent) had diagnosed medical illnesses, 334 (72 percent) had performed physical examinations, 68 (15 percent) had acted as a family member's primary attending physician in the hospital, and 44 (9 percent) had operated on a family member. In addition, 152 (33 percent) reported that they had observed another physician "inappropriately involved" in a family member's care, and 103 (22 percent) had acceded to a specific request about which they felt uncomfortable. Conclusions. Practicing physicians often attend and treat their family members and diagnose their illnesses. They may often experience some disquiet in doing so. For physicians, complete medical data, proper training, and sound judgment are essential when family members request treatment.	LUTHERAN GEN HOSP,DEPT FAMILY PRACTICE,PK RIDGE,IL 60068; UNIV CHICAGO,CTR CLIN MED ETHICS,CHICAGO,IL 60637; UNIV CHICAGO,GEN INTERNAL MED SECT,CHICAGO,IL 60637	University of Chicago; University of Chicago	LAPUMA, J (corresponding author), LUTHERAN GEN HOSP,CTR CLIN ETHICS,1775 DEMPSTER,PK RIDGE,IL 60068, USA.							CAVEAT, 1977, OPINIONS REPORTS JUD; CRANFORD RE, 1990, ETHICS BEDSIDE, P194; FREEMAN DL, 1991, ANN INTERN MED, V114, P694, DOI 10.7326/0003-4819-114-8-694; LAPUMA J, 1988, ANN INTERN MED, V108, P121, DOI 10.7326/0003-4819-108-1-121; MCSHERRY J, 1988, CAN MED ASSOC J, V139, P420; SPOCK BM, 1962, PEDIATRICS, V30, P109; TUMULTY PA, 1970, NEW ENGL J MED, V283, P20, DOI 10.1056/NEJM197007022830105; 1990, IMMEDIATE RELATIVE S, P10; 1966, JAMA-J AM MED ASSOC, V195, P299; 1901, CODE ETHICS AM MED A, P15	10	72	72	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 31	1991	325	18					1290	1294		10.1056/NEJM199110313251806	http://dx.doi.org/10.1056/NEJM199110313251806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GM041	1922224				2022-12-28	WOS:A1991GM04100006
J	MONTELL, DJ; KESHISHIAN, H; SPRADLING, AC				MONTELL, DJ; KESHISHIAN, H; SPRADLING, AC			LASER ABLATION STUDIES OF THE ROLE OF THE DROSOPHILA OOCYTE NUCLEUS IN PATTERN-FORMATION	SCIENCE			English	Article							MELANOGASTER; GENE; VASA; ANTEROPOSTERIOR; LOCALIZATION; OOGENESIS; EMBRYO; LOCI	Somatic and germline cells interact during oogenesis to establish the pattern axes of the Drosophila eggshell and embryo. The role of the oocyte nucleus in pattern formation was tested with the use of laser ablation. Ablation in stage 6 to 9 egg chambers caused partial or complete ventralization of the eggshell, phenotypes similar to those of eggs produced by gurken or torpedo females. Accumulation of vasa protein at the posterior pole of treated oocytes was also disrupted. Thus the oocyte nucleus is required as late as stage 9 for dorsoventral patterning within the follicle cells and for polar plasm assembly in the oocyte.	HOWARD HUGHES MED INST,BALTIMORE,MD 21210; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	MONTELL, DJ (corresponding author), CARNEGIE INST WASHINGTON,BALTIMORE,MD 21210, USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ASHBURNER M, 1990, GENETICS, V126, P679; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1970, ROUX ARCH DEV BIOL, V165, P8; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; STEVENS L, 1990, NATURE, V335, P275; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670	16	42	42	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					290	293		10.1126/science.1925585	http://dx.doi.org/10.1126/science.1925585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1925585				2022-12-28	WOS:A1991GJ64200041
J	INFANTERIVARD, C; DAVID, M; GAUTHIER, R; RIVARD, GE				INFANTERIVARD, C; DAVID, M; GAUTHIER, R; RIVARD, GE			LUPUS ANTICOAGULANTS, ANTICARDIOLIPIN ANTIBODIES, AND FETAL LOSS - A CASE CONTROL STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIPER VENOM TIME; ANTIPHOSPHOLIPID ANTIBODIES; SPONTANEOUS-ABORTION; HABITUAL ABORTION; WOMEN; MISCARRIAGE; DIAGNOSIS; ABORTERS; DEATH	Background. Lupus anticoagulants and anticardiolipin antibodies are antiphospholipid antibodies that have been associated with fetal loss, but they have not been shown unequivocally to be a risk factor for this event. Methods. To estimate the risk of fetal loss in association with these antibodies, we conducted a hospital-based case-control study of 331 women with spontaneous abortion or fetal death (case patients) and 993 controls. The subjects were included in the study only if they reported that they had had no previous spontaneous fetal loss. Each control was a pregnant woman who, in the same period of pregnancy as a case patient, had not had a fetal loss. Lupus anticoagulants were identified in blood samples through a series of coagulation tests, and IgG anticardiolipins by an enzyme-linked immunosorbent assay. Each subject was interviewed in person to obtain information on potential confounding variables, such as sociodemographic characteristics and medical conditions. Results. Lupus anticoagulants were found in blood from 17 case patients (5.1 percent) and 38 controls (3.8 percent). The crude odds ratio for the association between lupus anticoagulants and fetal loss was 1.36 (95 percent confidence interval, 0.75 to 2.43); the odds ratio adjusted for confounders was 1.42 (95 percent confidence interval, 0.72 to 2.80). An IgG anticardiolipin level of 5 units or more was found in 4 case patients (1.2 percent) and 15 controls (1.5 percent). The crude and adjusted odds ratios for fetal loss were 0.80 (95 percent confidence interval, 0.26 to 2.41) and 1.28 (95 percent confidence interval, 0.38 to 4.21), respectively. Conclusions. There is no apparent justification for considering lupus anticoagulants or IgG anticardiolipins to be risk factors for fetal loss among women who present with spontaneous abortion or fetal death and have had no previous spontaneous fetal loss.	UNIV MONTREAL,HOP ST JUSTINE,DEPT OBSTET & GYNECOL,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT COMMUNITY HLTH,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT HEMATOL,MONTREAL H3T 1C5,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal	INFANTERIVARD, C (corresponding author), MCGILL UNIV,SCH OCCUPAT HLTH,1130 PINE AVE W,MONTREAL H3A 1A3,QUEBEC,CANADA.							Bakketeig L. S., 1984, PERINATAL EPIDEMIOLO, P99; BARBUI T, 1988, FERTIL STERIL, V50, P589; BRANDT JT, 1989, ARCH PATHOL LAB MED, V113, P1376; Breslow N, 1980, STATISTICAL METHODS, V32; EDELMAN P, 1986, PRESSE MED, V15, P961; ELIAS M, 1984, ARCH INTERN MED, V144, P510, DOI 10.1001/archinte.144.3.510; FIRKIN BG, 1978, AM J HEMATOL, V5, P81, DOI 10.1002/ajh.2830050202; FRANCOIS A, 1988, ANN INTERN MED, V109, P993, DOI 10.7326/0003-4819-109-12-993; GLADEN BC, 1986, STAT MED, V5, P557, DOI 10.1002/sim.4780050602; HARRIS EN, 1990, BRIT J HAEMATOL, V74, P1, DOI 10.1111/j.1365-2141.1990.tb02530.x; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; HOWARD MA, 1987, AM J HEMATOL, V26, P175, DOI 10.1002/ajh.2830260208; KACZOR DA, 1991, AM J CLIN PATHOL, V95, P408, DOI 10.1093/ajcp/95.3.408; Kline J., 1984, PERINATAL EPIDEMIOLO, P23; LESPERANCE B, 1988, THROMB HAEMOSTASIS, V60, P217; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; MAIER DB, 1989, FERTIL STERIL, V51, P280; MODVIG J, 1990, AM J EPIDEMIOL, V132, P1021, DOI 10.1093/oxfordjournals.aje.a115744; PETRI M, 1987, ARTHRITIS RHEUM, V30, P601, DOI 10.1002/art.1780300601; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; THIAGARAJAN P, 1986, BLOOD, V68, P869; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; WALLENBURG HCS, 1987, AM J OBSTET GYNECOL, V157, P1230, DOI 10.1016/S0002-9378(87)80300-9	29	164	169	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1063	1066		10.1056/NEJM199110103251503	http://dx.doi.org/10.1056/NEJM199110103251503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1909770				2022-12-28	WOS:A1991GJ10800003
J	HUNKAPILLER, T; KAISER, RJ; KOOP, BF; HOOD, L				HUNKAPILLER, T; KAISER, RJ; KOOP, BF; HOOD, L			LARGE-SCALE AND AUTOMATED DNA-SEQUENCE DETERMINATION	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; SINGLE-STRANDED-DNA; SCANNING TUNNELING MICROSCOPY; FLUORESCENCE DETECTION; MASS-SPECTROMETRY; ENZYMATIC AMPLIFICATION; GENOME PROJECT; ELECTROPHORESIS; PRIMERS; OLIGONUCLEOTIDES	DNA sequence analysis is a multistage process that includes the preparation of DNA, its fragmentation and base analysis, and the interpretation of the resulting sequence information. New technological advances have led to the automation of certain steps in this process and have raised the possibility of large-scale DNA sequencing efforts in the near future [for example, 1 million base pairs (Mb) per year]. New sequencing methodologies, fully automated instrumentation, and improvements in sequencing-related computational resources may render genome-size sequencing projects (100 Mb or larger) feasible during the next 5 to 10 years.			HUNKAPILLER, T (corresponding author), CALTECH, DIV BIOL, NATL SCI FDN, SCI & TECHNOL CTR MOLEC BIOTECHNOL, PASADENA, CA 91125 USA.		Koop, Ben F./A-8151-2008	Koop, Ben F./0000-0003-0045-5200				ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; AHMED A, 1987, METHOD ENZYMOL, V155, P177; ALLISON DP, 1990, SCANNING MICROSCOPY, V4, P517; ANDERSON S, 1981, NUCLEIC ACIDS RES, V9, P3015, DOI 10.1093/nar/9.13.3015; ANSORGE W, 1987, NUCLEIC ACIDS RES, V15, P4593, DOI 10.1093/nar/15.11.4593; BANKIER AT, 1989, NUCLEIC ACID SEQUENC, P37; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BIRREN BW, 1990, NUCLEIC ACIDS RES, V18, P1481, DOI 10.1093/nar/18.6.1481; BROMLEY RL, IN PRESS NUCLEIC ACI; BRUMBAUGH JA, 1988, P NATL ACAD SCI USA, V85, P5610, DOI 10.1073/pnas.85.15.5610; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CERKRENJAKOU P, COMMUNICATION; CHAIT BT, 1990, 200TH AM CHEM SOC M; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; COLLINS J, 1978, P NATL ACAD SCI USA, V75, P4242, DOI 10.1073/pnas.75.9.4242; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CUNHA JD, 1990, BIOTECHNIQUES, V9, P80; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DELISI C, 1988, AM SCI, V76, P488; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DRMANAC R, 1990, DNA CELL BIOL, V9, P527, DOI 10.1089/dna.1990.9.527; DRMANAC R, 1989, GENOMICS, V4, P114; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; Elder J.K., 1987, NUCLEIC ACID PROTEIN, P165; ELDER JK, 1986, NUCLEIC ACIDS RES, V14, P417, DOI 10.1093/nar/14.1.417; ENGELKE DR, 1988, P NATL ACAD SCI USA, V85, P544, DOI 10.1073/pnas.85.2.544; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FREEMAN M, 1990, BIO-TECHNOL, V8, P147, DOI 10.1038/nbt0290-147; GILBERT W, COMMUNICATION; GROTJAHN L, 1985, ORG MASS SPECTROM, V20, P146, DOI 10.1002/oms.1210200214; GROTJAHN L, 1985, BIOMED MASS SPECTROM, V12, P514, DOI 10.1002/bms.1200120914; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; HUNKAPILLER T, 1991, CURR OPIN BIOTECH, V2, P92, DOI 10.1016/0958-1669(91)90066-E; HUNKAPILLER T, UNPUB; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JACOBSON KB, 1991, GENOMICS, V9, P51, DOI 10.1016/0888-7543(91)90220-9; JETT JH, 1989, J BIOMOL STRUCT DYN, V7, P301, DOI 10.1080/07391102.1989.10507773; JONES P, 1991, GENOME MAPPING SEQUE, P107; KAMBARA H, 1988, BIO-TECHNOL, V6, P816, DOI 10.1038/nbt0788-816; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KOOP BK, UNPUB; LINDSAY SM, 1991, GENET ANAL-BIOMOL E, V8, P8, DOI 10.1016/1050-3862(91)90003-A; LUCKEY JA, 1990, NUCLEIC ACIDS RES, V18, P4417, DOI 10.1093/nar/18.15.4417; MARDIS ER, 1989, BIOTECHNIQUES, V7, P840; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCNEAL CJ, 1980, P NATL ACAD SCI-BIOL, V77, P735, DOI 10.1073/pnas.77.2.735; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MESSING J, 1989, NUCLEIC ACIDS SEQUEN, P1; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MURRAY NE, 1974, NATURE, V251, P476, DOI 10.1038/251476a0; NGUYEN DC, 1987, ANAL CHEM, V56, P348; POHL FM, 1987, METHOD ENZYMOL, V155, P250; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; RICE PM, 1991, SEQUENCE ANAL PRIMER, P1; ROBERTS L, 1990, SCIENCE, V250, P756, DOI 10.1126/science.2237425; ROBERTS L, 1990, SCIENCE, V249, P1497, DOI 10.1126/science.2218490; ROBERTS L, 1991, SCIENCE, V252, P1618, DOI 10.1126/science.2047871; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361; Sambrook J, 1989, MOL CLONING LABORATO; Samuel W., COMMUNICATION; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SIEMIENIAK DR, 1990, GENE, V96, P121, DOI 10.1016/0378-1119(90)90350-Z; SMITH DP, 1990, BIOTECHNIQUES, V9, P48; SMITH LM, 1985, NUCLEIC ACIDS RES, V13, P2399, DOI 10.1093/nar/13.7.2399; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SORGE JA, 1989, P NATL ACAD SCI USA, V86, P9208, DOI 10.1073/pnas.86.23.9208; SOUTHERN EM, 1991, GENOME MAPPING SEQUE, P195; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; STUDIER FW, 1989, P NATL ACAD SCI USA, V86, P6917, DOI 10.1073/pnas.86.18.6917; SWERDLOW H, 1990, NUCLEIC ACIDS RES, V18, P1415, DOI 10.1093/nar/18.6.1415; SWINBANKS D, 1991, NATURE, V351, P593; SZYBALSKI W, 1990, GENE, V90, P177, DOI 10.1016/0378-1119(90)90458-4; TIZARD R, 1990, P NATL ACAD SCI USA, V87, P4514, DOI 10.1073/pnas.87.12.4514; UHLEN MT, 1989, J CELL BIOCH E, V13, P310; WADA A, 1987, NATURE, V325, P771, DOI 10.1038/325771a0; WEISENHORN AL, 1990, SCANNING MICROSCOPY, V4, P511; WILSON R., UNPUB; Wilson R. A., COMMUNICATION; WILSON RK, 1990, BIOTECHNIQUES, V8, P184; WILSON RK, 1988, BIOTECHNIQUES, V6, P776; ZIMMERMANN J, 1989, Methods in Molecular and Cellular Biology, V1, P29; 1986, OTAH298 OFF TECHN AS	93	259	290	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1991	254	5028					59	67		10.1126/science.1925562	http://dx.doi.org/10.1126/science.1925562			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925562				2022-12-28	WOS:A1991GH60500028
J	KJEMS, J; FRANKEL, AD; SHARP, PA				KJEMS, J; FRANKEL, AD; SHARP, PA			SPECIFIC REGULATION OF MESSENGER-RNA SPLICING INVITRO BY A PEPTIDE FROM HIV-1 REV	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-ACTIVATOR; GENE-PRODUCT; SEXUAL-DIFFERENTIATION; MUTATIONAL ANALYSIS; STRUCTURED REGION; TARGET SEQUENCE; TYPE-1 AFFECTS; PROTEIN; EXPRESSION	The Rev protein of HIV-1 regulates the synthesis of partially spliced forms of cytoplasmic viral mRNA by binding to a cis-acting RNA sequence, the Rev response element (RRE). We have investigated the regulation of splicing in vitro and have shown that Rev specifically inhibits splicing of pre-mRNAs containing an RRE by 3- to 4-fold. A synthetic peptide of 17 amino acids containing the RNA-binding domain of Rev is highly functional and specifically inhibits splicing by up to 30-fold. Other peptides that bind to the RRE with high affinity, but with low specificity, do not specifically inhibit splicing. Six repeated monomeric binding sites for the peptide can substitute for the RRE, indicating that regulation by Rev requires interactions with multiple sites. The peptide acts at a step in the assembly of splicing complexes, suggesting that one of the functions of the basic region of Rev is to prevent formation of a functional spliceosome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	KJEMS, J (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317	NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14051] Funding Source: Medline; NIAID NIH HHS [AI29135] Funding Source: Medline; NIGMS NIH HHS [GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRIS CH, 1989, MOL CELL BIOL, V9, P259, DOI 10.1128/MCB.9.1.259; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MALIM MH, 1991, CELL, V65, P251; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	52	111	113	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					169	178		10.1016/0092-8674(91)90580-R	http://dx.doi.org/10.1016/0092-8674(91)90580-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913815				2022-12-28	WOS:A1991GJ32000015
J	RASHBASS, P; COOKE, LA; HERRMANN, BG; BEDDINGTON, RSP				RASHBASS, P; COOKE, LA; HERRMANN, BG; BEDDINGTON, RSP			A CELL AUTONOMOUS FUNCTION OF BRACHYURY IN T/T EMBRYONIC STEM-CELL CHIMERAS	NATURE			English	Article							MESODERM FORMATION; MOUSE EMBRYO; T-GENE; INVERSION; MUTATION; COMPLEX; LOCUS	DEVELOPMENTAL genetics has shown that the Brachyury (T) gene has a key role in mesoderm formation during gastrulation in the mouse 1,2. Homozygous embryos (Fig. 1) have a defective allantois, degenerate or absent notochord and disrupted primitive streak and node. The neural tube is kinked and somite formation interrupted 3-6. The T gene has been cloned 7 and is expressed during the early stages of gastrulation, being restricted to the primitive streak region, nascent mesoderm and notochord 8. Neither the sequence of the gene nor its expression pattern define its developmental function 7,9. To study the cell autonomy of the T mutation we have isolated and genetically characterized embryonic stem cell lines and studied their behaviour in chimaeras. T/+ embryonic stem cells form normal chimaeras, whereas T/T <-> +/+ chimaeras mimic the T/T mutant phenotype. The results indicate that the T gene acts cell autonomously in the primitive streak and notochord but may activate a signalling pathway involved in the specification of other mesodermal tissues.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY	Max Planck Society	RASHBASS, P (corresponding author), AFRC,CTR GENOME RES,KINGS BLDG,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND.		Pillay, Nischalan/F-9536-2012					BENNETT D, 1978, NATURE, V272, P539, DOI 10.1038/272539a0; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; EICHER EM, 1978, P NATL ACAD SCI USA, V75, P949; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIMOTO H, 1983, DIFFERENTIATION, V25, P44; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; HERRMANN B, 1986, CELL, V44, P469, DOI 10.1016/0092-8674(86)90468-X; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; LYON M. F., 1959, JOUR HEREDITY, V50, P140; MACMURRAY A, 1988, GENETICS, V120, P545; MCLAREN A, 1981, GENET RES CAMB, V37, P305; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SEARLE AG, 1966, GENET RES, V7, P86, DOI 10.1017/S0016672300009496; TAM PPL, 1987, DEVELOPMENT, V99, P109; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLISON K, 1990, TRENDS GENET, V6, P104, DOI 10.1016/0168-9525(90)90106-G; YANAGISAWA KO, 1990, JPN J GENET, V65, P287, DOI 10.1266/jjg.65.287; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0	22	88	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					348	351		10.1038/353348a0	http://dx.doi.org/10.1038/353348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922339				2022-12-28	WOS:A1991GG65400059
J	VANLOHUIZEN, M; FRASCH, M; WIENTJENS, E; BERNS, A				VANLOHUIZEN, M; FRASCH, M; WIENTJENS, E; BERNS, A			SEQUENCE SIMILARITY BETWEEN THE MAMMALIAN BMI-1 PROTOONCOGENE AND THE DROSOPHILA REGULATORY GENES PSC AND SU(Z)2	NATURE			English	Article							ZESTE; EXPRESSION; MELANOGASTER; TRANSVECTION; COMPLEX	THE bmi-1 proto-oncogene can be activated by Moloney murine leukaemia proviral insertions in E-mu-myc transgenic mice 1,2. It encodes a highly conserved nuclear protein of 324 amino acids which belongs to a family of proteins containing a putative new zinc-finger. Another closely related member of this family is the mouse protein Mel-18 (ref. 3). Here we report on the cloning and characterization of a homologous gene (D-bmi) from Drosophila melanogaster. Our analysis indicates that distinct domains of the mouse Bmi-1 protein, including the putative zinc-finger motif, are highly conserved within the much larger D-Bmi protein. Chromosomal localization and sequence comparison reveal that D-bmi is identical to Posterior Sex Combs (Psc) 4-6 and indicate that the conserved domains between mouse bmi and Psc are also conserved within Suppressor-2 of Zeste (Su(z)2) 6-8.	UNIV AMSTERDAM,DEPT BIOCHEM,AMSTERDAM,NETHERLANDS; MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,W-7400 TUBINGEN,GERMANY	University of Amsterdam; Max Planck Society	VANLOHUIZEN, M (corresponding author), NETHERLANDS CANC INST,DIV MOLEC GENET,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798				ADLER P, IN PRESS DEV GENET; ADLER PN, 1989, DEV GENET, V10, P249, DOI 10.1002/dvg.1020100314; BICKEL S, 1990, EMBO J, V9, P2959, DOI 10.1002/j.1460-2075.1990.tb07488.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUNK BP, 1990, GENETICS, V124, P145; BRUNK BP, 1991, GENETICS, V128, P119; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; GAUNT SJ, 1990, TRENDS GENET, V6, P208; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE J, 1988, GENETICS, V120, P181; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WU CT, 1989, MOL GEN GENET, V218, P559, DOI 10.1007/BF00332424; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	22	199	212	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					353	355		10.1038/353353a0	http://dx.doi.org/10.1038/353353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1922340				2022-12-28	WOS:A1991GG65400061
J	QIZILBASH, N; JONES, L; WARLOW, C; MANN, J				QIZILBASH, N; JONES, L; WARLOW, C; MANN, J			FIBRINOGEN AND LIPID CONCENTRATIONS AS RISK-FACTORS FOR TRANSIENT ISCHEMIC ATTACKS AND MINOR ISCHEMIC STROKES	BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; ISCHEMIC ATTACKS; CEREBROVASCULAR-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; MEN BORN; COMMUNITY; MORTALITY; COHORT	Objective - To determine whether fibrinogen and lipid concentrations are risk factors for ischaemic stroke. Design-Case - control study with a population based comparison within the overall study. Setting - Oxfordshire community stroke project and a neurology clinic. Subjects - 105 patients who had a transient ischaemic attack or minor ischaemic stroke and 352 randomly chosen controls matched for age and sex from the same general practitioners as the incident cases. 52 controls were ineligible or refused interview. 104 cases and 241 controls gave blood samples for analysis. Main outcome measures - Response to structured questionnaire, height, weight, blood pressure, and serum concentrations of fibrinogen and lipids. Results - Adjusted for other variables, odds ratios of ischaemic stroke were 1.78 (95% confidence interval 0.91 to 3.48; p = 0.009) for fibrinogen concentrations > 3.6 g/l; 1.73 (0.90 to 3.29; p = 0.009) for total cholesterol concentrations > 6.0 mmol/l; 1.34 (0.69 to 2.61; p > 0.4) for low density lipoprotein cholesterol concentrations > 3.5 mmol/l; and 0.32 (0.15 to 0.69; p = 0.002) for high density lipoprotein cholesterol concentration > 1.2 mmol/l. Similar results emerged comparing only community derived cases with transient ischaemic attacks and controls. The effects of fibrinogen, total cholesterol, and high density lipoprotein cholesterol were significant in a test of trend after adjusting for all other variable in the study (chi-2 = 4.14, p < 0.05; chi-2 = 4.31, p < 0.05, and chi-2 = 12.15, p > 0.001, respectively). History of ischaemic heart disease and hypertension were the only other variables that showed significance, though both lost significance after adjustment (2.06, p = 0.08 and 1.53, p = 0.2, respectively). Conclusions - Fibrinogen and lipids are important risk factors for ischaemic stroke. The pattern of changes mirrors that found in ischaemic heart disease.	RADCLIFFE INFIRM,DEPT COMMUNITY MED & GEN PRACTICE,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; Radcliffe Infirmary; University of Oxford					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; Breslow N, 1980, STATISTICAL METHODS, V32; BURSTEIN M, 1970, J LIPID RES, V11, P583; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DIPERRI T, 1985, CEPHALALGIA S2, V51, P71; ELLIS BC, 1961, J LAB CLIN MED, V58, P477; GAMBINA G, 1984, ITAL J NEUROL SCI, V5, P157, DOI 10.1007/BF02043217; GLOMSET JA, 1968, J LIPID RES, V9, P155; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; HOSSMANN V, 1977, BRAIN HEART INFARCT, P81; HUMPHREY PRD, 1981, STROKE, V12, P765, DOI 10.1161/01.STR.12.6.765; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; MARKOWE HLJ, 1982, EUR HEART J SB, V3, P5; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; ONONOGBU IC, 1976, CLIN CHIM ACTA, V71, P397, DOI 10.1016/0009-8981(76)90090-5; OSTFELD AM, 1974, AM J PUBLIC HEALTH, V64, P450, DOI 10.2105/AJPH.64.5.450; OTT E, 1983, EUR NEUROL, V22, P35, DOI 10.1159/000115609; OTT E, 1979, CEREBRAL VASCULAR DI, P216; PARTINEN M, 1985, LANCET, V1, P893; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; RHOADS GG, 1980, STROKE, V11, P21, DOI 10.1161/01.STR.11.1.21; RHOADS GG, 1983, ARTERIOSCLEROSIS, V3, P316, DOI 10.1161/01.ATV.3.4.316; SADOSHIMA S, 1979, ATHEROSCLEROISIS, V34, P43; SALONEN JT, 1983, INT J EPIDEMIOL, V12, P26, DOI 10.1093/ije/12.1.26; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SIRTORI CR, 1979, ATHEROSCLEROSIS, V32, P205, DOI 10.1016/0021-9150(79)90084-4; SPRIGGS DA, 1990, AGE AGEING, V19, P288; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; UEDA K, 1980, J CHRON DIS, V33, P13, DOI 10.1016/0021-9681(80)90081-8; WARLOW CP, 1976, THROMB HAEMOSTASIS, V36, P127, DOI 10.1055/s-0038-1648016; WARLOW CP, 1987, OXFORD TXB MED; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; Wolf P A, 1983, Neurol Clin, V1, P317; 1985, SAS USERS GUIDE STAT; 1982, JAMA-J AM MED ASSOC, V248, P2853	40	160	162	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					605	609		10.1136/bmj.303.6803.605	http://dx.doi.org/10.1136/bmj.303.6803.605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932900	Green Published, Bronze			2022-12-28	WOS:A1991GF67500019
J	LAW, MR; WALD, NJ; MEADE, TW				LAW, MR; WALD, NJ; MEADE, TW			STRATEGIES FOR PREVENTION OF OSTEOPOROSIS AND HIP FRACTURE	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BONE-MINERAL DENSITY; MIDDLE-AGED WOMEN; POST-MENOPAUSAL WOMEN; PROXIMAL FEMUR; POSTMENOPAUSAL WOMEN; FEMORAL-NECK; CALCIUM SUPPLEMENTATION; PHYSICAL-ACTIVITY; TRABECULAR BONE; MUSCLE STRENGTH				LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					AITKEN JM, 1984, BMJ-BRIT MED J, V288, P597, DOI 10.1136/bmj.288.6417.597; ALOIA JF, 1978, ANN INTERN MED, V89, P356, DOI 10.7326/0003-4819-89-3-356; ANGUS RM, 1988, BONE MINER, V4, P265; ANGUS RM, 1988, MED J AUSTRALIA, V148, P630, DOI 10.5694/j.1326-5377.1988.tb116337.x; BOHR H, 1983, CLIN ORTHOP RELAT R, V179, P240; BOYCE WJ, 1985, LANCET, V1, P150; BOYCE WJ, 1988, AGE AGEING, V17, P319, DOI 10.1093/ageing/17.5.319; CAVANAUGH DJ, 1988, BONE, V9, P201, DOI 10.1016/8756-3282(88)90031-2; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; CHOW R, 1987, BMJ-BRIT MED J, V295, P1441, DOI 10.1136/bmj.295.6611.1441; CHRISTIANSEN C, 1981, LANCET, V1, P459; COHN SH, 1986, CALCIFIED TISSUE INT, V38, P9, DOI 10.1007/BF02556588; COOK PJ, 1982, J ROY COLL PHYS LOND, V16, P45; COOPER C, 1990, BRIT J IND MED, V47, P69; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; COOPER C, 1987, BMJ-BRIT MED J, V295, P13, DOI 10.1136/bmj.295.6589.13; Cooper C, 1990, SMOKING HORMONE RELA, P93; Cornell C N, 1988, J Orthop Trauma, V2, P212, DOI 10.1097/00005131-198802030-00006; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DALEN N, 1974, ACTA ORTHOP SCAND, V45, P170, DOI 10.3109/17453677408989136; DALEN N, 1976, ACTA ORTHOP SCAND, V47, P503, DOI 10.3109/17453677608988728; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DEQUEKER J, 1974, CLIN RADIOL, V25, P243, DOI 10.1016/S0009-9260(74)80061-9; ELSASSER U, 1980, CLIN SCI, V59, P393, DOI 10.1042/cs0590393; ERIKSSON SAV, 1988, ACTA ORTHOP SCAND, V59, P19, DOI 10.3109/17453678809149337; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIRCOZNIA H, 1986, RADIOLOGY, V159, P737; GOLDSMITH NF, 1975, J BONE JOINT SURG AM, V57, P657, DOI 10.2106/00004623-197557050-00014; HALL ML, 1990, BRIT J RADIOL, V63, P266, DOI 10.1259/0007-1285-63-748-266; Hansen M A, 1991, Osteoporos Int, V1, P95; HARMA M, 1985, ACTA ORTHOP SCAND, V56, P380; HASSAGER C, 1989, BONE, V10, P415, DOI 10.1016/8756-3282(89)90072-0; Heaney R P, 1991, Osteoporos Int, V1, P65, DOI 10.1007/BF01880445; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HORSMAN A, 1982, CLIN ORTHOP RELAT R, V166, P143; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUNT K, 1987, BRIT J HOSP MED, V38, P450; HUTCHINSON TA, 1979, LANCET, V2, P705; JENSEN GF, 1982, CLIN ORTHOP RELAT R, P75; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; KANIS JA, 1989, BRIT MED J, V298, P137, DOI 10.1136/bmj.298.6667.137; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; KHAIRI MRA, 1976, J BONE JOINT SURG AM, V58, P221, DOI 10.2106/00004623-197658020-00010; KIEL DP, 1990, CLIN RES, V38, pA512; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KRALL EA, 1991, J BONE MINER RES, V6, P331; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; KREIGER N, 1986, AM J EPIDEMIOL, V123, P291, DOI 10.1093/oxfordjournals.aje.a114237; KROLNER B, 1983, CLIN SCI, V64, P541, DOI 10.1042/cs0640541; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LALOR BC, 1986, Q J MED, V59, P497; LAMKE B, 1978, ACTA ORTHOP SCAND, V49, P143, DOI 10.3109/17453677809005740; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAW M, 1990, SMOKING HORMONE RELA, P83; LEE ST, 1987, OSTEOPOROSIS 1987, P180; LEICHTER I, 1982, CLIN ORTHOP RELAT R, P272; LINDSAY R, 1978, LANCET, V1, P1325; LIPS P, 1984, CLIN ORTHOP RELAT R, V183, P64; LOTZ JC, 1990, J COMPUT ASSIST TOMO, V14, P107, DOI 10.1097/00004728-199001000-00020; MARGULIES JY, 1986, J BONE JOINT SURG AM, V68A, P1090, DOI 10.2106/00004623-198668070-00018; MAZESS RB, 1982, CLIN ORTHOP RELAT R, P239; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MAZESS RB, 1987, BONE MINER, V2, P211; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MELTZER M, 1989, CALCIFIED TISSUE INT, V45, P142, DOI 10.1007/BF02556056; MINAIRE P, 1989, Clinical Rheumatology, V8, P95, DOI 10.1007/BF02207242; MUNKJENSEN N, 1988, BRIT MED J, V296, P1150, DOI 10.1136/bmj.296.6630.1150; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NILSSON BE, 1978, AM J ROENTGENOL, V131, P541; NILSSON BE, 1971, CLIN ORTHOP RELAT R, P179; NORDIN BEC, 1990, LANCET, V336, P1327, DOI 10.1016/0140-6736(90)93018-K; NORDIN BEC, 1985, J CLIN ENDOCR METAB, V60, P651, DOI 10.1210/jcem-60-4-651; NORDIN BEC, 1990, BMJ-BRIT MED J, V300, P1056, DOI 10.1136/bmj.300.6731.1056; NORIMATSU H, 1989, BONE MINER, V5, P213, DOI 10.1016/0169-6009(89)90098-6; PACIFICI R, 1987, J CLIN ENDOCR METAB, V64, P209, DOI 10.1210/jcem-64-2-209; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; POCOCK N, 1989, J BONE MINER RES, V4, P441; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; POGRUND H, 1981, CLIN ORTHOP RELAT R, V156, P189; PORTER RW, 1990, BMJ-BRIT MED J, V301, P638, DOI 10.1136/bmj.301.6753.638; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; RICO H, 1990, ALCOHOL ALCOHOLISM, V25, P345; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; ROBINSON B, 1987, MED J AUSTRALIA, V146, P297, DOI 10.5694/j.1326-5377.1987.tb120265.x; RUNDGREN A, 1984, ARCH GERONTOL GERIAT, V3, P243, DOI 10.1016/0167-4943(84)90025-6; SARTORIS DJ, 1985, INVEST RADIOL, V20, P476, DOI 10.1097/00004424-198508000-00007; SIMKIN A, 1987, CALCIFIED TISSUE INT, V40, P59, DOI 10.1007/BF02555706; SINAKI M, 1988, ARCH PHYS MED REHAB, V69, P277; SMITH EL, 1984, CALCIFIED TISSUE INT, V36, pS129, DOI 10.1007/BF02406146; SMITH EL, 1981, MED SCI SPORT EXER, V13, P60; SMITH EL, 1989, AM J CLIN NUTR, V50, P833, DOI 10.1093/ajcn/50.4.833; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; SUOMINEN H, 1984, AGE AGEING, V13, P273, DOI 10.1093/ageing/13.5.273; TALMAGE RV, 1986, BONE MINER, V1, P115; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; VANHEMERT AM, 1990, J CLIN EPIDEMIOL, V43, P579, DOI 10.1016/0895-4356(90)90162-I; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITE MK, 1984, INT ORTHOP, V7, P209; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; WOO SLY, 1981, J BONE JOINT SURG AM, V63, P780, DOI 10.2106/00004623-198163050-00013; WOOTTON R, 1979, CLIN SCI, V57, P93, DOI 10.1042/cs0570093; 1987, 1985 MIN AGR FISH FO; 1987, HOSPITAL INPATIENT E	117	233	233	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	1991	303	6800					453	459		10.1136/bmj.303.6800.453	http://dx.doi.org/10.1136/bmj.303.6800.453			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC465	1912840	Bronze, Green Published			2022-12-28	WOS:A1991GC46500020
J	CLACKSON, T; HOOGENBOOM, HR; GRIFFITHS, AD; WINTER, G				CLACKSON, T; HOOGENBOOM, HR; GRIFFITHS, AD; WINTER, G			MAKING ANTIBODY FRAGMENTS USING PHAGE DISPLAY LIBRARIES	NATURE			English	Article							IMMUNOGLOBULIN VARIABLE DOMAINS; POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; IMMUNE-RESPONSE; EXPRESSION; PROTEIN; LAMBDA; DNA; ANTI-2-PHENYLOXAZOLONE; REPERTOIRE	To by-pass hybridoma technology and animal immunization, we are trying to build antibodies in bacteria by mimicking features of immune selection1. Recently we used fd phage2 to display antibody fragments fused to a minor coat protein3,4, allowing enrichment of phage with antigen3. Using a random combinatorial library of the rearranged heavy (VH) and kappa (V-kappa) light chains5-8 from mice immune to the hapten 2-phenyloxazol-5-one (phOx), we have now displayed diverse libraries of antibody fragments on the surface of fd phage. After a single pass over a hapten affinity column, fd phage with a range of phOx binding activities were detected, at least one with high affinity (dissociation constant, K(d) = 10(-8) M). A second pass enriched for the strong binders at the expense of the weak. The binders were encoded by V genes similar to those found in anti-phOx hybridomas but in promiscuous combinations (where the same V gene is found with several different partners). By combining a promiscuous VH or V-kappa gene with diverse repertoires of partners to create hierarchical libraries, we elicited many more pairings with strong binding activities. Phage display offers new ways of making antibodies from V-gene libraries, altering V-domain pairings and selecting for antibodies with good affinities.	CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	CLACKSON, T (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Griffiths, Andrew D/A-1370-2010; Baird, Cheryl L/F-6569-2011	Griffiths, Andrew D/0000-0002-0808-3539; 				ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CATON AJ, 1991, P NATL ACAD SCI USA, V88, P1590; CLACKSON T, IN PRESS PCR PRACTIC; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEBELLIS D, 1990, NUCLEIC ACIDS RES, V18, P1311; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DILDROP R, 1984, IMMUNOL TODAY, V5, P85, DOI 10.1016/0167-5699(84)90034-3; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EISEN H N, 1964, Methods Med Res, V10, P115; FOOTE J, IN PRESS NATURE; GHERARDI E, 1990, J IMMUNOL METHODS, V126, P61, DOI 10.1016/0022-1759(90)90012-K; Gibson T.J., 1984, THESIS U CAMBRIDGE; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HARLOW E, 1988, ANTIBODIES LABORATOR; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUDSON NW, 1987, J IMMUNOL, V139, P2715; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; MAKELA O, 1978, J EXP MED, V148, P1644, DOI 10.1084/jem.148.6.1644; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCMANUS S, 1991, BIOCHEMISTRY-US, V30, P5851, DOI 10.1021/bi00238a007; MULLINAX RL, 1990, P NATL ACAD SCI USA, V87, P8095, DOI 10.1073/pnas.87.20.8095; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGAL I, 1975, ENZYME KINETICS, P73; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	45	929	2469	4	151	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					624	628		10.1038/352624a0	http://dx.doi.org/10.1038/352624a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1907718				2022-12-28	WOS:A1991GB21100057
J	AYLETT, M; KETCHIN, S				AYLETT, M; KETCHIN, S			STOPPING TREATMENT IN PATIENTS WITH HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article											AYLETT, M (corresponding author), GLENDALE SURG,WOOLER NE71 6DN,NORTHD,ENGLAND.							BERGLUND G, 1976, BRIT MED J, V2, P554, DOI 10.1136/bmj.2.6035.554; HART JT, 1987, HYPERTENSION, P132; SAUNDERS JB, 1987, BRIT MED J, V294, P1045, DOI 10.1136/bmj.294.6579.1045; WETHERALL DJ, 1987, OXFORD TXB MED, V13, P360; 1989, BMJ, V298, P694	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					345	345		10.1136/bmj.303.6798.345	http://dx.doi.org/10.1136/bmj.303.6798.345			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912776	Bronze, Green Published			2022-12-28	WOS:A1991GA60600022
J	CLARK, JD; LIN, LL; KRIZ, RW; RAMESHA, CS; SULTZMAN, LA; LIN, AY; MILONA, N; KNOPF, JL				CLARK, JD; LIN, LL; KRIZ, RW; RAMESHA, CS; SULTZMAN, LA; LIN, AY; MILONA, N; KNOPF, JL			A NOVEL ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PLA2 CONTAINS A CA2+-DEPENDENT TRANSLOCATION DOMAIN WITH HOMOLOGY TO PKC AND GAP	CELL			English	Article								We report the cloning and expression of a cDNA encoding a high molecular weight (85.2 kd) cytosolic phospholipase A2 (cPLA2) that has no detectable sequence homology with the secreted forms of PLA2. We show that cPLA2 selectively cleaves arachidonic acid from natural membrane vesicles and demonstrate that cPLA2 translocates to membrane vesicles in response to physiologically relevant changes in free calcium. Moreover, we demonstrate that an amino-terminal 140 amino acid fragment of cPLA2 translocates to natural membrane vesicles in a Ca2+-dependent fashion. Interestingly, we note that this 140 amino acid domain of cPLA2 contains a 45 amino acid region with homology to PKC, p65, GAP, and PLC. We suggest that this homology delineates a Ca2+-dependent phospholipid-binding motif, providing a mechanism for the second messenger Ca2+ to translocate and activate cytosolic proteins.	SYNTEX RES INC, INST BIOL SCI, PALO ALTO, CA 94304 USA	Syntex Corporation	CLARK, JD (corresponding author), GENET INST, CAMBRIDGE, MA 02140 USA.			Clark, James D./0000-0002-4801-0123				ALLEN G, 1981, SEQUENCING PROTEINS, P43; BAKER ME, 1989, MOL CELL ENDOCRINOL, V61, P129, DOI 10.1016/0303-7207(89)90197-4; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; DIEZ E, 1990, J BIOL CHEM, V265, P14654; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GORECKATISERA AM, 1986, CELL IMMUNOL, V100, P411, DOI 10.1016/0008-8749(86)90040-7; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HARLOW E, 1988, ANTIBODIES LABORATOR; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUANG FL, 1991, IN PRESS J BIOL CHEM; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAUFMAN R J, 1990, Technique (Philadelphia), V2, P221; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; MARGOLIS BL, 1988, BIOCHEM J, V256, P469, DOI 10.1042/bj2560469; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PARKER J, 1987, J BIOL CHEM, V262, P5385; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RAMESHA CS, 1991, ANAL BIOCHEM, V192, P173, DOI 10.1016/0003-2697(91)90203-6; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHALKWIJK CG, 1990, BIOCHIM BIOPHYS ACTA, V1044, P139, DOI 10.1016/0005-2760(90)90229-Q; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGA K, 1990, J BIOL CHEM, V265, P12363; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1991, IN PRESS MOL CELL BI; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAKU K, 1974, J BIOCHEM-TOKYO, V75, P1307, DOI 10.1093/oxfordjournals.jbchem.a130515; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I; YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430	54	1646	1678	0	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1043	1051		10.1016/0092-8674(91)90556-E	http://dx.doi.org/10.1016/0092-8674(91)90556-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1904318				2022-12-28	WOS:A1991FR04700015
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERFERON ALFA APPROVED FOR NON-A, NON-B HEPATITIS TYPE-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2934	2934						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	1903461				2022-12-28	WOS:A1991FP63500008
J	BINETRUY, B; SMEAL, T; KARIN, M				BINETRUY, B; SMEAL, T; KARIN, M			HA-RAS AUGMENTS C-JUN ACTIVITY AND STIMULATES PHOSPHORYLATION OF ITS ACTIVATION DOMAIN	NATURE			English	Article							TRANSCRIPTION FACTOR AP-1; PROTO-ONCOGENE; MOUSE FIBROBLASTS; GENE-EXPRESSION; TRANSFORMATION; INTERACTS; ENCODES; ELEMENT; PRODUCT; CELLS	Ha-Ras augments c-Jun-mediated transactivation by potentiating the activity of the c-Jun activation domain. Ha-Ras also causes a corresponding increase in phosphorylation of specific sites in that part of the c-Jun protein. A Ha-Ras-induced protein kinase cascade resulting in hyperphosphorylation of the c-Jun activation domain could explain how these oncoproteins cooperate to transform rat embryo fibroblasts.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, 0636, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AAG-7139-2022	Binetruy, Bernard/0000-0001-8012-7092; 				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DOTTO GP, 1985, NATURE, V318, P472; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCCORMICK F, 1989, ONCOGENES MOL ORIGIN, P125; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RADLER-POHL A, 1990, New Biologist, V2, P566; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YANG-YEN H-F, 1990, New Biologist, V2, P351; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	50	622	641	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					122	127		10.1038/351122a0	http://dx.doi.org/10.1038/351122a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903181				2022-12-28	WOS:A1991FL03500041
J	GROSSMAN, AD				GROSSMAN, AD			INTEGRATION OF DEVELOPMENTAL SIGNALS AND THE INITIATION OF SPORULATION IN BACILLUS-SUBTILIS	CELL			English	Review							BACILLUS-SUBTILIS; REGULATORY PROTEINS				GROSSMAN, AD (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.							ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; FREESE E, 1979, J GEN MICROBIOL, V115, P193, DOI 10.1099/00221287-115-1-193; GROSSMAN AD, 1988, P NATL ACAD SCI USA, V85, P4369, DOI 10.1073/pnas.85.12.4369; LOPEZ JM, 1979, BIOCHIM BIOPHYS ACTA, V587, P238, DOI 10.1016/0304-4165(79)90357-X; LOPEZ JM, 1981, J BACTERIOL, V146, P605, DOI 10.1128/JB.146.2.605-613.1981; OLMEDO G, 1990, J MOL BIOL, V215, P359, DOI 10.1016/S0022-2836(05)80357-2; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1991, IN PRESS J BACTERIAL, V173; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860	17	47	47	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					5	8		10.1016/0092-8674(91)90353-Z	http://dx.doi.org/10.1016/0092-8674(91)90353-Z			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1901517	Bronze			2022-12-28	WOS:A1991FF77300002
J	RAUB, W				RAUB, W			TAMOXIFEN FOUND TO LOWER GROWTH-FACTOR LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1990, J NATL CANCER I, V82, P1693	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-28	WOS:A1991FD65900004
J	MARTINEZ, C; MODOLELL, J				MARTINEZ, C; MODOLELL, J			CROSS-REGULATORY INTERACTIONS BETWEEN THE PRONEURAL ACHAETE AND SCUTE GENES OF DROSOPHILA	SCIENCE			English	Article							HAIRY-WING MUTATIONS; PATTERN FORMATION; FATE MAP; MELANOGASTER; COMPLEX; REGENERATION; DUPLICATION; HUNCHBACK; ELEMENTS; SYSTEM	The achaete (ac) and scute (sc) genes of Drosophila allow cells to become sensory organ mother cells. Although ac and sc have similar patterns of expression, deletion of either gene removes specific subsets of sensory organs. This specificity was shown to reside in the peculiar regulation of ac and sc expression. These genes are first activated in complementary spatial domains in response to different cis-regulatory sequences. Each gene product then stimulates expression of the other gene, thus generating similar patterns of expression. Therefore, removal of one gene leads to the absence of both proneural gene products and sensory organs in the sites specified by its cis-regulatory sequences.	UNIV AUTONOMA MADRID,MADRID 34,SPAIN	Autonomous University of Madrid	MARTINEZ, C (corresponding author), CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN.							ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAMPUZANO S, COMMUNICATION; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1989, DEVELOPMENT, V105, P35; HUANG F, IN PRESS DEVELOPMENT; LEYNS L, 1989, ROUX ARCH DEV BIOL, V198, P227, DOI 10.1007/BF00375909; MARTINEZ CJ, UNPUB; MURRAY MA, 1984, DEV BIOL, V104, P259, DOI 10.1016/0012-1606(84)90082-4; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RODRIGUEZ I, 1990, EMBO J, V11, P3583; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SKEATH J, COMMUNICATION; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VAESSIN H, COMMUNICATION; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	28	105	105	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1485	1487		10.1126/science.1900954	http://dx.doi.org/10.1126/science.1900954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1900954				2022-12-28	WOS:A1991FC85300048
J	DANESHDOOST, L; GENNARELLI, TA; BASHEY, HM; SAVINO, PJ; SERGOTT, RC; BOSLEY, TM; SNYDER, PJ				DANESHDOOST, L; GENNARELLI, TA; BASHEY, HM; SAVINO, PJ; SERGOTT, RC; BOSLEY, TM; SNYDER, PJ			RECOGNITION OF GONADOTROPH ADENOMAS IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SECRETING PITUITARY-ADENOMAS; THYROTROPIN-RELEASING-HORMONE; CELL ADENOMAS; LUTEINIZING-HORMONE; ALPHA-SUBUNIT; FSH; CULTURE; INVITRO; INVIVO; BROMOCRIPTINE	Background. Pituitary adenomas that arise from the gonadotroph cells are being recognized with increasing frequency in men, but they are still rarely recognized in women. This rarity could be the result of an actual difference in occurrence or of greater difficulty in recognition. The tumors are usually recognized in men more than 50 years old, but elevated serum gonadotropin levels in women of that age could be produced by normal gonadotroph cells. Methods. Because the stimulation of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and the beta subunit of LH (LH-beta) by thyrotropin-releasing hormone (TRH) is a characteristic of gonadotroph adenomas in men, we administered TRH to 16 women with apparently nonsecreting pituitary macroadenomas and measured serum FSH, LH, LH-beta, and the glycoprotein hormone alpha-subunit every 15 minutes for 90 minutes before and 90 minutes after. The results were compared with the responses in 16 healthy women matched for age and in 10 women with macroadenomas secreting prolactin, growth hormone, or corticotropin. The tumors from 12 of the women with nonsecreting adenomas were cultured, and the secretion of FSH, LH, and LH-beta in culture was determined. Results. Eleven of the 16 women with apparently nonsecreting adenomas had significant increases in serum LH-beta in response to TRH, 3 had FSH responses, and 4 had LH responses. None of the 16 healthy women and none of the 10 women with secreting macroadenomas had LH-beta, FSH, or LH responses to TRH. Ten of the 12 adenomas that were cultured secreted readily detectable amounts of FSH, LH, and LH-beta, and their secretion in vitro correlated with the patients' responses to TRH in vivo. Conclusions. Most apparently nonsecreting pituitary macroadenomas in women arise from gonadotroph cells. The majority of these can be recognized, even in postmenopausal women, by the serum LH-beta responses to TRH, and some can be recognized by the responses of serum FSH and LH.	WILLS EYE HOSP & RES INST,NEUROOPHTHALMOL SERV,PHILADELPHIA,PA 19107; UNIV PENN,SCH MED,DEPT MED,ENDOCRINOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104	Jefferson University; University of Pennsylvania; University of Pennsylvania					NCRR NIH HHS [RR-40] Funding Source: Medline; NIDDK NIH HHS [DK-42139] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042139] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1986, J CLIN ENDOCR METAB, V62, P1011, DOI 10.1210/jcem-62-5-1011; BECKERS A, 1985, J CLIN ENDOCR METAB, V61, P525, DOI 10.1210/jcem-61-3-525; BECKPECCOZ P, 1985, J CLIN ENDOCR METAB, V61, P541, DOI 10.1210/jcem-61-3-541; BLACK PM, 1987, J NEUROSURG, V66, P244, DOI 10.3171/jns.1987.66.2.0244; CUNNINGHAM GR, 1977, J CLIN ENDOCR METAB, V44, P248, DOI 10.1210/jcem-44-2-248; FRIEND JN, 1976, J CLIN ENDOCR METAB, V43, P650, DOI 10.1210/jcem-43-3-650; JAMESON JL, 1987, J CLIN INVEST, V80, P1472, DOI 10.1172/JCI113228; KOVACS K, 1978, FERTIL STERIL, V29, P622; KWEKKEBOOM DJ, 1989, J CLIN ENDOCR METAB, V68, P1128, DOI 10.1210/jcem-68-6-1128; LAMBERTS SWJ, 1987, J CLIN ENDOCR METAB, V64, P524, DOI 10.1210/jcem-64-3-524; MASHITER K, 1981, CLIN ENDOCRINOL, V15, P103, DOI 10.1111/j.1365-2265.1981.tb00643.x; SNYDER PJ, 1980, J CLIN ENDOCR METAB, V51, P744, DOI 10.1210/jcem-51-4-744; SNYDER PJ, 1984, J CLIN ENDOCR METAB, V59, P1169, DOI 10.1210/jcem-59-6-1169; SNYDER PJ, 1985, ENDOCR REV, V6, P552, DOI 10.1210/edrv-6-4-552; SNYDER PJ, 1985, J CLIN ENDOCR METAB, V61, P1061, DOI 10.1210/jcem-61-6-1061; SNYDER PJ, 1976, J CLIN ENDOCR METAB, V42, P544, DOI 10.1210/jcem-42-3-544; TROUILLAS J, 1986, SEMIN DIAGN PATHOL, V3, P42; WHITE MC, 1986, CLIN ENDOCRINOL, V25, P173, DOI 10.1111/j.1365-2265.1986.tb01679.x; WHITE MC, 1990, CLIN ENDOCRINOL, V32, P681, DOI 10.1111/j.1365-2265.1990.tb00914.x; WIDE L, 1981, J CLIN ENDOCR METAB, V53, P923, DOI 10.1210/jcem-53-5-923; WOOLF PD, 1974, J CLIN ENDOCR METAB, V38, P561, DOI 10.1210/jcem-38-4-561	21	109	113	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 28	1991	324	9					589	594		10.1056/NEJM199102283240904	http://dx.doi.org/10.1056/NEJM199102283240904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY886	1899470				2022-12-28	WOS:A1991EY88600004
J	VANTWUYVER, E; MOOIJAART, RJD; TENBERGE, IJM; VANDERHORST, AR; WILMINK, JM; KAST, WM; MELIEF, CJM; DEWAAL, LP				VANTWUYVER, E; MOOIJAART, RJD; TENBERGE, IJM; VANDERHORST, AR; WILMINK, JM; KAST, WM; MELIEF, CJM; DEWAAL, LP			PRETRANSPLANTATION BLOOD-TRANSFUSION REVISITED	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOCYTE-T PRECURSORS; CLASS-II DISPARITY; H-2 CLASS-I; TRANSPLANTATION TOLERANCE; ADULT MICE; ALLOGRAFT ENHANCEMENT; CELL REPERTOIRE; INDUCTION; CYCLOSPORINE; RECIPIENTS	Background. Blood transfusion before organ transplantation has a beneficial effect on allograft survival; the mechanism of this effect has remained a mystery. In murine models, the presence of common histocompatibility antigens in the blood donor and the recipient favors the induction of allograft tolerance. Methods. To investigate the effect of HLA compatibility between blood donor and recipient on the induction of allograft tolerance, we determined the relative frequency of cytotoxic T-lymphocyte precursors specific for donor cells before and at several times after blood transfusion in 23 patients awaiting a first renal transplant. We correlated the results with the presence of shared HLA antigens. Results. T-cell nonresponsiveness against donor cells developed after blood transfusion in 10 of the 23 patients. Tolerance developed only if the blood donor and the recipient had one HLA haplotype or at least one HLA-B and one HLA-DR antigen in common (as was observed in 9 of these 10 patients). Tolerance developed relatively late after blood transfusion (one to two months) and was long-lasting. No decline in the T-cell response against donor alloantigens was observed in any of the 13 patients who received transfusions without having HLA-antigen compatibility with the donor. Conclusions. Blood transfusion in which there is a common HLA haplotype or shared HLA-B and HLA-DR antigens induces tolerance to donor antigens. This finding may lead to the development of new strategies with which to induce tolerance for transplantation after blood transfusion. Perhaps transplant donors will be selected not only by HLA-antigen matching, but also on the basis of acceptable HLA-antigen mismatches associated with T-cell non-responsiveness induced by selected blood transfusion.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,RENAL TRANSPLANT UNIT,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV HOSP,DEPT IMMUNOHEMATOL,2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)				Kast, W Martin/0000-0003-2321-3159				BREURVRIESENDORP BS, 1990, HUM IMMUNOL, V27, P1, DOI 10.1016/0198-8859(90)90091-3; DEWAAL LP, 1991, CRIT REV IMMUNOL, V10, P417; HEEG K, 1990, J EXP MED, V172, P719, DOI 10.1084/jem.172.3.719; HENON P, 1991, LANCET, P961; HERZOG WR, 1987, TRANSPLANTATION, V43, P384, DOI 10.1097/00007890-198703000-00013; IRSCHICK E, 1989, TRANSPLANTATION, V48, P986, DOI 10.1097/00007890-198912000-00018; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; KAST WM, 1988, EUR J IMMUNOL, V18, P2105; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LAZDA VA, 1990, TRANSPLANTATION, V49, P1084, DOI 10.1097/00007890-199006000-00011; LEIVESTAD T, 1984, TRANSPLANTATION, V37, P175, DOI 10.1097/00007890-198402000-00012; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; MCCARTHY DM, 1984, CRC CR REV CL LAB SC, V20, P1; OPELZ G, 1987, TRANSPLANT P, V19, P149; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; SALVATIERRA O, 1987, TRANSPL P, V19, P160; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; VANDEKERCKHOVE BAE, 1989, TRANSPLANTATION, V48, P672; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; VANTWUYVER E, 1989, TRANSPLANTATION, V48, P844; VANTWUYVER E, 1990, EUR J IMMUNOL, V20, P441, DOI 10.1002/eji.1830200232; 1988, LANCET, V1, P567	24	176	180	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 24	1991	325	17					1210	1213		10.1056/NEJM199110243251704	http://dx.doi.org/10.1056/NEJM199110243251704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GL282	1922208				2022-12-28	WOS:A1991GL28200004
J	SCHUSTER, CR				SCHUSTER, CR			MONITORING THE IMPACT OF COCAINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SCHUSTER, CR (corresponding author), NIDA,ROCKVILLE,MD, USA.							POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233	1	3	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 23	1991	266	16					2273	2273						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK661	1920729				2022-12-28	WOS:A1991GK66100039
J	ABO, A; PICK, E; HALL, A; TOTTY, N; TEAHAN, CG; SEGAL, AW				ABO, A; PICK, E; HALL, A; TOTTY, N; TEAHAN, CG; SEGAL, AW			ACTIVATION OF THE NADPH OXIDASE INVOLVES THE SMALL GTP-BINDING PROTEIN P21RAC1	NATURE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; 2 CYTOSOLIC COMPONENTS; SODIUM DODECYL-SULFATE; DEPENDENT SUPEROXIDE PRODUCTION; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; CYTOCHROME-B; GUANINE-NUCLEOTIDES; RESPIRATORY BURST	PROFESSIONAL phagocytes, such as neutrophils and monocytes, have an NADPH oxidase that generates superoxide and other reduced oxygen species important in killing microorganisms (reviewed in ref. 1). Several components of the oxidase complex have been identified as targets of genetic defects causing chronic granulomatous disease 2-4. The complex consists of an electron transport chain that has as its substrate cytosolic NADPH and which discharges superoxide into the cavity of the intracellular phagocytic vacuole. The only electron transport component identified so far is a low-potential cytochrome b (refs 5, 6), apparently the only membrane component required 7. At least three cytosolic factors are also necessary, two of which, p67phox and p47phox, have been identified by their absence in patients with chronic granulomatous disease 8-11. A third component, sigma-1 (refs 12, 13), is required for stimulation of oxidase activity in a cell-free system 14-16. The active components of purified sigma-1 are two proteins that associate as heterodimers 17, and here we report that these are the small GTP-binding protein p2lrac1 and the GDP-dissociation inhibitor rhoGDI.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,RAYNE INST,DEPT MED,LONDON WC1E 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; King's College London; University College London	ABO, A (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,IMMUNOPHARMACOL LAB,TEL AVIV,ISRAEL.		; Pick, Edgar/B-1795-2008	Segal, Anthony/0000-0001-7602-9043; Pick, Edgar/0000-0003-4625-3233	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, IN PRESS J BIOL CHEM; AHARONI I, 1990, J LEUKOCYTE BIOL, V48, P107, DOI 10.1002/jlb.48.2.107; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HALL A, 1986, J BIOL CHEM, V261, P963; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIGETI E, 1988, BIOCHEMISTRY-US, V27, P193, DOI 10.1021/bi00401a029; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PICK E, 1987, J BIOL CHEM, V262, P16476; PICK E, 1989, J IMMUNOL, V143, P4180; PICK E, 1981, CELL IMMUNOL, V59, P301, DOI 10.1016/0008-8749(81)90411-1; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SHAAG D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P405, DOI 10.1016/0167-4838(90)90044-G; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	39	854	867	1	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 17	1991	353	6345					668	670		10.1038/353668a0	http://dx.doi.org/10.1038/353668a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK672	1922386				2022-12-28	WOS:A1991GK67200074
J	GAUTIER, J; SOLOMON, MJ; BOOHER, RN; BAZAN, JF; KIRSCHNER, MW				GAUTIER, J; SOLOMON, MJ; BOOHER, RN; BAZAN, JF; KIRSCHNER, MW			CDC25 IS A SPECIFIC TYROSINE PHOSPHATASE THAT DIRECTLY ACTIVATES P34CDC2	CELL			English	Article							MATURATION-PROMOTING FACTOR; LEUKOCYTE-COMMON ANTIGEN; EMBRYONIC-CELL CYCLE; PROTEIN-KINASE; FISSION YEAST; IMMUNOGLOBULIN SUPERFAMILY; SCHIZOSACCHAROMYCES-POMBE; MITOTIC INDUCER; HUMAN-PLACENTA; HUMAN HOMOLOG	cdc25 controls the activity of the cyclin-p34cdc2 complex by regulating the state of tyrosine phosphorylation of p34cdc2. Drosophila cdc25 protein from two different expression systems activates inactive cyclin-p34cdc2 and induces M phase in Xenopus oocytes and egg extracts. We find that the cdc25 sequence shows weak but significant homology to a phylogenetically diverse group of protein tyrosine phosphatases. cdc25 itself is a very specific protein tyrosine phosphatase. Bacterially expressed cdc25 directly dephosphorylates bacterially expressed p34cdc2 on Tyr-15 in a minimal system devoid of eukaryotic cell components, but does not dephosphorylate other tyrosine-phosphorylated proteins at appreciable rates. In addition, mutations in the putative catalytic site abolish the in vivo activity of cdc25 and its phosphatase activity in vitro. Therefore, cdc25 is a specific protein phosphatase that dephosphorylates tyrosine and possibly threonine residues on p34cdc2 and regulates MPF activation.			GAUTIER, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Bazan, J. Fernando/B-4562-2010; Gautier, jean/A-2774-2008					BARKER WC, 1990, METHOD ENZYMOL, V183, P31; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JESSUS C, 1991, DEVELOPMENT, V111, P813; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUANG J, 1991, IN PRESS P NATL ACAD; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEHNER C, 1990, EMBO J, V9, P3579; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATTHEWS RJ, 1991, IMMUNOGENETICS, V33, P33; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1991, IN PRESS J CELL BIOL; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORIA AO, 1989, CELL, V58, P193; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSTELIN T, 1990, ONCOGENE, V5, P809; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR WR, 1990, PROG BIOPHYS MOL BIO, V54, P159; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	84	797	814	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					197	211		10.1016/0092-8674(91)90583-K	http://dx.doi.org/10.1016/0092-8674(91)90583-K			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1913817				2022-12-28	WOS:A1991GJ32000018
J	HENDRICKSON, WA				HENDRICKSON, WA			DETERMINATION OF MACROMOLECULAR STRUCTURES FROM ANOMALOUS DIFFRACTION OF SYNCHROTRON RADIATION	SCIENCE			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; PROTEIN CRYSTALLOGRAPHY; CORE STREPTAVIDIN; LAUE DIFFRACTION; HIGH-RESOLUTION; SCATTERING; DISPERSION; DIFFRACTOMETER; WAVELENGTHS	Resonance between beams of x-ray waves and electronic transitions from bound atomic orbitals leads to a phenomenon known as anomalous scattering. This effect can be exploited in x-ray crystallographic studies on biological macromolecules by making diffraction measurements at selected wavelengths associated with a particular resonant transition. In this manner the problem of determining the three-dimensional structure of thousands of atoms is reduced to that of initially solving for a few anomalous scattering centers that can then be used as a reference for developing the entire structure. This method of multi-wavelength anomalous diffraction has now been applied in a number of structure determinations. Optimal experiments require appropriate synchrotron instrumentation, careful experimental design, and sophisticated analytical procedures. There are rich opportunities for future applications.			HENDRICKSON, WA (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.				NIGMS NIH HHS [GM-34102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R37GM034102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEMIYA Y, 1988, NUCL INSTRUM METH A, V266, P645, DOI 10.1016/0168-9002(88)90458-5; BATTERMAN BW, COMMUNICATION; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BROWN DB, 1971, J APPL PHYS, V42, P4044, DOI 10.1063/1.1659722; BROWN DB, 1975, J APPL PHYS, V46, P4537, DOI 10.1063/1.321390; CROMER DT, 1970, J CHEM PHYS, V53, P1891, DOI 10.1063/1.1674266; CUFF ME, UNPUB; DETITTA GT, 1990, AM CRYSTALLOGR ASS 2, V18, P20; FANCHON E, 1990, ACTA CRYSTALLOGR A, V46, P809, DOI 10.1107/S0108767390005967; FENKELSTEIN K, UNPUB; Fourme R., 1990, SYNCHROTRON RAD BIOP, P156; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GREENHOUGH TJ, 1983, PROG BIOPHYS MOL BIO, V41, P67, DOI 10.1016/0079-6107(83)90026-3; GUSS JM, 1988, SCIENCE, V241, P806, DOI 10.1126/science.3406739; HAJDU J, 1990, BIOCHEMISTRY-US, V29, P1669, DOI 10.1021/bi00459a001; HARADA S, 1986, J APPL CRYSTALLOGR, V19, P448, DOI 10.1107/S0021889886088970; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HERZENBERG A, 1967, ACTA CRYSTALLOGR, V22, P24, DOI 10.1107/S0365110X67000040; HOPPE W, 1975, ANOMALOUS SCATTERING, P437; JAMES RW, 1948, OPTICAL PRINCIPLES D, P135; KAHN R, 1985, FEBS LETT, V179, P133, DOI 10.1016/0014-5793(85)80207-6; KAHN R, 1986, NUCL INSTRUM METH A, V246, P596, DOI 10.1016/0168-9002(86)90158-0; KARLE J, 1989, ACTA CRYSTALLOGR A, V45, P765, DOI 10.1107/S0108767389007403; KARLE J, 1980, INT J QUANTUM CHEM, V18, P357; KARLE J, 1967, APPL OPTICS, V6, P2132, DOI 10.1364/AO.6.002132; KOLATKAR PR, IN PRESS ACTA CRYSTA; LEAHY DJ, UNPUB; LYE RC, 1980, P NATL ACAD SCI-BIOL, V77, P5884, DOI 10.1073/pnas.77.10.5884; MITCHELL CM, 1957, ACTA CRYSTALLOGR, V10, P475, DOI 10.1107/S0365110X57001656; MOFFAT K, 1984, SCIENCE, V223, P1423, DOI 10.1126/science.223.4643.1423; MURTHY HMK, 1988, J BIOL CHEM, V263, P18430; NAKAGAWA A, 1990, J BIOCHEM-TOKYO, V108, P701, DOI 10.1093/oxfordjournals.jbchem.a123267; NARAYAN R, 1981, ACTA CRYSTALLOGR A, V37, P636, DOI 10.1107/S0567739481001459; OGATA CM, UNPUB; OKAYA Y, 1956, PHYS REV, V103, P1645, DOI 10.1103/PhysRev.103.1645; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PAHLER A, 1987, J BIOL CHEM, V262, P13933; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; PHIZACKERLEY RP, 1986, NUCL INSTRUM METH A, V246, P579, DOI 10.1016/0168-9002(86)90157-9; Raman S., 1959, P INDIAN ACAD SCI A, V50, P95; RAMASESHAN S, 1959, P INDIAN ACAD SCI A, V46, P95; ROSENBAU.G, 1971, NATURE, V230, P434, DOI 10.1038/230434a0; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATOW Y, 1989, REV SCI INSTRUM, V60, P2390, DOI 10.1063/1.1140728; SHENOY GK, COMMUNICATION; SHENOY GK, 1988, ANL889 REP; STAUDENMANN JL, 1989, REV SCI INSTRUM, V60, P1939, DOI 10.1063/1.1140894; STUHRMANN HB, 1990, SYNCHROTRON RAD BIOP, P223; TEMPLETON LK, 1982, ACTA CRYSTALLOGR A, V38, P74, DOI 10.1107/S056773948200014X; TEMPLETON LK, 1988, ACTA CRYSTALLOGR A, V44, P1045, DOI 10.1107/S0108767388007810; WEIS WI, UNPUB; XUONG NH, 1990, AM CRYSTALLOGR ASS 2, V18, P20; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	60	1028	1056	0	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1991	254	5028					51	58		10.1126/science.1925561	http://dx.doi.org/10.1126/science.1925561			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1925561				2022-12-28	WOS:A1991GH60500027
J	ALBERTI, KGMM				ALBERTI, KGMM			THE HEALTH OF THE NATION - RESPONSES - ROLE OF DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE				ALBERTI, KGMM (corresponding author), UNIV NEWCASTLE UPON TYNE, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, ENGLAND.							ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; [Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; CAMPBELL I, 1991, DIABETIC MED, V8, P3, DOI 10.1111/j.1464-5491.1991.tb01507.x; CULLINAN TR, 1982, DIABETOLOGIA, V23, P504; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOME PD, IN PRESS DIABETES AN; MARSHALL SM, 1989, Q J MED, V70, P61; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MILLER LV, 1972, NEW ENGL J MED, V286, P1388, DOI 10.1056/NEJM197206292862605; MOGENSEN CE, 1988, DIABETES ANN 4, P411; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCULPHER MJ, 1991, DIABETIC MED, V8, P644, DOI 10.1111/j.1464-5491.1991.tb01671.x; TUNBRIDGE WMG, 1981, LANCET, V2, P569; Williams D R, 1985, Diabet Med, V2, P27; 1989, VINCENT DECLARATION; 1983, DIABETOLOGIA, V24, P404; [No title captured]; 1985, PROVISION MED CARE A; 1991, CM1523; 1988, DIABETIC MED, V5, P79	25	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1991	303	6805					769	772		10.1136/bmj.303.6805.769	http://dx.doi.org/10.1136/bmj.303.6805.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG981	1932942	Bronze, Green Published			2022-12-28	WOS:A1991GG98100027
J	BARKER, DJP; GODFREY, KM; FALL, C; OSMOND, C; WINTER, PD; SHAHEEN, SO				BARKER, DJP; GODFREY, KM; FALL, C; OSMOND, C; WINTER, PD; SHAHEEN, SO			RELATION OF BIRTH-WEIGHT AND CHILDHOOD RESPIRATORY-INFECTION TO ADULT LUNG-FUNCTION AND DEATH FROM CHRONIC OBSTRUCTIVE AIRWAYS DISEASE	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW OBSTRUCTION; POCKET SPIROMETER; WHOOPING-COUGH; CHILDREN; BRONCHIOLITIS; BRONCHITIS; INFANCY	Objective - To examine whether birth weight, infant weight, and childhood respiratory infection are associated with adult lung function and death from chronic obstructive airways disease. Design - Follow up study of men born during 1911-30 whose birth weights, weights at 1 year, and childhood illnesses were recorded at the time by health visitors. Setting - Hertfordshire, England. Subjects - 5718 men born in the county during 1911-30 and a subgroup of 825 men born in the county during 1920-30 and still living there. Main outcome measures - Death from chronic obstructive airways disease, mean forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), and respiratory symptoms. Results - 55 men died of chronic obstructive airways disease. Death rates fell with increasing birth weight and weight at 1 year. Mean FEV1 at age 59 to 70 years, adjusted for height and age, rose by 0.06 litre (95% confidence interval 0.02 to 0.09) with each pound (450 g) increase in birth weight, independently of smoking habit and social class. Bronchitis or pneumonia in infancy was associated with a 0.17 litre (0.02 to 0.32) reduction in adult FEV1 and with an increased odds ratio of wheezing and persistent sputum production in adult life independently of birth weight, smoking habit, and social class. Whooping cough in infancy was associated with a 0.22 litre (0.02 to 0.42) reduction in adult FEV1.			BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Godfrey, Keith/0000-0002-4643-0618; Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1986, BRIT MED J, V293, P1271, DOI 10.1136/bmj.293.6557.1271; BOCK GR, 1991, CIBA F S, V156; Breslow N, 1980, STATISTICAL METHODS, V32; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BRITTEN N, 1986, BRIT MED J, V292, P441, DOI 10.1136/bmj.292.6518.441; BUCHER U., 1961, THORAX, V16, P207, DOI 10.1136/thx.16.3.207; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHEN Y, 1989, LANCET, V2, P54; DAVIS DL, 1991, LANCET, V337, P123; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GUNAWARDENA KA, 1987, THORAX, V42, P689, DOI 10.1136/thx.42.9.689; HALLIDAY JL, 1928, MRC SPECIAL REPORT S, V120; HOSIE HE, 1988, ANAESTHESIA, V43, P233; JOHNSTON IDA, 1983, LANCET, V2, P1104; KATTAN M, 1977, PEDIATRICS, V59, P683; MCCALL MG, 1968, J CHRON DIS, V21, P349, DOI 10.1016/0021-9681(68)90043-X; MOK JYQ, 1984, ARCH DIS CHILD, V59, P306, DOI 10.1136/adc.59.4.306; OSMOND C, 1990, SERIES DS, V9; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; REID DD, 1969, P ROY SOC MED, V62, P311, DOI 10.1177/003591576906200401; REID DD, 1971, BRIT MED BULL, V27, P59, DOI 10.1093/oxfordjournals.bmb.a070816; ROWLAND MGM, 1988, AM J CLIN NUTR, V47, P134, DOI 10.1093/ajcn/47.1.134; THJURLBECK WM, 1982, THORAX, V37, P564; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; 1985, BMJ, V290, P1937; 1986, QUESTIONNAIRE RESPIR	27	604	618	1	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					671	675		10.1136/bmj.303.6804.671	http://dx.doi.org/10.1136/bmj.303.6804.671			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1912913	Green Published, Bronze			2022-12-28	WOS:A1991GG98000017
J	DELVAL, M; SCHLICHT, HJ; RUPPERT, T; REDDEHASE, MJ; KOSZINOWSKI, UH				DELVAL, M; SCHLICHT, HJ; RUPPERT, T; REDDEHASE, MJ; KOSZINOWSKI, UH			EFFICIENT PROCESSING OF AN ANTIGENIC SEQUENCE FOR PRESENTATION BY MHC CLASS-I MOLECULES DEPENDS ON ITS NEIGHBORING RESIDUES IN THE PROTEIN	CELL			English	Article							HEPATITIS-B VIRUS; CYTOLYTIC LYMPHOCYTE-T; IMMEDIATE-EARLY PROTEIN-PP89; RECOMBINANT VACCINIA VIRUS; INFLUENZA HEMAGGLUTININ; VIRAL PEPTIDES; CORE PROTEIN; CELL-SURFACE; RECOGNITION; GENE	Processing of endogenously synthesized proteins generates short peptides that are presented by MHC class I molecules to CD8 T lymphocytes. Here it is documented that not only the sequence of the presented peptide but also the residues by which it is flanked in the protein determine the efficiency of processing and presentation. This became evident when a viral sequence of proven antigenicity was inserted at different positions into an unrelated carrier protein. Not different peptides, but different amounts of the antigenic insert itself were retrieved by isolation of naturally processed peptides from cells expressing the different chimeric proteins. Low yield of antigenic peptide from an unfavorable integration site could be overcome by flanking the insert with oligo-alanine to space it from disruptive neighboring sequences. Notably, the degree of protection against lethal virus disease related directly to the amount of naturally processed antigenic peptide.			DELVAL, M (corresponding author), UNIV ULM, DEPT VIROL, ALBERT EINSTEIN ALLEE 11, W-7900 ULM, GERMANY.		Del Val, Margarita/E-4769-2010; Ruppert, Thomas/AAC-2467-2021	Del Val, Margarita/0000-0001-6769-4279; Ruppert, Thomas/0000-0001-9152-2266; Reddehase, Matthias/0000-0002-3509-7573				BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; DELVAL M, 1989, CELL, V58, P305, DOI 10.1016/0092-8674(89)90845-3; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; JONJIC S, 1988, J VIROL, V62, P1653; JUNKER M, 1987, NUCLEIC ACIDS RES, V15, P10117, DOI 10.1093/nar/15.24.10117; KEIL GM, 1987, J VIROL, V61, P1901, DOI 10.1128/JVI.61.6.1901-1908.1987; NASSAL M, 1988, GENE, V66, P279, DOI 10.1016/0378-1119(88)90364-2; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; PONTA H, 1985, EMBO J, V4, P3447, DOI 10.1002/j.1460-2075.1985.tb04103.x; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; REDDEHASE MJ, 1991, EUR J IMMUNOL, V21, P1697, DOI 10.1002/eji.1830210717; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; VANBLEEK GM, 1990, NATURE, V348, P213; VOLKMER H, 1987, J EXP MED, V166, P668, DOI 10.1084/jem.166.3.668; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	32	237	242	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1145	1153		10.1016/0092-8674(91)90037-Y	http://dx.doi.org/10.1016/0092-8674(91)90037-Y			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1913805	Green Published			2022-12-28	WOS:A1991GG55200009
J	BRADLEY, SF; TERPENNING, MS; RAMSEY, MA; ZARINS, LT; JORGENSEN, KA; SOTTILE, WS; SCHABERG, DR; KAUFFMAN, CA				BRADLEY, SF; TERPENNING, MS; RAMSEY, MA; ZARINS, LT; JORGENSEN, KA; SOTTILE, WS; SCHABERG, DR; KAUFFMAN, CA			METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS - COLONIZATION AND INFECTION IN A LONG-TERM CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article						METHICILLIN RESISTANCE; STAPHYLOCOCCUS-AUREUS; LONG-TERM CARE; COST BENEFIT ANALYSIS; CROSS INFECTION	NURSING-HOME; NOSOCOMIAL INFECTIONS; UNITED-STATES; OUTBREAK; ERADICATION; EPIDEMIC; CARRIAGE; REHABILITATION; CIPROFLOXACIN; MUPIROCIN	Objective: To assess methicillin-resistant Staphylococcus aureus (MRSA) colonization, transmission, and infection over a 1-year period in a long-term care facility with endemic MRSA. Design: Monthly surveillance for MRSA colonization of nares, perineum, rectum, and wounds. Setting: Long-term care facility attached to an acute care Veterans Affairs medical center. Patients: All 341 patients in the facility had monthly surveillance cultures for 1 year. Outcome Measurements: Colonization and infection with MRSA. Main Results: The monthly MRSA colonization rate was 23% +/- 1.0%; colonization occurred most commonly in the nares and wounds. Poor functional status was associated with MRSA colonization. Most patients (65%) never acquired MRSA; 25% of patients were already colonized at admission to the facility or at the start of the study, and only 10% of newly admitted patients acquired MRSA while in the facility. These latter patients acquired several different strains in a pattern of acquisition similar to that generally seen within the facility. In the course of 1 year, only nine patients who acquired MRSA had a roommate with the same phage type; no clustering was evident, and none of these patients developed infection. Nine other patients (3%) developed MRSA infection; five of these patients required hospitalization, but none died as a result of infection. Conclusions: In the long-term care facility in which our study took place, MRSA was endemic, and the infection rate was low. In such settings, the cost effectiveness of aggressive management of MRSA (wide-spread screening for MRSA and eradication with antimicrobial agents) needs to be assessed.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; MICHIGAN DEPT PUBL HLTH, HOUGHTON, MI 49931 USA	University of Michigan System; University of Michigan	BRADLEY, SF (corresponding author), DEPT VET AFFAIRS MED CTR, 2215 FULLER RD, ANN ARBOR, MI 48105 USA.							AEILTS GD, 1982, J CLIN MICROBIOL, V16, P218, DOI 10.1128/JCM.16.2.218-223.1982; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; BITAR CM, 1987, INFECT CONT HOSP EP, V8, P15, DOI 10.1017/S0195941700066935; BOYCE JM, 1982, INFECT CONT HOSP EP, V3, P377, DOI 10.1017/S0195941700057337; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639; CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; COOKSON B, 1989, J CLIN MICROBIOL, V27, P1471, DOI 10.1128/JCM.27.7.1471-1476.1989; CROSSLEY K, 1979, J INFECT DIS, V139, P280, DOI 10.1093/infdis/139.3.280; DAUM TE, 1990, ANTIMICROB AGENTS CH, V34, P1862, DOI 10.1128/AAC.34.9.1862; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HSU CCS, 1988, ARCH INTERN MED, V148, P569, DOI 10.1001/archinte.148.3.569; KAUFFMAN CA, 1990, INFECT CONT HOSP EP, V11, P600; LINNEMANN CC, 1990, 3RD P DEC INT C NOS; MAKI DG, 1990, 3RD P DEC INT C NOS; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MULLIGAN ME, 1987, AM J MED, V82, P215; MURRAYLEISURE KA, 1990, INFECT CONT HOSP EP, V11, P343; OTOOLE RD, 1970, J AMER MED ASSOC, V213, P257, DOI 10.1001/jama.213.2.257; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PENINGTON GR, 1982, AUST NZ J SURG, V52, P534, DOI 10.1111/j.1445-2197.1982.tb06047.x; PREHEIM LC, 1987, INFECT CONT HOSP EP, V8, P191, DOI 10.1017/S0195941700065929; RAHMAN M, 1989, EPIDEMIOL INFECT, V102, P261, DOI 10.1017/S0950268800029939; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; REBOLI AC, 1990, INFECT CONT HOSP EP, V11, P291, DOI 10.1086/646174; REBOLI AC, 1989, AM J DIS CHILD, V143, P34, DOI 10.1001/archpedi.1989.02150130044013; RUTALA WA, 1983, J CLIN MICROBIOL, V18, P683, DOI 10.1128/JCM.18.3.683-688.1983; SMITH PB, 1972, STAPHYLOCOCCI, P431; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36, DOI 10.2307/30147087; THOMAS JC, 1989, INFECT CONT HOSP EP, V10, P106, DOI 10.1086/645976; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; THORNSBERRY C, 1983, J CLIN MICROBIOL, V18, P1084, DOI 10.1128/JCM.18.5.1084-1091.1983; WARD TT, 1981, INFECT CONT HOSP EP, V2, P453, DOI 10.1017/S0195941700055715; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	36	243	246	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					417	422		10.7326/0003-4819-115-6-417	http://dx.doi.org/10.7326/0003-4819-115-6-417			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1908198				2022-12-28	WOS:A1991GE81000001
J	EGGER, M; SMITH, GD; IMHOOF, H; TEUSCHER, A				EGGER, M; SMITH, GD; IMHOOF, H; TEUSCHER, A			RISK OF SEVERE HYPOGLYCEMIA IN INSULIN TREATED DIABETIC-PATIENTS TRANSFERRED TO HUMAN INSULIN - A CASE CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RARE DISEASE ASSUMPTION; PORCINE INSULIN; HYPOGLYCEMIA UNAWARENESS; AWARENESS	Objective - To examine whether transfer from animal insulin to human insulin is associated with an increased risk of severe hypoglycaemia. Design - Matched case-control study of insulin treated diabetic patients admitted to hospital because of hypoglycaemia during 1984-7, the period when human insulin was introduced into treatment. Setting - Case admissions and control admissions were obtained from eight public hospitals within the Swiss canton of Berne and a second control group comprised members of the Bernese section of the Swiss Diabetes Association. Subjects - 94 patients with insulin treated diabetes with a total of 112 admissions for hypoglycaemia during 1984-7 (case admissions), 182 patients with insulin treated diabetes seen in the same hospitals for reasons other than hypoglycaemia with a total of 225 admissions (control admissions), and 86 insulin treated diabetic patients who were members of the Bernese section of the Swiss Diabetes Association. Main outcome measures - Type of insulin used at time of admission, glycaemic control as measured by amount of glycated haemoglobin or glucose concentration; severity of hypoglycaemia. Results - Treatment with human insulin at admission was more common in cases than controls (52/112 (46%) admissions v 77/225 (34%); p = 0.003). 116 out of 129 (90%) of admissions taking human insulin had been transferred from animal insulin, mainly because of non-availability of porcine insulins. The ratio of rate of hypoglycaemia in those taking human insulin to the rate in those taking animal insulin was 2.4 (95% confidence interval 1.3 to 4.4). Other risk factors for hypoglycaemia were a history of hypoglycaemic coma (rate ratio of history to no history 3.8, 2.3 to 6.4) and good glycaemic control (rate ratio of good to poor control 3.9, 1.4 to 7.5). With multivariate analysis the increase in rate ratio associated with use of human insulin rose to 3.0 (1.4 to 6.4). Comparison with the diabetes association controls also showed an increased risk associated with use of human insulin (2.2; 1.1 to 4.8). Conclusions - Transfer of treatment from animal insulin to human insulin was associated with an increased risk of severe hypoglycaemia. Caution should be exercised when transferring diabetic patients to human insulin. Further studies are required to elucidate why this effect occurs,	UNIV BERN, DEPT MED, DIABET SECT, CH-3000 BERN, SWITZERLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of Bern; University of London; London School of Hygiene & Tropical Medicine			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; CASPARIE AF, 1985, DIABETES CARE, V8, P141, DOI 10.2337/diacare.8.2.141; CLARK AJL, 1982, LANCET, V2, P354; CRYER PE, 1990, DIABETES CARE, V13, P536, DOI 10.2337/diacare.13.5.536; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; HEINE RJ, 1989, LANCET, V2, P946; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; Home P D, 1984, Diabet Med, V1, P93; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; NIULSSON A, 1988, ACTA MED SCAND, V224, P257; PEACOCK I, 1983, LANCET, V1, P149; PHILLIPS AN, IN PRESS J CLIN EPID; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; RIFKIN H, 1988, PHYSICIANS GUIDE NON; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P257, DOI 10.1136/jech.44.4.257; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; TEUSCHER A, 1987, LANCET, V2, P382; 1983, PROJEKTBESCHRIEB DIA; 1986, BMJ, V292, P155	28	48	48	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1991	303	6803					617	621		10.1136/bmj.303.6803.617	http://dx.doi.org/10.1136/bmj.303.6803.617			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932902	Bronze, Green Published			2022-12-28	WOS:A1991GF67500022
J	SHAW, J; HOLLOWAY, J				SHAW, J; HOLLOWAY, J			WHO IS YOUR GENERAL-PRACTITIONER	BRITISH MEDICAL JOURNAL			English	Article											SHAW, J (corresponding author), PRESTWICH HOSP,REG SECURE UNIT,SALFORD,ENGLAND.			shaw, jennifer/0000-0003-2569-7687				BLUEGLASS R, 1983, GUIDE MENTAL HLTH AC	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					628	628		10.1136/bmj.303.6803.628	http://dx.doi.org/10.1136/bmj.303.6803.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF675	1932906	Bronze, Green Published			2022-12-28	WOS:A1991GF67500026
J	NUNEZ, G; HOCKENBERY, D; MCDONNELL, TJ; SORENSEN, CM; KORSMEYER, SJ				NUNEZ, G; HOCKENBERY, D; MCDONNELL, TJ; SORENSEN, CM; KORSMEYER, SJ			BCL-2 MAINTAINS B-CELL MEMORY	NATURE			English	Article							ANTIGEN-DRIVEN SELECTION; IMMUNOLOGICAL MEMORY; GERMINAL-CENTERS; BONE-MARROW; SECONDARY; EXPRESSION; SURVIVAL; MICE; POPULATION; RESPONSES	THE number of lymphocytes in an animal is remarkably constant despite antigen-driven proliferation and a high rate of B-cell lymphopoiesis. This reflects the relatively brief lifespan of many newly generated B cells and argues for a well-regulated death mechanism 1-3. Even so, a secondary immune response can be generated years after a primary exposure to antigen 4. Antigen that might restimulate B cells persists for extended periods on follicular dendritic cells in the light zone of germinal centres 5-13. Antigen binding B cells have also been found months after the end of obvious cell division 14. The precise signal that enables certain B cells to emerge as long-term surviving memory cells 14-17 is unknown. Bcl-2, an inner mitochondrial membrane protein 18, blocks programmed cell death in B cells 18-20. We report here that this proto-oncogene maintains immune responsiveness. Transgenic mice overproducing Bcl-2 have a long-term persistence of immunoglobulin-secreting cells and an extended lifetime for memory B cells.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	NUNEZ, G (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110, USA.		Nuñez, Gabriel/A-7160-2014					BEREK C, 1987, EUR J IMMUNOL, V17, P1121, DOI 10.1002/eji.1830170808; CELADA F, 1967, J EXP MED, V125, P199, DOI 10.1084/jem.125.2.199; COICO RF, 1983, J IMMUNOL, V131, P2254; COLLE JH, 1988, EUR J IMMUNOL, V18, P1307, DOI 10.1002/eji.1830180902; FLIEDNER TM, 1964, ANN NY ACAD SCI, V113, P578, DOI 10.1111/j.1749-6632.1964.tb40692.x; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GOWANS JL, 1966, J EXP MED, V124, P1017, DOI 10.1084/jem.124.5.1017; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GRAY D, 1988, J EXP MED, V167, P805, DOI 10.1084/jem.167.3.805; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, IN PRESS P NATN ACAD; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KOSKO MH, 1989, IMMUNOLOGY, V68, P312; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; KRAAL G, 1988, CELL IMMUNOL, V115, P78, DOI 10.1016/0008-8749(88)90163-3; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PEZELLA F, 1990, AM J PATHOL, V137, P225; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; TEW TG, 1979, IMMUNOLOGY, V37, P69; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	28	213	216	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					71	73		10.1038/353071a0	http://dx.doi.org/10.1038/353071a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1908951				2022-12-28	WOS:A1991GD80500060
J	WILMORE, DW; MOSES, A				WILMORE, DW; MOSES, A			CATABOLIC ILLNESS - STRATEGIES FOR ENHANCING RECOVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							TUMOR NECROSIS FACTOR; HUMAN GROWTH-HORMONE; CHAIN AMINO-ACIDS; PARENTERAL-NUTRITION; SURGICAL PATIENTS; NITROGEN-BALANCE; FACTOR-I; SEPTIC SHOCK; PROTEIN LOSS; HUMAN-BEINGS		HARVARD UNIV, SCH MED, DEPT SURG, SURG METAB & NUTR LABS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SURG, NUTR SUPPORT SERV, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	WILMORE, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT SURG, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM036428] Funding Source: NIH RePORTER; NIGMS NIH HHS [5P50 GM36428] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI TT, 1975, DIABETES, V24, P463, DOI 10.2337/diabetes.24.5.463; ARDAWI MSM, 1985, BIOCHEM J, V231, P713, DOI 10.1042/bj2310713; BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BARBUL A, 1981, SURGERY, V90, P244; BAUMGARTNER JD, 1985, LANCET, V2, P59; BEISEL WR, 1975, ANNU REV MED, V26, P9, DOI 10.1146/annurev.me.26.020175.000301; BITTINER SB, 1988, LANCET, V1, P378; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CALDWELL MD, 1989, METABOLISM, V38, P34, DOI 10.1016/0026-0495(89)90137-6; CERRA FB, 1987, SURGERY, V101, P1; CHANDRA RK, 1983, LANCET, V1, P688; CHENEY CL, 1987, J AM COLL NUTR, V6, P223; CLEMMONS DR, 1987, J CLIN ENDOCR METAB, V64, P878, DOI 10.1210/jcem-64-5-878; Cuthbertson DP, 1932, Q J MED, V1, P233; DALY JM, 1988, ANN SURG, V208, P512, DOI 10.1097/00000658-198810000-00013; EBERLEIN TJ, 1989, ARCH SURG-CHICAGO, V124, P542; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HAMMARQVIST F, 1989, ANN SURG, V209, P455, DOI 10.1097/00000658-198904000-00011; HERDON DN, 1990, ANN SURG, V212, P424; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; KAWAKAMI M, 1984, P IUPHAR, V2, P377; Keys A, 1950, BIOL HUMAN STARVATIO; KINNEY JM, 1985, ACTA CHIR SCAND, P45; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LILJEDAHL STEN-OTTO, 1961, ACTA CHIR SCAND, V122, P1; LODER PB, 1990, ANN SURG, V211, P360, DOI 10.1097/00000658-199003000-00008; MANSON JM, 1986, SURGERY, V100, P188; MICHIE HR, 1988, SURGERY, V104, P280; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; NAYLOR CD, 1989, GASTROENTEROLOGY, V97, P1033, DOI 10.1016/0016-5085(89)91517-5; NEWSHOLME EA, 1988, NUTRITION, V4, P261; PARRYBILLINGS M, 1990, LANCET, V336, P523, DOI 10.1016/0140-6736(90)92083-T; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; SAX HC, 1986, ARCH SURG-CHICAGO, V121, P358; SHERNAN S K, 1989, Surgical Forum (Chicago), V40, P37; SHIZGAL HM, 1983, SURGICAL NUTRITION, P3; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; SUN XM, 1988, J CLIN INVEST, V81, P1328, DOI 10.1172/JCI113459; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; UNDERWOOD LE, 1986, HORM RES, V24, P166, DOI 10.1159/000180556; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WELBOURNE TC, 1987, AM J PHYSIOL, V253, pF1069, DOI 10.1152/ajprenal.1987.253.6.F1069; WILMORE DW, 1974, SURG GYNECOL OBSTET, V138, P875; WILMORE DW, 1976, SURG CLIN N AM, V56, P999; WILMORE DW, 1983, NUTRITIONAL SUPPORT, P33; WINDMUELLER HG, 1982, ADV ENZYMOL RAMB, V53, P201; WINDSOR JA, 1988, BRIT J SURG, V75, P880, DOI 10.1002/bjs.1800750917; WINDSOR JA, 1988, BRIT J SURG, V75, P135, DOI 10.1002/bjs.1800750215; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZIEGLER TR, 1988, ANN SURG, V208, P6, DOI 10.1097/00000658-198807000-00002; ZIEGLER TR, 1990, JPEN-PARENTER ENTER, V14, P574, DOI 10.1177/0148607190014006574; [No title captured]	56	282	288	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					695	702						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1908058				2022-12-28	WOS:A1991GD49700005
J	JEWELL, D				JEWELL, D			THE FUTURE OF GENERAL-PRACTICE .8. GENERAL-PRACTICE EDUCATION - THINGS TO COME	BRITISH MEDICAL JOURNAL			English	Article											JEWELL, D (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND.							BOLAND M, 1991, BRIT J GEN PRACT, V41, P295; FORBES JA, 1979, EVALUATING PRIMARY C; Fraser RC, 1988, 42 ROYAL COLL GEN PR; HART JT, 1985, J ROY COLL GEN PRACT, V35, P63; JEWELL D, 1991, BRIT J GEN PRACT, V41, P1; MCMANUS IC, 1989, BRIT MED J, V298, P1051, DOI 10.1136/bmj.298.6680.1051; RICHARDS C, 1988, J ROY COLL GEN PRACT, V38, P535; SMITH CH, 1989, BRIT MED J, V299, P494, DOI 10.1136/bmj.299.6697.494; Spaulding W., 1991, REV MED ED MCMASTER, V115; 1990, 49 ROYAL COLL GEN PR; 1989, LANCET, V1, P702; 1968, REPORT ROYAL COMMISS	12	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1991	303	6801					510	512		10.1136/bmj.303.6801.510	http://dx.doi.org/10.1136/bmj.303.6801.510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD804	1912864	Bronze, Green Published			2022-12-28	WOS:A1991GD80400021
J	MARKUS, A; LOCKWOOD, M				MARKUS, A; LOCKWOOD, M			IS IT PERMISSIBLE TO EDIT MEDICAL RECORDS	BRITISH MEDICAL JOURNAL			English	Editorial Material									UNIV OXFORD,DEPT CONTINUING EDUC,OXFORD OX1 2JA,ENGLAND	University of Oxford	MARKUS, A (corresponding author), DEPT PUBL HLTH & PRIMARY MED,OXFORD OX2 6HE,ENGLAND.							1987, PROFESSIONAL CONDUCT	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					349	351		10.1136/bmj.303.6798.349	http://dx.doi.org/10.1136/bmj.303.6798.349			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1912779	Bronze, Green Published			2022-12-28	WOS:A1991GA60600025
J	OHASHI, PS; OEHEN, S; BUERKI, K; PIRCHER, H; OHASHI, CT; ODERMATT, B; MALISSEN, B; ZINKERNAGEL, RM; HENGARTNER, H				OHASHI, PS; OEHEN, S; BUERKI, K; PIRCHER, H; OHASHI, CT; ODERMATT, B; MALISSEN, B; ZINKERNAGEL, RM; HENGARTNER, H			ABLATION OF TOLERANCE AND INDUCTION OF DIABETES BY VIRUS-INFECTION IN VIRAL-ANTIGEN TRANSGENIC MICE	CELL			English	Article								To address the mechanisms of tolerance to extrathymic proteins, we have generated transgenic mice expressing the lymphocytic choriomeningitis viral (LCMV) glycoprotein (GP) in the beta-islet cells of the pancreas. The fate of LCMV GP-specific T cells was followed by breeding the GP transgenic mice with T cell receptor transgenic mice, specific for LCMV and H-2D(b). These studies suggest that "peripheral tolerance" of self-reactive T cells does not involve clonal deletion, clonal anergy, or a decrease in the density of T cell receptors or accessory molecules. Instead, this model indicates that self-reactive cytotoxic T cells may remain functionally unresponsive, owing to a lack of appropriate T cell activation. Infection of transgenic mice with LCMV readily abolishes peripheral unresponsiveness to the self LCMV GP antigen, resulting in a CD8+ T cell-mediated diabetes. These data suggest that similar mechanisms may operate in several so-called "T cell-mediated autoimmune diseases."	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND; CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Novartis; Sandoz; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	OHASHI, PS (corresponding author), UNIV HOSP ZURICH, INST PATHOL, DEPT EXPTL PATHOL, CH-8091 ZURICH, SWITZERLAND.		; Malissen, Bernard/AAK-4659-2020	Ohashi, Pamela S./0000-0003-2915-9317; Malissen, Bernard/0000-0003-1340-9342				ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BAEKKESKOV S, 1981, P NATL ACAD SCI-BIOL, V78, P6456, DOI 10.1073/pnas.78.10.6456; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FAUSTMAN D, 1980, J EXP MED, V151, P1563, DOI 10.1084/jem.151.6.1563; FERRICK DA, 1990, IMMUNOL REV, V118, P257, DOI 10.1111/j.1600-065X.1990.tb00819.x; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1990, ANNU REV CELL BIOL, V6, P493, DOI 10.1146/annurev.cellbio.6.1.493; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HOGAN B, 1986, MANIPULATING MOUSE E; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LIKE AA, 1982, SCIENCE, V216, P644, DOI 10.1126/science.7041259; LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MILLER BJ, 1988, J IMMUNOL, V140, P52; MILLER J, 1990, J IMMUNOL, V144, P334; MILLER JFA, 1989, IMMUNOLOGY, V1, P137; MOMBURG F, 1986, J IMMUNOL, V136, P940; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MOSKOPHIDIS D, 1991, IN PRESS J VIROL; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NAGATA M, 1989, J IMMUNOL, V143, P1155; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; ROSA F, 1984, IMMUNOL TODAY, V5, P261, DOI 10.1016/0167-5699(84)90135-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; WOOD PJ, 1987, J IMMUNOL, V139, P3236; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	75	1087	1093	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					305	317		10.1016/0092-8674(91)90164-T	http://dx.doi.org/10.1016/0092-8674(91)90164-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1901764				2022-12-28	WOS:A1991FH09200013
J	OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M				OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M			DOES EARLY INTERVENTION REDUCE THE NUMBER OF ELDERLY PEOPLE WITH DEMENTIA ADMITTED TO INSTITUTIONS FOR LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL STATE; COMMUNITY; SERVICES; VALIDITY	Objective-To test whether early diagnosis and practical help reduce the number of elderly people with dementia admitted to institutions. Design-Controlled trial of effect of help from a multidisciplinary team on admission rates of people with dementia. Setting-Seven general practices in Cambridge. Subjects-2889 subjects aged 75 and over, of whom 159 were identified as having dementia with a two stage community survey. Eighty six subjects were referred for extra help if they or their supporters wished. The other 73 subjects had access to the usual services and served as controls. Intervention-Subjects and families in the action group were offered a wide range of help, including financial benefits, physical aids, home helps, respite admissions, practical advice, and psychiatric assessments. Main outcome measure-Permanent admission to long term care within two years after diagnosis. Results-Early intervention did not affect admission rates in subjects who lived with supporters. By contrast, nine of the 14 (64%) subjects with moderate or severe dementia living alone were admitted in the action group in the study's second year compared with only one of 13 (8%) controls (p = 0.004). Conclusions-Some people with moderate or severe dementia who lived alone and were at serious risk may have been identified earlier by the resource team. Without the team these people would not have become known to the responsible authorities until families, neighbours, and wardens became unable to cope. The study was conducted during the team's formative period, however, and greater experience might have allowed some subjects to remain at home for longer.	HUGHES HALL PROJECT LATER LIFE,CAMBRIDGE CB1 2EW,ENGLAND	University of Cambridge				O'Connor, Daniel/0000-0003-0188-1340				ASKHAM J, 1990, DEMENTIA HOME CARE; BLENKNER M, 1971, SOC CASEWORK-JCSW, V52, P483, DOI 10.1177/104438947105200801; BOAS JW, 1971, BRIT J RADIOL, V44, P122; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Challis D, 1986, CASE MANAGEMENT COMM; Challis D., 1990, CASE MANAGEMENT SOCI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilleard C. J., 1984, LIVING DEMENTIA COMM; GODBER C, 1977, AGE AGEING, V6, P100; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P203, DOI 10.1002/gps.930040405; OCONNOR DW, 1989, J PSYCHIAT RES, V23, P87, DOI 10.1016/0022-3956(89)90021-6; OCONNOR DW, 1989, ACTA PSYCHIAT SCAND, V79, P190, DOI 10.1111/j.1600-0447.1989.tb08587.x; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; OCONNOR DW, 1990, ACTA PSYCHIAT SCAND, V81, P78, DOI 10.1111/j.1600-0447.1990.tb06453.x; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P339, DOI 10.1002/gps.930040607; OPIT LJ, 1977, BRIT MED J, V1, P30, DOI 10.1136/bmj.1.6052.30; Pollitt PA, 1989, AGEING SOC, V9, P261; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; 1987, DIAGNOSTIC STATISTIC; 1989, CARING PEOPLE	21	66	66	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					871	875		10.1136/bmj.302.6781.871	http://dx.doi.org/10.1136/bmj.302.6781.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	1902752	Bronze, Green Published			2022-12-28	WOS:A1991FG42100019
J	GORVEL, JP; CHAVRIER, P; ZERIAL, M; GRUENBERG, J				GORVEL, JP; CHAVRIER, P; ZERIAL, M; GRUENBERG, J			RAB5 CONTROLS EARLY ENDOSOME FUSION INVITRO	CELL			English	Article							GTP-BINDING PROTEINS; CELL-FREE SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; ENDOPLASMIC-RETICULUM; ONCOGENE PRODUCT; GOLGI-APPARATUS; PLASMA-MEMBRANE; YEAST YPT1; TRANSPORT; SECRETION	The small GTP-binding protein rab5 was previously localized on early endosomes and on the cytoplasmic face of the plasma membrane. Using a cell-free assay, we have now tested whether rab5 is involved in controlling an early endocytic fusion event. Fusion could be inhibited by cytosol containing the overexpressed mutant rab5IIe133, which does not bind GTP on blots, and by antibodies against rab5, but not against rab2 or rab7. In contrast, fusion was stimulated with cytosol containing overexpressed wild-type rab5. Cytosols containing high levels of rab2 or mutant rab5 with the 9 carboxy-terminal amino acids deleted, which bind GTP on blots, had no effects. Finally, the inhibition mediated by anti-rab5 antibodies could be overcome by complementing the assay with the cytosol containing wild-type rab5, but not with the same cytosol depleted of rab5, nor with cytosol containing the rab5 mutants or rab2. These in vitro finding strongly suggest that rab5 is involved in the process of early endosome fusion.			GORVEL, JP (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY.		CHAVRIER, Philippe/B-4707-2010; CHAVRIER, Philippe/AAG-2645-2020; Gorvel, Jean-Pierre/O-1332-2018	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Gorvel, Jean-Pierre/0000-0002-2829-9804				BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BEKCERS CJM, 1989, NATURE, V339, P397; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1987, P NATL ACAD SCI USA, V84, P5758, DOI 10.1073/pnas.84.16.5758; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Maizel JV, 1971, METHOD VIROL, V5, P179; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; VONFISCHER M, 1990, P NATL ACAD SCI USA, V87, P1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	59	928	941	2	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					915	925		10.1016/0092-8674(91)90316-Q	http://dx.doi.org/10.1016/0092-8674(91)90316-Q			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1900457				2022-12-28	WOS:A1991FA94000009
